PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HOEG, JM				HOEG, JM			FAMILIAL HYPERCHOLESTEROLEMIA - WHAT THE ZEBRA CAN TEACH US ABOUT THE HORSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							LOW-DENSITY-LIPOPROTEIN; LIVER-TRANSPLANTATION; PLASMA-EXCHANGE; DEFICIENT RABBITS; DRUG-THERAPY; GENE-THERAPY; RECEPTOR; ATHEROSCLEROSIS; CHOLESTEROL; METABOLISM				HOEG, JM (corresponding author), NHLBI, MOLEC DIS BRANCH, CELL BIOL SECT, 9000 ROCKVILLE PIKE, BLDG 10, BETHESDA, MD 20892 USA.							BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BORBERG H, 1990, PROG CLIN BIOL RES, P163; Borberg H, 1988, Prog Clin Biol Res, V255, P317; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BRUSH JE, 1988, AM HEART J, V116, P1365, DOI 10.1016/0002-8703(88)90467-X; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; EDGE SB, 1986, J BIOL CHEM, V261, P3800; Eisenhauer T, 1987, ASAIO Trans, V33, P395; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GORDON BR, 1992, AM J CARDIOL, V70, P1010, DOI 10.1016/0002-9149(92)90352-Y; HARDERSPENGEL K, 1982, P NATL ACAD SCI-BIOL, V79, P6355, DOI 10.1073/pnas.79.20.6355; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOBBS HH, 1989, J CLIN INVEST, V84, P656, DOI 10.1172/JCI114212; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HOEG JM, 1984, J CLIN INVEST, V73, P429, DOI 10.1172/JCI111229; HOEG JM, 1991, ANN NY ACAD SCI, V623, P275, DOI 10.1111/j.1749-6632.1991.tb43737.x; HOEG JM, 1986, BIOCHIM BIOPHYS ACTA, V876, P646, DOI 10.1016/0005-2760(86)90054-8; ILLINGWORTH DR, 1990, CLIN INVEST MED, V13, P211; Postiglione A, 1985, Prog Clin Biol Res, V188, P213; SCRIVER CR, 1989, INBORN FACTORS DISEA, P248; SPRECHER DL, 1984, AM J CARDIOL, V54, P20, DOI 10.1016/0002-9149(84)90298-4; SPRECHER DL, 1985, METABOLISM, V34, P294, DOI 10.1016/0026-0495(85)90015-0; STARZL TE, 1984, LANCET, V1, P1382; STEIN EA, 1986, CLIN CARDIOL, V9, P115, DOI 10.1002/clc.4960090306; STEIN EA, 1981, ATHEROSCLEROSIS, V38, P149, DOI 10.1016/0021-9150(81)90112-X; STOFFEL W, 1981, LANCET, V2, P1005; TATAMI R, 1992, ATHEROSCLEROSIS, V95, P1, DOI 10.1016/0021-9150(92)90170-L; WILSON JM, 1992, J BIOL CHEM, V267, P963; WILSON JM, 1990, MOL BIOL MED, V7, P223; WITZTUM JL, 1989, CIRCULATION, V79, P16, DOI 10.1161/01.CIR.79.1.16	32	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					543	546		10.1001/jama.271.7.543	http://dx.doi.org/10.1001/jama.271.7.543			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301770				2022-12-28	WOS:A1994MV42300038
J	WITT, MD; GOSTIN, LO				WITT, MD; GOSTIN, LO			CONFLICT-OF-INTEREST DILEMMAS IN BIOMEDICAL-RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNIVERSITY		AMER SOC LAW MED & ETH,BOSTON,MA		WITT, MD (corresponding author), TECHNOL RESOURCE GRP,3108 CLAIRIDGE WAY,SACRAMENTO,CA 95821, USA.							BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BOOTH W, 1988, SCIENCE, V242, P1497, DOI 10.1126/science.3201233; BROWN PB, 1982, FORBES          1011, P196; Bulleit Thomas N, 1989, J Law Health, V4, P1; FLINT A, 1993, BOSTON GLOBE    0131, P10; HOPPIN ME, 1987, AM J CLIN NUTR, V46, P226, DOI 10.1093/ajcn/46.1.226; MARSHALL E, 1990, SCIENCE, V248, P152, DOI 10.1126/science.2326628; Rodwin M. A., 1993, MED MONEY MORALS PHY; SCHULMAN S, 1990, NATURE          0308, V344, P97; WALTERSCHEID EC, 1990, HARVARD J LAW TECHNO, V3, P103; WALTERSCHIED EC, 1990, HARV JL TECH, V3, P131; 1990, J CLIN RES, V38, P239; 1991, FED REGISTER, V56, P27384; 1988, COMMUNICATION   0927; 1989, NIH GUIDE GRANTS CON, V18, P3; 1991, PHS8250000 DEP HLTH; 1990, ACAD MED, V65, P485; 1990, JAMA-J AM MED ASSOC, V263, P2790; 1983, PUB PAPERS, V248; 1982, ECONOMIST       0522, P107; 1982, BUSINESS WEEK   1220, P58	21	30	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					547	551		10.1001/jama.271.7.547	http://dx.doi.org/10.1001/jama.271.7.547			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV423	8301771				2022-12-28	WOS:A1994MV42300039
J	SHAPIRO, DW; WENGER, NS; SHAPIRO, MF				SHAPIRO, DW; WENGER, NS; SHAPIRO, MF			THE CONTRIBUTIONS OF AUTHORS TO MULTIAUTHORED BIOMEDICAL-RESEARCH PAPERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTEGRITY; PUBLISH; FRAUD	Objective.-To determine the contributions of each author to multiauthored biomedical research papers. Design.-Mailed, self-administered survey. Participants.-A total of 184 first authors from a consecutive sample of 200 papers with four or more authors published in 10 leading biomedical journals. Main Outcome Measures.-First authors' ratings of which authors had made substantial contributions to the following: initial conception of the study, design of the study, provision of needed resources, collection of data, analysis and interpretation of data, and writing the first draft of the paper or revising drafts for important intellectual content. Results.-The contributions of nonfirst authors varied greatly within and among papers. Even second and last authors-though they generally contributed more than other nonfirst authors-were markedly inconsistent in the extent and pattern of their contributions. Time spent on the research differed among authors by orders of magnitude. An appreciable number of authors made few or no substantial contributions to the research. Conclusions.-The nature and extent of contributions of nonfirst authors to biomedical research reported in multiauthored papers cannot reliably be discerned (or discounted) by authorship or order of authors. The two core purposes of scientific authorship-to confer credit and denote responsibility for research-are not adequately being met by these authorship practices.	VET AFFAIRS MED CTR, DIV GEN INTERNAL MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, MED CTR, DIV GEN INTERNAL MED, LOS ANGELES, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								ANGELL M, 1986, ANN INTERN MED, V104, P261, DOI 10.7326/0003-4819-104-2-261; BROAD WJ, 1981, SCIENCE, V211, P1137, DOI 10.1126/science.7008199; CHEW FS, 1988, AM J ROENTGENOL, V150, P23, DOI 10.2214/ajr.150.1.23; DARDIK H, 1977, SURG GYNECOL OBSTET, V145, P418; ENGLER RL, 1988, NEW ENGL J MED, V318, P1395; FRIESINGER GC, 1986, J AM COLL CARDIOL, V8, P1240, DOI 10.1016/S0735-1097(86)80408-9; FYE WB, 1990, ANN INTERN MED, V113, P317, DOI 10.7326/0003-4819-113-4-317; HAMILTON DP, 1992, SCIENCE, V255, P1636, DOI 10.1126/science.11642983; HOWELL JD, 1988, NEW ENGL J MED, V318, P1395; HUTH EJ, 1986, ANN INTERN MED, V104, P257, DOI 10.7326/0003-4819-104-2-257; LOCKE R, 1986, NATURE, V324, P401, DOI 10.1038/324401a0; LUNDBERG GD, 1989, JAMA-J AM MED ASSOC, V262, P2003, DOI 10.1001/jama.262.14.2003; MOULOPOULOS SD, 1983, BRIT MED J, V287, P1608, DOI 10.1136/bmj.287.6405.1608; RELMAN AS, 1983, NEW ENGL J MED, V308, P1415, DOI 10.1056/NEJM198306093082311; RIESENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1857, DOI 10.1001/jama.264.14.1857; SOBAL J, 1990, NEW ENGL J MED, V323, P488; STEWART WW, 1987, NATURE, V325, P207, DOI 10.1038/325207a0; STRUB RL, 1976, LANCET, V2, P1090; WOOLF PK, 1986, ANN INTERN MED, V104, P254, DOI 10.7326/0003-4819-104-2-254; 1992, SCIENCE, V255, P283; 1991, JAMA-J AM MED ASSOC, V265, P2697; 1991, NEW ENGL J MED, V324, P424	22	216	223	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					438	442		10.1001/jama.271.6.438	http://dx.doi.org/10.1001/jama.271.6.438			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295318				2022-12-28	WOS:A1994MU49100030
J	SCHILD, H; MAVADDAT, N; LITZENBERGER, C; EHRICH, EW; DAVIS, MM; BLUESTONE, JA; MATIS, L; DRAPER, RK; CHIEN, YH				SCHILD, H; MAVADDAT, N; LITZENBERGER, C; EHRICH, EW; DAVIS, MM; BLUESTONE, JA; MATIS, L; DRAPER, RK; CHIEN, YH			THE NATURE OF MAJOR HISTOCOMPATIBILITY COMPLEX RECOGNITION BY GAMMA-DELTA-T-CELLS	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; LIPID-LINKED FORM; HLA-DR MOLECULES; CLASS-I; MONOCLONAL-ANTIBODIES; RECEPTOR; BINDING; EXPRESSION; GENE	Despite intensive efforts, the general rules for gammadelta T cell recognition remain undefined. Here, we take advantage of the detailed knowledge of the molecular structure and biosynthetic pathways of major histocompatibility complex (MHC) molecules to analyze the recognition properties of the gammadelta T cell clones LBK5 (specific for the class II MHC, IE(k)) and G8 (specific for the nonclassical class I MHC, TL10b). We find that the activation of these clones requires neither class I nor class II antigen-processing and that peptides do not confer specificity. Epitope mapping also shows that the topology of gammadelta T cell receptor interaction with the MHC is distinct from that of alphabeta T cells. These results suggest that the molecular nature of gammadelta T cell recognition is fundamentally different than that of alphabeta T cells.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV WESTERN AUSTRALIA,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; ALEXION PHARMACEUT,NEW HAVEN,CT 06511; UNIV TEXAS,PROGRAM MOLEC & CELLULAR BIOL,RICHARDSON,TX 75083	Stanford University; University of Western Australia; Howard Hughes Medical Institute; Stanford University; University of Chicago; University of Texas System; University of Texas Dallas				Davis, Mark/0000-0001-6868-657X; Mavaddat, Nasim/0000-0003-0307-055X				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLBAUGH PA, 1993, ENDOSOMES LYSOSOMES, V1, P169; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HOULDEN BA, 1989, COLD SH Q B, V54, P45; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JOLY E, 1991, GENE, V97, P213, DOI 10.1016/0378-1119(91)90054-F; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KABELITZ D, 1990, J IMMUNOL, V145, P2827; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI MZ, 1987, J IMMUNOL, V139, P3973; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MCCOY KL, 1989, J IMMUNOL, V143, P29; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; OZATO K, 1980, J IMMUNOL, V124, P533; PFEFFER K, 1992, J IMMUNOL, V148, P575; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCK EP, 1994, J EXP MED, V179, P985; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Schrader J W, 1983, Lymphokine Res, V2, P83; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YAGI JJ, 1990, J IMMUNOL, V144, P892; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	50	383	393	2	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					29	37		10.1016/0092-8674(94)90170-8	http://dx.doi.org/10.1016/0092-8674(94)90170-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287478				2022-12-28	WOS:A1994MR49500004
J	OADES, PJ; BUCHDAHL, RM; BUSH, A				OADES, PJ; BUCHDAHL, RM; BUSH, A			PREDICTION OF HYPOXEMIA AT HIGH-ALTITUDE IN CHILDREN WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article							AIR-TRAVEL; HYPOXIA; OXYGEN	Objective-To assess the usefulness of a hypoxic challenge in a laboratory at sea level in predicting acute desaturation at altitude in children with lung disease. Design--Comparison of responses to hypoxic challenge in different settings. Subjects-22 children (12 boys) aged 11 to 16 years with cystic fibrosis in whom the mean forced expiratory volume in one second was 64% (range 24-100%). Setting-Lung function laboratory, the Alps, and aboard commercial jet aircraft. Main outcome measures-Spirometric lung function at sea level and finger probe oximetry with air and 15% oxygen. Oximetry during high altitude flight and on a mountain at altitude of 1800 m. Results-Significant desaturation (range 0 to 12%) occurred with all hypoxic challenges (P < 0.002). The best predictor of hypoxic response from a single reading was the laboratory test (r2=76% for flight and r2=47% for mountain altitude), but the mean errors of prediction were not clinically significantly different. In six children who showed the greatest desaturation the laboratory test overestimated desaturation, but other predictors underestimated desaturation in three by up to 5%. Conclusions-The laboratory hypoxic challenge directly predicted the worst case of desaturation during flight and at equivalent high altitude. Spirometry and baseline oxygen saturations may underestimate individual hypoxic response. The test may have wider applications to other patients with stable chronic lung diseases, particularly in determining who needs supplementary oxygen during air travel and who should be advised against holidays at high altitude.			OADES, PJ (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT PAEDIAT,SYDNEY ST,LONDON SW3 6NP,ENGLAND.			Oades, Patrick/0000-0001-5265-6923				BERG BW, 1992, CHEST, V101, P638, DOI 10.1378/chest.101.3.638; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; DARGA LL, 1986, PEDIATR PULM, V2, P82, DOI 10.1002/ppul.1950020205; GONG H, 1989, ANN INTERN MED, V111, P349, DOI 10.7326/0003-4819-111-5-349; HARDING RM, 1988, AVIATION MED; LAMBERT RK, 1982, J APPL PHYSIOL, V52, P44, DOI 10.1152/jappl.1982.52.1.44; LIBBY DM, 1981, AM REV RESPIR DIS, V123, P171; LOZANO JM, 1992, ARCH DIS CHILD, V67, P299, DOI 10.1136/adc.67.3.299; RAFFLES A, 1984, BRIT MED J, V288, P322, DOI 10.1136/bmj.288.6413.322; REBUCK AS, 1974, AM REV RESPIR DIS, V109, P345; Ryan B. F., 1985, MINITAB HDB; SCHNECK HJ, 1989, DEUT MED WOCHENSCHR, V114, P123, DOI 10.1055/s-2008-1066563; SPEECHLYDICK ME, 1992, RESP MED, V86, P55, DOI 10.1016/S0954-6111(06)80150-2	14	50	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					15	18		10.1136/bmj.308.6920.15	http://dx.doi.org/10.1136/bmj.308.6920.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298345	Green Published			2022-12-28	WOS:A1994MQ09600022
J	CLAPHAM, DE				CLAPHAM, DE			MUTATIONS IN G-PROTEIN-LINKED RECEPTORS - NOVEL INSIGHTS ON DISEASE	CELL			English	Review							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; EXPRESSION; CALCIUM; TUMORS; GENE				CLAPHAM, DE (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905, USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BROWN EM, 1993, IN PRESS NATURE; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARX SJ, 1985, AM J MED, V78, P15, DOI 10.1016/0002-9343(85)90455-3; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; REIHSAUS E, 1993, AM J RECEPTR CELL MO, V8, P834; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536	19	67	71	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1237	1239		10.1016/0092-8674(93)90609-T	http://dx.doi.org/10.1016/0092-8674(93)90609-T			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269505				2022-12-28	WOS:A1993MP86900001
J	HARRIS, CC				HARRIS, CC			P53 - AT THE CROSSROADS OF MOLECULAR CARCINOGENESIS AND RISK ASSESSMENT	SCIENCE			English	Editorial Material							CELL-CYCLE CHECKPOINT; DNA-REPAIR; CANCER; GENE; MUTATIONS; TUMORS; CARCINOMA; ONCOGENE; LUNG				HARRIS, CC (corresponding author), NCI,DIV CANC ETIOL,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892, USA.							AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; [Anonymous], 1993, ISSUES RISK ASSESSME; BARRETT JC, 1992, PROG CLIN BIOL RES, V376, P1; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOYLE JO, 1993, CANCER RES, V53, P4477; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS MK, 1993, CANCER RES, V53, P5377; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1991, CANCER RES, V51, pS5023; HARRIS SS, 1993, NEW ENGL J MED, V329, P1315; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MILLER CW, 1992, CANCER RES, V52, P1695; NGUYEN T, 1992, BIOCHEMISTRY-US, V285, P1173; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P37; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SUZUKI H, 1993, CANCER RES, V53, P4477; TAKESHIMA Y, 1993, LANCET, V342, P520; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; 1993, RISK ENV IMPROVING R	41	482	499	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1980	1981		10.1126/science.8266092	http://dx.doi.org/10.1126/science.8266092			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266092				2022-12-28	WOS:A1993MN10800025
J	BILJAN, MM; HART, CA; SUNDERLAND, D; MANASSE, PR; KINGSLAND, CR				BILJAN, MM; HART, CA; SUNDERLAND, D; MANASSE, PR; KINGSLAND, CR			MULTICENTER RANDOMIZED DOUBLE BIND CROSSOVER TRIAL ON CONTAMINATION OF CONVENTIONAL TIES AND BOW TIES IN ROUTINE OBSTETRIC AND GYNECOLOGICAL PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess level of contamination of neckwear worn by gynecologists and obstetricians during routine working week. Design-Multicentre randomised double blind crossover trial. Participants wore the same conventional ties for three days in one week and bow ties for the same period in second week. Setting-Two teaching and three district general hospitals in the midlands, Wales, and north England. Subjects-15 registrars and senior registrars. Interventions-A swab soaked in sterile saline was taken from specific area on ties at end of first and third working days and sent in transport medium for culture on chocolatised blood and Macconkey agar for 48 hours. Main outcome measures-Level of bacteriological growth assessed semiquantitatively (0 for no contamination; +++ for heavy contamination) after swabs had been cultured. At end of study the participants completed a questionnaire to assess their attitude toward wearing different types of necktie. Results-12 doctors (80%) completed the study. Although bow ties were significantly less contaminated at end of first working day (z= -2.354, p=0.019), this difference was not maintained; there was no difference in level of contamination on third day. Level of contamination did not increase between first and third day of wearing the same garment. One of the 10 doctors who returned the questionnaire found the bow tie very uncomfortable. All participants would consider wearing a bow tie if it proved to be less contaminated than a conventional tie. Conclusions-Although a significant difference in contamination was established between conventional and bow ties on first day of study, this difference was not confirmed on third day and there is unlikely to be any real association between tie type and bacterial contamination. Because of its negative image and difficulty to tie, the bow tie will probably remain a minority fashion.	UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT MED MICROBIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool								AMINES H, 1990, TIE, P6; BETTMAN OL, 1979, PICTORIAL HIST MED; BYRDE P, 1979, MALE IMAGE NECKTIE, P111; De Marly Diana, 1986, WORKING DRESS HIST O; GODLEE R, 1927, LISTER HIS WORK, P100; MARGOTTA R, 1967, ILLUSTRATED HIST MED, P229; MOLLOY JT, 1976, DRESS SUCCESS, P76; SAKULA A, 1988, PORTRAITS PAINTING S, P150; TOOLEY S, 1904, LIFE FLORENCE NIGHTI, P119; 1990, TAILOR CUTTER   0318, P3	10	15	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1582	1584		10.1136/bmj.307.6919.1582	http://dx.doi.org/10.1136/bmj.307.6919.1582			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292945	Green Published, Bronze			2022-12-28	WOS:A1993MN10700008
J	NAYLOR, JR; MULLEY, GP				NAYLOR, JR; MULLEY, GP			COMMODES - INCONVENIENT CONVENIENCES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate use of commodes and attitudes of users and carers to them. Design-Interview with semi-structured questionnaire of subjects supplied with commodes from Leeds community appliance centre. Subjects-140 users of a commode and 105 of their carers. Results-Main reasons for being supplied with a commode were impaired mobility (130 subjects), difficulty in climbing stairs (128), and urinary incontinence (127). Main concerns of users and carers were lack of privacy (120 subjects felt embarrassed about using their commode, and 96 would not use it if someone was present); unpleasant smells (especially for 20 subjects who were confined to one room); physical appearance of commode chair (101 users said it had an unfavourable appearance, and 44 had tried to disguise it); and lack of follow up after commode was supplied (only 15 users and carers knew who to contact if there were problems). Users generally either had very positive or very negative attitudes to their commodes but most carers viewed them very negatively, especially with regard to cleaning them. Conclusions-Health professionals should be aware of people's need for privacy when advising them where to keep their commode. A standard commode is inappropriate for people confined to one room, and alternatives such as a chemical toilet should be considered. Regular follow up is needed to identify any problems such as uncomfortable or unsafe chairs. More thought should be given to the appearance of commodes in their design.	ST JAMES UNIV HOSP TRUST,DEPT MED ELDERLY,LEEDS LS9 7TF,ENGLAND	Saint James's University Hospital								Clarke M, 1984, Health Trends, V16, P3; GEORGE J, 1988, BRIT MED J, V296, P1365, DOI 10.1136/bmj.296.6633.1365; GLOAG D, 1985, BRIT MED J, V290, P220, DOI 10.1136/bmj.290.6463.220; PENN ND, 1988, BRIT MED J, V296, P918, DOI 10.1136/bmj.296.6626.918; 1992, STANDARDISED ASSESSM	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1258	1260		10.1136/bmj.307.6914.1258	http://dx.doi.org/10.1136/bmj.307.6914.1258			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281060	Green Published, Bronze			2022-12-28	WOS:A1993MH00100025
J	LOMBARDI, G; GALLAGHER, EJ; GENNIS, P				LOMBARDI, G; GALLAGHER, EJ; GENNIS, P			OUTCOME OF OUT-OF-HOSPITAL CARDIAC-ARREST IN NEW-YORK-CITY THE PREHOSPITAL ARREST SURVIVAL EVALUATION (PHASE) STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL TECHNICIANS; AUTOMATIC EXTERNAL DEFIBRILLATOR; VENTRICULAR-FIBRILLATION; CARDIOPULMONARY RESUSCITATION; PREHOSPITAL DEFIBRILLATION; IMPROVING SURVIVAL; PARAMEDIC PROGRAMS; METROPOLITAN-AREA; BYSTANDER CPR; LIFE-SUPPORT	Objective.-To determine survival from out-of-hospital cardiac arrest in New York City and to compare this with other urban, suburban, and rural areas. Design-Observational cohort study. Setting.-New York City. Participants.-Consecutive out-of-hospital cardiac arrests occurring between October 1, 1990, and April 1, 1991. Intervention.-Trained paramedics performed immediate postarrest interviews with care providers, using a standardized questionnaire. Main Outcome Measures.-Entry criteria, elapsed time intervals, and nodal events conformed to Utstein recommendations. The single target end point was death or discharge home. Results.-Of 3243 consecutive cardiac arrests on which resuscitation was attempted, 2329 (72%) met entry criteria as primary cardiac events. Overall survival was 1.4% (99% confidence interval [CI], 0.9% to 2.3%). No patients were lost to follow-up. Survival from witnessed Ventricular fibrillation was 5.3% (99% CI, 2.9% to 8.8%). Using survival from witnessed ventricular fibrillation for intersystem comparison, our survival rate was similar to that of Chicago, Ill (4.0%; 99% CI, 1.9% to 7.5%; P=.41), the only other large city on which data were available. However, it was significantly tower than that reported from midsized urban/suburban areas (33.0%; 99% CI, 30.4% to 35.6%; P<.0001) and suburban/rural areas (12.6%; 99% CI, 8.9% to 16.3%, P<.0001). Survival rate among arrests occurring after arrival of emergency medical services personnel (8.5%; 99% CI, 4.7% to 14.0%) was comparable with Chicago (6.6%; 99% CI, 3.3% to 11.5%; P=.41) but markedly lower than King County, Washington (36%; 99% CI, 28.6% to 43.8%; P<.0001). Conclusions.-Survival from out-of-hospital cardiac arrest in New York City was poor. This was partly attributable to lengthy elapsed time intervals at every step in the chain of survival. However, examination of survival among arrests occurring after emergency medical services arrival suggests that other features may predispose residents of large cities to higher cardiac arrest mortality than individuals living in more suburban or rural settings. Since half the US population resides in large metropolitan areas, this represents a public health problem of considerable magnitude.	ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY USA; ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL, BRONX, NY USA; ALBERT EINSTEIN COLL MED, DEPT SOCIAL MED, BRONX, NY USA; YALE UNIV, SCH MED, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, NEW HAVEN, CT USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University								Amey B D, 1976, JACEP, V5, P429, DOI 10.1016/S0361-1124(76)80251-1; [Anonymous], 1986, Am J Emerg Med, V4, P72; ATKINS J, 1989, PREHOSP DISASTER MED, V1, P69; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BAINTON CR, 1963, NEW ENGL J MED, V268, P569, DOI 10.1056/NEJM196303142681102; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKERLB, 1993, ANN EMERG MED, V22, P86; BENNETT AE, 1975, QUESTIONNAIRES MED, P7; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; BOSSAERT L, 1989, RESUSCITATION, V17, pS99, DOI 10.1016/0300-9572(89)90094-4; BRISON RJ, 1992, CAN MED ASSOC J, V147, P191; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CARPENTER A, 1992, FACTS CITIES; COWIE MR, 1993, AM J PUBLIC HEALTH, V83, P955, DOI 10.2105/AJPH.83.7.955; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DUGGER CW, 1993, NY TIMES        1116, pA1; DUGGER CW, 1993, NY TIMES        1116, pB4; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P39, DOI 10.2105/AJPH.69.1.39; EISENBERG MS, 1988, AM J EMERG MED, V6, P319, DOI 10.1016/0735-6757(88)90146-5; EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; EISENBERG MS, 1986, AM J EMERG MED, V4, P116, DOI 10.1016/0735-6757(86)90154-3; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P46; GOLDSTEIN S, 1981, CIRCULATION, V64, P977, DOI 10.1161/01.CIR.64.5.977; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GUDJONSSON H, 1982, ACTA MED SCAND, V212, P247; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; HECKER MM, 1985, REPORT SECRETARYS TA, V1; HUNT RC, 1989, AM J EMERG MED, V7, P68, DOI 10.1016/0735-6757(89)90089-2; JAKOBSSON J, 1989, J INTERN MED, V225, P297, DOI 10.1111/j.1365-2796.1989.tb00085.x; JENNETT B, 1975, LANCET, V1, P480; KELSEY JL, 1986, METHODS OBSERVATIONA, P96; KULLER L, 1969, AM J CARDIOL, V24, P617, DOI 10.1016/0002-9149(69)90450-0; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LEWIS LM, 1990, AM J EMERG MED, V8, P118, DOI 10.1016/0735-6757(90)90196-7; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LONGSTRETH WT, 1993, ANN EMERG MED, V22, P64, DOI 10.1016/S0196-0644(05)80252-5; LUND I, 1976, LANCET, V2, P702; MCNEILLY RH, 1968, BMJ-BRIT MED J, V3, P139, DOI 10.1136/bmj.3.5611.139; MCSWAIN GR, 1980, ANN EMERG MED, V9, P341, DOI 10.1016/S0196-0644(80)80108-9; MOSESSO VN, 1993, ANN EMERG MED, V22, P1311, DOI 10.1016/S0196-0644(05)80114-3; MULLIE A, 1989, RESUSCITATION, V17, pS23, DOI 10.1016/0300-9572(89)90088-9; NEWMAN MM, 1987, J EMERG MED SERV, V12, P40; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PIONKOWSKI RS, 1983, ANN EMERG MED, V12, P733, DOI 10.1016/S0196-0644(83)80245-5; PRESSLEY JC, 1984, AM J EMERG MED, V2, P215, DOI 10.1016/0735-6757(84)90006-8; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SAMMEL NL, 1981, MED J AUSTRALIA, V2, P546, DOI 10.5694/j.1326-5377.1981.tb112982.x; SILFVAST T, 1990, AM J EMERG MED, V8, P359, DOI 10.1016/0735-6757(90)90097-J; SPAITE DW, 1990, ANN EMERG MED, V19, P1264, DOI 10.1016/S0196-0644(05)82285-1; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; TWEED WA, 1980, CAN MED ASSOC J, V122, P297; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; VALENZUELA TD, 1993, ANN EMERG MED, V22, P1678, DOI 10.1016/S0196-0644(05)81305-8; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WHITE RD, 1993, ANN EMERG MED, V22, P901; WHITEHEAD M, 1988, INEQUALITIES HLTH; WILSON BH, 1984, AM J CARDIOL, V53, P68, DOI 10.1016/0002-9149(84)90685-4; 1990, 1990 CENSUS POPULATI; 1992, JAMA-J AM MED ASSOC, V268, P2172	78	327	335	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					678	683						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309030				2022-12-28	WOS:A1994MX57000028
J	SCHWARTZ, RS				SCHWARTZ, RS			MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	2	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					472	472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289854				2022-12-28	WOS:A1994MW48000006
J	BAINES, CJ				BAINES, CJ			THE CANADIAN NATIONAL BREAST SCREENING STUDY - A PERSPECTIVE ON CRITICISMS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER-DETECTION; DEATH RATES; MAMMOGRAPHY; WOMEN; TRIAL; MORTALITY; QUALITY; PROGRAM	Recently published 7-year results from the Canadian National Breast Screening Study (NBSS) generated much controversy and criticism. In women aged 40 to 49 years at entry, no reduction in breast cancer mortality was observed when screened women were compared with virtually unscreened women. In women aged 50 to 59 years, breast cancer mortality was similar when annual screening with mammography and physical examination was compared with annual screening with physical examination alone. Although NBSS results in 40- to 49-year-old women are similar to those from previously published screening studies, critics have attacked the study's design, randomization, execution, mammography, follow-up procedures, contamination of controls, and analysis. The absence of benefit observed in mammographically screened women who were 50 to 59 years old has been used to support criticism of mammography. Important facts have been ignored. The NBSS controls, aged 50 to 59 years, unlike in other studies, received thorough annual physical examinations. Cancer detection rates in both age groups were higher in the mammography than the comparison groups. Screen and interval cancer detection rates, sensitivity and specificity estimates, and prevalence to incidence ratios at first screen met or exceeded standards established by other screening studies. Claims that randomization was flawed, in particular, that more symptomatic women were assigned to mammography, are not supported by the distribution of descriptive variables collected before randomization was done. As for the ''contamination'' of 26% of controls aged 40 to 49 years, who reported receiving mammography, it is improbable that single or occasional diagnostic mammograms in one quarter of the control group could obliterate the benefit of four or five annual mammograms in almost 100% of the mammography group. Much remains unknown about the efficacy of breast screening.	UNIV TORONTO, NATL BREAST SCREENING STUDY, CENT OFF, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto								ALLISON M, 1992, SCIENCE, V256, P1128, DOI 10.1126/science.256.5060.1128; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1990, CANCER, V66, P570, DOI 10.1002/1097-0142(19900801)66:3<570::AID-CNCR2820660327>3.0.CO;2-L; BAINES CJ, 1990, AM J ROENTGENOL, V155, P743, DOI 10.2214/ajr.155.4.2119103; BAINES CJ, 1990, INVEST RADIOL, V25, P971, DOI 10.1097/00004424-199009000-00002; BAINES CJ, 1992, CAN MED ASSOC J, V146, P2147; BAINES CJ, 1990, CANCER, V65, P1663, DOI 10.1002/1097-0142(19900401)65:7<1663::AID-CNCR2820650735>3.0.CO;2-A; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAINES CJ, 1984, CONTROL CLIN TRIALS, V5, P129, DOI 10.1016/0197-2456(84)90119-3; BAINES CJ, 1986, J CAN ASSOC RADIOL, V37, P256; BAINES CJ, 1989, CANCER, V63, P1816; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; HOLOWATY PH, 1993, CANCER EPIDEM BIOMAR, V2, P11; KOPANS DB, 1990, AM J ROENTGENOL, V155, P748, DOI 10.2214/ajr.155.4.ajronline_155_4_001; KOPANS DB, 1992, J NATL CANCER I, V84, P745, DOI 10.1093/jnci/84.10.745; KOPANS DB, 1993, LANCET, V341, P957, DOI 10.1016/0140-6736(93)91246-I; KOPANS DB, 1993, AM J ROENTGENOL, V161, P755, DOI 10.2214/ajr.161.4.8372752; MERZ B, 1992, J NATL CANCER I, V84, P832; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1981, CLIN INVEST MED, V4, P227; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1991, CAN J PUBLIC HEALTH, V82, P162; MILLER AB, 1990, AM J ROENTGENOL, V155, P1133, DOI 10.2214/ajr.155.5.2120947; MOSKOWITZ M, 1992, RADIOL CLIN N AM, V30, P221; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; RASULI P, 1993, CAN MED ASSOC J, V149, P136; ROSENTHAL E, 1992, NY TIMES        0513, pB7; SHAPIRO S, 1977, CANCER, V39, P2772, DOI 10.1002/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K; STACEYCLEAR A, 1992, LANCET, V340, P991; SUNDT TM, 1987, NEW ENGL J MED, V316, P814, DOI 10.1056/NEJM198703263161318; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; WARREN L, 1993, CAN MED ASSOC J, V148, P877; YAFFE MJ, 1983, P SOC PHOTO-OPT INST, V419, P23, DOI 10.1117/12.936000; 1992, GLOBE MAIL      1119, V19, pA6; 1992, SCIENCE, V258, P739	39	58	58	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					326	334		10.7326/0003-4819-120-4-199402150-00011	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291826				2022-12-28	WOS:A1994MW10300011
J	COOK, DJ; FULLER, HD; GUYATT, GH; MARSHALL, JC; LEASA, D; HALL, R; WINTON, TL; RUTLEDGE, F; TODD, TJR; ROY, P; LACROIX, J; GRIFFITH, L; WILLAN, A; NOSEWORTHY, T; POWLES, P; OPPENHEIMER, L; HEWSON, J; LANG, J; LEE, H; GUSLITS, B; HEULE, M				COOK, DJ; FULLER, HD; GUYATT, GH; MARSHALL, JC; LEASA, D; HALL, R; WINTON, TL; RUTLEDGE, F; TODD, TJR; ROY, P; LACROIX, J; GRIFFITH, L; WILLAN, A; NOSEWORTHY, T; POWLES, P; OPPENHEIMER, L; HEWSON, J; LANG, J; LEE, H; GUSLITS, B; HEULE, M			RISK-FACTORS FOR GASTROINTESTINAL-BLEEDING IN CRITICALLY ILL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNIT; STRESS-ULCER PROPHYLAXIS; RANDOMIZED TRIAL; ANTACID PROPHYLAXIS; INTUBATED PATIENTS; CIMETIDINE; PREVENTION; SUCRALFATE; COMPLICATIONS; VENTILATION	Background. The efficacy of prophylaxis against stress ulcers in preventing gastrointestinal bleeding in critically ill patients has led to its widespread use. The side effects and cost of prophylaxis, however, necessitate targeting preventive therapy to those patients most likely to benefit. Methods. We conducted a prospective multicenter cohort study in which we evaluated potential risk factors for stress ulceration in patients admitted to intensive care units and documented the occurrence of clinically important gastrointestinal bleeding (defined as overt bleeding in association with hemodynamic compromise or the need for blood transfusion). Results. Of 2252 patients, 33 (1.5 percent; 95 percent confidence interval, 1.0 to 2.1 percent) had clinically important bleeding. Two strong independent risk factors for bleeding were identified: respiratory failure (odds ratio, 15.6) and coagulopathy (odds ratio, 4.3). Of 847 patients who had one or both of these risk f actors, 31 (3.7 percent; 95 percent confidence interval, 2.5 to 5.2 percent) had clinically important bleeding. Of 1405 patients without these risk factors, 2 (0.1 percent; 95 percent confidence interval, 0.02 to 0.5 percent) had clinically important bleeding. The mortality rate was 48.5 percent in the group with bleeding and 9.1 percent in the group without bleeding (P<0.001). Conclusions. Few critically ill patients have clinically important gastrointestinal bleeding, and therefore prophylaxis against stress ulcers can be safely withheld from critically ill patients unless they have coagulopathy or require mechanical ventilation.	MCMASTER UNIV,FAC HLTH SCI,HAMILTON L8S 4L8,ONTARIO,CANADA; TORONTO GEN HOSP,TORONTO M5G 1L7,ONTARIO,CANADA; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV WESTERN ONTARIO,UNIV HOSP,LONDON N6A 5A5,ONTARIO,CANADA; UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA; VICTORIA GEN HOSP,HALIFAX B3H 2Y9,NS,CANADA; HOP ST JUSTINE,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,MONTREAL H3C 3J7,QUEBEC,CANADA; DALHOUSIE UNIV,HALIFAX B3H 4H2,NS,CANADA	McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); Dalhousie University; University of Victoria; Universite de Montreal; Universite de Montreal; Dalhousie University	COOK, DJ (corresponding author), ST JOSEPHS HOSP,DEPT MED,DIV CRIT CARE,50 CHARLTON AVE E,HAMILTON L8N 4A6,ON,CANADA.							BASSO N, 1981, AM J SURG, V141, P339, DOI 10.1016/0002-9610(81)90191-4; BORRERO E, 1986, ARCH SURG-CHICAGO, V121, P810; BORRERO E, 1985, AM J MED, V79, P62, DOI 10.1016/0002-9343(85)90575-3; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; COOK DJ, 1991, AM J MED, V91, P670; Cook DJ, 1991, J INTENSIVE CARE MED, V6, P167; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FOGELMAN MJ, 1966, AM J SURG, V112, P651, DOI 10.1016/0002-9610(66)90098-5; FRIEDMAN CJ, 1982, CRIT CARE MED, V10, P316; GOODMAN AA, 1968, ANN SURG, V167, P180, DOI 10.1097/00000658-196802000-00004; GOTTLIEB JE, 1986, AM J GASTROENTEROL, V81, P227; GROLL A, 1986, GUT, V27, P135, DOI 10.1136/gut.27.2.135; HARRIS SK, 1977, CHEST, V72, P301, DOI 10.1378/chest.72.3.301; HASTINGS PR, 1978, NEW ENGL J MED, V298, P1041, DOI 10.1056/NEJM197805112981901; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; KHAN F, 1981, CHEST, V79, P409, DOI 10.1378/chest.79.4.409; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LACROIX J, 1992, CRIT CARE MED, V20, P35, DOI 10.1097/00003246-199201000-00013; LACROIX J, 1986, CLIN INVEST MED, V9, pA22; LAGGNER AN, 1988, ANAESTHESIST, V37, P704; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MCALHANY JC, 1976, J TRAUMA, V16, P645, DOI 10.1097/00005373-197608000-00009; NOSEWORTHY TW, 1987, CRIT CARE MED, V15, P817, DOI 10.1097/00003246-198709000-00003; PINILLA JC, 1985, CRIT CARE MED, V13, P646, DOI 10.1097/00003246-198508000-00007; POLESKI MH, 1986, AM J GASTROENTEROL, V81, P107; PRIEBE HJ, 1980, NEW ENGL J MED, V302, P426, DOI 10.1056/NEJM198002213020802; SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9; SHUMAN RB, 1987, ANN INTERN MED, V106, P562, DOI 10.7326/0003-4819-106-4-562; SKILLMAN JJ, 1969, AM J SURG, V117, P523, DOI 10.1016/0002-9610(69)90011-7; STOTHERT JC, 1980, ANN SURG, V192, P169, DOI 10.1097/00000658-198008000-00006; TRYBA M, 1985, AM J MED, V79, P55, DOI 10.1016/0002-9343(85)90574-1; TRYBA M, 1983, HEPATO-GASTROENTEROL, V30, P154; VANDENBERG B, 1985, DIGESTION, V31, P1, DOI 10.1159/000199170; WEIGELT JA, 1981, ARCH SURG-CHICAGO, V116, P597; ZINNER MJ, 1981, SURG GYNECOL OBSTET, V153, P214	35	668	732	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					377	381		10.1056/NEJM199402103300601	http://dx.doi.org/10.1056/NEJM199402103300601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284001				2022-12-28	WOS:A1994MV27900001
J	PERMERT, J; LARSSON, J; WESTERMARK, GT; HERRINGTON, MK; CHRISTMANSON, L; POUR, PM; WESTERMARK, P; ADRIAN, TE				PERMERT, J; LARSSON, J; WESTERMARK, GT; HERRINGTON, MK; CHRISTMANSON, L; POUR, PM; WESTERMARK, P; ADRIAN, TE			ISLET AMYLOID POLYPEPTIDE IN PATIENTS WITH PANCREATIC-CANCER AND DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN RESISTANCE; AMYLIN; GLUCOSE; CELLS; IMMUNOREACTIVITY; EXPRESSION; PEPTIDE; INVITRO; INVIVO; LIVER	Background. The diabetes mellitus that occurs in patients with pancreatic cancer is characterized by marked insulin resistance that declines after tumor resection. Islet amyloid polypeptide (IAPP), a hormonal factor secreted from the pancreatic beta cells, reduces insulin sensitivity in vivo and glycogen synthesis in vitro. In this study, we examined the relation between IAPP and diabetes in patients with pancreatic cancer. Methods. We measured IAPP in plasma from 30 patients with pancreatic cancer, 46 patients with other cancers, 23 patients with diabetes, and 25 normal subjects. IAPP immunoreactivity and IAPP messenger RNA were studied in pancreatic cancers, pancreatic tissue adjacent to cancers, and normal pancreatic tissue. Results. Plasma IAPP concentrations were elevated in the patients with pancreatic cancer as compared with the normal subjects (mean [+/-SD], 22.3+/-13.6 vs. 8.0+/-5.0 pmol per liter; P<0.001), normal in the patients with other cancers, and normal or low in the patients with diabetes. Among the patients with pancreatic cancer, the concentrations were 25.0+/-8.7 pmol per liter in the 7 patients with diabetes who required insulin, 31.4+/-12.6 pmol per liter in the 11 patients with diabetes who did not require insulin, and 12.2+/-2.4 pmol per liter in the 9 patients with normal glucose tolerance (3 patients had impaired glucose tolerance; their mean plasma IAPP concentration was 11.7+/-5.5 pmol per liter). Plasma IAPP concentrations decreased after surgery in the seven patients with pancreatic cancer who were studied before and after subtotal pancreatectomy (28.9+/-16.4 vs. 5.6+/-3.4 pmol per liter, P = 0.01). Pancreatic cancers contained IAPP, but the concentrations were lower than in normal pancreatic tissue (17+/-16 vs. 183+/-129 pmol per gram, P<0.001). In samples from the patients with both pancreatic cancer and diabetes, immunostaining for IAPP was reduced in islets of pancreatic tissue surrounding the tumor; in situ hybridization studies suggested that transcription occurred normally in these islets. Conclusions. Plasma IAPP concentrations are elevated in patients with pancreatic cancer who have diabetes. Since IAPP may cause insulin resistance, its overproduction may contribute to the diabetes that occurs in these patients.	CREIGHTON UNIV, SCH MED, DEPT BIOMED SCI, 2500 CALIF ST, OMAHA, NE 68178 USA; UNIV LINKOPING, DEPT SURG, LINKOPING, SWEDEN; UNIV LINKOPING, DEPT PATHOL, LINKOPING, SWEDEN; UNIV UPPSALA, DEPT PATHOL, S-75105 UPPSALA, SWEDEN; UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68105 USA	Creighton University; Linkoping University; Linkoping University; Uppsala University; University of Nebraska System; University of Nebraska Medical Center			Adrian, Thomas E/D-8484-2012	Adrian, Thomas/0000-0002-5051-1111	NATIONAL CANCER INSTITUTE [R01CA044799] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; ARNELO U, 1993, GASTROENTEROLOGY, V104, pA294; BERKOWITZ D, 1962, AM J MED SCI, V243, P228; BOYLE P, 1989, INT J PANCREATOL, V5, P327, DOI 10.1007/BF02924298; BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; BRETHERTONWATT D, 1992, J CLIN ENDOCR METAB, V74, P1032, DOI 10.1210/jc.74.5.1032; BRETHERTONWATT D, 1990, DIABETOLOGIA, V33, P115, DOI 10.1007/BF00401050; BUTLER PC, 1990, DIABETES, V39, P752, DOI 10.2337/diabetes.39.6.752; CHANCE WT, 1991, BRAIN RES, V539, P352, DOI 10.1016/0006-8993(91)91644-G; CIARALDI TP, 1992, DIABETES, V41, P975, DOI 10.2337/diabetes.41.8.975; GREEN RC, 1958, DIABETES, V7, P308, DOI 10.2337/diab.7.4.308; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; JOHNSON KH, 1989, AM J PATHOL, V135, P245; KOOPMANS SJ, 1991, DIABETOLOGIA, V34, P218, DOI 10.1007/BF00405079; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; OBRIEN TD, 1991, DIABETES, V40, P1701, DOI 10.2337/diabetes.40.12.1701; PERMERT J, 1993, AM J SURG, V165, P61, DOI 10.1016/S0002-9610(05)80405-2; PERMERT J, 1993, BRIT J SURG, V80, P1047, DOI 10.1002/bjs.1800800841; PERMERT J, 1993, EUR J SURG, V159, P101; PERMERT J, 1992, INT J PANCREATOL, V11, P23; SANKE T, 1991, DIABETOLOGIA, V34, P129, DOI 10.1007/BF00500385; SCHWARTZ SS, 1978, AM J DIG DIS, V23, P1107, DOI 10.1007/BF01072886; SHERIFF S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P219, DOI 10.1016/0167-4889(92)90260-I; SOWA R, 1990, DIABETOLOGIA, V33, P118, DOI 10.1007/BF00401051; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TURNER RC, 1982, RECENT ADV ENDOCRINO, V2, P73; WESTERMARK GT, 1993, DIABETOLOGIA, V36, P323, DOI 10.1007/BF00400235; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1987, DIABETOLOGIA, V30, P887	30	181	193	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					313	318		10.1056/NEJM199402033300503	http://dx.doi.org/10.1056/NEJM199402033300503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277951	Bronze			2022-12-28	WOS:A1994MU48900003
J	LEE, M; CRYER, B; FELDMAN, M				LEE, M; CRYER, B; FELDMAN, M			DOSE EFFECTS OF ASPIRIN ON GASTRIC PROSTAGLANDINS AND STOMACH MUCOSAL INJURY	ANNALS OF INTERNAL MEDICINE			English	Article							CYCLOOXYGENASE; INDOMETHACIN; THROMBOXANE; INHIBITION; SMOKING; HUMANS; DAMAGE	Objective: To determine if a dose of aspirin exists that might inhibit thromboxane dependent platelet function without causing gastric mucosal injury. we studied the effects of a wide range of doses of aspirin (3 mg/d to 2600 mg/d) on gastric juice prostaglandins (PGE2 and PGF2alpha), on serum thromboxane B2, and on stomach mucosal injury as reflected by gastric juice hemoglobin and DNA concentrations. Design: A randomized, placebo-controlled study. Setting: Research laboratory at a Veterans Affairs medical center. Participants: 16 healthy volunteers (5 men and 11 women). Intervention: In the first part of the study, volunteers received placebo; aspirin, 324 mg/d; 1300 mg/d; or 2600 mg/d for 2 days. In the second part, volunteers received placebo; aspirin, 3 mg/d; 10 mg/d; 30 mg/d; or 81 mg/d for 8 days. Measurements: Gastric juice PGE2 and PGF2alpha, hemoglobin and DNA concentrations; gastric juice volume and acidity; and serum salicylate and thromboxane B2 concentrations. Results: In the first part, significant and similar (approximately 50%) inhibition of gastric juice prostaglandin output was observed with daily aspirin doses of 324 to 2600 mg. However, a significant increase in gastric juice hemoglobin output occurred only with 2600 mg/d. In the second part, significant inhibition (approximately 50%) of gastric PGE2 output was noted at a daily aspirin dose of 30 mg. Lower aspirin doses did not reduce PGE2 output significantly, although these doses did significantly reduce serum thromboxane B2 in a dose-related manner. Conclusions: Aspirin can significantly reduce serum thromboxane B2 at doses of 3 mg/d or 10 mg/d, which are significantly below the threshold dose for significant gastric prostaglandin inhibition and acute stomach mucosal injury.	VET AFFAIRS MED CTR, MED SERV 111, 4500 S LANCASTER RD, DALLAS, TX 75216 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV GASTROENTEROL, SAN ANTONIO, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016816] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK16816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHILD C, 1976, GUT, V17, P54, DOI 10.1136/gut.17.1.54; COHEN MM, 1982, PROSTA LEUKOTR MED, V9, P241, DOI 10.1016/0262-1746(82)90013-0; CRYER B, 1990, GASTROENTEROLOGY, V99, P1616, DOI 10.1016/0016-5085(90)90465-D; CRYER B, 1992, ANN INTERN MED, V116, P636, DOI 10.7326/0003-4819-116-8-636; FELDMAN M, 1992, GASTROENTEROLOGY, V102, P175, DOI 10.1016/0016-5085(92)91798-9; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; GODFREY K, 1986, MED USES STATISTICS, P205; GOLDIN E, 1988, ALIMENT PHARM THERAP, V2, P369; HAWKEY CJ, 1986, AM J MED, V81, P50, DOI 10.1016/S0002-9343(86)80011-0; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KALLMAN R, 1987, THROMB RES, V45, P355, DOI 10.1016/0049-3848(87)90224-6; KAUFFMAN G, 1989, GASTROENTEROLOGY, V96, P606, DOI 10.1016/S0016-5085(89)80056-3; KURATA JH, 1990, J CLIN GASTROENTEROL, V12, P260, DOI 10.1097/00004836-199006000-00005; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIVONEN M, 1992, SCAND J GASTROENTERO, V27, P912; MOORE EW, 1965, GASTROENTEROLOGY, V49, P178; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PESKAR BM, 1980, PROSTAGLANDINS, V20, P419, DOI 10.1016/S0090-6980(80)80059-1; QUIMBY GF, 1986, ANN INTERN MED, V104, P616, DOI 10.7326/0003-4819-104-5-616; REDFERN JS, 1987, GASTROENTEROLOGY, V92, P969, DOI 10.1016/0016-5085(87)90972-3; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WINKELMAN E, 1961, GASTROENTEROLOGY, V40, P56; WOODS KL, 1988, DIGEST DIS SCI, V33, P769, DOI 10.1007/BF01550961; [No title captured]	27	68	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					184	189		10.7326/0003-4819-120-3-199402010-00002	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273981				2022-12-28	WOS:A1994MU30300002
J	SPRENT, J				SPRENT, J			T-MEMORY AND B-MEMORY CELLS	CELL			English	Review							CELLULAR BASIS; IMMUNE-RESPONSES; ANTIGENIC-STIMULATION; IMMUNOLOGICAL MEMORY; ADHESION MOLECULES; GERMINAL-CENTERS; ENTEROTOXIN-B; LYMPHOCYTE; SUBSETS; EXPRESSION				SPRENT, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA025803, R37CA038355, R01CA038355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021487] Funding Source: NIH RePORTER; NCI NIH HHS [CA25803, CA38355] Funding Source: Medline; NIAID NIH HHS [AI21487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ada G L, 1970, Transplant Rev, V5, P105; Ahmed R, 1992, Semin Immunol, V4, P105; AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; Beverley P C, 1992, Semin Immunol, V4, P35; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1987, J IMMUNOL, V138, P3120; CAMP RL, 1991, J EXP MED, V173, P763, DOI 10.1084/jem.173.3.763; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; COHEN JJ, 1991, NATURE, V352, P199, DOI 10.1038/352199b0; COLLE JH, 1990, CRIT REV IMMUNOL, V10, P259; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; ERNST DN, 1993, J IMMUNOL, V151, P575; FELDBUSH TL, 1973, CELL IMMUNOL, V8, P435, DOI 10.1016/0008-8749(73)90134-2; FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381; FOWELL D, 1991, IMMUNOL REV, V123, P37, DOI 10.1111/j.1600-065X.1991.tb00605.x; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; Hall J G, 1980, Monogr Allergy, V16, P100; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HO F, 1986, EUR J IMMUNOL, V16, P1297, DOI 10.1002/eji.1830161018; HOU S, 1993, J IMMUNOL, V150, P5494; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KIRKBERG J, 1993, EUR J IMMUNOL, V23, P1963; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; KROEMER G, 1992, RES IMMUNOL, V143, P267, DOI 10.1016/S0923-2494(92)80116-3; LEANDERSON T, 1992, IMMUNOL REV, V126, P47, DOI 10.1111/j.1600-065X.1992.tb00630.x; LEE WT, 1991, CELL IMMUNOL, V132, P215, DOI 10.1016/0008-8749(91)90020-C; Linton P J, 1992, Semin Immunol, V4, P3; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LINTON PJ, 1991, J IMMUNOL, V146, P4099; MACDONALD HR, 1991, EUR J IMMUNOL, V21, P1963, DOI 10.1002/eji.1830210827; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MACLENNAN ICM, 1994, IN PRESS ANN REV IMM, V14; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MARRACK P, 1993, IMMUNOL REV, V133, P119, DOI 10.1111/j.1600-065X.1993.tb01513.x; MARSHALLCLARKE S, 1982, EUR J IMMUNOL, V12, P733, DOI 10.1002/eji.1830120907; MCGREGOR DD, 1963, J EXP MED, V117, P303, DOI 10.1084/jem.117.2.303; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MITCHISON NA, 1968, IMMUNOLOGY, V15, P509; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NOSSAL GJV, 1992, CELL, V68, P1, DOI 10.1016/0092-8674(92)90198-L; NOSSAL GJV, 1989, FUNDAMENTAL IMMUNOLO, P571; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POWRIE F, 1989, J EXP MED, V169, P653, DOI 10.1084/jem.169.3.653; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; RAYCHAUDHURI S, 1985, J EXP MED, V161, P816, DOI 10.1084/jem.161.4.816; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SIMONSEN M, 1962, PROG ALLERGY, V6, P349, DOI 10.1159/000313805; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOUT RD, 1992, CELL IMMUNOL, V141, P433, DOI 10.1016/0008-8749(92)90161-H; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; STROBER S, 1975, TRANSPLANT REV, V24, P84; Swain S L, 1992, Semin Immunol, V4, P59; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TABI Z, 1988, CELL IMMUNOL, V113, P268, DOI 10.1016/0008-8749(88)90026-3; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1993, IMMUNOL REV, V131, P169, DOI 10.1111/j.1600-065X.1993.tb01535.x; WEBB SR, 1994, IN PRESS J IMMUNOL; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; YIN XM, 1992, INT IMMUNOL, V4, P691, DOI 10.1093/intimm/4.6.691	89	270	274	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					315	322		10.1016/0092-8674(94)90338-7	http://dx.doi.org/10.1016/0092-8674(94)90338-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293465				2022-12-28	WOS:A1994MU67800014
J	ZOU, ZQ; ANISOWICZ, A; HENDRIX, MJC; THOR, A; NEVEU, M; SHENG, SJ; RAFIDI, K; SEFTOR, E; SAGER, R				ZOU, ZQ; ANISOWICZ, A; HENDRIX, MJC; THOR, A; NEVEU, M; SHENG, SJ; RAFIDI, K; SEFTOR, E; SAGER, R			MASPIN, A SERPIN WITH TUMOR-SUPPRESSING ACTIVITY IN HUMAN MAMMARY EPITHELIAL-CELLS	SCIENCE			English	Article							DOWN-REGULATION; MESSENGER-RNAS; METASTASIS; GENES; LINES	A gene encoding a protein related to the serpin family of protease inhibitors was identified as a candidate tumor suppressor gene that may play a role in human breast cancer. The gene product, called maspin, is expressed in normal mammary epithelial cells but not in most mammary carcinoma cell lines. Transfection of MDA-MB-435 mammary carcinoma cells with the maspin gene did not alter the cells' growth properties in vitro, but reduced the cells' ability to induce tumors and metastasize in nude mice and to invade through a basement membrane matrix in vitro. Analysis of human breast cancer specimens revealed that loss of maspin expression occurred most frequently in advanced cancers. These results support the hypothesis that maspin functions as a tumor suppressor.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,44 BINNEY ST,BOSTON,MA 02115; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85724; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Arizona; Harvard University; Massachusetts General Hospital					NCI NIH HHS [P01 CA22427, CA39814, R01 CA59702] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022427, R01CA059702, R35CA039814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; HARLOW E, 1988, ANTIBODIES LABORATOR, pCH8; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HENDRIX MJC, UNPUB; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIANG P, 1992, CANCER RES, V52, P6966; LIOTTA LA, 1991, CANCER RES, V51, pS5054; PRICE JE, 1990, CANCER RES, V50, P717; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SHENG S, UNPUB; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; ZOU Z, UNPUB	21	810	897	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					526	529		10.1126/science.8290962	http://dx.doi.org/10.1126/science.8290962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290962				2022-12-28	WOS:A1994MT96600035
J	PERSHAGEN, G; AKERBLOM, G; AXELSON, O; CLAVENSJO, B; DAMBER, L; DESAI, G; ENFLO, A; LAGARDE, F; MELLANDER, H; SVARTENGREN, M; SWEDJEMARK, GA				PERSHAGEN, G; AKERBLOM, G; AXELSON, O; CLAVENSJO, B; DAMBER, L; DESAI, G; ENFLO, A; LAGARDE, F; MELLANDER, H; SVARTENGREN, M; SWEDJEMARK, GA			RESIDENTIAL RADON EXPOSURE AND LUNG-CANCER IN SWEDEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDOOR RADON; RADIATION EXPOSURE; NORTHERN SWEDEN; SMOKING; INFORMATION; CIGARETTE; MORTALITY; CARCINOMA; MODELS; WOMEN	Background. Residential radon is the principal source of exposure to ionizing radiation in most countries. To determine the implications for the risk of lung cancer, we performed a nationwide case-control study in Sweden. Methods. The study included 586 women and 774 men 35 to 74 years of age with lung cancer that was diagnosed between 1980 and 1984. For comparison, 1380 female and 1467 male controls were studied. Radon was measured in 8992 dwellings occupied by the study subjects at some time since 1947. Information on smoking habits and other risk factors for lung cancer was obtained from questionnaires. Results. Radon levels followed a log-normal distribution, with geometric and arithmetic means of 1.6 and 2.9 pCi per liter (60.5 and 106.5 Bq per cubic meter), respectively. The risk of lung cancer increased in relation to both estimated cumulative and time-weighted exposure to radon. In comparison with time-weighted average radon concentrations up to 1.4 pCi per liter (50 Bq per cubic meter), the relative risk was 1.3 (95 percent confidence interval, 1.1 to 1.6) for average radon concentrations of 3.8 to 10.8 pCi per liter (140 to 400 Bq per cubic meter), and it was 1.8 (95 percent confidence interval, 1.1 to 2.9) at concentrations exceeding 10.8 pCi per liter. The estimates of risk were in the same range as those projected from data in miners. The interaction between radon exposure and smoking with regard to lung cancer exceeded additivity and was closer to a multiplicative effect. Conclusions. Residential exposure to radon is an important cause of lung cancer in the general population. The risks appear consistent with earlier estimates based on data in miners.	SWEDISH RADIAT PROTECT INST,STOCKHOLM,SWEDEN; BJERKING INGENJORSBYRA,UPPSALA,SWEDEN; UMEA UNIV HOSP,DEPT ONCOL,S-90185 UMEA,SWEDEN; LINKOPING UNIV HOSP,DEPT OCCUPAT & ENVIRONM MED,S-58185 LINKOPING,SWEDEN	Umea University; Linkoping University	PERSHAGEN, G (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DEPT EPIDEMIOL,BOX 210,S-17177 STOCKHOLM,SWEDEN.		Svartengren, Magnus/AAM-7777-2021; Desai, Girish Narayanrao/AAS-6073-2021	Svartengren, Magnus/0000-0002-8165-7236; Desai, Girish Narayanrao/0000-0001-7620-3785; Pershagen, Goran/0000-0002-9701-1130				Air quality guidelines for Europe, 1987, WHO REGIONAL PUBLICA, V23; [Anonymous], 1982, Am J Clin Pathol, V77, P123; ARCHER VE, 1974, CANCER, V34, P2056, DOI 10.1002/1097-0142(197412)34:6<2056::AID-CNCR2820340626>3.0.CO;2-Z; ARVELA H, 1988, RADIAT PROT DOSIM, V24, P231; AXELSON O, 1991, ANNU REV PUBL HEALTH, V12, P235, DOI 10.1146/annurev.pu.12.050191.001315; AXELSON O, 1988, SCAND J WORK ENV HEA, V14, P286, DOI 10.5271/sjweh.1918; BAVERSTAM U, 1991, RADIAT PROT DOSIM, V36, P107; BLOT WJ, 1990, J NATL CANCER I, V82, P1025, DOI 10.1093/jnci/82.12.1025; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; BURENHAGLUND A, 1990, SSI9005 STAT STRALSK; CARSTENSEN J, 1987, THESIS KAROLINSKA I; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; CEDERLOF R, 1975, RELATIONSHIP SMOKING; DAMBER L, 1982, ACTA RADIOL ONCOL, V21, P305, DOI 10.3109/02841868209134020; DAMBER L, 1986, THESIS U UMEA UMEA; DAMBER LA, 1987, BRIT J IND MED, V44, P446; FALK R, 1990, J RES NATL INST STAN, V95, P115, DOI 10.6028/jres.095.011; HUBBARD LM, IN PRESS INDOOR AIR; HUTCHINSON JMR, 1992, APPL RADIAT ISOTOPES, V43, P175, DOI 10.1016/0883-2889(92)90090-2; KUNZ E, 1979, HEALTH PHYS, V36, P699, DOI 10.1097/00004032-197906000-00006; LUBIN JH, 1988, YALE J BIOL MED, V61, P195; MAJBORN B, 1992, RADIAT PROT DOSIM, V45, P443; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MELLANDER H, 1992, RADIAT PROT DOSIM, V45, P65; MJONES L, 1986, SSI8622 SWED RAD PRO; MJONES L, 1984, A8423 STAT STRALSK I; PERSHAGEN G, 1985, AM J EPIDEMIOL, V122, P684, DOI 10.1093/oxfordjournals.aje.a114147; PERSHAGEN G, 1982, SCAND J WORK ENV HEA, V8, P24, DOI 10.5271/sjweh.2500; PERSHAGEN G, 1992, HEALTH PHYS, V63, P179, DOI 10.1097/00004032-199208000-00004; Pershagen G, 1990, IARC Sci Publ, P240; PRESTON DL, 1990, EPICURE RISK REGRESS; RUOSTEENOJA E, 1991, THESIS FINNISH CTR R; SAMET JM, 1989, J NATL CANCER I, V81, P745, DOI 10.1007/s00484-020-01860-w; SCHOENBERG JB, 1990, CANCER RES, V50, P6520; STRAND T, 1991, RADON NORSKE BOLIGER; SVENSSON C, 1988, THESIS KAROLINSKA I; Swedjemark G. A, 1993, INDOOR AIR, V4, P491; SWEDJEMARK GA, 1985, THESIS U STOCKHOLM S; THOMAS DC, 1981, BIOMETRICS, V37, P673, DOI 10.2307/2530149; TOLSTOY N, 1984, M8410 STAT I BYGGN F; WESTRELL C, 1984, LIVING HABITS SWEDEN; 1988, HLTH RISKS RADON OTH; 1991, COMP DOSIMETRY RADON; 1992, CITIZENS GUIDE RADON; 1988, VENTILATION KUNSKAPS; 1987, ANN ICRP, V17, P1	47	288	299	2	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					159	164		10.1056/NEJM199401203300302	http://dx.doi.org/10.1056/NEJM199401203300302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264737				2022-12-28	WOS:A1994MQ86300002
J	ANDERSSON, R; HUGANDER, A; THULIN, A; NYSTROM, PO; OLAISON, G				ANDERSSON, R; HUGANDER, A; THULIN, A; NYSTROM, PO; OLAISON, G			INDICATIONS FOR OPERATION IN SUSPECTED APPENDICITIS AND INCIDENCE OF PERFORATION	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; APPENDECTOMY; RATES; AGE; ULTRASONOGRAPHY; POPULATION	Objective-To clarify poorly understood epidemiological features of appendicitis. Design-Retrospective study of consecutive cases from a defined population and analysis of data from published studies. Setting-County of Jonkoping, Sweden. 3029 patients who underwent operation in 1984-9 and 4717 patients from the county town who underwent operation in 1970-89, all for suspected appendicitis, plus 48 426 cases from six reported studies. Main outcome measures-Incidences specific for age and sex and temporal trends of perforating and non-perforating appendicitis and removal of a normal appendix. Associations between diagnostic accuracy, rate of perforation, and incidences of removal of a normal appendix and of perforating and non-perforating appendicitis. Results-The incidence of appendicitis was 116/100000 inhabitants. Appendicitis was more common in male patients. The incidence of perforating appendicitis was independent of age, stable over time, and uninfluenced by the rate of laparotomy, whereas the incidence of non-perforating appendicitis was age dependent, decreasing over time, and related to the diagnostic accuracy and rate of removal of a normal appendix. Conclusions-Perforating and non-perforating appendicitis seem to be separate entities, and appendicitis that resolves spontaneously is common. This may have important implications for managing suspected appendicitis.	LINKOPING UNIV HOSP,DEPT SURG,S-58185 LINKOPING,SWEDEN	Linkoping University	ANDERSSON, R (corresponding author), RYHOV HOSP,DEPT SURG,S-55185 JONKOPING,SWEDEN.			Andersson, Roland/0000-0002-1460-0248				ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; AMLAND PF, 1989, ACTA CHIR SCAND, V155, P185; ANDERSSON RE, 1992, EUR J SURG, V158, P37; ARNBJORNSSON E, 1983, ACTA CHIR SCAND, V149, P789; ARNBJORNSSON E, 1982, ACTA CHIR SCAND, V148, P461; ATTWOOD SE, 1987, J EPIDEMIOL COMMUN H, V41, P72, DOI 10.1136/jech.41.1.72; BARKER DJP, 1981, BMJ, V238, P1083; BUTSCH DW, 1973, POSTGRAD MED, V54, P132, DOI 10.1080/00325481.1973.11713586; Condon R. E., 1986, TXB SURG, P967; Dean A. G., 1990, EPI INFO VERSION 5 W; FOSTER HM, 1989, BRIT J SURG, V76, P368, DOI 10.1002/bjs.1800760417; GRAHAM DF, 1977, BRIT MED J, V2, P1375, DOI 10.1136/bmj.2.6099.1375; HELLER MB, 1993, AM J EMERG MED, V11, P51, DOI 10.1016/0735-6757(93)90060-O; HOWIE JGR, 1964, LANCET, V1, P1240; Lichtner S, 1971, Med Care, V9, P311, DOI 10.1097/00005650-197107000-00003; LUCKMANN R, 1989, AM J EPIDEMIOL, V129, P905, DOI 10.1093/oxfordjournals.aje.a115224; NOER T, 1975, ACTA CHIR SCAND, V141, P431; OLSEN JB, 1993, BRIT J SURG, V80, P922, DOI 10.1002/bjs.1800800744; PELTOKALLIO P, 1981, ARCH SURG-CHICAGO, V116, P153; PIEPER R, 1982, ACTA CHIR SCAND, V148, P45; PIEPER R, 1982, ACTA CHIR SCAND, V148, P51; PIEPER R, 1983, ANN SURG, V197, P368, DOI 10.1097/00000658-198303000-00019; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RICCI MA, 1988, AM SURGEON, V54, P273; RUTKOW IM, 1981, SURGERY, V89, P151; THOMSON HJ, 1986, AM J SURG, V152, P522, DOI 10.1016/0002-9610(86)90220-5; VANDIEIJENVISSER MP, 1991, EUR J CLIN CHEM CLIN, V29, P749; WALDRON R, 1983, IRAN MED J, V6, P446; WEST RR, 1978, BRIT MED J, V1, P1662, DOI 10.1136/bmj.1.6128.1662; WILLIAMS GT, 1987, SYSTEMIC PATHOLOGY, V3, P292	30	181	182	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					107	110		10.1136/bmj.308.6921.107	http://dx.doi.org/10.1136/bmj.308.6921.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298378	Green Published			2022-12-28	WOS:A1994MR17300013
J	XU, MQ; SOUTHWORTH, MW; MERSHA, FB; HORNSTRA, LJ; PERLER, FB				XU, MQ; SOUTHWORTH, MW; MERSHA, FB; HORNSTRA, LJ; PERLER, FB			IN-VITRO PROTEIN SPLICING OF PURIFIED PRECURSOR AND THE IDENTIFICATION OF A BRANCHED INTERMEDIATE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; CATALYTIC SUBUNIT; GENE-PRODUCT; MEMBRANES; SEQUENCE; VMA1	Protein splicing is a posttranslational processing event in which an internal polypeptide is excised from a protein precursor and the terminal polypeptides are then ligated together, resulting in the production of two proteins. This report presents direct evidence for protein splicing by demonstrating in vitro splicing of purified precursor that accumulated when the protein splicing element from Pyrococcus DNA polymerase was cloned into a foreign gene. In vitro splicing was temperature and pH dependent. A slowly migrating species exhibited kinetic properties of a splicing intermediate and was shown to be a branched molecule by N-terminal sequencing. The precursor and slowly migrating species were interconvertible in response to pH shifts.			XU, MQ (corresponding author), NEW ENGLAND BIOLABS INC,32 TOZER RD,BEVERLY,MA 01915, USA.		Wood, David W/B-2992-2012					Ando, 1967, METHOD ENZYMOL, V11, P263; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; DOOLITTLE RF, 1993, P NATL ACAD SCI USA, V90, P5379, DOI 10.1073/pnas.90.12.5379; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GU HH, 1993, J BIOL CHEM, V268, P7372; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; STEEL C, 1990, J IMMUNOL, V145, P3917; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; WALLACE CJA, 1993, PROTEIN SCI, V2, P697, DOI 10.1002/pro.5560020501	22	192	226	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1371	1377		10.1016/0092-8674(93)90623-X	http://dx.doi.org/10.1016/0092-8674(93)90623-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269515				2022-12-28	WOS:A1993MP86900015
J	FARABAUGH, PJ; ZHAO, H; VIMALADITHAN, A				FARABAUGH, PJ; ZHAO, H; VIMALADITHAN, A			A NOVEL PROGRAMMED FRAMESHIFT EXPRESSES THE POL3 GENE OF RETROTRANSPOSON-TY3 OF YEAST - FRAMESHIFTING WITHOUT TRANSFER-RNA SLIPPAGE	CELL			English	Article							SYNONYMOUS CODONS DIFFER; ELONGATION-FACTOR-TU; RELEASE FACTOR-II; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BASE-PAIR; TY3; SUPPRESSION; TRANSLATION; RIBOSOMES	Most retroviruses and retrotransposons express their pol gene as a translational fusion to the upstream gag gene, often involving translational frameshifting. We describe here an unusual translational frameshift event occurring between the GAG3 and POL3 genes of the retrotransposon Ty3 of yeast. A + 1 frameshift occurs within the sequence GCG AGU U (shown as codons of GAG3), encoding alanine-valine (GCG A GUU). Unlike other programed translational frameshifts described, this event does not require tRNA slippage between cognate or near-cognate codons in the mRNA. Two features distal to the GCG codon stimulate frameshifting. The low availability of the tRNA specific for the ''hungry'' serine codon, AGU, induces a translational pause required for frameshifting. A sequence of 12 nt distal to the AGU codon (termed the Ty3 ''context'') also stimulates the event.			FARABAUGH, PJ (corresponding author), UNIV MARYLAND, DEPT BIOL SCI, CATONSVILLE, MD 21228 USA.			Farabaugh, Philip/0000-0002-5658-7141	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM029480, R01GM029480] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29480] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1991, ANNU REV GENET, V25, P201; AYER D, 1986, SCIENCE, V231, P393, DOI 10.1126/science.3510456; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BOSSI L, 1984, P NATL ACAD SCI-BIOL, V81, P6105, DOI 10.1073/pnas.81.19.6105; CHALKER DL, 1990, GENETICS, V126, P837; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1987, SCIENCE, V238, P1545, DOI 10.1126/science.3685992; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; DIX DB, 1989, P NATL ACAD SCI USA, V86, P6888, DOI 10.1073/pnas.86.18.6888; FARABAUGH P, 1989, MOL CELL BIOL, V9, P4824, DOI 10.1128/MCB.9.11.4824; FARABAUGH PJ, 1993, MOL CELL BIOL, V13, P2081, DOI 10.1128/MCB.13.4.2081; GALLANT J, 1980, RIBOSOMES STRUCTURE, P615; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HANSEN LJ, 1990, J VIROL, V64, P2599, DOI 10.1128/JVI.64.6.2599-2607.1990; HUGHES D, 1987, EMBO J, V6, P4235, DOI 10.1002/j.1460-2075.1987.tb02772.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKS T, 1990, CURR TOP MICROBIOL, V157, P93; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KIRCHNER J, 1992, J VIROL, V66, P6081, DOI 10.1128/JVI.66.10.6081-6092.1992; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; KURLAND CG, 1986, ACCURACY MOL PROCESS, P127; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; PETER K, 1992, NEW BIOL, V4, P520; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Rose MD., 1990, METHODS YEAST GENETI; SANDBAKEN MG, 1988, GENETICS, V120, P923; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; SPANJAARD RA, 1988, P NATL ACAD SCI USA, V85, P7967, DOI 10.1073/pnas.85.21.7967; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; THOMAS LK, 1988, P NATL ACAD SCI USA, V85, P4242, DOI 10.1073/pnas.85.12.4242; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; TUOHY TMF, 1992, J MOL BIOL, V228, P1042, DOI 10.1016/0022-2836(92)90313-9; TUOHY TMF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P274, DOI 10.1016/0167-4781(90)90180-A; VIJGENBOOM E, 1989, J BIOL CHEM, V264, P13012; WEISS R, 1983, NATURE, V302, P389, DOI 10.1038/302389a0; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1986, GENETICS, V112, P727; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WILLIAMS JM, 1989, EUR J BIOCHEM, V186, P515, DOI 10.1111/j.1432-1033.1989.tb15237.x	46	134	138	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					93	103		10.1016/0092-8674(93)90297-4	http://dx.doi.org/10.1016/0092-8674(93)90297-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8267715	Green Published, Bronze			2022-12-28	WOS:A1993LN62500010
J	MINTZ, PD				MINTZ, PD			PARTICIPATION OF HIV-INFECTED PATIENTS IN AUTOLOGOUS BLOOD PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOMEGALO-VIRUS; TRANSFUSION; PROGRESSION; ANTIBODY; DISEASE; DONORS; AIDS		UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	University of Virginia	MINTZ, PD (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BLOOD BANK & TRANSFUS SERV,BOX 286,CHARLOTTESVILLE,VA 22908, USA.							ANDERSON BV, 1988, TRANSFUSION, V28, P394, DOI 10.1046/j.1537-2995.1988.28488265277.x; BALFOUR HH, 1993, TRANSFUSION, V33, P101, DOI 10.1046/j.1537-2995.1993.33293158038.x; BUSCH MP, 1992, BLOOD, V80, P2128; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DZIK WH, 1989, TRANSFUSION, V29, P743, DOI 10.1046/j.1537-2995.1989.29890020447.x; GROSSMAN BJ, 1988, TRANSFUSION, V28, P283, DOI 10.1046/j.1537-2995.1988.28388219162.x; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; KENNEY S, 1988, P NATL ACAD SCI USA, V85, P1652, DOI 10.1073/pnas.85.5.1652; LANG DJ, 1989, J ACQ IMMUN DEF SYND, V2, P540; LEWIS WF, 1992, TRANSFUSION, V32, pS56; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; PARKMAN PD, 1989, GUIDANCE AUTOLOGOUS; PARKMAN PD, 1990, AUTOLOGOUS BLOOD COL; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; QUINNAN GV, 1991, FDA RECOMMENDATIONS; QUINNAN GV, 1991, DISPOSITION BLOOD PR; QUINNAN GV, 1990, TESTING ANTIBODY HEP; QUINNAN GV, 1991, CLARIFICATION FDA RE; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P328; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBSTER A, 1989, LANCET, V2, P63; ZOON KC, 1992, REVISED RECOMMENDATI	33	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2892	2894		10.1001/jama.269.22.2892	http://dx.doi.org/10.1001/jama.269.22.2892			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8292121				2022-12-28	WOS:A1993LE93600028
J	KLONOFF, EA; FRITZ, JM; LANDRINE, H; RIDDLE, RW; TULLYPAYNE, L				KLONOFF, EA; FRITZ, JM; LANDRINE, H; RIDDLE, RW; TULLYPAYNE, L			THE PROBLEM AND SOCIOCULTURAL CONTEXT OF SINGLE-CIGARETTE SALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SMOKING PREVENTION; FOLLOW-UP; MINORS; CHILDREN	Objective.-To provide data on the sale of single cigarettes to adults and miners and to examine the sociocultural context in which these sales occur. Design.-A naturalistic observation study using repeated measures. Two hundred six stores in a convenience sample were visited by one minor and one adult who each attempted to purchase a single cigarette. Main Outcome Measures.-Single-cigarette sales to an adult and/or minor. Data were obtained on type of store and, if a sale occurred, on the price, brand, and packaging of the cigarette. The ethnic composition of the neighborhood surrounding each store was determined. Results.-One hundred one (49.1%) of the stores sold single cigarettes. Singles were sold significantly more often to miners than to adults, and when both could make a purchase, miners paid more for these singles than did adults. Singles were least likely to be sold in white neighborhoods, more likely to be sold in integrated neighborhoods, and most likely to be sold in minority neighborhoods. Miners were able to purchase single cigarettes during 34.4% of the visits to white neighborhoods but could do so during 71.2% of the visits to minority neighborhoods; adults were able to make similar purchases during 24% of the visits to white neighborhoods and 37.3% of the visits to minority neighborhoods. Conclusions.-The illegal sale of single cigarettes involves complex sociocultural factors heretofore unexamined. An understanding of such factors may be useful in planning merchant education programs and drafting policy to control illegal sales.	UNIV CINCINNATI, SCH PLANNING, CINCINNATI, OH USA; PUBL HLTH FDN ENTERPRISES, CITY OF INDUSTRY, CA USA	University System of Ohio; University of Cincinnati	KLONOFF, EA (corresponding author), CALIF STATE COLL SAN BERNARDINO, INST BEHAV HLTH, 5500 UNIV PKWY, SAN BERNARDINO, CA 92407 USA.							ALTMAN DG, 1991, AM J PUBLIC HEALTH, V81, P891, DOI 10.2105/AJPH.81.7.891; ALTMAN DG, 1989, JAMA-J AM MED ASSOC, V261, P80, DOI 10.1001/jama.261.1.80; ARCHBALD C, 1993, PEDIATRICS, V91, P851; BIGLAN A, 1987, J BEHAV MED, V10, P613, DOI 10.1007/BF00846658; BIGLAN A, 1987, J BEHAV MED, V10, P159, DOI 10.1007/BF00846424; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; FLAY BR, 1989, AM J PUBLIC HEALTH, V79, P1371, DOI 10.2105/AJPH.79.10.1371; FLAY BR, 1985, HEALTH PSYCHOL, V4, P449, DOI 10.1037/0278-6133.4.5.449; FOSTER JL, 1992, PREV MED, V21, P320; HANSEN WB, 1988, PREV MED, V17, P135, DOI 10.1016/0091-7435(88)90059-X; JOHNSON P R L, 1986, Journal of Biochemical Toxicology, V1, P15, DOI 10.1002/jbt.2570010104; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3323; MURRAY DM, 1987, J BEHAV MED, V10, P595, DOI 10.1007/BF00846657; WARNER KE, 1986, JAMA-J AM MED ASSOC, V255, P1028, DOI 10.1001/jama.255.8.1028; 1991, DHHS CDC923316 US DE; 1989, DHHS CDC898411 US DE; 1990, TAX BURDEN TOBACCO H, P25; 1990, MMWR MORB MORTAL WKL, V39, P349	18	39	39	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					618	620		10.1001/jama.271.8.618	http://dx.doi.org/10.1001/jama.271.8.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301795				2022-12-28	WOS:A1994MW47700026
J	PIERCE, JP; LEE, L; GILPIN, EA				PIERCE, JP; LEE, L; GILPIN, EA			SMOKING INITIATION BY ADOLESCENT GIRLS, 1944 THROUGH 1988 - AN ASSOCIATION WITH TARGETED ADVERTISING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; UNITED-STATES; ANTISMOKING CAMPAIGN; TRENDS; CHILDREN; WOMEN; CAMEL	Objective.-To identify trends in smoking initiation among persons aged 10 to 20 years that might reflect the impact of specific targeting of tobacco advertising to women. Design.-Data from the National Health Interview Surveys on age of initiation of smoking (survey years 1970, 1978, 1979, 1980, 1987, and 1988) were used to construct age-specific rates of smoking initiation for males and females aged 10 to 20 years from 1944 through the middle 1980s. The raw rates were smoothed to allow trends to be more easily identified. Participants.-Information from 102 626 respondents was used. Results.-In 18- to 20-year-old women, initiation rates peaked in the early 1960s and steadily declined thereafter. In girls younger than 18 years, smoking initiation increased abruptly around 1967, when tobacco advertising aimed at selling specific brands to women was introduced. This increase was particularly marked in those females who never attended college (1.7-fold higher). Initiation rates for females younger than 18 years peaked around 1973, at about the same time sales of these brands peaked. After a steep postwar (1944 to 1949) decline, initiation rates in 18- to 20-year-old men did not decrease until the middle to late 1960s. Initiation rates for boys younger than 16 years showed little change during the entire study period. Conclusions.-The tobacco advertising campaigns targeting women, which were launched in 1967, were associated with a major increase in smoking uptake that was specific to females younger than the legal age for purchasing cigarettes.			PIERCE, JP (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,CANC PREVENT & CONTROL PROGRAM,LA JOLLA,CA 92093, USA.			Pierce, John/0000-0002-0075-7471				ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; CHAMBERS JM, 1992, STATISTICAL MODELS, P314; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; ERNSTER VL, 1985, NEW YORK STATE J MED, V85, P335; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; JONES KE, 1987, WOMENS BRANDS CIGARE; KENNET L, 1987, GI AM SOLDIER WORLD, P94; LARSEN RJ, 1986, INTRO MATH STATISTIC; LEVENTHAL H, 1980, PSYCHOL BULL, V88, P370, DOI 10.1037/0033-2909.88.2.370; MACASKILL P, 1992, AM J PUBLIC HEALTH, V82, P96, DOI 10.2105/AJPH.82.1.96; Pierce J.P, 1993, TOBACCO USE CALIFORN; PIERCE JP, 1991, J NATL CANCER I, V83, P1009, DOI 10.1093/jnci/83.14.1009; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; RAFTERY J, 1989, BRIT J ADDICT, V84, P1241; Roberts D., 1984, HDB SOCIAL PSYCHOL, V2, P539; Tye J B, 1987, J Public Health Policy, V8, P492, DOI 10.2307/3342275; Warner K.E., 1992, TOB CONTROL, V1, P25; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WHITESIDE T, 1971, SELLING DEATH CIGARE; 1989, SAMPLE DESIGN ESTIMA; 1985, PHS851320 US DEP HLT; 1988, CDC888406 US DEP HLT; 1990, MMWR MORB MORTAL WKL, V39, P261; 1991, 1989 FED TRAD COMM R; 1989, CDC898411 US DEP HLT	30	161	161	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					608	611		10.1001/jama.271.8.608	http://dx.doi.org/10.1001/jama.271.8.608			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW477	8301793				2022-12-28	WOS:A1994MW47700024
J	VASCONCELLOS, CA; ALLEN, PG; WOHL, ME; DRAZEN, JM; JANMEY, PA; STOSSEL, TP				VASCONCELLOS, CA; ALLEN, PG; WOHL, ME; DRAZEN, JM; JANMEY, PA; STOSSEL, TP			REDUCTION IN VISCOSITY OF CYSTIC-FIBROSIS SPUTUM IN-VITRO BY GELSOLIN	SCIENCE			English	Article							D-BINDING-PROTEIN; F-ACTIN; PLASMA GELSOLIN; BREVIN; SERUM; VISCOELASTICITY; FILAMENTS; PLATELETS; DISEASE; CONTAIN	Obstruction of airways by viscous sputum causes lung damage in patients with cystic fibrosis (CF). Sputum samples from OF patients were shown to contain filamentous actin. Human plasma gelsolin, a protein that severs actin filaments, rapidly decreased the viscosity of CF sputum samples in vitro. Gc globulin and deoxyribonuclease I, proteins that sequester monomeric actin but do not sever actin filaments, were less efficient than gelsolin in diminishing sputum viscosity. These results suggest that gelsolin may have therapeutic potential as a mucolytic agent in CF patients.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV RESP MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Drazen, Jeffrey M/E-5841-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, P50HL019170, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429, HL19170] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHARMAN J, 1973, Biorheology, V10, P295; COUE M, 1986, EUR J BIOCHEM, V160, P273, DOI 10.1111/j.1432-1033.1986.tb09967.x; HANSON J, 1963, J MOL BIOL, V6, P46, DOI 10.1016/S0022-2836(63)80081-9; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1986, BIOCHEM BIOPH RES CO, V136, P72, DOI 10.1016/0006-291X(86)90878-8; JANMEY PA, 1987, BLOOD, V70, P524; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; JANMEY PA, 1992, BLOOD, V80, P928; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LEES A, 1984, BIOCHEMISTRY-US, V23, P3038, DOI 10.1021/bi00308a030; LETHEM MI, 1990, AM REV RESPIR DIS, V142, P1053, DOI 10.1164/ajrccm/142.5.1053; LIEBERMAN J, 1968, J AMER MED ASSOC, V205, P312, DOI 10.1001/jama.205.5.312; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; MARKEY F, 1982, BIOCHIM BIOPHYS ACTA, V709, P122, DOI 10.1016/0167-4838(82)90429-0; MARKS MI, 1981, J PEDIATR-US, V98, P173, DOI 10.1016/S0022-3476(81)80631-2; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; NEWMAN J, 1985, BIOCHEMISTRY-US, V24, P1538, DOI 10.1021/bi00327a037; Oosawa F., 1975, THERMODYNAMICS POLYM; PICOT R, 1978, THORAX, V33, P235, DOI 10.1136/thx.33.2.235; PUCHELLE E, 1985, EUR J CLIN INVEST, V15, P389, DOI 10.1111/j.1365-2362.1985.tb00290.x; ROSENBLUTH M, 1974, ARCH DIS CHILD, V49, P606, DOI 10.1136/adc.49.8.606; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1992, INFLAMMATION BASIC P, P459; VANBAELEN H, 1980, J BIOL CHEM, V255, P270; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	36	157	167	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					969	971		10.1126/science.8310295	http://dx.doi.org/10.1126/science.8310295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310295				2022-12-28	WOS:A1994MX16500036
J	LUCAS, R; MAGEZ, S; DELEYS, R; FRANSEN, L; SCHEERLINCK, JP; RAMPELBERG, M; SABLON, E; DEBAETSELIER, P				LUCAS, R; MAGEZ, S; DELEYS, R; FRANSEN, L; SCHEERLINCK, JP; RAMPELBERG, M; SABLON, E; DEBAETSELIER, P			MAPPING THE LECTIN-LIKE ACTIVITY OF TUMOR-NECROSIS-FACTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; FACTOR-ALPHA; FACTOR-BETA; MUTATIONAL ANALYSIS; BINDING-PROPERTIES; FACTOR RECEPTORS; PROTEINS; EXPRESSION; UROMODULIN; SITES	Tumor necrosis factor (TNF), but not lymphotoxin (LT), is directly trypanolytic for salivarian trypanosomes. This activity was not blocked by soluble 55-kilodalton and 75-kilodalton TNF receptors, but was potently inhibited by N,N'-diacetylchitobiose, an oligosaccharide that binds TNF. Comparative sequence analysis of TNF and LT localized the trypanocidal region, and synthetic peptides were trypanolytic. TNF molecules in which the trypanocidal region was mutated or deleted retained tumoricidal activity. Thus, trypanosome-TNF interactions occur via a TNF domain, probably with lectin-like affinity, which is functionally and spatially distinct from the mammalian TNF receptor binding sites.	VRIJE UNIV BRUSSELS,GEN BIOL LAB,B-1640 RHODE ST GENESE,BELGIUM; INNOGENET NV,B-9052 ZWIJNAARDE,BELGIUM	Vrije Universiteit Brussel; Innogenetics NV	LUCAS, R (corresponding author), VRIJE UNIV BRUSSELS,CELLULAR IMMUNOL LAB,CAMPUS RODE,PAARDENSTR 65,B-1640 RHODE ST GENESE,BELGIUM.		De Baetselier, Patrick/D-3866-2014; Lucas, Rudolf/ABA-3011-2020; Magez, Stefan/D-9497-2014; Magez, Stefan/AAC-5682-2021; Lucas, Rudolf/G-5197-2012	Magez, Stefan/0000-0003-3760-7968; Magez, Stefan/0000-0003-3760-7968; Lucas, Rudolf/0000-0003-3805-8868; Scheerlinck, Jean-Pierre/0000-0002-8385-353X				AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; CICCO NA, 1990, BLOOD, V75, P2049; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; KOEFFLER HP, 1987, BLOOD, V70, P55; KONGSHAVN PAL, 1988, PARASITE IMMUNOL, V10, P581, DOI 10.1111/j.1365-3024.1988.tb00245.x; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lucas R., UNPUB; LUO G, 1983, INFECT IMMUN, V61, P830; MAGEZ S, 1993, PARASITE IMMUNOL, V15, P635, DOI 10.1111/j.1365-3024.1993.tb00577.x; OSTER W, 1987, BLOOD, V70, P1700; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	29	174	187	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					814	817		10.1126/science.8303299	http://dx.doi.org/10.1126/science.8303299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303299				2022-12-28	WOS:A1994MV86600037
J	SPOLAR, RS; RECORD, MT				SPOLAR, RS; RECORD, MT			COUPLING OF LOCAL FOLDING TO SITE-SPECIFIC BINDING OF PROTEINS TO DNA	SCIENCE			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; REPRESSOR-OPERATOR INTERACTION; GENE ACTIVATOR PROTEIN; HEAT-CAPACITY CHANGES; COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRP REPRESSOR; GLUCOCORTICOID RECEPTOR	Thermodynamic studies have demonstrated the central importance of a large negative heat capacity change (DELTAC(assoc)degrees) in site-specific protein-DNA recognition. Dissection of the large negative DELTAC(assoc)degrees and the entropy change of protein-ligand and protein-DNA complexation provide a thermodynamic signature identifying processes in which local folding is coupled to binding. Estimates of the number of residues that fold on binding obtained from this analysis agree with structural data. Structural comparisons indicate that these local folding transitions create key parts of the protein-DNA interface. The energetic implications of this ''induced fit'' model for DNA site recognition are considered.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	SPOLAR, RS (corresponding author), UNIV WISCONSIN, DEPT CHEM, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R37GM023467] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23467] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abola E. E., 1987, CRYSTALLOGRAPHIC DAT; ALBER T, 1993, CURR BIOL, V3, P182, DOI 10.1016/0960-9822(93)90268-S; ALBER T, 1981, THESIS MIT; ALBER T, 1982, MOBILITY FUNCTION PR, P4; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1617; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; CONNELLY PR, 1992, P NATL ACAD SCI USA, V89, P4781, DOI 10.1073/pnas.89.11.4781; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; CREIGHTON TE, 1983, PROTEINS; DILL KA, 1989, BIOCHEMISTRY-US, V28, P5439, DOI 10.1021/bi00439a019; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; FILIMONOV VV, 1978, BIOPHYS CHEM, V8, P117, DOI 10.1016/0301-4622(78)80003-9; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FORMISANO S, 1977, P NATL ACAD SCI USA, V74, P3340, DOI 10.1073/pnas.74.8.3340; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRANKEL AD, 1992, P NATL ACAD SCI USA, V89, P11653, DOI 10.1073/pnas.89.24.11653; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GRIKO YV, 1992, BIOCHEMISTRY-US, V31, P12701, DOI 10.1021/bi00165a022; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HERSCHLAG D, 1988, BIOORG CHEM, V16, P62, DOI 10.1016/0045-2068(88)90038-7; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; JARDETZKY O, COMMUNICATION; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; JIN LH, 1993, BIOCHEMISTRY-US, V32, P7302, DOI 10.1021/bi00079a029; KARPLUS M, 1987, BIOPHYS J, V52, P1083, DOI 10.1016/S0006-3495(87)83303-9; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KIM KS, 1993, PROTEIN SCI, V2, P588; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUNDBACK T, 1993, BIOCHEMISTRY-US, V32, P5074, DOI 10.1021/bi00070a015; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; OBEYSEKARE U, UNPUB; OHLENDORF D, UNPUB; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; POST CB, UNPUB; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1992, J MOL BIOL, V224, P715, DOI 10.1016/0022-2836(92)90555-X; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RECORD MT, 1988, UNUSUAL DNA STRUCTUR, P237; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SUSSMAN J, UNPUB; SUURKUUSK J, 1972, EUR J BIOCHEM, V28, P438, DOI 10.1111/j.1432-1033.1972.tb01930.x; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; TANFORD C, 1980, HYDROPHOBIC EFFECT; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; VERSHON AK, 1987, J MOL BIOL, V195, P311, DOI 10.1016/0022-2836(87)90652-8; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WILCOX W, 1992, PROTEIN SCI, V1, P641, DOI 10.1002/pro.5560010510; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	112	1362	1373	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	1994	263	5148					777	784		10.1126/science.8303294	http://dx.doi.org/10.1126/science.8303294			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303294				2022-12-28	WOS:A1994MV86600026
J	STURGILLKOSZYCKI, S; SCHLESINGER, PH; CHAKRABORTY, P; HADDIX, PL; COLLINS, HL; FOK, AK; ALLEN, RD; GLUCK, SL; HEUSER, J; RUSSELL, DG				STURGILLKOSZYCKI, S; SCHLESINGER, PH; CHAKRABORTY, P; HADDIX, PL; COLLINS, HL; FOK, AK; ALLEN, RD; GLUCK, SL; HEUSER, J; RUSSELL, DG			LACK OF ACIDIFICATION IN MYCOBACTERIUM PHAGOSOMES PRODUCED BY EXCLUSION OF THE VESICULAR PROTON-ATPASE	SCIENCE			English	Article							LYSOSOME FUSION; PATHOGENIC MYCOBACTERIUM; PARASITOPHOROUS VACUOLES; COMPLEMENT RECEPTORS; HUMAN MACROPHAGES; TUBERCULOSIS; LEPRAE; INHIBITION; AVIUM; PHAGOCYTOSIS	The success of Mycobacterium species as pathogens depends on their ability to maintain an infection inside the phagocytic vacuole of the macrophage. Although the bacteria are reported to modulate maturation of their intracellular vacuoles, the nature of such modifications is unknown. In this study, vacuoles formed around Mycobacterium avium failed to acidify below pH 6.3 to 6.5. Immunoelectron microscopy of infected macrophages and immunoblotting of isolated phagosomes showed that Mycobacterium vacuoles acquire the lysosomal membrane protein LAMP-1, but not the vesicular proton-adenosine triphosphatase (ATPase) responsible for phagosomal acidification. This suggests either a selective inhibition of fusion with proton-ATPase-containing vesicles or a rapid removal of the complex from Mycobacterium phagosomes.	WASHINGTON UNIV, MED CTR, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, MED CTR, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, MED CTR, DEPT LOW TEMP ENGN PHYS, ST LOUIS, MO 63130 USA; UNIV HAWAII, DEPT MICROBIOL, HONOLULU, HI 96822 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Hawaii System			Schlesinger, Paul H/C-6049-2012; Russell, David G/D-4533-2009; Russell, David G/N-5280-2019	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X	NIAID NIH HHS [AI26889, AI34207] Funding Source: Medline; NIAMS NIH HHS [AR42370] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026889, R01AI034207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; APPELBERG R, 1993, IMMUNOLOGY, V80, P352; BLOOM BR, 1992, NATURE, V358, P538, DOI 10.1038/358538b0; Chakraborty A., UNPUB; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHEN JW, 1986, BIOCHEM SOC SYMP, P97; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; FOK AK, IN PRESS J CELL SCI; FREHEL C, 1986, INFECT IMMUN, V52, P252, DOI 10.1128/IAI.52.1.252-262.1986; FREHEL C, 1987, INFECT IMMUN, V55, P2916, DOI 10.1128/IAI.55.12.2916-2921.1987; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MELLMAN I, 1992, J EXP BIOL, V172, P39; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; PERIN MS, 1991, J BIOL CHEM, V266, P3877; RASTOGI N, 1992, FEMS MICROBIOL IMMUN, V89, P273, DOI 10.1111/j.1574-6968.1992.tb05006.x; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SIBLEY LD, 1987, INFECT IMMUN, V55, P680, DOI 10.1128/IAI.55.3.680-685.1987; STEINHOFF U, 1989, INFECT IMMUN, V57, P1008, DOI 10.1128/IAI.57.3.1008-1010.1989; Xu S., UNPUB; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	29	988	1018	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					678	681		10.1126/science.8303277	http://dx.doi.org/10.1126/science.8303277			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303277				2022-12-28	WOS:A1994MU96400048
J	ZELISSEN, PMJ; CROUGHS, RJM; VANRIJK, PP; RAYMAKERS, JA				ZELISSEN, PMJ; CROUGHS, RJM; VANRIJK, PP; RAYMAKERS, JA			EFFECT OF GLUCOCORTICOID REPLACEMENT THERAPY ON BONE-MINERAL DENSITY IN PATIENTS WITH ADDISON-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							OSTEOPOROSIS	Objective: To study the influence of glucocorticoid replacement therapy on bone mineral density. Design: Cross-sectional. Setting: University hospital in the Netherlands. Patients: 91 patients with Addison disease who had been receiving glucocorticoid replacement therapy for a mean of 10.6 years (range, 0.5 to 36.5 years). Measurements: Bone mineral density of the lumbar spine and both femoral necks using a dual-energy x-ray absorptiometer and basal serum concentrations of adrenocorticotropin, gonadal hormones, and adrenal androgens. Results: Decreased bone mineral density (less than 2 standard deviations [SD] of the mean value of an age-matched reference population) was found in 10 of 31 men (32%; 95% CI, 17% to 51%) and in 4 of 60 women (7%; CI, 2% to 16%). No statistically significant differences were found between men and women with regard to age, duration of glucocorticoid substitution, or glucocorticoid dose, either in absolute quantities or when expressed per kilogram of body weight. However, in men with decreased bone mineral density, the daily hydrocortisone dose per kilogram of body weight (0.43 +/- 0.08 mg/kg; mean +/- SD) was significantly (P = 0.032) higher than in men with normal bone mineral density (0.35 +/- 0.10 mg/kg). After correction for possible confounding variables, a significant linear correlation was found between hydrocortisone dose per kilogram of body weight and bone mineral density of the lumbar spine in the men (regression coefficient, -0.86; CI, -1.60 to -0.13; P = 0.029) but not in the women. Conclusions; Long-term treatment with standard replacement doses of glucocorticoids may induce bone loss in men with Addison disease. Adjustment of glucocorticoid therapy to the lowest acceptable dose is mandatory in Addison disease, and regular measurement of bone mineral density may be helpful in identifying men at risk for the development of osteoporosis.	UNIV HOSP UTRECHT, DEPT NUCL MED, 3508 GA UTRECHT, NETHERLANDS; UNIV HOSP UTRECHT, DEPT INTERNAL MED & GERIATR, 3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	ZELISSEN, PMJ (corresponding author), UNIV HOSP UTRECHT, DEPT ENDOCRINOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							ANDERSON DC, 1992, BRIT MED J, V305, P489, DOI 10.1136/bmj.305.6852.489; BOYCE BF, 1991, J BONE MINER RES  S1, V6, pS108; BURKE CW, 1992, CLIN ENDOCRINOL, P393; DEVOGELAER JP, 1987, BRIT MED J, V294, P798, DOI 10.1136/bmj.294.6575.798; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; HAHN TJ, 1978, ARCH INTERN MED, V138, P882; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; MANNING PJ, 1992, CLIN ENDOCRINOL, V36, P229, DOI 10.1111/j.1365-2265.1992.tb01437.x; MASON AS, 1968, LANCET, V2, P744; RYAN PJ, 1992, BRIT J RHEUMATOL, V31, P823; SCHOT LPC, 1990, J STEROID BIOCHEM, V37, P167, DOI 10.1016/0960-0760(90)90325-F; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265	12	166	169	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					207	210		10.7326/0003-4819-120-3-199402010-00005	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273983				2022-12-28	WOS:A1994MU30300005
J	ASKWITH, C; EIDE, D; VANHO, A; BERNARD, PS; LI, LT; DAVISKAPLAN, S; SIPE, DM; KAPLAN, J				ASKWITH, C; EIDE, D; VANHO, A; BERNARD, PS; LI, LT; DAVISKAPLAN, S; SIPE, DM; KAPLAN, J			THE FET3 GENE OF SACCHAROMYCES-CEREVISIAE ENCODES A MULTICOPPER OXIDASE REQUIRED FOR FERROUS IRON UPTAKE	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ASCORBATE OXIDASE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; FERRIC REDUCTASE; STREPTONIGRIN; SEQUENCE; LOCALIZATION; ORIENTATION; RESISTANCE	S. cerevisiae accumulate iron by a process requiring a ferrireductase and a ferrous transporter. We have isolated a mutant, fet3, defective for high affinity Fe(II) uptake. The wild-type FET3 gene was isolated by complementation of the mutant defect. Sequence analysis of the gene revealed the presence of an open reading frame coding for a protein with strong similarity to the family of blue multicopper oxidoreductases. Consistent with the role of copper in iron transport, growth of wild-type cells in copper-deficient media resulted in decreased ferrous iron transport. Addition of copper, but not other transition metals (manganese or zinc), to the assay media resulted in the recovery of Fe(II) transporter activity. We suggest that the catalytic activity of the Fet3 protein is required for cellular iron accumulation.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,DULUTH,MN 55812	University of Minnesota System; University of Minnesota Duluth	ASKWITH, C (corresponding author), UNIV UTAH,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132, USA.				NIDDK NIH HHS [T32 DK07115-16, DK 5-30534] Funding Source: Medline; NIGMS NIH HHS [GM 48139] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048139] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAO W, 1993, SCIENCE, V260, P672, DOI 10.1126/science.260.5108.672; BRAUN V, 1983, MOL GEN GENET, V192, P131, DOI 10.1007/BF00327658; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; COHEN MS, 1987, ANTIMICROB AGENTS CH, V31, P1507, DOI 10.1128/AAC.31.10.1507; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DANIS A, 1994, CELL, V76, P393; DESILVA D, 1992, ARCH BIOCHEM BIOPHYS, V293, P409, DOI 10.1016/0003-9861(92)90413-Q; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EIDE D, 1992, J BIOL CHEM, V267, P20774; EIDE D, 1992, J GEN MICROBIOL, V138, P34; GEITZ RD, 1988, GENE, V74, P527; GUTTERIDGE JMC, 1984, BIOCHEM PHARMACOL, V33, P3059, DOI 10.1016/0006-2952(84)90609-9; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; KOJIMA Y, 1990, J BIOL CHEM, V265, P15224; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; OHKAWA J, 1989, P NATL ACAD SCI USA, V86, P1239, DOI 10.1073/pnas.86.4.1239; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SHERMAN F, 1986, LABORATORY COURSE MA; TSUBOI M, 1981, MOL GEN GENET, V182, P1, DOI 10.1007/BF00422758; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WHITE JR, 1982, BIOCHEM BIOPH RES CO, V106, P407, DOI 10.1016/0006-291X(82)91125-1; WHITE JR, 1977, BIOCHEM BIOPH RES CO, V77, P387, DOI 10.1016/S0006-291X(77)80209-X	40	591	607	2	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					403	410		10.1016/0092-8674(94)90346-8	http://dx.doi.org/10.1016/0092-8674(94)90346-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293473				2022-12-28	WOS:A1994MU67800022
J	KEMBLE, GW; DANIELI, T; WHITE, JM				KEMBLE, GW; DANIELI, T; WHITE, JM			LIPID-ANCHORED INFLUENZA HEMAGGLUTININ PROMOTES HEMIFUSION, NOT COMPLETE FUSION	CELL			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; CONFORMATIONAL CHANGE; DISULFIDE BONDS; PROTEIN; LIPOSOMES; PEPTIDE; EVENTS; CELLS; ERYTHROCYTES	It has been proposed that membrane fusion events such as virus-cell fusion proceed through a hemifusion intermediate, a state where lipids but not contents of the fusing compartments mix. We engineered the influenza hemagglutinin (HA) such that it would be anchored in membranesvia a glycosylphosphatidylinositol (GPI) tail. GPI-anchored HA forms a trimer that can bind red blood cells (RBCs) and change conformation under fusion-inducing conditions. Using RBCs labeled with fluorescent lipid or fluorescent soluble content probes, we found that GPI-anchored HA mediated lipid mixing with similar time course and efficiency as wt-HA, yet did not mediate transfer of soluble contents. Hence, GPI-anchored HA appears to initiate, but not complete, a fusion reaction. We interpret our results as evidence for uncoupling a physiological fusion reaction, for trapping a hemifusion intermediate, and for assigning a role to a transmembrane domain in a fusion event.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI22470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022470] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BNROWN D, 1992, CELL, V68, P533; BODIAN DL, 1993, BIOCHEMISTRY-US, V32, P2967, DOI 10.1021/bi00063a007; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; CURRAN MJ, 1993, J MEMBRANE BIOL, V133, P61; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DISIMONE C, 1992, VIROLOGY, V191, P338, DOI 10.1016/0042-6822(92)90196-V; DOMS RW, 1985, J BIOL CHEM, V260, P2973; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; Edidin Michael, 1992, Trends in Cell Biology, V2, P376, DOI 10.1016/0962-8924(92)90050-W; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GUY HR, 1992, BIOPHYS J, V62, P95, DOI 10.1016/S0006-3495(92)81790-3; HARTER C, 1989, J BIOL CHEM, V264, P6459; KALDERON N, 1979, J CELL BIOL, V81, P411, DOI 10.1083/jcb.81.2.411; KEMBLE GW, 1993, J CELL BIOL, V122, P1253, DOI 10.1083/jcb.122.6.1253; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LEVENTIS R, 1986, BIOCHEMISTRY-US, V25, P6978, DOI 10.1021/bi00370a600; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; ORNBERG RL, 1981, J CELL BIOL, V90, P40, DOI 10.1083/jcb.90.1.40; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; Pinto da Silva P., 1977, J CELL BIOL, V73, P161; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; SIMPSON DA, 1992, J VIROL, V66, P790, DOI 10.1128/JVI.66.2.790-803.1992; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SONG LY, 1991, BIOCHIM BIOPHYS ACTA, V1065, P54, DOI 10.1016/0005-2736(91)90010-6; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1982, NATURE, V300, P658, DOI 10.1038/300658a0; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WUNDERLIALLENSPACH H, 1990, BIOCHEMISTRY-US, V29, P1990, DOI 10.1021/bi00460a005	51	460	468	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					383	391		10.1016/0092-8674(94)90344-1	http://dx.doi.org/10.1016/0092-8674(94)90344-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293471				2022-12-28	WOS:A1994MU67800020
J	BARRETTCONNOR, E; CHANG, JC; EDELSTEIN, SL				BARRETTCONNOR, E; CHANG, JC; EDELSTEIN, SL			COFFEE-ASSOCIATED OSTEOPOROSIS OFFSET BY DAILY MILK CONSUMPTION - THE RANCHO-BERNARDO STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL CONTENT; ELDERLY WOMEN; HIP FRACTURE; CAFFEINE; CALCIUM; RISK; MASS	Objective.-To describe the association of lifetime intake of caffeinated coffee, in cup-years, to bone mineral density (BMD) of the hip and spine in postmenopausal women; and to determine the effect of regular milk intake on this association. Design.-Women from an established epidemiologic cohort had measures of BMD and gave a medical and behavioral history that included caffeinated coffee and daily milk intake between the ages of 12 and 18 years, 20 and 50 years, and 50 years of age and older. Setting.-A community-based population of older women, Rancho Bernardo, Calif. Participants.-All 980 postmenopausal women aged 50 to 98 years (mean age, 72.7 years) who participated between 1988 and 1991. Main Outcome Measures.-Bone density at the hip and lumbar spine measured by dual energy x-ray absorptiometry. Main Results.-There was a statistically significant graded association between increasing lifetime intake of caffeinated coffee and decreasing BMD at both the hip and spine, independent of age, obesity, parity, years since menopause, and the use of tobacco, alcohol, estrogen, thiazides, and calcium supplements. Bone density did not vary by lifetime coffee intake in women who reported drinking at least one glass of milk per day during most of their adult lives. Conclusions.-Lifetime caffeinated coffee intake equivalent to two cups per day is associated with decreased bone density in older women who do not drink milk on a daily basis.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NIA NIH HHS [R37AG07181-06] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARGERLUX MJ, 1990, AM J CLIN NUTR, V52, P722, DOI 10.1093/ajcn/52.4.722; Barone J.J., 1984, CAFFEINE; BARRETTCONNOR E, 1989, CALCIFIED TISSUE INT, V44, P303, DOI 10.1007/BF02556308; BAUER DC, 1991, CLIN RES, V39, pA571; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOPER C, 1992, J BONE MINER RES, V7, P465; ELIEL LP, 1983, CALCIFIED TISSUE INT, V35, P669; FLEISS JL, 1973, STATISTICAL METHODS; GILBERT RM, 1976, CAN MED ASSOC J, V114, P205; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; JOHANNSON CH, 1990, 3RD P INT S OST ALB, P10; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KREIGER N, 1992, INT J EPIDEMIOL, V21, P953, DOI 10.1093/ije/21.5.953; MASSEY LK, 1991, J BONE MINER RES, V6, P1149; MASSEY LK, 1989, J BONE MINER RES SS1, V4, P249; PICARD D, 1988, BONE MINER, V4, P299; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH S, 1989, ARCH INTERN MED, V149, P2517, DOI 10.1001/archinte.149.11.2517; SOROKO S, 1993, AM J EPIDEMIOL, V138, P6; YANO K, 1985, AM J CLIN NUTR, V42, P877, DOI 10.1093/ajcn/42.5.877	25	129	134	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					280	283		10.1001/jama.271.4.280	http://dx.doi.org/10.1001/jama.271.4.280			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295286				2022-12-28	WOS:A1994MR22100023
J	ROIZEN, MF				ROIZEN, MF			COST-EFFECTIVE PREOPERATIVE LABORATORY TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ROIZEN, MF (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BLERY C, 1986, LANCET, V1, P139; KAPLAN EB, 1985, JAMA-J AM MED ASSOC, V253, P3576, DOI 10.1001/jama.253.24.3576; LUTNER RE, 1991, ANESTHESIOLOGY, V75, P394, DOI 10.1097/00000542-199109000-00003; MACARIO A, 1992, SURG GYNECOL OBSTET, V175, P539; ROIZEN MF, 1992, MED CARE, V30, pMS74, DOI 10.1097/00005650-199205001-00007; ROIZEN MF, 1990, ANESTHESIA, V1, P793; Sox HC, 1987, COMMON DIAGNOSTIC TE	8	25	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					319	320						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295297				2022-12-28	WOS:A1994MR22100034
J	KOSNETT, MJ; BECKER, CE; OSTERLOH, JD; KELLY, TJ; PASTA, DJ				KOSNETT, MJ; BECKER, CE; OSTERLOH, JD; KELLY, TJ; PASTA, DJ			FACTORS INFLUENCING BONE LEAD CONCENTRATION IN A SUBURBAN COMMUNITY ASSESSED BY NONINVASIVE K-X-RAY FLUORESCENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD LEAD; HUMAN TISSUES; EXPOSURE; CHILDREN; INDUSTRY; SMOKING; BURDEN; POPULATION; CADMIUM; ALCOHOL	Objective.-To determine the influence of demographic, exposure, and medical factors on the bone lead concentration of subjects with background (nonindustrial) environmental lead exposure. Design.-Survey. Setting.-Suburban residential community. Participants.-A total of 101 subjects (49 males, 52 females; aged 11 to 78 years) were recruited from 49 of 123 households geographically located in a suburban residential neighborhood unexposed to any major source of industrial lead emissions. Main Outcome Measurements.-Cortical bone lead concentrations in the mid-shaft of the tibia were noninvasively measured by in vivo K x-ray fluorescence. Blood lead concentrations were measured by anodic stripping voltammetry. An administered questionnaire assessed potential sources of lead exposure and medical conditions affecting bone metabolism. Results.-After the exclusion of one outlier, log-transformed bone lead concentration was highly correlated with age (r=.71; P less-than-or-equal-to .0001). Bone lead concentration showed no significant change up to age 20 years, increased with the same slope in men and women between ages 20 and 55 years, and then increased at a faster rate in men older than 55 years. In addition to the variables age and sex, the best fitting multiple regression model for bone lead concentration (R2=.66; P less-than-or-equal-to .0001) revealed a positive correlation with total pack-years of cigarette smoking and a negative correlation with a history of having nursed an infant for longer than 2 weeks. Blood lead concentrations of the subjects were low (geometric mean, 0.24 mumol/L [4.9 mug/dL]) and after log transformation were weakly correlated with log-transformed bone lead concentration (r=.23; P=.02). Conclusions.-The age- and sex-related increases in bone lead concentration found by K x-ray fluorescence concur with published postmortem studies of bone lead concentration and are consistent with the kinetics of bone turnover and secular trends in lead exposure. These data help to establish a reference range for assessing the lead burden of other populations with environmental or occupational lead exposure.	DMA CORP, LOS ALTOS, CA USA; SAN FRANCISCO GEN HOSP, DIV OCCUPAT & ENVIRONM MED, SAN FRANCISCO, CA 94110 USA	San Francisco General Hospital Medical Center	KOSNETT, MJ (corresponding author), UNIV CALIF SAN FRANCISCO, CTR OCCUPAT & ENVIRONM HLTH, BOX 0843, SAN FRANCISCO, CA 94143 USA.			Pasta, David/0000-0003-2637-9293	NIOSH CDC HHS [1 K01 OH001 08-01] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [K01OH000108] Funding Source: NIH RePORTER	NIOSH CDC HHS; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; BARRY PSI, 1975, BRIT J IND MED, V32, P119; BELLINGER D, 1991, PEDIATRICS, V87, P219; BERODE M, 1991, ENVIRON RES, V55, P1, DOI 10.1016/S0013-9351(05)80136-7; BOHM J, 1986, THESIS U MUNCHEN; BRANGSTRUPHANSE.JP, 1981, J OCCUP MED, V23, P39; Burger D E, 1990, Basic Life Sci, V55, P287; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CHRISTOFFERSSON JO, 1984, AM J IND MED, V6, P447, DOI 10.1002/ajim.4700060608; COHEN J., 1983, APPL MULTIPLE REGRES, V2; DRASCH GA, 1987, SCI TOTAL ENVIRON, V64, P303, DOI 10.1016/0048-9697(87)90252-X; EMMERSON BT, 1961, MED J AUSTRALIA, V1, P243, DOI 10.5694/j.1326-5377.1961.tb82436.x; ERKKILA J, 1992, BRIT J IND MED, V49, P631; FROINES JR, 1990, AM J IND MED, V18, P1; GRANDJEAN P, 1981, INT ARCH OCC ENV HEA, V48, P391, DOI 10.1007/BF00378687; GROSS SB, 1975, TOXICOL APPL PHARM, V32, P638, DOI 10.1016/0041-008X(75)90127-1; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; HU H, 1991, ENVIRON HEALTH PERSP, V94, P107, DOI 10.2307/3431301; JONES KW, 1987, IN VIVO BODY COMPOSI, P363; KAYE WE, 1987, ARCH ENVIRON HEALTH, V42, P161, DOI 10.1080/00039896.1987.9935815; KELLER CA, 1980, TOXICOL APPL PHARM, V55, P220, DOI 10.1016/0041-008X(80)90083-6; KERIEY ER, 1965, AM J PHYS ANTHROPOL, V23, P149; MANTON WI, 1985, BRIT J IND MED, V42, P168; MASSIE HR, 1992, GERONTOLOGY, V38, P13; MORGAN WD, 1990, BIOL TRACE ELEM RES, V26-7, P407, DOI 10.1007/BF02992695; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NUSBAUM RE, 1965, ARCH ENVIRON HEALTH, V10, P227, DOI 10.1080/00039896.1965.10663989; OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P313, DOI 10.1016/0041-008X(91)90033-B; OSTERLOH JD, 1990, J ANAL TOXICOL, V14, P8, DOI 10.1093/jat/14.1.8; OTT J, 1987, THESIS U MUNCHEN; PRICE J, 1984, BRIT J RADIOL, V57, P29, DOI 10.1259/0007-1285-57-673-29; QUINN MJ, 1989, HUM TOXICOL, V8, P205, DOI 10.1177/096032718900800302; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHUTZ A, 1987, SCI TOTAL ENVIRON, V61, P201, DOI 10.1016/0048-9697(87)90367-6; SHAPER AG, 1982, BMJ-BRIT MED J, V284, P299, DOI 10.1136/bmj.284.6312.299; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1991, AM IND HYG ASSOC J, V52, P409, DOI 10.1080/15298669191364956; SIEBER WK, 1991, AM J IND MED, V20, P163, DOI 10.1002/ajim.4700200204; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; SOMERVAILLE LJ, 1988, BRIT J IND MED, V45, P174; TELL I, 1992, SCAND J WORK ENV HEA, V18, P113, DOI 10.5271/sjweh.1603; TODD AC, 1992, ENVIRON RES, V57, P117, DOI 10.1016/S0013-9351(05)80073-8; TOLA S, 1973, BRIT J IND MED, V30, P134; Tukey J. W., 1977, EXPLORATORY DATA ANA; WEDEEN RP, 1979, ARCH INTERN MED, V139, P53, DOI 10.1001/archinte.139.1.53; WEDEEN RP, 1987, IN VIVO BODY COMPOSI, P357; WILLERS S, 1988, SCAND J WORK ENV HEA, V14, P385, DOI 10.5271/sjweh.1905; WITTMERS LE, 1988, ARCH ENVIRON HEALTH, V43, P381, DOI 10.1080/00039896.1988.9935855; 1986, US EPA SW846 PUBL; 1991, DRAFT TOXIOLOGICAL P; 1984, NATIONAL CTR HLTH ST, V11; 1977, TASK GROUP ENV HLTH; 1973, ALKALINE EARTH METAB; 1986, US EPA600883028F PUB	61	95	97	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					197	203		10.1001/jama.271.3.197	http://dx.doi.org/10.1001/jama.271.3.197			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277545				2022-12-28	WOS:A1994MQ64500032
J	SCHWACHA, A; KLECKNER, N				SCHWACHA, A; KLECKNER, N			IDENTIFICATION OF JOINT MOLECULES THAT FORM FREQUENTLY BETWEEN HOMOLOGS BUT RARELY BETWEEN SISTER CHROMATIDS DURING YEAST MEIOSIS	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CHROMOSOME SYNAPSIS; GENE CONVERSION; INITIATION SITE; RECA PROTEIN; DNA; EXCHANGE	We have investigated DNA interactions between homologs and between sister chromatids during meiosis in S. cerevisiae. We have detected a DNA species containing information from both parental chromosomes at a specific hotspot for melotic recombination and double strand breaks (DSBs). These joint molecules are a prominent feature of melotic prophase. They appear to be a major intermediate stage in DSB-promoted recombination, because they occur with appropriate timing and require known recombination functions. Other possibilities cannot be completely dismissed, however. Most or all joint molecules contain two full-length nonrecombinant strands from each parental duplex and thus do not consist of single Holliday junctions. Joint molecules form between sister chromatids at approximately 10% the interhomolog level. Also, joint molecule formation is aberrant in a mutant defective in the HOP1 gene, which encodes a melotic chromosome structure component. General models for discrimination between homologs and sisters during meiosis are discussed.			SCHWACHA, A (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BELL L, 1979, P NATL ACAD SCI USA, V76, P3445, DOI 10.1073/pnas.76.7.3445; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P5328, DOI 10.1073/pnas.74.12.5328; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; GAME JC, 1989, GENETICS, V123, P695; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HABER JE, 1984, GENETICS, V106, P185; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; JACKSON JA, 1985, GENETICS, V109, P303; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLECKNER N, 1994, IN PRESS COLD SPRING, V58; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; MALONE RE, 1983, MOL GEN GENET, V189, P405, DOI 10.1007/BF00325902; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Sambrook J, 1989, MOL CLONING LABORATO; SENA EP, 1986, MOL GEN GENET, V202, P421, DOI 10.1007/BF00333272; SHI YB, 1988, BIOCHEMISTRY-US, V27, P5174, DOI 10.1021/bi00414a034; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STACK SM, 1991, GENOME, V34, P900, DOI 10.1139/g91-138; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; THORNE LW, 1993, GENETICS, V134, P29; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; UZAWA S, 1992, J CELL SCI, V101, P267; VONWETTS.D, 1971, P NATL ACAD SCI USA, V68, P851, DOI 10.1073/pnas.68.4.851; WAGSTAFF JE, 1985, MOL CELL BIOL, V5, P3532, DOI 10.1128/MCB.5.12.3532; WU TC, 1993, MEIOSIS, V2; WU TC, 1994, IN PRESS SCIENCE; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	55	287	291	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					51	63		10.1016/0092-8674(94)90172-4	http://dx.doi.org/10.1016/0092-8674(94)90172-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287479				2022-12-28	WOS:A1994MR49500006
J	TWIDDY, PAU				TWIDDY, PAU			THE MIDAS TOUCH	BRITISH MEDICAL JOURNAL			English	Article								Objective-To test the hypothesis that GP trainees are worth their weight in gold. Design-Data collected from 100 consecutive patients analysed with reference to practice statistics, fees, and allowances. Setting-General practice, Edinburgh. Results-In the year April 1992 to April 1993 the trainee saw 3439 patients, who were worth over 18 000 Pounds in capitation fees. The training grant is 4570 Pounds, the trainee performed child health surveillance worth 1000 Pounds, and items of service fees earned more than 8500 Pounds. The trainee brought over 31 000 Pounds into the practice in one year. Conclusion-Trainees are (almost) worth their weight in gold.											0	0	0	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1587	1588		10.1136/bmj.307.6919.1587	http://dx.doi.org/10.1136/bmj.307.6919.1587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292947	Green Published, Bronze			2022-12-28	WOS:A1993MN10700010
J	DEODHAR, HA; MARSHALL, RJ; BARNES, JN				DEODHAR, HA; MARSHALL, RJ; BARNES, JN			LESSON OF THE WEEK - INCREASED RISK OF SEPSIS AFTER SPLENECTOMY	BRITISH MEDICAL JOURNAL			English	Article							POSTSPLENECTOMY SEPSIS; PNEUMOCOCCAL VACCINE		ROYAL CORNWALL HOSP,RENAL UNIT,TRURO TR1 3LJ,CORNWALL,ENGLAND; ROYAL CORNWALL HOSP,DEPT PATHOL,TRURO TR1 3LJ,CORNWALL,ENGLAND	Royal Cornwall Hospital; Royal Cornwall Hospital								ADDIEGO JE, 1980, LANCET, V2, P450; BADDELEY PG, 1993, HOSPITAL UPDATE, V19, P365; FOSTER PN, 1987, J ROY COLL PHYS LOND, V21, P188; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; ONEAL BJ, 1981, ANN SURG, V194, P775, DOI 10.1097/00000658-198112000-00020; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SHAW JHF, 1989, BRIT J SURG, V76, P1074, DOI 10.1002/bjs.1800761029; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; TRAUB A, 1987, NEW ENGL J MED, V317, P1559, DOI 10.1056/NEJM198712173172503; ZARRABI MH, 1986, ARCH INTERN MED, V146, P1207, DOI 10.1001/archinte.146.6.1207; 1985, LANCET, V2, P928; 1992, IMMUNISATION INFECTI, P100; 1989, JAMA-J AM MED ASSOC, V261, P1265	13	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1408	1409		10.1136/bmj.307.6916.1408	http://dx.doi.org/10.1136/bmj.307.6916.1408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274896	Green Published, Bronze			2022-12-28	WOS:A1993MK42000026
J	OPPENHEIMER, C				OPPENHEIMER, C			ORGANIZING MIDWIFERY LED CARE IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL-MORTALITY	The growing pressure for changes in the care available for pregnant women at low risk found a voice in the report on maternity services from the House of Commons Health Committee published in February 1992. The demand for greater autonomy and responsibility by midwives and the need to rationalise medical working practices in the light of changes in junior doctors' hours adds urgency to the need to find ways of instituting change while maintaining safety. A visit to the Netherlands allowed first hand evaluation of aspects of the Dutch model of maternity care of relevance to establishing midwifery led care for women with uncomplicated pregnancies in the United Kingdom.			OPPENHEIMER, C (corresponding author), LEICESTER ROYAL INFIRM,DEPT OBSTET & GYNAECOL,CLIN SCI BLDG,LEICESTER LE2 7LX,ENGLAND.							BERGHS G, 1988, THESIS U NIJMEGEN NI; BREYER HBG, 1971, NED TIJDSCHR GENEES, V115, P1638; Campbell R, 1991, BMJ, V303, P1487; DOORNBOS JPR, 1987, AM J OBSTET GYNECOL, V156, P1183, DOI 10.1016/0002-9378(87)90138-4; Hoogendoorn D, 1986, Ned Tijdschr Geneeskd, V130, P1436; IELTY P, 1992, PREGNANCY CARE 1990S, P77; JENKINS R, 1992, PREGNANCY CARE 1990S, P166; KEIRSE MJN, 1982, EFFECTIVENESS SATISF, P222; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, P200; KLEIVERDA G, 1990, EUR J OBSTET GYN R B, V35, P1; Kloosterman G J, 1978, Ned Tijdschr Geneeskd, V122, P1161; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MELIA RJW, 1991, BRIT J OBSTET GYNAEC, V98, P1307; SIMMONS S, 1992, MATERNITY CARE NEW N; SMITS F, 1975, THESIS U NIJMEGEN NI; TREFFERS PE, 1990, JAMA-J AM MED ASSOC, V264, P2206; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; VANALTEN D, 1992, BRIT MED J, V305, P1155, DOI 10.1136/bmj.305.6862.1155; 1992, COMPLETE RESPONSE RE; 1992, MATERNITY SERVICES	20	13	13	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1400	1402		10.1136/bmj.307.6916.1400	http://dx.doi.org/10.1136/bmj.307.6916.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274894	Bronze, Green Published			2022-12-28	WOS:A1993MK42000024
J	WORKOWSKI, KA; LAMPE, MF; WONG, KG; WATTS, MB; STAMM, WE				WORKOWSKI, KA; LAMPE, MF; WONG, KG; WATTS, MB; STAMM, WE			LONG-TERM ERADICATION OF CHLAMYDIA-TRACHOMATIS GENITAL-INFECTION AFTER ANTIMICROBIAL THERAPY - EVIDENCE AGAINST PERSISTENT INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ENZYME-IMMUNOASSAY; URETHRITIS; WOMEN	Objective.-To determine whether Chlamydia trachomatis urogenital infections persist or relapse after antimicrobial therapy by serial measurement of chlamydial-specific DNA using the polymerase chain reaction (PCR), cell cultures, and serological studies. Design.-Prospective evaluation of an inception cohort. Setting.-University student health clinic. Participants.-Twenty women with culture-proven and PCR-proven C trachomatis urogenital infections. Measurements.-Incidence of persistent infection as determined by PCR, culture, and serial measurement of local and systemic antibody to C trachomatis for 5 months after doxycycline therapy. Results.-Prior to therapy, C trachomatis was isolated in cell culture from the cervix in 19 of 20 women, from the urethra in 13 women, and from the rectum in 13 women. All culture-positive specimens were also PCR-positive. Immediately after completion of antimicrobial therapy, all women had negative cell cultures for chlamydia. Ten of 20 culture-negative cervical specimens and two culture-negative urethral specimens had chlamydial DNA present immediately after treatment. In addition, three women had detectable DNA from cervical specimens 1 week after treatment. The presence of cervicitis (P=.01), high inclusion counts (P=.004), and serological evidence of recent infection (P=.0004) were each significantly associated with PCR positivity after treatment. All 384 subsequent cervical, rectal, and urethral specimens collected over 5 months were negative by both PCR and culture with the exception of one woman who was reinfected. Serum immunoglobulin M (IgM) titers, geometric mean serum immunoglobulin G (IgG) titers, and prevalence of local antibody to chlamydia progressively declined after treatment. Conclusions.-Standard antimicrobial therapy is effective in the long-term microbiologic eradication of uncomplicated C trachomatis urogenital infections. The presence of chlamydial DNA after antimicrobial therapy is of short duration and reflects excretion of nonviable organisms rather than persistent infection.			WORKOWSKI, KA (corresponding author), EMORY UNIV, DIV INFECT DIS, 20 LINDEN AVE NE, SUITE 101-G, ATLANTA, GA 30308 USA.				NIAID NIH HHS [AI-27456] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEIGER BE, 1989, J INFECT DIS, V159, P661, DOI 10.1093/infdis/159.4.661; BELL TA, 1992, JAMA-J AM MED ASSOC, V267, P400, DOI 10.1001/jama.267.3.400; BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L; Cerin A, 1991, Int J STD AIDS, V2, P176; HATCH TP, 1975, INFECT IMMUN, V12, P211, DOI 10.1128/IAI.12.1.211-220.1975; HOOTON TM, 1990, JAMA-J AM MED ASSOC, V264, P1418, DOI 10.1001/jama.264.11.1418; LOEFFELHOLZ MJ, 1992, J CLIN MICROBIOL, V30, P2847, DOI 10.1128/JCM.30.11.2847-2851.1992; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; NACHAMKIN I, 1987, J CLIN MICROBIOL, V25, P1774, DOI 10.1128/JCM.25.9.1774-1775.1987; Oriel J D, 1982, Eur J Clin Microbiol, V1, P69, DOI 10.1007/BF02014194; OSTERGAARD L, 1990, J CLIN MICROBIOL, V28, P1254, DOI 10.1128/JCM.28.6.1254-1260.1990; PATTON DL, 1987, J INFECT DIS, V155, P292; SANDERS LL, 1986, JAMA-J AM MED ASSOC, V255, P1750, DOI 10.1001/jama.255.13.1750; SCHACHTER J, 1978, NEW ENGL J MED, V298, P540, DOI 10.1056/NEJM197803092981005; SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805; SCHACHTER J, 1978, NEW ENGL J MED, V298, P490, DOI 10.1056/NEJM197803022980905; SHEPARD MK, 1989, FERTIL STERIL, V52, P232; SOREN K, 1989, AM J DIS CHILD, V143, P51, DOI 10.1001/archpedi.1989.02150130061015; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; SUCHLAND RJ, 1991, J CLIN MICROBIOL, V29, P1333, DOI 10.1128/JCM.29.7.1333-1338.1991; TOOMEY KE, 1990, REV INFECT DIS, V12, pS645; WANG SP, 1975, J CLIN MICROBIOL, V1, P250, DOI 10.1128/JCM.1.3.250-255.1975; Ward ME, 1988, MICOBIOLOGY CHLAMYDI, P71; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070	25	88	88	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2071	2075		10.1001/jama.270.17.2071	http://dx.doi.org/10.1001/jama.270.17.2071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8305018				2022-12-28	WOS:A1993MD88200026
J	QUINTERO, RA; REICH, H; PUDER, KS; BARDICEF, M; EVANS, MI; COTTON, DB; ROMERO, R				QUINTERO, RA; REICH, H; PUDER, KS; BARDICEF, M; EVANS, MI; COTTON, DB; ROMERO, R			UMBILICAL-CORD LIGATION OF AN ACARDIAC TWIN BY FETOSCOPY AT 19 WEEKS OF GESTATION - BRIEF REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SELECTIVE DELIVERY; ACEPHALIC TWIN; PREGNANCIES; HYSTEROTOMY		WYOMING VALLEY GYN ASSOCIATES, KINGSTON, PA USA; NICHHD, PERINATOL RES BRANCH, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	QUINTERO, RA (corresponding author), WAYNE STATE UNIV, HUTZEL HOSP, CTR FETAL DIAG & THERAPY, DEPT OBSTET & GYNECOL, DETROIT, MI 48201 USA.		Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121				COURTENA.H, 1972, FERTIL STERIL, V23, P274; FRIES MH, 1992, OBSTET GYNECOL, V79, P601; GINSBERG NA, 1992, AM J OBSTET GYNECOL, V167, P33, DOI 10.1016/S0002-9378(11)91620-2; GRAB D, 1992, FETUS, V2, P11; Hamada H, 1989, Nihon Sanka Fujinka Gakkai Zasshi, V41, P1803; JAMES WH, 1977, TERATOLOGY, V16, P211, DOI 10.1002/tera.1420160216; MOORE TR, 1990, AM J OBSTET GYNECOL, V163, P907, DOI 10.1016/0002-9378(90)91094-S; PLATT LD, 1983, AM J OBSTET GYNECOL, V146, P857, DOI 10.1016/0002-9378(83)91090-6; PORRECO RP, 1991, LANCET, V337, P326, DOI 10.1016/0140-6736(91)90946-M; QUINTERO RA, 1993, AM J OBSTET GYNECOL, V168, P1552, DOI 10.1016/S0002-9378(11)90797-2; ROBIE GF, 1989, NEW ENGL J MED, V320, P512, DOI 10.1056/NEJM198902233200808; SIMPSON PC, 1983, AM J OBSTET GYNECOL, V147, P842, DOI 10.1016/0002-9378(83)90056-X; VANALLEN MI, 1983, SEMIN PERINATOL, V7, P285; [No title captured]	14	152	158	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					469	471		10.1056/NEJM199402173300705	http://dx.doi.org/10.1056/NEJM199402173300705			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289853				2022-12-28	WOS:A1994MW48000005
J	RODIN, A; THAKKAR, H; TAYLOR, N; CLAYTON, R				RODIN, A; THAKKAR, H; TAYLOR, N; CLAYTON, R			HYPERANDROGENISM IN POLYCYSTIC-OVARY-SYNDROME - EVIDENCE OF DYSREGULATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING HORMONE; INSULIN RESISTANCE; 21-HYDROXYLASE DEFICIENCY; ANDROGEN OVERPRODUCTION; MALE-TRANSSEXUALS; ADRENAL-FUNCTION; HIRSUTE WOMEN; DISEASE; ENDOCRINE; CATHETERIZATION	Background. Hyperandrogenemia is the hallmark of the polycystic ovary syndrome, yet the relative contributions of the adrenal cortex and ovary to the overproduction of androgen remain unclear. To identify possible causes of adrenocortical overactivity, we studied the metabolism of adrenal and ovarian steroid hormones in women with this disorder. Methods, We measured 24-hour urinary excretion of steroid hormone metabolites by high-resolution capillary gas chromatography in 65 women with the polycystic ovary syndrome and 45 normal women matched for body-mass index. Results. After adjustment for body-mass index, the urinary excretion of testosterone and androstenedione metabolites was 1.9 times higher in the women with the syndrome than in the normal women, and the excretion of dehydroepiandrosterone metabolites (C19 steroid sulfates) and cortisol metabolites was 1.5 and 1.3 times higher, respectively (P<0.01 for all comparisons). The affected women also had significantly higher ratios of 11-oxo (oxygenated) metabolites to 11-hydroxy metabolites of cortisol (1.4 times higher, P<0.001) and of 11-oxo to 11-hydroxy metabolites of corticosterone (1.8 times higher, P<0.001). In the group with the polycystic ovary syndrome, 55 percent of the nonobese women and 24 percent of the obese women had ratios above the upper limit of normal; the ratios in the obese women did not differ significantly from those in the nonobese women. Conclusions. Adrenal secretion of cortisol and androgens is increased in women with the polycystic ovary syndrome. The increases may be explained by dysregulation of 11 beta-hydroxysteroid dehydrogenase causing increased oxidation of cortisol to cortisone, which cannot be accounted for by obesity.	ROYAL LONDON HOSP,DEPT CLIN BIOCHEM,LONDON,ENGLAND; KINGS COLL,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DIV BIOCHEM MED,LONDON,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; King's College London; St Georges University London	RODIN, A (corresponding author), N STAFFORDSHIRE ROYAL INFIRM,DEPT ENDOCRINOL,HARTSHILL,STOKE ON TRENT ST4 7LN,STAFFS,ENGLAND.							ABRAHAM GE, 1975, OBSTET GYNECOL, V46, P169; ADAMS J, 1985, LANCET, V2, P1375; AXELROD LR, 1962, J CLIN ENDOCR METAB, V22, P431, DOI 10.1210/jcem-22-4-431; BARDIN CW, 1968, J CLIN ENDOCR METAB, V28, P1300, DOI 10.1210/jcem-28-9-1300; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; CARMINA E, 1990, GYNECOL ENDOCRINOL, V4, P225, DOI 10.3109/09513599009024976; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; CLAYTON RN, 1992, CLIN ENDOCRINOL, V37, P127, DOI 10.1111/j.1365-2265.1992.tb02296.x; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FEUILLAN P, 1988, J CLIN ENDOCR METAB, V67, P154, DOI 10.1210/jcem-67-1-154; FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; FUTTERWEIT W, 1986, J CLIN ENDOCR METAB, V62, P16, DOI 10.1210/jcem-62-1-16; FUTTERWEIT W, 1984, POLYCYSTIC OVARIAN D, P97; GADIR AA, 1990, CLIN ENDOCRINOL, V32, P749, DOI 10.1111/j.1365-2265.1990.tb00921.x; GIVENS JR, 1975, J CLIN ENDOCR METAB, V40, P988, DOI 10.1210/jcem-40-6-988; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GROSS MD, 1986, J CLIN ENDOCR METAB, V62, P197, DOI 10.1210/jcem-62-1-197; HAGUE WM, 1986, J ENDOCRINOL, V111, P46; HORTON R, 1968, J CLIN ENDOCR METAB, V28, P479, DOI 10.1210/jcem-28-4-479; KIRSCHNER MA, 1971, J CLIN ENDOCR METAB, V33, P199, DOI 10.1210/jcem-33-2-199; LACHELIN GCL, 1979, J CLIN ENDOCR METAB, V49, P892, DOI 10.1210/jcem-49-6-892; LOBO RA, 1981, OBSTET GYNECOL, V57, P69; LOUGHLIN T, 1986, J CLIN ENDOCR METAB, V62, P142, DOI 10.1210/jcem-62-1-142; MIGEON CJ, 1989, ENDOCRINOLOGY, V2, P1676; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; NELSON DH, 1989, ENDOCRINOLOGY, V2, P1660; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; ORSINI LF, 1985, FERTIL STERIL, V43, P709; PACHE TD, 1991, HISTOPATHOLOGY, V19, P445, DOI 10.1111/j.1365-2559.1991.tb00235.x; ROBINSON S, 1992, BRIT J OBSTET GYNAEC, V99, P232, DOI 10.1111/j.1471-0528.1992.tb14505.x; SHACKLETON CHL, 1980, CLIN CHIM ACTA, V107, P231, DOI 10.1016/0009-8981(80)90451-9; SOMMERS SC, 1956, AM J OBSTET GYNECOL, V72, P160, DOI 10.1016/S0002-9378(16)37526-3; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; STRAIN GW, 1989, METABOLISM, V29, P980; WAJCHENBERG BL, 1986, J CLIN ENDOCR METAB, V63, P1204, DOI 10.1210/jcem-63-5-1204; WALKER BR, 1991, CLIN ENDOCRINOL, V35, P281, DOI 10.1111/j.1365-2265.1991.tb03537.x; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	41	171	173	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					460	465		10.1056/NEJM199402173300703	http://dx.doi.org/10.1056/NEJM199402173300703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289851				2022-12-28	WOS:A1994MW48000003
J	ELLIOTT, WJ				ELLIOTT, WJ			ANTIHYPERTENSIVE THERAPY IN A PATIENT WITH GOUT AND ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONVERTING ENZYME-INHIBITORS; INDUCED COUGH; BRONCHIAL HYPERREACTIVITY; BLOOD-PRESSURE; CAPTOPRIL; HYPERTENSION; RESPONSIVENESS; VERAPAMIL; DISEASE; AIRWAY				ELLIOTT, WJ (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612, USA.							AMBROSIONI E, 1992, EUR J EPIDEMIOL, V8, P129, DOI 10.1007/BF00145364; ARIE E, 1989, DRUGS, V37, P566, DOI 10.2165/00003495-198937040-00008; AYACHE A S, 1991, Harefuah, V120, P190; BUCCA C, 1990, CHEST, V98, P1133, DOI 10.1378/chest.98.5.1133; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; CANESSA PA, 1990, MED-RIV ENC MED ITAL, V10, P296; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ELLIOTT WJ, 1993, AM J HYPERTENS, V6, pA94; FOGARI R, 1992, J CARDIOVASC PHARM, V19, P670; Fujimori K, 1991, Arerugi, V40, P1327; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GOH T C, 1991, SMJ Singapore Medical Journal, V32, P183; KATSUMATA U, 1991, TOHOKU J EXP MED, V164, P103, DOI 10.1620/tjem.164.103; KAUFMAN J, 1989, CHEST, V95, P544, DOI 10.1378/chest.95.3.544; KAUFMAN J, 1992, CHEST, V101, P922, DOI 10.1378/chest.101.4.922; KAUFMAN J, 1992, J HYPERTENS        S, V10, pS135; MIDTBO K, 1988, ANGIOLOGY, V39, P1025, DOI 10.1177/000331978803901204; OGIHARA T, 1991, AM J HYPERTENS, V4, pS46, DOI 10.1093/ajh/4.1.46S; OVERLACK A, 1992, J HUM HYPERTENS, V6, P387; OVERLACK A, 1992, AGENT ACTION SUPPL, V38, P482; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RISKA H, 1990, J CARDIOVASC PHARM, V15, P57, DOI 10.1097/00005344-199001000-00009; SALENA BJ, 1986, ARCH INTERN MED, V146, P202, DOI 10.1001/archinte.146.1.202	24	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					555	555		10.1001/jama.271.7.555	http://dx.doi.org/10.1001/jama.271.7.555			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301774				2022-12-28	WOS:A1994MV42300042
J	WARREN, ST; NELSON, DL				WARREN, ST; NELSON, DL			ADVANCES IN MOLECULAR ANALYSIS OF FRAGILE-X SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTALLY-RETARDED MALES; ABNORMAL METHYLATION; HUMAN-CHROMOSOMES; UNSTABLE DNA; INSTABILITY; EXPRESSION; REPEAT; SITE; GENE; HETEROGENEITY	Fragile X syndrome is a common cause of mental retardation that is inherited as an X-linked dominant disorder with reduced penetrance. Fragile X syndrome has been shown to be caused by an unstable CGG repeat within the fragile X mental retardation-1 (FMR1) gene. The repeat is normally polymorphic with six to 52 repeats, while affected males and females exhibit a massive expansion resulting in 230 to more than 1000 repeats. Such expansions, called ''full mutations,'' are associated with abnormal methylation of the FMR1 gene leading to transcriptional suppression. The resulting absence of the encoded protein, FMRP, a cytosolic RNA-binding protein, is believed to result in the phenotype. Nonpenetrant male carriers and many female carriers exhibit premutation alleles of intermediate length (50 to 230 repeats), which are normally expressed. Male carriers transmit only unstable premutations while female premutation carriers can have carrier off spring with premutations or affected children with full mutations. The risk of having an affected child is directly related to the number of maternal repeats, with sequentially increasing probabilities of these alleles converting to full mutations as they are transmitted to subsequent generations. Advances have led to highly accurate laboratory diagnoses of both carrier and affected individuals as well as markedly improved prenatal diagnosis. In addition, a previously unrecognized class of mutation, later found responsible for several other important genetic diseases, has emerged.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,ATLANTA,GA 30322; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030	Emory University; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	WARREN, ST (corresponding author), EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,1510 CLIFTON RD NE,ATLANTA,GA 30322, USA.		Warren, Stephen T/A-2498-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029256, R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29256, HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROOK JD, 1992, CELL, V68, P790; BROWN WT, 1990, AM J HUM GENET, V47, P175; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; BUTLER MG, 1992, PEDIATRICS, V89, P1059; BUTLER MG, 1991, AM J MED GENET, V38, P260, DOI 10.1002/ajmg.1320380220; BUTLER MG, 1991, CLIN GENET, V39, P347; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DEVYS D, 1992, AM J MED GENET, V43, P208, DOI 10.1002/ajmg.1320430134; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EICHLER EE, 1993, HUM MOL GENET, V2, P1147, DOI 10.1093/hmg/2.8.1147; FRYNS JP, 1987, CLIN GENET, V32, P388; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GEDEON AK, 1992, NAT GENET, V1, P341, DOI 10.1038/ng0892-341; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HAGERMAN R, 1993, AM J HUM GENET S, V53, pA144; Hagerman R, 1991, FRAGILE X SYNDROME D, P3; Hagerman R. J., 1991, FRAGILE X SYNDROME D, P173; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST MC, 1993, HUM MOL GENET, V2, P197, DOI 10.1093/hmg/2.2.197; HOCKEY A, 1988, AM J MED GENET, V30, P61, DOI 10.1002/ajmg.1320300104; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V1, P9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LOEHR JP, 1986, AM J MED GENET, V23, P189, DOI 10.1002/ajmg.1320230113; LOESCH DZ, 1993, AM J HUM GENET, V53, P1064; LUBS HA, 1969, AM J HUM GENET, V21, P231; Martin JP, 1943, J NEUROL PSYCHIATRY, V6, P154, DOI 10.1136/jnnp.6.3-4.154; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; McKusick VA, 1990, MENDELIAN INHERITANC; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; NUSSBAUM RL, 1989, METABOLIC BASIS INHE, P327; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OUDET C, 1993, AM J HUM GENET, V52, P297; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; REYNIERS E, 1993, NAT GENET, V4, P143, DOI 10.1038/ng0693-143; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; ROUSSEAU F, 1993, AM J HUM GENET, V53, pA3; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sherman S., 1991, FRAGILE X SYNDROME D, P69; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; SNOW K, 1993, AM J HUM GENET, V53, P1217; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERLAND GR, 1991, NEW ENGL J MED, V325, P1720, DOI 10.1056/NEJM199112123252407; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1992, AM J HUM GENET, V51, P7; Sutherland Grant R., 1992, Human Molecular Genetics, V1, P111, DOI 10.1093/hmg/1.2.111; TARLETON JC, 1993, J PEDIATR-US, V122, P169, DOI 10.1016/S0022-3476(06)80110-1; TORRES W, 1993, AM J HUM GENET, V53, P1241; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1980, J PEDIATR-US, V96, P837, DOI 10.1016/S0022-3476(80)80552-X; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG Q, 1993, LANCET, V342, P1025, DOI 10.1016/0140-6736(93)92882-T; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; WHRLE D, 1992, AM J HUM GENET, V51, P299; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]; 1993, CELL, V72, P971	81	163	164	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					536	542		10.1001/jama.271.7.536	http://dx.doi.org/10.1001/jama.271.7.536			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301769				2022-12-28	WOS:A1994MV42300037
J	MENZIES, R; VISSANDJEE, B; ROCHER, I; STGERMAIN, Y				MENZIES, R; VISSANDJEE, B; ROCHER, I; STGERMAIN, Y			THE BOOSTER EFFECT IN 2-STEP TUBERCULIN TESTING AMONG YOUNG-ADULTS IN MONTREAL	ANNALS OF INTERNAL MEDICINE			English	Article							SKIN-TEST; CALMETTE-GUERIN; SCHOOL-CHILDREN; BCG VACCINATION; SENSITIVITY; INFECTION; BIRTH; MYCOBACTERIA; POPULATION; CONVERSION	Objectives: No consensus exists regarding the definition and interpretation of a significant boosting reaction after sequential tuberculin testing. The booster phenomenon is thought to represent remote tuberculous infection where tuberculin reactivity has waned, but it has also been described among persons with previous exposure to other mycobacteria or Bacille Calmette-Guerin (BCG) vaccine. We studied the factors affecting the booster phenomenon among Canadian-born young adults to determine the definition that would maximize sensitivity and specificity of a positive booster reaction in these persons. Design: Point-prevalence survey of initial tuberculin reactions and response to repeated tuberculin testing after 1 to 4 weeks. Setting: Community-based study of all students entering health professional training programs at six post-secondary institutions. Measurements: In 1989, 1990, and 1991, students completed self-administered questionnaires, underwent two-step tuberculin testing with purified protein derivative-tuberculin (PPD-T), and had their childhood BCG vaccination status verified. In 1991, students were also tested with purified protein derivative-Battey (PPD-B) (for Mycobacterium intracellulare). Results: Overall, 74 students (5.2%) had positive booster reactions, which were significantly associated with older age (P < 0.001), larger initial tuberculin reactions (P < 0.001), previous BCG vaccination (P < 0.001), older age when vaccinated (P < 0.02), longer interval from vaccination to testing (P < 0.01), and sensitivity to PPD-B (P < 0.001). Boosting was not associated with the number of BCG vaccinations, sex, or risk factors for tuberculous infection. The pattern, mean, and mode of the frequency distributions of booster reactions among those with BCG vaccination and sensitivity to PPD-B were similar to those with assumed tuberculous infection. Conclusions: In young adults, booster reactions due to previous tuberculous infection are uncommon and cannot be distinguished from false-positive reactions due to past exposure to other mycobacteria.	UNIV MONTREAL, DEPT NURSING, MONTREAL H2X 2P4, PQ, CANADA; MCGILL UNIV, RESP EPIDEMIOL UNIT, MONTREAL H3A 2T5, QUEBEC, CANADA	Universite de Montreal; McGill University	MENZIES, R (corresponding author), MONTREAL CHEST HOSP, 3650 ST URBAIN ST, MONTREAL H2X 2P4, PQ, CANADA.							ALVAREZ S, 1987, AM REV RESPIR DIS, V136, P1193, DOI 10.1164/ajrccm/136.5.1193; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1985, AM REV RESPIR DIS, V132, P379; BASS JB, 1981, AM REV RESPIR DIS, V123, P394; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; Colton T., 1974, STAT MED, V1; COMSTOCK GW, 1978, AM REV RESPIR DIS, V118, P215; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EDWARDS LB, 1973, AM REV RESPIR DIS, V108, P1334; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P118; FRAPPIER A, 1971, CAN MED ASSOC J, V105, P707; FRAPPIERDAVIGNON L, 1989, CAN J PUBLIC HEALTH, V80, P335; FRIEDLAND IR, 1990, S AFR MED J, V77, P387; GORDIN FM, 1988, AM REV RESPIR DIS, V137, P153, DOI 10.1164/ajrccm/137.1.153; GRINDULIS H, 1984, ARCH DIS CHILD, V59, P614, DOI 10.1136/adc.59.7.614; HANKINS CA, 1990, CAN MED ASSOC J, V143, P885; HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95; HORWITZ O, 1972, B WORLD HEALTH ORGAN, V47, P49; HUEBNER RE, 1992, AM REV RESPIR DIS, V145, P1160, DOI 10.1164/ajrccm/145.5.1160; JONCAS JH, 1975, CAN MED ASSOC J, V113, P127; KLEINBAUM DG, 1978, APPLIED REGRESSION A; KNIGHT RA, 1963, AM REV RESPIR DIS, V88, P119; LANDI S, 1967, CAN MED ASSOC J, V97, P222; LYON AJ, 1986, BRIT MED J, V292, P1526, DOI 10.1136/bmj.292.6534.1526-a; MAGNUS K, 1955, LANCET, V2, P643; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; MENZIES R, 1992, AM REV RESPIR DIS, V146, P752, DOI 10.1164/ajrccm/146.3.752; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; PABST HF, 1980, J PEDIATR-US, V97, P519, DOI 10.1016/S0022-3476(80)80003-5; RICHARDS NM, 1979, AM REV RESPIR DIS, V120, P59; RUBEN FL, 1977, AM REV RESPIR DIS, V115, P23; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SEPULVEDA RL, 1990, AM REV RESPIR DIS, V142, P24, DOI 10.1164/ajrccm/142.1.24; SEPULVEDA RL, 1988, PEDIATR INFECT DIS J, V7, P578, DOI 10.1097/00006454-198808000-00009; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; VANDENBRANDE P, 1992, CHEST, V101, P447, DOI 10.1378/chest.101.2.447; 1979, HEW798371 CTR DIS CO	43	112	114	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					190	198		10.7326/0003-4819-120-3-199402010-00003	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273982				2022-12-28	WOS:A1994MU30300003
J	MARRACK, P; KAPPLER, J				MARRACK, P; KAPPLER, J			SUBVERSION OF THE IMMUNE-SYSTEM BY PATHOGENS	CELL			English	Review							HERPES-SIMPLEX VIRUS; INTERLEUKIN-1-BETA CONVERTING ENZYME; PHAGOSOME-LYSOSOME FUSION; CELL-SURFACE EXPRESSION; MAMMARY-TUMOR VIRUS; CLASS-I ANTIGENS; T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; 3-DIMENSIONAL STRUCTURE; STAPHYLOCOCCUS-AUREUS		UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MARRACK, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, HOWARD HUGHES MED INST, DENVER, CO 80206 USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017134, R37AI017134, P01AI022295, R37AI018785, R56AI017134, R01AI018785] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18785, AI 22295, AI 17134] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALTHAGE A, 1992, EUR J IMMUNOL, V22, P1803, DOI 10.1002/eji.1830220720; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BABBITT BP, 1986, P NATL ACAD SCI USA, V83, P4509, DOI 10.1073/pnas.83.12.4509; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; BURNET FM, 1932, PATHOL BACTERIOL, V35, P477; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; EGGINK HF, 1982, CLIN EXP IMMUNOL, V50, P17; ELSE KJ, 1992, IMMUNOLOGY, V75, P232; ERNTELL M, 1986, ACTA PATH MICRO IM B, V94, P377; FAUCI A, 1993, AIDS, V6, P655; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FORSGREN M, 1983, SCAND J IMMUNOL, V17, P201; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GOODING LR, 1992, CELL, V71, P5; GOREN MB, 1976, P NATL ACAD SCI USA, V73, P2510, DOI 10.1073/pnas.73.7.2510; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GROVER S, 1992, BIOCHEM BIOPH RES CO, V182, P1075, DOI 10.1016/0006-291X(92)91841-D; HARRIS SL, 1990, J INFECT DIS, V162, P331, DOI 10.1093/infdis/162.2.331; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAYRY P, 1970, SCIENCE, V168, P133, DOI 10.1126/science.168.3927.133; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; INGANAS M, 1981, SCAND J IMMUNOL, V13, P343, DOI 10.1111/j.1365-3083.1981.tb00143.x; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KEWP LM, 1990, NEURON, V4, P215; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; KOZAK M, 1983, MICROBIOL REV, V47, P1; KULKARNI AB, 1993, AM J PATHOL, V143, P3; KUNDIG TM, 1993, SCIENCE, V262, P1059, DOI 10.1126/science.8235625; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LAVER W G, 1973, Virology, V51, P383, DOI 10.1016/0042-6822(73)90437-6; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MOLLER G, 1972, CELL IMMUNOL, V4, P416, DOI 10.1016/0008-8749(72)90043-3; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURPHY BR, 1990, VIROLOGY, P1091; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; PAABO S, 1986, P NATL ACAD SCI USA, V83, P9665, DOI 10.1073/pnas.83.24.9665; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PANGBURN MK, 1986, IMMUNOBIOLOGY COMPLE; PAYS E, 1985, PROG NUCLEIC ACID RE, V32, P1, DOI 10.1016/S0079-6603(08)60344-X; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RAJASEKAR R, 1990, P NATL ACAD SCI USA, V87, P1767, DOI 10.1073/pnas.87.5.1767; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBERTS WK, 1982, J INTERFERON RES, V2, P519, DOI 10.1089/jir.1982.2.519; SAWTELL NM, 1992, J VIROL, V66, P2150, DOI 10.1128/JVI.66.4.2150-2156.1992; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHOLTISSEK C, 1978, VIROLOGY, V89, P506, DOI 10.1016/0042-6822(78)90192-7; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SEARS AE, 1991, J VIROL, V65, P2929, DOI 10.1128/JVI.65.6.2929-2935.1991; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; STAHL RE, 1982, AM J MED, V73, P171, DOI 10.1016/0002-9343(82)90174-7; STEVENS DA, 1975, J INFECT DIS, V131, P509, DOI 10.1093/infdis/131.5.509; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; SWAIN SL, 1983, J EXP MED, V157, P720, DOI 10.1084/jem.157.2.720; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TEW JG, 1980, IMMUNOL REV, V53, P175; THONG YH, 1975, INFECT IMMUN, V12, P76, DOI 10.1128/IAI.12.1.76-80.1975; TROUSDALE MD, 1991, J VIROL, V65, P6989, DOI 10.1128/JVI.65.12.6989-6993.1991; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; Vickerman K., 1993, Immunology and molecular biology of parasitic infections., P170; WEBSTER RG, 1979, VIROLOGY, V96, P258, DOI 10.1016/0042-6822(79)90189-2; WHITLEY RJ, 1990, VIROLOGY, P1843; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	103	187	196	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					323	332		10.1016/0092-8674(94)90339-5	http://dx.doi.org/10.1016/0092-8674(94)90339-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293466				2022-12-28	WOS:A1994MU67800015
J	COMO, JA; DISMUKES, WE				COMO, JA; DISMUKES, WE			ORAL AZOLE DRUGS AS SYSTEMIC ANTIFUNGAL THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BONE-MARROW TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; B PLUS FLUCYTOSINE; AMPHOTERICIN-B; CRYPTOCOCCAL MENINGITIS; KETOCONAZOLE THERAPY; ITRACONAZOLE THERAPY; INVASIVE ASPERGILLOSIS; FUNGAL-INFECTIONS		UNIV ALABAMA,SCH MED,DEPT MED,DIV INFECT DIS,THT 229,BIRMINGHAM,AL 35294; UNIV ALABAMA HOSP & CLIN,DEPT PHARM,BIRMINGHAM,AL 35233	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AISNER J, 1977, ANN INTERN MED, V86, P539, DOI 10.7326/0003-4819-86-5-539; ANAISSIE E, 1991, AM J MED, V91, P142, DOI 10.1016/0002-9343(91)90006-J; APSELOFF G, 1991, J CLIN PHARMACOL, V31, P358, DOI 10.1002/j.1552-4604.1991.tb03718.x; BACK DJ, 1991, BRIT J CLIN PHARMACO, V32, P624, DOI 10.1111/j.1365-2125.1991.tb03963.x; BARONE JA, 1993, ANTIMICROB AGENTS CH, V37, P778, DOI 10.1128/AAC.37.4.778; BENNETT JE, 1979, NEW ENGL J MED, V301, P126, DOI 10.1056/NEJM197907193010303; BERRY AJ, 1992, ANTIMICROB AGENTS CH, V36, P690, DOI 10.1128/AAC.36.3.690; BLUM RA, 1991, ANN INTERN MED, V114, P755, DOI 10.7326/0003-4819-114-9-755; BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161; BOELAERT J, 1988, ANTIMICROB AGENTS CH, V32, P1595, DOI 10.1128/AAC.32.10.1595; BOOGAERTS MA, 1989, MYCOSES, V32, P103, DOI 10.1111/j.1439-0507.1989.tb02299.x; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; BRADSHER RW, 1985, ANN INTERN MED, V103, P872, DOI 10.7326/0003-4819-103-6-872; BRAMMER KW, 1991, DRUG METAB DISPOS, V19, P764; BROOKS RG, 1989, ARCH INTERN MED, V149, P2226, DOI 10.1001/archinte.149.10.2226; BROWN MW, 1985, CLIN PHARMACOL THER, V37, P290, DOI 10.1038/clpt.1985.42; BURCH PA, 1987, J CLIN ONCOL, V5, P1985, DOI 10.1200/JCO.1987.5.12.1985; CAMERON ML, 1993, ANTIMICROB AGENTS CH, V37, P2449, DOI 10.1128/AAC.37.11.2449; CATANZARO A, 1990, CHEST, V97, P666, DOI 10.1378/chest.97.3.666; CAUWENBERGH G, 1988, J AM ACAD DERMATOL, V18, P263, DOI 10.1016/S0190-9622(88)70037-7; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DANESHMEND TK, 1983, CLIN PHARMACOKINET, V8, P17, DOI 10.2165/00003088-198308010-00002; DEBRABANDER M, 1980, SABOURAUDIA, V18, P197; DEBRUYNE D, 1990, CLIN PHARMACOKINET, V18, P491, DOI 10.2165/00003088-199018060-00006; DEGANS J, 1992, AIDS, V6, P185, DOI 10.1097/00002030-199202000-00007; DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0; DENNING DW, 1990, MYCOSES IN AIDS PATIENTS, P305; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DISMUKES WE, 1992, AM J MED, V93, P489, DOI 10.1016/0002-9343(92)90575-V; DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; DUPONT B, 1990, J AM ACAD DERMATOL, V23, P607, DOI 10.1016/0190-9622(90)70263-H; EDWARDS JE, 1992, CLIN INFECT DIS, V14, pS106, DOI 10.1093/clinids/14.Supplement_1.S106; ENGELHARD D, 1984, NEW ENGL J MED, V311, P1681, DOI 10.1056/NEJM198412273112606; EVANS TG, 1991, J INFECT DIS, V164, P1232, DOI 10.1093/infdis/164.6.1232; FANHAVARD P, 1991, ANTIMICROB AGENTS CH, V35, P2302, DOI 10.1128/AAC.35.11.2302; FISHER MA, 1989, ANTIMICROB AGENTS CH, V33, P1443, DOI 10.1128/AAC.33.9.1443; FRANCIS P, 1992, CLIN INFECT DIS, V15, P1003, DOI 10.1093/clind/15.6.1003; FRASER VJ, 1992, CLIN INFECT DIS, V15, P414, DOI 10.1093/clind/15.3.414; GALGIANI JN, 1993, ANTIMICROB AGENTS CH, V37, P2517, DOI 10.1128/AAC.37.12.2517; GALGIANI JN, 1988, AM J MED, V84, P603, DOI 10.1016/0002-9343(88)90143-X; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1987, ANTIMICROB AGENTS CH, V31, P1867, DOI 10.1128/AAC.31.12.1867; GALLIS HA, 1990, REV INFECT DIS, V12, P308; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRANT SM, 1990, DRUGS, V40, P862, DOI 10.1007/BF03259618; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; HANGER DP, 1988, ANTIMICROB AGENTS CH, V32, P646, DOI 10.1128/AAC.32.5.646; HANN IM, 1982, LANCET, V1, P826; HARDIN TC, 1988, ANTIMICROB AGENTS CH, V32, P1310, DOI 10.1128/AAC.32.9.1310; HECTOR RF, 1990, ANTIMICROB AGENTS CH, V34, P448, DOI 10.1128/AAC.34.3.448; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HOSTETLER JS, 1992, ANTIMICROB AGENTS CH, V36, P477, DOI 10.1128/AAC.36.2.477; HUMPHREY MJ, 1985, ANTIMICROB AGENTS CH, V28, P648, DOI 10.1128/AAC.28.5.648; JOLY V, 1992, ANTIMICROB AGENTS CH, V36, P1799, DOI 10.1128/AAC.36.9.1799; KANDROTAS RJ, 1987, CLIN PHARMACOL THER, V42, P465, DOI 10.1038/clpt.1987.179; KAUFFMAN CA, 1991, AM J MED, V91, P137, DOI 10.1016/0002-9343(91)90005-I; KRAMER MR, 1990, ANN INTERN MED, V113, P327, DOI 10.7326/0003-4819-113-4-327; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LAZAR JD, 1990, REV INFECT DIS, V12, pS327; LAZAR JD, 1990, SEMIN ONCOL, V17, P14; LECCIONES JA, 1992, CLIN INFECT DIS, V14, P875, DOI 10.1093/clinids/14.4.875; LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; LOPEZGIL JA, 1993, ANN PHARMACOTHER, V27, P427, DOI 10.1177/106002809302700405; MCQUILLEN DP, 1992, CLIN INFECT DIS, V14, P472, DOI 10.1093/clinids/14.2.472; MILEFCHIK E, 1993, 9TH INT C AIDS 4TH S, V1; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MUNOZ P, 1991, ARCH INTERN MED, V151, P1020, DOI 10.1001/archinte.151.5.1020; NEGRONI R, 1980, REV INFECT DIS, V2, P643; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; NOLLASALAS J, 1992, CLIN INFECT DIS, V14, P952, DOI 10.1093/clinids/14.4.952; ODDS FC, 1993, J ANTIMICROB CHEMOTH, V31, P463, DOI 10.1093/jac/31.4.463; PAPPAS PG, 1991, 31ST INT C ANT AG CH, P292; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; PHILLIPS P, 1987, ANTIMICROB AGENTS CH, V31, P647, DOI 10.1128/AAC.31.4.647; PISCITELLI SC, 1991, ANTIMICROB AGENTS CH, V35, P1765, DOI 10.1128/AAC.35.9.1765; PONT A, 1984, ARCH INTERN MED, V144, P2150, DOI 10.1001/archinte.144.11.2150; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; RESTREPO A, 1986, ARCH DERMATOL, V122, P413, DOI 10.1001/archderm.122.4.413; Restrepo A, 1983, Am J Med, V74, P48; RESTREPO A, 1987, REV INFECT DIS, V9, pS51; REX JH, 1993, 33RD INT C ANT AG CH, P267; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SACHS MK, 1993, CLIN INFECT DIS, V16, P400, DOI 10.1093/clind/16.3.400; SANDVEN P, 1993, ANTIMICROB AGENTS CH, V37, P2443, DOI 10.1128/AAC.37.11.2443; SANTEN RJ, 1983, J CLIN ENDOCR METAB, V57, P732, DOI 10.1210/jcem-57-4-732; SAVANI DV, 1987, ANTIMICROB AGENTS CH, V31, P6, DOI 10.1128/AAC.31.1.6; SCHMITT HJ, 1992, CHEMOTHERAPY, V38, P118, DOI 10.1159/000238951; SHARKEY PK, 1991, ANTIMICROB AGENTS CH, V35, P707, DOI 10.1128/AAC.35.4.707; SHARKEYMATHIS PK, 1993, AM J MED, V95, P279, DOI 10.1016/0002-9343(93)90280-3; SHEPP DH, 1985, J INFECT DIS, V152, P1257, DOI 10.1093/infdis/152.6.1257; SLAVIN M, 1992, 32ND INT C ANT AG CH, P214; SONINO N, 1987, NEW ENGL J MED, V317, P812, DOI 10.1056/NEJM198709243171307; SUD IJ, 1979, ANTIMICROB AGENTS CH, V16, P660, DOI 10.1128/AAC.16.5.660; TERRELL CL, 1992, MAYO CLIN PROC, V67, P69, DOI 10.1016/S0025-6196(12)60281-X; TOON S, 1990, BRIT J CLIN PHARMACO, V29, P221, DOI 10.1111/j.1365-2125.1990.tb03623.x; TRICOT G, 1987, REV INFECT DIS, V9, pS94; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; TUCKER RM, 1988, ANTIMICROB AGENTS CH, V32, P369, DOI 10.1128/AAC.32.3.369; TUCKER RM, 1990, J ANTIMICROB CHEMOTH, V26, P561, DOI 10.1093/jac/26.4.561; TUCKER RM, 1992, CLIN INFECT DIS, V14, P165, DOI 10.1093/clinids/14.1.165; VANDENBOSSCHE H, 1986, DRUG DEVELOP RES, V8, P287, DOI 10.1002/ddr.430080133; VANDENBOSSCHE H, 1983, BIOCHEM SOC T, V11, P665, DOI 10.1042/bst0110665; VANPEER A, 1989, EUR J CLIN PHARMACOL, V36, P423, DOI 10.1007/BF00558308; WARNOCK DW, 1988, J ANTIMICROB CHEMOTH, V21, P93, DOI 10.1093/jac/21.1.93; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WHEAT LJ, 1992, 32ND INT C ANT AG CH, P312; WHITE M, 1992, J INFECT DIS, V165, P960, DOI 10.1093/infdis/165.5.960; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; 1985, ANN INTERN MED, V103, P861	118	482	493	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					263	272						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272088				2022-12-28	WOS:A1994MR49600007
J	MCCARTY, DJ				MCCARTY, DJ			GOUT WITHOUT HYPERURICEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											MCCARTY, DJ (corresponding author), MED COLL WISCONSIN, INST ARTHRITIS, DEPT MED, DIV RHEUMATOL, MCMC BOX 120, MILWAUKEE, WI 53226 USA.							HADLER NM, 1974, AM J MED, V56, P715, DOI 10.1016/0002-9343(74)90639-1; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; Levinson Dennis J., 1993, P1773; LOEB JN, 1972, ARTHRITIS RHEUM-US, V15, P189, DOI 10.1002/art.1780150209; MACFARLANE DG, 1985, BRIT J RHEUMATOL, V24, P155; MCCARTY DJ, 1991, URATE DEPOSITION MAN, P12; RODNAN GP, 1980, CLIN RES, V28, pA359; SEEGMILLER J. E., 1965, ARTHRITIS RHEUM, V8, P714, DOI 10.1002/art.1780080431; Wyngaarden JB, 1983, METABOLIC BASIS INHE, P1043	9	62	68	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					302	303		10.1001/jama.271.4.302	http://dx.doi.org/10.1001/jama.271.4.302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295290				2022-12-28	WOS:A1994MR22100027
J	RUBIN, SM; STRULL, WM; FIALKOW, MF; WEISS, SJ; LO, B				RUBIN, SM; STRULL, WM; FIALKOW, MF; WEISS, SJ; LO, B			INCREASING THE COMPLETION OF THE DURABLE POWER OF ATTORNEY FOR HEALTH-CARE - A RANDOMIZED, CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-DETERMINATION ACT; LIFE-SUSTAINING TREATMENT; ADVANCE DIRECTIVES; LIVING WILLS; PATIENT; OUTPATIENTS; PREFERENCES; ATTITUDES; DECISION; PROXY	Objective.-Wider use of written advance directives may prevent many ethical dilemmas about life-sustaining interventions for patients who have lost decision-making capacity. We investigated whether a simple educational intervention increased patient completion of the durable power of attorney for health care. Design.-A randomized, controlled trial. Setting.-A health maintenance organization. Subjects.-All patients aged 65 years and older and discharged from a hospital between January 1991 and May 1991 (n=1101) were randomized to either an intervention group or a control group. Intervention.-An educational pamphlet on the durable power of attorney for health care and a durable power of attorney for health care form were mailed to all patients in the intervention group. The control group received conventional care only. Main Outcome Measure.-Completion of the durable power of attorney for health care form. Results.-There were no significant baseline differences between the intervention group and the control group. Following our intervention, 18.5% of the subjects in the experimental group completed a durable power of attorney for health care form, compared with 0.4% of the control group (P<.0001). Conclusions.-A simple educational intervention significantly increased the completion of the durable power of attorney for health care. Our findings should stimulate further efforts to empower patients to make informed decisions about their health care.	UNIV CALIF SAN FRANCISCO, PROGRAM MED ETHICS, SAN FRANCISCO, CA 94143 USA; KAISER PERMANENTE MED CTR, SAN FRANCISCO, CA USA; PERMANENTE MED GRP INC, OAKLAND, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Kaiser Permanente; Permanente Medical Groups; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [P50MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGELI M, 1990, NEW ENGL J MED, V322, P1226, DOI 10.1056/NEJM199004263221710; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BUCHANAN A, 1986, MILBANK Q, V64, P17, DOI 10.2307/3349960; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1992, ANN INTERN MED, V117, P947	25	114	114	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					209	212		10.1001/jama.271.3.209	http://dx.doi.org/10.1001/jama.271.3.209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277547				2022-12-28	WOS:A1994MQ64500034
J	RICE, WR				RICE, WR			DEGENERATION OF A NONRECOMBINING CHROMOSOME	SCIENCE			English	Article							EVOLUTIONARY ADVANTAGE; RECOMBINATION; RATCHET; GENES; MODEL; SEX	Comparative studies suggest that sex chromosomes begin as ordinary autosomes that happen to carry a major sex determining locus. Over evolutionary time the Y chromosome is selected to stop recombining with the X chromosome, perhaps in response to accumulation of alleles beneficial to the heterogametic but harmful to the homogametic sex. Population genetic theory predicts that a nonrecombining Y chromosome should degenerate. Here this prediction is tested by application of specific selection pressures to Drosophila melanogaster populations. Results demonstrate the decay of a nonrecombining, nascent Y chromosome and the capacity for recombination to ameliorate such decay.			RICE, WR (corresponding author), UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064, USA.							Bull J.J., 1983, EVOLUTION SEX DETERM; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DOBZHANSKY T, 1947, EVOLUTION, V1, P191, DOI 10.2307/2405495; FELSENSTEIN J, 1974, GENETICS, V78, P737; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lindsley D.L., 1968, GENETIC VARIATIONS D; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; MUKAI T, 1964, GENETICS, V50, P1; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; OHNISHI O, 1977, GENETICS, V87, P529; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1990, BIOMETRICS, V46, P303, DOI 10.2307/2531435; RICE WR, 1987, GENETICS, V116, P161; RICE WR, 1988, BIOMETRICS, V44, P1, DOI 10.2307/2531892; Vrijenhoek R.C., 1990, P175	19	153	154	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					230	232		10.1126/science.8284674	http://dx.doi.org/10.1126/science.8284674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284674				2022-12-28	WOS:A1994MQ87900036
J	WATKINS, KP; DUNGAN, JM; AGABIAN, N				WATKINS, KP; DUNGAN, JM; AGABIAN, N			IDENTIFICATION OF A SMALL RNA THAT INTERACTS WITH THE 5' SPLICE-SITE OF THE TRYPANOSOMA-BRUCEI SPLICED LEADER RNA IN-VIVO	CELL			English	Article							PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; RIBOSOMAL-RNA; DISCONTINUOUS SYNTHESIS; TRANSCRIPTION UNIT; CROSS-LINKING; C-ELEGANS; GROUP-II; SNRNA; SEQUENCES	In vivo psoralen cross-linking of the trypanosome spliced leader (SL) RNA has led to the discovery of a small RNA that we provisionally call the spliced leader associated (SLA) RNA. The 72 nt SLA RNA is unlike any known small RNA except for a small region that resembles U5 snRNA. The SL/SLA RNA cross-links map to two regions, the predominant interactions occurring between the 5' splice site region of the SL RNA and a CUUUUA sequence in the SLA RNA. The resemblance between these cross-links and interactions of U5 snRNA with cis-spliced pre-mRNAs suggests that the SLA RNA may be the trans-splicing analog of U5 snRNA in trypanosomes.			WATKINS, KP (corresponding author), UNIV CALIF SAN FRANCISCO & UNIV CALIF BERKELEY, INTERCAMPUS PROGRAM MOLEC PARASITOL, SAN FRANCISCO, CA 94143 USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BIENEN EJ, 1981, EXP PARASITOL, V51, P408, DOI 10.1016/0014-4894(81)90128-4; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; DELANGE T, 1984, NUCLEIC ACIDS RES, V12, P3777, DOI 10.1093/nar/12.9.3777; England T E, 1980, Methods Enzymol, V65, P65; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; HASAN G, 1984, GENE, V27, P75, DOI 10.1016/0378-1119(84)90240-3; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Moore M., 1993, RNA WORLD, P303; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; ORUM H, 1991, J MOL BIOL, V222, P219, DOI 10.1016/0022-2836(91)90208-N; PARSONS M, 1984, CELL, V38, P309, DOI 10.1016/0092-8674(84)90552-X; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMPSON JF, 1983, CELL, V32, P1355, DOI 10.1016/0092-8674(83)90316-1; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707; ZWIEB C, 1980, NUCLEIC ACIDS RES, V8, P2397, DOI 10.1093/nar/8.11.2397	58	42	42	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					171	182		10.1016/0092-8674(94)90181-3	http://dx.doi.org/10.1016/0092-8674(94)90181-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287476				2022-12-28	WOS:A1994MR49500015
J	RUDNICKI, MA; SCHNEGELSBERG, PNJ; STEAD, RH; BRAUN, T; ARNOLD, HH; JAENISCH, R				RUDNICKI, MA; SCHNEGELSBERG, PNJ; STEAD, RH; BRAUN, T; ARNOLD, HH; JAENISCH, R			MYOD OR MYF-5 IS REQUIRED FOR THE FORMATION OF SKELETAL-MUSCLE	CELL			English	Article							REGULATORY GENE; ACETYLCHOLINE-RECEPTOR; MESSENGER-RNAS; CDNA CLONE; EXPRESSION; FAMILY; MYOGENESIS; MEMBER; CELLS; INACTIVATION	Mice carrying null mutations in the myogenic regulatory factors Myf-5 or MyoD have apparently normal skeletal muscle. To address whether these two factors functionally substitute for one another in myogenesis, mice carrying mutant Myf-5 and MyoD genes were interbred. While mice lacking both MyoD and Myf-5 were born alive, they were immobile and died soon after birth. Northern blot and S1 nuclease analyses indicated that Myf-5(-/-);MyoD(-/-) mice expressed no detectable skeletal muscle-specific mRNAs. Histological examination of these mice revealed a complete absence of skeletal muscle. Immunohistochemical analysis indicated an absence of desmin-expressing myoblast-like cells. These observations suggest that either Myf-5 or MyoD is required for the determination of skeletal myoblasts, their propagation, or both during embryonic development and indicate that these factors play, at least in part, functionally redundant roles in myogenesis.	MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8S 4K1,ONTARIO,CANADA; INST BIOCHEM & BIOTECHNOL,ZELL & MOLEK BIOL ABT,D-38106 BRAUNSCHWEIG,GERMANY	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); McMaster University	RUDNICKI, MA (corresponding author), MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON L8S 4K1,ONTARIO,CANADA.		Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NCI NIH HHS [5R35CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bancroft JD, 1990, THEORY PRACTICE HIST; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Maniatis T., 1982, MOL CLONING; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; STEAD RH, 1989, GASTROENTEROLOGY, V97, P575, DOI 10.1016/0016-5085(89)90627-6; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	31	1320	1370	4	60	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1351	1359		10.1016/0092-8674(93)90621-V	http://dx.doi.org/10.1016/0092-8674(93)90621-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269513				2022-12-28	WOS:A1993MP86900013
J	LEE, WM				LEE, WM			MEDICAL PROGRESS - ACUTE LIVER-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FULMINANT HEPATIC-FAILURE; HEPATOCYTE GROWTH-FACTOR; ACUTE FATTY LIVER; D-BINDING-PROTEIN; BONE-MARROW TRANSPLANTATION; CEREBRAL PERFUSION-PRESSURE; TUMOR-NECROSIS-FACTOR; VIRUS-LIKE PARTICLES; BLOOD-BRAIN-BARRIER; ACUTE-RENAL-FAILURE				LEE, WM (corresponding author), UNIV TEXAS,SW MED CTR,SW MED SCH,LIVER UNIT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ABECASSIS M, 1987, J CLIN INVEST, V80, P881, DOI 10.1172/JCI113147; AKRIVIADIS EA, 1989, ANN INTERN MED, V110, P838, DOI 10.7326/0003-4819-110-10-838; ALMASIO PL, 1986, HEPATOLOGY, V6, P1340, DOI 10.1002/hep.1840060620; ALMDAL T, 1989, SCAND J GASTROENTERO, V24, P299, DOI 10.3109/00365528909093050; ASHER LVS, 1990, J MED VIROL, V31, P229; BAERG RD, 1970, ANN INTERN MED, V73, P713, DOI 10.7326/0003-4819-73-5-713; BAILEY RJ, 1976, LANCET, V1, P1162; BARTON JR, 1992, AM J OBSTET GYNECOL, V167, P1538, DOI 10.1016/0002-9378(92)91735-S; BASILE AS, 1991, NEW ENGL J MED, V325, P473, DOI 10.1056/NEJM199108153250705; BASILE AS, 1990, P NATL ACAD SCI USA, V87, P5263, DOI 10.1073/pnas.87.14.5263; BENHAMOU JP, 1991, ACUTE LIVER FAILURE, P6; BENHAMOU JP, 1972, LIVER DRUGS, P213; BERGER RL, 1966, NEW ENGL J MED, V274, P497, DOI 10.1056/NEJM196603032740906; BERMAN DH, 1991, GASTROENTEROLOGY, V100, P1129, DOI 10.1016/0016-5085(91)90294-U; BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BIHARI D, 1985, CRIT CARE MED, V13, P1034, DOI 10.1097/00003246-198512000-00010; BIHARI D, 1991, ACUTE LIVER FAILURE, P42; BIHARI DJ, 1986, SEMIN LIVER DIS, V6, P119, DOI 10.1055/s-2008-1040595; BIRD GLA, 1989, Q J MED, V73, P895; BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; CAMPBELL DA, 1991, AM SURGEON, V57, P546; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHAPMAN RW, 1990, LANCET, V335, P32, DOI 10.1016/0140-6736(90)90150-4; COBDEN I, 1982, BRIT MED J, V284, P21, DOI 10.1136/bmj.284.6308.21; DAVENPORT A, 1990, CRIT CARE MED, V18, P286, DOI 10.1097/00003246-199003000-00008; DELAMATA M, 1990, CLIN EXP IMMUNOL, V82, P479; DEMETRIOU AA, 1991, ACUTE LIVER FAILURE, P66; DENIS J, 1978, GUT, V19, P787, DOI 10.1136/gut.19.9.787; DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1002/hep.1840160509; DIRIX LY, 1989, Q J MED, V73, P1037; DONOVAN JP, 1992, HEPATOLOGY, V16, P267, DOI 10.1002/hep.1840160138; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; EDE RJ, 1986, SEMIN LIVER DIS, V6, P107, DOI 10.1055/s-2008-1040594; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; FAGAN E, 1990, J MED VIROL, V30, P131, DOI 10.1002/jmv.1890300210; FAGAN EA, 1989, J MED VIROL, V28, P150, DOI 10.1002/jmv.1890280308; FAGAN EA, 1990, BRIT MED BULL, V46, P462, DOI 10.1093/oxfordjournals.bmb.a072410; FAGAN EA, 1992, J MED VIROL, V38, P71, DOI 10.1002/jmv.1890380115; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; GAZZARD BG, 1975, GUT, V16, P617, DOI 10.1136/gut.16.8.617; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; GODWIN JE, 1991, CHEST, V99, P752, DOI 10.1378/chest.99.3.752; GOHDA E, 1991, DIGEST DIS SCI, V36, P785, DOI 10.1007/BF01311238; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GRIMM G, 1988, LANCET, V2, P1392; GUARNER F, 1988, HEPATOLOGY, V8, P248, DOI 10.1002/hep.1840080210; GUARNER F, 1987, GUT, V28, P1643, DOI 10.1136/gut.28.12.1643; GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HOFFMAN BJ, 1990, J CLIN GASTROENTEROL, V12, P306, DOI 10.1097/00004836-199006000-00015; HUGHES R D, 1991, Gut, pS86; JONES EA, 1990, HEPATOLOGY TXB LIVER, V1, P460; KATO M, 1992, HEPATOLOGY, V15, P1060, DOI 10.1002/hep.1840150615; KEAYS R, 1991, Q J MED, V79, P425; KLEIN AS, 1989, AM J MED, V86, P187, DOI 10.1016/0002-9343(89)90267-2; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; KRAUSS EA, 1979, AM J GASTROENTEROL, V72, P651; KUMAR S, 1991, ARCH INTERN MED, V151, P1189, DOI 10.1001/archinte.151.6.1189; KUSNE S, 1991, J INFECT DIS, V163, P1001, DOI 10.1093/infdis/163.5.1001; LANGLEY PG, 1991, HEPATOLOGY, V14, P251, DOI 10.1016/0270-9139(91)91411-S; LANGLEY PG, 1990, EUR J CLIN INVEST, V20, P627, DOI 10.1111/j.1365-2362.1990.tb01911.x; LEE WM, 1985, HEPATOLOGY, V5, P271, DOI 10.1002/hep.1840050220; LEE WM, 1987, HEPATOLOGY, V7, P825, DOI 10.1002/hep.1840070506; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LIANG TJ, 1993, GASTROENTEROLOGY, V104, P556, DOI 10.1016/0016-5085(93)90426-D; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; MACDOUGALL BRD, 1978, GASTROENTEROLOGY, V74, P464; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MCCLUNG HJ, 1990, PEDIATR RES, V28, P227, DOI 10.1203/00006450-199009000-00014; MCCULLOUGH AJ, 1983, GASTROENTEROLOGY, V84, P161; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; METSELAAR HJ, 1990, LANCET, V335, P1156, DOI 10.1016/0140-6736(90)91158-7; Moore K, 1991, ACUTE LIVER FAILURE, P47; MORITZ MJ, 1990, TRANSPLANTATION, V50, P524, DOI 10.1097/00007890-199009000-00036; MULLEN KD, 1988, LANCET, V1, P457; MUNOZ SJ, 1991, HEPATOLOGY, V13, P209, DOI 10.1002/hep.1840130202; MUTO Y, 1988, LANCET, V2, P72; NOUEL O, 1980, DIGEST DIS SCI, V25, P49, DOI 10.1007/BF01312732; OBRIEN CJ, 1987, GUT, V28, P93, DOI 10.1136/gut.28.1.93; OCKNER SA, 1990, HEPATOLOGY, V11, P59, DOI 10.1002/hep.1840110112; OGRADY JG, 1986, SEMIN LIVER DIS, V6, P159, DOI 10.1055/s-2008-1040599; OGRADY JG, 1991, ACUTE LIVER FAILURE, P77; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P4439; PANOS MZ, 1991, GUT, V32, P85, DOI 10.1136/gut.32.1.85; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; PINSON CW, 1990, AM J SURG, V159, P493, DOI 10.1016/S0002-9610(05)81254-1; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; PRSTON FE, 1991, ACUTE LIVER FAILURE, P36; RAB SM, 1967, AM J MED, V43, P811, DOI 10.1016/0002-9343(67)90124-6; RAKELA J, 1985, MAYO CLIN PROC, V60, P289, DOI 10.1016/S0025-6196(12)60534-5; RIELY CA, 1987, ANN INTERN MED, V106, P703, DOI 10.7326/0003-4819-106-5-703; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; ROLFES DB, 1985, HEPATOLOGY, V5, P1149, DOI 10.1002/hep.1840050615; ROSENBLOOM AJ, 1991, CHEST, V100, P870, DOI 10.1378/chest.100.3.870; ROZGA J, 1993, LANCET, V343, P898; RUPRAH M, 1985, LANCET, V1, P1027, DOI 10.1016/S0140-6736(85)91624-1; SALLIE R, 1992, HEPATOLOGY, V16, P1206, DOI 10.1016/0270-9139(92)90016-3; SANDLE GI, 1980, LANCET, V1, P1199; SARACCO G, 1988, ANN INTERN MED, V108, P380, DOI 10.7326/0003-4819-108-3-380; SAWABE M, 1990, CANCER, V65, P169, DOI 10.1002/1097-0142(19900101)65:1<169::AID-CNCR2820650132>3.0.CO;2-9; SCHALM SW, 1991, ACUTE LIVER FAILURE, P11; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SHEINER P, 1992, HEPATOLOGY, V16, pA88; SHOEMAKER WC, 1990, CRIT CARE MED, V18, pS19; SINCLAIR SB, 1989, J CLIN INVEST, V84, P1063, DOI 10.1172/JCI114268; SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SOBUE R, 1991, NEW ENGL J MED, V324, P1290, DOI 10.1056/NEJM199105023241818; SUSSMAN NL, 1992, HEPATOLOGY, V16, P60, DOI 10.1002/hep.1840160112; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TAYLOR RJ, 1981, ARCH INTERN MED, V141, P1519, DOI 10.1001/archinte.141.11.1519; Thiele D L, 1990, Gastroenterology, V98, P1088; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; TRABER PG, 1987, HEPATOLOGY, V7, P1272, DOI 10.1002/hep.1840070616; Trey C, 1970, Prog Liver Dis, V3, P282; VANDAM J, 1990, BONE MARROW TRANSPL, V5, P57; WALSH TJ, 1983, ARCH INTERN MED, V143, P1189, DOI 10.1001/archinte.143.6.1189; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; WENDON J, 1991, ACUTE LIVER FAILURE, P39; WENDON JA, 1992, HEPATOLOGY, V15, P1067, DOI 10.1002/hep.1840150616; WILKINSON SP, 1974, BMJ-BRIT MED J, V1, P186, DOI 10.1136/bmj.1.5900.186; WILKINSON SP, 1974, LANCET, V1, P521, DOI 10.1016/s0140-6736(74)92711-1; WILLIAMS R, 1991, DIGEST DIS SCI, V36, P820, DOI 10.1007/BF01311243; WOODS WG, 1980, AM J MED, V68, P285, DOI 10.1016/0002-9343(80)90368-X; WOOTTON FT, 1990, SOUTHERN MED J, V83, P1047, DOI 10.1097/00007611-199009000-00017; WYKE R J, 1982, Liver, V2, P45; YOUNG WO, 1987, J LAB CLIN MED, V110, P83; ZAFRANI ES, 1983, HEPATOLOGY, V3, P428; 1991, AM J MED, V90, P374; 1991, LANCET, V338, P156	142	476	491	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1862	1872		10.1056/NEJM199312163292508	http://dx.doi.org/10.1056/NEJM199312163292508			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8305063				2022-12-28	WOS:A1993ML58800008
J	FRANKEL, SR; EARDLEY, A; HELLER, G; BERMAN, E; MILLER, WH; DMITROVSKY, E; WARRELL, RP				FRANKEL, SR; EARDLEY, A; HELLER, G; BERMAN, E; MILLER, WH; DMITROVSKY, E; WARRELL, RP			ALL-TRANS-RETINOIC ACID FOR ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF THE NEW-YORK STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, MYELOCYTIC, ACUTE; TRETINOIN; REMISSION INDUCTION; ANTINEOPLASTIC AGENTS, COMBINED; DISSEMINATED INTRAVASCULAR COAGULATION	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RECEPTOR-ALPHA GENE; DIFFERENTIATION THERAPY; PROGNOSTIC FACTORS; TRANSLOCATION; CHEMOTHERAPY; INDUCTION; T(15-17); RELAPSE	Objective: To evaluate the safety and efficacy of all-trans retinoic acid to induce complete remission and to examine its effects on duration of remission and survival in patients with acute promyelocytic leukemia. Design: Phase II evaluation and comparison with historical control patients. Setting: Tertiary care cancer referral center. Patients: Consecutive patients with morphologic diagnoses of acute promyelocytic leukemia were treated during a 2-year period with all-trans retinoic acid (daily oral dose, 45 mg/m2). Newly diagnosed patients discontinued the drug approximately 30 days after they achieved complete remission, at which time they received three courses of combination chemotherapy. Patients treated with previous cytotoxic chemotherapy who then relapsed were continued on all-trans retinoic acid as ''maintenance'' therapy until they relapsed again. Results: 56 patients entered the study: 34 were newly diagnosed and 22 had relapsed from previous treatment. Fifty-one patients subsequently were found to have the PML/RAR-alpha gene rearrangement indicative of acute promyelocytic leukemia, and 44 of these patients achieved complete remission (86%; 95% Cl, 76% to 96%). A distinctive respiratory distress syndrome developed in 13 patients (23%) during treatment, and 5 patients (9%; Cl, 3% to 20%) died of this complication. The 5 patients who lacked PML/RAR-alpha rearrangements were withdrawn and given chemotherapy. The 13 patients given all-trans retinoic acid alone as maintenance therapy (10 of whom had relapsed from a chemotherapy-induced remission) had a median duration of remission of only 3.5 months (range, 1 to 23 months). Only 3 of 19 patients who relapsed from a remission induced by all-trans retinoic acid could be brought into remission again using this drug. The median survival time of all newly diagnosed patients has not been reached, but it now exceeds 31 months (range, 0.4 to 36+ months). No decrease in the early mortality rate was observed compared with a historical control group composed of 80 consecutive, newly diagnosed patients treated only with chemotherapy at this center; however, overall survival was superior. Conclusions: All-trans retinoic acid is an effective agent to induce remission in patients with a molecular diagnosis of acute promyelocytic leukemia, but remissions are short and resistance develops rapidly. Although the incidence of early death was not reduced, the use of all-trans retinoic acid to induce remission, followed by cytotoxic chemotherapy for ''consolidation,'' was associated with longer survival times when compared with historical controls treated only with chemotherapy. Additional studies to prevent or mitigate consequences of the ''retinoic acid syndrome'' and to identify specific patients who might benefit from earlier intervention with chemotherapy are needed to maximize the advantages of this approach.	MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [R01CA057645, R43CA055449] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57645, CA-55449] Funding Source: Medline; FDA HHS [FD-R-000764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERMAN E, 1991, BLOOD S, V78, P43; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1990, BLOOD S, V6, P260; CASTAIGNE S, 1992, BLOOD S, V80, P360; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CORDONNIER C, 1985, CANCER-AM CANCER SOC, V55, P18, DOI 10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B; CORNIC M, 1992, CANCER RES, V52, P3329; CUNNINGHAM I, 1989, BLOOD, V73, P1116; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOMBRET H, 1992, LEUKEMIA, V6, P1237; EARDLEY A, 1992, BLOOD S, V80, P109; FENAUX P, 1992, BLOOD, V80, P2176; FENAUX P, 1991, LEUKEMIA LYMPHOMA, V4, P239, DOI 10.3109/10428199109068072; FENAUX P, 1993, P AN M AM SOC CLIN, V12, P300; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOLDBERG MA, 1987, BLOOD, V69, P187; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; GORDON MS, 1991, P AN M AM SOC CLIN, V10, P225; GRALNICK HR, 1974, HUM PATHOL, V5, P661, DOI 10.1016/S0046-8177(74)80037-7; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JURCIC JG, 1993, P AN M AM SOC CLIN, V12, P311; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANTARJIAN HM, 1986, AM J MED, V80, P789, DOI 10.1016/0002-9343(86)90617-0; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; MARTY M, 1984, NOUV REV FR HEMATOL, V26, P371; MASLAK P, 1993, BLOOD, V81, P1666; Michaeli J, 1992, Cancer Chemother Biol Response Modif, V13, P286; MILLER WH, 1993, BLOOD, V82, P1689; MUINDI J, 1992, BLOOD, V79, P299; MUINDI JF, 1993, CANCER RES, V53, P1226; MUINDI JRF, 1992, CANCER RES, V52, P2138; OHNO R, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P234; RODEGHIERO F, 1990, BLOOD, V75, P2112; SANZ MA, 1988, CANCER, V61, P7, DOI 10.1002/1097-0142(19880101)61:1<7::AID-CNCR2820610103>3.0.CO;2-6; SCHIFFER CA, 1989, BLOOD, V73, P263; STONE RM, 1990, J CLIN ONCOL, V8, P1913, DOI 10.1200/JCO.1990.8.11.1913; TALLMAN MS, 1992, BLOOD, V79, P543; THOMAS X, 1991, LEUKEMIA LYMPHOMA, V4, P249, DOI 10.3109/10428199109068073; VENTURA G J, 1989, Hematologic Pathology, V3, P23; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304	48	244	245	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					278	286		10.7326/0003-4819-120-4-199402150-00004	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291820				2022-12-28	WOS:A1994MW10300004
J	HAYNES, MR; STURA, EA; HILVERT, D; WILSON, IA				HAYNES, MR; STURA, EA; HILVERT, D; WILSON, IA			ROUTES TO CATALYSIS - STRUCTURE OF A CATALYTIC ANTIBODY AND COMPARISON WITH ITS NATURAL COUNTERPART	SCIENCE			English	Article							CHORISMATE MUTASE REACTION; CLAISEN REARRANGEMENT; TRANSITION-STATE; CRYSTAL-STRUCTURES; ENZYMIC CATALYSIS; PREPHENATE; MECHANISM; STEREOCHEMISTRY; REFINEMENT; BINDING	The three-dimensional structure of a catalytic antibody (1F7) with chorismate mutase activity has been determined to 3.0 angstrom resolution as a complex with a transition state analog. The structural data suggest that the antibody stabilizes the same conformationally restricted pericyclic transition state as occurs in the uncatalyzed reaction. Overall shape and charge complementarity between the combining site and the transition state analog dictate preferential binding of the correct substrate enantiomer in a conformation appropriate for reaction. Comparison with the structure of a chorismate mutase enzyme indicates an overall similarity between the catalytic mechanism employed by the two proteins. Differences in the number of specific interactions available for restricting the rotational degrees of freedom in the transition state, and the lack of multiple electrostatic interactions that might stabilize charge separation in this highly polarized metastable species, are likely to account for the observed 10(4) times lower activity of the antibody relative to that of the natural enzymes that catalyze this reaction. The structure of the 1F7 Fab'-hapten complex provides confirmation that the properties of an antibody catalyst faithfully reflect the design of the transition state analog.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute	HAYNES, MR (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23498] Funding Source: Medline; NIGMS NIH HHS [GM-38273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDADI L, 1983, BIOCHEMISTRY-US, V22, P4494, DOI 10.1021/bi00288a022; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; AVIES DR, 1990, ANNU REV BIOCHEM, V59, P439; BARTLETT PA, 1988, J ORG CHEM, V53, P3195, DOI 10.1021/jo00249a013; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRESLOW R, 1972, J AM CHEM SOC, V94, P2110, DOI 10.1021/ja00761a051; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURROWS CJ, 1981, J AM CHEM SOC, V103, P6983, DOI 10.1021/ja00413a045; CAMPBELL AP, 1993, P NATL ACAD SCI USA, V90, P8663, DOI 10.1073/pnas.90.18.8663; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHOOK YM, COMMUNICATION; COATES RM, 1987, J AM CHEM SOC, V109, P1160, DOI 10.1021/ja00238a028; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; COPLEY SD, 1987, J AM CHEM SOC, V109, P5008, DOI 10.1021/ja00250a040; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GAJEWSKI JJ, 1987, J AM CHEM SOC, V109, P1170, DOI 10.1021/ja00238a029; GORISCH H, 1978, BIOCHEMISTRY-US, V17, P3700, DOI 10.1021/bi00611a004; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; GUILFORD WJ, 1987, J AM CHEM SOC, V109, P5013, DOI 10.1021/ja00250a041; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HAYNES MR, 1994, PROTEINS, V18, P201; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1993, ACCOUNTS CHEM RES, V26, P552, DOI 10.1021/ar00034a006; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON DY, 1992, ANGEW CHEM INT EDIT, V31, P182, DOI 10.1002/anie.199201821; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; Jencks W, 1969, CATALYSIS CHEM ENZYM, P288; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1978, J APL CRYSTALLOGR, V11, P262; KABAT EA, 1991, J IMMUNOL, V147, P1709; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; PAWLAK JL, 1989, J AM CHEM SOC, V111, P3374, DOI 10.1021/ja00191a040; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SEVERANCE DL, 1992, J AM CHEM SOC, V114, P10966, DOI 10.1021/ja00053a046; SOGO SG, 1984, J AM CHEM SOC, V106, P2701, DOI 10.1021/ja00321a039; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWART JD, 1993, ACCOUNTS CHEM RES, V26, P396, DOI 10.1021/ar00032a002; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	52	152	152	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					646	652		10.1126/science.8303271	http://dx.doi.org/10.1126/science.8303271			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303271				2022-12-28	WOS:A1994MU96400037
J	SANNER, M				SANNER, M			A COMPARISON OF PUBLIC-ATTITUDES TOWARD AUTOPSY, ORGAN DONATION, AND ANATOMIC DISSECTION - A SWEDISH SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate people's reactions to procedures involving the dead body by comparing their attitudes toward autopsy, organ donation, and dissection. Design.-Survey, using a questionnaire with 24 items that address reactions toward autopsy, organ donation, and donation of the whole body, including religious and sociodemographic issues. Participants.-An age-stratified, random sample of 1950 individuals in Sweden, 18 to 75 years old. The response rate was 65%. Results.-Eighty-four percent reported acceptance of an autopsy for themselves and 80% for a close relative. Sixty-two percent were willing to donate their own organs and 39% to donate the organs of a family member; 15% accepted donation of their whole body for dissection. Practically all who accepted dissection also were willing to donate their organs and to be autopsied; practically all who were willing to donate their organs also accepted autopsy. About 65% to 70% felt some discomfort at the thought of autopsy and organ donation. Women seemed more sensitive toward operations on the dead body than men. Conclusions.-The rank order of medical procedures after death, based on the proportion of individuals positive toward the procedures, can be used to form a scale with autopsy and dissection at each end point and organ donation in the middle. This scale has the characteristics of a Guttman scale and can be looked on as a comfort-discomfort continuum regarding procedures involving the dead body.	UNIV UPPSALA,DEPT SOCIAL MED,S-75105 UPPSALA,SWEDEN	Uppsala University								BELK RW, 1988, J CONSUM RES, V15, P139, DOI 10.1086/209154; DOMINGUEZ JM, 1991, TRANSPL P, V23, P1804; EVERS S, 1988, CAN MED ASSOC J, V138, P237; GABEL H, 1989, LAKARTIDNINGEN, V86, P3681; GABEL H, 1987, LAKARTIDNINGEN, V84, P1065; Galtung J., 1967, THEORY METHODS SOCIA; HILL RB, 1991, MILBANK Q, V69, P51, DOI 10.2307/3350121; HORTON RL, 1991, SOC SCI MED, V33, P1037, DOI 10.1016/0277-9536(91)90009-2; MARTINEZ L, 1991, TRANSPLANT P, V23, P2528; MOORES S, 1976, BMJ, V1, P629; PARISI N, 1986, HEALTH PSYCHOL, V5, P565, DOI 10.1037/0278-6133.5.6.565; PROTTAS JM, 1983, MILBANK FUND Q, V61, P278, DOI 10.2307/3349908; SANNER M, 1992, SOU1992, P17; SANNER M, 1989, SOU1989, P99; SANNER M, 1991, DODA KROPPEN PSYKOLO; SANNER M, IN PRESS SOC SCI MED; 1989, US PUBLICS ATTITUDES; 1992, SOU1992 COMM TRANSPL, P16; 1991, REPORT JOINT WORKING	19	140	142	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					284	288		10.1001/jama.271.4.284	http://dx.doi.org/10.1001/jama.271.4.284			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR221	8295287				2022-12-28	WOS:A1994MR22100024
J	WULFSBERG, EA; HOFFMANN, DE; COHEN, MM				WULFSBERG, EA; HOFFMANN, DE; COHEN, MM			ALPHA-1-ANTITRYPSIN DEFICIENCY - IMPACT OF GENETIC DISCOVERY ON MEDICINE AND SOCIETY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-SPECIFIC EXPRESSION; NATURAL-HISTORY; NEUTROPHIL ELASTASE; TRANSGENIC MICE; EMPHYSEMA; ALPHA1-ANTITRYPSIN; DISCRIMINATION; ANTITRYPSIN; INSURANCE; LUNG	An increasing body of molecular information resulting from advances in basic research is being incorporated into clinical practice by medical genetics. The process by which these research advances progress from the laboratory to the bedside and their medical, social, and legal impact is a topic of intense current interest. Some authors have claimed that new genetic information may lead to discrimination in insurance and employment; change the way courts allocate responsibility for injury and resultant damages; and be inappropriately interpreted by the medical profession. To address some of these issues, we chose, as a model, to review alpha1-antitrypsin deficiency, described over 30 years ago. At this time, such concerns with respect to alpha1-antitrypsin deficiency have not yet been realized, perhaps for the following reasons: (1) knowledge of alpha1-antitrypsin deficiency, while common among geneticists and pulmonologists, has not been well disseminated in the medical community; (2) insurers, employers, lawyers, and judges are not generally aware of the deficiency and its implications; (3) insurers, if they are aware of the deficiency, have not found it cost-effective to screen for the condition; and (4) in the legal context, case law involving other types of preexisting conditions is being applied to genetic predispositions.	UNIV MARYLAND, SCH LAW, BALTIMORE, MD 21201 USA; UNIV MARYLAND, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	WULFSBERG, EA (corresponding author), UNIV MARYLAND, SCH MED, DIV HUMAN GENET, SUITE 400, 405 W REDWOOD ST, BALTIMORE, MD 21201 USA.				NHGRI NIH HHS [R01-HG00419] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000419] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALLEN RC, 1974, AM J CLIN PATHOL, V62, P732; BEECHAM L, 1992, BRIT MED J, V305, P1244; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROCK DJH, 1993, LANCET, V341, P495, DOI 10.1016/0140-6736(93)90249-G; BUIST AS, 1990, LUNG, V168, P543, DOI 10.1007/BF02718177; BUIST AS, 1990, AM REV RESPIR DIS, V141, P1078, DOI 10.1164/ajrccm/141.4_Pt_1.1078a; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; COX DW, 1982, NATURE, V297, P428, DOI 10.1038/297428a0; COX DW, 1980, HUM GENET, V53, P429, DOI 10.1007/BF00287070; EBERT RV, 1963, ARCH INTERN MED, V111, P34, DOI 10.1001/archinte.1963.03620250038006; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; Eriksson S., 1991, ANN N Y ACAD SCI, V624, P1; FAGERHOL MK, 1967, CLIN CHIM ACTA, V16, P199, DOI 10.1016/0009-8981(67)90181-7; FELLS G, 1987, American Review of Respiratory Disease, V135, pA291; Gadek J., 1982, METABOLIC BASIS INHE, P1450; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GADEK JE, 1990, LUNG, V168, P552, DOI 10.1007/BF02718178; GADEK JE, 1980, CLIN RES PROC, V16, P27; GEORGE PM, 1984, LANCET, V2, P1426; GOSTIN L, 1991, AM J LAW MED, V17, P109; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; HEIMBURGER N, 1970, P INT RES C PROTEINA, P1; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; HUTCHISON DCS, 1990, LUNG, V168, P535, DOI 10.1007/BF02718176; JANOFF A, 1972, AM REV RESPIR DIS, V105, P121; JUENGST ET, 1991, JAMA-J AM MED ASSOC, V266, P1835, DOI 10.1001/jama.266.13.1835; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; KUEPPERS F, 1974, AM REV RESPIR DIS, V110, P176; LAENNEC RTH, 1838, TREATISE DISEASES CH, P161; LARSON A, 1992, LAW WORKMENS COMPENS; LARSSON C, 1978, ACTA MED SCAND, V204, P345, DOI 10.1111/j.0954-6820.1978.tb08452.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LIEBERMAN J, 1990, PRINCIPLES PRACTICES, P1179; LOWDEN JA, 1992, AM J HUM GENET, V51, P901; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1991, HOSP PRACT, V26, P74; MCNEIL TF, 1988, THORAX, V43, P505, DOI 10.1136/thx.43.7.505; OLSEN GN, 1975, J CLIN INVEST, V55, P427, DOI 10.1172/JCI107947; OSTRER H, 1993, AM J HUM GENET, V52, P565; PIERCE JA, 1988, JAMA-J AM MED ASSOC, V259, P2890, DOI 10.1001/jama.259.19.2890; REYNOLDS MA, 1993, LANCET, V341, P495; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SHOENBORN CA, 1988, VITAL HLTH STAT, V166, P85; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; STOLLER JK, 1993, AM REV RESPIR DIS, V147, pA871; SVEGER T, 1988, ACTA PAEDIATR SCAND, V77, P847, DOI 10.1111/j.1651-2227.1988.tb10767.x; SVEGER T, 1990, BIRTH DEFECTS ENCY, P90; TETLEY TD, 1992, RESP MED, V86, P187, DOI 10.1016/S0954-6111(06)80053-3; THELIN T, 1985, ACTA PAEDIATR SCAND, V74, P841, DOI 10.1111/j.1651-2227.1985.tb10046.x; TOBIN MJ, 1983, BRIT J DIS CHEST, V77, P14, DOI 10.1016/S0007-0971(83)80054-0; TURINO GM, 1991, ANN NY ACAD SCI, V624, P18, DOI 10.1111/j.1749-6632.1991.tb17002.x; TURINO GM, 1980, CLIN RES PROC, V16, P43; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WEWERS MD, 1989, AM J RESP CELL MOL, V1, P423, DOI 10.1165/ajrcmb/1.5.423; WIMPFHEIMER F, 1961, AM REV RESPIR DIS, V83, P697; 1992, GENETIC TESTS HLTH I	64	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					217	222		10.1001/jama.271.3.217	http://dx.doi.org/10.1001/jama.271.3.217			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277549				2022-12-28	WOS:A1994MQ64500036
J	STAHL, N; BOULTON, TG; FARRUGGELLA, T; IP, NY; DAVIS, S; WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; BARBIERI, G; PELLEGRINI, S; IHLE, JN; YANCOPOULOS, GD				STAHL, N; BOULTON, TG; FARRUGGELLA, T; IP, NY; DAVIS, S; WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; BARBIERI, G; PELLEGRINI, S; IHLE, JN; YANCOPOULOS, GD			ASSOCIATION AND ACTIVATION OF JAK-TYK KINASES BY CNTF-LIF-OSM-IL-6 BETA-RECEPTOR COMPONENTS	SCIENCE			English	Article							LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; PROTEIN-TYROSINE KINASES; ONCOSTATIN-M; GP130; INTERLEUKIN-6; FAMILY; CYTOKINES; MEMBER	A recently defined family of cytokines, consisting of ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and interleukin-6 (IL-6), utilize the Jak-Tyk family of cytoplasmic tyrosine kinases. The beta receptor components for this cytokine family, gp130 and LIF receptor beta, constitutively associate with Jak-Tyk kinases. Activation of these kinases occurs as a result of ligand-induced dimerization of the receptor beta components. Unlike other cytokine receptors studied to date, the receptors for the CNTF cytokine family utilize all known members of the Jak-Tyk family, but induce distinct patterns of Jak-Tyk phosphorylation in different cell lines.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE	St Jude Children's Research Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015; witthuhn, bruce/GSE-3193-2022; Barbieri, Giovanna/AAH-3645-2019	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589; BARBIERI, GIOVANNA/0000-0002-5895-1795; Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOLEN JB, 1993, ONCOGENE, V8, P2025; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EISEMAN E, 1992, NATURE, V355, P78; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, UNPUB; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, UNPUB; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	33	920	947	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					92	95		10.1126/science.8272873	http://dx.doi.org/10.1126/science.8272873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272873				2022-12-28	WOS:A1994MQ30100038
J	HEEMELS, MT; SCHUMACHER, TNM; WONIGEIT, K; PLOEGH, HL				HEEMELS, MT; SCHUMACHER, TNM; WONIGEIT, K; PLOEGH, HL			PEPTIDE TRANSLOCATION BY VARIANTS OF THE TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING	SCIENCE			English	Article							CLASS-I MOLECULE; MHC; EXPRESSION; PROTEINS; REGION; GENES; CIM	Major histocompatibility complex (MHC) class I molecules associate with peptides that are delivered from the cytosol to the lumen of the endoplasmic reticulum by the transporter associated with antigen processing (TAP). Liver microsomes of SHR and Lewis rats, which express different alleles of TAP (cim(b) and cim(a), respectively), accumulate different sets of peptides. Use of MHC congenic rats assigned this difference to the MHC, independent of the class I products expressed. Both the cim(a) and cim(b) TAP complexes translocate peptides with a hydrophobic carboxyl terminus, but translocation of peptides with a carboxyl-terminal His, Lys, or Arg residue is unique to cim(a). Thus, the specificity of the TAP peptide translocator restricts the peptides available for antigen presentation.	MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139; HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30625 HANNOVER,GERMANY	Massachusetts Institute of Technology (MIT); Hannover Medical School			Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Heemels, Marie Therese/0000-0002-4364-3116	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033456] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI3 3456-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIJLMAKERS MJ, 1993, CURR OPIN IMMUNOL, V5, P21, DOI 10.1016/0952-7915(93)90076-5; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FUKUMOTO T, 1982, EUR J IMMUNOL, V12, P237, DOI 10.1002/eji.1830120313; GASKINS HR, 1992, SCIENCE, V256, P1826, DOI 10.1126/science.1352067; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HOWARD JC, 1993, P NATL ACAD SCI USA, V90, P3777, DOI 10.1073/pnas.90.9.3777; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157, DOI 10.1007/BF00205818; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SCHUMACHER TNM, IN PRESS J EXP MED; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; TSOMIDES TJ, 1993, ANAL BIOCHEM, V210, P129, DOI 10.1006/abio.1993.1162; WALTER P, 1983, METHOD ENZYMOL, V96, P84	27	194	195	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2059	2063		10.1126/science.8266106	http://dx.doi.org/10.1126/science.8266106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266106				2022-12-28	WOS:A1993MN10800046
J	WICKHAM, JEA				WICKHAM, JEA			MINIMALLY INVASIVE SURGERY .3. TREATMENT OF URINARY-TRACT STONES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHOCK-WAVE LITHOTRIPSY; PIEZOELECTRIC EXTRACORPOREAL LITHOTRIPSY; PERCUTANEOUS NEPHROLITHOTOMY; URETERAL CALCULI; CONSECUTIVE PATIENTS; RENAL CALCULI; KIDNEY-STONES; COMPLICATIONS; REMOVAL; EXPERIENCE	Replacement of open surgery with minimally invasive techniques for treating stones in the renal tract has greatly reduced patients' morbidity and mortality and the period of hospitalisation and covalescence. Extracorporeal shockwave lithotripsy does not require anaesthesia and requires little analgesia so that treatment can be given on an outpatient basis, and there is no wound to heal. Only a small puncture site is needed for percutaneous endoscopic lithotomy, and with the advent of prophylactic antibiotics there are few complications. Of renal stones, about 85% can now be successfully treated by extracorporeal lithotripsy alone, and almost all of the stones too large or hard for lithotripsy can be treated endoscopically, with ultrasonic or electrohydraulic probes being used to fragment the stone. Stones in the upper and lower thirds of the ureter can be treated by extracorporeal lithotripsy, but stones in the middle third, which cannot normally be visualised to allow focusing of the shockwaves, usually require ureteroscopy. Nearly all bladder stones can be treated by transurethral endoscopy with an electrohydraulic probe. Only the largest renal tract stones require open surgery.			WICKHAM, JEA (corresponding author), COMBINED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV MINIMALLY INVAS SURG, LONDON, ENGLAND.							ALKEN P, 1982, EUR UROL, V8, P304; ALKEN P, 1983, BR J UROL S, P1; BASKIN LS, 1989, J ENDOUROL, V3, P51; BECHT E, 1988, J UROLOGY, V139, P916, DOI 10.1016/S0022-5347(17)42714-5; BEGUN FP, 1992, J ENDOUROL, V6, P347, DOI 10.1089/end.1992.6.347; CHARIG CR, 1986, BRIT MED J, V292, P879, DOI 10.1136/bmj.292.6524.879; CHAUSSY C, 1980, LANCET, V2, P1265; CLAYMAN RV, 1984, J UROLOGY, V132, P228, DOI 10.1016/S0022-5347(17)49573-5; CLAYMAN RV, 1983, BR J UROL S, P6; COPTCOAT MJ, 1987, J UROLOGY, V137, P1122, DOI 10.1016/S0022-5347(17)44424-7; COPTCOAT MJ, 1987, J ENDOUROL, V1, P119; DAMM O, 1986, SCANDINAVIAN J S101, V20, P29; DRETLER SP, 1990, J UROLOGY, V143, P267, DOI 10.1016/S0022-5347(17)39929-9; DRETLER SP, 1986, ENDOUROLOGY NEWSLETT, V1, P13; FUCHS GJ, 1987, WORLD J UROL, V5, P237, DOI 10.1007/BF00327227; FUCHS GJ, 1988, UROLITHIASIS, P963; GLEESON MJ, 1989, BR J UROL, V142, P259; HAUPT G, 1989, J UROLOGY, V142, P259, DOI 10.1016/S0022-5347(17)38724-4; HOLMES SAV, 1992, BRIT J UROL, V70, P352, DOI 10.1111/j.1464-410X.1992.tb15786.x; JONES DJ, 1991, J UROLOGY, V145, P481, DOI 10.1016/S0022-5347(17)38374-X; LIEDL B, 1989, UROLITHIASIS, P929; LINGEMAN JE, 1987, J UROLOGY, V137, pA142, DOI 10.1016/S0022-5347(17)75304-9; LINGEMAN JE, 1990, JAMA-J AM MED ASSOC, V263, P1789, DOI 10.1001/jama.263.13.1789; MARBERGER M, 1988, J UROLOGY, V139, P695, DOI 10.1016/S0022-5347(17)42603-6; MARBERGER M, 1983, BR J UROL S, P41; MARCELLAN FJR, 1986, EUR UROL, V12, P73; NEWMAN DM, 1986, J UROLOGY, V136, P238, DOI 10.1016/S0022-5347(17)44826-9; Perez-Castro Ellendt E, 1980, Arch Esp Urol, V33, P445; PHILP T, 1988, LANCET, V1, P41; PSIHRAMIS KE, 1987, J UROLOGY, V138, P707, DOI 10.1016/S0022-5347(17)43349-0; RASSWEILER J, 1990, J UROLOGIE, V96, P149; RASSWEILER J, 1986, EUR UROL, V12, P294; SCHULZE H, 1986, J UROLOGY, V135, P1138, DOI 10.1016/S0022-5347(17)46017-4; SEGURA JW, 1985, J UROLOGY, V134, P1077, DOI 10.1016/S0022-5347(17)47633-6; SEGURA JW, 1983, J UROLOGY, V130, P1051, DOI 10.1016/S0022-5347(17)51678-X; SMITH AD, 1983, BR J UROL S, P84; STACKL W, 1986, J UROLOGY, V136, P386, DOI 10.1016/S0022-5347(17)44876-2; TISELIUS HG, 1989, J UROLOGY, V141, P280, DOI 10.1016/S0022-5347(17)40740-3; TURK C, 1990, AKTUEL UROL, V21, P89, DOI 10.1055/s-2008-1060681; VAHLENSIECK W, 1979, UROLITHIASIS, P110; VALLANCIEN G, 1988, J UROLOGY, V139, P689, DOI 10.1016/S0022-5347(17)42602-4; WATSON GM, 1986, LANCET, V1, P1357; Wickham J E, 1971, Br J Urol, V43, P648; WICKHAM JEA, 1981, BRIT MED J, V283, P1571, DOI 10.1136/bmj.283.6306.1571; WICKHAM JEA, 1983, J UROLOGY, V129, P904, DOI 10.1016/S0022-5347(17)52450-7; WICKHAM JEA, 1983, BR J UROL S, P103; WILLIAMS CM, 1988, AM J ROENTGENOL, V150, P311, DOI 10.2214/ajr.150.2.311	47	25	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1993	307	6916					1414	1417		10.1136/bmj.307.6916.1414	http://dx.doi.org/10.1136/bmj.307.6916.1414			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274898	Green Published, Bronze			2022-12-28	WOS:A1993MK42000028
J	NISTICO, A; YOUNG, NS				NISTICO, A; YOUNG, NS			GAMMA-INTERFERON GENE-EXPRESSION IN THE BONE-MARROW OF PATIENTS WITH APLASTIC-ANEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						ANEMIA, APLASTIC; INTERFERON TYPE II; BONE MARROW; GENE EXPRESSION; LYMPHOKINES	CHRONIC MYELOGENOUS LEUKEMIA; LYMPHOCYTES-T; PROGENITOR CELLS; VIRUS-INFECTIONS; TRANSGENIC MICE; SUPPRESSION; DISEASES; INVITRO; HEMATOPOIESIS; PROLIFERATION	Objective: To determine gamma-interferon gene expression in the bone marrow of patients with aplastic anemia and controls. Most patients with acquired aplastic anemia respond to immunosuppressive therapy, implicating an immune pathophysiologic origin for this disease.			NISTICO, A (corresponding author), NHLBI, HEMATOL BRANCH, BLDG 10, ROOM 7C103, BETHESDA, MD 20892 USA.							ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BACIGALUPO A, 1980, J IMMUNOL, V125, P1449; BORDEN EC, 1992, CLIN IMMUNOL IMMUNOP, V62, pS18, DOI 10.1016/0090-1229(92)90037-O; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; CAMITTA BM, 1976, BLOOD, V48, P63; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CAUX C, 1992, BLOOD, V79, P2628; CLANET M, 1989, BIOMED PHARMACOTHER, V43, P355, DOI 10.1016/0753-3322(89)90061-9; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; HINTERBERGER W, 1989, BLOOD, V74, P2713; HOFFMAN R, 1977, NEW ENGL J MED, V296, P10, DOI 10.1056/NEJM197701062960103; HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444; JOKLIK W K, 1990, P383; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; KAWANO Y, 1991, BLOOD, V77, P2118; KOTT E, 1990, Q J MED, V76, P951; KURANE I, 1989, J EXP MED, V170, P763, DOI 10.1084/jem.170.3.763; KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457; LAVER J, 1988, BRIT J HAEMATOL, V69, P545, DOI 10.1111/j.1365-2141.1988.tb02413.x; NAKAO S, 1992, BLOOD, V79, P2532; PAZDERKA F, 1991, TRANSPLANT P, V23, P241; RIVIERE Y, 1977, P NATL ACAD SCI USA, V74, P2135, DOI 10.1073/pnas.74.5.2135; ROSENFELD S, 1992, BLOOD S, V80, pA282; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; TAKAMATSU Y, 1993, BRIT J HAEMATOL, V83, P21, DOI 10.1111/j.1365-2141.1993.tb04625.x; TALPAZ M, 1986, EXP HEMATOL, V14, P668; TALPAZ M, 1992, CANCER, V69, P410, DOI 10.1002/1097-0142(19920115)69:2<410::AID-CNCR2820690222>3.0.CO;2-V; TOROKSTORB B, 1987, BLOOD, V69, P629; VIALE M, 1991, BLOOD, V78, P1268; VILCEK J, 1984, PROG MED VIROL, V30, P62; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; Young N. S., 1994, APLASTIC ANEMIA ACQU; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; ZOUMBOS NC, 1985, P NATL ACAD SCI USA, V82, P188, DOI 10.1073/pnas.82.1.188; ZOUMBOS NC, 1984, J IMMUNOL, V133, P769; [No title captured]	40	106	114	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					463	469		10.7326/0003-4819-120-6-199403150-00003	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311369				2022-12-28	WOS:A1994NB62500003
J	MURNICK, DE; PEER, BJ				MURNICK, DE; PEER, BJ			LASER-BASED ANALYSIS OF CARBON-ISOTOPE RATIOS	SCIENCE			English	Article							OPTOGALVANIC SPECTROSCOPY; CO2	A laser technique for analysis of carbon-13:carbon-12 ratios with the specificity of laser resonance spectroscopy and the sensitivity and accuracy typical of isotope ratio mass spectrometers is reported. The technique is based on laser optogalvanic effect spectroscopy, in which an electrical (galvanic) signal is detected in response to the optical stimulation of a resonance transition in a gas discharge species. Carbon dioxide molecular gas lasers are used, with the probed transitions being identical to the lasing transitions. Measurements for carbon dioxide samples with 100-second averaging times yield isotopic ratios with a precision of better than 10 parts per million.			MURNICK, DE (corresponding author), RUTGERS STATE UNIV, DEPT PHYS, NEWARK, NJ 07102 USA.				NCRR NIH HHS [R03 RR06976-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R03RR006976] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARBIERI B, 1990, REV MOD PHYS, V62, P603, DOI 10.1103/RevModPhys.62.603; BRADLEY LC, 1986, IEEE J QUANTUM ELECT, V22, P234, DOI 10.1109/JQE.1986.1072967; CHAOHUA W, 1986, CHINESE PHYS LETT, V3, P501; CHAPMAN TE, 1991, STABLE ISOTOPES PAED; DULEY WW, 1976, CO2 LASERS EFFECTS A; GRAHAM DY, 1987, LANCET, V1, P1174; KELES T, 1991, STABLE ISOTOPES PAED, P279; KRUMBIEGEL P, 1991, STABLE ISOTOPE PHARM; LEE PS, 1986, APPL PHYS LETT, V48, P619, DOI 10.1063/1.96722; MAY RD, 1986, REV SCI INSTRUM, V57, P2242, DOI 10.1063/1.1138691; MUENCHAUSEN RE, 1984, OPT COMMUN, V48, P317, DOI 10.1016/0030-4018(84)90307-9; NELSON DE, 1991, SCIENCE, V251, P552, DOI 10.1126/science.1990430; PATEL CKN, 1964, PHYS REV LETT, V13, P617, DOI 10.1103/PhysRevLett.13.617; PLANAROSA P, 1984, J OPT SOC AM B, V1, P704; QUADE J, 1990, SCIENCE, V250, P1549, DOI 10.1126/science.250.4987.1549; QUAY PD, 1992, SCIENCE, V256, P74, DOI 10.1126/science.256.5053.74; SILVER M, 1970, J APPL PHYS, V41, P4566, DOI 10.1063/1.1658497; STEWART RS, 1991, OPTOGALVANIC SPECTRO, V113	19	70	78	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					945	947		10.1126/science.8310291	http://dx.doi.org/10.1126/science.8310291			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310291				2022-12-28	WOS:A1994MX16500028
J	FLETCHER, JC; HOFFMANN, DE				FLETCHER, JC; HOFFMANN, DE			ETHICS COMMITTEES - TIME TO EXPERIMENT WITH STANDARDS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONSULTATION; SERVICE	Ethics committees now exist in most hospitals. Their recent establishment in many institutions was a response to a 1991 mandate by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Proposed or new legislation in a few states is elevating the status of these committees, either requiring their use in certain cases, allowing them to substitute for judicial review, or granting immunity to those who follow their advice. Despite these recent JCAHO and legislative developments, it is widely recognized that there is a significant lack of data on the effectiveness of these committees and that committee members often lack the requisite education and skills for effective participation in case consultation. We argue that before granting ethics committees additional authority, there is a need for more research on their performance and a period of experimentation with quality standards governing their membership and operations.	UNIV MARYLAND, SCH LAW, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	FLETCHER, JC (corresponding author), UNIV VIRGINIA, CTR BIOMED ETHICS, BOX 348 HSC, CHARLOTTESVILLE, VA 22908 USA.							ANNAS GJ, 1991, HASTINGS CENT REP, V21, P18, DOI 10.2307/3563317; Brennan Troyen A, 1992, Law Med Health Care, V20, P336; CULVER CM, 1990, ETHICS BEDSIDE; FLEETWOOD J, 1994, ANN INTERN MED, V120, P320, DOI 10.7326/0003-4819-120-4-199402150-00010; Fletcher J C, 1992, QRB Qual Rev Bull, V18, P12; FOX E, 1993, JAMA-J AM MED ASSOC, V270, P2578, DOI 10.1001/jama.270.21.2578; Fry-Revere S, 1993, Camb Q Healthc Ethics, V2, P449; GREEN W, 1989, HASTINGS CENT REP, V19, P26; Hoffman Diane, 1991, MD Law Rev, V50, P746; HOFFMANN DE, 1994, MILBANK Q, V71, P4; La Puma J, 1992, QRB Qual Rev Bull, V18, P17; LAPUMA J, 1988, JAMA-J AM MED ASSOC, V260, P808, DOI 10.1001/jama.260.6.808; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; MACKLIN R, 1993, ENEMIES PATIENTS, P212; MCCLUNG JA, 1993, NEWSLETTER SOC B SUM, P8; NIEMIRA DA, 1988, ANN INTERN MED, V109, P981, DOI 10.7326/0003-4819-109-12-981; PELLEGRINO ED, 1990, J CLIN ETHIC, V1, P263; PERKINS HS, 1988, AM J MED, V85, P761; SCHUYVE PM, 1993, NEWSLETTER SOC BIOTH, V1, P4; Scofield G R, 1993, Camb Q Healthc Ethics, V2, P417; Siegler M, 1992, QRB Qual Rev Bull, V18, P15; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; Simpson K H, 1992, J Clin Ethics, V3, P124; SMITH MF, 1993, EVALUATION EFFECTIVE; TULSKY JA, 1992, AM J MED, V92, P343, DOI 10.1016/0002-9343(92)90261-9; Wilson R F, 1993, HEC Forum, V5, P1, DOI 10.1007/BF01454915; Wolf Susan M, 1991, MD Law Rev, V50, P798; 1983, DECIDING FOREGO LIFE, P5; 1989, MAY SOC BIOTH CONS S; 1992, ACCREDITATION MANUAL, P106; 1984, FED REG         0112, V49, P1622; 1966, PPO129 US PHS DHEW; BIOETHICS ED EXPANDI	35	55	56	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					335	338		10.7326/0003-4819-120-4-199402150-00012	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291827				2022-12-28	WOS:A1994MW10300012
J	FLAM, F				FLAM, F			CULTURAL SHIFTS - EX-DEFENSE SCIENTISTS COME IN FROM THE COLD	SCIENCE			English	Editorial Material								For many researchers who have spent their careers working on military projects, the end of the Cold War has brought an end to an era of secure funding. Uncertain new priorities such as ''technology transfer'' and ''economic competitiveness'' now determine whether their work will continue to be supported-and at what level. As a result, thousands of researchers who depended on defense money in national labs and universities are struggling to make the transition to civilian science in a research culture very different from the closed world of secret research, Many of them have found some seemingly unlikely uses for their skills The computer algorithms developed to detect incoming missiles can also identify errant cells in the human body, and the plasma physics vital to understanding the detonation of a hydrogen bomb can also be applied to pollution control. But these gentler research goals don't always mean a gentler research environment, say some ex-military scientists. Cold War veterans are finding that the civilian research world, rife with the struggle for funds and the search for ''spinoffs,'' can be a pretty cold place itself.											0	1	1	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					623	624		10.1126/science.8303268	http://dx.doi.org/10.1126/science.8303268			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303268				2022-12-28	WOS:A1994MU96400027
J	JOHN, CC				JOHN, CC			FLOGGING TROLLS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													John, Chandy/GNP-8431-2022; John, Chandy C/B-4164-2008	John, Chandy/0000-0002-1634-1411; 					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					242	242		10.7326/0003-4819-120-3-199402010-00011	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273989				2022-12-28	WOS:A1994MU30300011
J	VERDINE, GL				VERDINE, GL			THE FLIP SIDE OF DNA METHYLATION	CELL			English	Review							CRYSTAL-STRUCTURE; METHYLTRANSFERASE; MECHANISM; BINDING; DOMAINS; COMPLEX				VERDINE, GL (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.							BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1993, CURR BIOL, V3, P384, DOI 10.1016/0960-9822(93)90209-7; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; DAVIES K, 1992, NATURE, V360, P492, DOI 10.1038/360492a0; ERLANSON DA, 1993, J AM CHEM SOC, V115, P12583, DOI 10.1021/ja00079a047; FINNEGAN J, 1993, NUCLEIC ACIDS RES, V21, P2383; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; HANCK T, 1993, NUCLEIC ACIDS RES, V21, P303, DOI 10.1093/nar/21.2.303; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1993, NATURE, V365, P512; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LANGE C, 1991, NATURE, V352, P645, DOI 10.1038/352645a0; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MOORE MH, 1994, IN PRESS EMBO J; MYERS LC, 1993, BIOCHEMISTRY-US, V32, P14089, DOI 10.1021/bi00214a003; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4684; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REINISCH K, 1994, IN PRESS J MOL BIOL; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TROTTIER Y, 1993, CURR BIOL, V3, P783, DOI 10.1016/0960-9822(93)90032-J; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WU JC, 1987, J BIOL CHEM, V262, P4778	33	67	67	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					197	200		10.1016/0092-8674(94)90326-3	http://dx.doi.org/10.1016/0092-8674(94)90326-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293456				2022-12-28	WOS:A1994MU67800002
J	CLEAVER, JE				CLEAVER, JE			IT WAS A VERY GOOD YEAR FOR DNA-REPAIR	CELL			English	Review											CLEAVER, JE (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1994, METABOLIC BASIS INHE; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; KRAMER M, 1993, J BIOL CHEM, V268, P6734; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; MARTIN JB, 1993, SCIENCE, V262, P674, DOI 10.1126/science.8235586; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SUNG P, 1993, J BIOL CHEM, V268, P26391; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	19	144	154	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					1	4		10.1016/0092-8674(94)90165-1	http://dx.doi.org/10.1016/0092-8674(94)90165-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287470				2022-12-28	WOS:A1994MR49500001
J	ABELIOVICH, A; PAYLOR, R; CHEN, C; KIM, JJ; WEHNER, JM; TONEGAWA, S				ABELIOVICH, A; PAYLOR, R; CHEN, C; KIM, JJ; WEHNER, JM; TONEGAWA, S			PKC-GAMMA MUTANT MICE EXHIBIT MILD DEFICITS IN SPATIAL AND CONTEXTUAL LEARNING	CELL			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; DENTATE AREA; HIPPOCAMPAL; RATS; MEMORY	We are undertaking a genetic approach to investigate the role that synaptic modulation in the mammalian central nervous system plays in learning and memory and to identify relevant molecular components. We have generated mice deficient in the gamma isoform of protein kinase C (PKCgamma), an enzyme that has previously been implicated in both long-term potentiation (LTP) and learning and memory. These mice have a modified LTP of synaptic transmission in the hippocampus. We demonstrate that PKCgamma-mutant mice can learn to carry out hippocampus-dependent tasks, although mild deficits are evident. Thus, hippocampal CA1 LTP induced by the conventional tetanic stimulation is not essential for the mice to exhibit spatial and contextual learning. Furthermore, the modification of hippocampal synaptic plasticity correlates with the learning deficits we observe.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; UNIV COLORADO,SCH PHARM,BOULDER,CO 80309; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Southern California	ABELIOVICH, A (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			Kim, Jeansok/0000-0001-7964-106X	NIAAA NIH HHS [AA-00141] Funding Source: Medline; NIMH NIH HHS [MH-48663] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048663] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BANK B, 1989, MOL NEUROBIOL, V3, P55, DOI 10.1007/BF02935588; BANK B, 1988, P NATL ACAD SCI USA, V85, P1988, DOI 10.1073/pnas.85.6.1988; BEKKERS JH, 1990, COLD SPRING HARB SYM, V50, P131; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; Eichenbaum H, 1991, MEMORY ORG LOCUS CHA, P163; Flourens P, 1824, RECHERCHES EXPT PROP; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HEBB DO, 1949, BEHAV BIOL, V12, P421; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morris RGM, 1991, LONG TERM POTENTIATI, P267; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLDS JL, 1991, NEW BIOL, V3, P27; OLDS JL, 1990, J NEUROSCI, V10, P3707; PAYLOR R, 1993, PSYCHOBIOLOGY, V21, P11; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE L, 1987, MEMORY HIPPOCAMPUS S; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; VANDERZEE EA, 1992, J NEUROSCI, V12, P4808; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y	41	401	409	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1263	1271		10.1016/0092-8674(93)90614-V	http://dx.doi.org/10.1016/0092-8674(93)90614-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269510				2022-12-28	WOS:A1993MP86900006
J	KOBE, B; DEISENHOFER, J				KOBE, B; DEISENHOFER, J			CRYSTAL-STRUCTURE OF PORCINE RIBONUCLEASE INHIBITOR, A PROTEIN WITH LEUCINE-RICH REPEATS	NATURE			English	Article							KINETIC CHARACTERIZATION; TRANSMEMBRANE PROTEIN; GENE; DROSOPHILA; CEREVISIAE; SEQUENCE; HOMOLOGY; DOMAINS; CYCLASE; YEAST	RIBONUCLEASE inhibitor is a cytoplasmic protein that tightly binds and inhibits ribonucleases of the pancreatic ribonuclease superfamily1. The primary sequence of this inhibitor contains leucine-rich repeats2 (LRRs); these motifs are present in many proteins that participate in protein-protein interactions and have different functions and cellular locations. In vivo, ribonuclease inhibitor may have a role in the regulation of RNA turnover in mammalian cells3 and in angiogenesis4. To define the structural features of LRR proteins and to understand better the nature of the tight interaction of ribonuclease inhibitor with ribonucleases, we have determined the crystal structure of the porcine inhibitor. To our knowledge, this is the first three-dimensional structure of a protein containing LRRs and represents a new class of alpha/beta protein fold. Individual repeats constitute beta-alpha structural units that probably also occur in other proteins containing LRRs. The non-globular shape of the structure and the exposed face of the parallel beta-sheet may explain why LRRs are used to achieve strong protein-protein interactions. A possible ribonuclease-binding region incorporates the surface formed by the parallel beta-sheet and the betaalpha loops.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KOBE, B (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				BODE W, 1985, BIOL CHEM H-S, V366, P287, DOI 10.1515/bchm3.1985.366.1.287; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P105; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1991, J BIOL CHEM, V266, P24198; HOFSTEENGE J, 1991, BIOCHEM J, V275, P541, DOI 10.1042/bj2750541; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOBE B, 1993, J MOL BIOL, V231, P137, DOI 10.1006/jmbi.1993.1263; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEE FS, 1990, BIOCHEMISTRY-US, V29, P6633, DOI 10.1021/bi00480a012; LEUNG KY, 1989, J BACTERIOL, V171, P4623, DOI 10.1128/jb.171.9.4623-4632.1989; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NEUMANN U, 1993, J MOL BIOL, V231, P505, DOI 10.1006/jmbi.1993.1299; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; QUIRINSTRICKER C, 1968, BIOCHIM BIOPHYS ACTA, V159, P75, DOI 10.1016/0005-2744(68)90245-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; STEIGEMANN W, 1992, PROTEIN PROGRAM SYST; TAN FL, 1990, J BIOL CHEM, V265, P13; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	40	535	552	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					751	756		10.1038/366751a0	http://dx.doi.org/10.1038/366751a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264799				2022-12-28	WOS:A1993MN26400031
J	GROVES, T				GROVES, T			INFORMATION SHARING - GETTING JOURNALS AND BOOKS TO DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article													Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				JONGSMA A, 1993, LANCET, V341, P376, DOI 10.1016/0140-6736(93)90182-G; SKANDHAN KP, 1992, LANCET, V340, P1165; 1993, INASP DIRECTORY 1993	3	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1614	1617		10.1136/bmj.307.6919.1614	http://dx.doi.org/10.1136/bmj.307.6919.1614			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MN107	8292959	Green Published, Bronze			2022-12-28	WOS:A1993MN10700024
J	LENEMAN, L				LENEMAN, L			MEDICAL WOMEN IN THE WORLD-WAR-I - RANKING NOWHERE	BRITISH MEDICAL JOURNAL			English	Article											LENEMAN, L (corresponding author), UNIV ST ANDREWS,DEPT SCOTTISH HIST,ST ANDREWS KY16 9ST,FIFE,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAKE C, 1990, CARGE PARASOLS WOMEN; MURRAY F, 1913, NEW STATESMAN SOC, pR16; MURRAY F, 1920, WOMENS ARMY SURGEONS; 1919, BMJ, V2, P288; 1919, BMA ARCH; 1918, TIMES           0704; SAMWFC159 WELLC I HI; SAWMFC163 WELLC I HI; 1919, BMA ARCH        0324; 1918, BMA ARCH        1007; 1918, BMJ, V2, P554	11	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1592	1594		10.1136/bmj.307.6919.1592	http://dx.doi.org/10.1136/bmj.307.6919.1592			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MN107	8292950	Bronze, Green Published			2022-12-28	WOS:A1993MN10700013
J	PATERSONBROWN, S; WYATT, JC; FISK, NM				PATERSONBROWN, S; WYATT, JC; FISK, NM			ARE CLINICIAN INTERESTED IN UP-TO-DATE REVIEWS OF EFFECTIVE CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	PATERSONBROWN, S (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP, ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W6 0XG, ENGLAND.		Fisk, Nicholas M/B-2126-2009; Wyatt, Jeremy/F-8160-2010	Fisk, Nicholas M/0000-0003-0031-7975; Wyatt, Jeremy/0000-0001-7008-1473				CARDOZO L, 1993, BRIT MED J, V306, P840, DOI 10.1136/bmj.306.6881.840; FISK NM, 1990, EARLY HUM DEV, V24, P181; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; PAINTIN DB, 1990, BRIT J OBSTET GYNAEC, V97, P967, DOI 10.1111/j.1471-0528.1990.tb02464.x; 1992, MATERNITY SERVICES	5	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	1993	307	6917					1464	1464		10.1136/bmj.307.6917.1464	http://dx.doi.org/10.1136/bmj.307.6917.1464			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281089	Green Published, Bronze			2022-12-28	WOS:A1993MK79700025
J	BRECKER, SJD; STEVENSON, RN; ROBERTS, R; UTHAYAKUMAR, S; TIMMIS, AD; BALCON, R				BRECKER, SJD; STEVENSON, RN; ROBERTS, R; UTHAYAKUMAR, S; TIMMIS, AD; BALCON, R			ACUTE MYOCARDIAL-INFARCTION IN PATIENTS WITH NORMAL CORONARY-ARTERIES	BRITISH MEDICAL JOURNAL			English	Article									LONDON CHEST HOSP,DEPT CARDIAC,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London								ARNETT EN, 1976, CIRCULATION, V53, P395, DOI 10.1161/01.CIR.53.3.395; BETRIU A, 1981, AM J CARDIOL, V48, P28, DOI 10.1016/0002-9149(81)90568-3; KHAN AH, 1974, NEW ENGL J MED, V291, P427, DOI 10.1056/NEJM197408292910901; RAYMOND R, 1988, J AM COLL CARDIOL, V11, P471, DOI 10.1016/0735-1097(88)91519-7; ROSENBLATT A, 1977, CIRCULATION, V55, P578, DOI 10.1161/01.CIR.55.4.578	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1255	1256		10.1136/bmj.307.6914.1255	http://dx.doi.org/10.1136/bmj.307.6914.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281058	Bronze, Green Published			2022-12-28	WOS:A1993MH00100022
J	MERKATZ, RB; TEMPLE, R; SOBEL, S; FEIDEN, K; KESSLER, DA				MERKATZ, RB; TEMPLE, R; SOBEL, S; FEIDEN, K; KESSLER, DA			WOMEN IN CLINICAL-TRIALS OF NEW DRUGS - A CHANGE IN FOOD-AND-DRUG-ADMINISTRATION POLICY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL-CONTRACEPTIVE STEROIDS; SEX-DIFFERENCES; PHARMACOKINETICS; METABOLISM; DISPOSITION; GENDER; ADENOCARCINOMA; VAGINA; AGE				MERKATZ, RB (corresponding author), US FDA,HS-1,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							ABERNETHY DR, 1982, CLIN PHARMACOL THER, V31, P783, DOI 10.1038/clpt.1982.111; [Anonymous], 1989, GUIDELINE STUDY DRUG; ARTHUR MJP, 1984, CLIN SCI, V67, P397, DOI 10.1042/cs0670397; BACK DJ, 1981, DRUGS, V21, P46, DOI 10.2165/00003495-198121010-00003; BENET LZ, 1984, PHARMACOKINETIC BASI; BERTOLI A, 1980, J CLIN ENDOCR METAB, V50, P246, DOI 10.1210/jcem-50-2-246; CHRISTIE GA, 1962, LANCET, V2, P249; DIVOLL M, 1981, J PHARM SCI, V70, P1104, DOI 10.1002/jps.2600701004; EVANS WE, 1986, APPLIED PHARMACOKINE; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GREENBLATT DJ, 1980, J PHARMACOL EXP THER, V215, P86; GUSTAVSON LE, 1986, J CLIN ENDOCR METAB, V62, P234, DOI 10.1210/jcem-62-1-234; Hamilton J, 1983, J Am Med Womens Assoc (1972), V38, P126; Hamilton J A, 1986, NIDA Res Monogr, V65, P14; HEINZ J, 1983, COMMUNICATION   0927; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HOOPER WD, 1990, CLIN PHARMACOL THER, V48, P633, DOI 10.1038/clpt.1990.207; JOHNSON TL, 1993, J WOMENS HEALTH, V2, P95; KESSLER DA, 1989, NEW ENGL J MED, V320, P281, DOI 10.1056/NEJM198902023200504; KIRSCHSTEIN RL, 1991, AM J PUBLIC HEALTH, V81, P291, DOI 10.2105/AJPH.81.3.291; Levine C., 1993, EMERGING ISSUES BIOM, V2, P169; MINERS JO, 1986, BRIT J CLIN PHARMACO, V22, P135, DOI 10.1111/j.1365-2125.1986.tb05240.x; NAFZIGER AN, 1989, EUR J CLIN PHARMACOL, V37, P97; ORME ML, 1983, CLIN PHARMACOKINET, V8, P95, DOI 10.2165/00003088-198308020-00001; PINN VW, 1992, JAMA-J AM MED ASSOC, V268, P1921, DOI 10.1001/jama.268.14.1921; PIPER JM, 1992, OBSTET GYNECOL, V80, P429; PRITCHARD JF, 1992, CLIN PHARMACOL THER, V51, P51, DOI 10.1038/clpt.1992.7; RAY BA, 1986, NATIONAL I DRUG ABUS, V65; REISMAN EK, 1992, OCT WOM CLIN TRIALS; SHENFIELD GM, 1991, CLIN PHARMACOKINET, V20, P15, DOI 10.2165/00003088-199120010-00002; TEMPLE R, 1987, CLIN PHARMACOL THER, V42, P681, DOI 10.1038/clpt.1987.222; WALLE T, 1989, CLIN PHARMACOL THER, V46, P257, DOI 10.1038/clpt.1989.136; WIDOM B, 1992, DIABETES CARE, V15, P213, DOI 10.2337/diacare.15.2.213; WING LMH, 1984, CLIN PHARMACOL THER, V355, P695; 1985, DHHS PHS8550206 PUBL, V2; 1977, HEW FDA773040 PUBL; 1992, GAOHRD9317 PUBL; 1988, GUIDELINE FORMAT CON; 1991, FORGING WOMENS HLTH; 1992, NIH923457A PUBL; IN PRESS GUIDELINE S; 1993, FORUM DRUG DEV WOMEN; 1991, RES IMPROVE WOMENS H; 1978, DHEW OS780012 PUBL; IN PRESS FOOD DRUG L	46	177	178	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					292	296		10.1056/NEJM199307223290429	http://dx.doi.org/10.1056/NEJM199307223290429			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LM682	8305004	Bronze			2022-12-28	WOS:A1993LM68200036
J	MARON, BJ				MARON, BJ			SUDDEN-DEATH IN YOUNG ATHLETES - LESSONS FROM THE GATHERS,HANK AFFAIR	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE				MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN, MINNEAPOLIS, MN 55407 USA.							BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; MARON BJ, 1990, CIRCULATION, V82, P239; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1985, J AM COLL CARDIOL, V6, P1189; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; Noren G R, 1977, J Forensic Sci, V22, P188; SHAPIRO L, 1992, WASHINGTON POST 0404, pD1; SMALE D, 1991, OFFICIAL NATIONAL CO, P84; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; [No title captured]	18	140	141	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					55	57		10.1056/NEJM199307013290113	http://dx.doi.org/10.1056/NEJM199307013290113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8292123				2022-12-28	WOS:A1993LJ33800013
J	COLDITZ, GA; BREWER, TF; BERKEY, CS; WILSON, ME; BURDICK, E; FINEBERG, HV; MOSTELLER, F				COLDITZ, GA; BREWER, TF; BERKEY, CS; WILSON, ME; BURDICK, E; FINEBERG, HV; MOSTELLER, F			EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IMMUNIZATION; INFECTION; OUTBREAK; INDIANS; TRIALS; LIFE	Objective.-To quantify the efficacy of BCG vaccine against tuberculosis (TB). Data Sources.-MEDLINE with index terms BCG vaccine, tuberculosis, and human. Experts from the Centers for Disease Control and Prevention and the World Health Organization, among others, provided lists of all known studies. Study Selection.-A total of 1264 articles or abstracts were reviewed for details on BCG vaccination, concurrent vaccinated and unvaccinated groups, and SB outcome; 70 articles were reviewed in depth for method of vaccine allocation used to create comparable groups, equal surveillance and follow-up for recipient and concurrent control groups, and outcome measures of TB cases and/or deaths. Fourteen prospective trials and 12 case-control studies were included in the analysis. Data Extraction.-We recorded study design, age range of study population, number of patients enrolled, efficacy of vaccine, and items to assess the potential for bias in study design and diagnosis. At least two readers independently extracted data and evaluated validity. Data Synthesis.-The relative risk (RR) or odds ratio (OR) of TB provided the measure of vaccine efficacy that we analyzed. The protective effect was then computed by 1-RR or 1-OR. A random-effects model estimated a weighted average RR or OR from those provided by the trials or case-control studies. In the trials, the RR of TB was 0.49 (95% confidence interval [CI], 0.34 to 0.70) for vaccine recipients compared with nonrecipients (protective effect of 51%). In the case-control studies, the OR for TB was 0.50 (95% CI, 0.39 to 0.64), or a 50% protective effect. Seven trials reporting tuberculous deaths showed a protective effect from BCG vaccine of 71% (RR, 0.29; 95% CI, 0.16 to 0.53), and five studies reporting on meningitis showed a protective effect from BCG vaccine of 64% (OR, 0.36; 95% CI, 0.18 to 0.70). Geographic latitude of the study site and study validity score explained 66% of the heterogeneity among trials in a random-effects regression model. Conclusion.-On average, BCG vaccine significantly reduces the risk of TB by 50%. Protection is observed across many populations, study designs, and forms of TB. Age at vaccination did not enhance predictiveness of BCG efficacy. Protection against tuberculous death, meningitis, and disseminated disease is higher than for total TB cases, although this result may reflect reduced error in disease classification rather than greater BCG efficacy.	BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114; MT AUBURN HOSP,INFECT DIS UNIT,CAMBRIDGE,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Mount Auburn Hospital	COLDITZ, GA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,TECHNOL ASSESSMENT GRP,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009; Trajman, Anete/C-7679-2016	Colditz, Graham/0000-0002-7307-0291; Trajman, Anete/0000-0002-4000-4984				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ARONSON JD, 1958, ARCH INTERN MED, V101, P881, DOI 10.1001/archinte.1958.00260170037006; ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255; BERKEY CS, 1993, EFFICACY BCG PREVENT; BURRILL D, 1985, CAN MED ASSOC J, V132, P137; CAMARGOS PAM, 1988, INT J EPIDEMIOL, V17, P193, DOI 10.1093/ije/17.1.193; CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; Coetzee A M, 1968, Proc Mine Med Off Assoc, V48, P41; COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1974, AM J PUBLIC HEALTH, V64, P283, DOI 10.2105/AJPH.64.3.283; DEFRIEZ AI, 1957, NEW ENGL J MED, V257, P161, DOI 10.1056/NEJM195707252570403; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKIE HA, 1950, ANN INTERN MED, V33, P941, DOI 10.7326/0003-4819-33-4-941; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FERGUSON R. G., 1949, TUBERCLE, V30, P5, DOI 10.1016/S0041-3879(49)80055-9; FERGUSON RG, 1946, AM REV TUBERC PULM, V54, P325, DOI 10.1164/art.1946.54.4-5.325; FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; Frimodt-Moller J, 1973, Bull Int Union Tuberc, V48, P40; GEISELER PJ, 1986, AM REV RESPIR DIS, V133, P773; HALVORSENKT, 1992, MED USES STATISTICS, P413; HAMBURG MA, 1992, NEW YORK STATE J MED, V92, P291; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HEIMBECK J., 1936, Tubercle, V18, P97, DOI 10.1016/S0041-3879(36)80249-9; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P79; HOUGHTON HGH, 1950, LANCET, V2, P533; HOUSTON S, 1990, AM J EPIDEMIOL, V131, P340, DOI 10.1093/oxfordjournals.aje.a115503; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Levine M. I., 1948, AM REV TUBERC, V53, P517; MICELI I, 1988, INT J EPIDEMIOL, V17, P629, DOI 10.1093/ije/17.3.629; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; MYINT TT, 1987, ANN TROP PAEDIATR, V7, P159, DOI 10.1080/02724936.1987.11748499; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; PATEL A, 1991, B WORLD HEALTH ORGAN, V69, P425; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PUTRALI J, 1983, P E REGIONAL TUBERCU, P194; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RODRIGUES LC, 1991, J EPIDEMIOL COMMUN H, V45, P78, DOI 10.1136/jech.45.1.78; ROSENTHAL S, 1961, PEDIATRICS, V28, P622; ROSENTHAL SR, 1955, JAMA-J AM MED ASSOC, V157, P801, DOI 10.1001/jama.1955.02950270019006; ROSENTHAL SR, 1960, AM REV RESPIR DIS, V84, P690; ROSENTHAL SR, 1953, T NATIONAL TUBERCULO, P161; ROSENTHAL SR, 1943, HOSPITALS, V17, P75; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; SIRINAVIN S, 1991, PEDIATR INFECT DIS J, V10, P350; SMITH PG, 1987, 26TH P WORLD C INT U, P73; SPRINGETT VH, 1970, BMJ-BRIT MED J, V4, P148, DOI 10.1136/bmj.4.5728.148; STEIN SC, 1953, AM REV TUBERC, V68, P692; ten Dam H G, 1984, Adv Tuberc Res, V21, P79; TENDAM HG, 1976, B WORLD HEALTH ORGAN, V54, P255; TENDAM HG, 1993, TUBERCULOSIS COMPREH, P251; VANDIVIERE HM, 1973, AM REV RESPIR DIS, V108, P301; VONREYN CF, 1987, LANCET, V2, P669; WUNSCHFILHO V, 1993, INT J EPIDEMIOL, V22, P149, DOI 10.1093/ije/22.1.149; YOUNG TK, 1986, AM J PUBLIC HEALTH, V76, P783, DOI 10.2105/AJPH.76.7.783; 1988, MMWR MORB MORTAL WKL, V37, P663; 1991, MMWR MORB MORTAL WKL, V40, P585; 1980, LANCET, V1, P73; 1992, MMWR MORB MORTAL WKL, V42, P696; 1988, MMWR MORB MORTAL WKL, V37, P669; 1992, MMWR MORB MORTAL WKL, V42, P703; 1979, B WORLD HEALTH ORGAN, V57, P819; 1992, MMWR MORB MORTAL WKL, V41, P5; 1980, INDIANJ MED RES S, V72, P1; 1992, COMBINING INFORMATIO; 1981, LANCET, P1309	70	1523	1612	1	163	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					698	702		10.1001/jama.271.9.698	http://dx.doi.org/10.1001/jama.271.9.698			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309034				2022-12-28	WOS:A1994MX57000032
J	EMANUEL, EJ; EMANUEL, LL				EMANUEL, EJ; EMANUEL, LL			THE ECONOMICS OF DYING - THE ILLUSION OF COST SAVINGS AT THE END OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CANCER; RANDOMIZED TRIAL; CRITICALLY ILL; MEDICAL-CARE; ADVANCE DIRECTIVES; NATIONAL HOSPICE; CHEMOTHERAPY; RESUSCITATION; EXPENDITURES; PREFERENCES		HARVARD UNIV,SCH MED,DIV MED ETH,BOSTON,MA	Harvard University; Harvard Medical School	EMANUEL, EJ (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.							BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; DORONZIO JC, 1993, NY TIMES        0608, pA25; EMANUEL EI, 1994, WASHINGTON POST 0102, pC3; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Ginzberg E, 1980, Inquiry, V17, P293; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; GODEC MS, 1993, WASHINGTON POST 0502, pC3; GREER DS, 1986, J CHRON DIS, V39, P5, DOI 10.1016/0021-9681(86)90102-5; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; HANNAN EL, 1984, INQUIRY-J HEALTH CAR, V21, P338; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KANE RL, 1984, LANCET, V1, P890; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LANTOS JD, 1989, AM J MED, V87, P81; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Levit K R, 1991, Health Care Financ Rev, V13, P29; LOCWY EH, 1993, ARCH INTERN MED, V153, P429; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MCCALL N, 1984, MED CARE, V22, P329, DOI 10.1097/00005650-198404000-00004; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MOR V, 1985, HEALTH SERV RES, V20, P407; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; RUCKDESCHEL JC, 1990, J CLIN ONCOL, V8, P1293, DOI 10.1200/JCO.1990.8.8.1293; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1986, ANNU REV PUBL HEALTH, V7, P59, DOI 10.1146/annurev.pu.07.050186.000423; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SIU AL, 1987, MED SOC CLIN DECISIO, P20; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; TENO J, 1993, CLIN RES, V41, pA551; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TURNBULL AD, 1979, CRIT CARE MED, V7, P20, DOI 10.1097/00003246-197901000-00005; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; VITELLI CE, 1991, J CLIN ONCOL, V9, P111, DOI 10.1200/JCO.1991.9.1.111; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	59	274	276	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					540	544		10.1056/NEJM199402243300806	http://dx.doi.org/10.1056/NEJM199402243300806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX436	8302321				2022-12-28	WOS:A1994MX43600006
J	SMALL, PLC; RAMAKRISHNAN, L; FALKOW, S				SMALL, PLC; RAMAKRISHNAN, L; FALKOW, S			REMODELING SCHEMES OF INTRACELLULAR PATHOGENS	SCIENCE			English	Editorial Material							MYCOBACTERIUM-AVIUM; MACROPHAGES		STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	SMALL, PLC (corresponding author), NIAID,ROCKY MT LABS,HAMILTON,MT 59840, USA.			Ramakrishnan, Lalita/0000-0003-0692-5533				APUCHEARANDA CM, 1994, J EXP MED, V179, P601; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; CLEMENS DL, 1992, J EXP MED, V175, P1317, DOI 10.1084/jem.175.5.1317; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FINLEY B, 1991, MICROBIOL REV, V53, P210; FREHEL C, 1986, INFECT IMMUN, V52, P252, DOI 10.1128/IAI.52.1.252-262.1986; HACKSTADT T, 1983, J BACTERIOL, V154, P598, DOI 10.1128/JB.154.2.598-603.1983; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277	13	71	72	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					637	639		10.1126/science.8303269	http://dx.doi.org/10.1126/science.8303269			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303269				2022-12-28	WOS:A1994MU96400034
J	WEISS, A; LITTMAN, DR				WEISS, A; LITTMAN, DR			SIGNAL-TRANSDUCTION BY LYMPHOCYTE ANTIGEN RECEPTORS	CELL			English	Review							PROTEIN-TYROSINE KINASE; T-CELL RECEPTOR; VAV PROTOONCOGENE PRODUCT; LEUKOCYTE-COMMON ANTIGEN; CROSS-LINKING; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; MONOCLONAL-ANTIBODY; PHOSPHATASE CD45; CYCLOSPORINE-A		UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	WEISS, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBER G, 1993, CURR BIOL, V3, P333, DOI 10.1016/0960-9822(93)90196-U; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BYRNE JA, 1988, J IMMUNOL, V141, P3249; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1992, J IMMUNOL, V148, P2012; GRABER M, 1992, INT IMMUNOL, V4, P1201, DOI 10.1093/intimm/4.11.1201; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; Ledbetter J A, 1990, Semin Immunol, V2, P99; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; NEL AE, 1990, J IMMUNOL, V144, P2683; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALCEDO TW, 1993, SCIENCE, V177, P1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SGROI D, 1993, J BIOL CHEM, V268, P7011; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1993, J IMMUNOL, V151, P777; Veillette A, 1991, Semin Immunol, V3, P143; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1993, CURR OPIN IMMUNOL, V5, P235, DOI 10.1016/0952-7915(93)90010-P; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODROW MA, 1993, J IMMUNOL, V150, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	125	1996	2060	3	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					263	274		10.1016/0092-8674(94)90334-4	http://dx.doi.org/10.1016/0092-8674(94)90334-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293463				2022-12-28	WOS:A1994MU67800010
J	WU, TC; LICHTEN, M				WU, TC; LICHTEN, M			MEIOSIS-INDUCED DOUBLE-STRAND BREAK SITES DETERMINED BY YEAST CHROMATIN STRUCTURE	SCIENCE			English	Article							MEIOTIC GENE CONVERSION; SYNAPTONEMAL COMPLEX-FORMATION; RECOMBINATION INITIATION SITE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; ARG4 LOCUS; DNA; PROMOTER; SEQUENCE; MAP	Double-strand DNA breaks (DSBs) occur at recombination hotspots during Saccharomyces cerevisiae meiosis and are thought to initiate exchange at these loci. Analysis of DSB sites in three regions of the yeast genome indicated that breaks occur at or near many potential transcription promoters and that DSBs initiate most, if not all, meiotic recombination. DSB sites displayed deoxyribonuclease I hypersensitivity in chromatin from mitotic and meiotic cells, and changes in chromatin structure produced parallel changes in the occurrence of DSBs. Thus, features of chromatin structure that are established before meiosis play a role in determining where meiotic recombination events initiate.	NCI,DIV CANC BIOL DIAGN & CTR,BIOCHEM LAB,BLDG 37,ROOM 4D14,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lichten, Michael/C-5795-2013	Lichten, Michael/0000-0001-9707-2956				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BERGMAN L, COMMUNICATION; BERGMAN LW, 1983, J BIOL CHEM, V268, P7223; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Davisson M. T., 1981, Genetic variants and strains of the laboratory mouse., P283; DEMASSY B, 1993, EMBO J, V12, P1459, DOI 10.1002/j.1460-2075.1993.tb05789.x; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; GAME JC, 1992, DEV GENET, V13, P485, DOI 10.1002/dvg.1020130610; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Malone R., COMMUNICATION; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1990, GENETICS, V125, P753; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROCCO V, 1993, YEAST, V9, P1111, DOI 10.1002/yea.320091012; ROCCO V, 1992, P NATL ACAD SCI USA, V89, P12068, DOI 10.1073/pnas.89.24.12068; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SCHULTES NP, COMMUNICATION; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYMINGTON LS, 1991, GENETICS, V128, P717; THOMAS BJ, 1991, CELL, V64, P1, DOI 10.1016/0092-8674(91)90199-9; THON G, 1992, GENETICS, V131, P287; WHITE MA, 1992, CURR GENET, V21, P109, DOI 10.1007/BF00318468; WU TC, UNPUB; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	42	373	383	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					515	518		10.1126/science.8290959	http://dx.doi.org/10.1126/science.8290959			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290959				2022-12-28	WOS:A1994MT96600031
J	PHILLIPS, DM				PHILLIPS, DM			IMAGES IN CLINICAL MEDICINE - CLOSTRIDIUM-DIFFICILE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,NEW YORK,NY 10021, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					256	256						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272087				2022-12-28	WOS:A1994MR49600005
J	RAJAGOPALAN, S; XU, YH; BRENNER, MB				RAJAGOPALAN, S; XU, YH; BRENNER, MB			RETENTION OF UNASSEMBLED COMPONENTS OF INTEGRAL MEMBRANE-PROTEINS BY CALNEXIN	SCIENCE			English	Article							T-CELL RECEPTOR; PRE-GOLGI DEGRADATION; ENDOPLASMIC-RETICULUM; ANTIGEN RECEPTORS; COMPLEX; BINDING; IDENTIFICATION; GLYCOPROTEINS; MOLECULES; REQUIRES	Quality control mechanisms prevent the cell surface expression of incompletely assembled multisubunit receptors such as the T cell receptor (TCR). The molecular chaperone function of calnexin (IP90, p88), a 90-kilodalton protein that resides in the endoplasmic reticulum (ER), in the retention of representative chains of the TCR-CD3 complex in the ER was tested. Truncation mutants of calnexin, when transiently expressed in COS cells, were exported from the ER and either accumulated in the Golgi or progressed to the cell surface. CD3 epsilon chains cotransfected with the forms of calnexin that were not retained in the ER exited the ER and colocalized with calnexin. Since engineered calnexin determined the intracellular localization of the proteins associated with it, it is concluded that calnexin interacts with incompletely assembled TCR components and retains them in the ER.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,ELECTRON MICROSCOPY & STRUCT MOLEC BIOL LAB,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	RAJAGOPALAN, S (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.							ALARCON B, 1988, J BIOL CHEM, V263, P2953; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOCH G, 1986, J CELL SCI, V86, P217; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, UNPUB; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; WADA I, 1991, J BIOL CHEM, V266, P19599; WATKINS S, 1991, HISTOCHEM J, V22, P507; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	27	226	227	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					387	390		10.1126/science.8278814	http://dx.doi.org/10.1126/science.8278814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278814				2022-12-28	WOS:A1994MT03400037
J	LEVINE, JJ; ILOWITE, NT				LEVINE, JJ; ILOWITE, NT			SCLERODERMA-LIKE ESOPHAGEAL DISEASE IN CHILDREN BREAST-FED BY MOTHERS WITH SILICONE BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; SYSTEMIC-SCLEROSIS	Objective.-To determine whether breast-fed children of mothers with silicone implants are at increased risk for the development of sclerodermalike esophageal involvement compared with children not exposed to silicone implants. Design.-Case-control study. Setting.-Referral-based pediatric gastroenterology clinic. Patients.-Eleven children (mean age, 6.0 years; range, 1.5 to 13 years; six boys and five girls) referred for abdominal pain who were born to mothers who had silicone breast implants (eight breast-fed children and three bottle-fed) were compared with 17 patients (mean age, 10.7 years; range, 2 to 18 years; 11 boys and six girls) with abdominal pain who were not exposed to silicone implants. Methods.-All children underwent esophageal manometry and upper intestinal endoscopy with esophageal biopsy and were tested for antinuclear antibody and autoantibodies to Scl-70, centromere, ribonucleoprotein, Sm, Ro, La, and phospholipid. Results.-Six of the eight breast-fed children from mothers with silicone implants had significantly abnormal esophageal motility with nearly absent peristalsis in the distal two thirds of the esophagus and decreased lower sphincter pressure. Upper esophageal pressures and motility were normal. Compared with controls, the breast-fed children had significantly decreased lower sphincter pressure and abnormal esophageal wave propagation. These manometric abnormalities were not seen in the three bottle-fed children. There was no difference in the expression of autoantibodies in the breast-fed children compared with the bottle-fed children or controls. Conclusions.-A relationship appears to exist between breast-feeding by mothers with silicone implants and abnormal esophageal motility. Studies evaluating larger numbers of children are needed to determine the extent of the risk.	ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,DIV RHEUMATOL,NEW HYDE PK,NY 11042	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University	LEVINE, JJ (corresponding author), ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11042, USA.			Levine, Jeremiah/0000-0002-7676-538X				BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; CAULFIELD M, 1989, J PEDIATR-US, V115, P339, DOI 10.1016/S0022-3476(89)80829-7; CUCCHIARA S, 1986, J PEDIATR-US, V108, P907, DOI 10.1016/S0022-3476(86)80925-8; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; FLICK JA, 1988, PEDIATRICS, V82, P107; GARRETT JM, 1971, MAYO CLIN PROC, V46, P92; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; GRAY RG, 1977, ARTHRITIS RHEUM, V20, P35, DOI 10.1002/art.1780200106; KLEIN HA, 1992, GASTROENTEROLOGY, V102, P1551, DOI 10.1016/0016-5085(92)91713-E; LAWTON AR, 1989, IMMUNOLOGIC DISORDER, P1; LUGANO EM, 1984, AM REV RESPIR DIS, V129, P767, DOI 10.1164/arrd.1984.129.5.767; REIMER G, 1990, RHEUM DIS CLIN N AM, V16, P169; REISER KM, 1979, TOXICOLOGY, V13, P51, DOI 10.1016/S0300-483X(79)80010-4; RODNAN GP, 1962, JAMA-J AM MED ASSOC, V180, P665, DOI 10.1001/jama.1962.03050210027006; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; VARGAS A, 1979, PLAST RECONSTR SURG, V64, P252, DOI 10.1097/00006534-197908000-00025	21	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					213	216		10.1001/jama.271.3.213	http://dx.doi.org/10.1001/jama.271.3.213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277548				2022-12-28	WOS:A1994MQ64500035
J	VLADECK, BC				VLADECK, BC			FROM THE HEALTH-CARE-FINANCING-ADMINISTRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,WASHINGTON,DC, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					180	180		10.1001/jama.271.3.180	http://dx.doi.org/10.1001/jama.271.3.180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ645	8277535				2022-12-28	WOS:A1994MQ64500009
J	CHUA, TP; FARRELL, T; LIPKIN, DP				CHUA, TP; FARRELL, T; LIPKIN, DP			MYOCLONUS ASSOCIATED WITH PROPAFENONE	BRITISH MEDICAL JOURNAL			English	Letter											CHUA, TP (corresponding author), ROYAL FREE HOSP,DEPT CARDIOL,LONDON NW3 2QG,ENGLAND.							DEVOIZE JL, 1986, PRESSE MED, V8, P15; DUKES ID, 1984, EUR HEART J, V5, P115, DOI 10.1093/oxfordjournals.eurheartj.a061621	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					113	113		10.1136/bmj.308.6921.113b	http://dx.doi.org/10.1136/bmj.308.6921.113b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298383	Green Published			2022-12-28	WOS:A1994MR17300019
J	SANDISON, A; JONES, PA				SANDISON, A; JONES, PA			URINE CULTURE IN THE DIAGNOSIS OF COLOVESICAL FISTULA	BRITISH MEDICAL JOURNAL			English	Article											SANDISON, A (corresponding author), MAIDSTONE HLTH AUTHOR,MAIDSTONE ME16 9QQ,KENT,ENGLAND.							KIRSH GM, 1991, SURG GYNECOL OBSTET, V173, P91	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1588	1588		10.1136/bmj.307.6919.1588	http://dx.doi.org/10.1136/bmj.307.6919.1588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292948	Green Published, Bronze			2022-12-28	WOS:A1993MN10700011
J	OSMOND, C; BARKER, DJP; WINTER, PD; FALL, CHD; SIMMONDS, SJ				OSMOND, C; BARKER, DJP; WINTER, PD; FALL, CHD; SIMMONDS, SJ			EARLY GROWTH AND DEATH FROM CARDIOVASCULAR-DISEASE IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; BLOOD-PRESSURE; INFANT GROWTH; FETAL; GLUCOSE; WEIGHT; LIFE	Objective-To determine whether the link suggested between growth in utero and during infancy and death from cardiovascular disease in men is also present in women. Design-Follow up study of women and men whose birth weight and weight at 1 year of age had been recorded. Setting-Hertfordshire, England. Subjects-5585 women and 10141 men born during 1911-30. Main outcome measures-Standardised mortality ratios for cardiovascular disease. Results-Among women and men death rates from cardiovascular disease fell progressively between the low and high birth weights groups (chi2=4.3, p=0.04 for women, chi2=8.5, p<0.005 for men). Cardiovascular deaths in men but not women were also strongly related to weight at 1 year, falling progressively between the low and high weight groups (chi2=27.5, p<0.0001). The highest cardiovascular death rates in women were among those with below average birth weight but above average weight at 1 year. In men the highest rates were among those with below average birth weight and below average weight at 1 year. Conclusion-Relations between cardiovascular disease and birth weight are similar in men and women. In men cardiovascular disease is also related to weight gain in infancy.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton				Osmond, Clive/0000-0002-9054-4655				ATHENS M, 1993, DIABETES, V42, pA61; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FOWDEN AL, 1989, J DEV PHYSIOL, V12, P173; GLUCKMAN PD, 1992, J PEDIATR-US, V121, P920, DOI 10.1016/S0022-3476(05)80342-7; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; HOLMES GE, 1977, AM J DIS CHILD, V3, P1078; LANGLEY SC, IN PRESS CLIN SCI; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEWIS DS, IN PRESS BIOL NEONAT; MARTYN CN, 1993, J EPIDEMIOL COMMUN H, V47, P76, DOI 10.1136/jech.47.1.76; MCCANCE DR, 1993, DIABETOLOGIA, V36, pA4; PEDERSEN JF, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; PHILLIPS DIW, 1993, ACTA ENDOCRINOL-COP, V129, P134, DOI 10.1530/acta.0.1290134; PHILLIPS DIW, IN PRESS DIABETOLOGI; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; VILLAR J, 1984, PEDIATRICS, V74, P783; WIDDOWSON EM, 1963, PROC R SOC SER B-BIO, V158, P329, DOI 10.1098/rspb.1963.0051; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	33	541	553	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1519	1524		10.1136/bmj.307.6918.1519	http://dx.doi.org/10.1136/bmj.307.6918.1519			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274920	Green Published, Bronze			2022-12-28	WOS:A1993ML86900019
J	KERBL, K; CLAYMAN, RV; MCDOUGALL, EM; KAVOUSSI, LR				KERBL, K; CLAYMAN, RV; MCDOUGALL, EM; KAVOUSSI, LR			MINIMALLY INVASIVE SURGERY .4. LAPAROSCOPIC NEPHRECTOMY	BRITISH MEDICAL JOURNAL			English	Article								Since the first clinical operation in June 1990 laparoscopic nephrectomy for benign renal disease has become widely accepted. Although tle laparoscopic operation takes much longer than open surgery, there are considerable reductions in the length of postoperative hospital stay and the time taken to return to normal activities and to full recovery. Major complications were relatively common in early operations, but with more experience morbidity has been reduced. Laparoscopic nephrectomy for malignant renal disease is still controversial, largely because of the fear of release of malignant tissue into the abdominal cavity during the morcellation and retrieval of the diseased kidney. To prevent this, the kidney is removed intact through a 5-7 cm incision. Long term follow up is needed, however, before we will know whether the laparoscopic procedure is effective in preventing recurrence of cancer. New developments have improved various technical aspects of the operation, but stringent assessment of new techniques is necessary so that the medical community can decide which procedures should become routine practice.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL,4960 CHILDRENS PL,ST LOUIS,MO 63110; JOHNS HOPKINS UNIV,DEPT UROL,BALTIMORE,MD 21224	Washington University (WUSTL); Johns Hopkins University								CLAYMAN R V, 1990, Journal of Endourology, V4, P247, DOI 10.1089/end.1990.4.247; COPTCOAT MJ, 1992, MINIM INVAS THER S1, V1, pB25; EHRLICH RM, 1992, J ENDOUROL, V6, P463, DOI 10.1089/end.1992.6.463; GAUR DD, 1993, J UROLOGY, V149, P103, DOI 10.1016/S0022-5347(17)36012-3; GAUR DD, 1992, J UROLOGY, V148, P1137, DOI 10.1016/S0022-5347(17)36842-8; IKARI O, 1990, J UROLOGY, V144, P966, DOI 10.1016/S0022-5347(17)39634-9; KERBL K, 1993, J UROLOGY, V149, P1437, DOI 10.1016/S0022-5347(17)36408-X; KERBL K, 1993, J ENDOUROL, V7, P23, DOI 10.1089/end.1993.7.23; Matsuda T, 1992, Hinyokika Kiyo, V38, P759; RASSWEILER J, 1992, J ENDOUROL, V6, pS58; SMITH AD, 1992, MINIM INVAS THER S1, V1, pB21; Weinberg J. J., 1988, J ENDOUROL, V2, P355	12	12	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1488	1489		10.1136/bmj.307.6917.1488	http://dx.doi.org/10.1136/bmj.307.6917.1488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281096	Green Published, Bronze			2022-12-28	WOS:A1993MK79700033
J	NICHOLSON, DA; DRISCOLL, PA; HODGKINSON, DW; FORBES, WS				NICHOLSON, DA; DRISCOLL, PA; HODGKINSON, DW; FORBES, WS			ABC OF EMERGENCY RADIOLOGY - THE SKULL	BRITISH MEDICAL JOURNAL			English	Article											NICHOLSON, DA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1476	1481		10.1136/bmj.307.6917.1476	http://dx.doi.org/10.1136/bmj.307.6917.1476			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281093	Green Published, Bronze			2022-12-28	WOS:A1993MK79700030
J	CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; CHRISTIE, P; BREWSTER, D				CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; CHRISTIE, P; BREWSTER, D			INITIAL EFFECTS OF THE GROUNDING OF THE TANKER BRAER ON HEALTH IN SHETLAND	BRITISH MEDICAL JOURNAL			English	Article							PETROLEUM-HYDROCARBONS; MIST	Objective-To determine if the oil spillage from the tanker Braer had any immediate health effects on the exposed resident population. Design-Cohort study with a comparison against controls, exposure status being assigned on the basis of geographical location. Setting-Rural Shetland. Subjects-All those resident on or after 5 january 1993 (day 0) within 4.5 km of the site of tanker's grounding. Controls matched for sex and age were drawn from a general practice list 95 km distant. Outcome measures-Demographic details; smoking and alcohol consumption; perception of health and reported presence or absence of specific symptoms; peak expiratory flow; results of haematology, liver and renal function tests, and blood and urine toxicology. Results-Of subjects contacted, 420 (66%) exposed people and 92 (68%) controls were studied; 56 non-attenders were surveyed. Principal health effects arose on days 1 and 2 and were headache, throat irritation, and itchy eyes. No significant differences between those exposed and controls were found for any of the biological markers. Toxicological studies did not show any exposures that are known to affect human health. Conclusions-The study confirmed the anecdotal reports of certain acute symptoms. No evidence of pulmonary, haematological, renal, or hepatic damage was detected at the population level. Toxicological samples from exposed people did not find levels known to affect human health. Further studies are required to ascertain whether there have been any long term effects on the population.	SHETLAND HLTH BOARD,SHETLAND ZE1 0RB,SCOTLAND; GRAMPIAN AREA HLTH BOARD,ABERDEEN AB9 1RE,SCOTLAND; COMMON SERV AGCY SCOTTISH HLTH SERV,EDINBURGH EH5 3SQ,SCOTLAND		CAMPBELL, D (corresponding author), RUCHILL HOSP,ENVIRONM HLTH SCOTLAND UNIT,GLASGOW G20 9NB,SCOTLAND.			Brewster, David/0000-0002-5346-5608				BELL GM, 1989, TOLUENE TOXICITY REV, V20, P34; BELL GM, 1992, XYLENES TOXICITY REV, V26, P25; BINGHAM E, 1979, J ENVIRON PATHOL TOX, V3, P483; CAMPBELL DM, 1993, BRIT MED J, V306, P519, DOI 10.1136/bmj.306.6876.519-a; CHRISTIE B, 1993, BRIT MED J, V306, P230; DALYELL T, 1993, NEW SCI         0220, P50; Dean A. G., 1990, EPI INFO VERSION 5 W; DELZELL E, 1988, OCCUP MED, V3, P455; FIELDER RJ, 1982, BENZENE TOXICITY REV, V4, P11; GOLDSTEI.DH, 1970, ARCH ENVIRON HEALTH, V21, P600, DOI 10.1080/00039896.1970.10667302; GORMAN RW, 1991, HLTH HAZARD EVALUATI; JARVHOLM B, 1982, J OCCUP ENVIRON MED, V24, P473; KING RW, 1988, OCCUP MED, V3, P409; MACFARLAND HN, 1988, OCCUP MED, V3, P445; MENEZ JF, 1978, PENN AR BED, V94, P367; PEARCE F, 1993, NEW SCI         0130, P11; SMITH G, 1993, HERALD          0109, V1, P5; SMITH HM, 1968, BUREAU MINES B, V642, P136; ZEDECK MS, 1980, J ENVIRON PATHOL TOX, V3, P537; 1993, OCCUPATIONAL EXPOSUR; 1990, WATER POLLUTION LOWE; 1989, WATER POLLUTION LOWE	22	56	56	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1251	1255		10.1136/bmj.307.6914.1251	http://dx.doi.org/10.1136/bmj.307.6914.1251			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281057	Bronze, Green Published			2022-12-28	WOS:A1993MH00100021
J	HODGKINSON, DW; ODRISCOLL, BR; DRISCOLL, PA; NICHOLSON, DA				HODGKINSON, DW; ODRISCOLL, BR; DRISCOLL, PA; NICHOLSON, DA			ABC OF EMERGENCY RADIOLOGY - CHEST RADIOGRAPHS .1.	BRITISH MEDICAL JOURNAL			English	Article											HODGKINSON, DW (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1202	1206		10.1136/bmj.307.6913.1202	http://dx.doi.org/10.1136/bmj.307.6913.1202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8292203	Green Published, Bronze			2022-12-28	WOS:A1993MF82400032
J	FIHN, SD; MCDONELL, M; MARTIN, D; HENIKOFF, J; VERMES, D; KENT, D; WHITE, RH				FIHN, SD; MCDONELL, M; MARTIN, D; HENIKOFF, J; VERMES, D; KENT, D; WHITE, RH			RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						WARFARIN; THROMBOEMBOLISM; HEMORRHAGE; PROTHROMBIN TIME	TERM WARFARIN THERAPY; ST-JUDE-VALVE; THROMBOEMBOLIC COMPLICATIONS; BLEEDING COMPLICATIONS; ATRIAL-FIBRILLATION; RANDOMIZED TRIAL; HEART-VALVES; ASPIRIN; REPLACEMENT; OUTPATIENTS	Objective: To define risk factors for complications that occur during warfarin therapy. Design: Retrospective cohort study. Setting: Five anticoagulation clinics. Patients: Nine hundred twenty-eight consecutive patients receiving 1103 courses of warfarin. Main Outcome Measures: Hemorrhagic and thromboembolic complications. Results: In 1950 patient-years of follow-up, there were 1332 bleeding events (4 were classified as fatal, 31 as life-threatening, 226 as serious, and 1071 as minor). The cumulative incidence of fatal bleeding was 1% at 1 year and 2% at 3 years. The cumulative incidences of first episodes of life-threatening and serious bleeding at 1, 2, 4, and 8 years were 1%, 2%, 5%, and 9% and 12%, 20%, 28%, and 40%, respectively. Of 156 patients who had a serious or life-threatening hemorrhage, 32% suffered a recurrence, typically within 1 year. Independent predictors of a first episode of serious bleeding included a mean prothrombin time ratio (PTR) of 2.0 or more during the course of treatment (relative risk, 3.0; 95% Cl, 1.9 to 4.7); recent initiation of warfarin therapy (relative risk during the first 3 months compared with the rest of the first year, the second year, and anytime thereafter, 1.9 [Cl, 1.3 to 3.0], 3.0 [Cl, 1.8 to 4.8], and 5.9 [Cl, 3.8 to 9.3], respectively); variability of the PTR over time (relative risk for the highest compared with the lowest tertile, 1.6 [Cl, 1.2 to 2.7]); and the presence of 3 or more comorbid conditions (RR, 1.4 [Cl, 1.1 to 2.5]). Age, reason for anticoagulation, use of interfering drugs, and hypertension were not associated with risk for bleeding. The risk for a thromboembolic complication at a PTR of less than 1.3 was 3.6 (Cl, 2.1 to 6.4) times higher than at a PTR of 1.3 to 1.5. Conclusions: The incidence of warfarin-associated bleeding may be reduced by attending to modifiable risk factors (that is, highly variable PTRs and values greater than 2.0), frequent monitoring early in treatment, and careful patient selection. Older age, in and of itself, is not a risk factor.	SEATTLE VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM 152, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT GEN MED, SACRAMENTO, CA 95817 USA	University of California System; University of California Davis			Greiver, Michelle/N-8764-2015; Fihn, Stephan/ABA-1040-2020	Greiver, Michelle/0000-0001-8957-0285; 				ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; BEYTH RJ, 1992, CLIN RES, V40, pA552; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; BUSSEY HI, 1989, PHARMACOTHERAPY, V9, P214; BUTCHART EG, 1988, CIRCULATION, V78, P66; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CZER LSC, 1990, J THORAC CARDIOV SUR, V100, P44; DISESA VJ, 1989, ANN THORAC SURG, V48, P280, DOI 10.1016/0003-4975(89)90089-1; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1992, CLIN RES, V40, pA566; FORFAR JC, 1979, BRIT HEART J, V42, P128; GOTTLIEB LK, 1992, CLIN RES, V40, pA582; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; GURWITZ JH, 1992, ANN INTERN MED, V116, P901, DOI 10.7326/0003-4819-116-11-901; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; HIRSH J, 1986, ACCP NHLBI NATIONAL, V89, pS11; KENT DL, 1992, MED DECIS MAKING, V12, P132, DOI 10.1177/0272989X9201200206; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LAWLESS JF, 1982, STATISTICAL MODELS M; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LOELIGER EA, 1982, LANCET, V1, P64; MEADE TW, 1990, AM J CARDIOL, V65, pC7, DOI 10.1016/0002-9149(90)90108-D; MYERS ML, 1989, J AM COLL CARDIOL, V13, P57, DOI 10.1016/0735-1097(89)90549-4; NAIR CK, 1990, AM J CARDIOL, V65, P217, DOI 10.1016/0002-9149(90)90088-I; PETERSEN P, 1989, LANCET, V1, P175; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; 1979, DHEW PHS791352 NAT C; 1990, NEW ENGL J MED, V322, P863	40	613	631	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					511	520		10.7326/0003-4819-118-7-199304010-00005	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8280198				2022-12-28	WOS:A1993KU07900005
J	KASMAN, DL				KASMAN, DL			WHEN A HEART STOPS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											KASMAN, DL (corresponding author), PROVIDENCE RAINIER MED CLIN, 8444 RAINIER AVE S, SEATTLE, WA 98118 USA.								0	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					432	433		10.7326/0003-4819-120-5-199403010-00012	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304662				2022-12-28	WOS:A1994MY49700012
J	PETERS, WP; ROGERS, MC				PETERS, WP; ROGERS, MC			VARIATION IN APPROVAL BY INSURANCE COMPANIES OF COVERAGE FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS; MODEST PROPOSAL; PATIENT-CARE; REIMBURSEMENT; THERAPY	Background. The proper evaluation of new forms of technology depends on the results of clinical trials. However, the treatment of patients in grant-sponsored clinical trials of cancer therapy usually requires that the proposed treatment be approved in advance by an insurance carrier in a process called predetermination. Methods, We examined the consistency of predetermination decisions by insurance companies for 533 patients enrolled in grant-supported clinical trials of high-dose chemotherapy and autologous bone marrow transplantation (ABMT) for breast cancer from 1989 through 1992. These decisions about coverage were compared with peer-reviewed decision making according to the study protocol and with clinical outcomes. Results. Requests for insurance coverage for ABMT were approved in 77 percent of the cases. Of these patients, 23 percent did not undergo bone marrow transplantation for protocol-based or medical reasons. Insurance coverage for ABMT was denied in response to the other requests, primarily because the therapy was considered experimental; of these patients, 51 percent eventually underwent bone marrow transplantation despite the denial of insurance. In some instances, the patient had to hire an attorney to gain coverage. The frequency of approval was not influenced by the pretreatment clinical characteristics of the patients, the design or phase of the study, the year in which the predetermination request was made, or the response to induction therapy. There was substantial inconsistency in the frequency of approval of coverage both among insurers and between decisions made by some individual insurers, even for patients in the same study protocol. Conclusions. The predetermination process as applied to patients receiving care in clinical research trials of cancer therapy was arbitrary and capricious. Although most of the patients eventually received financial coverage for entry into clinical trials, the process of predetermination by insurers did not correlate with protocol-based medical decision making, and it was a barrier to obtaining treatment.	DUKE UNIV HOSP,DURHAM,NC; DUKE COMPREHENS CANC CTR,DURHAM,NC	Duke University; Duke University	PETERS, WP (corresponding author), DUKE UNIV,BONE MARROW TRANSPLANT PROGRAM,25101 MORRIS BLDG,DUMC BOX 3961,DURHAM,NC 27710, USA.				NATIONAL CANCER INSTITUTE [P01CA047741] Funding Source: NIH RePORTER; NCI NIH HHS [CA-PO1-47741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARON HENRY, 1991, SERIOUS UNSTABLE CON, P24; ANTMAN K, 1988, NEW ENGL J MED, V319, P46, DOI 10.1056/NEJM198807073190109; ANTMAN KH, 1989, SEMIN HEMATOL, V26, P32; BUDMAN DR, 1992, P AM SOC CLIN ONCOL, V11, P29; CANELLOS GP, 1990, J CLIN ONCOL, V8, P1775, DOI 10.1200/JCO.1990.8.11.1775; CHASE M, 1993, WALL ST J       0217, pA1; COVA JL, 1992, J NATL CANCER I, V84, P744, DOI 10.1093/jnci/84.10.744; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; FARRAR WB, 1991, CANCER, V67, P1779, DOI 10.1002/cncr.2820671815; FRIEDMAN MA, 1992, J NATL CANCER I, V84, P760, DOI 10.1093/jnci/84.10.760; Gleeson S, 1992, Semin Oncol Nurs, V8, P13, DOI 10.1016/0749-2081(92)90049-9; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; JONES RB, 1990, CANCER, V66, P431, DOI 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X; KIRSCHNER CG, 1993, PHYSICIANS CURRENT P; LEARY WE, 1989, NY TIMES        0302, pB14; MCCABE M, 1989, J NATL CANCER I, V81, P1585, DOI 10.1093/jnci/81.20.1585; MCKENNA RJ, 1990, CANCER-AM CANCER SOC, V65, P2405, DOI 10.1002/1097-0142(19900515)65:10+<2405::AID-CNCR2820651512>3.0.CO;2-M; Molino P J, 1991, J Health Hosp Law, V24, P329; MONACO GP, 1991, CANCER INVEST, V9, P85, DOI 10.3109/07357909109032803; MORTENSON LE, 1989, WALL STREET J   0511, pA14; Peters W P, 1991, Important Adv Oncol, P135; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; SPITZER TR, 1991, CANCER INVEST, V9, P93, DOI 10.3109/07357909109032804; WITTES RE, 1987, CANCER TREAT REP, V71, P107; 1993, NBC DATELINE    0420; 1989, VIABILITY CLIN RES C; 1989, REMEDIES COSTS DIFFI, P9; 1990, DHHS PHS911232; 1988, IOM8807 I MED PUBL, P7; 1990, FINAL REPORT NATIONA	30	88	88	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					473	477		10.1056/NEJM199402173300707	http://dx.doi.org/10.1056/NEJM199402173300707			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289855				2022-12-28	WOS:A1994MW48000007
J	LAL, RB; OWEN, SM; SEGURADO, AAC; GONGORABIACHI, RA				LAL, RB; OWEN, SM; SEGURADO, AAC; GONGORABIACHI, RA			MOTHER-TO-CHILD TRANSMISSION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-II (HTLV-II)	ANNALS OF INTERNAL MEDICINE			English	Note							CELL LEUKEMIA-VIRUS; MILK		CTR INVEST REG MERIDA, YUCATAN, MEXICO		LAL, RB (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA.		Segurado, Aluisio C/K-2229-2012	Segurado, Aluisio C/0000-0002-6311-8036				BRODINE SK, IN PRESS TRANSFUSION; GONGORABIACHI RA, 1992, J ACQ IMMUN DEF SYND, V5, P104; HENEINE W, 1992, LANCET, V340, P1157, DOI 10.1016/0140-6736(92)93182-M; HJELLE B, 1992, ANN INTERN MED, V116, P90, DOI 10.7326/0003-4819-116-1-90; KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851; KAPLAN JE, 1992, J INFECT DIS, V166, P892, DOI 10.1093/infdis/166.4.892; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; LAL RB, 1992, BLOOD, V80, P544; MANNS A, 1991, BLOOD, V77, P896; YAMANOUCHI K, 1985, JPN J CANCER RES, V76, P481	10	8	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					300	301		10.7326/0003-4819-120-4-199402150-00007	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291823				2022-12-28	WOS:A1994MW10300007
J	MOERTEL, CG; JOHNSON, CM; MCKUSICK, MA; MARTIN, JK; NAGORNEY, DM; KVOLS, LK; RUBIN, J; KUNSELMAN, S				MOERTEL, CG; JOHNSON, CM; MCKUSICK, MA; MARTIN, JK; NAGORNEY, DM; KVOLS, LK; RUBIN, J; KUNSELMAN, S			THE MANAGEMENT OF PATIENTS WITH ADVANCED CARCINOID-TUMORS AND ISLET-CELL CARCINOMAS	ANNALS OF INTERNAL MEDICINE			English	Review							HEPATIC-ARTERY EMBOLIZATION; SOMATOSTATIN ANALOG; STREPTOZOCIN; FLUOROURACIL; PALLIATION	Objective: To determine the effectiveness of hepatic artery occlusion alone and with sequenced chemotherapy for patients with hepatic-dominant metastases of islet cell carcinomas and carcinoid tumors. Design: Nonrandomized, observational study with follow-up from 2.5 to 10 years. Patients: 111 ambulatory patients referred to a multidisciplinary tertiary care center who had histologically proven islet cell carcinoma or carcinoid tumor and symptomatic measurable metastatic lesions in the liver or hormonal abnormalities or both. The patients were ambulatory but were having substantial symptoms because of their endocrine syndromes or their tumors. Intervention: All patients had hepatic artery occlusion done surgically or by catheterization and embolization. After this procedure, 71 patients were selected for chemotherapy with alternating two-drug regimens of doxorubicin plus dacarbazine and streptozocin plus fluorouracil. Main outcome measures of response to therapy were rates of tumor regression, rates of improvement in endocrine abnormalities, symptomatic improvement, and duration of favorable response. Results: Objective regressions were observed in 60% of patients treated with occlusion alone and in 80% with chemotherapy added. Regressions were associated with substantial or complete relief from the endocrine syndromes. With occlusion alone, the median duration of regression was 4.0 months and with chemotherapy added, it was 18.0 months. Any comparative inferences about the two treatment regimens must be guarded, because this was not a randomized trial and marked differences occurred in the distribution of prognostic factors between the patient groups. Side effects of arterial occlusion included fever, nausea, pain, and abnormalities in liver function. Side effects of chemotherapy included nausea, vomiting, leukopenia, and alopecia. Conclusions: Hepatic arterial occlusion can frequently produce major regression of neuroendocrine tumors with relief from the hormonal syndromes. Sequential chemotherapy may improve the rate and duration of the regression.	MAYO CLIN JACKSONVILLE, JACKSONVILLE, FL 32224 USA; PENN STATE UNIV, UNIV PK, PA 16802 USA	Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	MOERTEL, CG (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							AJANI JA, 1988, ANN INTERN MED, V108, P340, DOI 10.7326/0003-4819-108-3-340; CARRASCO CH, 1986, AM J ROENTGENOL, V147, P149, DOI 10.2214/ajr.147.1.149; ERIKSSON B, 1986, LANCET, V2, P1307; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESSINGER A, 1983, CANCER, V51, P790, DOI 10.1002/1097-0142(19830301)51:5<790::AID-CNCR2820510507>3.0.CO;2-3; KVOLS LK, 1987, ANN INTERN MED, V107, P162, DOI 10.7326/0003-4819-107-2-162; KVOLS LK, 1986, NEW ENGL J MED, V315, P663, DOI 10.1056/NEJM198609113151102; MCENTEE GP, 1990, SURGERY, V108, P1091; MOERTEL CG, 1992, NEW ENGL J MED, V326, P519, DOI 10.1056/NEJM199202203260804; MOERTEL CG, 1987, J CLIN ONCOL, V5, P1503; MOERTEL CG, 1980, NEW ENGL J MED, V303, P1189, DOI 10.1056/NEJM198011203032101	11	228	229	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					302	309		10.7326/0003-4819-120-4-199402150-00008	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291824				2022-12-28	WOS:A1994MW10300008
J	SCHIEVINK, WI; MOKRI, B; OFALLON, WM				SCHIEVINK, WI; MOKRI, B; OFALLON, WM			RECURRENT SPONTANEOUS CERVICAL-ARTERY DISSECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL CAROTID-ARTERY; SYNDROME TYPE-IV; INTRACRANIAL ANEURYSMS; STROKE	Background. Spontaneous dissection of the internal carotid and vertebral arteries is increasingly recognized as a cause of ischemic stroke in young people. An underlying arteriopathy is often suspected in the pathogenesis of such dissection, but the frequency of recurrent dissection is unknown. Methods. We describe the long-term follow-up of 200 consecutive patients (104 women and 96 men) with spontaneous cervical-artery dissections evaluated at the Mayo Clinic between 1970 and 1990. All diagnoses were confirmed by angiography. Results. The mean age of the patients was 44.9 years (range, 16 to 76). Internal carotid arteries were affected in 150 patients, vertebral arteries in 37, and both in 13. Multivessel dissections were present in 28 percent of the patients. The mean follow-up was 7.4 years. Recurrent dissection occurred only in arteries not previously involved by dissection. A recurrent arterial dissection developed in 16 patients (8 percent) - within a month after the initial dissection in 4 patients (2 percent) and between 1.4 and 8.6 years later in 12 patients (a rate of 1 percent per year). The cumulative rate of recurrent dissection among patients followed for 10 years was 11.9 percent. Younger patients had a greater risk of recurrent dissection. Conclusions. Although dissections in multiple cervical vessels are common at presentation, after the first month the risk of recurrent dissection is only about 1 percent per year.	MAYO CLIN & MAYO FDN,DEPT NEUROL,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								ANDERSON RM, 1959, J NEUROL NEUROSUR PS, V22, P195, DOI 10.1136/jnnp.22.3.195; AUSTIN MG, 1957, ARCH PATHOL, V64, P205; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P817; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P137, DOI 10.1001/archneur.1987.00520140009010; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P479, DOI 10.1001/archneur.1987.00520170009012; BOSTROM K, 1967, NEUROLOGY, V17, P179, DOI 10.1212/WNL.17.2.179; BRICE JG, 1964, BRIT MED J, V2, P790; BROWN OL, 1973, AM J ROENTGENOL, V118, P648, DOI 10.2214/ajr.118.3.648; CHATILLON JD, 1990, PRESSE MED, V19, P661; COX DR, 1972, J R STAT SOC B, V34, P187; Cronqvist S E, 1986, Acta Radiol Suppl, V369, P34; FISHER CM, 1978, CAN J NEUROL SCI, V5, P9, DOI 10.1017/S0317167100024690; Hart R G, 1983, Neurol Clin, V1, P155; HOUSER OW, 1984, AM J NEURORADIOL, V5, P27; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1967, BIOMETRICS, V23, P65, DOI 10.2307/2528282; MAS JL, 1987, STROKE, V18, P1037, DOI 10.1161/01.STR.18.6.1037; MOKRI B, 1987, STROKE, V18, P246, DOI 10.1161/01.STR.18.1.246; MOKRI B, 1990, J NEUROL, V237, P356, DOI 10.1007/BF00315659; MOKRI B, 1985, STROKE, V16, P959, DOI 10.1161/01.STR.16.6.959; MOKRI B, 1986, ANN NEUROL, V19, P126, DOI 10.1002/ana.410190204; MOKRI B, 1992, ARCH OTOLARYNGOL, V118, P431; MOKRI B, 1988, NEUROLOGY, V38, P880, DOI 10.1212/WNL.38.6.880; Mokri B, 1991, J Stroke Cerebrovasc Dis, V1, P117, DOI 10.1016/S1052-3057(10)80002-3; Mokri B, 1992, J Stroke Cerebrovasc Dis, V2, P100, DOI 10.1016/S1052-3057(10)80214-9; Mokri B, 1987, OCCLUSIVE CEREBROVAS, P38; ROHR J, 1987, REV NEUROL, V143, P115; SCHIEVINK WI, 1991, J NEUROSURG, V74, P991, DOI 10.3171/jns.1991.74.6.0991; SCHIEVINK WI, 1990, STROKE, V21, P626, DOI 10.1161/01.STR.21.4.626; SCHIEVINK WI, 1993, NEUROLOGY, V43, P1938, DOI 10.1212/WNL.43.10.1938; SCHIEVINK WI, 1993, STROKE, V24, P1678, DOI 10.1161/01.STR.24.11.1678; SCHIEVINK WI, 1991, STROKE, V22, P1426, DOI 10.1161/01.STR.22.11.1426; SCHIEVINK WI, 1992, J NEUROSURG, V76, P62, DOI 10.3171/jns.1992.76.1.0062; YOUL BD, 1990, STROKE, V21, P618, DOI 10.1161/01.STR.21.4.618	34	348	363	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					393	397		10.1056/NEJM199402103300604	http://dx.doi.org/10.1056/NEJM199402103300604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284004				2022-12-28	WOS:A1994MV27900004
J	SHAFRAN, SD; DESCHENES, J; MILLER, M; PHILLIPS, P; TOMA, E				SHAFRAN, SD; DESCHENES, J; MILLER, M; PHILLIPS, P; TOMA, E			UVEITIS AND PSEUDOJAUNDICE DURING A REGIMEN OF CLARITHROMYCIN, RIFABUTIN, AND ETHAMBUTOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									MCGILL UNIV,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER V6L 1Z1,BC,CANADA; UNIV MONTREAL,MONTREAL H3C 3T7,PQ,CANADA	McGill University; University of British Columbia; Universite de Montreal	SHAFRAN, SD (corresponding author), UNIV ALBERTA,EDMONTON T6G 2B7,AB,CANADA.							SIEGAL FP, 1990, AIDS, V4, P433, DOI 10.1097/00002030-199005000-00009	1	113	117	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					438	439		10.1056/NEJM199402103300616	http://dx.doi.org/10.1056/NEJM199402103300616			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284019	Bronze			2022-12-28	WOS:A1994MV27900029
J	MILLER, EK; DESIMONE, R				MILLER, EK; DESIMONE, R			PARALLEL NEURONAL MECHANISMS FOR SHORT-TERM-MEMORY	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; HIPPOCAMPAL-FORMATION; RECOGNITION MEMORY; MONKEYS; TASKS	Although objects that have just been seen may persist in memory automatically for a time and interact passively with incoming stimulation, some tasks require that the memory be actively maintained and used. To test for the existence of separate automatic and volitional mechanisms of short-term memory, recordings were made from neurons in the inferior temporal cortex of monkeys while the monkeys held a sample picture ''in mind'' and signaled when it was repeated in a sequence of pictures, ignoring other stimulus repetitions. Some neurons were suppressed by any picture repetition, regardless of relevance, whereas others were enhanced, but only when a picture matched the sample. Short-term memory appears to reflect the parallel operation of these two mechanisms-one being automatic and the other active.			MILLER, EK (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 49,ROOM 1B80,BETHESDA,MD 20892, USA.		Desimone, Robert/G-1121-2018; Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958				Baddeley A.D., 1986, WORKING MEMORY THOUG; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Chelazzi L., 1993, Society for Neuroscience Abstracts, V19, P975; ESKANDAR EN, 1992, J NEUROPHYSIOL, V68, P1277, DOI 10.1152/jn.1992.68.4.1277; FUSTER JM, 1982, EXP NEUROL, V77, P679, DOI 10.1016/0014-4886(82)90238-2; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GAFFAN D, 1992, BEHAV NEUROSCI, V106, P30, DOI 10.1037/0735-7044.106.1.30; GROSS CG, 1979, NEUROPSYCHOLOGIA, V17, P215, DOI 10.1016/0028-3932(79)90012-5; HOREL JA, 1987, BEHAV BRAIN RES, V23, P29, DOI 10.1016/0166-4328(87)90240-3; MEUNIER M, 1993, J NEUROSCI, V13, P5419; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; RICHES IP, 1991, J NEUROSCI, V11, P1763; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355	16	435	437	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					520	522		10.1126/science.8290960	http://dx.doi.org/10.1126/science.8290960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290960				2022-12-28	WOS:A1994MT96600033
J	WEBSTER, NR; WARD, MJ				WEBSTER, NR; WARD, MJ			BATTLEFIELD TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WEBSTER, NR (corresponding author), ARMED SERV BLOOD PROGRAM OFF,FALLS CHURCH,VA, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					319	319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295296				2022-12-28	WOS:A1994MR22100033
J	LILFORD, R				LILFORD, R			FORMAL MEASUREMENT OF CLINICAL UNCERTAINTY - PRELUDE TO A TRIAL IN PERINATAL MEDICINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									MALMO GEN HOSP, S-21401 MALMO, SWEDEN; QUEENS MED CTR, NOTTINGHAM NG7 2UH, ENGLAND; GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; N MANCHESTER GRP HOSP, MANCHESTER, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; UNIV TURIN, I-10124 TURIN, ITALY; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND; UNIV GLASGOW, GLASGOW G12 8QQ, SCOTLAND	University of Nottingham; Leeds General Infirmary; St Georges University London; University of Turin; MRC Biostatistics Unit; University of Glasgow	LILFORD, R (corresponding author), UNIV LEEDS, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876; Walker, James/0000-0002-8922-083X; Todros, Tullia/0000-0003-3016-1510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, V2, P349; JOHNSON N, 1991, J MED ETHICS, V17, P30, DOI 10.1136/jme.17.1.30; ODENDAAL HJ, 1990, OBSTET GYNECOL, V76, P1070; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; Williams C, 1992, INTRO NEW TREATMENTS, P49	5	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	1994	308	6921					111	112		10.1136/bmj.308.6921.111	http://dx.doi.org/10.1136/bmj.308.6921.111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298380	Green Published			2022-12-28	WOS:A1994MR17300015
J	NUNNARI, J; FOX, TD; WALTER, P				NUNNARI, J; FOX, TD; WALTER, P			A MITOCHONDRIAL PROTEASE WITH 2 CATALYTIC SUBUNITS OF NONOVERLAPPING SPECIFICITIES	SCIENCE			English	Article							MICROSOMAL SIGNAL PEPTIDASE; CYTOCHROME-C1 HEME LYASE; COLI LEADER PEPTIDASE; YEAST SEC11 PROTEIN; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; NUCLEAR GENE; PROCESSING PROTEASE; MEMBRANE-PROTEIN	The mitochondrial inner membrane protease is required for the maturation of mitochondrial proteins that are delivered to the intermembrane space. In the yeast Saccharomyces cerevisiae, this protease is now shown to be a complex that contains two catalytic subunits, Imp2p and the previously identified Imp1p. Primary structure similarity indicates that Imp1p and Imp2p are related to each other and to the family of eubacterial and eukaryotic signal peptidases. Imp1p and Imp2p have separate, nonoverlapping substrate specificities. In addition to its catalyzing the cleavage of intermembrane space sorting signals, Imp2p is required for the stable and functional expression of Imp1p. Thus, inner membrane protease, and by analogy eukaryotic multisubunit signal peptidases, may have acquired multiple catalytic subunits by gene duplication to broaden their range of substrate specificity.	CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA	Cornell University	NUNNARI, J (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Fox, Thomas/0000-0001-7629-3661				BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKSON GHD, 1989, J BIOL CHEM, V264, P10114; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DAUM G, 1982, J BIOL CHEM, V257, P3028; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; EVANS EA, 1986, J BIOL CHEM, V103, P291; FOLLEY LS, 1991, GENETICS, V129, P659; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK BS, 1992, CELL, V69; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HORTIN G, 1981, CELL, V24, P453, DOI 10.1016/0092-8674(81)90336-6; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; MULERO JJ, IN PRESS MOL GEN GEN; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PRATJE E, 1983, EMBO J, V2, P1049, DOI 10.1002/j.1460-2075.1983.tb01544.x; REID GA, 1982, J BIOL CHEM, V257, P3068; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SEVARINO KA, 1980, P NATL ACAD SCI-BIOL, V77, P142, DOI 10.1073/pnas.77.1.142; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WAKABAYASHI S, 1980, BIOCHEM BIOPH RES CO, V97, P1548, DOI 10.1016/S0006-291X(80)80042-8; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	54	193	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					1997	2004		10.1126/science.8266095	http://dx.doi.org/10.1126/science.8266095			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266095				2022-12-28	WOS:A1993MN10800028
J	SILVER, JR				SILVER, JR			THE DANGERS OF SLEDGING	BRITISH MEDICAL JOURNAL			English	Article											SILVER, JR (corresponding author), STOKE MANDEVILLE HOSP,NATL SPINAL INJURIES CTR,AYLESBURY HP21 8AL,BUCKS,ENGLAND.							Gissane W, 1970, INJURY, V1, P195; HEDGES JR, 1980, ANN EMERG MED, V9, P131, DOI 10.1016/S0196-0644(80)80267-8; KLINE DG, 1985, SPORTS INJURIES MECH; SILVER JR, 1993, BRIT J SPORT MED, V27, P115, DOI 10.1136/bjsm.27.2.115; SLOAN JP, 1985, BRIT MED J, V290, P821, DOI 10.1136/bmj.290.6471.821	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1602	1603		10.1136/bmj.307.6919.1602	http://dx.doi.org/10.1136/bmj.307.6919.1602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292954	Bronze, Green Published			2022-12-28	WOS:A1993MN10700017
J	NEWLON, CS				NEWLON, CS			2 JOBS FOR THE ORIGIN REPLICATION COMPLEX	SCIENCE			English	Editorial Material							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; CHROMOSOMAL ORIGIN; CELL-CYCLE; S-PHASE; YEAST; PROTEIN				NEWLON, CS (corresponding author), UNIV MED & DENT NEW JERSEY,DEPT MICROBIOL & MOLEC GENET,185 S ORANGE AVE,NEWARK,NJ 07103, USA.							BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DUBLEY DD, 1991, MOL CELL BIOL, V11, P5346; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Kornberg A., 1992, DNA REPLICATION; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LUCHE RM, 1993, MOL CELL BIOL, V13, P5749, DOI 10.1128/MCB.13.9.5749; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160	23	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1830	1831		10.1126/science.8266070	http://dx.doi.org/10.1126/science.8266070			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266070				2022-12-28	WOS:A1993MM51100024
J	MARGETTS, BM; JACKSON, AA				MARGETTS, BM; JACKSON, AA			INTERACTIONS BETWEEN PEOPLES DIET AND THEIR SMOKING-HABITS - THE DIETARY AND NUTRITIONAL SURVEY OF BRITISH ADULTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKERS	Objective-To compare diet, nutrient intakes, and biochemical measures between Design-Analysis of data collected in cross sectional survey conducted in 1986 and 1987. Subjects were recruited from electoral wards in England, Wales, and Scotland to reflect the regional distribution of the population. Subjects-2197 subjects (70% of those asked) aged between 16 and 64 undertook dietary assessment. Of these, 1842 subjects were considered to have kept a record typical of their usual dietary intake and had given data on smoking, and their results were analysed: 1224 non-smokers (631 men), 359 light smokers (166 men), and 259 heavy smokers (153 men). Main outcome measures-Differences in dietary, nutrient, and biochemical measures between non-smokers and smokers. Results-Smokers ate more white bread, sugar, cooked meat dishes, butter, and whole milk and less wholemeal bread, high fibre breakfast cereals, fruit, and carrots. Smokers had lower intakes of poly-unsaturated fat, protein, carbohydrate, fibre, iron, carotene, and ascorbic acid. Adjusting for other covariates did not substantially alter the pattern of intakes. At the same dietary intake of carotenoids smokers were more likely to have lower circulating serum beta carotene concentrations than non-smokers. Conclusions-The diet and nutrient intakes and circulating levels of nutrients of smokers were different from those of non-smokers. Smokers were more likely to have an imbalance between the dietary intake of antioxidant nutrients and the metabolic demand for antioxidant protection. This imbalance is likely to make smokers more susceptible to oxidative damage. Smokers are at increased risk of chronic disease because their diets are different and because smoking creates an altered pattern of demand for specific nutrients. The diets of smokers not only fail to meet the unusual requirements for specific nutrients to satisfy the altered pattern of demand but are likely to exacerbate the damage caused by smoking.			MARGETTS, BM (corresponding author), UNIV SOUTHAMPTON, INST HUMAN NUTR, SOUTHAMPTON SO9 5NH, HANTS, ENGLAND.							BOLTONSMITH C, 1993, BRIT J NUTR, V69, P315, DOI 10.1079/BJN19930036; BRIDGES RB, 1990, ANN NY ACAD SCI, V587, P218, DOI 10.1111/j.1749-6632.1990.tb00149.x; CADE JE, 1991, J EPIDEMIOL COMMUN H, V45, P270, DOI 10.1136/jech.45.4.270; CARROLL KK, 1991, NUTR CANCER, V16, P79, DOI 10.1080/01635589109514146; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; FLEET JC, 1992, J NUTR, V122, P294, DOI 10.1093/jn/122.2.294; Gregory F., 1990, DIETARY NUTR SURVEY; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HALLIWELL B, 1993, J ROY SOC HEALTH, V113, P91, DOI 10.1177/146642409311300209; Kish L, 1965, SURVEY SAMPLING; MULROONEY HM, 1993, CLIN SCI, V84, P105, DOI 10.1042/cs0840105; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRICKLAND D, 1992, PREV MED, V21, P228, DOI 10.1016/0091-7435(92)90021-9; Thompson R. L., 1992, Nutrition Research Reviews, V5, P131, DOI 10.1079/NRR19920011; Troughton Kerry, 1993, Proceedings of the Nutrition Society, V52, p84A; WHICHELOW MJ, 1991, BRIT J ADDICT, V86, P71; 1992, STATE PUBLIC HLTH AN	17	185	188	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1993	307	6916					1381	1384		10.1136/bmj.307.6916.1381	http://dx.doi.org/10.1136/bmj.307.6916.1381			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274889	Bronze, Green Published			2022-12-28	WOS:A1993MK42000017
J	HUNTER, DJ; MANSON, JE; COLDITZ, GA; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE; WILLETT, WC				HUNTER, DJ; MANSON, JE; COLDITZ, GA; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE; WILLETT, WC			A PROSPECTIVE-STUDY OF THE INTAKE OF VITAMIN-C, VITAMIN-E, AND VITAMIN-A AND THE RISK OF BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-TOCOPHEROL LEVELS; BETA-CAROTENE; DIETARY-FAT; QUESTIONNAIRE; CARCINOGENESIS; ISOTRETINOIN; EPIDEMIOLOGY; CONSUMPTION; VALIDATION; INHIBITION	Background. Although it has been hypothesized that large intakes of the antioxidant vitamins C, E, and A reduce the risk of breast cancer, few prospective data are available. Methods. We prospectively studied 89,494 women who were 34 to 59 years old in 1980 and who did not have diagnosed cancer. Their intakes of vitamins C, E, and A from foods and supplements were assessed at base line and in 1984 with the use of a validated semiquantitative food-frequency questionnaire. Results. Breast cancer was diagnosed in 1439 women during eight years of follow-up. After multivariate adjustment for known risk factors, the relative risk among women in the highest quintile group for intake of vitamin C as compared with the risk among those in the lowest quintile group was 1.03 (95 percent confidence interval, 0.87 to 1.21); for vitamin E, after vitamin A intake had been controlled for, the relative risk was 0.99 (95 percent confidence interval, 0.83 to 1.19). In contrast, among women in the highest quintile group for intake of total vitamin A the relative risk was 0.84 (95 percent confidence interval, 0.71 to 0.98; P for trend = 0.001). Among women in the lowest quintile group for intake of vitamin A from food, consumption of vitamin A from supplements was associated with a reduced risk (P = 0.03). The significant inverse association of vitamin A intake with the risk of breast cancer was also found on study of data based on the 1984 questionnaire and four years of follow-up. Conclusions. Large intakes of vitamin C or E did not protect women in our study from breast cancer. A low intake of vitamin A may increase the risk of this disease; any benefit of vitamin A supplements may be limited to women with diets low in vitamin A.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HUNTER, DJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA050597, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50597, CA-40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS AA, 1965, NEW ENGL J MED, V272, P1080; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BIERI JG, 1983, NEW ENGL J MED, V308, P1063, DOI 10.1056/NEJM198305053081805; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAMERON E, 1979, CANCER RES, V39, P663; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; EWERTZ M, 1990, INT J CANCER, V46, P779, DOI 10.1002/ijc.2910460505; FRAKER LD, 1984, CANCER RES, V44, P5757; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; HARMAN D, 1969, Clinical Medicine, V17, P125; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KATSOUYANNI K, 1988, CANCER-AM CANCER SOC, V61, P181, DOI 10.1002/1097-0142(19880101)61:1<181::AID-CNCR2820610130>3.0.CO;2-J; KING MM, 1983, CANCER RES, V43, P2485; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; LEE C, 1979, P AM ASSOC CANC RES, V20, P132; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; MARUBINI E, 1988, CANCER, V61, P173, DOI 10.1002/1097-0142(19880101)61:1&lt;173::AID-CNCR2820610129&gt;3.0.CO;2-P; MCCORMICK DL, 1981, J NATL CANCER I, V66, P559; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MOON RC, 1977, NATURE, V267, P620, DOI 10.1038/267620a0; MOON RC, 1983, CANCER RES, V43, P2469; PAGANINIHILL A, 1987, JNCI-J NATL CANCER I, V79, P443; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; POTISCHMAN N, 1990, AM J CLIN NUTR, V52, P909, DOI 10.1093/ajcn/52.5.909; PRASAD KN, 1990, J AM COLL NUTR, V9, P28; PRENTICE RL, 1989, CANCER RES, V49, P3147; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, MONOGRAPHS EPIDEMIOL, V15; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1963, COMPOSITION FOODS RA; [No title captured]	48	250	250	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					234	240		10.1056/NEJM199307223290403	http://dx.doi.org/10.1056/NEJM199307223290403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8292129				2022-12-28	WOS:A1993LM68200003
J	CHALFIE, M; TU, Y; EUSKIRCHEN, G; WARD, WW; PRASHER, DC				CHALFIE, M; TU, Y; EUSKIRCHEN, G; WARD, WW; PRASHER, DC			GREEN FLUORESCENT PROTEIN AS A MARKER FOR GENE-EXPRESSION	SCIENCE			English	Article							TOUCH RECEPTOR NEURONS; BETA-TUBULIN GENE; CAENORHABDITIS-ELEGANS; RNA-POLYMERASE; C-ELEGANS; NEMATODE; VECTORS; SYSTEM; MEC-7	A complementary DNA for the Aequorea victoria green fluorescent protein (GFP) produces a fluorescent product when expressed in prokaryotic (Escherichia coli) or eukaryotic (Caenorhabditis elegans) cells. Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms.	RUTGERS STATE UNIV,COOK COLL,DEPT BIOCHEM & MICROBIOL,NEW BRUNSWICK,NJ 08903; WOODS HOLE OCEANOG INST,DEPT BIOL,WOODS HOLE,MA 02543	Rutgers State University New Brunswick; Woods Hole Oceanographic Institution	CHALFIE, M (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.		Albers, Pieter/I-2563-2017		NIGMS NIH HHS [GM31997] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; COXON A, COMMUNICATION; CUTLER ML, UNPUB; DUGGAN A, UNPUB; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HEIM R, COMMUNICATION; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANINI L, COMMUNICATION; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER JP, 1979, SCIENCE, V206, P702, DOI 10.1126/science.386514; MITANI S, 1993, DEVELOPMENT, V119, P773; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; MORISE H, 1974, BIOCHEMISTRY-US, V13, P2656, DOI 10.1021/bi00709a028; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRENDERGAST F, COMMUNICATION; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sanbrook J, 1989, MOL CLONING LABORATO; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1979, FEBS LETT, V104, P220, DOI 10.1016/0014-5793(79)80818-2; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; STEWART GSAB, 1992, J GEN MICROBIOL, V138, P1289, DOI 10.1099/00221287-138-7-1289; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WALTHALL WW, 1988, SCIENCE, V239, P643, DOI 10.1126/science.3340848; WANG SS, COMMUNICATION; WARD WE, COMMUNICATION; WARD WW, 1980, PHOTOCHEM PHOTOBIOL, V31, P611, DOI 10.1111/j.1751-1097.1980.tb03755.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	35	5070	5891	85	2318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					802	805		10.1126/science.8303295	http://dx.doi.org/10.1126/science.8303295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303295				2022-12-28	WOS:A1994MV86600033
J	ROSSLE, M; HAAG, K; OCHS, A; SELLINGER, M; NOLDGE, G; PERARNAU, JM; BERGER, E; BLUM, U; GABELMANN, A; HAUENSTEIN, K; LANGER, M; GEROK, W				ROSSLE, M; HAAG, K; OCHS, A; SELLINGER, M; NOLDGE, G; PERARNAU, JM; BERGER, E; BLUM, U; GABELMANN, A; HAUENSTEIN, K; LANGER, M; GEROK, W			THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT PROCEDURE FOR VARICEAL BLEEDING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISTAL SPLENORENAL SHUNT; SIDE PORTACAVAL-SHUNT; PROSPECTIVE RANDOMIZED TRIAL; ALCOHOLIC LIVER-DISEASE; LONG-TERM MANAGEMENT; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGEAL-VARICES; FOLLOW-UP; INJECTION SCLEROTHERAPY; ELECTIVE TREATMENT	Background. Transjugular placement of an intrahepatic stent is a new technique to establish a portosystemic shunt for treatment of portal hypertension. A puncture needle is advanced in a catheter through the inferior vena cava into a hepatic vein; then an intrahepatic branch of the portal vein is punctured and an expandable stent of metallic mesh is implanted to establish the shunt. Methods. We attempted the stent-shunt procedure in 100 of 112 consecutive patients with variceal bleeding due to cirrhosis, who were then followed for a mean (+/-SD) of 12+/-6 months. Of the 100 patients, 22 had Child-Pugh class C cirrhosis, 10 were treated on an emergency basis, and 68 had alcoholic cirrhosis. The shunt was established with use of Palmaz stents expanded to 8 to 12 mm in diameter. Results. Technical success was achieved in 93 percent of the patients. The mean (+/-SD) time for the procedure was 1.2+/-0.3 hours. The shunt reduced the portal venous pressure gradient by 57 percent. Major complications were hemorrhage (intraabdominal bleeding in six patients, biliary bleeding in four, and bleeding in the liver capsule in three) and migration of the stent into the pulmonary artery (in two patients). At follow-up, stenosis of the shunt was evident in 21 patients and occlusion in 10 patients; 10 of these 31 patients had variceal rebleeding. Stenoses and occlusions of the shunt were all treated successfully by redilation, thrombolysis, or implantation of an additional stent. Hepatic encephalopathy (stages I to III) developed in 25 percent of the patients. The proportion of patients with shunts who remained free of variceal rebleeding was 92 percent at six months and 82 percent at one year. The 30-day mortality was 3 percent. The cumulative one-year survival was 85 percent. Conclusions. These results suggest that the transjugular placement of an intrahepatic portosystemic stent is an effective and safe treatment for variceal hemorrhage in patients with portal hypertension due to cirrhosis.	UNIV FREIBURG,RADIOL CLIN,W-7800 FREIBURG,GERMANY; HOP BON SECOURS,METZ,FRANCE	University of Freiburg; CHR Metz-Thionville	ROSSLE, M (corresponding author), UNIV FREIBURG,MED KLIN,HUGSTETTERSTR 55,D-79106 FREIBURG,GERMANY.							BURGENER FA, 1984, FORTSCHR RONTG NEUEN, V141, P327; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DIMAGNO EP, 1985, MAYO CLIN PROC, V60, P149, DOI 10.1016/S0025-6196(12)60211-0; FISCHER JE, 1981, ANN SURG, V194, P531, DOI 10.1097/00000658-198110000-00016; FLEIG WE, 1987, HEPATOLOGY, V7, P355, DOI 10.1002/hep.1840070224; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GORDON JD, 1987, CAN J SURG, V30, P45; GRACE ND, 1988, HEPATOLOGY, V8, P1475, DOI 10.1002/hep.1840080602; GUSBERG RJ, 1992, DIGEST DIS, V10, P84, DOI 10.1159/000171391; HARLEY HAJ, 1986, GASTROENTEROLOGY, V91, P802, DOI 10.1016/0016-5085(86)90679-7; HENDERSON JM, 1990, ANN INTERN MED, V112, P262, DOI 10.7326/0003-4819-112-4-262; HENDERSON JM, 1984, WORLD J SURG, V8, P722, DOI 10.1007/BF01655769; INK O, 1992, HEPATOLOGY, V16, P912, DOI 10.1002/hep.1840160410; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LANGER B, 1985, GASTROENTEROLOGY, V88, P424, DOI 10.1016/0016-5085(85)90502-5; MILLIKAN WJ, 1985, ANN SURG, V201, P712; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; PERARNAU JM, 1991, PRESSE MED, V20, P1770; PLANAS R, 1991, GASTROENTEROLOGY, V100, P1078, DOI 10.1016/0016-5085(91)90285-S; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RICHTER GM, 1990, CARDIOVASC INTER RAD, V13, P200, DOI 10.1007/BF02575474; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1984, AM J SURG, V147, P89, DOI 10.1016/0002-9610(84)90040-0; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; ROBERTS JP, 1991, TRANSPLANTATION, V52, P160, DOI 10.1097/00007890-199107000-00036; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; ROSSLE M, 1989, DEUT MED WOCHENSCHR, V114, P1511, DOI 10.1055/s-2008-1066789; ROSSLE M, 1988, HEPATOLOGY, V8, P1348; ROSSLE M, 1992, DIGEST SURG, V9, P6, DOI 10.1159/000172049; SARFEH IJ, 1986, ANN SURG, V204, P356, DOI 10.1097/00000658-198610000-00003; SCHOMERUS H, 1981, DIGEST DIS SCI, V26, P622, DOI 10.1007/BF01367675; SPINA GP, 1988, AM J SURG, V155, P564, DOI 10.1016/S0002-9610(88)80411-2; SPINA GP, 1990, ANN SURG, V211, P178, DOI 10.1097/00000658-199002000-00010; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; TERBLANCHE J, 1989, ANN SURG, V210, P725, DOI 10.1097/00000658-198912000-00006; TERES J, 1987, HEPATOLOGY, V7, P430, DOI 10.1002/hep.1840070303; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	44	657	670	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					165	171		10.1056/NEJM199401203300303	http://dx.doi.org/10.1056/NEJM199401203300303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264738				2022-12-28	WOS:A1994MQ86300003
J	LIM, AG; HINE, KR				LIM, AG; HINE, KR			FEVER, VASCULITIC RASH, ARTHRITIS, PERICARDITIS, AND PERICARDIAL-EFFUSION AFTER MESALAZINE	BRITISH MEDICAL JOURNAL			English	Letter											LIM, AG (corresponding author), PRINCESS ROYAL HOSP,HAYWARDS,HEATH RH16 4EX,W SUSSEX,ENGLAND.							DENT MT, 1992, BRIT MED J, V305, P159, DOI 10.1136/bmj.305.6846.159-b; HABAL FM, 1990, AM J GASTROENTEROL, V83, P15; JENSS H, 1990, AM J GASTROENTEROL, V85, P332; WAANDERS H, 1991, AM J GASTROENTEROL, V86, P219	4	31	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					113	113						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298382				2022-12-28	WOS:A1994MR17300017
J	SANVILLE, P; NICHOLSON, DA; DRISCOLL, PA				SANVILLE, P; NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE KNEE	BRITISH MEDICAL JOURNAL			English	Article											SANVILLE, P (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					121	125						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298387				2022-12-28	WOS:A1994MR17300024
J	LUNDE, H; HEDNER, T; SAMUELSSON, O; LOTVALL, J; ANDREN, L; LINDHOLM, L; WIHOLM, BE				LUNDE, H; HEDNER, T; SAMUELSSON, O; LOTVALL, J; ANDREN, L; LINDHOLM, L; WIHOLM, BE			DYSPNEA, ASTHMA, AND BRONCHOSPASM IN RELATION TO TREATMENT WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERREACTIVITY; COUGH; CAPTOPRIL; ENALAPRIL; BRADYKININ; RESPONSES	Objective-To evaluate the occurrence of asthma and dyspnoea precipitated or worsened by angiotensin converting enzyme inhibitors. Design-Summary of reports of adverse respiratory reaction in relation to treatment with angiotensin converting enzyme inhibitors that were submitted to Swedish Adverse Drug Reactions Advisory Committee and to World Health Organisation's international drug information system until 1992. Sales of angiotensin converting enzyme inhibitors in Sweden were also summarised. Subjects-Patients receiving angiotensin converting enzyme inhibitors who reported adverse respiratory reactions. Main outcome measures-Clinical characteristics of adverse reactions of asthma, bronchospasm, and dyspnoea. Results-In Sweden 424 adverse respiratory reactions were reported, of which most (374) were coughing. However, 36 patients had adverse drug reactions diagnosed as asthma, bronchospasm, or dyspnoea. In 33 of these cases the indication for treatment with angiotensin converting enzyme inhibitors was hypertension, in only three heart failure. The respiratory symptoms occurred in about half of the patients within the first two weeks of treatment, and about one third needed hospitalisation or drug treatment. Dyspnoea symptoms occurred in conjunction with other symptoms from the airways or skin in 23 out of the 36 cases. In the WHO database there were 318 reports of asthma or bronchospasm, 516 reports of dyspnoea, and 7260 reports of cough in relation to 11 different angiotensin converting enzyme inhibitors. Conclusion-Symptoms of airway obstruction in relation to treatment with angiotensin converting enzyme inhibitors seem to be a rare but potentially serious reaction generally occurring within the first few weeks of treatment.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT NEPHROL,S-41345 GOTHENBURG,SWEDEN; SWEDISH MED PROD AGCY,UPPSALA,SWEDEN; LUND UNIV,HLTH SCI CTR,DALBY,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Medical Products Agency; Lund University	LUNDE, H (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN.			Lotvall, Jan/0000-0001-9195-9249				BERKIN KE, 1989, EUR RESPIR J, V2, P198; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; DUSSER DJ, 1988, J PHARMACOL EXP THER, V244, P531; GOH T C, 1991, SMJ Singapore Medical Journal, V32, P183; HEDNER T, 1992, BRIT MED J, V304, P941, DOI 10.1136/bmj.304.6832.941; INMAN WHW, 1988, BRIT MED J, V297, P826, DOI 10.1136/bmj.297.6652.826; KAUFMAN J, 1989, CHEST, V95, P544, DOI 10.1378/chest.95.3.544; KAUFMAN J, 1992, CHEST, V101, P922, DOI 10.1378/chest.101.4.922; KRANE NK, 1987, GERIATRICS, V42, P45; LINDGREN BR, 1989, CHEST, V95, P1225, DOI 10.1378/chest.95.6.1225; LOTVALL JO, 1991, EUR J PHARMACOL, V200, P211, DOI 10.1016/0014-2999(91)90574-A; MUE S, 1990, CLIN THER, V12, P335; POPA V, 1987, AM REV RESPIR DIS, V136, P999, DOI 10.1164/ajrccm/136.4.999; RISKA H, 1987, J CARDIOVASC PHARM, V10, pS79, DOI 10.1097/00005344-198706110-00030; SEMPLE PF, 1986, NEW ENGL J MED, V314, P61; SIMONSSON BG, 1973, RESPIRATION, V30, P378, DOI 10.1159/000193051; SKIDGEL RA, 1987, CLIN EXP HYPERTENS A, V9, P243, DOI 10.3109/10641968709164184; WIHOLM BE, 1984, ACTA MED SCAND S, V683, P107; 1989, INT MONITORING ADVER	20	54	55	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					18	21		10.1136/bmj.308.6920.18	http://dx.doi.org/10.1136/bmj.308.6920.18			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298346	Green Published			2022-12-28	WOS:A1994MQ09600023
J	MARCOVITCH, H				MARCOVITCH, H			FORTNIGHTLY REVIEW - FAILURE-TO-THRIVE	BRITISH MEDICAL JOURNAL			English	Article							NONORGANIC FAILURE; TO-THRIVE; GROWTH; INFANTS; WEIGHT				MARCOVITCH, H (corresponding author), HORTON GEN HOSP NHS TRUST,BANBURY OX16 9AL,OXON,ENGLAND.							BARBERO GJ, 1992, NELSON TXB PEDIATRIC, P214; BERWICK DM, 1982, ARCH DIS CHILD, V57, P347, DOI 10.1136/adc.57.5.347; DAVIS DR, 1978, BRIT MED J, V1, P539, DOI 10.1136/bmj.1.6112.539; EDWARDS AGK, 1990, ARCH DIS CHILD, V65, P1263, DOI 10.1136/adc.65.11.1263; FISCHOFF J, 1971, J PEDIATR-US, V79, P209, DOI 10.1016/S0022-3476(71)80103-8; FRANK DA, 1988, PEDIATR CLIN N AM, V35, P1187; HANNAWAY PJ, 1970, CLIN PEDIATR, V9, P96, DOI 10.1177/000992287000900214; HOMER C, 1981, AM J DIS CHILD, V135, P848, DOI 10.1001/archpedi.1981.02130330058019; HUFTON IW, 1977, PEDIATRICS, V59, P73; ILLINGWORTH RS, 1984, COMMON SYMPTOMS DISE; KITCHEN WH, 1989, ARCH DIS CHILD, V64, P379, DOI 10.1136/adc.64.3.379; KOTELCHUCK M, 1983, J AM ACAD CHILD PSY, V22, P322, DOI 10.1016/S0002-7138(09)60666-X; MURPHY JF, 1981, ARCH DIS CHILD, V56, P295, DOI 10.1136/adc.56.4.295; PORTER B, 1991, ARCH DIS CHILD, V66, P905, DOI 10.1136/adc.66.7.905-a; POSKITT EME, 1993, ARCH DIS CHILD, V68, P158, DOI 10.1136/adc.68.2.158; PUGLIESE MT, 1987, PEDIATRICS, V80, P175; SKUSE DH, 1985, ARCH DIS CHILD, V60, P173, DOI 10.1136/adc.60.2.173; SMITH DW, 1976, J PEDIATR-US, V89, P225, DOI 10.1016/S0022-3476(76)80453-2; TANNER JM, 1987, GROWTH ADOLESCENCE; THOMAS AG, 1992, ARCH DIS CHILD, V67, P741, DOI 10.1136/adc.67.6.741; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833	21	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					35	38		10.1136/bmj.308.6920.35	http://dx.doi.org/10.1136/bmj.308.6920.35			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298353	Green Published			2022-12-28	WOS:A1994MQ09600029
J	KANDELSLEWIS, S; SERAPHIN, B				KANDELSLEWIS, S; SERAPHIN, B			ROLE OF U6 SNRNA IN 5' SPLICE-SITE SELECTION	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; U1 SNRNA; SACCHAROMYCES-CEREVISIAE; TACTAAC BOX; YEAST; U2; MUTATIONS; GENE	Two models describing the interaction between U6 small nuclear RNA (snRNA) and the 5' splice site of introns have been proposed on the basis of cross-linking experiments. Here it is shown that a conserved sequence present in U6 snRNA forms base pairs with conserved nucleotides at the 5' splice junction and that this interaction is involved in 5' splice site choice. These results demonstrate a specific function for U6 snRNA in splicing and suggest that U6 snRNA has a proofreading role during splice site selection. A model is presented in which this new interaction, in concert with previously described interactions between U6 snRNA, U2 snRNA, and the pre-messenger RNA, would position the branch point near the 5' splice site for the catalysis of the first splicing step.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Seraphin, Bertrand/0000-0002-5168-1921				BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	35	247	248	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2035	2039		10.1126/science.8266100	http://dx.doi.org/10.1126/science.8266100			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266100				2022-12-28	WOS:A1993MN10800039
J	DARBY, SC; KENDALL, GM; FELL, TP; DOLL, R; GOODILL, AA; CONQUEST, AJ; JACKSON, DA; HAYLOCK, RGE				DARBY, SC; KENDALL, GM; FELL, TP; DOLL, R; GOODILL, AA; CONQUEST, AJ; JACKSON, DA; HAYLOCK, RGE			FURTHER FOLLOW-UP OF MORTALITY AND INCIDENCE OF CANCER IN MEN FROM THE UNITED-KINGDOM WHO PARTICIPATED IN THE UNITED-KINGDOM ATMOSPHERIC NUCLEAR-WEAPON TESTS AND EXPERIMENTAL PROGRAMS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To study the long term effects of participation in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes and to test hypotheses generated by an earlier report, including the possibility that participation in tests caused small hazards of leukaemia and multiple myeloma. Design-Follow up study of mortality and cancer incidence. Subjects-21 358 servicemen and civilians from the United Kingdom who participated in the tests and a control group of 22 333 non-participants. Main outcome measures-Numbers of deaths; standardised mortality ratios; relative risks of mortality from all causes and 27 types of cancer. Results-During seven further years of follow up the numbers of deaths observed in participants were fewer than expected from national rates for all causes, all neoplasms, leukaemia, and multiple myeloma (standardised mortality ratios 0.86, 0.85, 0.57, and 0.46); death rates were lower than in controls (relative risks 0.99, 0.96, 0.57, and 0.57; 90% confidence intervals all included 1.00). In the period more than 10 years after the initial participation in tests the relative risk of death in participants compared with controls was near unity for all causes (relative risk 0.99 (0.95 to 1.04)) and all neoplasms (0.95 (0.87 to 1.04)); it was raised for bladder cancer (2.69 (1.42 to 5.20)) and reduced for cancers of the mouth, tongue, and pharynx (0.45 (0.22 to 0.93)) and for lung cancer (0.85 (0.73 to 0.99)). For leukaemia mortality was equal to that expected from national rates but greater than in controls for both the whole follow up period (1.75 (1.01 to 3.06)) and the period 2-25 years after the tests (3.38 (1.45 to 8.25)). Conclusion-Participation in nuclear weapon tests had no detectable effect on expectation of life or on subsequent risk of developing cancer or other fatal diseases. The excess of leukaemia in participants compared with controls seems to be principally due to a chance deficit in the controls, but the possibility that participation in the tests may have caused a small risk of leukaemia in the early years afterwards cannot be ruled out.	NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,HARKNESS LAB,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	DARBY, SC (corresponding author), UNIV OXFORD,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD,ENGLAND.							[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; DARBY SC, 1988, BRIT MED J, V296, P332, DOI 10.1136/bmj.296.6618.332; DARBY SC, 1988, NRPB R214 REP; DARBY SC, IN PRESS MORTALITY C; PEARCE N, 1990, BRIT MED J, V300, P1161, DOI 10.1136/bmj.300.6733.1161; 1993, DOCUMENTS NRPB, V4, P15; [No title captured]; 1990, ICRP PUBLICATION, V60	9	40	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1530	1535		10.1136/bmj.307.6918.1530	http://dx.doi.org/10.1136/bmj.307.6918.1530			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274923	Green Published, Bronze			2022-12-28	WOS:A1993ML86900022
J	GALLICHAN, M				GALLICHAN, M			SELF MONITORING OF BLOOD-GLUCOSE	BRITISH MEDICAL JOURNAL			English	Letter							DIABETES-MELLITUS; CONTROLLED TRIAL; IMPACT				GALLICHAN, M (corresponding author), E CORNWALL HOSP,CORNWALL PL31 2EN,ENGLAND.							ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; BAUM JD, 1981, ARCH DIS CHILD, V56, P897, DOI 10.1136/adc.56.12.897; COHEN M, 1983, MED J AUSTRALIA, V2, P377, DOI 10.5694/j.1326-5377.1983.tb122531.x; FORBONNE A, 1989, DIABETES METAB, V25, P255; MARTIN BJ, 1986, PRACTICAL DIABETES, V3, P37; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; SONKSEN PPH, 1978, LANCET, V1, P732; TATTERSALL R, 1992, BRIT MED J, V305, P1171, DOI 10.1136/bmj.305.6863.1171; WING RR, 1986, AM J MED, V81, P830, DOI 10.1016/0002-9343(86)90354-2; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233	10	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					332	332		10.1136/bmj.306.6873.332-a	http://dx.doi.org/10.1136/bmj.306.6873.332-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8297405	Green Published			2022-12-28	WOS:A1993KK71800054
J	HOELDTKE, RD; BODEN, G				HOELDTKE, RD; BODEN, G			EPINEPHRINE SECRETION, HYPOGLYCEMIA UNAWARENESS, AND DIABETIC AUTONOMIC NEUROPATHY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INSULIN-INDUCED HYPOGLYCEMIA; GLUCOSE COUNTER-REGULATION; PANCREATIC-POLYPEPTIDE; DEPENDENT DIABETICS; RESPONSES; COUNTERREGULATION; MELLITUS; PREVALENCE; HORMONES; SYMPTOMS	The pathophysiology of iatrogenic hypoglycemia in patients with insulin-dependent diabetes mellitus has been studied extensively during the past decade. It is now widely recognized that some patients with longstanding diabetes lose their ability to secrete the major counterregulatory hormones, glucagon and epinephrine, and fail to have hypoglycemia-related autonomic warning symptoms. Many investigators focused initially on the role of autonomic neuropathy, assuming that the latter might explain the diminished epinephrine response to hypoglycemia and the blunted adrenergic warning signs. Although these studies confirmed that patients with advanced diabetic autonomic neuropathy have attenuated counterregulatory hormonal responses to hypoglycemia, many patients with inadequate counterregulatory hormone secretion lack the typical signs, symptoms, or cardiovascular reflex abnormalities typical of diabetic autonomic neuropathy. These patients may have a new variant of diabetic autonomic failure that selectively affects the central and peripheral autonomic mechanisms, which initiate epinephrine secretion and the defense against hypoglycemia. A potentially reversible cause for the failure of the counterregulatory hormone response to hypoglycemia has also been recently described. In this instance, the central nervous system fails to recognize hypoglycemia. The brain does not activate counter-regulation, and the patient develops no symptoms of hypoglycemia. Decreased central recognition of hypoglycemia results from either strict antecedent control or from a recent hypoglycemic event.	TEMPLE UNIV, PHILADELPHIA, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	HOELDTKE, RD (corresponding author), W VIRGINIA UNIV, DEPT MED, POB 9159, HLTH SCI CTR N, MORGANTOWN, WV 26506 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-349] Funding Source: Medline; NIA NIH HHS [R01-AG-07988] Funding Source: Medline; NIDDK NIH HHS [R01-DK-32239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON U, 1984, ACTA MED SCAND, V216, P215; AMAN J, 1988, ACTA PAEDIATR SCAND, V77, P542, DOI 10.1111/j.1651-2227.1988.tb10697.x; [Anonymous], 1988, DIABETES, V37, P1000; BARKAI L, 1991, ARCH DIS CHILD, V66, P1438, DOI 10.1136/adc.66.12.1438; BERLIN I, 1988, J CLIN ENDOCR METAB, V66, P273, DOI 10.1210/jcem-66-2-273; BODEN G, 1981, NEW ENGL J MED, V305, P1200, DOI 10.1056/NEJM198111123052007; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CAMPBELL LV, 1977, BMJ-BRIT MED J, V2, P1527, DOI 10.1136/bmj.2.6101.1527; CRYER PE, 1992, DIABETES, V41, P255, DOI 10.2337/diabetes.41.3.255; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P1388, DOI 10.1210/jcem-72-6-1388; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; GRIMALDI A, 1990, HORM METAB RES, V22, P90, DOI 10.1055/s-2007-1004858; HELLER SR, 1987, LANCET, V2, P359; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; HEPBURN DA, 1992, DIABETES S1, V41, pA216; HILSTED J, 1987, NEW ENGL J MED, V317, P421, DOI 10.1056/NEJM198708133170705; HOELDTKE RD, 1982, ANN INTERN MED, V96, P459, DOI 10.7326/0003-4819-96-4-459; HOFFMAN RP, 1991, DIABETES CARE, V14, P81, DOI 10.2337/diacare.14.2.81; HORIE H, 1984, HORM METAB RES, V16, P398, DOI 10.1055/s-2007-1014802; KENNEDY FP, 1988, ANN INTERN MED, V108, P54, DOI 10.7326/0003-4819-108-1-54; KENNEDY FP, 1987, J CLIN ENDOCR METAB, V64, P602, DOI 10.1210/jcem-64-3-602; POLINSKY RJ, 1980, J CLIN ENDOCR METAB, V51, P1401, DOI 10.1210/jcem-51-6-1401; POLONSKY K, 1982, NEW ENGL J MED, V307, P1106, DOI 10.1056/NEJM198210283071802; POPP DA, 1982, J CLIN INVEST, V69, P315, DOI 10.1172/JCI110455; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; SAMPSON MJ, 1990, Q J MED, V75, P635; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMONSON DC, 1985, ANN INTERN MED, V103, P184, DOI 10.7326/0003-4819-103-2-184; SJOBOM NC, 1989, DIABETOLOGIA, V32, P818; SUNDARESAN PR, 1984, ENDOCRINOLOGY, V114, P1358, DOI 10.1210/endo-114-4-1358; WEBB SM, 1985, CLIN PHYSIOL, V5, P66; WHITE NH, 1985, DIABETES, V34, P870, DOI 10.2337/diabetes.34.9.870; WIDOM B, 1992, DIABETES, V41, P1597, DOI 10.2337/diabetes.41.12.1597; WILKE RA, 1993, DIABETES, V42, P862, DOI 10.2337/diabetes.42.6.862	36	38	38	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					512	517		10.7326/0003-4819-120-6-199403150-00011	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311375				2022-12-28	WOS:A1994NB62500011
J	COCKCROFT, S; THOMAS, GMH; FENSOME, A; GENY, B; CUNNINGHAM, E; GOUT, I; HILES, I; TOTTY, NF; TRUONG, Q; HSUAN, JJ				COCKCROFT, S; THOMAS, GMH; FENSOME, A; GENY, B; CUNNINGHAM, E; GOUT, I; HILES, I; TOTTY, NF; TRUONG, Q; HSUAN, JJ			PHOSPHOLIPASE-D - A DOWNSTREAM EFFECTOR OF ARF IN GRANULOCYTES	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; GOLGI MEMBRANES; NEUTROPHILS; ACTIVATION; VESICLES; FLUORIDE; BOVINE; CELLS; BRAIN	Activation of the phospholipase D (PLD) pathway is a widespread response when cells are activated by agonists that bind receptors on the cell surface. A 16-kD cytosolic component can reconstitute guanosine triphosphate (GTP)-mediated activation of phospholipase D in HL60 cells depleted of their cytosol by permeabilization. This factor was purified and identified as two small GTP-binding proteins, ARF1 and ARF3. Recombinant ARF1 substituted for purified ARF proteins in the reconstitution assay. These results indicate that phospholipase D is a downstream effector of ARF1 and ARF3. The well-established role of ARF in vesicular traffic would suggest that alterations in lipid content by PLD are an important determinant in vesicular dynamics.	UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	COCKCROFT, S (corresponding author), UNIV LONDON UNIV COLL, DEPT PHYSIOL, ROCKEFELLER BLDG, UNIV ST, LONDON WC1E 6JJ, ENGLAND.		Hsuan, Justin/C-8825-2009; Cockcroft, Shamshad/F-9480-2011	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ENGLISH D, 1991, BLOOD, V77, P2746; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P1; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; LENNARD JM, 1992, J BIOL CHEM, V267, P13047; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Thomas GWC, UNPUB; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; YANG SF, 1967, J BIOL CHEM, V242, P477	30	627	634	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					523	526		10.1126/science.8290961	http://dx.doi.org/10.1126/science.8290961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290961				2022-12-28	WOS:A1994MT96600034
J	WITTINGHOFER, A				WITTINGHOFER, A			THE STRUCTURE OF TRANSDUCIN-G(ALPHA-T) - MORE TO VIEW THAN JUST RAS	CELL			English	Review							TRIPHOSPHATE CONFORMATION; MOLECULAR MECHANISM; G-PROTEINS; DOMAIN; TRANSDUCTION; GTP; P21; DEACTIVATION; HYDROLYSIS; TU				WITTINGHOFER, A (corresponding author), MAX PLANCK INST MOLEK PHYSIOL,STRUKT BIOL ABT,D-44139 DORTMUND,GERMANY.							ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN G, 1992, CELL, V70, P411; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LACOUR TFM, 1985, EMBO J, V4, P191; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGEN R, 1992, BIOCHEMISTRY-US, V31, P8691, DOI 10.1021/bi00152a002; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; VANDOP C, 1984, J BIOL CHEM, V259, P696; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383	34	23	23	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					201	204		10.1016/0092-8674(94)90327-1	http://dx.doi.org/10.1016/0092-8674(94)90327-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293457				2022-12-28	WOS:A1994MU67800003
J	STANDISH, A; ENQUIST, LW; SCHWABER, JS				STANDISH, A; ENQUIST, LW; SCHWABER, JS			INNERVATION OF THE HEART AND ITS CENTRAL MEDULLARY ORIGIN DEFINED BY VIRAL TRACING	SCIENCE			English	Article							PSEUDORABIES VIRUS; VISUAL-SYSTEM; CAT; NEURONS	The vagus nerve exerts a profound influence on the heart, regulating the heart rate and rhythm. An extensive vagal innervation of the cardiac ventricles and the central origin and extent of this innervation was demonstrated by transynaptic transport of pseudorabies virus with a virulent and two attenuated pseudorabies viral strains. The neurons that innervate the ventricles are numerous, and their distribution within the nucleus ambiguus and dorsal motor nucleus of the vagus is similar to that of neurons innervating other cardiac targets, such as the sino-atrial node. These data provide a neuroanatomical correlate to the physiological influence of the vagus nerve on ventricular function.	DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880	DuPont	STANDISH, A (corresponding author), DUPONT CO INC,NEURAL COMPUTAT GRP,E323 130,WILMINGTON,DE 19880, USA.			schwaber, james/0000-0003-0598-7345	NIMH NIH HHS [MH-43787] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH043787] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BURKHOLDER T, 1992, ANAT REC, V232, P44; CALARESU FR, 1965, J PHYSIOL-LONDON, V176, P252, DOI 10.1113/jphysiol.1965.sp007548; CARD JP, 1990, J NEUROSCI, V10, P1974; CARD JP, 1991, NEURON, V6, P957, DOI 10.1016/0896-6273(91)90236-S; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; CARD JP, 1992, J VIROL, V66, P3032, DOI 10.1128/JVI.66.5.3032-3041.1992; CIRIELLO J, 1980, AM J PHYSIOL, V238, pR57, DOI 10.1152/ajpregu.1980.238.1.R57; DEGEEST H, 1965, CIRC RES, V17, P222, DOI 10.1161/01.RES.17.3.222; ESCARDO J A, 1991, Society for Neuroscience Abstracts, V17, P993; GEIS GS, 1980, CIRC RES, V46, P606, DOI 10.1161/01.RES.46.5.606; HOFF H. E., 1936, ANN MED HIST, V8, P138; Hopkins D.A., 1987, CARDIOGENIC REFLEXES, P185; IZZO PN, 1993, J COMP NEUROL, V327, P572, DOI 10.1002/cne.903270408; Levy M.N., 1984, P68; Loewy AD, 1990, CENTRAL REGULATION A, P68; LOFFELHOLZ K, 1985, PHARMACOL REV, V37, P1; MCALLEN RM, 1976, J PHYSIOL-LONDON, V258, P187, DOI 10.1113/jphysiol.1976.sp011414; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NOSAKA S, 1982, AM J PHYSIOL, V243, pR92, DOI 10.1152/ajpregu.1982.243.1.R92; STRACK AM, 1989, BRAIN RES, V491, P156, DOI 10.1016/0006-8993(89)90098-X; THOMAS MR, 1974, AM J PHYSIOL, V226, P1344, DOI 10.1152/ajplegacy.1974.226.6.1344; TODO K, 1977, BRAIN RES, V130, P545, DOI 10.1016/0006-8993(77)90116-0; UGOLINI G, 1987, BRAIN RES, V422, P242, DOI 10.1016/0006-8993(87)90931-0	23	133	134	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					232	234		10.1126/science.8284675	http://dx.doi.org/10.1126/science.8284675			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284675				2022-12-28	WOS:A1994MQ87900037
J	YAN, Y; WINOGRAD, E; VIEL, A; CRONIN, T; HARRISON, SC; BRANTON, D				YAN, Y; WINOGRAD, E; VIEL, A; CRONIN, T; HARRISON, SC; BRANTON, D			CRYSTAL-STRUCTURE OF THE REPETITIVE SEGMENTS OF SPECTRIN	SCIENCE			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; CROSS-LINKING PROTEINS; RAY-DIFFRACTION DATA; COMPLETE SEQUENCE; HEREDITARY ELLIPTOCYTOSIS; ALPHA-SPECTRIN; COILED-COIL; REFINEMENT; DYSTROPHIN; DETECTOR	The elongated proteins of the spectrin family (dystrophin, alpha-actinin, and spectrin) contain tandemly repeated segments and form resilient cellular meshworks by cross-linking actin filaments. The structure of one of the repetitive segments of alpha-spectrin was determined at a 1.8 angstrom resolution. A segment consists of a three-helix bundle. A model of the interface between two tandem segments suggests that hydrophobic interactions between segments may constrain intersegment flexibility. The helix side chain interactions explain how mutations that are known to produce hemolytic anemias disrupt spectrin associations that sustain the integrity of the erythrocyte membrane.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	YAN, Y (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL CANCER INSTITUTE [R37CA013202, R01CA013202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017411] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13202] Funding Source: Medline; NHLBI NIH HHS [HL 17411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P89; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PALEK J, 1990, HEMATOLOGY, P569; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788	33	335	342	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2027	2030		10.1126/science.8266097	http://dx.doi.org/10.1126/science.8266097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266097				2022-12-28	WOS:A1993MN10800036
J	JAGADEESH, B; WHEAT, HS; FERSTER, D				JAGADEESH, B; WHEAT, HS; FERSTER, D			LINEARITY OF SUMMATION OF SYNAPTIC POTENTIALS UNDERLYING DIRECTION SELECTIVITY IN SIMPLE CELLS OF THE CAT VISUAL-CORTEX	SCIENCE			English	Article							STRIATE CORTEX; NEURONS; INHIBITION; MECHANISM; MOTION	Intracellular recordings from simple cells of the cat visual cortex were used to test linear models for the generation of selectivity for the direction of visual motion. Direction selectivity has been thought to arise in part from nonlinear processes, as suggested by previous experiments that were based on extracellular recordings of action potentials. In intracellular recordings, however, the fluctuations in membrane potential evoked by moving stimuli were accurately predicted by the linear summation of responses to stationary stimuli. Nonlinear mechanisms were not required.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University					NEI NIH HHS [R01 EY04726] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004726] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT DG, 1991, VISUAL NEUROSCI, V7, P531, DOI 10.1017/S0952523800010336; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; EMERSON RC, 1987, J NEUROPHYSIOL, V58, P33, DOI 10.1152/jn.1987.58.1.33; FERSTER D, 1987, J NEUROSCI, V7, P1780; FERSTER D, 1990, VISUAL NEUROSCI, V4, P115, DOI 10.1017/S0952523800002285; FERSTER D, 1988, J NEUROSCI, V8, P1172; GANZ L, 1984, J NEUROPHYSIOL, V51, P294, DOI 10.1152/jn.1984.51.2.294; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEEGER D, IN PRESS J NEUROPHYS; KOCH C, 1985, MODELS VISUAL CORTEX, P408; MCLEAN J, IN PRESS VISUAL NEUR; POGGIO T, 1973, KYBERNETIK, V13, P223, DOI 10.1007/BF00274887; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; REID RC, 1991, J NEUROPHYSIOL, V66, P505, DOI 10.1152/jn.1991.66.2.505; SAUL AB, 1992, J NEUROPHYSIOL, V68, P1190, DOI 10.1152/jn.1992.68.4.1190; TOLHURST DJ, 1991, VISUAL NEUROSCI, V6, P421, DOI 10.1017/S0952523800001280; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; WEHMEIER U J, 1988, Society for Neuroscience Abstracts, V14, P898	19	170	172	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1901	1904		10.1126/science.8266083	http://dx.doi.org/10.1126/science.8266083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266083				2022-12-28	WOS:A1993MM51100044
J	DISCH, DL; GREENBERG, ML; HOLZBERGER, PT; MALENKA, DJ; BIRKMEYER, JD				DISCH, DL; GREENBERG, ML; HOLZBERGER, PT; MALENKA, DJ; BIRKMEYER, JD			MANAGING CHRONIC ATRIAL-FIBRILLATION - A MARKOV DECISION-ANALYSIS COMPARING WARFARIN, QUINIDINE, AND LOW-DOSE AMIODARONE	ANNALS OF INTERNAL MEDICINE			English	Article						ATRIAL FIBRILLATION; DECISION-SUPPORT TECHNIQUES; AMIODARONE; QUINIDINE; WARFARIN	COMMUNITY STROKE PROJECT; CASE FATALITY RATES; SINUS RHYTHM; CEREBROVASCULAR-DISEASE; THROMBOEMBOLIC COMPLICATIONS; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; CARDIAC-ARRHYTHMIAS; RANDOMIZED TRIAL; NATURAL-HISTORY	Objective: To compare the relative risks and benefits of several clinical strategies for managing patients with chronic atrial fibrillation. Design: Five recent randomized controlled trials of warfarin in atrial fibrillation, 6 randomized controlled trials of quinidine, and 13 longitudinal studies of low-dose amiodarone were used. A MEDLINE search was also done (1966 to present). Measurements: A Markov decision analysis model was used to assess outcomes in large, hypothetical cohorts of patients with atrial fibrillation followed from 65 to 70 years of age within four clinical strategies: 1) no treatment; 2) warfarin; 3) electrical cardioversion followed by quinidine to maintain normal sinus rhythm; and 4) electrical cardioversion followed by low-dose amiodarone. Results: In this hypothetical cohort, fewer patients had disabling events with amiodarone (1.4%) than with quinidine (1.8%), warfarin (2.6%), or no treatment (7.4%). Amiodarone appeared to be associated with the lowest 5-year mortality (13.6%) when compared with warfarin (14.4%), quinidine (15.2%), and no treatment (18.2%). In terms of quality-adjusted life-years, amiodarone had the highest expected value (4.75 years), followed by warfarin (4.72 years), quinidine (4.68 years), and no treatment (4.55 years). Amiodarone remained the preferred strategy using the most plausible scenarios of risks associated with atrial fibrillation. Choices among warfarin, quinidine, and no treatment depended on estimates of bleeding rates with warfarin, stroke rates after discontinuing warfarin, quinidine-related mortality, and the quality of life with warfarin. Conclusion: Cardioversion followed by low-dose amiodarone to maintain normal sinus rhythm appears to be a relatively safe and effective treatment for patients with chronic atrial fibrillation.	DEPT VET AFFAIRS MED CTR, WHITE RIVER JCT, VT USA; DARTMOUTH HITCHCOK CHRON MED CTR, LEBANON, NH USA	Dartmouth College					NLM NIH HHS [5 T15 LM07044] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [T15LM007044] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Beck J R, 1981, Med Decis Making, V1, P285, DOI 10.1177/0272989X8100100309; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; Boissel J P, 1981, Eur Heart J, V2, P49; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; BRODERICK JP, 1992, STROKE, V23, P1250, DOI 10.1161/01.STR.23.9.1250; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CANDELISE L, 1991, STROKE, V22, P169, DOI 10.1161/01.STR.22.2.169; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHRISTIE D, 1981, MED J AUSTRALIA, V2, P182, DOI 10.5694/j.1326-5377.1981.tb100891.x; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ESTES NAM, 1992, JAMA-J AM MED ASSOC, V267, P3332, DOI 10.1001/jama.267.24.3332; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; GUSTAFSSON C, 1991, J INTERN MED, V230, P11, DOI 10.1111/j.1365-2796.1991.tb00400.x; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HART RG, 1983, STROKE, V14, P688, DOI 10.1161/01.STR.14.5.688; HARTEL G, 1970, BRIT HEART J, V32, P57; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HERRE JM, 1992, ANN INTERN MED, V117, P972; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; JANCIN B, 1993, INTERNAL MED NE 0315, P2; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOWEY PR, 1988, CHEST, V93, P54, DOI 10.1378/chest.93.1.54; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1992, CHEST, V102, pS426, DOI 10.1378/chest.102.4_Supplement.426S; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; LLOYD EA, 1984, S AFR MED J, V65, P367; LODDER J, 1988, BMJ-BRIT MED J, V296, P1435, DOI 10.1136/bmj.296.6634.1435; LOWN B, 1967, BRIT HEART J, V29, P469; LUNDSTROM T, 1989, J INTERN MED, V225, P137, DOI 10.1111/j.1365-2796.1989.tb00053.x; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MIDDLEKAUFF H R, 1991, Journal of the American College of Cardiology, V17, p92A; MIDDLEKAUFF HR, 1992, ANN INTERN MED, V116, P1017, DOI 10.7326/0003-4819-116-12-1017; MORGANROTH J, 1985, AM HEART J, V110, P1176, DOI 10.1016/0002-8703(85)90008-0; NACCARELLI GV, 1985, PHARMACOTHERAPY, V5, P298; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; PETERSEN P, 1989, LANCET, V1, P175; PRIMEAU R, 1989, CAN J CARDIOL, V5, P98; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; SAGE JI, 1983, STROKE, V14, P537, DOI 10.1161/01.STR.14.4.537; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; SANDERCOCK PAG, 1983, BRIT MED J, V287, P713; SCMIDT EV, 1988, STROKE, V19, P942, DOI 10.1161/01.STR.19.8.942; SMITH WM, 1986, AM J CARDIOL, V57, P1288, DOI 10.1016/0002-9149(86)90206-7; SODERMARK T, 1975, BRIT HEART J, V37, P486; SONNENBERG FA, 1988, 11TH P ANN S COMP AP; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WARD G, 1988, STROKE, V19, P1501, DOI 10.1161/01.STR.19.12.1501; WEINBERG DM, 1989, AM J CARDIOL, V63, P745, DOI 10.1016/0002-9149(89)90264-6; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; [No title captured]; 1990, NEW ENGL J MED, V32, P1505; 1991, VITAL STATISTICS US, V2	78	74	74	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					449	457		10.7326/0003-4819-120-6-199403150-00001	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311367				2022-12-28	WOS:A1994NB62500001
J	SPIGELMAN, AD				SPIGELMAN, AD			SITUS-INVERSUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SPIGELMAN, AD (corresponding author), ST MARYS HOSP,SCH MED,LONDON W2,ENGLAND.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					606	606						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302343				2022-12-28	WOS:A1994MY57300005
J	CROESE, J; LOUKAS, A; OPDEBEECK, J; FAIRLEY, S; PROCIV, P				CROESE, J; LOUKAS, A; OPDEBEECK, J; FAIRLEY, S; PROCIV, P			HUMAN ENTERIC INFECTION WITH CANINE HOOKWORMS	ANNALS OF INTERNAL MEDICINE			English	Article						HOOKWORM INFECTIONS; ANCYLESTOMATOIDEA; INTESTINAL DISEASES, PARASITIC; ABDOMINAL PAIN; DISEASE RESERVOIRS	EOSINOPHILIC ENTERITIS; NORTH	Objective: To describe a zoonotic ancylostomiasis (canine), acquired from domestic pets by patients living in developed, urban communities. Design: An 8-year, retrospective case study. Setting: A clinical gastroenterologic practice in Townsville and a university parasitology department in Brisbane, Australia. Patients: Nine patients, each with enteric hookworm infection diagnosed by finding a single organism in situ; five were treated by us, and the rest were referred to us for parasite identification. Measurements: Clinical and demographic data, complete blood examinations, total serum immunoglobulin E assay, and serologic testing with enzyme-linked immunosorbent assay and Western blot using excretory-secretory antigens of Ancylostoma caninum. Gut biopsy specimens were examined histologically, and hookworms were identified using morphologic criteria. Results: The infections in three of the patients were diagnosed during the initial 6 years and six in the last 2 years. All owned a dog and described activity potentially exposing them to infection with canine hookworm larvae. Three patients had a laparotomy for acute abdominal pain, and six had colonoscopies (five with pain and one without symptoms). Six of the nine had blood eosinophilia (mean, 0.97 x 10(9)/L), and five of eight had elevated immunoglobulin E levels (mean level, 756 mu g/L); six of eight had eosinophilic inflammation of the gut. In six patients, the worm was identified as A. caninum, whereas in three, damage to the specimen did not allow specific identification; however, they were unlikely to be human parasite species. Although all parasites were in the adult stage, none were sexually mature. Positive serologic findings in seven of the eight patients tested confirmed presence of antibody to the parasite. Conclusions: Human enteric infections with A. caninum are being diagnosed more frequently in northeastern Australia. Although infection may be subclinical, the chief symptom is abdominal pain, sometimes sudden and severe. The pathologic finding is focal or diffuse eosinophilic inflammation caused by a type 1 hypersensitivity response to secreted antigens. Infection by sexually immature worms is scant and nonpatent, indicating poor adaptation to the human host. Serologic testing assists in identification of occult infection. Advanced hygiene and sanitation afford little protection because the parasite reservoir is a large and growing pool of infected domestic pets.	UNIV QUEENSLAND, ST LUCIA, QLD 4072, AUSTRALIA	University of Queensland			Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441				BEAVER PC, 1984, CLIN PARASITOLOGY, P276; Biocca E., 1954, Rivista di Parassitologia, V15, P267; BURROWS RB, 1962, J PARASITOL, V48, P715, DOI 10.2307/3275261; CARRIAS VR, 1985, REV SOC BRASILEIRA M, V18, P57; CARROLL SM, 1980, HOOKWORM DISEASE CUR, P33; CROESE J, 1990, MED J AUSTRALIA, V153, P415, DOI 10.5694/j.1326-5377.1990.tb125502.x; CROESE TJ, 1988, AUST NZ J MED, V18, P848, DOI 10.1111/j.1445-5994.1988.tb01643.x; DEANE MARIA PAUMGARTTEN, 1950, REV SERV ESPECIAL SAuDE PuBLICA, V3, P443; KALKOFEN UP, 1987, VET CLIN N AM-SMALL, V17, P1341, DOI 10.1016/S0195-5616(87)50005-5; KOMMA M D, 1969, Revista Goiana de Medicina, V15, P169; LOUKAS A, 1992, T ROY SOC TROP MED H, V86, P650, DOI 10.1016/0035-9203(92)90175-C; LOUKAS A, 1994, IN PRESS AM J TROP M; MANALANG C, 1925, 6TH T C FAR E ASS TR, P351; MAXWELL C, 1987, AM J TROP MED HYG, V37, P126, DOI 10.4269/ajtmh.1987.37.126; NAWALINSKI TA, 1974, AM J TROP MED HYG, V23, P895, DOI 10.4269/ajtmh.1974.23.895; PROCIV P, 1993, MED J AUSTRALIA, V158, P160, DOI 10.5694/j.1326-5377.1993.tb121693.x; PROCIV P, 1990, LANCET, V335, P1299, DOI 10.1016/0140-6736(90)91186-E; SANDFORD N, 1991, MED J AUSTRALIA, V154, P490, DOI 10.5694/j.1326-5377.1991.tb121189.x; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; Witenberg G., 1951, Harefuah, V41, P178	20	76	77	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					369	374		10.7326/0003-4819-120-5-199403010-00003	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304653				2022-12-28	WOS:A1994MY49700003
J	FROEHLING, DA; SILVERSTEIN, MD; MOHR, DN; BEATTY, CW				FROEHLING, DA; SILVERSTEIN, MD; MOHR, DN; BEATTY, CW			DOES THIS DIZZY PATIENT HAVE A SERIOUS FORM OF VERTIGO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAROXYSMAL POSITIONAL VERTIGO; AMBULATORY CARE; DIZZINESS; NYSTAGMUS		MAYO CLIN & MAYO FDN,DIV AREA GEN INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT OTORHINOLARYNGOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								Aantaa E, 1979, Acta Otorhinolaryngol Belg, V33, P401; ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P216; ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P552; ALFORD B R, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P1462; Baloh R W, 1979, Am J Otolaryngol, V1, P1, DOI 10.1016/S0196-0709(79)80002-2; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Barber H O, 1973, Otolaryngol Clin North Am, V6, P169; BERKOWITZ BW, 1985, ARCH NEUROL-CHICAGO, V42, P874, DOI 10.1001/archneur.1985.04060080056016; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; FISHER CM, 1967, ARCHIV OTOLARYNGOL, V85, P529; Frederic M W, 1973, Otolaryngol Clin North Am, V6, P267; FROEHLING DA, 1991, MAYO CLIN PROC, V66, P596, DOI 10.1016/S0025-6196(12)60518-7; HARBERT F, 1970, ARCH OPHTHALMOL-CHIC, V84, P298; HARNER SG, 1981, NEUROSURGERY, V9, P373, DOI 10.1227/00006123-198110000-00004; HERR RD, 1989, ANN EMERG MED, V18, P664, DOI 10.1016/S0196-0644(89)80524-4; JACKSON GG, 1971, J INFECT DIS, V124, pS130, DOI 10.1093/infdis/124.Supplement_1.S130; KATSARKAS A, 1978, J OTOLARYNGOL, V7, P320; KELLY JP, 1985, PRINCIPLES NEURAL SC, P591; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; LACHMAN J, 1967, NEUROLOGY, V17, P376, DOI 10.1212/WNL.17.4.376; LEHRER J F, 1987, Comprehensive Therapy, V13, P31; LELIEVER WC, 1981, LARYNGOSCOPE, V91, P1; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; MOHR DN, 1986, WESTERN J MED, V145, P645; MYLEN CO, 1950, J LARYNGOL OTOL, V64, P295; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; NYLEN CO, 1939, ACTA OTO-LARYNGOL, V33, P5; OLSSON JE, 1987, OTOLARYNG CLIN N AM, V20, P83; PLUM F, 1980, DIAGNOSIS STUPOR COM, P58; Pulec J L, 1973, Otolaryngol Clin North Am, V6, P25; ROWLAND LP, 1985, PRINCIPLES NEURAL SC, P599; SCHUKNECHT HF, 1969, ARCH OTOLARYNGOL, V90, P765; Silvoniemi P, 1988, Acta Otolaryngol Suppl, V453, P1; SLATER R, 1979, J NEUROL NEUROSUR PS, V42, P363, DOI 10.1136/jnnp.42.4.363; THOMAS JE, 1981, MAYO CLIN PROC, V56, P17; VERNICK DM, 1987, OFFICE PRACTICE MED, P291; WATSON P, 1981, CAN J NEUROL SCI, V8, P133, DOI 10.1017/S0317167100043031; WOODWELL DA, 1992, ADV DATA, V209, P1; 1981, CLIN EXAMINATIONS NE, P63; 1986, WEBSTERS 3RD NEW INT, P664	42	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					385	388		10.1001/jama.271.5.385	http://dx.doi.org/10.1001/jama.271.5.385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283588				2022-12-28	WOS:A1994MR98300035
J	MARTINEZLAVIN, M; MANSILLA, J; PINEDA, C; PIJOAN, C; OCHOA, P				MARTINEZLAVIN, M; MANSILLA, J; PINEDA, C; PIJOAN, C; OCHOA, P			EVIDENCE OF HYPERTROPHIC OSTEOARTHROPATHY IN HUMAN SKELETAL REMAINS FROM PRE-HISPANIC MESOAMERICA	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE	Hypertrophic osteoarthropathy is one of the earliest recognized disease entities in the history of medicine. lt has a peculiar periosteal proliferation distinctive from other bone diseases. In its advanced stage, it leaves an indelible mark on the skeleton. It has been recently shown that digital clubbing is accompanied by a bone remodeling process of the underlying phalanges. Thus, theoretically, this entity can be recognized in ancient human skeletal remains. We studied part of the collection of skeletal remains from pre-Hispanic Mesoamerica preserved at the National Museum of Anthropology of Mexico City. We examined 1000 specimens and found 2 skeletons with widespread, bilateral, symmetric periosteal proliferation of the tubular bones in addition to the bone remodeling changes of the distal phalanges. One of the specimens was from the Formative period (2000 B.C. to 100 A. D.). We conclude that hypertrophic osteoarthropathy can be recognized in ancient human skeletal remains and that this disease was present in Mesoamerica near the time of the original description of clubbing by Hippocrates about 2500 years ago.	INST NACL ANTHROPOL & HIST, MEXICO CITY, MEXICO		MARTINEZLAVIN, M (corresponding author), INST NACL CARDIOL IGNACIO CHAVEZ, DEPT RHEUMATOL, JUAN BADIANO 1, MEXICO CITY 14080, DF, MEXICO.							ALLISON MJ, 1976, MED COLL VA QUART, V12, P49; MARTINEZLAVIN M, 1994, RHEUMATOLOGY; ORTNER DJ, 1985, IDENTIFICATION PATHO, P245; PINACHAN R, 1979, AM J MED, V67, P88; PINEDA CJ, 1987, AM J ROENTGENOL, V148, P773, DOI 10.2214/ajr.148.4.773; PINEDA CJ, 1985, SEMIN ARTHRITIS RHEU, V14, P263, DOI 10.1016/0049-0172(85)90045-9; Resnick D, 1988, DIAGNOSIS BONE JOINT, P4073	7	25	31	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					238	241		10.7326/0003-4819-120-3-199402010-00010	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273988				2022-12-28	WOS:A1994MU30300010
J	FENG, JA; JOHNSON, RC; DICKERSON, RE				FENG, JA; JOHNSON, RC; DICKERSON, RE			HIN RECOMBINASE BOUND TO DNA - THE ORIGIN OF SPECIFICITY IN MAJOR AND MINOR-GROOVE INTERACTIONS	SCIENCE			English	Article							REPRESSOR-OPERATOR COMPLEX; CRYSTAL-STRUCTURE; BINDING DOMAIN; STRAND EXCHANGE; TRP REPRESSOR; RESOLUTION; PROTEIN; RECOGNITION; HOMEODOMAIN; ENHANCER	The structure of the 52-amino acid DNA-binding domain of prokaryotic Hin recombinase, complexed with a DNA recombination half-site, has been solved by x-ray crystallography at 2.3 angstrom resolution. The Hin domain consists of a three-alpha-helix bundle, with the carboxyl-terminal helix inserted into the major groove of DNA, and two flanking extended polypeptide chains that contact bases in the minor groove. The overall structure displays features resembling both a prototypical bacterial helix-turn-helix and the eukaryotic homeodomain, and in many respects is an intermediate between these two DNA-binding binding motifs. In addition, a new structural motif is seen: the six-amino acid carboxyl-terminal peptide of the Hin domain runs along the minor groove at the edge of the recombination site, with the peptide backbone facing the floor of the groove and side chains extending away toward the exterior. The x-ray structure provides an almost complete explanation for DNA mutant binding studies in the Hin system and for DNA specificity observed in the Hin-related family of DNA invertases.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038509, R01GM038509, P01GM031299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38509, GM-31299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BRUIST MF, 1987, SCIENCE, V235, P777, DOI 10.1126/science.3027895; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; FENG JA, 1993, J MOL BIOL, V232, P982, DOI 10.1006/jmbi.1993.1443; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; GLASGOW AC, 1989, MOBILE DNA, P637; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES KT, 1992, EMBO J, V11, P2695, DOI 10.1002/j.1460-2075.1992.tb05335.x; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; MACK DP, 1990, BIOCHEMISTRY-US, V29, P6561, DOI 10.1021/bi00480a003; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PRIVE GG, 1991, J MOL BIOL, V217, P117; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YUAN HS, 1991, P NATL ACAD SCI USA, V88, P9558, DOI 10.1073/pnas.88.21.9558; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	178	187	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					348	355		10.1126/science.8278807	http://dx.doi.org/10.1126/science.8278807			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278807				2022-12-28	WOS:A1994MT03400025
J	LAM, PYS; JADHAV, PK; EYERMANN, CJ; HODGE, CN; RU, Y; BACHELER, LT; MEEK, JL; OTTO, MJ; RAYNER, MM; WONG, YN; CHANG, CH; WEBER, PC; JACKSON, DA; SHARPE, TR; ERICKSONVIITANEN, S				LAM, PYS; JADHAV, PK; EYERMANN, CJ; HODGE, CN; RU, Y; BACHELER, LT; MEEK, JL; OTTO, MJ; RAYNER, MM; WONG, YN; CHANG, CH; WEBER, PC; JACKSON, DA; SHARPE, TR; ERICKSONVIITANEN, S			RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; HOST GUEST COMPLEXATION; CRYSTAL-STRUCTURE; TYPE-1 PROTEASE; PROTEINASE; RESOLUTION; BINDING; ISOSTERE; LIGAND; AIDS	Mechanistic information and structure-based design methods have been used to design a series of nonpeptide cyclic ureas that are potent inhibitors of human immunodeficiency virus (HIV) protease and HIV replication. A fundamental feature of these inhibitors is the cyclic urea carbonyl oxygen that mimics the hydrogen-bonding features of a key structural water molecule. The success of the design in both displacing and mimicking the structural water molecule was confirmed by x-ray crystallographic studies. Highly selective, preorganized inhibitors with relatively low molecular weight and high oral bioavailability were synthesized.	DUPONT MERCK PHARMACEUT CO, DEPT CHEM & PHYS SCI, WILMINGTON, DE 19880 USA	DuPont	LAM, PYS (corresponding author), DUPONT MERCK PHARMACEUT CO, DEPT VIROL RES, WILMINGTON, DE 19880 USA.							ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; ANDREETTI GD, 1974, CRYST STRUCT COMMUN, V3, P145; BABINE RE, 1992, BIOORG MED CHEM LETT, V2, P541, DOI 10.1016/S0960-894X(01)81194-X; BACHELER L, IN PRESS ANTIVIRAL C; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLANEY JM, DGEOM590 QUANT CHEM; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURES MG, 1990, TETRAHEDRON COMP MET, V3, P673; CALABRESE JC, UNPUB; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; CRAM DJ, 1986, TETRAHEDRON, V42, P1607, DOI 10.1016/S0040-4020(01)87577-3; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; CRAM DJ, 1984, J AM CHEM SOC, V106, P7150, DOI 10.1021/ja00335a049; CRAM DJ, 1985, J AM CHEM SOC, V107, P3657, DOI 10.1021/ja00298a041; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027; DREYER GB, 1992, BIOCHEMISTRY-US, V31, P6646, DOI 10.1021/bi00144a004; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; EYERMANN CJ, UNPUB; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; GHOSH AK, 1993, J MED CHEM, V36, P292, DOI 10.1021/jm00054a015; GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203; GUTSCHINA A, 1990, FEBS LETT, V269, P269; HOLMES DS, 1993, BIOORG MED CHEM LETT, V3, P503, DOI 10.1016/S0960-894X(01)81216-6; IKEDA S, 1992, J AM CHEM SOC, V114, P7604, DOI 10.1021/ja00045a067; IWAKURA Y, 1992, AIDS, V6, P1069, DOI 10.1097/00002030-199210000-00002; JADHAV PK, 1991, Patent No. 9118866; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JOHNSON F, 1968, CHEM REV, V68, P375, DOI 10.1021/cr60254a001; JONAK G, UNPUB; KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003; KLEINERT HD, 1992, SCIENCE, V257, P1940, DOI 10.1126/science.1411510; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LAI MHT, 1993, J ACQ IMMUN DEF SYND, V6, P24; LAM PM, UNPUB; LAM PYS, 1993, Patent No. 9307128; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; March J., 1985, ADV ORGANIC CHEM REA, P125; MARTIN JA, 1992, ANTIVIR RES, V17, P265, DOI 10.1016/0166-3542(92)90022-W; MARTIN YC, 1992, J MED CHEM, V35, P2145, DOI 10.1021/jm00090a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MUIRHEAD GJ, 1992, P BRIT PHARM SOC, P170; NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141; OTTO MJ, 1993, 2ND INT WORKSH HIV D; OTTO MJ, 1992, 8TH INT C AIDS AMST, V1, P203; PLATTNER JJ, 1990, DRUG DISCOVERY TECHN, P92; RAYNER M, UNPUB; RICH DH, 1992, J MED CHEM, V35, P3803, DOI 10.1021/jm00099a008; RIPKA WC, 1993, 2ND P INT C CHEM INF, P303; ROSENBERG SH, 1993, J MED CHEM, V36, P449, DOI 10.1021/jm00056a005; SCHATZL H, 1991, ARCH VIROL, V120, P71, DOI 10.1007/BF01310950; SHAW TM, 1992, P BRIT PHARM SOC, P167; SMALLHEER JM, 1993, IN PRESS ANTIVIRAL C, V4, P27; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; THANKI N, 1992, PROTEIN SCI, V1, P1061, DOI 10.1002/pro.5560010811; THOMPSON WJ, 1993, J AM CHEM SOC, V115, P801, DOI 10.1021/ja00055a069; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5633; TOMASSELLI AG, 1991, CHEM TODAY       MAY, P6; TUCKER TJ, 1992, J MED CHEM, V35, P2525, DOI 10.1021/jm00092a002; VANDRIE JH, 1989, J COMPUT AID MOL DES, V3, P225, DOI 10.1007/BF01533070; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILLIAMS PEO, 1992, P BRIT PHARM SOC, P156; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YARCHOAN R, 1993, TRENDS PHARMACOL SCI, V14, P196, DOI 10.1016/0165-6147(93)90208-2	72	856	911	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	1994	263	5145					380	384		10.1126/science.8278812	http://dx.doi.org/10.1126/science.8278812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MT034	8278812				2022-12-28	WOS:A1994MT03400035
J	OCALLAGHAN, CA; ANDREWS, PA; OGG, CS				OCALLAGHAN, CA; ANDREWS, PA; OGG, CS			RENAL-DISEASE AND USE OF TOPICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS				OCALLAGHAN, CA (corresponding author), GUYS HOSP,RENAL UNIT,LONDON SE1 9RT,ENGLAND.							DOOGAN DP, 1989, LANCET, V2, P1270; FELLNER SK, 1985, AM J NEPHROL, V5, P142, DOI 10.1159/000166921; MURRAY MD, 1990, AM J MED SCI, V299, P222, DOI 10.1097/00000441-199004000-00002; PIRSON Y, 1986, AM J KIDNEY DIS, V8, P338, DOI 10.1016/S0272-6386(86)80108-1; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165	5	40	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					110	111		10.1136/bmj.308.6921.110	http://dx.doi.org/10.1136/bmj.308.6921.110			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298379	Green Published			2022-12-28	WOS:A1994MR17300014
J	BASSING, CH; YINGLING, JM; HOWE, DJ; WANG, TW; HE, WW; GUSTAFSON, ML; SHAH, P; DONAHOE, PK; WANG, XF				BASSING, CH; YINGLING, JM; HOWE, DJ; WANG, TW; HE, WW; GUSTAFSON, ML; SHAH, P; DONAHOE, PK; WANG, XF			A TRANSFORMING GROWTH-FACTOR-BETA TYPE-I RECEPTOR THAT SIGNALS TO ACTIVATE GENE-EXPRESSION	SCIENCE			English	Article							CELL-PROLIFERATION; FAMILY	Transforming growth factor beta (TGF-beta) is a multifunctional factor that regulates many aspects of cellular functions. TGF-beta signals through a heteromeric complex of the type I and type II TGF-beta receptors. However, the molecular mechanism of signal transduction by this receptor complex remains unresolved. The type II receptor belongs to a transmembrane receptor serine-threonine kinase family. A new member of this receptor family (R4) was identified and shown to be a functional TGF-beta type I receptor on the basis of its ability to restore a TGF-beta-induced gene response in mutant cell lines lacking endogenous type I receptor. Both ligand binding and signaling of the R4 protein were dependent on the presence of a functional type II receptor. The type I receptor has an intrinsic serine-threonine kinase activity, which was essential for signal transduction.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NICHD NIH HHS [NICHD T32HD07396] Funding Source: Medline; NIDDK NIH HHS [DK45746] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASSING CH, UNPUB; BOYD FT, 1989, J BIOL CHEM, V264, P2272; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P1; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHEWS LS, 1991, CELL, V65, P973; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SEGARANI P, IN PRESS BIOCH BIOPH; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	18	290	303	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					87	89		10.1126/science.8272871	http://dx.doi.org/10.1126/science.8272871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272871				2022-12-28	WOS:A1994MQ30100036
J	OHSUMI, K; KATAGIRI, C; KISHIMOTO, T				OHSUMI, K; KATAGIRI, C; KISHIMOTO, T			CHROMOSOME CONDENSATION IN XENOPUS MITOTIC EXTRACTS WITHOUT HISTONE H1	SCIENCE			English	Article							NUCLEOSOME ASSEMBLY INVITRO; TOPOISOMERASE-II; EGG EXTRACTS; CELL-CYCLE; SPERM NUCLEI; G2 PHASE; PHOSPHORYLATION; CHROMATIN; PROTEIN; H-1	The contribution of histone H1 to mitotic chromosome condensation was examined with the use of a cell-free extract from Xenopus eggs, which transforms condensed sperm nuclei into metaphase chromosomes. When H1 was removed from the extract, the resultant metaphase chromosomes were indistinguishable from those formed in complete extract. Nucleosomal spacing was the same for both. Thus, H1 is not required for the structural reorganization that leads to condensed metaphase chromosomes in this egg extract.	HOKKAIDO UNIV,GRAD SCH SCI,DIV BIOL SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	OHSUMI, K (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI,CELL & DEV BIOL LAB,4259 NAGATSUTA,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; ITOH T, 1993, DEV GROWTH DIFFER, V35, P59; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MUELLER RD, 1985, J BIOL CHEM, V260, P5081; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; OHSUMI K, 1988, GAMETE RES, V20, P1, DOI 10.1002/mrd.1120200102; OHSUMI K, UNPUB; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sambrook J., 1989, MOL CLONING; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; van Holde K.E., 1988, CHROMATIN	37	139	146	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2033	2035		10.1126/science.8266099	http://dx.doi.org/10.1126/science.8266099			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266099				2022-12-28	WOS:A1993MN10800038
J	PETTIT, MJ; SCHWARK, HD				PETTIT, MJ; SCHWARK, HD			RECEPTIVE-FIELD REORGANIZATION IN DORSAL COLUMN NUCLEI DURING TEMPORARY DENERVATION	SCIENCE			English	Article							PRIMARY SOMATOSENSORY CORTEX; PRIMARY AFFERENT-FIBERS; FELINE CUNEATE NUCLEUS; DIGIT DENERVATION; RAT; CAT; DEAFFERENTATION; PLASTICITY; NEURONS	Altered sensory input can result in the reorganization of somatosensory maps in the cerebral cortex and thalamus, but the extent to which reorganization occurs at lower levels of the somatosensory system is unknown. In cat dorsal column nuclei (DCN), the injection of local anesthetic into the receptive fields of DCN neurons resulted in the emergence of a new receptive field in all 13 neurons studied. New receptive fields emerged rapidly (within minutes), sometimes accompanied by changes in adaptation rates and stimulus selectivity, suggesting that the new fields arose from the unmasking of previously ineffective inputs. Receptive field reorganization was not imposed by descending cortical inputs to the DCN, because comparable results were obtained in 10 additional cells when the somatosensory and motor cortex were removed before recording. These results suggest that mechanisms underlying somatotopic reorganization exist at the earliest stages of somatosensory processing. Such mechanisms may participate in adaptive responses of the nervous system to injury or continuously changing sensory stimulation.	UNIV N TEXAS,DEPT BIOL SCI,DENTON,TX 76203	University of North Texas System; University of North Texas Denton					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025729] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 25729] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BYRNE JA, 1991, BRAIN RES, V565, P218, DOI 10.1016/0006-8993(91)91652-H; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; EYSEL UT, 1981, EXP BRAIN RES, V41, P256; FYFFE REW, 1986, J NEUROPHYSIOL, V56, P1284, DOI 10.1152/jn.1986.56.5.1284; FYFFE REW, 1986, J NEUROPHYSIOL, V56, P1268, DOI 10.1152/jn.1986.56.5.1268; GARRAGHTY PE, 1991, NEUROREPORT, V2, P747, DOI 10.1097/00001756-199112000-00004; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KALASKA J, 1982, BRAIN RES, V236, P35, DOI 10.1016/0006-8993(82)90032-4; KUYPERS HGJ, 1964, J ANAT, V98, P143; LANDRY P, 1981, J COMP NEUROL, V199, P345, DOI 10.1002/cne.901990304; MCMAHON SB, 1983, EXP NEUROL, V80, P195, DOI 10.1016/0014-4886(83)90016-X; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; Nakahama H, 1966, Prog Brain Res, V21, P180; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; SCHWARK HD, 1992, EXP BRAIN RES, V91, P425; SNOW PJ, 1988, SOMATOSENS MOT RES, V5, P349, DOI 10.3109/07367228809144636; WAITE PME, 1984, J PHYSIOL-LONDON, V352, P425, DOI 10.1113/jphysiol.1984.sp015301; WEINBERG RJ, 1990, J COMP NEUROL, V300, P113, DOI 10.1002/cne.903000108	24	101	102	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2054	2056		10.1126/science.8266104	http://dx.doi.org/10.1126/science.8266104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266104				2022-12-28	WOS:A1993MN10800044
J	BULSTRODE, CJK				BULSTRODE, CJK			TRAVELING AS A DOCTOR	BRITISH MEDICAL JOURNAL			English	Article											BULSTRODE, CJK (corresponding author), JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND.							KING M, MED DEV COUNTRIES; Lawrence T. E., 7 PILLARS WISDOM	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1611	1613		10.1136/bmj.307.6919.1611	http://dx.doi.org/10.1136/bmj.307.6919.1611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292958	Green Published, Bronze			2022-12-28	WOS:A1993MN10700022
J	SHRIVASTAVA, A; SALEQUE, S; KALPANA, GV; ARTANDI, S; GOFF, SP; CALAME, K				SHRIVASTAVA, A; SALEQUE, S; KALPANA, GV; ARTANDI, S; GOFF, SP; CALAME, K			INHIBITION OF TRANSCRIPTIONAL REGULATOR YIN-YANG-1 BY ASSOCIATION WITH C-MYC	SCIENCE			English	Article							SERUM RESPONSE FACTOR; DNA-BINDING; PROTEIN; MAX; YY1; IDENTIFICATION; PROMOTER; ACTIVATION; REPRESSOR; ONCOGENES	Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc. Depending on the context, YY1 acts as a transcriptional repressor, a transcriptional activator, or a transcriptional initiator. The yeast two-hybrid system was used to screen a human complementary DNA (cDNA) library for proteins that associate with YY1, and a c-myc cDNA was isolated. Affinity chromatography confirmed that YY1 associates with c-Myc but not with Max. In cotransfections, c-Myc inhibits both the repressor and the activator functions of YY1, which suggests that one way c-Myc acts is by modulating the activity of YY1.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University				Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL CANCER INSTITUTE [R01CA038571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029361] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38571] Funding Source: Medline; NIGMS NIH HHS [GM29361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DALLAFAVERA R, ORIGINS HUMAN CANCER, P543; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHENK T, COMMUNICATION; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SRTANDI S, 1993, METHODS MOL GENET, V1, P267; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264	36	243	250	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1889	1892		10.1126/science.8266081	http://dx.doi.org/10.1126/science.8266081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266081				2022-12-28	WOS:A1993MM51100041
J	LAUNER, LJ; HOFMAN, A; GROBBEE, DE				LAUNER, LJ; HOFMAN, A; GROBBEE, DE			RELATION BETWEEN BIRTH-WEIGHT AND BLOOD-PRESSURE - LONGITUDINAL-STUDY OF INFANTS AND CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; PLACENTAL SIZE; HYPERTENSION; CHILDHOOD; GROWTH; BROMPTON; HEART; FETAL; RISK	Objective-To study the relation between birth weight and systolic blood pressure in infancy and early childhood. Design-Longitudinal study of infants from birth to 4 years of age. Setting-A middle class community in the Netherlands. Participants--476 Dutch infants born in 1980 to healthy women after uncomplicated pregnancies. Main outcome measures-Systolic blood pressure and body weight measured at birth and at 3 months and 4 years of age; the relation between systolic blood pressure and birth weight as estimated by multiple regression models that include current weight and previous blood pressure and control for gestational age, length at birth, and sex. Results-Complete data were available on 392 infants. At 4 years of age the relation between blood pressure and birth weight appeared to be U shaped; low and high birthweight infants had raised blood pressure. Current weight and previous blood pressure were also positively associated with blood pressure at that age. Low birthweight infants (birth weight <3100 g) had a greater gain in blood pressure and weight in early infancy. High birthweight infants (birth weight greater-than-or-equal-to 3700 g) had high blood pressure at birth, and weight and blood pressure tended to remain high thereafter. Conclusions-Even among normal infants there seem to be subgroups defined by birth weight in which blood pressure is regulated differently. Future investigations are needed to examine the physiological basis of these differences. Studies of correlates of adult disease related to birth weight should investigate mechanisms related to increased risk separately in infants of low and high birth weight.			LAUNER, LJ (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS.		Launer, Lenore J/A-8218-2010; Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1987, PEDIATRICS, V79, P1; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERENSON GS, 1989, SEMIN NEPHROL, V9, P236; BINKIN NJ, 1988, PEDIATRICS, V82, P828; DAVIES DP, 1979, ARCH DIS CHILD, V54, P703, DOI 10.1136/adc.54.9.703; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; DESWIET M, 1980, PEDIATRICS, V65, P1028; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; GARN SM, 1985, AM J CLIN NUTR, V42, P57, DOI 10.1093/ajcn/42.1.57; HEATH D, 1990, BRIT MED J, V301, P441; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; SCHACHTER J, 1982, AM J EPIDEMIOL, V116, P29, DOI 10.1093/oxfordjournals.aje.a113400; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; STRACHAN DP, 1990, BRIT MED J, V301, P552, DOI 10.1136/bmj.301.6751.552; VOORS AW, 1980, HYPERTENSION, V2, pI102, DOI 10.1161/01.HYP.2.4_Pt_2.I102; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411; 1985, SAS USERS GUIDE STAT	22	111	117	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	1993	307	6917					1451	1454		10.1136/bmj.307.6917.1451	http://dx.doi.org/10.1136/bmj.307.6917.1451			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281086	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1993MK79700019
J	KOEHLER, JE; GLASER, CA; TAPPERO, JW				KOEHLER, JE; GLASER, CA; TAPPERO, JW			ROCHALIMAEA-HENSELAE INFECTION - A NEW ZOONOSIS WITH THE DOMESTIC CAT AS A RESERVOIR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACILLARY ANGIOMATOSIS; SCRATCH DISEASE; SP-NOV; PELIOSIS; LESIONS; AIDS	Objective.-To determine the reservoir and vector(s) for Rochalimaea henselae, a causative agent of bacillary angiomatosis (BA) and cat scratch disease, and to estimate the percentage of domestic cats with R henselae bacteremia in the Greater San Francisco Bay Region of Northern California. Design.-Hospital-based survey of patients diagnosed with BA who also had significant exposure to at least one pet cat, as well as a convenience sampling of pet or impounded cats for prevalence of Rochalimaea bacteremia. Setting.-Community and university hospitals and clinics; veterinary clinics treating privately owned or impounded cats. Patients.-Patients with or without human immunodeficiency virus infection, with biopsy-confirmed BA, who had prolonged exposure to pet cats prior to developing BA. Main Outcome Measures.-Cultures and laboratory studies were performed on blood drawn from pet cats associated with patients with BA. The Rochalimaea species infecting pet cats and fleas and causing the BA lesions in human contacts of these cats was identified by culture, polymerase chain reaction-restriction fragment length polymorphism analysis, and DNA sequencing. The presence of R henselae bacteremia in pet cats was documented, and predictor variables for culture positivity were evaluated. Results.-Four patients diagnosed with BA who had prolonged contact with seven pet cats were identified. The Rochalimaea species causing BA lesions in these patients was determined to be R henselae. The seven pet cats were found to be bacteremic with R henselae; this bacterium was also detected in fleas taken from an infected cat by both direct culture and polymerase chain reaction. Blood samples were cultured from pet and impounded cats (N=61) in the Greater San Francisco Bay Region, and Rhenselae was isolated from 41% (25/61) of these cats. Conclusion.-We have documented that the domestic cat serves as a major persistent reservoir for R henselae, with prolonged, asymptomatic bacteremia from which humans, especially the immunocompromised, may acquire potentially serious infections. Antibiotic treatment of infected cats and control of flea infestation are potential strategies for decreasing human exposure to R henselae.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	KOEHLER, JE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 1204,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Biberstein E. L., 1987, Diseases of the cat: medicine and surgery. Volume 1., P279; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P501, DOI 10.1016/0190-9622(90)70071-O; DALY JS, 1993, J CLIN MICROBIOL, V31, P872, DOI 10.1128/JCM.31.4.872-881.1993; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; HARWOOD RF, 1979, NETOMOLOGY HUMAN ANI, P48; JACKSON LA, 1993, AM J PUBLIC HEALTH, V83, P1707, DOI 10.2105/AJPH.83.12.1707; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LEBOIT PE, 1988, LANCET, V1, P960; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; PEDERSEN NC, 1988, FELINE INFECT DIS, P225; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REGNERY R, 1992, LANCET, V340, P557, DOI 10.1016/0140-6736(92)91760-6; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOTT DW, 1987, DISEASES CAT, P664; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; Strong RP, 1918, TRENCH FEVER REPORT, P40; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102; 1992, J AM VET MED ASSOC, V201, P990	29	399	410	2	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					531	535		10.1001/jama.271.7.531	http://dx.doi.org/10.1001/jama.271.7.531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301768				2022-12-28	WOS:A1994MV42300036
J	KOTLOFF, KL; JOHNSON, JP; NAIR, P; HICKMAN, D; LIPPINCOTT, P; WILSON, PD; CLEMENS, JD				KOTLOFF, KL; JOHNSON, JP; NAIR, P; HICKMAN, D; LIPPINCOTT, P; WILSON, PD; CLEMENS, JD			DIARRHEAL MORBIDITY DURING THE 1ST 2 YEARS OF LIFE AMONG HIV-INFECTED INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; LONGITUDINAL DATA-ANALYSIS; PERSISTENT DIARRHEA; SYNDROME AIDS; VIRUS TYPE-1; CHILDREN; WOMEN; ENTEROPATHY; COMMUNITY; PATTERNS	Objective.-To determine the incidence, cause, and patterns of diarrhea during the first 2 years of life among infants infected perinatally with the human immunodeficiency virus (HIV). Design.-A cohort study in which infants were enrolled shortly after birth and followed up longitudinally using biweekly surveillance for the occurrence of diarrhea. Stool specimens collected at the onset of diarrhea were evaluated for enteropathogens. Infants who were infected with HIV were compared with uninfected infants. Subjects.-Infants born to HIV-infected women at the University of Maryland Hospital, Baltimore, were recruited at 0 to 3 months of age. This analysis included 58 infants enrolled in the cohort and followed up at least 15 months (unless death intervened) whose HIV status was established (18 HIV-infected infants and 40 HIV-uninfected infants). Measurements and Results.-The overall incidence of diarrhea in HIV-infected infants was 3.2 episodes per 12 child-months compared with 1.5 episodes per 12 child-months among HIV-uninfected infants (incidence density ratio, 2.2; P<.05). An enteropathogen was identified in stool specimens collected during 20% of diarrheal episodes occurring in HIV-infected infants and during 25% of diarrheal episodes occurring in HIV-uninfected infants. Episodes that persisted tor 14 days or longer were significantly more common among HIV-infected infants. The peak incidence of diarrhea occurred at 0 to 5 months of age for HIV-infected infants compared with 6 to 11 months for HIV-uninfected infants. Early onset of diarrhea (<6 months old) in HIV-infected infants was associated with the later development of persistent episodes of diarrhea, and those with persistent episodes had more severe HIV infection, characterized by a significantly higher frequency of opportunistic infections and lower CD4+ T-lymphocyte counts by 1 year of age. Conclusions.-Both acute and persistent episodes of diarrhea are major sources of morbidity in HIV-infected infants. Moreover, persistent diarrhea is a marker for rapid progression of HIV disease.	UNIV MARYLAND,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV TROP PEDIAT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV PEDIAT IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV PEDIAT EDUC,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PREVENT MED,BALTIMORE,MD 21201; NICHHD,EPIDEMIOL BRANCH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KOTLOFF, KL (corresponding author), UNIV MARYLAND,SCH MED,CTR VACCINE DEV,10 S PINE ST,BALTIMORE,MD 21201, USA.		kotloff, karen l/E-7768-2012	kotloff, karen l/0000-0003-1808-6431	NICHD NIH HHS [1R01 HD26691] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026691] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balows A, 1991, MANUAL CLIN MICROBIO; CRAVIOTO A, 1991, LANCET, V337, P262, DOI 10.1016/0140-6736(91)90868-P; DWORKIN B, 1985, AM J GASTROENTEROL, V80, P774; GILLIN JS, 1985, ANN INTERN MED, V102, P619, DOI 10.7326/0003-4819-102-5-619; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KOOPMAN JS, 1984, AM J EPIDEMIOL, V119, P114, DOI 10.1093/oxfordjournals.aje.a113712; KOSTER FT, 1987, AM J CLIN NUTR, V46, P115, DOI 10.1093/ajcn/46.1.115; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; LANATA CF, 1991, J PEDIATR GASTR NUTR, V12, P82, DOI 10.1097/00005176-199101000-00017; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIMA AAM, 1992, EPIDEMIOL REV, V14, P222, DOI 10.1093/oxfordjournals.epirev.a036088; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MONTO AS, 1983, J INFECT DIS, V148, P284, DOI 10.1093/infdis/148.2.284; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; ROGERS MF, 1987, PEDIATRICS, V79, P1008; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SALISBURY FT, 1980, J PEDIATR, V97, P61; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SHADID NS, 1988, BRIT MED J, V297, P1096; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; THOMAS JC, 1992, INT J EPIDEMIOL, V21, P589, DOI 10.1093/ije/21.3.589; ULLRICH R, 1989, ANN INTERN MED, V111, P1; WALKER BD, 1990, BASIC VIROLOGIC TECH, P57; YOLKEN RH, 1991, J INFECT DIS, V164, P61, DOI 10.1093/infdis/164.1.64; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR MORB MORTAL WKL, V36, P224; 1988, LANCET, V1, P1043	34	20	20	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					448	452		10.1001/jama.271.6.448	http://dx.doi.org/10.1001/jama.271.6.448			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295320				2022-12-28	WOS:A1994MU49100032
J	LIEU, TA; COCHI, SL; BLACK, SB; HALLORAN, ME; SHINEFIELD, HR; HOLMES, SJ; WHARTON, M; WASHINGTON, AE				LIEU, TA; COCHI, SL; BLACK, SB; HALLORAN, ME; SHINEFIELD, HR; HOLMES, SJ; WHARTON, M; WASHINGTON, AE			COST-EFFECTIVENESS OF A ROUTINE VARICELLA VACCINATION PROGRAM FOR UNITED-STATES CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTHY-CHILDREN; ACYCLOVIR TREATMENT; IMMUNIZATION; CHICKENPOX; ZOSTER; LEUKEMIA; COMPLICATIONS; ADOLESCENTS; EFFICACY; BENEFITS	Objective.-To evaluate the economic consequences of a routine varicella vaccination program that targets healthy children, Methods.-Decision analysis was used to compare the costs, outcomes, and cost-effectiveness of a routine vaccination program with no intervention. Clinical outcomes were based on a mathematical model of vaccine efficacy that relied on published and unpublished data and on expert opinion. Medical utilization rates and costs were collected from multiple sources, including the Kaiser Permanente Medical Care Program and the California Hospital Discharge Database. Results.-A routine varicella vaccination program for healthy children would prevent 94% of all potential cases of chickenpox, provided the vaccination coverage rate is 97% at school entry. lt would cost approximately $162 million annually if one dose of vaccine per child were recommended at a cost of $35 per dose. From the societal perspective, which includes work-loss costs as well as medical costs, the program would save more than $5 for every dollar invested in vaccination. However, from the health care payer's perspective (medical costs only), the program would cost approximately $2 per chickenpox case prevented, or $2500 per life-year saved. The medical cost of disease prevention was sensitive to the vaccination coverage rate and vaccine price but was relatively insensitive to assumptions about vaccine efficacy within plausible ranges. An additional program for catch-up vaccination of 12-year-olds would have high incremental costs if the vaccination coverage rate of children of preschool age were 97%, but would result in net savings at a coverage rate of 50%. Conclusions.-A routine varicella vaccination program for healthy children would result in net savings from the societal perspective, which includes work-loss costs as well as medical costs. Compared with other prevention programs, it would also be relatively cost-effective from the health care payers perspective.	UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,SURVEILLANCE INVEST & RES BRANCH,ATLANTA,GA; KAISER PERMANENTE PEDIAT VACCINE STUDY CTR,OAKLAND,CA; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV GEN PEDIAT,SAN FRANCISCO,CA 94143; EMORY UNIV,SCH PUBL HLTH,DIV BIOSTAT,ATLANTA,GA 30322; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,MEDTEP RES CTR MINOR POPULAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; Kaiser Permanente; University of California System; University of California San Francisco; Emory University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LIEU, TA (corresponding author), PERMANENTE MED GRP INC,DIV RES,3451 PIEDMONT AVE,OAKLAND,CA 94611, USA.							ARBETER AM, 1986, PEDIATRICS, V78, P748; ASANO Y, 1985, PEDIATRICS, V75, P667; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BRUNELL PA, 1986, PEDIATRICS, V77, P53; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; FLEISHER G, 1981, AM J DIS CHILD, V135, P896, DOI 10.1001/archpedi.1981.02130340008004; GRABOWSKY M, 1991, J INFECT DIS, V164, P1237, DOI 10.1093/infdis/164.6.1237; GUESS HA, 1984, AM J DIS CHILD, V138, P1055, DOI 10.1001/archpedi.1984.02140490055013; HALLORAN ME, IN PRESS MATH BIOSCI; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; HAY JW, 1990, PEDIATR INFECT DIS J, V9, P246, DOI 10.1097/00006454-199004000-00005; HINMAN AR, 1984, JAMA-J AM MED ASSOC, V251, P3109, DOI 10.1001/jama.251.23.3109; JACKSON MA, 1992, PEDIATR INFECT DIS J, V11, P441, DOI 10.1097/00006454-199206000-00004; JOHNSON CD, 1992, PEDIATR RES 2, V31, P165; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LAWRENCE R, 1988, NEW ENGL J MED, V318, P543, DOI 10.1056/NEJM198803033180904; LIEU TA, IN PRESS PEDIATR INF; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PLOTKIN SA, 1989, J INFECT DIS, V159, P1000, DOI 10.1093/infdis/159.5.1000; PREBLUD SR, 1985, POSTGRAD MED J, V61, P17; PREBLUD SR, 1986, PEDIATRICS S, V78, P738; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; SULLIVANBOLYAI JZ, 1987, PEDIATR INFECT DIS J, V6, P33, DOI 10.1097/00006454-198701000-00009; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WATSON BM, 1993, PEDIATRICS, V91, P17; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WHARTON M, 1990, 30TH INT C ANT AG CH; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITE CJ, 1991, PEDIATRICS, V87, P604; 1992, 1990 DISCHARGE DATA; 1988, OTAH345 US C OFF TEC; 1993, COST EFFECTIVENESS V	41	311	319	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					375	381		10.1001/jama.271.5.375	http://dx.doi.org/10.1001/jama.271.5.375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283587				2022-12-28	WOS:A1994MR98300033
J	SHORR, RI; FOUGHT, RL; RAY, WA				SHORR, RI; FOUGHT, RL; RAY, WA			CHANGES IN ANTIPSYCHOTIC DRUG-USE IN NURSING-HOMES DURING IMPLEMENTATION OF THE OBRA-87 REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE-DRUGS; IMPACT; RESIDENTS; MEDICARE; QUALITY; CARE; RISK	Objectives.-To describe the changes in antipsychotic drug use in nursing homes during the period surrounding the implementation of federal legislation designed to reduce unnecessary use (the Omnibus Budget Reconciliation Act of 1987 [OBRA-87]) and to identify nursing home characteristics associated with such changes. Design.-Longitudinal study of 9432 Tennessee Medicaid enrollees 65 years of age or older who continuously resided in Tennessee from April 1, 1989, to September 30,1991, a 30-month period surrounding implementation of OBRA-87. Main Outcome Measures.-Changes in the use of antipsychotic and other psychotropic drugs. Results.-During the 30-month period, antipsychotic drug use decreased from 23.9 to 17.5 days per 100 days of residence, a 26.7% decline (P<.001), which resulted from both a decrease in new users (P<.001) and a reduction in long-term use of antipsychotic drugs (P<.001). There was no concomitant increase in other psychotropic drug use. A multivariate analysis revealed that changes in antipsychotic use were strongly associated with baseline antipsychotic use (P=.001) and third-shift staffing levels (P=.003). Nursing homes with baseline antipsychotic drug use and third-shift staffing above the median reduced antipsychotic drug use by 41%, compared with a 2% increase in nursing homes where both of these factors were below the median (P<.0001). Conclusions.-A substantial decrease in antipsychotic drug use coincided with the implementation of OBRA-87. Although this decrease is consistent with an improvement in quality of nursing home care, further research is needed to determine the effects of this legislation on resident outcomes.			SHORR, RI (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV PHARMACOEPIDEMIOL,NASHVILLE,TN 37232, USA.				PHS HHS [K08-00559] Funding Source: Medline; FDA HHS [FD-U-000073] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BALDESSARINI RJ, 1985, GOODMAN GILMANS PHAR, P387; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BURKE WJ, 1991, AM FAM PHYSICIAN, V43, P2125; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; DRAPER NR, 1981, APPLIED REGRESSION A; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; GARRARD J, 1992, J GERONTOL, V47, pM183, DOI 10.1093/geronj/47.6.M183; GARRARD J, 1991, JAMA-J AM MED ASSOC, V265, P463, DOI 10.1001/jama.265.4.463; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; KATZ IR, 1992, NEW ENGL J MED, V327, P1392; KIDDER SW, 1987, CONSULT PHARM, V2, P394; LINN MW, 1977, AM J PUBLIC HEALTH, V67, P337, DOI 10.2105/AJPH.67.4.337; LYLES YM, 1986, J AM GERIATR SOC, V34, P573, DOI 10.1111/j.1532-5415.1986.tb05762.x; NEEL AB, 1993, CONSULT PHARM, V8, P245; PIES R, 1992, NEW ENGL J MED, V327, P1392; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; ROVNER BW, 1992, AM J PSYCHIAT, V149, P1390; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SALZMAN C, 1987, PSYCHOPHARMACOLOGY 3, P1167; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; Spector W D, 1991, J Aging Health, V3, P427, DOI 10.1177/089826439100300401; STERNBERG J, 1990, Journal of Geriatric Drug Therapy, V4, P47; SVARSTAD BL, 1991, J AM GERIATR SOC, V39, P869, DOI 10.1111/j.1532-5415.1991.tb04453.x; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P724, DOI 10.1111/j.1532-5415.1991.tb03629.x; WOLLSTADT LJ, 1992, CLIN RES, V40, pA575; 1989, SAS STAT USERS GUIDE, P890; 1992, J AM GERIATR SOC, V40, P946	35	153	154	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					358	362						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR983	8283585				2022-12-28	WOS:A1994MR98300030
J	NOCTON, JJ; DRESSLER, F; RUTLEDGE, BJ; RYS, PN; PERSING, DH; STEERE, AC				NOCTON, JJ; DRESSLER, F; RUTLEDGE, BJ; RYS, PN; PERSING, DH; STEERE, AC			DETECTION OF BORRELIA-BURGDORFERI DNA BY POLYMERASE CHAIN-REACTION IN SYNOVIAL-FLUID FROM PATIENTS WITH LYME ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IXODES-DAMMINI TICKS; CEREBROSPINAL-FLUID; RHEUMATOID-ARTHRITIS; DISEASE SPIROCHETE; SKIN BIOPSIES; JOINT FLUID; DIAGNOSIS; AMPLIFICATION; INFECTION; NEUROBORRELIOSIS	Background. Borrelia burgdorferi is difficult to detect in synovial fluid, which limits our understanding of the pathogenesis of Lyme arthritis, particularly when arthritis persists despite antibiotic therapy. Methods. Using the polymerase chain reaction (PCR), we attempted to detect B. burgdorferi DNA in joint-fluid samples obtained over a 17-year period. The samples were tested in two separate laboratories with four sets of primers and probes, three of which target plasmid DNA that encodes outer-surface protein A (OspA). Results. B. burgdorferi DNA was detected in 75 of 88 patients with Lyme arthritis (85 percent) and in none of 64 control patients. Each of the three OspA primer-probe sets was sensitive, and the results were moderately concordant in the two laboratories (kappa = 0.54 to 0.73). Of 73 patients with Lyme arthritis that was untreated or treated with only short courses of oral antibiotics, 70 (96 percent) had positive PCR results. In contrast, of 19 patients who received either parenteral antibiotics or long courses of oral antibiotics (greater-than-or-equal-to 1 month), only 7 (37 percent) had positive tests (P<0.001). None of these seven patients had received more than two months of oral antibiotic treatment or more than three weeks of intravenous antibiotic treatment. Of 10 patients with chronic arthritis (continuous joint inflammation for one year or more) despite multiple courses of antibiotics, 7 had consistently negative tests in samples obtained three months to two years after treatment. Conclusions. PCR testing can detect B. burgdorferi DNA in synovial fluid. This test may be able to show whether Lyme arthritis that persists after antibiotic treatment is due to persistence of the spirochete.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT PEDIAT RHEUMATOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111; MAYO CLIN & MAYO FDN,CLIN MICROBIOL SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,INFECT DIS SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,EXPTL PATHOL SECT,ROCHESTER,MN 55905	Tufts Medical Center; Tufts University; Mayo Clinic; Mayo Clinic; Mayo Clinic	NOCTON, JJ (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DIV RHEUMATOL IMMUNOL,750 WASHINGTON ST,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853; Nocton, James/0000-0003-3560-6099	NIAMS NIH HHS [AR-20358, AR-07570, AR-40576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007570, R01AR040576, R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BERGER BW, 1985, J AM ACAD DERMATOL, V13, P444, DOI 10.1016/S0190-9622(85)70187-9; BERGSTROM S, 1992, RES MICROBIOL, V143, P623, DOI 10.1016/0923-2508(92)90120-D; CIMINO GD, 1991, NUCLEIC ACIDS RES, V19, P99, DOI 10.1093/nar/19.1.99; DATTWYLER RJ, 1988, LANCET, V1, P1191; GARON CF, 1989, SCANNING MICROSCOPY, V3, P109; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; GUY EC, 1991, J CLIN PATHOL, V44, P610, DOI 10.1136/jcp.44.7.610; HOLODNIY M, 1991, J CLIN MICROBIOL, V29, P676, DOI 10.1128/JCM.29.4.676-679.1991; JAULHAC B, 1991, NEW ENGL J MED, V324, P1440; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; KELLER TL, 1992, NEUROLOGY, V42, P32, DOI 10.1212/WNL.42.1.32; KRUGER WH, 1991, J MED MICROBIOL, V35, P98, DOI 10.1099/00222615-35-2-98; LEBECH AM, 1991, J CLIN MICROBIOL, V29, P731, DOI 10.1128/JCM.29.4.731-737.1991; LEBECH AM, 1992, J CLIN MICROBIOL, V30, P1646, DOI 10.1128/JCM.30.7.1646-1653.1992; LIEBLING MR, 1993, ARTHRITIS RHEUM-US, V36, P665, DOI 10.1002/art.1780360514; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P872; MALAWISTA SE, 1992, ARTHRITIS RHEUM, V35, P246, DOI 10.1002/art.1780350220; MALLOY DC, 1990, J CLIN MICROBIOL, V28, P1089, DOI 10.1128/JCM.28.6.1089-1093.1990; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; NIELSEN SL, 1990, CLIN RES, V38, pA402; NIELSEN SL, 1990, MOL CELL PROBE, V4, P73, DOI 10.1016/0890-8508(90)90041-W; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1994, J INFECT DIS, V169, P664; RABB DC, 1992, J AM ACAD DERMATOL, V26, P267, DOI 10.1016/S0190-9622(08)80309-X; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; ROTBART HA, 1987, MOL CELL PROBE, V1, P347, DOI 10.1016/0890-8508(87)90016-8; SCHMIDLI J, 1988, J INFECT DIS, V158, P905, DOI 10.1093/infdis/158.4.905; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1988, ARTHRITIS RHEUM, V31, P487, DOI 10.1002/art.1780310405; STEERE AC, 1993, ARTHRITIS RHEUM, V36, pS40; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; WHITMIRE WM, 1993, INFECT IMMUN, V61, P1460, DOI 10.1128/IAI.61.4.1460-1467.1993; WILLIAMS WV, 1992, DNA CELL BIOL, V11, P207, DOI 10.1089/dna.1992.11.207; 1991, PEDIATRICS, V88, P176; 1991, PEDIATRICS, V88, P840	46	441	459	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					229	234		10.1056/NEJM199401273300401	http://dx.doi.org/10.1056/NEJM199401273300401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272083				2022-12-28	WOS:A1994MR49600001
J	COLLINS, I; NEWLON, CS				COLLINS, I; NEWLON, CS			MEIOSIS-SPECIFIC FORMATION OF JOINT DNA-MOLECULES CONTAINING SEQUENCES FROM HOMOLOGOUS CHROMOSOMES	CELL			English	Article							MEIOTIC GENE CONVERSION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE CHROMOSOME; INITIATION SITE; ESCHERICHIA-COLI; MISMATCH-REPAIR; S-CEREVISIAE; PHYSICAL MAP; RECOMBINATION; YEAST	All recombination models postulate one or more recombination intermediates that are joint molecules containing two homologous parental molecules. A spike of branched DNA molecules not seen in DNA from mitotic cells was found in the two-dimensional gel analysis of melotic DNA from S. cerevisiae. The mass of molecules in the spike, the timing of its appearance and disappearance, and its absence from a recombination-defective spo11 mutant are consistent with the hypothesis that it contains recombination intermediates. The spike changes in mass as predicted for joint molecules containing DNA from homologous chromosomes rather than sister chromatids in a strain heterozygous for an RFLP. Finally, joint molecules containing DNA from homeologous chromosomes were not found, suggesting that the block to recombination between homeologous sequences occurs prior to the formation of joint molecules.	UNIV MED & DENT NEW JERSEY, GRAD SCH BIOMED SCI, NEWARK, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	COLLINS, I (corresponding author), UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA.							ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAILIS AM, 1990, GENETICS, V126, P535; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BELL L, 1979, P NATL ACAD SCI USA, V76, P3445, DOI 10.1073/pnas.76.7.3445; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BORTS RH, 1990, GENETICS, V124, P573; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COLEMAN KG, 1986, MOL CELL BIOL, V6, P4516, DOI 10.1128/MCB.6.12.4516; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLMBERG S, 1982, CARLSBERG RES COMMUN, V47, P233, DOI 10.1007/BF02907875; JACKSON JA, 1985, GENETICS, V109, P303; JINKSROBERTSON S, 1985, P NATL ACAD SCI USA, V82, P3350, DOI 10.1073/pnas.82.10.3350; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; JOHNSTON LH, 1982, EXP CELL RES, V141, P53, DOI 10.1016/0014-4827(82)90067-2; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1985, GENETICS, V110, P187; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LICHTEN M, 1987, GENETICS, V115, P233; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NEWLON CS, 1991, GENETICS, V129, P343; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; NILSSONTILLGREN T, 1981, CARLSBERG RES COMMUN, V46, P65, DOI 10.1007/BF02906199; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PORTER SE, 1993, GENETICS, V134, P5; POTTER H, 1976, P NATL ACAD SCI USA, V73, P3000, DOI 10.1073/pnas.73.9.3000; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; ROTH R, 1969, J BACTERIOL, V98, P831, DOI 10.1128/JB.98.2.831-832.1969; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTES NP, 1990, GENETICS, V126, P813; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WAGSTAFF JE, 1985, MOL CELL BIOL, V5, P3532, DOI 10.1128/MCB.5.12.3532; Williamson D H, 1975, Methods Cell Biol, V12, P335; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	53	86	87	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					65	75		10.1016/0092-8674(94)90173-2	http://dx.doi.org/10.1016/0092-8674(94)90173-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287480				2022-12-28	WOS:A1994MR49500007
J	WEINTRAUB, H				WEINTRAUB, H			THE MYOD FAMILY AND MYOGENESIS - REDUNDANCY, NETWORKS, AND THRESHOLDS	CELL			English	Review							GENE MYF-5; MUSCLE; DIFFERENTIATION; INACTIVATION; LINEAGES; EMBRYOS				WEINTRAUB, H (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CLINE TW, 1991, SCIENCE, V251, P1071; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HOLTZER H, 1975, Q REV BIOPHYS, V8, P523, DOI 10.1017/S0033583500001980; HOLTZER H, 1953, J EXP ZOOL, V123, P335, DOI 10.1002/jez.1401230206; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1992, DEVELOPMENT, V114, P853; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	24	952	987	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1241	1244		10.1016/0092-8674(93)90610-3	http://dx.doi.org/10.1016/0092-8674(93)90610-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269506				2022-12-28	WOS:A1993MP86900002
J	JEFFERY, R; JEFFERY, A				JEFFERY, R; JEFFERY, A			METACHROMATIC LEUKODYSTROPHY - 2 SIDES OF A COIN	BRITISH MEDICAL JOURNAL			English	Article											JEFFERY, R (corresponding author), HOPE HOSP,DEPT ORTHOPAED SURG,CLIN SCI BLDG,ECCLES OLD RD,SALFORD M6 8HD,LANCS,ENGLAND.			Jeffery, Alison/0000-0001-7539-5957					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1631	1632		10.1136/bmj.307.6919.1631	http://dx.doi.org/10.1136/bmj.307.6919.1631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292966	Green Published, Bronze			2022-12-28	WOS:A1993MN10700034
J	SIRUMCONNOLLY, K; MASON, TL				SIRUMCONNOLLY, K; MASON, TL			FUNCTIONAL REQUIREMENT OF A SITE-SPECIFIC RIBOSE METHYLATION IN RIBOSOMAL-RNA	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL RIBOSOME; NUCLEAR GENE; YEAST MITOCHONDRIA; PROTEIN; EXPRESSION; SEQUENCE; SUBUNIT; CONSTRUCTION	The product of the PET56 nuclear gene of Saccharomyces cerevisiae was shown to be required for ribose methylation ata universally conserved nucleotide in the peptidyl transferase center of the mitochondrial large ribosomal RNA (21S rRNA). Cells reduced i n this activity were deficient in formation of functional large subunits of the mitochondrial ribosome. The purified Pet56 protein catalyzed the site-specific formation of 2'-O-methylguanosine on in vitro transcripts of both mitochondrial 21S rRNA and Escherichia coli 23S rRNA. These results provide evidence for an essential modified nucleotide in rRNA.	UNIV MASSACHUSETTS, DEPT BIOCHEM & MOLEC BIOL, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, GRAD PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALARIF A, 1972, ANAL BIOCHEM, V48, P386, DOI 10.1016/0003-2697(72)90091-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAER RJ, 1981, NUCLEIC ACIDS RES, V9, P323, DOI 10.1093/nar/9.2.323; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; CHELBIALIX MK, 1981, EUR J BIOCHEM, V115, P627; CHIU MI, 1992, GENETICS, V132, P987; CUNDLIFFE E, 1981, J GEN MICROBIOL, V126, P185; CUNNINGHAM PR, 1991, BIOCHIMIE, V73, P789, DOI 10.1016/0300-9084(91)90058-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBIN DT, 1978, J MOL BIOL, V121, P523, DOI 10.1016/0022-2836(78)90398-4; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; KLOOTWIJK J, 1975, J MOL BIOL, V97, P337, DOI 10.1016/S0022-2836(75)80044-1; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; KUECHLER E, 1988, METHOD ENZYMOL, V164, P361; LAMBOWITZ AM, 1976, J BIOL CHEM, V251, P3081; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MELANCON P, 1987, BIOCHEM CELL BIOL, V65, P1022, DOI 10.1139/o87-134; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; Sambrook J, 1989, MOL CLONING LABORATO; SIRUMCONNOLLY K, UNPUB; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THOMPSON J, 1991, BIOCHIMIE, V73, P1131, DOI 10.1016/0300-9084(91)90156-U; ZHU H, 1987, MOL CELL BIOL, V7, P2530, DOI 10.1128/MCB.7.7.2530	42	107	108	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1886	1889		10.1126/science.8266080	http://dx.doi.org/10.1126/science.8266080			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266080				2022-12-28	WOS:A1993MM51100040
J	DILLNER, L				DILLNER, L			SENIOR HOUSE OFFICERS - THE LOST TRIBES	BRITISH MEDICAL JOURNAL			English	Article								There are more senior house officers than doctors in any other training grade in Britain but nobody knows what they do in hospitals or has a clear idea what skills they should be learning. Nobody is responsible for them and they suffer from having a poor career structure and inadequate training. Now that there are government initiatives to reduce the hours that junior doctors work and to limit the time it takes to train to become a specialist, the problems that senior house officers face can no longer be ignored. A conference for senior house officers held last week talked about the problems that they face and tried to find some solutions.											0	39	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1549	1551		10.1136/bmj.307.6918.1549	http://dx.doi.org/10.1136/bmj.307.6918.1549			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274928	Green Published, Bronze			2022-12-28	WOS:A1993ML86900028
J	SHADER, RI; GREENBLATT, DJ				SHADER, RI; GREENBLATT, DJ			DRUG-THERAPY - USE OF BENZODIAZEPINES IN ANXIETY DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TERM DIAZEPAM THERAPY; PANIC DISORDER; ANXIOUS PATIENTS; PLASMA-CONCENTRATIONS; REBOUND ANXIETY; ABUSE LIABILITY; DOUBLE-BLIND; ALPRAZOLAM; WITHDRAWAL; LORAZEPAM		NEW ENGLAND MED CTR,DIV CLIN PHARMACOL,BOSTON,MA	Tufts Medical Center	SHADER, RI (corresponding author), TUFTS UNIV,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,136 HARRISON AVE,BOSTON,MA 02111, USA.			Shader, Richard/0000-0002-1888-7565	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH034223, R37MH034223] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-34223] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLGULANDER C, 1991, ARCH GEN PSYCHIAT, V48, P599; ANGST J, 1991, ACTA PSYCHIAT SCAND, V84, P446, DOI 10.1111/j.1600-0447.1991.tb03176.x; BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413; BALTER MB, 1974, NEW ENGL J MED, V290, P769, DOI 10.1056/NEJM197404042901404; BOWDEN CL, 1982, J CLIN PSYCHOPHARM, V2, P110; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; BUSTO U, 1986, NEW ENGL J MED, V315, P854, DOI 10.1056/NEJM198610023151403; CHARNEY DS, 1989, J CLIN PSYCHIAT, V50, P418; CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P27, DOI 10.1097/00004714-199002000-00005; CIRAULO DA, 1986, J CLIN PHARMACOL, V26, P292, DOI 10.1002/j.1552-4604.1986.tb03526.x; COHN JB, 1984, PHARMACOTHERAPY, V4, P93; COWLEY DS, 1992, AM J MED, V92, pS41, DOI 10.1016/0002-9343(92)90136-Y; CROFTJEFFREYS C, 1989, PSYCHOL MED, V19, P549, DOI 10.1017/S0033291700024132; CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V105, P1; DEWIT H, 1991, DRUG ALCOHOL DEPEN, V28, P83, DOI 10.1016/0376-8716(91)90054-3; DIETCH JT, 1988, J CLIN PSYCHIAT, V49, P184; ELLINWOOD EH, 1985, PSYCHOPHARMACOLOGY, V86, P392, DOI 10.1007/BF00427897; FABRE LF, 1981, J INT MED RES, V9, P191, DOI 10.1177/030006058100900308; FONTAINE R, 1984, AM J PSYCHIAT, V141, P848; FRIEDMAN H, 1986, JAMA-J AM MED ASSOC, V256, P2227, DOI 10.1001/jama.256.16.2227; Garattini S., 1973, BENZODIAZEPINES; GHONEIM MM, 1990, ANESTHESIOLOGY, V72, P926; Greenblatt D. J., 1974, BENZODIAZEPINES CLIN; Greenblatt D. J., 1978, PSYCHOPHARMACOLOGY G, P1381; GREENBLATT DJ, 1981, BRIT J CLIN PHARMACO, V11, P35, DOI 10.1111/j.1365-2125.1981.tb01099.x; GREENBLATT DJ, 1983, NEW ENGL J MED, V309, P354; GREENBLATT DJ, 1983, NEW ENGL J MED, V309, P410; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1983, DRUG METAB REV, V14, P251, DOI 10.3109/03602538308991391; GREENBLATT DJ, 1990, J PSYCHIAT RES, V24, P73, DOI 10.1016/0022-3956(90)90038-R; GREENBLATT DJ, IN PRESS ARCH GEN PS; Greenblatt DJ, 1987, PSYCHOPHARMACOLOGY 3, P1377; Haefely W., 1990, HDB ANXIETY NEUROBIO, P165; HALL RCW, 1981, BRIT J CLIN PHARMACO, V11, pS99; HIGGITT A, 1990, ACTA PSYCHIAT SCAND, V82, P165, DOI 10.1111/j.1600-0447.1990.tb01375.x; HINDMARCH I, 1991, ALCOHOL ALCOHOLISM, V26, P71; HOLLISTER LE, 1961, PSYCHOPHARMACOLOGIA, V2, P63, DOI 10.1007/BF00429621; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; JUDD FK, 1986, INT CLIN PSYCHOPHARM, V1, P3, DOI 10.1097/00004850-198601000-00002; KATON WJ, 1992, AM J MED, V92, pS7, DOI 10.1016/0002-9343(92)90130-4; KING DJ, 1992, HUM PSYCHOPHARM CLIN, V7, P79, DOI 10.1002/hup.470070202; KLERMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P742, DOI 10.1001/jama.265.6.742; KOSTEN TR, 1987, BRIT J PSYCHIAT, V151, P834, DOI 10.1192/bjp.151.6.834; LADER M, 1983, J CLIN PSYCHIAT, V44, P121; LESSER IM, 1992, AM J PSYCHIAT, V149, P1556; LINNOILA M, 1983, J CLIN PSYCHOPHARM, V3, P88; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; LUCKI I, 1986, PSYCHOPHARMACOLOGY, V88, P426; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MARKS J, 1985, BENZODIAZEPINES USE; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; MILLER LG, 1988, J PHARMACOL EXP THER, V246, P170; MILLER LG, 1987, J PHARMACOL EXP THER, V240, P516; MUNJACK DJ, 1989, J CLIN PSYCHOPHARM, V9, P22; MURPHY SM, 1989, BRIT J PSYCHIAT, V154, P529, DOI 10.1192/bjp.154.4.529; NOYES R, 1991, J AFFECT DISORDERS, V22, P1, DOI 10.1016/0165-0327(91)90077-6; NOYES R, 1988, J CLIN PSYCHIAT, V49, P382; NOYES R, 1980, ARCH GEN PSYCHIAT, V37, P173; NOYES R, 1984, ARCH GEN PSYCHIAT, V41, P287; OTTO MW, 1992, J PSYCHIAT RES, V26, P29, DOI 10.1016/0022-3956(92)90013-E; PARRY HJ, 1973, ARCH GEN PSYCHIAT, V28, P769; POLLACK MH, 1990, J CLIN PSYCHIAT, V51, P12; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REICH J, 1986, J NERV MENT DIS, V174, P129, DOI 10.1097/00005053-198603000-00001; RICKELS K, 1990, ARCH GEN PSYCHIAT, V47, P899; RICKELS K, 1983, JAMA-J AM MED ASSOC, V250, P767, DOI 10.1001/jama.250.6.767; RICKELS K, 1988, ARCH GEN PSYCHIAT, V45, P444; RICKELS K, 1986, J CLIN PSYCHOPHARM, V6, P32; RICKELS K, 1988, AM J PSYCHIAT, V145, P312; RICKELS K, 1991, ARCH GEN PSYCHIAT, V48, P51; RICKELS K, 1980, INT PHARMACOPSYCHIAT, V15, P186, DOI 10.1159/000468436; RICKELS K, 1984, PHARMACOPSYCHIATRY, V17, P44, DOI 10.1055/s-2007-1017406; RICKELS K, 1991, AM J PSYCHIAT, V148, P757; RIFKIN A, 1989, AM J PSYCHIAT, V146, P1331; ROMACH MK, 1992, J CLIN PSYCHOPHARM, V12, P316; ROTH T, 1984, BRIT J CLIN PHARMACO, V18, pS45, DOI 10.1111/j.1365-2125.1984.tb02581.x; Roy-Byrne P.P., 1991, BENZODIAZEPINES CLIN; ROYBYRNE PP, 1988, AM J MED, V84, P1041, DOI 10.1016/0002-9343(88)90309-9; SALMONS P, 1981, BRIT J PSYCHIAT, V139, P43, DOI 10.1192/bjp.139.1.43; SCHWEIZER E, 1988, PSYCHOPHARMACOL BULL, V24, P224; Shader R I, 1982, J Clin Psychopharmacol, V2, p2S, DOI 10.1097/00004714-198212001-00001; SHADER RI, 1986, CLIN PHARMACOL THER, V39, P526, DOI 10.1038/clpt.1986.90; SMITH DE, 1983, J PSYCHOACTIVE DRUGS, V15, P1; SMITH RB, 1984, PSYCHOPHARMACOLOGY, V84, P452, DOI 10.1007/BF00431449; TESAR GE, 1991, J CLIN PSYCHIAT, V52, P69; TYRER P, 1988, PHARMACOL THERAPEUT, V36, P173, DOI 10.1016/0163-7258(88)90105-2; TYRER P, 1984, J AFFECT DISORDERS, V7, P1, DOI 10.1016/0165-0327(84)90059-4; UHLENHUTH EH, 1983, ARCH GEN PSYCHIAT, V40, P1167; Usdin E, 1982, PHARM BENZODIAZEPINE; WEISSMAN MM, 1989, NEW ENGL J MED, V321, P1209, DOI 10.1056/NEJM198911023211801; WILKINSON G, 1991, PSYCHOL MED, V21, P991, DOI 10.1017/S0033291700029986; WOODS JH, 1987, PHARMACOL REV, V39, P251; WOODS JH, 1988, PHARMACOL REV, V40, P85; WOODS JH, 1992, PHARMACOL REV, V44, P151; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; ZORUMSKI CF, 1991, AM J PSYCHIAT, V148, P162; 1987, DIAGNOSTIC STATISTIC; 1988, INT CLASSIFICATION D, V10; 1992, BRIT J PSYCHIAT, V160, P191; 1990, BENZODIAZEPINE DEPEN	100	276	279	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1398	1405						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB495	8292115				2022-12-28	WOS:A1993LB49500007
J	BECK, JT; HSU, SM; WIJDENES, J; BATAILLE, R; KLEIN, B; VESOLE, D; HAYDEN, K; JAGANNATH, S; BARLOGIE, B				BECK, JT; HSU, SM; WIJDENES, J; BATAILLE, R; KLEIN, B; VESOLE, D; HAYDEN, K; JAGANNATH, S; BARLOGIE, B			ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMANS DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							INTERLEUKIN-6		UNIV ARKANSAS MED SCI HOSP,ARKANSAS CANC RES CTR,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,ARKANSAS CANC RES CTR,DEPT PATHOL,LITTLE ROCK,AR; JOHN L MCCLELLAN MEM VET ADM MED CTR,DEPT PATHOL,LITTLE ROCK,AR 72205; CHU NANTES,DEPT HEMATOL,NANTES,FRANCE; INNOTHERAPIE LABS,BESANCON,FRANCE	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Nantes Universite; CHU de Nantes					NATIONAL CANCER INSTITUTE [P01CA055819] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; HATA H, 1993, BLOOD, V81, P3357; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HSU SM, 1992, AM J PATHOL, V141, P129; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; NIJSTEN MWN, 1987, LANCET, V2, P921; WIJDENES J, 1990, LYMPHOKINE RES, V9, P593; YOSHIZAKI K, 1989, BLOOD, V74, P1360	15	283	367	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					602	605		10.1056/NEJM199403033300904	http://dx.doi.org/10.1056/NEJM199403033300904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302342				2022-12-28	WOS:A1994MY57300004
J	BENSIMON, G; LACOMBLEZ, L; MEININGER, V; BOUCHE, P; DELWAIDE, C; COURATIER, P; BLIN, O; VIADER, F; PEYROSTPAUL, H; DAVID, J; MALOTEAUX, JM; HUGON, J; LATERRE, EC; RASCOL, A; CLANET, M; VALLAT, JM; DUMAS, A; SERRATRICE, G; LECHEVALLIER, B; PEUCH, AJ; NGUYEN, T; SHU, C; BASTIEN, P; PAPILLON, C; DURRLEMAN, S; LOUVEL, E; GUILLET, P; LEDOUX, L; ORVOENFRIJA, E; DIB, M				BENSIMON, G; LACOMBLEZ, L; MEININGER, V; BOUCHE, P; DELWAIDE, C; COURATIER, P; BLIN, O; VIADER, F; PEYROSTPAUL, H; DAVID, J; MALOTEAUX, JM; HUGON, J; LATERRE, EC; RASCOL, A; CLANET, M; VALLAT, JM; DUMAS, A; SERRATRICE, G; LECHEVALLIER, B; PEUCH, AJ; NGUYEN, T; SHU, C; BASTIEN, P; PAPILLON, C; DURRLEMAN, S; LOUVEL, E; GUILLET, P; LEDOUX, L; ORVOENFRIJA, E; DIB, M			A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHAIN AMINO-ACIDS	Background. Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis. Methods. To evaluate the efficacy and safety of the antiglutamate agent riluzole, we conducted a prospective, double-blind, placebo-controlled trial in 155 outpatients with amyotrophic lateral sclerosis. The dose of riluzole was 100 mg per day. Randomization was stratified according to the site of disease onset (the bulbar region or the limbs). The primary end points were survival and rates of change in functional status. The main secondary end point was change in muscle strength. Analyses were undertaken after 12 months of treatment and at the end of the placebo-controlled period (median follow-up, 573 days). Results. After 12 months, 45 of 78 patients (58 percent) in the placebo group were still alive, as compared with 57 of 77 patients (74 percent) in the riluzole group (P = 0.014). For patients with bulbar-onset disease, one-year survival rates were 35 percent (6 of 17) with placebo and 73 percent (11 of 15) with riluzole (P = 0.014), whereas for those with limb-onset disease one-year survival was 64 percent and 74 percent, respectively (P = 0.17). The survival advantage with riluzole was smaller (37 percent [29 of 78] with placebo vs. 49 percent [38 of 77] with riluzole) at the end of the placebo-controlled period, but it remained significant in the overall population (P = 0.046) as well as in the patients with bulbar-onset disease (18 percent [3 of 17] vs. 53 percent [8 of 15], P = 0.013). The deterioration of muscle strength was significantly slower in the riluzole group than in the placebo group (P = 0.028). Adverse reactions to riluzole included asthenia, spasticity, and mild elevations in aminotransferase levels. Twenty-seven patients in the riluzole group withdrew from the study, as compared with 17 in the placebo group. Conclusions. The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset.	HOP HOTEL DIEU, CTR SLA, SERV PNEUMOL, F-75004 PARIS, FRANCE; GRP HOSP PITIE SALPETRIERE, F-75634 PARIS, FRANCE; UNIV LOUVAIN, LOUVAIN, BELGIUM; HOP PURPAN, TOULOUSE, FRANCE; HOP DUPUYTREN, LIMOGES, FRANCE; CHU TIMONE, MARSEILLE, FRANCE; CHU COTE NACRE, CAEN, FRANCE; RHONE POULENC RORER, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; CHU Limoges; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU de Caen NORMANDIE; Universite de Caen Normandie; Sanofi-Aventis								BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1992, Neurology, V42, P202; BROOKS BR, 1991, ADV NEUROL, V56, P521; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; Charcot JM ., 1877, LECONS MALADIES SYST, P213; COX DR, 1972, J R STAT SOC B, V34, P187; CPMP Working Party on Efficacy of Medicinal Products, 1990, PHARMACOL TOXICOL, V67, P361; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DURRLEMAN S, 1989, NEUROLOGY, V39, P768, DOI 10.1212/WNL.39.6.768; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; HUGON J, 1989, NEUROLOGY, V39, P956, DOI 10.1212/WNL.39.7.956; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KONDO K, 1984, Neuroepidemiology, V3, P129, DOI 10.1159/000110849; LACOMBLEZ L, 1989, NEUROLOGY, V39, P1635, DOI 10.1212/WNL.39.12.1635; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARTIN D, 1991, British Journal of Pharmacology, V104, p240P; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; NORRIS FH, 1989, CLIN NEUROL, V29, P1485; PETO R, 1982, TREATMENT CANCER, P868; PLAITAKIS A, 1991, ADV NEUROL, V56, P319; PLAITAKIS A, 1988, LANCET, V1, P1015; PLAITAKIS A, 1987, ANN NEUROL, V22, P575, DOI 10.1002/ana.410220503; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROWLAND LP, 1991, ADV NEUROL, V56, P3; ROZIER A, 1990, J NEUROSCI S, V98, P3216; SWASH M, 1992, NEUROMUSCULAR DISORD, V2, P7, DOI 10.1016/0960-8966(92)90020-7; TESTA D, 1989, J NEUROL, V236, P445, DOI 10.1007/BF00328503; WU MC, 1988, BIOMETRICS, V44, P175, DOI 10.2307/2531905	28	1562	1618	1	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					585	591		10.1056/NEJM199403033300901	http://dx.doi.org/10.1056/NEJM199403033300901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302340				2022-12-28	WOS:A1994MY57300001
J	BERO, LA; GALBRAITH, A; RENNIE, D				BERO, LA; GALBRAITH, A; RENNIE, D			SPONSORED SYMPOSIA ON ENVIRONMENTAL TOBACCO-SMOKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PASSIVE SMOKING; PUBLICATION BIAS; HEART-DISEASE; RISK	Objective.-To test the hypothesis that symposia on environmental tobacco smoke (ETS) are more likely to present unbalanced data and be authored by tobacco industry-affiliated individuals than journal articles on ETS. To compare the publication records and affiliations of authors of symposia with the authors of scientific consensus documents on ETS. Design.-Content analysis of articles; computerized literature searches of English-language publications (except for one symposium) supplemented with additional sources. Participants (Articles).-All 297 symposium articles on ETS and a random sample of 100 journal articles on ETS published between January 1, 1965, and March 31, 1993; the 1986 Surgeon General's report on ETS; and the 1986 National Research Council's report on ETS. Main Outcome Measures.-For each article, regardless of whether it had a methods section, agreement with the tobacco industry position that ETS is not harmful; topic; funding source(s); affiliation(s) of author; and publication records of authors. Results.-Of the symposium articles 41% were reviews, compared with 10% of journal articles. A total of 83% of original symposium articles and 100% of journal articles contained methods sections (P=.0001). Symposium articles were more likely to agree with the tobacco industry position (46% vs 20%), less likely to assess the health effects of ETS (22% vs 49%), less likely to disclose their source of funding (22% vs 60%), and more likely to be written by tobacco industry-affiliated authors (35% vs 6%) than journal articles (P=.0001). Symposium authors published a lower proportion of peer-reviewed articles (71% vs 81%) (P=.0001) and were more likely to be affiliated with the tobacco industry (50% vs O%) than consensus document authors (P=.0004). Conclusions.-Symposium articles on ETS differ from journal articles and consensus documents in ways that suggest that symposia are not balanced.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DIV CLIN PHARM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BERO, LA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,1388 SUTTER ST,11TH FLOOR,SAN FRANCISCO,CA 94109, USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				ANGIER N, 1993, NY TIMES        0630, pA8; [Anonymous], 1986, ENV TOBACCO SMOKE ME; ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BERO LA, 1993, 2ND P INT C PEER REV, P17; BERO LA, 1993, TOB CONTROL, V2, P103; CATANOSO J, 1992, NEWS RECORD     0926, pA4; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DURBIN R, 1993, TOB CONTROL, V2, P8; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; ECOBICHON D, 1990, 1989 P INT S MCGILL, P1; ECOBICHON DJ, 1990, ENV TOBACCO SMOKE, pR21; FREEDMAN AM, 1993, WALL STREET J   0211, pA6; FREEDMAN AM, 1993, WALL ST J       0922, pA1; FREEDMAN AM, 1993, WALL STREET J   0211, pA7; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GLANTZ SA, 1983, 5TH P WORLD C TOB HL, P287; GREENHOUSE L, 1993, NY TIMES        0802, pA9; HEDGES LV, 1990, M I MATH STATISTICS; Hulley SB, 1988, DESIGNING CLIN RES, P247; Hunter J.E., 1990, METHODS META ANAL CO; KRIPPENDORFF K, 1980, SAGE COMMTEXT SERIES, V62; PETERSON J, 1990, WISCONSIN STATE 0806, pB4; RENNIE D, 1990, JAMA-J AM MED ASSOC, V263, P1317, DOI 10.1001/jama.1990.03440100011001; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; RENNIE D, 1990, CBE VIEWS, V13, P31; REPACE JL, 1992, TOB CONTROL, V1, P208; RYLANDER R, 1990, INT J EPIDEMIOL, V19, pS3, DOI 10.1093/ije/19.Supplement_1.S3; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STERLING TD, 1992, AM J PUBLIC HEALTH, V82, P1292, DOI 10.2105/AJPH.82.9.1292-a; STRUM C, 1992, NY TIMES        0208, pA1; SULLUM J, 1991, REASON           FEB, P28; TAYLOR ST, 1992, HLTH LETT        OCT, P1; TIMMINS N, 1988, INDEPENDENT     0324; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; WEBER RP, 1990, SERIES QUANTITATIVE, V49; WU JM, 1990, ENV TOBACCO SMOKE, P367; 1989, REQUEST APPLICATIONS; 1986, DHHS CDC878398 US DE, P332; 1984, CIGARETTE SMOKE NONS; 1981, FTC STAFF REPORT CIG; 1985, PASSIVE SMOKING ACTI; 1978, STUDY PUBLIC ATTITUD, P1; SMOKING RESTRICTIONS; 1993, CARDIOVASC DRUG T S3, V7, P493; 1992, NBC NIGHTLY NEW 0610; ENV TOBACCO SMOKE HL; SMOKERS RIGHTS WORKP; 1990, SMOKERS ADVOCATE JUN, P2; SMOKING WORKPLACE SO; 1992, RESPIRATORY HLTH EFF; 1990, P MORRIS MAGAZIN SEP, P41; 1986, TOBACCO SMOKE NONSMO	57	52	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					612	617		10.1001/jama.271.8.612	http://dx.doi.org/10.1001/jama.271.8.612			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301794				2022-12-28	WOS:A1994MW47700025
J	ELIOPOULOS, C; KLEIN, J; PHAN, MK; KNIE, B; GREENWALD, M; CHITAYAT, D; KOREN, G				ELIOPOULOS, C; KLEIN, J; PHAN, MK; KNIE, B; GREENWALD, M; CHITAYAT, D; KOREN, G			HAIR CONCENTRATIONS OF NICOTINE AND COTININE IN WOMEN AND THEIR NEWBORN-INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FOLLOW-UP; PREGNANCY; EXPOSURE; SMOKING; CIGARETTES; METABOLISM; MARIJUANA; BEHAVIOR; ALCOHOL; COCAINE	Background.-To date, no biological markers have been identified that can predict the extent of fetal exposure to the toxic constituents of cigarette smoke. A variety of xenobiotic agents have been shown to accumulate in growing hair. Patients and Methods.-We measured maternal and neonatal hair concentrations of nicotine and cotinine in 94 mother-infant pairs. Mothers who were active smokers, nonsmokers, and passive smokers and their infants were included. Results.-Mothers who were active smokers (n=36) had mean (SEM) hair concentrations of 19.2 (4.9) ng/mg for nicotine and 6.3 (4.0) ng/mg for cotinine, significantly higher than concentrations in nonsmokers (n=35) (1.2 [0.4] ng/mg for nicotine and 0.3 [0.06] ng/mg for cotinine, P<.0001). Infants of smokers had mean hair concentrations of 2.4 (0.9) ng/mg for nicotine (range, 0 to 27.3 ng/mg) and 2.8 (0.8) ng/mg for cotinine (range, 0 to 12.2 ng/mg), significantly higher than concentrations in infants of nonsmokers (0.4 [0.09] ng/mg for nicotine and 0.26 [0.04] ng/mg for cotinine, P<.01). Mothers with passive smoke exposure and their infants (n=23) had significantly higher hair concentrations of nicotine (3.2 [0.8] ng/mg for mothers and 0.28 [0.05] ng/mg for infants) and cotinine (0.9 [0.3] ng/mg for mothers and 0.6 [0.15] ng/mg for infants) than nonsmoking mothers and their infants (P<.01). There was a significant correlation between maternal and neonatal hair concentrations of nicotine (r=.49, P<.001) or cotinine (r=.85, P=.0001). Conclusions.-This is the first biochemical evidence that infants of passive smokers are at risk of measurable exposure to cigarette smoke. Hair accumulation of cigarette smoke constituents reflects long-term systemic exposure to these toxins and therefore may be well correlated with perinatal risks.	HOSP SICK CHILDREN, MOTHERISK PROGRAM, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT PEDIAT, TORONTO, ON, CANADA; HOSP SICK CHILDREN, DIV CLIN PHARMACOL & TOXICOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DIV CLIN GENET, TORONTO, ON, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ON, CANADA; YORK FINCH GEN HOSP, DEPT PEDIAT, N YORK, ON, CANADA; YORK FINCH GEN HOSP, DEPT PHARMACOL, N YORK, ON, CANADA; UNIV TORONTO, TORONTO GEN HOSP, TORONTO M5G 1L7, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ABEL EL, 1984, J PSYCHOACTIVE DRUGS, V16, P327, DOI 10.1080/02791072.1984.10472303; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; FORMAN R, 1992, LIFE SCI, V50, P1333, DOI 10.1016/0024-3205(92)90284-V; FORMAN R, IN PRESS CLIN INVEST; FRIED PA, 1992, J DEV BEHAV PEDIATR, V13, P383; FRIED PA, 1992, NEUROTOXICOL TERATOL, V14, P299, DOI 10.1016/0892-0362(92)90036-A; GRAHAM K, 1989, JAMA-J AM MED ASSOC, V262, P3328, DOI 10.1001/jama.262.23.3328; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HALEY NJ, 1985, CLIN CHEM, V31, P1598; ISHIYAMA I, 1983, J FORENSIC SCI, V28, P380; KINTZ P, 1993, J FORENSIC SCI, V38, P119; KLEIN J, 1993, NEW ENGL J MED, V328, P66, DOI 10.1056/NEJM199301073280116; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; KYEREMATEN GA, 1991, DRUG METAB REV, V23, P3, DOI 10.3109/03602539109029754; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LONGO LD, 1977, AM J OBSTET GYNECOL, V129, P69, DOI 10.1016/0002-9378(77)90824-9; MAKIN J, 1991, NEUROTOXICOL TERATOL, V13, P5, DOI 10.1016/0892-0362(91)90021-N; MARSH DO, 1981, CLIN TOXICOL, V18, P1311, DOI 10.3109/00099308109035071; MARTIN TR, 1986, AM J EPIDEMIOL, V124, P633, DOI 10.1093/oxfordjournals.aje.a114436; Pilotti A, 1980, Acta Physiol Scand Suppl, V479, P13; RUSH D, 1989, ANN NY ACAD SCI, V562, P74, DOI 10.1111/j.1749-6632.1989.tb21008.x; STILLMAN RJ, 1986, FERTIL STERIL, V46, P545; TRIEBIG G, 1984, PREV MED, V13, P570, DOI 10.1016/S0091-7435(84)80007-9; 1989, CDC898411 US DEP HLT, P71	25	127	130	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					621	623		10.1001/jama.271.8.621	http://dx.doi.org/10.1001/jama.271.8.621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301796				2022-12-28	WOS:A1994MW47700027
J	WEINGARTEN, SR; RIEDINGER, MS; CONNER, L; LEE, TH; HOFFMAN, I; JOHNSON, B; ELLRODT, AG				WEINGARTEN, SR; RIEDINGER, MS; CONNER, L; LEE, TH; HOFFMAN, I; JOHNSON, B; ELLRODT, AG			PRACTICE GUIDELINES AND REMINDERS TO REDUCE DURATION OF HOSPITAL STAY FOR PATIENTS WITH CHEST PAIN - AN INTERVENTIONAL TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						PRACTICE GUIDELINES; LENGTH OF STAY; CHEST PAIN; CORONARY CARE UNITS; HOSPITALIZATION	CORONARY-CARE-UNIT; ACUTE MYOCARDIAL-INFARCTION; LOW-RISK PATIENTS; EMERGENCY ROOM PATIENTS; PREDICTIVE INSTRUMENT; FUTURE-DIRECTIONS; INTENSIVE-CARE; DECISION AIDS; ADMISSION; MULTICENTER	Objective: The acceptability, safety, and efficacy of practice guidelines have rarely been evaluated. Moreover, despite the recent development of guidelines and decision aids for patients admitted to coronary care and intermediate care units, few have been tested in clinical practice. Design: A prospective, controlled clinical trial with an alternate-month design, Setting. A large teaching community hospital. Patients: Patients admitted to coronary care and intermediate care units with chest pain who were considered at low risk for complications according to a practice guideline (n = 375). Intervention: Physicians caring for patients with chest pain who were at low risk for complications received concurrent, personalized written and verbal reminders regarding a guideline that recommended a 2-day hospital stay. Results: Use of the practice guideline recommendation with concurrent reminders was associated with a 50% to 69% increase in guideline compliance (P < 0.001) and a decrease in length of stay from 3.54 +/- 4.1 to 2.63 +/- 3.0 days (0.91-day reduction, 95% Cl, 0.18 to 1.63; P = 0.02) for all patients with chest pain considered at low risk for complications. The intervention was associated with a total (direct and indirect) cost reduction of $1397 per patient (Cl, $176 to $2618; P = 0.03). No significant difference was found in the hospital complication rate between patients admitted to the hospital during control and intervention periods, and no significant difference was noted in complications, patient health status, or patient satisfaction when measUred 1 month after hospital discharge. Conclusion: These results suggest that implementation of this practice guideline through concurrent reminders reduced hospital costs for patients with chest pain considered at low risk for complications. Further studY of the guideline is warranted.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	WEINGARTEN, SR (corresponding author), CEDARS SINAI MED CTR, DEPT MED, BECKER 146, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.							AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DAY HW, 1963, DIS CHEST, V44, P423, DOI 10.1378/chest.44.4.423; DIVINE GW, 1992, J GEN INTERN MED, V7, P623, DOI 10.1007/BF02599201; EAGLE KA, 1991, NEW ENGL J MED, V324, P1282, DOI 10.1056/NEJM199105023241811; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; Ellrodt A G, 1992, QRB Qual Rev Bull, V18, P456; FALK RH, 1979, POSTGRAD MED J, V55, P870, DOI 10.1136/pgmj.55.650.870; Field MJ, 1990, CLINICAL PRACTICE GU; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FRIEDMAN P, 1991, GB STAT VERSION 3 0; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HACKETT TP, 1968, NEW ENGL J MED, V279, P1365, DOI 10.1056/NEJM196812192792504; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HAYS RD, 1991, MED CARE, V29, P661, DOI 10.1097/00005650-199107000-00006; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LEE TH, 1988, ANN INTERN MED, V108, P887, DOI 10.7326/0003-4819-108-6-887; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOWN, 1968, AM J CARDIOL, V22, P597; LOWN B, 1968, Scientific American, V219, P19; MULLEY AG, 1980, NEW ENGL J MED, V302, P943, DOI 10.1056/NEJM198004243021704; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SCHWARTZ JS, 1982, ANN INTERN MED, V96, P246, DOI 10.7326/0003-4819-96-2-246; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1989, AM J MED, V87, P491; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SYKES DH, 1989, J PSYCHOSOM RES, V33, P477, DOI 10.1016/0022-3999(89)90009-3; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; Weingarten S, 1992, QRB Qual Rev Bull, V18, P449; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; YOUNG MJ, 1987, ARCH INTERN MED, V147, P1219, DOI 10.1001/archinte.147.7.1219; 1990, BMDP STATISTICAL SOF, V1; 1985, SAS USERS GUIDE STAT; 1990, BMDP STATISTICAL SOF, V2; 1992, TRUE EPISTAT SOFTWAR	52	143	146	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					257	263		10.7326/0003-4819-120-4-199402150-00001	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291818				2022-12-28	WOS:A1994MW10300001
J	VONHIPPEL, PH				VONHIPPEL, PH			PROTEIN-DNA RECOGNITION - NEW PERSPECTIVES AND UNDERLYING THEMES	SCIENCE			English	Editorial Material							REPRESSOR-OPERATOR INTERACTION; COLI-LAC REPRESSOR; BINDING-SITES; NUCLEIC-ACIDS; SPECIFICITY; SEQUENCES; DRIVEN		UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	VONHIPPEL, PH (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1993, CURR BIOL, V3, P182, DOI 10.1016/0960-9822(93)90268-S; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P2236; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PTASHNE M, 1967, NATURE, V214, P232, DOI 10.1038/214232a0; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REVZIN A, 1977, BIOCHEMISTRY-US, V16, P4769, DOI 10.1021/bi00641a002; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; von Hippel P. H, 1979, BIOL REGULATION DEV, V1, P279; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; YARUS M, 1969, ANNU REV BIOCHEM, V38, P841, DOI 10.1146/annurev.bi.38.070169.004205	30	130	130	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					769	770		10.1126/science.8303292	http://dx.doi.org/10.1126/science.8303292			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303292				2022-12-28	WOS:A1994MV86600024
J	HOPPER, JL; SEEMAN, E				HOPPER, JL; SEEMAN, E			THE BONE-DENSITY OF FEMALE TWINS DISCORDANT FOR TOBACCO USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; HIP FRACTURE; OSTEOPOROSIS; MASS; AGE; RISK; ESTROGENS; OBESITY	Background. Smoking is recognized as a risk factor for vertebral, forearm, and hip fractures. Since bone density is an important determinant of bone strength, we conducted a study to ascertain whether a deficit in bone density is associated with tobacco use and, if so, to identify the responsible mechanisms. Methods. We conducted a cross-sectional study of bone density at the lumbar spine and the femoral neck and shaft in 41 pairs of female twins (21 monozygotic pairs), 27 to 73 years of age (mean, 49), who were discordant for at least 5 pack-years of smoking (mean, 23; maximum, 64). Bone density was measured by dual-photon absorptiometry. The difference in bone density between the members of a pair was expressed as a percentage of the mean value for the pair. Results. For every 10 pack-years of smoking, the bone density of the twin who smoked more heavily was 2.0 percent lower at the lumbar spine (P = 0.01), 0.9 percent lower at the femoral neck (P = 0.25), and 1.4 percent lower at the femoral shaft (P = 0.04). These results were not confounded by measured lifestyle factors. In the 20 pairs who were discordant by 20 or more pack-years (mean, 35), the (mean +/- SE) within-pair differences in bone density at the three sites were 9.3 +/- 3.1 percent (P = 0.008), 5.8 +/- 2.9 percent (P = 0.06), and 6.5 +/- 3.2 percent (P = 0.05), respectively. Smoking was associated with higher serum concentrations of follicle-stimulating hormone (P = 0.02) and luteinizing hormone (P = 0.03) and lower serum concentrations of parathyroid hormone (P = 0.05). Differences in spinal bone density between members of a pair were associated with differences in the serum concentrations of parathyroid hormone (P = 0.01) and calcium (P = 0.05) and urinary pyridinoline excretion (P = 0.06), a marker of bone resorption. Conclusions. Women who smoke one pack of cigarettes each day throughout adulthood will, by the time of menopause, have an average deficit of 5 to 10 percent in bone density, which is sufficient to increase the risk of fracture.	UNIV MELBOURNE,AUSTIN HOSP,DEPT MED,ENDOCRINE UNIT,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV MELBOURNE,FAC MED,EPIDEMIOL UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne			Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X				BROWN JB, 1976, METHODS HORMONE ANAL, P446; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DELMAS PD, 1983, J CLIN INVEST, V71, P1316, DOI 10.1172/JCI110882; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JARDINE R, 1984, Genetic Epidemiology, V1, P89, DOI 10.1002/gepi.1370010202; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LINDQUIST O, 1979, ACTA MED SCAND, V205, P73; LONGCOPE C, 1988, J CLIN ENDOCR METAB, V67, P379, DOI 10.1210/jcem-67-2-379; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MAZESS RB, 1982, CLIN ORTHOPAEDICS, V165, P239; MCCULLAGH P, 1989, MONOGRAPHS STATISTIC, V37; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MONTGOMERY DC, 1982, INTRO LINEAR REGRESS, P367; NOBBS BT, 1975, CLIN CHIM ACTA, V64, P219, DOI 10.1016/0009-8981(75)90206-5; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIGOTTI NA, 1989, NEW ENGL J MED, V320, P931, DOI 10.1056/NEJM198904063201409; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1989, DHHS CDC898411 DEP H	29	291	302	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					387	392		10.1056/NEJM199402103300603	http://dx.doi.org/10.1056/NEJM199402103300603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284003				2022-12-28	WOS:A1994MV27900003
J	LOWENSTEIN, CJ; DINERMAN, JL; SNYDER, SH				LOWENSTEIN, CJ; DINERMAN, JL; SNYDER, SH			NITRIC-OXIDE - A PHYSIOLOGICAL MESSENGER	ANNALS OF INTERNAL MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; TRANSFORMING GROWTH FACTOR-BETA-1; ENDOTHELIUM-DEPENDENT RELAXATION; CHRONIC GRANULOMATOUS-DISEASE; NEURONAL NADPH DIAPHORASE; FOCAL CEREBRAL-ISCHEMIA; METHYL-L-ARGININE; RELAXING FACTOR; MOLECULAR-CLONING	Purpose: To review the physiologic role of nitric oxide, an unusual messenger molecule that mediates blood vessel relaxation, neurotransmission, and pathogen suppression. Data Sources: A MEDLINE search of articles published from 1987 to 1993 that addressed nitric oxide and the enzyme that synthesizes it, nitric oxide synthase. Study Selection: Animal and human studies were selected from 3044 articles to analyze the clinical importance of nitric oxide. Descriptions of the structure and function of nitric oxide synthase were selected to show how nitric oxide acts as a biological messenger molecule. Data Extraction: Biochemical and physiologic studies were analyzed if the same results were found by three or more independent observers. Data Synthesis: Two major classes of nitric oxide synthase enzymes produce nitric oxide. The constitutive isoforms found in endothelial cells and neurons release small amounts of nitric oxide for brief periods to signal adjacent cells, whereas the inducible isoform found in macrophages releases large amounts of nitric oxide continuously to eliminate bacteria and parasites. By diffusing into adjacent cells and binding to enzymes that contain iron, nitric oxide plays many important physiologic roles. lt regulates blood pressure, transmits signals between neurons, and suppresses pathogens. Excess amounts, however, can damage host cells, causing neurotoxicity during strokes and causing the hypotension associated with sepsis. Conclusions: Nitric oxide is a simple molecule with many physiologic roles in the cardiovascular, neurologic, and immune systems. Although the general principles of nitric oxide synthesis are known, further research is necessary to determine what role it plays in causing disease.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Lowenstein, Charles/0000-0003-0485-7514	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00266] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline; NCHHSTP CDC HHS [PSA K1102451] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCHHSTP CDC HHS		ADAIKAN PG, 1992, JPN J PHARMACOL, V58, pP300; ADAMS LB, 1991, J IMMUNOL, V147, P1642; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; ALSPAUGH JA, 1991, INFECT IMMUN, V59, P2291, DOI 10.1128/IAI.59.7.2291-2296.1991; AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x; BAUMANN JE, 1992, AM J PHYSIOL, V263, pF208, DOI 10.1152/ajprenal.1992.263.2.F208; BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BENYO Z, 1991, CARDIOVASC RES, V25, P700, DOI 10.1093/cvr/25.8.700; BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; BOWEN R, 1991, J CARDIOVASC PHARM, V17, P424, DOI 10.1097/00005344-199103000-00011; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROTEN TP, 1992, AM J PHYSIOL, V262, pH1579, DOI 10.1152/ajpheart.1992.262.5.H1579; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1990, P NATL ACAD SCI USA, V87, P3304, DOI 10.1073/pnas.87.9.3304; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; BUSH PA, 1992, J UROLOGY, V147, P1650, DOI 10.1016/S0022-5347(17)37671-1; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CALVER A, 1992, J HYPERTENS, V10, P1025; CAREY C, 1992, CIRC SHOCK, V38, P209; CASTRO A, 1993, HEPATOLOGY, V18, P367, DOI 10.1016/0270-9139(93)90020-N; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHU A, 1990, AM J PHYSIOL, V258, pH1250; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; CURNUTTE JT, 1974, NEW ENGL J MED, V290, P593, DOI 10.1056/NEJM197403142901104; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DENG AH, 1993, AM J PHYSIOL, V264, pF212, DOI 10.1152/ajprenal.1993.264.2.F212; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; DURANTE W, 1992, BLOOD, V79, P110; ELSNER D, 1991, CARDIOVASC RES, V25, P438; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FARACI FM, 1992, J CEREBR BLOOD F MET, V12, P500, DOI 10.1038/jcbfm.1992.68; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FINEMAN JR, 1991, AM J PHYSIOL, V260, pH1299, DOI 10.1152/ajpheart.1991.260.4.H1299; FLAVAHAN NA, 1993, AM J PHYSIOL, V264, pH722, DOI 10.1152/ajpheart.1993.264.3.H722; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FORSTERMANN U, 1988, CIRC RES, V62, P185, DOI 10.1161/01.RES.62.2.185; FORTIER AH, 1992, INFECT IMMUN, V60, P817, DOI 10.1128/IAI.60.3.817-825.1992; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREEN SJ, 1990, J IMMUNOL, V144, P278; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GRYGLEWSKI RJ, 1989, J CARDIOVASC PHARM, V14, pS124, DOI 10.1097/00005344-198914110-00024; GRYGLEWSKI RJ, 1989, INT J TISSUE REACT, V11, P269; GUSTAFSSON LE, 1990, BIOCHEM BIOPH RES CO, V173, P106, DOI 10.1016/S0006-291X(05)81028-9; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HOTCHKISS RS, 1992, LANCET, V339, P434, DOI 10.1016/0140-6736(92)90127-O; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IKEDA K, 1992, CLIN EXP PHARM PHYSL, V19, P53; IVANOVA K, 1993, EUR J PHARM-MOLEC PH, V244, P37, DOI 10.1016/0922-4106(93)90057-G; IWAMA Y, 1992, HYPERTENSION, V19, P326, DOI 10.1161/01.HYP.19.4.326; IWATA F, 1992, AM J PHYSIOL, V263, pG149, DOI 10.1152/ajpgi.1992.263.2.G149; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JAYAKODY L, 1987, CIRC RES, V60, P251, DOI 10.1161/01.RES.60.2.251; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; JONES LF, 1992, J PHARMACOL EXP THER, V260, P627; JUNQUERO DC, 1992, J PHYSIOL-LONDON, V454, P451, DOI 10.1113/jphysiol.1992.sp019273; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KELM M, 1991, CARDIOVASC RES, V25, P831, DOI 10.1093/cvr/25.10.831; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLABUNDE RE, 1991, EUR J PHARMACOL, V199, P51, DOI 10.1016/0014-2999(91)90636-5; KNISPEL HH, 1992, UROL RES, V20, P253, DOI 10.1007/BF00300254; KOBAYASHI Y, 1991, CLIN EXP PHARMACOL P, V18, P397, DOI 10.1111/j.1440-1681.1991.tb01470.x; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMONTAGNE D, 1992, CIRC RES, V70, P123, DOI 10.1161/01.RES.70.1.123; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LIEW FY, 1990, IMMUNOLOGY, V71, P556; LIN JY, 1992, J IMMUNOL, V148, P3999; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LONG CJ, 1985, BLOOD VESSELS, V22, P205; LORSBACH RB, 1992, INFECT IMMUN, V60, P2133, DOI 10.1128/IAI.60.5.2133-2135.1992; LOT TY, 1993, N-S ARCH PHARMACOL, V347, P115; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; LUSCHER TF, 1992, BRIT J CLIN PHARMACO, V34, pS29, DOI 10.1111/j.1365-2125.1992.tb04146.x; LUSCHER TF, 1990, CLIN EXP HYPERTENS A, V12, P897, DOI 10.3109/10641969009073507; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; MAURICE DH, 1990, MOL PHARMACOL, V37, P671; MAYER J, 1993, INFECT IMMUN, V61, P491, DOI 10.1128/IAI.61.2.491-497.1993; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MENON NK, 1991, P SOC EXP BIOL MED, V196, P461; MENON NK, 1989, P SOC EXP BIOL MED, V191, P316; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NELSON BJ, 1991, J IMMUNOL, V146, P1849; NOLTE C, 1991, J BIOL CHEM, V266, P14808; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCHOA JB, 1992, J NATL CANCER I, V84, P864, DOI 10.1093/jnci/84.11.864; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PASQUI AL, 1991, THROMB RES, V61, P113, DOI 10.1016/0049-3848(91)90238-R; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PIZCUETA P, 1992, GASTROENTEROLOGY, V103, P1909, DOI 10.1016/0016-5085(92)91451-9; POHL U, 1991, AM J PHYSIOL, V261, pH2016, DOI 10.1152/ajpheart.1991.261.6.H2016; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RAIFER J, 1992, NEW ENGL J MED, V326, P90; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; RIBEIRO MO, 1992, HYPERTENSION, V20, P298, DOI 10.1161/01.HYP.20.3.298; RICHARD V, 1991, BRIT J PHARMACOL, V104, P59, DOI 10.1111/j.1476-5381.1991.tb12385.x; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SAFFREY MJ, 1992, NEUROREPORT, V3, P333, DOI 10.1097/00001756-199204000-00011; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SANDERS KM, 1992, JPN J PHARMACOL, V58, pP220; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHROR K, 1991, BASIC RES CARDIOL, V86, P117; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SIEBER CC, 1993, GASTROENTEROLOGY, V104, P1750, DOI 10.1016/0016-5085(93)90655-V; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SINEY L, 1992, EUR J PHARMACOL, V229, P223, DOI 10.1016/0014-2999(92)90559-M; SNEDDON JM, 1988, P NATL ACAD SCI USA, V85, P2800, DOI 10.1073/pnas.85.8.2800; SOGNI P, 1992, HEPATOLOGY, V16, P980, DOI 10.1002/hep.1840160421; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; TODA N, 1990, AM J PHYSIOL, V259, pH1511, DOI 10.1152/ajpheart.1990.259.5.H1511; TOTTRUP A, 1992, GASTROENTEROLOGY, V102, P409, DOI 10.1016/0016-5085(92)90084-C; TRIGOROCHA F, 1993, AM J PHYSIOL, V264, pH419, DOI 10.1152/ajpheart.1993.264.2.H419; UEEDA M, 1992, CIRC RES, V70, P1296, DOI 10.1161/01.RES.70.6.1296; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; VALLANCE P, 1992, LANCET, V339, P572; VALLANCE P, 1992, EUR J CLIN PHARMACOL, V42, P37, DOI 10.1007/BF00314917; VALLANCE P, 1989, LANCET, V2, P997; VARELA AF, 1992, AM J OBSTET GYNECOL, V167, P1599, DOI 10.1016/0002-9378(92)91748-Y; VINCENDEAU P, 1991, J IMMUNOL, V146, P4338; WENNMALM A, 1990, ANAL BIOCHEM, V187, P359, DOI 10.1016/0003-2697(90)90470-T; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YAMAKADO T, 1982, THROMB RES, V26, P135, DOI 10.1016/0049-3848(82)90023-8; YOUNG HM, 1992, HISTOCHEMISTRY, V97, P375, DOI 10.1007/BF00270041; YUKIMURA T, 1992, AM J HYPERTENS, V5, P484, DOI 10.1093/ajh/5.7.484; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZHANG J, 1993, BIOCHEMISTRY-US, V32, P2228, DOI 10.1021/bi00060a014	181	799	862	3	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					227	237		10.7326/0003-4819-120-3-199402010-00009	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273987				2022-12-28	WOS:A1994MU30300009
J	GERMAIN, RN				GERMAIN, RN			MHC-DEPENDENT ANTIGEN-PROCESSING AND PEPTIDE PRESENTATION - PROVIDING LIGANDS FOR T-LYMPHOCYTE ACTIVATION	CELL			English	Review							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MOLECULES; HLA-DR MOLECULES; INVARIANT CHAIN; ENDOPLASMIC-RETICULUM; SELF-PEPTIDES; CELL RECEPTOR; CIS-GOLGI; SPECIFICITY; PROTEINS				GERMAIN, RN (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BETHESDA, MD 20892 USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					ABBAS AK, 1985, J IMMUNOL, V135, P1661; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BONNEROT C, 1994, IN PRESS EMBO J; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; COUNCE S, 1956, ANN SURG, V144, P198, DOI 10.1097/00000658-195608000-00009; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1990, Semin Immunol, V2, P273; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KLINMAN NR, 1972, J EXP MED, V136, P241, DOI 10.1084/jem.136.2.241; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MANCA F, 1988, J IMMUNOL, V140, P2893; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, CURR OPIN IMMUNOL, V4, P70, DOI 10.1016/0952-7915(92)90128-2; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLSON TS, 1991, BIOMED BIOCHIM ACTA, V50, P393; OZAKI S, 1987, J IMMUNOL, V138, P4133; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROJO JM, 1989, COLD SPRING HARB SYM, V2, P657; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SETTE A, 1989, J IMMUNOL, V143, P1265; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585	83	1247	1293	0	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					287	299		10.1016/0092-8674(94)90336-0	http://dx.doi.org/10.1016/0092-8674(94)90336-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293464				2022-12-28	WOS:A1994MU67800012
J	SCHLUPP, I; MARLER, C; RYAN, MJ				SCHLUPP, I; MARLER, C; RYAN, MJ			BENEFIT TO MALE SAILFIN MOLLIES OF MATING WITH HETEROSPECIFIC FEMALES	SCIENCE			English	Article							SEXUAL SELECTION; MATE CHOICE; BODY SIZE; POECILIA; FISH; EVOLUTION; STABILITY; FORMOSA; COPY	Female gynogens reproduce clonally but rely on sperm from heterospecific males to initiate embryogenesis. lt has been assumed that males gain no benefit from such matings; thus, selection should favor males that avoid them. Here it is shown that males gain a benefit by mating with female gynogens in an asexual-sexual complex of fish. The sexual females increase their preference for males whom they observe consorting with female gynogens. Thus, gynogenetic species might persist because selection favors males to be sexually parasitized.	UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin			Marler, Catherine/AAB-6883-2020; Marler, Catherine/D-1285-2011; Schlupp, Ingo/C-3913-2012	Schlupp, Ingo/0000-0002-2460-5667; Marler, Catherine/0000-0002-2783-1029	NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010204] Funding Source: NIH RePORTER; NIMH NIH HHS [F32 MH10204] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AVISE JC, 1991, EVOLUTION, V45, P1530, DOI 10.1111/j.1558-5646.1991.tb02657.x; Balsano J.S., 1989, P277; BALSANO JS, 1981, ENVIRON BIOL FISH, V6, P39, DOI 10.1007/BF00001798; BASOLO A, 1990, ANIM BEHAV, V40, P339; BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; Bell G., 1982, MASTERPIECE NATURE; BISCHOFF RJ, 1985, BEHAV ECOL SOCIOBIOL, V17, P253, DOI 10.1007/BF00300143; CLUTTONBROCK T, 1993, BEHAV ECOL, V4, P191, DOI 10.1093/beheco/4.3.191; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Darwin C., 1959, WHATS NEW, V67, P2; Dawley Robert M., 1989, New York State Museum Bulletin, V466, P1; Dobzhansky T., 1937; DUGATKIN LA, 1992, AM NAT, V139, P1384, DOI 10.1086/285392; GIBSON RM, 1992, TRENDS ECOL EVOL, V7, P229, DOI 10.1016/0169-5347(92)90050-L; GODIN JGJ, 1992, P R SOC LONDON B, V249, P179; GOLDSCHMIDT T, 1993, ANIM BEHAV, V45, P541, DOI 10.1006/anbe.1993.1064; HEDGES SB, 1992, NATURE, V356, P708, DOI 10.1038/356708a0; Hubbs C., 1964, Bulletin of the Texas Memorial Museum, VNo. 8, P1; Hubbs CL, 1932, SCIENCE, V76, P628, DOI 10.1126/science.76.1983.628; KALLMAN KD, 1962, J GENET, V58, P7, DOI 10.1007/BF02986114; KIRKENDALL LR, 1990, EVOLUTION, V44, P698, DOI 10.1111/j.1558-5646.1990.tb05949.x; MAYNARDSMITH J, 1979, EVOLUTION SEX; MCKAY FE, 1971, ECOLOGY, V52, P778, DOI 10.2307/1936025; MCPEEK MA, 1992, BEHAV ECOL, V3, P1, DOI 10.1093/beheco/3.1.1; PRUETTJONES S, 1992, AM NAT, V140, P1000, DOI 10.1086/285452; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; RYAN MJ, 1990, BEHAV ECOL SOCIOBIOL, V26, P231; RYAN MJ, UNPUB; SCHARTL M, 1991, P NATL ACAD SCI USA, V88, P8759, DOI 10.1073/pnas.88.19.8759; SCHLUPP I, 1991, ETHOLOGY, V88, P215, DOI 10.1111/j.1439-0310.1991.tb00276.x; SCHULTZ RJ, 1971, AM ZOOL, V11, P351; SMITH JM, 1992, NATURE, V356, P661, DOI 10.1038/356661a0; SPOLSKY CM, 1992, NATURE, V356, P706, DOI 10.1038/356706a0; STENSETH NC, 1985, EVOLUTION, V39, P294, DOI 10.1111/j.1558-5646.1985.tb05667.x; Turner B.J., 1982, Progress in Clinical and Biological Research, V96, P265; Vrijenhoek R.C., 1989, P386; WADE MJ, 1990, P NATL ACAD SCI USA, V87, P5749, DOI 10.1073/pnas.87.15.5749; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WOODHEAD AD, 1985, J FISH BIOL, V27, P593, DOI 10.1111/j.1095-8649.1985.tb03204.x	40	187	188	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	1994	263	5145					373	374		10.1126/science.8278809	http://dx.doi.org/10.1126/science.8278809			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278809				2022-12-28	WOS:A1994MT03400032
J	SADLER, MA; SHAPIRO, RS				SADLER, MA; SHAPIRO, RS			IMAGES IN CLINICAL MEDICINE - TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SADLER, MA (corresponding author), CUNY MT SINAI SCH MED,NEW YORK,NY 10029, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					182	182						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264741				2022-12-28	WOS:A1994MQ86300006
J	BILDERBACK, DH; HOFFMAN, SA; THIEL, DJ				BILDERBACK, DH; HOFFMAN, SA; THIEL, DJ			NANOMETER SPATIAL-RESOLUTION ACHIEVED IN HARD X-RAY-IMAGING AND LAUE DIFFRACTION EXPERIMENTS	SCIENCE			English	Article							SINGLE-CRYSTAL; OPTICS	Tapered glass capillaries have successfully condensed hard x-ray beams to ultrasmall dimensions providing unprecedented spatial resolution for the characterization of materials. A spatial resolution of 50 nanometers was obtained while imaging a lithographically prepared gold pattern with x-rays in the energy range of 5 to 8 kiloelectron volts. This is the highest resolution scanning x-ray image made to date with hard x-rays. With a beam 360 nanometers in diameter, Laue diffraction was observed from the smallest sample volume ever probed by x-ray diffraction, 5 x 10(-3) cubic micrometers.	CORNELL UNIV,SCH APPL & ENGN PHYS,ITHACA,NY 14853	Cornell University	BILDERBACK, DH (corresponding author), CORNELL UNIV,CORNELL HIGH ENERGY SYNCHROTRON SOURCE,ITHACA,NY 14853, USA.				NCRR NIH HHS [RR01646-10] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON EH, 1992, XRAY MICROSCOPY, V3, P75; ANDREWS SJ, 1987, ACTA CRYSTALLOGR A, V43, P70, DOI 10.1107/S0108767387099872; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BILDERBACK DH, 1981, P SOC PHOTO-OPT INST, V315, P90; BROWN KT, 1986, ADV MICROPIPETTE TEC, pCH6; CARPENTER DA, 1988, MICROBEAM ANAL, P391; Chapman H N, 1990, J Xray Sci Technol, V2, P117, DOI 10.3233/XST-1990-2203; COOKE D, 1990, NATURE, V346, P802, DOI 10.1038/346802a0; ENGSTROM P, 1991, NUCL INSTRUM METH A, V302, P547, DOI 10.1016/0168-9002(91)90373-X; HOFFMAN SA, IN PRESS OPT ENG; KUMAKHOV MA, 1990, PHYS REP, V191, P289, DOI 10.1016/0370-1573(90)90135-O; OHSUMI K, 1991, J APPL CRYSTALLOGR, V24, P340, DOI 10.1107/S0021889891002133; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SKELTON EF, 1991, SCIENCE, V253, P1123, DOI 10.1126/science.253.5024.1123; STERN EA, 1988, APPL OPTICS, V27, P5135, DOI 10.1364/AO.27.005135; THIEL DJ, 1992, NUCL INSTRUM METH A, V317, P597, DOI 10.1016/0168-9002(92)91006-U; TRANQUADA JM, 1989, NATURE, V337, P720, DOI 10.1038/337720a0; YUN WB, 1993, P SOC PHOTO-OPT INS, V1740, P117, DOI 10.1117/12.138694; 1990, LBL28001 UC411 U CAL, P4	19	191	196	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					201	203		10.1126/science.8284671	http://dx.doi.org/10.1126/science.8284671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284671				2022-12-28	WOS:A1994MQ87900025
J	HARRISON, CJ; BOHM, AA; NELSON, HCM				HARRISON, CJ; BOHM, AA; NELSON, HCM			CRYSTAL-STRUCTURE OF THE DNA-BINDING DOMAIN OF THE HEAT-SHOCK TRANSCRIPTION FACTOR	SCIENCE			English	Article							MOLECULAR-CLONING; PROTEIN; GENES; RECOGNITION; EXPRESSION; ANGLE; UNIT	The structure of the DNA binding domain, determined at 1.8 angstrom resolution, contains a three-helix bundle that is capped by a four-stranded antiparallel beta sheet. This structure is a variant of the helix-turn-helix motif, typified by catabolite activator protein. In the heat shock transcription factor, the first helix of the motif (alpha2) has an alpha-helical bulge and a proline-induced kink. The angle between the two helices of the motif (alpha2 and alpha3) is about 20-degrees smaller than the average for canonical helix-turn-helix proteins. Nevertheless, the relative positions of the first and third helices of the bundle (alpha1 and alpha3) are conserved. It is proposed here that the first helix of the three-helix bundle be considered a component of the helix-turn-helix motif.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NIGMS NIH HHS [GM08295, GM44086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295, R01GM044086] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 ONE; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJITA A, 1989, GENE, V85, P321; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HEINZ DW, IN PRESS PROTEIN ENG; HUBL S, UNPUB; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEITING B, 1993, EMBO J, V12, P1797, DOI 10.1002/j.1460-2075.1993.tb05827.x; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PABO CO, 1993, ANNU REV BIOCHEM, V74, P773; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RYE HS, 1993, J BIOL CHEM, V268, P25229; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q	52	222	232	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	1994	263	5144					224	227		10.1126/science.8284672	http://dx.doi.org/10.1126/science.8284672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284672				2022-12-28	WOS:A1994MQ87900034
J	WESTAWAY, D; DEARMOND, SJ; CAYETANOCANLAS, J; GROTH, D; FOSTER, D; YANG, SL; TORCHIA, M; CARLSON, GA; PRUSINER, SB				WESTAWAY, D; DEARMOND, SJ; CAYETANOCANLAS, J; GROTH, D; FOSTER, D; YANG, SL; TORCHIA, M; CARLSON, GA; PRUSINER, SB			DEGENERATION OF SKELETAL-MUSCLE, PERIPHERAL-NERVES, AND THE CENTRAL-NERVOUS-SYSTEM IN TRANSGENIC MICE OVEREXPRESSING WILD-TYPE PRION PROTEINS	CELL			English	Article							RECEPTOR-INDUCING ACTIVITY; CREUTZFELDT-JAKOB DISEASE; ACETYLCHOLINE-RECEPTOR; SCRAPIE; GENE; BRAIN; EXPRESSION; SUBUNIT; ACID	Prion diseases of humans and animals are known to be caused by infection with prions containing PrP(Sc) or mutation of the prion protein (PrP) gene. During transgenetic studies, we discovered that uninoculated older mice harboring high copy numbers of wild-type (wt) PrP transgenes derived from Syrian hamsters (SHa), sheep (She), and PrP-B mice developed truncal ataxia, hindlimb paralysis, and tremors. These transgenic (Tg) mice exhibited a profound necrotizing myopathy involving skeletal muscle, a demyelinating polyneuropathy, and focal vacuolation of the central nervous system. Development of disease was dependent on transgene dosage. For example, half of all Tg(SHaPrP+/+)7 mice homozygous for the SHaPrP transgene array developed disease by approximately 460 days of age, while no hemizygous Tg(SHaPrP+/0)7 mice became ill before 650 days. The novel neurologic syndrome found in older Tg(wtPrP) mice implies that overexpression of wtPrP(C) is pathogenic and widens the spectrum of prion diseases.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; MCLAUGHLIN RES INST,GREAT FALLS,MT 59405	University of California System; University of California San Francisco; University of California System; University of California San Francisco; McLaughlin Research Institute for Biomedical Sciences, Inc.	WESTAWAY, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.							BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BEER J, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P473; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOSANQUET FD, 1956, LANCET, V2, P737; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1993, GENETICS, V133, P979; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DAVIS RL, 1991, TXB NEUROPATHOLOGY, P486; DEARMOND SJ, 1992, PROG BRAIN RES, V94, P437; DUBOVITZ V, 1985, MUSCLE BIOPSY PRACTI, P14; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FOROLONI G, 1993, NATURE, V362, P543; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; HARRIS DA, 1988, P NATL ACAD SCI USA, V85, P1983, DOI 10.1073/pnas.85.6.1983; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HULLAND T. J., 1958, JOUR COMP PATHOL AND THERAP, V68, P264, DOI 10.1016/S0368-1742(58)80027-2; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KUNCL RW, 1989, ACTA NEUROPATHOL, V78, P615, DOI 10.1007/BF00691288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANSON J, 1992, DEVELOPMENT, V115, P117; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; NEUFELD MY, 1992, MUSCLE NERVE, V15, P1234, DOI 10.1002/mus.880151103; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12278; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; ROSENTHAL NP, 1976, ARCH NEUROL-CHICAGO, V33, P252, DOI 10.1001/archneur.1976.00500040036005; ROY S, 1992, CAN J NEUROL SCI, V19, P453, DOI 10.1017/S0317167100041639; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SPARKES RS, 1986, P NATL ACAD SCI USA, V83, P7358, DOI 10.1073/pnas.83.19.7358; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; VIRELIZIER JL, 1975, INFECT IMMUN, V12, P1127, DOI 10.1128/IAI.12.5.1127-1140.1975; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1989, TRENDS NEUROSCI, V12, P221, DOI 10.1016/0166-2236(89)90126-4; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	50	309	325	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					117	129		10.1016/0092-8674(94)90177-5	http://dx.doi.org/10.1016/0092-8674(94)90177-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287472				2022-12-28	WOS:A1994MR49500011
J	ALTMAN, R; CARRERAS, L; DIAZ, R; FIGUEROA, E; PAOLASSO, E; PARODI, JC; CADE, JF; DONNAN, G; EADIE, MJ; GAVAGHAN, TP; OSULLIVAN, EF; PARKIN, D; RENNY, JTG; SILAGY, C; VINAZZER, H; ZEKERT, F; ADRIAENSEN, H; BERTRANDHARDY, JM; BRAN, M; DAVID, JL; DRICOT, J; LAVENNEPARDONGE, E; LIMET, R; LOWENTHAL, A; MORIAU, M; SCHAPIRA, S; SMETS, P; SYMOENS, J; VERHAEGHE, R; VERSTRAETE, M; ATALLAH, A; BARNETT, H; BATISTA, R; BLAKELY, J; CAIRNS, JA; COTE, R; CROUCH, J; EVANS, G; FINDLAY, JM; GENT, M; LANGLOIS, Y; LECLERC, J; NORRIS, J; PINEO, GF; POWERS, PJ; ROBERTS, R; SCHWARTZ, L; SICURELLA, J; TAYLOR, W; THEROUX, P; TURPIE, AG; WEISEL, RD; CUI, J; LIU, L; PIRK, J; BAY, C; BOYSEN, G; KNUDSEN, JB; PETERSEN, P; SORENSEN, PS; TONNESEN, HK; HARJOLA, PT; ARCAN, JC; BALKAU, B; BLANCHARD, J; BOISSEL, JP; BONEU, B; BOUSSER, MG; BROCHIER, M; CLOAREC, M; CRIBIER, G; DECHAVANNE, M; DROUIN, P; ESCHWEGE, E; GUIRAUDCHAUMEIL, B; HUGONOT, R; LEIZOROVICZ, A; LORIA, Y; MICHAT, L; MIROUZE, J; PANAK, E; PASTEYER, J; RASCOL, A; REVOL, L; ROY, M; SELLES, J; SLAMA, G; STARKMAN, C; TEULE, M; THIBULT, N; VERRY, M; ALBERT, FW; ANDRASSY, K; BREDDIN, K; ECKEL, R; ENCKE, A; FROHLICH, J; HARTUNG, B; HEISS, HW; HESS, H; HOFLING, B; KRAUSE, D; LATTA, G; LINKE, H; LOEW, D; LORENZ, R; MIDDLETON, K; NOVAK, G; OLDENDORF, M; PFLUGER, N; RAITHEL, D; REUTER, R; SCHETTLER, G; SCHNITKER, J; SCHOOP, W; STIEGLER, H; UBERLA, K; VOGEL, G; WEBER, M; WELBERS, I; ZEITLER, E; ARAPAKIS, G; CHAN, T; MOK, CK; SZABO, R; MISRA, NP; REDDY, K; FITZGERALD, GA; APOLLONIO, A; BALSANO, F; BASELLINI, A; CANDELISE, L; CATALANO, M; CIAVARELLA, N; CIUFFETTI, G; COCCHERI, S; CORTELLARO, M; CORVI, G; COTO, V; DAVI, G; DECATERINA, R; DIPERRI, T; FIESCHI, C; GENTILE, R; GREGORATTI, L; GRESELE, P; LAVEZZARI, M; LIBRETTI, A; MAGNANI, B; NENCI, G; PAGANO, G; PATRONO, C; PEDRINI, L; PINI, M; PRANDONI, P; ROMEO, F; ROVELLI, F; RUDELLI, G; RUVOLO, G; SIGNORINI, GP; TOGNONI, G; VIOLI, F; FUJIMORI, T; KAGEYAMA, M; KATSUMURA, T; KITAMURA, S; MAEDA, K; SUZUKI, A; TOHGI, H; UCHIYAMA, S; UTSUMI, H; GARCIA, AM; ALGRA, A; DENOTTOLANDER, GJH; KUPPER, AJF; VANGIJN, J; HART, H; KAPPELLE, LJ; KOUDSTAAL, PJ; LEMMENS, T; LODDER, J; PANNEBAKKER, M; SERRUYS, PW; VANDENBELT, A; VANDERMEER, J; VANDERVIJGH, AB; VERHEUGT, FWA; VETH, G; DALE, J; JOHANNESSEN, KA; THAULOW, E; POPESCU, P; TIBERIU, N; AZNAR, JRD; ESMATJES, E; GUITERAS, P; LASIERRA, J; LOPEZTRIGO, P; ORIOL, A; POMAR, L; ROCHA, E; SANCHEZ, FD; SANCHORIEGER, J; SANZ, G; BERGLUND, ULF; BLOMSTRAND, C; BOBERG, M; BRITTON, M; ELWIN, CE; HELMERS, C; HOLM, J; JANZON, L; JUULMOLLER, S; MULEC, H; OLSSON, JE; PERSSON, S; RASMANIS, G; ROSEN, A; SAMUELSSON, K; SOREFF, J; WAHLGREN, N; WALLENTIN, L; BAUR, HR; BOKSLAG, M; BOLLINGER, A; MEIER, B; PFISTERER, M; PFLUGER, N; SITTHIAMORN, C; ACHESON, EJ; APPLEBY, P; ASSCHER, AW; AUKLAND, A; BAIGENT, C; BALA, S; BARNETT, AH; BELL, P; BEWS, S; BORN, GVR; BRANAGAN, JP; BROOKS, N; BROWN, MJ; BROWSE, NL; CAPILDEO, R; CARMALT, M; CARTER, AE; CHALMERS, I; CLARKE, M; CLARKE, RJ; CLYNE, CAC; COLLINS, R; COOKE, ED; COUTTS, G; COVE, DH; CROWTHER, PS; CUTHBERTSON, WF; DEBONO, D; DICKERSON, C; DICKINSON, JP; DOLL, R; DORMANDY, JA; DUNBABIN, D; ELL, S; ELPHINSTONE, P; ELWOOD, P; ENGLISHBY, V; FARRELL, B; FISKERSTRAND, C; FLATHER, M; FOLEY, T; FOULDS, T; FOX, KM; FRANKS, P; FRASER, H; GARDECKI, T; GAWEL, M; GENT, AE; GERSHLICK, AH; GODWIN, J; GOLDMAN, M; GRAY, C; GRAY, D; GRAY, R; HANDOLL, H; HANKEY, G; HARRISON, MJG; HENDERSON, N; HEPTINSTALL, S; HOBBIGER, SF; JONES, EW; JONES, NAG; JOST, S; JULIAN, D; KELLETT, J; KESTER, RC; LOWE, G; MACKENZIE, J; MCCOLLUM, CN; MEAD, G; MEADE, TW; MENDELOW, D; MILLER, JC; MORRIS, GK; NICHOL, C; NOBLE, M; OBRIEN, JR; OGIER, M; PARISH, S; PARRY, MJ; PETO, R; POWELL, J; POZZILLI, P; QIZILBASH, N; RAHMAN, A; RAJAH, SM; RICHARDS, DH; RICHARDS, S; RIPLEY, R; ROBERTS, VC; ROSE, FC; RUSSELL, RWR; RUBIN, PC; RUCKLEY, CV; SANDERCOCK, P; SHAW, MDM; SHAW, KM; SHELLEY, JH; SLATTERY, J; SLEIGHT, P; SMITH, SJ; STEWARTLONG, P; SWEETNAM, PM; TANSEY, MJB; TINDALL, H; TURNEY, J; TYLER, HM; VAREY, NC; VESSEY, MP; WALKER, MG; WALKER, MA; WARLOW, CP; WILCOX, RG; WILLEMS, H; WOOD, EH; WYNJONES, E; ADAMS, HP; BARTON, B; BEDFORD, RF; BICK, BL; BINGHAM, S; BROWN, BG; BRYANT, T; BURING, J; CABOT, CF; CANNER, P; CHESEBRO, J; CHRISMAN, OD; CLAGETT, GP; COLWELL, JA; DYKEN, M; ELLIS, D; FIELDS, WS; FURBERG, C; FUSTER, V; GOLDMAN, S; GRANETT, J; GREEN, RM; GREEN, D; HARDY, R; HARKER, LA; HARRIS, WH; HART, RG; HASS, WK; HENNEKENS, C; HILL, D; HUME, M; IGLOE, MC; JOHNSON, G; JONAS, S; KNATTERUD, G; KOHLER, TR; LEMBO, NJ; LEWIS, D; LOCKHART, E; MAJERUS, P; MCENANY, MT; MCKENNA, R; MEHTA, JL; MEYER, JS; MOLONY, B; MORITZ, T; NICOLOFF, DM; NYCZ, G; ONO, H; PANTELY, GA; PHILLIPS, SJ; RIDKER, P; ROBERTSON, JT; ROTHBART, R; SALZMAN, EW; SAUTTER, RD; SCHLANT, RC; SCHOENBERGER, JA; SENGEKONTACKET, MV; SHARMA, G; STEELE, P; STEINNAGEL, KP; STRATTON, J; SULLIVAN, JM; TIMMIS, G; TOOLE, JF; WALKER, MD; WEISMAN, S; WHITE, CW; WIRECKI, M; WOMBOLT, D; WONG, R; YUSUF, S; ZADINA, K; ZUCKER, D				ALTMAN, R; CARRERAS, L; DIAZ, R; FIGUEROA, E; PAOLASSO, E; PARODI, JC; CADE, JF; DONNAN, G; EADIE, MJ; GAVAGHAN, TP; OSULLIVAN, EF; PARKIN, D; RENNY, JTG; SILAGY, C; VINAZZER, H; ZEKERT, F; ADRIAENSEN, H; BERTRANDHARDY, JM; BRAN, M; DAVID, JL; DRICOT, J; LAVENNEPARDONGE, E; LIMET, R; LOWENTHAL, A; MORIAU, M; SCHAPIRA, S; SMETS, P; SYMOENS, J; VERHAEGHE, R; VERSTRAETE, M; ATALLAH, A; BARNETT, H; BATISTA, R; BLAKELY, J; CAIRNS, JA; COTE, R; CROUCH, J; EVANS, G; FINDLAY, JM; GENT, M; LANGLOIS, Y; LECLERC, J; NORRIS, J; PINEO, GF; POWERS, PJ; ROBERTS, R; SCHWARTZ, L; SICURELLA, J; TAYLOR, W; THEROUX, P; TURPIE, AG; WEISEL, RD; CUI, J; LIU, L; PIRK, J; BAY, C; BOYSEN, G; KNUDSEN, JB; PETERSEN, P; SORENSEN, PS; TONNESEN, HK; HARJOLA, PT; ARCAN, JC; BALKAU, B; BLANCHARD, J; BOISSEL, JP; BONEU, B; BOUSSER, MG; BROCHIER, M; CLOAREC, M; CRIBIER, G; DECHAVANNE, M; DROUIN, P; ESCHWEGE, E; GUIRAUDCHAUMEIL, B; HUGONOT, R; LEIZOROVICZ, A; LORIA, Y; MICHAT, L; MIROUZE, J; PANAK, E; PASTEYER, J; RASCOL, A; REVOL, L; ROY, M; SELLES, J; SLAMA, G; STARKMAN, C; TEULE, M; THIBULT, N; VERRY, M; ALBERT, FW; ANDRASSY, K; BREDDIN, K; ECKEL, R; ENCKE, A; FROHLICH, J; HARTUNG, B; HEISS, HW; HESS, H; HOFLING, B; KRAUSE, D; LATTA, G; LINKE, H; LOEW, D; LORENZ, R; MIDDLETON, K; NOVAK, G; OLDENDORF, M; PFLUGER, N; RAITHEL, D; REUTER, R; SCHETTLER, G; SCHNITKER, J; SCHOOP, W; STIEGLER, H; UBERLA, K; VOGEL, G; WEBER, M; WELBERS, I; ZEITLER, E; ARAPAKIS, G; CHAN, T; MOK, CK; SZABO, R; MISRA, NP; REDDY, K; FITZGERALD, GA; APOLLONIO, A; BALSANO, F; BASELLINI, A; CANDELISE, L; CATALANO, M; CIAVARELLA, N; CIUFFETTI, G; COCCHERI, S; CORTELLARO, M; CORVI, G; COTO, V; DAVI, G; DECATERINA, R; DIPERRI, T; FIESCHI, C; GENTILE, R; GREGORATTI, L; GRESELE, P; LAVEZZARI, M; LIBRETTI, A; MAGNANI, B; NENCI, G; PAGANO, G; PATRONO, C; PEDRINI, L; PINI, M; PRANDONI, P; ROMEO, F; ROVELLI, F; RUDELLI, G; RUVOLO, G; SIGNORINI, GP; TOGNONI, G; VIOLI, F; FUJIMORI, T; KAGEYAMA, M; KATSUMURA, T; KITAMURA, S; MAEDA, K; SUZUKI, A; TOHGI, H; UCHIYAMA, S; UTSUMI, H; GARCIA, AM; ALGRA, A; DENOTTOLANDER, GJH; KUPPER, AJF; VANGIJN, J; HART, H; KAPPELLE, LJ; KOUDSTAAL, PJ; LEMMENS, T; LODDER, J; PANNEBAKKER, M; SERRUYS, PW; VANDENBELT, A; VANDERMEER, J; VANDERVIJGH, AB; VERHEUGT, FWA; VETH, G; DALE, J; JOHANNESSEN, KA; THAULOW, E; POPESCU, P; TIBERIU, N; AZNAR, JRD; ESMATJES, E; GUITERAS, P; LASIERRA, J; LOPEZTRIGO, P; ORIOL, A; POMAR, L; ROCHA, E; SANCHEZ, FD; SANCHORIEGER, J; SANZ, G; BERGLUND, ULF; BLOMSTRAND, C; BOBERG, M; BRITTON, M; ELWIN, CE; HELMERS, C; HOLM, J; JANZON, L; JUULMOLLER, S; MULEC, H; OLSSON, JE; PERSSON, S; RASMANIS, G; ROSEN, A; SAMUELSSON, K; SOREFF, J; WAHLGREN, N; WALLENTIN, L; BAUR, HR; BOKSLAG, M; BOLLINGER, A; MEIER, B; PFISTERER, M; PFLUGER, N; SITTHIAMORN, C; ACHESON, EJ; APPLEBY, P; ASSCHER, AW; AUKLAND, A; BAIGENT, C; BALA, S; BARNETT, AH; BELL, P; BEWS, S; BORN, GVR; BRANAGAN, JP; BROOKS, N; BROWN, MJ; BROWSE, NL; CAPILDEO, R; CARMALT, M; CARTER, AE; CHALMERS, I; CLARKE, M; CLARKE, RJ; CLYNE, CAC; COLLINS, R; COOKE, ED; COUTTS, G; COVE, DH; CROWTHER, PS; CUTHBERTSON, WF; DEBONO, D; DICKERSON, C; DICKINSON, JP; DOLL, R; DORMANDY, JA; DUNBABIN, D; ELL, S; ELPHINSTONE, P; ELWOOD, P; ENGLISHBY, V; FARRELL, B; FISKERSTRAND, C; FLATHER, M; FOLEY, T; FOULDS, T; FOX, KM; FRANKS, P; FRASER, H; GARDECKI, T; GAWEL, M; GENT, AE; GERSHLICK, AH; GODWIN, J; GOLDMAN, M; GRAY, C; GRAY, D; GRAY, R; HANDOLL, H; HANKEY, G; HARRISON, MJG; HENDERSON, N; HEPTINSTALL, S; HOBBIGER, SF; JONES, EW; JONES, NAG; JOST, S; JULIAN, D; KELLETT, J; KESTER, RC; LOWE, G; MACKENZIE, J; MCCOLLUM, CN; MEAD, G; MEADE, TW; MENDELOW, D; MILLER, JC; MORRIS, GK; NICHOL, C; NOBLE, M; OBRIEN, JR; OGIER, M; PARISH, S; PARRY, MJ; PETO, R; POWELL, J; POZZILLI, P; QIZILBASH, N; RAHMAN, A; RAJAH, SM; RICHARDS, DH; RICHARDS, S; RIPLEY, R; ROBERTS, VC; ROSE, FC; RUSSELL, RWR; RUBIN, PC; RUCKLEY, CV; SANDERCOCK, P; SHAW, MDM; SHAW, KM; SHELLEY, JH; SLATTERY, J; SLEIGHT, P; SMITH, SJ; STEWARTLONG, P; SWEETNAM, PM; TANSEY, MJB; TINDALL, H; TURNEY, J; TYLER, HM; VAREY, NC; VESSEY, MP; WALKER, MG; WALKER, MA; WARLOW, CP; WILCOX, RG; WILLEMS, H; WOOD, EH; WYNJONES, E; ADAMS, HP; BARTON, B; BEDFORD, RF; BICK, BL; BINGHAM, S; BROWN, BG; BRYANT, T; BURING, J; CABOT, CF; CANNER, P; CHESEBRO, J; CHRISMAN, OD; CLAGETT, GP; COLWELL, JA; DYKEN, M; ELLIS, D; FIELDS, WS; FURBERG, C; FUSTER, V; GOLDMAN, S; GRANETT, J; GREEN, RM; GREEN, D; HARDY, R; HARKER, LA; HARRIS, WH; HART, RG; HASS, WK; HENNEKENS, C; HILL, D; HUME, M; IGLOE, MC; JOHNSON, G; JONAS, S; KNATTERUD, G; KOHLER, TR; LEMBO, NJ; LEWIS, D; LOCKHART, E; MAJERUS, P; MCENANY, MT; MCKENNA, R; MEHTA, JL; MEYER, JS; MOLONY, B; MORITZ, T; NICOLOFF, DM; NYCZ, G; ONO, H; PANTELY, GA; PHILLIPS, SJ; RIDKER, P; ROBERTSON, JT; ROTHBART, R; SALZMAN, EW; SAUTTER, RD; SCHLANT, RC; SCHOENBERGER, JA; SENGEKONTACKET, MV; SHARMA, G; STEELE, P; STEINNAGEL, KP; STRATTON, J; SULLIVAN, JM; TIMMIS, G; TOOLE, JF; WALKER, MD; WEISMAN, S; WHITE, CW; WIRECKI, M; WOMBOLT, D; WONG, R; YUSUF, S; ZADINA, K; ZUCKER, D			COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-DOSE ASPIRIN; CORONARY-ARTERY BYPASS; TRANSIENT ISCHEMIC ATTACKS; PLACEBO-CONTROLLED TRIAL; VEIN-GRAFT PATENCY; STABLE ANGINA-PECTORIS; DOUBLE-BLIND TRIAL; THROMBOXANE SYNTHETASE INHIBITION; ARTERIOVENOUS-SHUNT THROMBOSIS; CANADIAN AMERICAN TICLOPIDINE	Objective-To determine the effects of ''prolonged'' antiplatelet therapy (that is, given for one month or more) on ''vascular events'' (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) in various categories of patients. Design-Overviews of 145 randomised trials of ''prolonged'' antiplatelet therapy versus control and 29 randomised comparisons between such antiplatelet regimens. Setting-Randomised trials that could have been available by March 1990. Subjects-Trials of antiplatelet therapy versus control included about 70 000 ''high risk'' patients (that is, with some vascular disease or other condition implying an increased risk of occlusive vascular disease) and 30 000 ''low risk'' subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10 000 high risk patients. Results-In each of four main high risk categories of patients antiplatelet therapy was definitely protective. The percentages of patients suffering a vascular event among those allocated antiplatelet therapy versus appropriately adjusted control percentages (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 20 000 patients with acute myocardial infarction, 10% antiplatelet therapy v 14% control (one month benefit about 40 vascular events avoided per 1000 patients treated (2P<0.00001)); (b) among about 20000 patients with a past history of myocardial infarction, 13% antiplatelet therapy v 17% control (two year benefit about 40/1000 (2P<0.00001)); (c) among about 10000 patients with a past history of stroke or transient ischaemic attack, 18% antiplatelet therapy v 22% control (three year benefit about 40/1000 (2P<0.00001)); (d) among about 20000 patients with some other relevant medical history (unstable angina, stable angina, vascular surgery, angioplasty, atrial fibrillation, valvular disease, peripheral vascular disease, etc), 9% v 14% in 4000 patients with unstable angina (six month benefit about 5011000 (2P<0.00001)) and 6% v 8% in 16000 other high risk patients (one year benefit about 20/1000 (2P < 0.00001)). Reductions in vascular events were about one quarter in each of these four main categories and were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and nondiabetic patients. Taking all high risk patients together showed reductions of about one third in non-fatal myocardial infarction, about one third in non-fatal stroke, and about one sixth in vascular death (each 2P<0.00001). There was no evidence that non-vascular deaths were increased, so in each of the four main high risk categories overall mortality was significantly reduced. The most widely tested antiplatelet regimen was ''medium dose'' (75-325 mg/day) aspirin. Doses throughout this range seemed similarly effective (although in an acute emergency it might be prudent to use an initial dose of 160-325 mg rather than about 75 mg). There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events. The optimal duration of treatment for patients with a past history of myocardial infarction, stroke, or transient ischaemic attack could not be determined directly because most trials lasted only one, two, or three years (average about two years). Nevertheless, there was significant (2P<0.0001) further benefit between the end of year 1 and the end of year 3, suggesting that longer treatment might well be more effective. Among low risk recipients of ''primary prevention'' a significant reduction of one third in non-fatal myocardial infarction was, however, accompanied by a non-significant increase in stroke. Furthermore, the absolute reduction in vascular events was much smaller than for high risk patients despite a much longer treatment period (4.4% antiplatelet therapy v 4.8% control; five year benefit only about four per 1000 patients treated) and was not significant (2P=0.09). Conclusions-Among a much wider range of patients at high risk of occlusive vascular disease than is currently treated routinely, some years of antiplatelet therapy-with aspirin 75-325 mg/day or some other antiplatelet regimen (provided there are no contraindications)-offers worthwhile protection against myocardial infarction, stroke, and death. Significant benefit is evident not only among patients with unstable angina, suspected acute myocardial infarction, or a past history of myocardial infarction, stroke, or transient ischaemic attack, but also among many other categories of high risk patients (such as those having vascular procedures and those with stable angina or peripheral vascular disease). There is as yet, however, no clear evidence on the balance of risks and benefits of antiplatelet therapy in primary prevention among low risk subjects.					Verheugt, F.W.A./H-8105-2014; Johannessen, Karl Arne Arne/AAW-9889-2021; Atallah, Álvaro N/K-7182-2013; Hankey, Graeme J/H-4968-2014; Johannessen, Karl-Arne/AAU-5528-2021; Mehta, jl/AAB-8832-2019; DONNAN, GEOFFREY A/A-9947-2008; Gresele, Paolo/F-6775-2013; sandercock, peter/GQI-3167-2022; Cairns, John/AAI-8744-2021; van Gijn, Jan/A-9444-2008; gresele, paolo/AAG-8019-2019; FitzGerald, Garret A/A-4222-2010; Fuster, Valentin/H-4319-2015; Mehta, JL/AAG-7572-2020	Johannessen, Karl Arne Arne/0000-0003-2679-0007; Hankey, Graeme J/0000-0002-6044-7328; Mehta, jl/0000-0003-0384-2097; Gresele, Paolo/0000-0001-5365-8445; sandercock, peter/0000-0001-8484-0135; Fuster, Valentin/0000-0002-9043-9986; 				ACHESON J, 1972, ATHEROSCLEROSIS, V15, P123, DOI 10.1016/0021-9150(72)90045-7; ACHESON J, 1969, BMJ-BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5644.614; Adriaensen H, 1976, Curr Med Res Opin, V4, P395, DOI 10.1185/03007997609111994; AGNEW TM, 1992, AUST NZ J MED, V22, P665, DOI 10.1111/j.1445-5994.1992.tb04868.x; Albert FW, 1978, KRANKENHAUSARZT, V51, P712; ALEXANDER RW, 001684 SAN INT REP; ALHO A, 1984, ANN CHIR GYNAECOL FE, V73, P225; ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; ANDRASSY K, 1974, KLIN WOCHENSCHR, V52, P348, DOI 10.1007/BF01468835; [Anonymous], 1987, Lancet, V2, P1351; [Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1990, Stroke, V21, P1122; [Anonymous], 1985, Stroke, V16, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P316; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1982, Lancet, V1, P237; [Anonymous], 1980, CIRCULATION, V62, P449; [Anonymous], 1988, NEW ENGL J MED; AOKI T, 1984, 0016126 SAN INT REP; AOSAKI M, 0016240 SAN INT REP; APOLLONIO A, 1989, J INT MED RES, V17, P28, DOI 10.1177/030006058901700104; ARCAN JC, 1988, ANGIOLOGY, V39, P802, DOI 10.1177/000331978803900904; AUKLAND A, 1982, J CLIN PATHOL, V35, P740, DOI 10.1136/jcp.35.7.740; AZAR JRD, 1982, HAEMOSTASIS, V12, P69; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BALSANO F, 1993, CIRCULATION, V87, P1563, DOI 10.1161/01.CIR.87.5.1563; BALSANO F, 1989, J LAB CLIN MED, V114, P84; BALSANO F, 1989, PLATELETS, V41, P164; BARNETT AH, 1984, LANCET, V1, P1322; BAUDOIN C, 1989, DIABETES, V38, P491; BAUMGARTNER I, 1992, VASA-J VASCULAR DIS, V21, P387; BAUR HR, 1982, AM J CARDIOL, V49, P420, DOI 10.1016/0002-9149(82)90519-7; BECKER MC, 1967, J NEWARK BETH ISRAEL, V18, P88; BEDFORD RF, 1979, ANESTHESIOLOGY, V51, P176, DOI 10.1097/00000542-197908000-00022; BELCARO G, 1993, ANGIOLOGY, V44, P328, DOI 10.1177/000331979304400410; BERGLUND U, 1991, EUR HEART J, V12, P428, DOI 10.1093/oxfordjournals.eurheartj.a059912; BERGLUND U, 1985, THROMB HAEMOSTASIS, V54, P808; BERGLUND U, 1987, EUR HEART J, V8, P25, DOI 10.1093/oxfordjournals.eurheartj.a062155; BERTRAND ME, 1990, CIRCULATION, V82, P190; BICK RL, 1981, THROMB HAEMOSTASIS, V46, P91; BILLER J, 1989, STROKE, V20, P441, DOI 10.1161/01.STR.20.4.441; BLAKELY JA, 1977, THROMB HAEMOSTASIS, V38, P238; BLAKELY JA, 1975, PLATELETS DRUGS THRO, P284; BLAKELY JA, 1979, 7 P INT C THROMB HAE, P161; BLANCHARD JF, 1992, NOUV REV FR HEMATOL, V34, P149; BOEHME K, 1977, MED WELT, V28, P1163; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BOLLINGER A, 1985, VASA-J VASCULAR DIS, V14, P272; BOURDE C, 1981, THROMB HAEMOSTASIS, V46, P91; BOURDE C, 1982, JMM, V4, P31; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOUSSER MG, 1983, PRESSE MED, V12, P3049; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; BRAN M, 1980, Revue Medicale de Bruxelles, V1, P71; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; BREDDIN K, 1980, CIRCULATION, V62, P63; BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951; BROMMER EJP, 1981, J INT MED RES, V9, P203, DOI 10.1177/030006058100900310; BROOKS N, 1985, BRIT HEART J, V53, P201; BROWN BG, 1985, CIRCULATION, V72, P138, DOI 10.1161/01.CIR.72.1.138; BROWN BG, 1983, CIRCULATION, V68, P398; BROWSE NL, 1969, LANCET, V2, P718; BUREN A, 1981, STROKE, V12, P578, DOI 10.1161/01.STR.12.5.578; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BUTTERMANN G, 1977, MED KLIN, V72, P1624; CADE JF, 1982, CIRCULATION, V66, P29, DOI 10.1161/01.CIR.66.1.29; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CANDELISE L, 1982, STROKE, V13, P175, DOI 10.1161/01.STR.13.2.175; CASEB JF, 1971, DIA MED, V43, P1023; CASTELLI P, 1986, INT SURG, V71, P252; Cavin R, 1977, Rev Med Suisse Romande, V97, P531; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; CHESEBRO JH, 1986, INT J CLIN PHARM RES, V6, P261; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; Chesebro JH, 1989, CIRCULATION S2, V80, pII; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; CHEVIGNE M, 1984, ANN THORAC SURG, V37, P370, DOI 10.1016/S0003-4975(10)60757-6; CIAVARELLA N, 1985, Cardiologia (Rome), V30, P301; CIUFFETTI G, 1990, ANGIOLOGY, V41, P505, DOI 10.1177/000331979004100701; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; CLOAREC M, 1986, THROMB RES, P160; CLYNE CAC, 1987, BRIT J SURG, V74, P246, DOI 10.1002/bjs.1800740406; COLDEBEYS C, 1981, THROMB HAEMOSTASIS, V46, P550; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1987, EUR HEART J, V8, P634; COLLINS R, 1992, OXFORD DATABASE PERI; COLWELL JA, 1986, DIABETES CARE, V9, P140, DOI 10.2337/diacare.9.2.140; COLWELL JA, 1984, CONTROL CLIN TRIALS, V5, P165, DOI 10.1016/0197-2456(84)90122-3; COMBERG HU, 1983, VASA-J VASCULAR DIS, V12, P172; COSPITE M, 1987, J INT MED RES, V15, P303, DOI 10.1177/030006058701500506; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; DAVIS JW, 1978, CLIN PHARMACOL THER, V23, P505; DAVIS P, 1990, INT C S SERIES, V168, P103; De Martiis M, 1986, Clin Ter, V116, P367; DECATERINA R, 1985, THROMB HAEMOSTASIS, V54, P528; DEHEN H, 1984, PRESSE MED, V13, P87; DENOTTOLANDER GJH, 1972, 3RD C INT SOC THROMB, P414; DESTORS JM, 1985, THERAPIE, V40, P451; DEWAR H A, 1961, Scott Med J, V6, P149; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DODD NJ, 1980, 6 P INT C MED LEAG T; DONALDSON DR, 1985, VASCULAR SURG, V19, P224, DOI 10.1177/153857448501900405; DROUIN P, 1980, P WORLD C ANGIOLOGY, P263; DYKEN ML, 1992, STROKE, V23, P1395, DOI 10.1161/01.STR.23.10.1395; EFRON B, 1977, SCI AM, V236, P119, DOI 10.1038/scientificamerican0577-119; EHRESMANN U, 1977, MED WELT, V28, P1157; EKESTROM SA, 1990, SCAND J THORAC CARD, V24, P191, DOI 10.3109/14017439009098068; ELL S, 1982, HAEMOSTASIS, V12, P180; ELLIS DJ, 1986, 32ND P INT COMM THRO, V63, P60; ELWOOD P, 1981, BRIT MED J, V282, P481, DOI 10.1136/bmj.282.6262.481; Elwood P C, 1979, J R Coll Gen Pract, V29, P413; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; ELWOOD PC, 1980, CIRCULATION, V62, P53; ERIKSSON SE, 1985, ACTA NEUROL SCAND, V71, P485; ESMATJES E, 1989, DIABETES RES CLIN PR, V7, P285, DOI 10.1016/0168-8227(89)90017-X; Evans G, 1972, Surg Forum, V23, P239; EVANS G, 1972, 3 C INT SOC THROMB H, P40; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1986, STROKE, V17, P12; FIELDS WS, 1983, STROKE, V14, P99; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; FINCI L, 1989, Z KARDIOL, V78, P50; FINDLAY JM, 1985, J NEUROSURG, V63, P693, DOI 10.3171/jns.1985.63.5.0693; FIORENTINI E, 1972, 4TH P NAT C CARD MEN; FISKERSTRAND CE, 1985, ARTIF ORGANS, V9, P61, DOI 10.1111/j.1525-1594.1985.tb04349.x; FORNARO G, 1993, CIRCULATION, V87, P162, DOI 10.1161/01.CIR.87.1.162; FORSTER W, 1987, CARDIOVASCULAR PHARM, P457; FOULDS T, 1960, BRIT MED J, V2, P835, DOI 10.1136/bmj.2.5202.835; FOX KM, 1982, LANCET, V2, P727; FOX KM, 1982, BRIT HEART J, V47, P207; FREED MD, 1974, AM HEART J, V87, P283, DOI 10.1016/0002-8703(74)90065-9; GARCIA AM, 1980, INVEST MED INT, V7, P3; GARDE A, 1983, STROKE, V14, P677, DOI 10.1161/01.STR.14.5.677; GAVAGHAN TP, 1990, J AM COLL CARDIOL, V15, P1250, DOI 10.1016/S0735-1097(10)80009-9; GAWEL M, 1982, ADV STROKE THERAPY, P158; GENT AE, 1968, BRIT MED J, V4, P366, DOI 10.1136/bmj.4.5627.366; GENT M, 1985, STROKE, V16, P416, DOI 10.1161/01.STR.16.3.416; GENT M, 1980, CIRCULATION, V62, P97; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; GENTILE R, 1986, 10 P WORLD C CARD, P302; GERSHLICK AH, 1988, BRIT HEART J, V60, P111; GOLDMAN M, 1984, VASCULAR SURG, V18, P217, DOI 10.1177/153857448401800404; GOLDMAN M, 1983, BRIT J SURG, V70, P635, DOI 10.1002/bjs.1800701019; GOLDMAN S, 1989, CIRCULATION, V80, P1190, DOI 10.1161/01.CIR.80.5.1190; GOLDMAN S, 1988, CIRCULATION, V77, P1324, DOI 10.1161/01.CIR.77.6.1324; GRAHAM A, 1989, 0016188 SAN INT REP; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN M, 1973, CIRCULATION, V48, P57; GREEN RM, 1982, SURGERY, V92, P1016; GRONTOFT KC, 1985, SCAND J UROL NEPHROL, V19, P55, DOI 10.3109/00365598509180223; GRUBER UF, 1977, EUR SURG RES, V9, P303, DOI 10.1159/000127949; GUIRAUDCHAUMEIL B, 1982, REV NEUROL, V138, P367; GUITERAS P, 1989, EUR HEART J, V10, P159, DOI 10.1093/oxfordjournals.eurheartj.a059456; GUSTAFSSON C, 1987, STROKE, V18, P299; GUYER RD, 1982, J BONE JOINT SURG AM, V64, P1040, DOI 10.2106/00004623-198264070-00011; HAMILTON WAP, 1981, P INT VASCULAR S LON; HARJOLA P, 1981, J CARDIOVASC SURG, V22, P141; HARKER LA, 1992, ANN INTERN MED, V116, P731, DOI 10.7326/0003-4819-116-9-731; HARRIS WH, 1974, J BONE JOINT SURG AM, VA 56, P1552, DOI 10.2106/00004623-197456080-00002; HART H, 1975, 5 P C INT SOC THROMB, V34, P927; HARTER HR, 1979, NEW ENGL J MED, V301, P577, DOI 10.1056/NEJM197909133011103; Hartung B, 1979, Folia Haematol Int Mag Klin Morphol Blutforsch, V106, P810; Hass W K, 1984, Agents Actions Suppl, V15, P273; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HEIKINHEIMO R, 1971, J AM GERIATR SOC, V19, P403, DOI 10.1111/j.1532-5415.1971.tb03234.x; HEISS HW, 1990, ANGIOLOGY, V41, P263, DOI 10.1177/000331979004100402; HEISS HW, 1987, CORVAS, V1, P25; HENDRA T, 1983, LANCET, V1, P1041; HENDRA T, 1984, INT J CARDIOL, V5, P382, DOI 10.1016/0167-5273(84)90119-0; HENNEKENS CH, 1990, BMJ-BRIT MED J, V300, P117, DOI 10.1136/bmj.300.6717.117-a; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERSKOVITS E, 1989, ACTA NEUROL SCAND, V80, P31, DOI 10.1111/j.1600-0404.1989.tb01808.x; HERSKOVITS E, 1985, EUR NEUROL, V24, P73, DOI 10.1159/000115765; HERSKOVITS E, 1981, LANCET, V1, P966; HERSKOVITS E, 1985, Journal of Neurology, V232, P237; HESS H, 1978, DEUT MED WOCHENSCHR, V103, P1994, DOI 10.1055/s-0028-1129383; HESS H, 1985, LANCET, V1, P415; HESS H, 1975, 3 P CALF S KOLN, P80; HEY D, 1973, MUNCHEN MED WOCHEN, V115, P197; HEY DM, 1972, 3 C THROMB INT SOC T, P426; HOFFMAN W, 1991, PROSTAGLANDINS LEUKO, V44, P59; HOLM J, 1984, VASA-J VASCULAR DIS, V13, P175; HOPPER AH, 1989, NEPHROL DIAL TRANSPL, V4, P140; Houtsmuller A J, 1984, Agents Actions Suppl, V15, P219; HUME M, 1973, ARCH SURG-CHICAGO, V107, P803; HUNT D, 1992, LANCET, V339, P753; HYNES KM, 1973, CIRCULATION, V47, P554, DOI 10.1161/01.CIR.47.3.554; IIDA N, 1984, 0016127 SAN INT REP; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; JOHANNESSEN KA, 1989, AM J CARDIOL, V63, P101, DOI 10.1016/0002-9149(89)91085-0; JONES EW, 1985, THESIS U NOTTINGHAM; JONES NAG, 1982, BRIT J SURG, V69, P38, DOI 10.1002/bjs.1800690113; JOSEFSSON G, 1987, ACTA ORTHOP SCAND, V58, P626, DOI 10.3109/17453678709146500; JOSEPH R, 1989, STROKE, V20, P609, DOI 10.1161/01.STR.20.5.609; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KADEL C, 1990, European Heart Journal, V11, P368; KAEGI A, 1975, CIRCULATION, V52, P497, DOI 10.1161/01.CIR.52.3.497; KAEGI A, 1974, NEW ENGL J MED, V290, P304, DOI 10.1056/NEJM197402072900604; KAJANOJA P, 1981, ANN CLIN RES, V13, P392; KAMITSUJI H, 1979, Medical Journal of Kobe University, V40, P119; KASAHARA T, 1981, SHINRYO TO SHINYAKU, V13, P133; KATSUMURA T, 1982, ANGIOLOGY, V33, P357, DOI 10.1177/000331978203300601; KAYE J, 1990, TRIAL EVALUATE RELAT; KELLETT JM, 1988, BRIT MED J, V297, P1473, DOI 10.1136/bmj.297.6661.1473-a; KHURMI NS, 1986, CLIN CARDIOL, V9, P493, DOI 10.1002/clc.4960091005; KINSELLA D, 1962, AM HEART J, V63, P146, DOI 10.1016/0002-8703(62)90190-4; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KNUDSEN JB, 1985, THROMB HAEMOSTASIS, V53, P332; KOBAYASHI K, 1980, THROMB RES, V20, P255, DOI 10.1016/0049-3848(80)90390-4; KOHLER TR, 1984, SURGERY, V96, P462; KOHN N, 1990, 0016186 SAN INT REP; KRAUSE D, 1983, 0016170 SAN INT REP; KUPPER AJF, 1989, AM J CARDIOL, V63, P917, DOI 10.1016/0002-9149(89)90139-2; KUPPER AJF, 1986, 10 P WORLD C CARD WA, P419; LASSILA R, 1991, WORLD J SURG, V15, P378, DOI 10.1007/BF01658734; LAVENNEPARDONGE E, 1987, THROMB HAEMOSTASIS, V58, P547; LEIBERMAN A, 1964, ANGIOLOGY, V15, P290, DOI 10.1177/000331976401500608; LEKIEFFRE J, 1981, 0016119 SAN INT REP; LEMAK NA, 1986, NEUROLOGY, V36, P705; LEMBO NJ, 1990, AM J CARDIOL, V65, P422, DOI 10.1016/0002-9149(90)90804-A; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LEWIS HD, 1985, CIRCULATION, V72, P155; LIBRETTI A, 1986, INT J CLIN PHARM RES, V6, P59; LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773; Limet R, 1984, Agents Actions Suppl, V15, P188; LIMET R, 1988, ACTA MED INT, V5, P47; LIMET R R, 1983, Journal of Cardiovascular Surgery, V24, P357; LINKE H, 1975, 3 COLF S KOLN, P88; LOELIGER EA, 1988, NEW ENGL J MED, V319, P951; LORENZ RL, 1984, LANCET, V1, P1261; MAHLER F, 1987, VASA-J VASCULAR DIS, V16, P381; MARUYAMA S, 1981, JAPANESE J CLIN EXPT, V58, P3617; MASLENIKOV V, 1985, Journal of Neurology, V232, P263; MATIASGUIU J, 1987, ACTA NEUROL SCAND, V76, P413, DOI 10.1111/j.1600-0404.1987.tb03596.x; MAYER JE, 1981, ANN THORAC SURG, V31, P204, DOI 10.1016/S0003-4975(10)60927-7; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCBRIDE R, 1990, STROKE, V21, P538; MCCOLLUM C, 1991, J VASC SURG, V13, P150, DOI 10.1016/0741-5214(91)90022-M; MCCOLLUM CN, 1989, COMMUNICATION; MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; MEHTA JL, 1983, 0016156 SAN INT REP; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MEISTER W, 1984, BRIT J CLIN PHARMACO, V17, P703, DOI 10.1111/j.1365-2125.1984.tb02407.x; MENDELOW AD, 1982, ACTA NEUROCHIR, V62, P195, DOI 10.1007/BF01403624; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; MICHELETTI T, 1991, DOUBLE BLIND CONTROL; MICHIE DD, 1977, CURR THER RES CLIN E, V22, P196; Minar E, 1991, Vasa Suppl, V33, P167; Mirouze J, 1984, Agents Actions Suppl, V15, P230; MISRA NP, 1983, CURR THER RES CLIN E, V34, P558; MITCHELL JRA, GRAND GLAXO RECEPTOR; MOK CK, 1985, CIRCULATION, V72, P1059, DOI 10.1161/01.CIR.72.5.1059; MORIAU M, 1982, THROMB HAEMOSTASIS, V47, P27; MORTENSEN SA, 1983, EUR HEART J S3, V4; MUFSON L, 1988, J AM COLL CARDIOL, V11, P236; MURAKAMI M, 1983, IGAKU NO AYUMI, V127, P950; NEVELSTEEN A, 1991, THROMB RES, V64, P363, DOI 10.1016/0049-3848(91)90007-J; NEWHOUSE MT, 1965, AM J CARDIOL, V16, P234, DOI 10.1016/0002-9149(65)90478-9; Noppeney T, 1988, Vasa Suppl, V24, P60; NYBERG G, 1984, CLIN NEPHROL, V21, P184; NYE ER, 1990, AUST NZ J MED, V20, P549, DOI 10.1111/j.1445-5994.1990.tb01311.x; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; OAKLEY NW, 1983, INVESTIGATION EFFECT; OBRIEN JR, 1971, LANCET, V1, P399; OLLIVIER JP, 1991, ARCH MAL COEUR VAISS, V84, P537; OLSSON JE, 1980, STROKE, V11, P4, DOI 10.1161/01.STR.11.1.4; OLSSON JE, 1981, UNPUB PRELIMINARY RE; Ono H, 1984, Agents Actions Suppl, V15, P259; ORTHNER E, 1986, THROMB RES, P85; Orthner E, 1990, Unfallchirurgie, V16, P128, DOI 10.1007/BF02588009; PAGANI A, 1989, CURR THER RES CLIN E, V45, P469; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PANNEBAKKER MAG, 1980, 6 P INT C MED LEAG T; PANTELY GA, 1979, NEW ENGL J MED, V301, P962, DOI 10.1056/NEJM197911013011803; PARRY MJ, 1982, LANCET, V2, P164; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PEDRINI L, 1988, CV WORLD REPORT, V1, P93; PELL E, 1975, CLIN STUDIES USING D, P2; PERSSON S, 1983, 0016179 SAN INT REP; PETERS SHA, 1982, THROMB HAEMOSTASIS, V48, P222; PETERSEN P, 1989, LANCET, V1, P175; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PFISTERER M, 1989, LANCET, V2, P1; PHILLIPS SJ, 1980, NEW ENGL J MED, V302, P866; PINEO GF, 1975, PLATELETS DRUGS THRO, P276; PINI M, 1985, J BONE JOINT SURG BR, V67, P305, DOI 10.1302/0301-620X.67B2.2579953; PIRK J, 1986, ANN THORAC SURG, V42, P312, DOI 10.1016/S0003-4975(10)62742-7; Pirk J, 1990, Cor Vasa, V32, P258; POLLOCK A, 1979, EFFECT TICLOPDINE PL; POPESCU P, 1986, MED INTERNE, V38, P525; Prandoni P, 1991, Minerva Cardioangiol, V39, P267; Pratschner T, 1990, Eur J Vasc Surg, V4, P285, DOI 10.1016/S0950-821X(05)80209-9; PRICE J, 1981, THESIS U P SABATIER; PUTZ P, 1991, ACTA CHIR BELG, P269; RAITHEL D, 1987, VASCULAR SURG, V21, P208, DOI 10.1177/153857448702100308; RAJAH SM, 1985, J THORAC CARDIOV SUR, V90, P373; RAJAH SM, 1979, 7 P INT C THROMB HAE, P160; RANKE C, 1993, CIRCULATION, V87, P1873, DOI 10.1161/01.CIR.87.6.1873; RASCOL A, 1982, ADV STROKE THERAPY, P147; RASMANIS G, 1988, LANCET, V2, P245; REUBEN SR, 1983, BRIT J CLIN PHARMACO, V15, pS83, DOI 10.1111/j.1365-2125.1983.tb02114.x; REUTHER R, 1980, MUNCHEN MED WOCHEN, V122, P795; REUTHER R, 1978, ACETYLSALICYLIC ACID, P97; REVOL L, 1980, 0016123 SAN INT REP; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RIESS H, 1986, THROMB RES, V42, P235, DOI 10.1016/0049-3848(86)90299-9; ROBERTS VC, 1980, 1050620058 SAN INT R; ROBERTSON JT, 1975, THROMB DIATH HAEMOST, V34, P598; RODEN S, 1981, POSTGRAD MED J, V57, P275, DOI 10.1136/pgmj.57.667.275; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; ROGERS PH, 1978, J BONE JOINT SURG AM, V60, P758, DOI 10.2106/00004623-197860060-00005; ROMEO F, 1982, 83RD P S SAT C IT SO, P155; ROTHLIN ME, 1985, EUR HEART J, V6, P168, DOI 10.1093/oxfordjournals.eurheartj.a061831; ROTHLIN ME, 1982, CORONARY ARTERY DIS, V557, P413; ROVELLI F, 1990, CIRCULATION, V82, P507; RUSSELL RWR, 1985, 1050620051 SAN INT R; SALZMAN EW, 1971, NEW ENGL J MED, V284, P1287, DOI 10.1056/NEJM197106102842303; SANCHEZ FDL, 1982, HAEMOSTASIS, V12, P69; Sancho Rieger J, 1984, Med Clin (Barc), V82, P62; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SANZ G, 1990, CIRCULATION, V82, P765, DOI 10.1161/01.CIR.82.3.765; SATIANI B, 1985, ANGIOLOGY, V36, P608, DOI 10.1177/000331978503600904; SAVAGE MP, 1991, AM HEART J, V122, P1239, DOI 10.1016/0002-8703(91)90561-U; SBAR S, 1967, J AMER MED ASSOC, V201, P865, DOI 10.1001/jama.201.11.865; SCHANZENBACHER P, 1989, CIRCULATION S2, V81, P99; SCHNITKER J, 1983, LABAZ010302 INT REP; SCHNITKER J, 1983, MULTIZENTRISCHE STUD; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; SCHONDORF TH, 1976, HAEMOSTASIS, V5, P250; SCHONDORF TH, 1977, DEUT MED WOCHENSCHR, V102, P1314, DOI 10.1055/s-0028-1105499; SCHONDORF TH, 1978, THROMB RES, V12, P153, DOI 10.1016/0049-3848(78)90093-2; SCHOOP W, 1984, INTERNIST, V25, P429; SCHOOP W, 1983, THROMB HAEMOSTASIS, V50, P137; SCHOOP W, 1983, 0016174 SAN INT REP; SCHOOP W, 1983, THROMBOZYTENFUNKTION, P49; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SCRUTINIO D, 1991, EUR HEART J, V12, P27; SEROTA H, 1990, CIRCULATION, V82, P361; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SHAPIRO LM, 1983, CURR MED RES OPIN, V8, P518, DOI 10.1185/03007998309109791; SHARMA GVRK, 1983, CIRCULATION, V68, P218; SHAW K, 1983, 0016241 SAN INT REP; SHAW MDM, 1985, J NEUROSURG, V63, P699, DOI 10.3171/jns.1985.63.5.0699; SHEEHAN SJ, 1987, BRIT J SURG, V74, P330; SHERRY S, 1982, NEW ENGL J MED, V306, P1005; SHERRY S, 1980, CIRCULATION, V62, P73; SHERRY S, 1980, NEW ENGL J MED, V302, P250; SIGNORINI GP, 1988, ANGIOLOGY, V39, P742, DOI 10.1177/000331978803900806; SILVERGLEID AJ, 1978, ORTHOPEDICS, V1, P19; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SITTHIAMORN C, 1988, RANDOMIZED TRIAL ASP; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; STARKMAN C, 1982, ARCH MAL COEUR VAISS, V75, P85; STEELE P, 1980, LANCET, V2, P1328; STEELE P, 1980, CIRCULATION, V62, P462, DOI 10.1161/01.CIR.62.3.462; STEELE P, 1978, AM J MED, V64, P441, DOI 10.1016/0002-9343(78)90230-9; STERN D, 1987, SCHWEIZ MED WSCHR, V117, P2084; STIEGLER H, 1984, DEUT MED WOCHENSCHR, V109, P1240, DOI 10.1055/s-2008-1069356; STRATTON JR, 1984, CIRCULATION, V69, P677, DOI 10.1161/01.CIR.69.4.677; STRATTON JR, 1986, AM J CARDIOL, V58, P152, DOI 10.1016/0002-9149(86)90260-2; STUART J, 1980, 6 P INT C MED LEAG T, P75; SUBRAMIAN VB, 1983, 0016243 SAN INT REP; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501; SUTER V, 1993, CIRCULATION, V87, P659; SZABO R, 1988, ORVOSI HETILAP, V38, P2023; TAGUCHI K, 1975, J CARDIOVASC SURG, V16, P8; TAYLOR RR, 1990, AUST NZ J MED, V28; TEMPLE R, 1980, NEW ENGL J MED, V303, P1488, DOI 10.1056/NEJM198012183032534; TEOH KH, 1987, ANN THORAC SURG, V44, P40, DOI 10.1016/S0003-4975(10)62354-5; TEOH KH, 1988, J THORAC CARDIOV SUR, V96, P332; THAULOW E, 1987, SCAND J THORAC CARD, V21, P215, DOI 10.3109/14017438709106027; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THORNTON MA, 1984, CIRCULATION, V69, P721, DOI 10.1161/01.CIR.69.4.721; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TILLBERG B, 1976, BRIT MED J, V1, P1256, DOI 10.1136/bmj.1.6020.1256-a; TOHGI H, 1990, SANG THROMB VAISS, P19; TSCHERNE H, 1978, UNFALLHEILKUNDE, V81, P178; TURIE AGG, 1993, NEW ENGL J MED, V329, P524; UBERLA K, 1978, ACETYLSALICYLIC ACID, P159; UGONOT R, 1983, 0016117 SAN INT REP; UTSUMI H, 1984, 0016128 SAN INT REP; VANDERMEER J, 1993, LANCET, V342, P257, DOI 10.1016/0140-6736(93)91815-4; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; VERHAEGHE R, 1981, J CARDIOVASC PHARM, V3, P279, DOI 10.1097/00005344-198103000-00006; VERHEUGT FWA, 1988, AM J CARDIOL, V61, P904, DOI 10.1016/0002-9149(88)90368-2; VERHEUGT FWA, 1989, LANCET, V1, P670; VERHEUGT FWA, 1990, AM J CARDIOL, V66, P267, DOI 10.1016/0002-9149(90)90833-M; VINAZZER H, 1987, FORTSCHR MED, V105, pA79; Vogel G, 1979, Folia Haematol Int Mag Klin Morphol Blutforsch, V106, P797; VOGEL G, 1981, PROPHYLAXIS VENOUS P, P123; VOLTA SD, 1989, BLOOD, V74, P176; VONSCHREIBER U, 1979, CHIRURG, V104, P1214; WALLENTIN L, 1990, LANCET, V336, P827; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; WEBER W, 1971, THERAPEUTISCHE BERIC, V43, P229; WEBER W, 1970, 1 P COLF S WUPP, P69; WHISNANT JP, 1980, AM HEART J, V99, P129, DOI 10.1016/0002-8703(80)90323-3; WHITE CW, 1987, CIRCULATION, V76, P400; WHITE CW, 1987, CIRCULATION, V76, P213; WIRECKI M, 1967, J CHRON DIS, V20, P139, DOI 10.1016/0021-9681(67)90048-3; WLCOX RG, 1980, BMJ-BRIT MED J, V281, P531; ZEITLER E, 1973, DEUT MED WOCHENSCHR, V98, P1285, DOI 10.1055/s-0028-1107016; Zekert F., 1975, THROMBOSEN EMBOLIEN, P68; 1991, OPHTHALMOOGY S, V98, P757; 1993, LANCET, V342, P1255; 1976, J CHRONIC DDIS, V29, P625; 1980, CIRCULATION S5, V62, P85; 1989, CIRCULATION S2, V80, P114; 1987, UNPUB ALDUSA ASPIRIN; 1973, CIRCULATION S1, V47, P1; 1990, TREATMENT EARLY BREA, V1, P12; IN PRESS BMJ; 1992, OPHTHALMOLOGICA, V204, P4; 1990, STROKE, V21, P169; ASASANTIN DVT MYOKAR; 1978, COEUR, P915; 1980, CIRCULATION S5, V62, P59; IN PRES BMJ	433	3387	3451	2	152	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	1994	308	6921					81	100		10.1136/bmj.308.6921.81	http://dx.doi.org/10.1136/bmj.308.6921.81			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298418				2022-12-28	WOS:A1994MR17300012
J	KAMMERLING, RM; OCONNOR, S				KAMMERLING, RM; OCONNOR, S			UNEMPLOYMENT RATE AS PREDICTOR OF RATE OF PSYCHIATRIC ADMISSION	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL DEPRIVATION; DEPRESSION; MEN	Objective-To examine the relation between rates of psychiatric admissions and both the rate of unemployment and the underprivileged area score within small areas. Design-Calculation of correlation coefficients and explanatory power by using data on psychiatric admissions from April 1990 to March 1992. Crude and age standardised rates were used based on all admissions and also on the number of people admitted regardless of the number of times each person was admitted. Setting-Sectors with an average population of 45 000 consisting of aggregations of neighbouring wards in Bristol and District Health Authority and electoral wards with an average population of 9400 in the city of Bristol. Results-Unemployment rates explained 93% of the variation in the crude person based admission rates standardised for age for those aged under 65 in the sectors. Person based rates correlated more strongly with unemployment than did rates based on all separate admissions. Inclusion of people aged 65 and over weakened the relation. Within electoral wards unemployment rates explained only about 50-60% of the variation but were still more powerful than the underprivileged area score. There was a significant negative correlation between average length of stay and readmission rates-that is, sectors with short lengths of stay were more likely to have patients readmitted (r = -0.64, 95% confidence interval -0.25 to -0.85). Conclusions-Unemployment rates are an extremely powerful indicator of the rates of serious mental illness that will need treatment in hospital in those aged under 65. This should be considered in the process of resource allocation, particularly to fundholders in general practice, or people with serious mental illness living in areas of high unemployment could be considerably disadvantaged.	BARROW HOSP,UNITED BRISTOL HEALTHCARE TRUST,BRISTOL,ENGLAND		KAMMERLING, RM (corresponding author), BRISTOL & DIST HLTH AUTHOR,DEPT PUBL HLTH MED,BRISTOL BS2 8EE,ENGLAND.							BOLTON W, 1987, PSYCHOL MED, V17, P453, DOI 10.1017/S0033291700025010; CAMPBELL DA, 1991, BMJ-BRIT MED J, V303, P750, DOI 10.1136/bmj.303.6805.750; EALES MJ, 1988, PSYCHOL MED, V18, P935, DOI 10.1017/S0033291700009867; Faris Robert E.L, 1939, MENTAL DISORDERS URB; HARE EH, 1956, J MENT SCI, V102, P349, DOI 10.1192/bjp.102.427.349; JARMAN B, 1992, BRIT MED J, V304, P1146, DOI 10.1136/bmj.304.6835.1146; KESSLER RC, 1989, AM SOCIOL REV, V54, P648, DOI 10.2307/2095885; MELVILLE DI, 1985, PSYCHOL MED, V15, P789, DOI 10.1017/S0033291700005018; NEWTON J, 1988, PREVENTING MENTAL IL; THORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475, DOI 10.1192/bjp.158.4.475; THORNICROFT G, 1992, BRIT J PSYCHIAT, V161, P621, DOI 10.1192/bjp.161.5.621; Warr P., 1987, WORK UNEMPLOYMENT ME; 1992, NHSME EL9248 HLTH CA; 1988, PSYCHIATRIC BEDS RES	14	64	64	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1536	1539		10.1136/bmj.307.6918.1536	http://dx.doi.org/10.1136/bmj.307.6918.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ML869	8274924	Green Published, Bronze			2022-12-28	WOS:A1993ML86900023
J	SCHUTZ, R; SAVARIT, D; KADJO, JC; BATTER, V; KONE, NV; LARUCHE, G; BONDURAND, A; DECOCK, KM				SCHUTZ, R; SAVARIT, D; KADJO, JC; BATTER, V; KONE, NV; LARUCHE, G; BONDURAND, A; DECOCK, KM			EXCLUDING BLOOD-DONORS AT HIGH-RISK OF HIV-INFECTION IN A WEST-AFRICAN CITY	BRITISH MEDICAL JOURNAL			English	Article							TRANSFUSION; KINSHASA; ZAIRE	Objective-To examine the potential impact of deferral of blood donors at high risk of HIV infection in a west African city where blood is screened for HIV antibodies but no other special measures are taken to protect the blood supply. Design-Cross sectional study. Setting-National Blood Transfusion Centre and Project RETRO-CI, an international collaborative AIDS research project, Abidjan, Cote d'Ivoire. Subjects-1257 male first time blood donors. Interventions-Blood donors were interviewed about demographic and behavioural characteristics and tested for HIV antibodies by enzyme immunoassay and, if positive, synthetic peptide based tests. Main outcome measures-HIV antibody status in relation to presence of behavioural risk factors; calculation of sensitivity, specificity, and predictive values of specific criteria for excluding HIV infected donors. Results-The overall prevalence of HIV infection was 11.4%. The most important risk factors for HIV positivity were prostitute contact and being aged 30-39 years. For identifying seropositive donors individual criteria had sensitivity, specificity, and positive predictive values ranging from 15% to 98%, 38% to 91%, and 17% to 30% respectively. Prostitute contact in the past five years would have excluded 31% of all donors and 73% of HIV infected donors. 27% of those excluded would have been HIV positive. Conclusions--The widespread assumption that donor deferral is not feasible in sub-Saharan Africa needs reassessment. In Abidjan this approach was well accepted and potentially effective. Donor deferral requires evaluation as a strategy for improving blood safety in resource poor areas with high rates of HIV infection.	CTR NATL TRANSFUS SANGUINE,ABIDJAN,COTE IVOIRE; PROJET SANTE ABIDJAN,ABIDJAN,COTE IVOIRE; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA	Centers for Disease Control & Prevention - USA								BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; CHIN J, 1989, B WORLD HEALTH ORGAN, V67, P1; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; JAGER H, 1991, AIDS, V5, pS163; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MANN J, 1992, AIDS WORLD, P421; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; PIOT P, 1990, HDB AIDS PREVENTION, P1; RYDER RW, 1992, AIDS, V6, P1395, DOI 10.1097/00002030-199211000-00026; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SETBON M, 1993, MONDE           0506	14	31	32	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1517	1519		10.1136/bmj.307.6918.1517	http://dx.doi.org/10.1136/bmj.307.6918.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274919	Green Published, Bronze			2022-12-28	WOS:A1993ML86900018
J	JATOI, I; BAUM, M				JATOI, I; BAUM, M			AMERICAN AND EUROPEAN RECOMMENDATIONS FOR SCREENING MAMMOGRAPHY IN YOUNGER WOMEN - A CULTURAL DIVIDE	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; AGE 50; MORTALITY; TRIAL	The American Cancer Society advocates mammoraphy screening for all women from age 40, whereas in Europe it is not recommended for women below the age of 50. Randomised prospective studies have failed to show a significant benefit from screening women aged under 50 and five potentially harmful effects of screening should be considered: lead time, overdiagnosis, radiation exposure, false positive results, and cost. Younger women must be properly informed about the potential for harm as well as for benefit before screening.	ROYAL MARSDEN HOSP,ACAD DEPT SURG,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAUER TL, 1991, SURG GYNECOL OBSTET, V173, P482; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1993, LANCET, V341, P439, DOI 10.1016/0140-6736(93)93033-W; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Payer Lynn, 1989, MED CULTURE; REIDY J, 1988, BRIT MED J, V297, P932, DOI 10.1136/bmj.297.6654.932; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1988, PERIODIC SCREENING B; STACEYCLEAR A, 1992, LANCET, V340, P991; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; IN PRESS BREAST; 1991, LANCET, V337, P1575	16	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1481	1483		10.1136/bmj.307.6917.1481	http://dx.doi.org/10.1136/bmj.307.6917.1481			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281094	Green Published			2022-12-28	WOS:A1993MK79700031
J	GOTZSCHE, PC				GOTZSCHE, PC			ZIDOVUDINE DOSAGE	BRITISH MEDICAL JOURNAL			English	Letter							CONTROLLED TRIAL				GOTZSCHE, PC (corresponding author), RIGSHOSP,DEPT INFECT DIS,NORD MED RES COUNCILS HIV THERAPY GRP,DK-2200 COPENHAGEN N,DENMARK.							FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1992, BMJ, V304, P13	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					682	683		10.1136/bmj.307.6905.682-b	http://dx.doi.org/10.1136/bmj.307.6905.682-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8292147	Green Published			2022-12-28	WOS:A1993LX47000054
J	NESS, RB; HARRIS, T; COBB, J; FLEGAL, KM; KELSEY, JL; BALANGER, A; STUNKARD, AJ; DAGOSTINO, RB				NESS, RB; HARRIS, T; COBB, J; FLEGAL, KM; KELSEY, JL; BALANGER, A; STUNKARD, AJ; DAGOSTINO, RB			NUMBER OF PREGNANCIES AND THE SUBSEQUENT RISK OF CARDIOVASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; YOUNG-WOMEN; REPRODUCTIVE HISTORY; FAT DISTRIBUTION; WHITE WOMEN; FRAMINGHAM; OBESITY; PARITY; HEALTH	Background. Whether increasing parity or gravidity is a risk factor for corona Methods. We tested the association between the number of pregnancies and a variety of cardiovascular end points in two groups of women who had completed childbearing. One group comprised 2357 women who were followed for 28 years through the Framingham Heart Study, and the other 2533 women followed for at least 12 years through the first National Health and Nutrition Examination Survey National Epidemiologic Follow-up Study (NHEFS). Results. The rates of coronary heart disease were higher among multigravid women than among women who had never been pregnant, in both the Framingham Heart Study and the NHEFS, but in both studies, the higher rates were statistically significant only in women with six or more pregnancies. For the women in the Framingham Study, the rate ratio adjusted for age and educational level in the group with six or more pregnancies (as compared with women who had never been pregnant) was 1.6 (95 percent confidence interval, 1.1 to 2.2). For the women in the NHEFS, the same adjusted rate ratio was 1.5 (95 percent confidence interval, 1.1 to 1.9). Adjustments for other known cardiovascular risk factors, including weight, did not markedly alter this risk. The rate of total cardiovascular disease was also significantly higher among multigravid women in the Framingham Study than in the women who had never been pregnant. Conclusions. In two prospective American studies, having six or more pregnancies was associated with a small but consistent increase in the risk of coronary heart disease and cardiovascular disease. Whether gravidity itself or some other unmeasured factor accounts for the increase in risk that we observed requires further investigation.	UNIV PENN, CLIN EPIDEMIOL UNIT, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PSYCHIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DEPT EMERGENCY, PHILADELPHIA, PA 19104 USA; CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, HYATTSVILLE, MD USA; STANFORD UNIV, DEPT HLTH RES & POLICY, SAN FRANCISCO, CA USA; BOSTON UNIV, DEPT MATH, STAT UNIT, BOSTON, MA 02215 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Stanford University; Boston University			Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X	NATIONAL CANCER INSTITUTE [T32CA009529] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09529] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BENGTSSON C, 1973, ACTA MED SCAND, V549, P75; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P861, DOI 10.1093/oxfordjournals.aje.a114723; COX DR, 1972, J R STAT SOC B, V34, P187; CUPPLES LA, 1989, MIH893039 PUBL; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DEALVAREZ RR, 1959, AM J OBSTET GYNECOL, V77, P743, DOI 10.1016/S0002-9378(16)36790-4; DENTONKELAAR I, 1990, INT J OBESITY, V14, P753; EAVENSON E, 1966, J AM OIL CHEM SOC, V43, P652, DOI 10.1007/BF02682563; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FAHRAEUS L, 1985, OBSTET GYNECOL, V66, P468; Feinleib M, 1985, Natl Cancer Inst Monogr, V67, P59; FLEGAL KM, 1990, AM J EPIDEMIOL, V132, P766; FORSTER JL, 1986, PREV MED, V15, P685, DOI 10.1016/0091-7435(86)90073-3; GORDON T, 1977, ANN INTERN MED, V87, P393, DOI 10.7326/0003-4819-87-4-393; HAYNES SG, 1980, AM J PUBLIC HEALTH, V70, P133, DOI 10.2105/AJPH.70.2.133; HELIOVAARA M, 1981, J EPIDEMIOL COMMUN H, V35, P197, DOI 10.1136/jech.35.3.197; HOLLINGSWORTH DR, 1983, AM J OBSTET GYNECOL, V146, P417, DOI 10.1016/0002-9378(83)90822-0; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KAYE SA, 1990, INT J OBESITY, V14, P583; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802; LAVECCHIA C, 1987, AM J OBSTET GYNECOL, V157, P1108, DOI 10.1016/S0002-9378(87)80271-5; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MANN JI, 1976, BRIT J PREV SOC MED, V30, P94; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Nelson N, 1944, J BIOL CHEM, V153, P375; OLIVER MF, 1974, BMJ-BRIT MED J, V4, P253, DOI 10.1136/bmj.4.5939.253; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; PYKE DA, 1956, LANCET, V270, P818; RITTERBRAND AB, 1963, CIRCULATION, V27, P237, DOI 10.1161/01.CIR.27.2.237; STEPHENS RC, 1978, J GERONTOLOGICAL SOC, V1, P33; STOKES J, 1987, CIRCULATION, V75, P65; VANSTIPHOUT WAHJ, 1987, AM J EPIDEMIOL, V126, P922; WINKELSTEIN W, 1964, AM HEART J, V67, P481, DOI 10.1016/0002-8703(64)90094-8; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; 1977, VITAL HLTH STATI 10B, V1; 1974, DHEW NIH75628 PUBL; 1988, DHHS PHS881122 NAT C, V2; 1987, VITAL HLTH STATIS 22, V1; 1973, VITAL HLTH STATI 10A, V1	47	224	228	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1528	1533		10.1056/NEJM199305273282104	http://dx.doi.org/10.1056/NEJM199305273282104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8267704				2022-12-28	WOS:A1993LC94100004
J	HLA, KM; YOUNG, TB; BIDWELL, T; PALTA, MM; SKATRUD, B; DEMPSEY, J				HLA, KM; YOUNG, TB; BIDWELL, T; PALTA, MM; SKATRUD, B; DEMPSEY, J			SLEEP-APNEA AND HYPERTENSION - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						SLEEP APNEA SYNDROMES; HYPERTENSION; SNORING; POLYSOMNOGRAPHY; BLOOD PRESSURE MONITORS	AMBULATORY BLOOD-PRESSURE; LEFT-VENTRICULAR HYPERTROPHY; ARTERIAL-PRESSURE; RISK FACTOR; PREVALENCE; HYPERSOMNIA; MEN; CATECHOLAMINES; TRACHEOSTOMY; BORDERLINE	Objective: To measure the independent association of sleep-disordered breathing (sleep apnea and habitual snoring) and hypertension in a healthy adult population. Design: A cross-sectional study of blood pressure during wakefulness and sleep among participants with and without sleep-disordered breathing. Setting: Community-based study. Participants: 147 men and women, aged 30 to 60 years, selected from Wisconsin State employees enrolled in the Wisconsin Sleep Cohort Study, an ongoing, prospective, epidemiologic study of sleep-disordered breathing. Measurements: Sleep and medical history interview, nocturnal polysomnography, and 24-hour ambulatory blood pressure monitoring in all participants. Results: Mean blood pressures were significantly higher among participants with sleep apnea (greater than or equal to 5 apneas or hypopneas per hour of sleep) compared with those without (131/80 +/- 1.7/1.1 mm Hg compared with 122/75 +/- 1.9/1.2 mm Hg during wakefulness and 113/66 +/- 1.8/1.1 mm Hg compared with 104/62 +/- 2/1.3 mm Hg during sleep, respectively; P < 0.05). The variability of the blood pressure during sleep was significantly greater in participants with sleep apnea or a history of snoring compared with those without (P < 0.05). After controlling for obesity, age, and sex, sleep apnea was significantly associated with hypertension in a dose-response fashion, with odds ratios ranging from 2.0 for 5 apneic or hypopneic episodes per hour of sleep to 5.0 for 25 apneic or hypopneic episodes. Conclusions: Our data indicate an association between hypertension and sleep apnea independent of obesity, age, and sex in a nonselected, community-based adult population.			HLA, KM (corresponding author), UNIV WISCONSIN, CTR CLIN SCI, DEPT MED, J5-210, 600 HIGHLAND AVE, MADISON, WI 53792 USA.				NCRR NIH HHS [RR 03186] Funding Source: Medline; NHLBI NIH HHS [P01 HL 42242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042242] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURACK B, 1984, AM HEART J, V107, P543, DOI 10.1016/0002-8703(84)90098-X; BURACK B, 1977, CIRCULATION, V56, P177; CARSKADON MA, 1989, PRINCIPLES PRACTICE, P3; COCCAGNA G, 1972, B PHYSIO-PATHOL RESP, V8, P1159; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; DEMENT WC, 1993, JAMA-J AM MED ASSOC, V269, P1548, DOI 10.1001/jama.269.12.1548; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; DRAYER JIM, 1987, HYPERTENSION, V9, P61; Drizd T, 1986, Vital Health Stat 11, P1; FLETCHER EC, 1985, ANN INTERN MED, V103, P190, DOI 10.7326/0003-4819-103-2-190; FLORAS JS, 1981, LANCET, V2, P107; GELLMAN M, 1990, PSYCHOPHYSIOLOGY, V27, P544, DOI 10.1111/j.1469-8986.1990.tb01972.x; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; GUILLEMINAULT C, 1981, ARCH INTERN MED, V141, P985, DOI 10.1001/archinte.141.8.985; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HALL JE, 1992, HYPERTENSION S, V19, P145; HOFFSTEIN V, 1988, LANCET, V2, P992; IRVING JB, 1976, POSTGRAD MED J, V52, P137; JENNUM P, 1989, AM J HYPERTENS, V2, P847, DOI 10.1093/ajh/2.11.847; KALES A, 1984, LANCET, V2, P1005; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KOSKENVUO M, 1985, LANCET, V1, P893; LAVIE P, 1984, AM HEART J, V108, P373, DOI 10.1016/0002-8703(84)90628-8; Lugaresi E, 1978, Adv Exp Med Biol, V99, P35; MESSERLI FH, 1982, AM HEART J, V104, P109, DOI 10.1016/0002-8703(82)90649-4; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; MORGAN BJ, 1993, J APPL PHYSIOL, V74, P2969, DOI 10.1152/jappl.1993.74.6.2969; MOTTA J, 1978, ANN INTERN MED, V89, P454, DOI 10.7326/0003-4819-89-4-454; NORTON PG, 1985, BRIT MED J, V291, P630, DOI 10.1136/bmj.291.6496.630; PACK AI, 1993, SLEEP MED REV, V1, P1; PEISER J, 1984, ANN SURG, V199, P112, DOI 10.1097/00000658-198401000-00020; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING TG, 1982, CLIN EXP HYPERTENS, V4, P675, DOI 10.3109/10641968209061606; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; RAUSCHER H, 1992, American Review of Respiratory Disease, V145, pA442; Rechtschaffen A, 1968, NIH PUBLICATION, V204; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; ROWLANDS DB, 1981, CLIN SCI, V61, pS101, DOI 10.1042/cs061101s; SCHWAN A, 1992, J HYPERTENS, V10, P189; Snedecor GW, 1980, STATISTICAL METHODS, P98; SOKOLOW M, 1966, CIRCULATION, V34, P279; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; STAESSEN J, 1990, J HYPERTENS, V8, pS57; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; TURJANMAA V, 1991, J HYPERTENS, V9, P665, DOI 10.1097/00004872-199107000-00012; TURNER JR, 1991, J PSYCHOSOM RES, V35, P289; VEERMAN DP, 1988, J HYPERTENS, V6, pS77, DOI 10.1097/00004872-198812040-00020; WEBER MA, 1988, HYPERTENSION, V11, P288, DOI 10.1161/01.HYP.11.3.288; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; WILCOX T, 1991, CIRCULATION S2, V84, P136; WILLIAMS AJ, 1985, AM J CARDIOL, V55, P1019, DOI 10.1016/0002-9149(85)90738-6; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1993, EXECUTIVE SUMMARY EX, V1	56	453	475	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					382	388		10.7326/0003-4819-120-5-199403010-00005	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304655				2022-12-28	WOS:A1994MY49700005
J	DEBELLE, JS; HEISENBERG, M				DEBELLE, JS; HEISENBERG, M			ASSOCIATIVE ODOR LEARNING IN DROSOPHILA ABOLISHED BY CHEMICAL ABLATION OF MUSHROOM BODIES	SCIENCE			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; SHORT-TERM-MEMORY; POSTEMBRYONIC NEUROBLASTS; APIS-MELLIFERA; MELANOGASTER; MUTANTS; GENE; BRAIN; RUTABAGA	The corpora pedunculata, or mushroom bodies (MBs), in the brain of Drosophila melanogaster adults consist of approximately 2500 parallel Kenyon cell fibers derived from four MB neuroblasts. Hydroxyurea fed to newly hatched larvae selectively deletes these cells, resulting in complete, precise MB ablation. Adult flies developing without MBs behave normally in most respects, but are unable to perform in a classical conditioning paradigm that tests associative learning of odor cues and electric shock. This deficit cannot be attributed to reductions in olfactory sensitivity, shock reactivity, or locomotor behavior. The results demonstrate that MBs mediate associative odor learning in flies.			DEBELLE, JS (corresponding author), UNIV WURZBURG, LEHRSTUHL GENET, THEODOR BOVERI INST BIOWISSENSCH, AM HUBLAND, D-97074 WURZBURG, GERMANY.							ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; ASZTALOS Z, 1993, J NEUROSCI, V13, P924; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BELLEN HJ, 1987, GENETICS, V115, P153; BOYNTON S, 1992, GENETICS, V131, P655; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CORFAS G, 1991, P NATL ACAD SCI USA, V88, P7252, DOI 10.1073/pnas.88.16.7252; DEBELLE JS, 1993, J NEUROGENET, V8, P225; DEBELLE JS, UNPUB; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DURST C, 1993, GENE BRAIN BEHAVIOUR; ERBER J, 1980, PHYSIOL ENTOMOL, V5, P343, DOI 10.1111/j.1365-3032.1980.tb00244.x; ERBER J, 1987, ARTHROPOD BRAIN ITS, pCH21; GOODWIN SF, 1993, J NEUROGENET, V8, P232; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HEISENBERG M, 1989, FORTS ZOOL, V37, P3; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; HEISENBERG M, 1980, DEV NEUROBIOLOGY DRO, P373; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; MENZEL R, 1991, BEHAVIOUR AND PHYSIOLOGY OF BEES, P323; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; MULLER U, 1989, J NEUROGENET, V6, P95, DOI 10.3109/01677068909107104; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; PROKOP A, 1991, DEVELOPMENT, V111, P79; PROKOP A, IN PRESS DEV BIOL; QUI Y, 1991, J MOL BIOL, V222, P553; SCHURMANN FW, 1987, ARTHROPOD BRAIN ITS, pCH11; SOKOLOWSKI MB, 1984, ANIM BEHAV, V32, P645, DOI 10.1016/S0003-3472(84)80139-6; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; STRAUSFELD NJ, 1976, ATLAS INSECT BRAIN, pCH3; STRAUSS R, 1993, J NEUROSCI, V13, P1852, DOI 10.1523/jneurosci.13-05-01852.1993; Strauss R, COMMUNICATION; TECHNAU G, 1982, NATURE, V295, P405, DOI 10.1038/295405a0; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TECHNAU GM, 1983, THESIS U WURZBURG; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1991, TRENDS NEUROSCI, V14, P163, DOI 10.1016/0166-2236(91)90096-D; TULLY T, 1991, PERSPECTIVES COGNITI, P46; WITHERS GS, 1993, NATURE, V364, P238, DOI 10.1038/364238a0; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; ZAR JH, 1984, BIOSTATISTICAL ANAL, pCH8; ZAR JH, 1985, SAS USERS GUIDE STAT; ZHONG Y, 1992, J NEUROSCI, V12, P644	55	599	607	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					692	695		10.1126/science.8303280	http://dx.doi.org/10.1126/science.8303280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303280				2022-12-28	WOS:A1994MU96400053
J	RAINNIE, DG; GRUNZE, HCR; MCCARLEY, RW; GREENE, RW				RAINNIE, DG; GRUNZE, HCR; MCCARLEY, RW; GREENE, RW			ADENOSINE INHIBITION OF MESOPONTINE CHOLINERGIC NEURONS - IMPLICATIONS FOR EEG AROUSAL	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; SLOW-WAVE SLEEP; CEREBRAL-CORTEX; BRAIN; CAFFEINE; RECEPTOR; SLICES; NUCLEI; RATS; MECHANISMS	Increased discharge activity of mesopontine cholinergic neurons participates in the production of electroencephalographic (EEG) arousal; such arousal diminishes as a function of the duration of prior wakefulness or of brain hyperthermia. Whole-cell and extracellular recordings in a brainstem slice show that mesopontine cholinergic neurons are under the tonic inhibitory control of endogenous adenosine, a neuromodulator released during brain metabolism. This inhibitory tone is mediated postsynaptically by an inwardly rectifying potassium conductance and by an inhibition of the hyperpolarization-activated current. These data provide a coupling mechanism linking neuronal control of EEG arousal with the effects of prior wakefulness, brain hyperthermia, and the use of the adenosine receptor blockers caffeine and theophylline.	HARVARD UNIV, DEPT PSYCHIAT, CAMBRIDGE, MA 02138 USA; VET ADM MED CTR, BROCKTON, MA 02401 USA	Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Rainnie, Donald/L-3853-2016; McCarley, Robert W/N-5562-2014; Shenton, Martha/V-8780-2019; Grunze, Heinz/J-1198-2019	Rainnie, Donald/0000-0003-0758-0530; McCarley, Robert W/0000-0001-5705-7495; Grunze, Heinz/0000-0003-4712-8979; Greene, Robert/0000-0003-1355-9797	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039683] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH039683] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERNE RM, 1982, CEREBRAL HYPOXIA PAT, P89; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Borbely A A, 1982, Hum Neurobiol, V1, P195; BRUNS RF, 1981, BIOCHEM PHARMACOL, V30, P325, DOI 10.1016/0006-2952(81)90062-9; BRUNS RF, 1980, P NATL ACAD SCI-BIOL, V77, P5547, DOI 10.1073/pnas.77.9.5547; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHOI OH, 1988, LIFE SCI, V43, P387, DOI 10.1016/0024-3205(88)90517-6; DESANCHEZ VC, 1993, BRAIN RES, V612, P115, DOI 10.1016/0006-8993(93)91651-8; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; DUNWIDDIE TV, 1981, N-S ARCH PHARMACOL, V316, P326, DOI 10.1007/BF00501365; FEINBERG I, 1985, ELECTROEN CLIN NEURO, V61, P134, DOI 10.1016/0013-4694(85)91051-X; FREIL DD, 1992, J PHYSL, V450, P217; Geiger J., 1990, ADENOSINE ADENOSINE; GREENE RW, 1985, BRIT J PHARMACOL, V85, P163, DOI 10.1111/j.1476-5381.1985.tb08843.x; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GU JG, 1992, J NEUROCHEM, V58, P1699, DOI 10.1111/j.1471-4159.1992.tb10043.x; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HORNE J, 1992, EXPERIENTIA, V48, P941, DOI 10.1007/BF01919141; KAMONDI A, 1992, J NEUROPHYSIOL, V68, P1359, DOI 10.1152/jn.1992.68.4.1359; KUBA K, 1980, J PHYSL, V298, P547; LUEBKE JI, 1993, J NEUROPHYSIOL, V70, P2128, DOI 10.1152/jn.1993.70.5.2128; LUEBKE JI, 1992, P NATL ACAD SCI USA, V89, P743, DOI 10.1073/pnas.89.2.743; MADSEN PL, 1991, J APPL PHYSIOL, V70, P2597, DOI 10.1152/jappl.1991.70.6.2597; MAQUET P, 1992, BRAIN RES, V571, P149, DOI 10.1016/0006-8993(92)90522-B; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MCGINTY D, 1990, TRENDS NEUROSCI, V13, P480, DOI 10.1016/0166-2236(90)90081-K; MCILWAIN H, 1986, J NEUROBIOL, V17, P39, DOI 10.1002/neu.480170105; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; NEERING IR, 1984, NATURE, V309, P158, DOI 10.1038/309158a0; PAPE HC, 1992, J PHYSIOL-LONDON, V447, P729, DOI 10.1113/jphysiol.1992.sp019026; PONS F, 1980, J NEUROCHEM, V34, P1319, DOI 10.1111/j.1471-4159.1980.tb09977.x; PULL I, 1972, BIOCHEM J, V130, P975, DOI 10.1042/bj1300975; RAINNIE DG, UNPUB; SATTIN A, 1970, MOL PHARMACOL, V6, P13; SCHRADER J, 1980, PFLUG ARCH EUR J PHY, V387, P245, DOI 10.1007/BF00580977; SEMBA K, 1989, PROG BRAIN RES, V79, P37; SNYDER SH, 1985, ANNU REV NEUROSCI, V8, P103; STERIADE M, 1990, J NEUROSCI, V10, P2541; STERIADE M, 1990, J NEUROSCI, V10, P2560; STERIADE M, 1988, NEUROSCIENCE, V25, P47, DOI 10.1016/0306-4522(88)90006-1; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VINCENT SR, 1983, NEUROSCI LETT, V43, P31, DOI 10.1016/0304-3940(83)90124-6; VIRUS RM, 1990, NEUROPSYCHOPHARMACOL, V3, P243; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; WU PH, 1984, NEUROCHEM INT, V6, P613, DOI 10.1016/0197-0186(84)90043-3; YANIK G, 1987, BRAIN RES, V403, P177, DOI 10.1016/0006-8993(87)90141-7	48	262	268	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					689	692		10.1126/science.8303279	http://dx.doi.org/10.1126/science.8303279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303279	Green Accepted			2022-12-28	WOS:A1994MU96400052
J	HUTSON, HR; ANGLIN, D; PRATTS, MJ				HUTSON, HR; ANGLIN, D; PRATTS, MJ			ADOLESCENTS AND CHILDREN INJURED OR KILLED IN DRIVE-BY SHOOTINGS IN LOS-ANGELES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIREARM	Background. Drive-by shootings by violent street gangs contribute to early morbidity and mortality among adolescents and children in Los Angeles. This study attempted to determine the frequency of this problem and the population at greatest risk, We also studied the most frequently injured areas of the body, the seasons in which the most shootings occurred, the most common sites for drive-by shootings, and the types of firearms used. Methods. We retrospectively reviewed the files of the Gang Information Section of the Los Angeles Police Department to identify all drive-by shootings in Los Angeles in 1991 in which a child or adolescent under the age of 18 was shot at, injured, or killed. Results. A total of 677 adolescents and children were shot at, among whom 429 (63 percent) had gunshot wounds and 36 (5.3 percent) died from their injuries. Three hundred three of those with gunshot wounds (71 percent) were gang members. Arms and legs were the areas of the body most commonly injured. Handguns were the most frequently used type of firearm. All the homicide victims were African American or Hispanic, and 97 percent were boys. African American and Hispanic children and adolescents, especially male gang members, had a significantly higher risk than their Asian and white counterparts of injury and death from drive-by shootings in Los Angeles (P<0.001). Conclusions. Drive-by shootings involving adolescents and children are frequent in Los Angeles. Although Los Angeles may be an atypical case, understanding why violent street gangs form, preventing causes of violence, and limiting access to firearms are essential steps in preventing this serious problem.			HUTSON, HR (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT EMERGENCY MED,RM 1011,1200 N STATE ST,LOS ANGELES,CA 90033, USA.							BAR JH, 1984, BIOSTATISTICAL ANAL; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; DEAN AG, 1990, EPIINFO VERSION 5 WO; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; HUTSON HR, 1992, ANN EMERG MED, V21, P1234; JACKSON RK, 1991, UNDERSTANDING STREET; JUAREZ PD, 1992, SUBSTANCE ABUSE GANG, P43; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KLEIN MW, 1991, CRIMINOLOGY, V29, P701; MEEHAN PJ, 1992, AM J DIS CHILD, V146, P683, DOI 10.1001/archpedi.1992.02160180041014; Miller WB., 1990, GANGS AM, P263; MORALES A, 1992, SUBSTANCE ABUSE GANG, P105; PROTHROWSTITH D, 1991, DEADLY CONSEQUENCES, P11; Pynoos R.S., 1988, J TRAUMA STRESS, V1, P445, DOI [DOI 10.1002/JTS.2490010406, https://doi.org/10.1002/jts.2490010406]; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; Vigil J.D., 1988, BARRIO GANGS STREET; 1992, PEDIATRICS, V89, P784; 1990, 8 LOS ANG POL DEP OR; 1993, INTELLIGENCE OPERATI, P2; 1992, PUBLICATION BUREAU C, V16; 1991, PUBLIC HLTH REP, V106, P225	21	44	44	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					324	327		10.1056/NEJM199402033300506	http://dx.doi.org/10.1056/NEJM199402033300506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277953				2022-12-28	WOS:A1994MU48900006
J	LAMBERTENGHIDELILIERS, G				LAMBERTENGHIDELILIERS, G			SPONTANEOUS HUMAN ERYTHROCYTE ROSETTE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LAMBERTENGHIDELILIERS, G (corresponding author), UNIV MILAN,I-20122 MILAN,ITALY.								0	0	0	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					323	323						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277952				2022-12-28	WOS:A1994MU48900005
J	RUNYON, BA				RUNYON, BA			CARE OF PATIENTS WITH ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPONTANEOUS BACTERIAL PERITONITIS; BLOOD CULTURE BOTTLES; CHRONIC LIVER-DISEASE; LARGE-VOLUME PARACENTESIS; CIRRHOTIC-PATIENTS; INTRAVENOUS ALBUMIN; TENSE ASCITES; REFRACTORY ASCITES; BACTERIOLOGICAL DIAGNOSIS; THERAPEUTIC PARACENTESIS		UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa								AGUADO JM, 1990, J CLIN GASTROENTEROL, V12, P550, DOI 10.1097/00004836-199010000-00013; AKRIVIADIS EA, 1990, GASTROENTEROLOGY, V98, P127, DOI 10.1016/0016-5085(90)91300-U; ALBILLOS A, 1990, GASTROENTEROLOGY, V98, P134, DOI 10.1016/0016-5085(90)91301-L; ANTILLON MR, 1991, GASTROENTEROLOGY, V101, P1455, DOI 10.1016/0016-5085(91)90116-3; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; ASCIONE A, 1990, GASTROENTEROL INT, V3, P120; BERNARDI M, 1985, GUT, V26, P629, DOI 10.1136/gut.26.6.629; BOBADILLA M, 1989, J CLIN MICROBIOL, V27, P2145, DOI 10.1128/JCM.27.10.2145-2147.1989; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; BOYER TD, 1979, GASTROENTEROLOGY, V77, P215; BRUNO S, 1992, BRIT MED J, V304, P1655, DOI 10.1136/bmj.304.6843.1655; CADRANEL JF, 1992, INT J ARTIF ORGANS, V15, P432, DOI 10.1177/039139889201500711; CAMERON JL, 1976, ANN SURG, V184, P587, DOI 10.1097/00000658-197611000-00009; CASTELLOTE J, 1990, AM J GASTROENTEROL, V85, P1605; Chetty R, 1990, Cytopathology, V1, P233, DOI 10.1111/j.1365-2303.1990.tb00352.x; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1016/0270-9139(93)90205-2; CORREIA JP, 1975, MED CLIN N AM, V59, P963, DOI 10.1016/S0025-7125(16)31995-2; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DASKALOPOULOS G, 1987, GASTROENTEROLOGY, V92, P1859, DOI 10.1016/0016-5085(87)90616-0; FOGEL MR, 1981, J CLIN GASTROENTEROL, V3, P73, DOI 10.1097/00004836-198100031-00016; GARRISON RN, 1986, ANN SURG, V203, P644, DOI 10.1097/00000658-198606000-00009; GATTA A, 1991, HEPATOLOGY, V14, P231, DOI 10.1002/hep.1840140205; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; GOLDBERG BB, 1970, RADIOLOGY, V96, P15, DOI 10.1148/96.1.15; HOEFS JC, 1983, J LAB CLIN MED, V102, P260; Kammerer J, 1982, Med Chir Dig, V11, P243; KAO HW, 1985, HEPATOLOGY, V5, P403, DOI 10.1002/hep.1840050310; KOCEN RS, 1963, LANCET, V1, P527; MAATHUIS JB, 1978, J ENDOCRINOL, V76, P123, DOI 10.1677/joe.0.0760123; MAUK PM, 1988, ARCH INTERN MED, V148, P1577, DOI 10.1001/archinte.148.7.1577; MCVAY PA, 1991, TRANSFUSION, V31, P164, DOI 10.1046/j.1537-2995.1991.31291142949.x; PEREZAYUSO RM, 1983, GASTROENTEROLOGY, V84, P961; PINTO PC, 1988, HEPATOLOGY, V8, P207, DOI 10.1002/hep.1840080202; PINZELLO G, 1983, HEPATOLOGY, V3, P545; PLANAS R, 1990, GASTROENTEROLOGY, V99, P1736, DOI 10.1016/0016-5085(90)90481-F; POCKROS PJ, 1986, GASTROENTEROLOGY, V90, P1827, DOI 10.1016/0016-5085(86)90249-0; POCKROS PJ, 1992, GASTROENTEROLOGY, V103, P1302, DOI 10.1016/0016-5085(92)91520-E; REYNOLDS TB, 1960, NEW ENGL J MED, V263, P734, DOI 10.1056/NEJM196010132631505; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; RUNYON BA, 1990, J CLIN MICROBIOL, V28, P2811, DOI 10.1128/JCM.28.12.2811-2812.1990; RUNYON BA, 1988, J CLIN GASTROENTEROL, V10, P410, DOI 10.1097/00004836-198808000-00013; RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; RUNYON BA, 1986, HEPATOLOGY, V6, P1443, DOI 10.1002/hep.1840060649; RUNYON BA, 1986, J HEPATOL, V3, P219, DOI 10.1016/S0168-8278(86)80029-0; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; RUNYON BA, 1987, ARCH INTERN MED, V147, P73, DOI 10.1001/archinte.147.1.73; RUNYON BA, 1986, ARCH INTERN MED, V146, P2259, DOI 10.1001/archinte.146.11.2259; RUNYON BA, 1991, HEPATOLOGY, V13, P929, DOI 10.1016/0270-9139(91)90265-W; RUNYON BA, 1989, GASTROENTEROLOGY, V97, P158, DOI 10.1016/0016-5085(89)91430-3; RUNYON BA, 1987, J CLIN GASTROENTEROL, V9, P172, DOI 10.1097/00004836-198704000-00012; RUNYON BA, 1992, HEPATOLOGY, V16, pA85; RUNYON BA, 1991, TXB GASTROENTEROLOGY, P846; Runyon BA, 1991, TXB GASTROENTEROLOGY, P2455; SHEAR L, 1970, NEW ENGL J MED, V282, P1391, DOI 10.1056/NEJM197006182822502; SIERSEMA PD, 1992, J CLIN MICROBIOL, V30, P667, DOI 10.1128/JCM.30.3.667-669.1992; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; SUNGAILA I, 1992, GASTROENTEROLOGY, V102, P1680, DOI 10.1016/0016-5085(92)91730-R; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; YAMADA S, 1970, GASTROENTEROLOGY, V59, P833	68	242	260	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					337	342		10.1056/NEJM199402033300508	http://dx.doi.org/10.1056/NEJM199402033300508			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277955				2022-12-28	WOS:A1994MU48900008
J	CARO, TM; LAURENSON, MK				CARO, TM; LAURENSON, MK			ECOLOGICAL AND GENETIC-FACTORS IN CONSERVATION - A CAUTIONARY TALE	SCIENCE			English	Article							ACINONYX-JUBATUS; POPULATION; CHEETAHS; BOTTLENECKS; PREVALENCE; RHINOCEROS; PATTERNS		GAME CONSERVANCY, UPLAND RES GRP, NEWTONMORE PH20 1BE, INVERNESS, SCOTLAND		CARO, TM (corresponding author), UNIV CALIF DAVIS, DEPT WILDLIFE & FISHERIES BIOL, DAVIS, CA 95616 USA.							Allendorf F.W., 1986, P57; ALLENDORF FW, 1991, INTRO EVOLUTIONARY E, P57; AMMANN K, 1987, BEHAV ECOL SOCIOBIOL, V20, P351; Burney D. A., 1980, THESIS U NAIROBI KEN; CARO TM, 1993, ZOO BIOL, V12, P19, DOI 10.1002/zoo.1430120105; CARO TM, IN PRESS CHEETAHS SE; DINERSTEIN E, 1990, CONSERV BIOL, V4, P417, DOI 10.1111/j.1523-1739.1990.tb00316.x; EHRLICH P R, 1987, Conservation Biology, V1, P122, DOI 10.1111/j.1523-1739.1987.tb00021.x; EVERMANN JF, 1993, ZOO BIOL, V12, P125, DOI 10.1002/zoo.1430120111; FRAMEG, 1981, SWIFT ENDURING CHEET; FRANCE RL, 1993, CONSERV BIOL, V7, P184, DOI 10.1046/j.1523-1739.1993.07010184.x; Franklin I.R., 1980, CONSERVATION BIOL EV; GREENWOOD PJ, 1978, NATURE, V271, P52, DOI 10.1038/271052a0; HARCOURT S, 1991, NATURE, V354, P10, DOI 10.1038/354010a0; HEENEY JL, 1990, J VIROL, V64, P1964, DOI 10.1128/JVI.64.5.1964-1972.1990; HILL JL, 1974, SCIENCE, V186, P1042, DOI 10.1126/science.186.4168.1042; HORZINEK M, 1978, AM J VET RES, V40, P1387; Lacy R.C., 1989, P83; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LAURENSON MK, 1992, RES EXPLOR, V8, P64; LAURENSON MK, IN PRESS SERENGETI, V2; LAURENSON MK, IN PRESS J ZOOL; LAURENSON MK, IN PRESS ANIM BEHAV; LAURENSON MK, UNPUB; LEADERWILLIAMS N, 1990, J APPL ECOL, V27, P1055, DOI 10.2307/2404395; LEBERG PL, 1993, CONSERV BIOL, V7, P194, DOI 10.1046/j.1523-1739.1993.07010194.x; LOUDON A.S.I., 1985, S ZOOLOGICAL SOC LON, V54, P183; LOVEJOY TE, 1990, J APPL ECOL, V27, P257; MARKER L, 1989, ZOO BIOL, V8, P3, DOI 10.1002/zoo.1430080103; MARKERKRAUS L, 1990, INT CHEETAH STUDBOOK; MYERS N, 1975, INT UNION CONSERV NA, V8; NEVO E, 1978, THEOR POPUL BIOL, V13, P121, DOI 10.1016/0040-5809(78)90039-4; NEWMAN A, 1985, J MAMMAL, V66, P256, DOI 10.2307/1381238; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; OBRIEN SJ, 1983, SCIENCE, V221, P459, DOI 10.1126/science.221.4609.459; OBRIEN SJ, 1987, P NATL ACAD SCI USA, V84, P508, DOI 10.1073/pnas.84.2.508; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; PACKER C, 1991, CONSERV BIOL, V5, P219, DOI 10.1111/j.1523-1739.1991.tb00127.x; PIMM SL, 1989, TRENDS ECOL EVOL, V4, P176, DOI 10.1016/0169-5347(89)90123-7; RALLS K, 1983, BIOL CONSERV, V25, P209, DOI 10.1016/0006-3207(83)90037-X; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; RIBBLE DO, 1992, CAN J ZOOL, V70, P820, DOI 10.1139/z92-116; SAVIDGE JA, 1987, ECOLOGY, V68, P660, DOI 10.2307/1938471; Schonewald-Cox C, 1983, GENETICS CONSERVATIO; SHAFFER ML, 1981, BIOSCIENCE, V31, P131, DOI 10.2307/1308256; SIMBERLOFF D, 1988, ANNU REV ECOL SYST, V19, P473, DOI 10.1146/annurev.ecolsys.19.1.473; SPENCER JA, 1991, J WILDLIFE DIS, V27, P578, DOI 10.7589/0090-3558-27.4.578; STANDER PE, 1991, THESIS CAMBRIDGE U; SUNQUIST F, 1992, WILDL CONS, V95, P38; WESTERN D, 1989, CONSERVATION 21ST CE; WILDT DE, 1993, ZOO BIOL, V12, P45, DOI 10.1002/zoo.1430120107; WILSON E O, 1992; Wright S., 1977, EVOLUTION GENETICS P, V3	54	254	266	1	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	1994	263	5146					485	486		10.1126/science.8290956	http://dx.doi.org/10.1126/science.8290956			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290956				2022-12-28	WOS:A1994MT96600021
J	LUTZ, GJ; ROME, LC				LUTZ, GJ; ROME, LC			BUILT FOR JUMPING - THE DESIGN OF THE FROG MUSCULAR SYSTEM	SCIENCE			English	Article							TWITCH MUSCLE-FIBERS; CONTRACTILE PROPERTIES; SWIMMING CARP; RANA-PIPIENS; TEMPERATURE; PERFORMANCE; COMPENSATION; VARIETIES; VELOCITY; EXTENT	Frogs must generate a high level of mechanical power when they jump. The muscular system of frogs that jump is presumably designed to deliver these high powers. The length changes and activation pattern that muscles undergo during jumping were measured, and isolated muscle bundles were driven through this in vivo pattern. During jumping muscles generated maximum power. Specifically the muscle fibers (i) operated at optimal sarcomere lengths, (ii) operated at optimal shortening velocities, and (iii) were maximally activated during power generation. Thus, many different parameters must have evolved in concert to produce a system capable of this explosive jumping movement.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104; MARINE BIOL LAB,WOODS HOLE,MA 02543	University of Pennsylvania; Marine Biological Laboratory - Woods Hole					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038404, R01AR038404] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38404] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1982, J ZOOL, V198, P293, DOI 10.1111/j.1469-7998.1982.tb02077.x; BAGNI MA, 1988, BIOPHYS J, V54, P1105, DOI 10.1016/S0006-3495(88)83046-7; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CALOW LJ, 1973, J ZOOL, V171, P293; EDMAN KAP, 1988, J PHYSIOL-LONDON, V395, P679, DOI 10.1113/jphysiol.1988.sp016941; FEDAK MA, 1982, J EXP BIOL, V79, P23; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HIRANO M, 1984, J EXP BIOL, V108, P429; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; JULIAN FJ, 1986, J PHYSIOL-LONDON, V370, P181, DOI 10.1113/jphysiol.1986.sp015929; LANNERGREN J, 1987, J MUSCLE RES CELL M, V8, P260, DOI 10.1007/BF01574594; LANNERGREN J, 1982, ACTA PHYSIOL SCAND, V114, P523, DOI 10.1111/j.1748-1716.1982.tb07020.x; LIEBER RL, 1992, ACTA ANAT, V145, P289; LUTZ GJ, 1988, NATURE, V355, P824; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; RENAUD JM, 1983, CAN J ZOOL, V61, P1284, DOI 10.1139/z83-172; RENAUD JM, 1984, J EXP BIOL, V108, P57; ROME LC, 1990, J EXP BIOL, V154, P163; ROME LC, 1993, SCIENCE, V261, P340, DOI 10.1126/science.8332898; ROME LC, 1991, AM J PHYSIOL, V260, pC289, DOI 10.1152/ajpcell.1991.260.2.C289; SMITH RS, 1973, J ANAT, V116, P1; Woledge RC., 1985, ENERGETIC ASPECTS MU	24	179	188	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					370	372		10.1126/science.8278808	http://dx.doi.org/10.1126/science.8278808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278808				2022-12-28	WOS:A1994MT03400031
J	TORGERSON, DJ; DONALDSON, C				TORGERSON, DJ; DONALDSON, C			AN ECONOMIC-VIEW OF HIGH COMPLIANCE AS A SCREENING OBJECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; TRIAL	Accepted wisdom holds that high compliance is essential for a screening programme to be successful. Indeed, a reason that the national breast screening programme is not routinely offered to women aged 65 or more is on the grounds of predicted poor compliance by older women. Increasing compliance is often associated with increased costs. These costs represent a lost opportunity for screening alternative target populations. We question the need for screening programmes to achieve high compliance, and we argue that a screening programme can be efficient with very low levels of compliance. Adopting compliance as a screening objective and as a measure of the success of screening may be detrimental to the efficiency of a screening programme.			TORGERSON, DJ (corresponding author), UNIV ABERDEEN, HLTH ECON RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Donaldson, Cam/0000-0003-4670-5340				CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHAMBERLAIN J, 1988, LANCET, V2, P411; CLARK RA, 1992, AM J ROENTGENOL, V158, P527, DOI 10.2214/ajr.158.3.1738989; CONSTANZA ME, 1992, CANCER S, V69, P1925; MOONEY G, 1986, CHOICES HLTH CARE PR; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; Townsend P., 1988, INEQUALITIES HLTH; WILLIAMS EMI, 1989, BMJ-BRIT MED J, V299, P158, DOI 10.1136/bmj.299.6692.158; WILLIAMS EMI, 1990, J PUBLIC HEALTH MED, V12, P51, DOI 10.1093/oxfordjournals.pubmed.a042506; 1989, GENERAL PRACTICE NAT; 1990, CONSOLIDATED GUIDANC; 1986, BREAST CANCER SCREEN	13	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	1994	308	6921					117	119		10.1136/bmj.308.6921.117	http://dx.doi.org/10.1136/bmj.308.6921.117			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298385	Green Published			2022-12-28	WOS:A1994MR17300022
J	YANG, JH; CEDERGREN, R; NADALGINARD, B				YANG, JH; CEDERGREN, R; NADALGINARD, B			CATALYTIC ACTIVITY OF AN RNA DOMAIN DERIVED FROM THE U6-U4 RNA COMPLEX	SCIENCE			English	Article							SMALL NUCLEAR-RNA; BASE-PAIRING INTERACTION; PRECURSOR MESSENGER-RNA; SELF-CLEAVAGE REACTION; SPLICING REACTION; U6 SNRNA; INTRONS; YEAST; SPLICEOSOME; BINDING	U6 RNA contains two regions that are essential for proper splicing of nuclear precursor messenger RNA (pre-mRNA). A comparison of putative secondary structures of the U6-U4 RNA complexes from different phyla revealed a conserved domain that is similar to the catalytic hammerhead RNA motif. Although no catalytic activity was detected in the mammalian U6-U4 RNA complexes, two nucleotide changes in U6 RNA and one in U4 RNA conferred cleavage activity to the complex. Furthermore, the highly conserved domain of the wild-type complex, without the accompanying flanking regions, cleaved an RNA substrate and exhibited other characteristics of the hammerhead ribozyme. The possible involvement of this structure in pre-mRNA splicing is also discussed.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT CARDIOL, BOSTON, MA 02115 USA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, QUEBEC, CANADA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Universite de Montreal					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036865] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR36865-08] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARK C, 1985, MOL CELL BIOL, V5, P943, DOI 10.1128/MCB.5.5.943; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CEDERGREN R, 1987, FEBS LETT, V226, P63, DOI 10.1016/0014-5793(87)80551-3; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; EPSTEIN LM, 1987, CELL, V48, P535, DOI 10.1016/0092-8674(87)90204-2; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUTHRIE C, 1988, ANNU REV GENET, V22, P397; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MARCINIEC T, 1989, ACTA BIOCHIM POL, V36, P183; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; REID SS, 1990, BIOCHEMISTRY-US, V29, P6025, DOI 10.1021/bi00477a021; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SMITH D, 1992, J BIOL CHEM, V267, P2429; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; UCHIMARU T, 1993, FASEB J, V7, P137, DOI 10.1096/fasebj.7.1.8422960; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; WASSARMAN BJ, 1990, CELL, V61, P685; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571	37	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	1994	263	5143					77	81		10.1126/science.8272868	http://dx.doi.org/10.1126/science.8272868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272868				2022-12-28	WOS:A1994MQ30100033
J	FISHER, N; TURNER, SW; PUGH, R; TAYLOR, C				FISHER, N; TURNER, SW; PUGH, R; TAYLOR, C			ESTIMATING NUMBERS OF HOMELESS AND HOMELESS MENTALLY-ILL PEOPLE IN NORTH-EAST WESTMINSTER BY USING CAPTURE-RECAPTURE ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL SERVICES; ASCERTAINMENT; LONDON	Objectives-To use routinely collected data to provide a reliable estimate of the size and psychiatric morbidity of the homeless population of a given geographical area by using capture-recapture analysis. Design-A multiple sample, log-linear capture-recapture method was applied to a defined area of central London during 6 months. The method calculates the total homeless population from the sum of the population actually observed and an estimate of the unobserved population. Data were collected from local agencies used by homeless people. Subjects-Homeless people in north east Westminster residing in bed and breakfast accommodation and hostels or sleeping rough who had contacted statutory or voluntary agencies in the area. Results-2150 contacts by 1640 homeless people were recorded. The estimated unobserved population was 3293, giving a total homeless population for the period of around 5000 (SD 1250). Mental health problems were significantly less prominent in the unobserved compared with the observed population (23% (754) v 40% (627), P < 0.0001). For both groups the prevalence varied greatly with age and sex. Conclusions-Capture-recapture techniques can overcome problems of ascertainment in estimating populations of homeless and homeless mentally ill people. Prevalences of mental illness derived from surveys that do not correct for ascertainment are likely to be falsely inflated while at the same time underestimating the total size of the homeless mentally ill population. Population estimates derived from capture-recapture techniques may usefully provide a good basis for including homeless populations in capitation calculations for allocating funds within health services.	CAMDEN & ISLINGTON COMMUNITY HLTH SERV NHS TRUST,HAMPSTEAD RD,LONDON NW12 2LT,ENGLAND; SPRINGFIELD HOSP,PATHFINDER COMMUNITY & SPECIALIST MENTAL HLTH SERV,LONDON SW17 7DJ,ENGLAND; INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND	St Georges University London; University of London; King's College London								BLACK ME, 1991, BRIT MED J, V303, P958, DOI 10.1136/bmj.303.6808.958; CONNELLY J, 1991, HOUSING HOMELESSNESS; CORMACK RM, 1989, BIOMETRICS, V45, P395, DOI 10.2307/2531485; FISHER N, 1991, PSYCHIATRIC B, V15, P73; FISHER N, 1990, LANCET, V335, P914; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; KEYES S, 1992, SICK DEATH HOMELESSN; MCCARTY DJ, 1993, INT J EPIDEMIOL, V22, P559, DOI 10.1093/ije/22.3.559; MORRISSEY JP, 1987, HOSP COMMUNITY PSYCH, V38, P811; OLDMAN J, 1990, WHO SAYS THERES NO H; PAYNE CD, 1986, GLIM SYSTEM RELEASE; SCOTT J, 1993, BRIT J PSYCHIAT, V162, P314, DOI 10.1192/bjp.162.3.314; SUDMAN S, 1988, SCIENCE, V240, P991, DOI 10.1126/science.240.4855.991; SUSSER E, 1989, HOSP COMMUNITY PSYCH, V40, P261; Tessler R., 1989, SYNTHESIS NIMH FUNDE; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725; WITTES JT, 1974, J CHRON DIS, V27, P25, DOI 10.1016/0021-9681(74)90005-8; 1991, 1991 CENSUS PRELIMIN; 1989, WORKING PATIENTS	19	72	72	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					27	30		10.1136/bmj.308.6920.27	http://dx.doi.org/10.1136/bmj.308.6920.27			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ096	8298348	Green Published			2022-12-28	WOS:A1994MQ09600025
J	INGBER, DE				INGBER, DE			THE RIDDLE OF MORPHOGENESIS - A QUESTION OF SOLUTION CHEMISTRY OR MOLECULAR CELL ENGINEERING	CELL			English	Review							NUCLEAR MATRIX; RNA		CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	INGBER, DE (corresponding author), CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115, USA.		Ingber, Donald E/AAC-5894-2019					ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BUXBAUM RE, 1988, J THEOR BIOL, V134, P379, DOI 10.1016/S0022-5193(88)80068-7; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; DAVIES PF, 1993, J CLIN INVEST, V91, P2640, DOI 10.1172/JCI116503; DEMBO M, 1989, BIOPHYS J, V55, P1053, DOI 10.1016/S0006-3495(89)82904-2; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; EVANS E, 1993, HDB BIOPHYSICS; FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; GERSHON ND, 1985, P NATL ACAD SCI USA, V82, P5030, DOI 10.1073/pnas.82.15.5030; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAMILL O, 1993, BIOPHYS J, V65, P17, DOI 10.1016/S0006-3495(93)81028-2; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; INGBER DE, 1993, J CELL SCI, V104, P613; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KISLAUSKIS EH, 1992, CURR OPIN CELL BIOL, V4, P95; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; MEIER UT, 1992, CELL, V70, P127; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEGRUTSKII BS, 1992, P NATL ACAD SCI USA, V89, P3601, DOI 10.1073/pnas.89.8.3601; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; SCALETTAR BA, 1991, P NATL ACAD SCI USA, V88, P8057, DOI 10.1073/pnas.88.18.8057; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SIMS JR, 1992, J CELL SCI, V103, P1215; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; URRY DW, 1992, PROG BIOPHYS MOL BIO, V57, P23, DOI 10.1016/0079-6107(92)90003-O; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WARD MD, 1993, BIOPHYS J, V64, P936, DOI 10.1016/S0006-3495(93)81456-5; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111	37	187	187	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1249	1252		10.1016/0092-8674(93)90612-T	http://dx.doi.org/10.1016/0092-8674(93)90612-T			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269508				2022-12-28	WOS:A1993MP86900004
J	KOLODKIN, AL; MATTHES, DJ; GOODMAN, CS				KOLODKIN, AL; MATTHES, DJ; GOODMAN, CS			THE SEMAPHORIN GENES ENCODE A FAMILY OF TRANSMEMBRANE AND SECRETED GROWTH CONE GUIDANCE MOLECULES	CELL			English	Article							IMMUNOGLOBULIN SUPERFAMILY; NEURONAL RECOGNITION; ADHESION MOLECULE; NERVOUS-SYSTEM; FASCICLIN-III; OPTIC CHIASM; DROSOPHILA; VIRUS; NEURITES; SEQUENCE	In addition to its expression on subsets of axons, grasshopper Semaphorin I (Sema I, previously called Fasciclin [Fas] IV) is expressed on an epithelial stripe in the limb bud, where it functions in the guidance of two sensory growth cones as they abruptly turn upon encountering this sema I boundary. We report here on the cloning and characterization of two sema genes in Drosophila, one in human, and the identification of two related viral sequences, all of which encode proteins with conserved Semaphorin domains. Drosophila, sema (D-Sema) I is a transmembrane protein, while D-Sema II and human Sema III are putative secreted proteins that are similar to the recently reported chick collapsin. D-Sema I and D-Sema II are expressed by subsets of neurons and muscles. Genetic analysis in Drosophila reveals that semaII is an essential gene that is required for both proper adult behavior and survival.			KOLODKIN, AL (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Matthes, David/N-3529-2017	Matthes, David/0000-0002-0198-9661	NINDS NIH HHS [NS 18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMEGADZIE BY, 1992, VIROLOGY, V186, P777, DOI 10.1016/0042-6822(92)90046-R; BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BROADIE K, IN PRESS DEVELOPMENT; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOODING LR, 1992, CELL, V71, P5; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P1595; KAPFHAMMER JP, 1986, J NEUROSCI, V6, P2527; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OCHMAN H, 1988, GENETICS, V120, P621; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBERTSON HM, 1988, GENETICS, V118, P461; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SMITH CA, 1990, SCIENCE, V248, P1029; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEHNER R, 1972, J INSECT PHYSL, V18, P1250; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	43	767	821	1	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1389	1399		10.1016/0092-8674(93)90625-Z	http://dx.doi.org/10.1016/0092-8674(93)90625-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269517				2022-12-28	WOS:A1993MP86900017
J	LI, JJ; HERSKOWITZ, I				LI, JJ; HERSKOWITZ, I			ISOLATION OF ORC6, A COMPONENT OF THE YEAST ORIGIN RECOGNITION COMPLEX BY A ONE-HYBRID SYSTEM	SCIENCE			English	Article							DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; PROTEIN; ACTIVATION; SEQUENCES; MUTANTS; GENE	Here a method is described to identify genes encoding proteins that recognize a specific DNA sequence. A bank of random protein segments tagged with a transcriptional activation domain is screened for proteins that can activate a reporter gene containing the sequence in its promoter. This strategy was used to identify an essential protein that interacts in vivo with the yeast origin of DNA replication. Matches between its predicted amino acid sequence and peptide sequence obtained from the 50-kilodalton subunit of the yeast origin recognition complex (ORC) established that the gene isolated here, ORC6, encodes this subunit. These observations provide evidence that ORC recognizes yeast replication origins in vivo.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIAID NIH HHS [AI18738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; Ausubel FM, 1988, MOL REPROD DEV; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Guthrie C, 1991, GUIDE YEAST GENETICS; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HICKS JB, 1976, GENETICS, V83, P245; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kornberg A., 1992, DNA REPLICATION; Li J. P. H., UNPUB; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Nigg E A, 1991, Semin Cell Biol, V2, P261; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	40	351	409	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1870	1874		10.1126/science.8266075	http://dx.doi.org/10.1126/science.8266075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266075				2022-12-28	WOS:A1993MM51100035
J	NOGUCHI, M; NAKAMURA, Y; RUSSELL, SM; ZIEGLER, SF; TSANG, M; CAO, XQ; LEONARD, WJ				NOGUCHI, M; NAKAMURA, Y; RUSSELL, SM; ZIEGLER, SF; TSANG, M; CAO, XQ; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN - A FUNCTIONAL COMPONENT OF THE INTERLEUKIN-7 RECEPTOR	SCIENCE			English	Article							CELL GROWTH-FACTOR; T-CELLS; SIGNAL TRANSDUCTION; FETAL THYMOCYTES; SUPERFAMILY; EXPRESSION; CLONING; SUBUNIT; GP130	The interleukin-2 receptor gamma chain (IL-2Rgamma) is a necessary component of functional IL-2 receptors. IL-2Rgamma mutations result in X-linked severe combined immunodeficiency (XSCID) in humans, a disease characterized by the presence of few or no T cells. In contrast, SCID patients with IL-2 deficiency and IL-2-deficient mice have normal numbers of T cells, suggesting that IL-2Rgamma is part of more than one cytokine receptor. By using chemical cross-linking, IL-2Rgamma was shown to be physically associated with the IL-7 receptor. The presence of IL-2Rgamma augmented both IL-7 binding affinity and the efficiency of internalization of IL-7. These findings may help explain the defects of XSCID. Given its role in more than one cytokine receptor system, the common gamma chain (gamma(c) is proposed as the designation for IL-2Rgamma.	NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; IMMUNEX CORP,SEATTLE,WA 98101	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Immunex Corporation			Leonard, Warren/AAA-1397-2022; Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FOXWELL BMJ, 1993, EUR J IMMUNOL, V23, P85, DOI 10.1002/eji.1830230114; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GOODWIN RG, 1990, CELL, V60, P940; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; HARADA N, 1992, J BIOL CHEM, V267, P22752; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, CELL, V66, P1174; LEONARD WJ, 1992, INTERLEUKIN 2, P29; LONDEI M, 1990, EUR J IMMUNOL, V20, P425, DOI 10.1002/eji.1830200228; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, UNPUB; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; WATSON JD, 1989, J IMMUNOL, V143, P1215; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	36	823	845	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1877	1880		10.1126/science.8266077	http://dx.doi.org/10.1126/science.8266077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266077	Green Submitted			2022-12-28	WOS:A1993MM51100037
J	KEE, F; TIRET, L; ROBO, JY; NICAUD, V; MCCRUM, E; EVANS, A; CAMBIEN, F				KEE, F; TIRET, L; ROBO, JY; NICAUD, V; MCCRUM, E; EVANS, A; CAMBIEN, F			RELIABILITY OF REPORTED FAMILY HISTORY OF MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; INDEPENDENT RISK FACTOR; ARTERY DISEASE; PARENTAL HISTORY; SUSCEPTIBILITY; POLYMORPHISM; HEALTH; ATTACK; MEN	Objective-To assess the reliability of reported family histories of myocardial infarction. Design-A case-control study in which reported histories of first degree relatives were validated from death certificates, general practitioners' records, and hospital notes. Setting-Participants enrolled in the Belfast centre of the World Health Organisation's study monitoring trends and determinants in cardiovascular disease (MONICA). Subjects-200 men who survived myocardial infarction and 200 age matched controls drawn randomly from the population. Main outcome measures-The sensitivity, specificity, positive predictive value, and proportion of overall agreement with validated records of reported family histories of myocardial infarction in first degree relatives; odds ratios for myocardial infarction, given at least one reported relative or at least one verified relative being affected. Results-349 of the 400 probands provided detailed family histories, reporting on 2812 first degree relatives. The overall sensitivity, specificity, and positive predictive value of reported histories were 67.3%, 96.5%, and 70.5% for cases and 68.5%, 97.7%, and 73.8% for controls. The K coefficients were modest: 0.65 for cases and 0.68 for controls. The odds ratios for myocardial infarction, given at least one affected relative, were not substantially inflated by recall bias. Some recall bias was evident for the probands' reports of their siblings' histories of myocardial infarction, the odds ratio for a reported history being 1.67 (95% confidence interval 1.09 to 2.57) and for the validated history 1.54 (1.01 to 2.37). Conclusions-Although the relative risk of disease is correctly estimated, the predictive accuracy of a casual family history of myocardial infarction may limit the effectiveness of targeted screening programmes. They may, however, complement other strategies based on genetic testing.	HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE; BANQUE ADN RECH CARDIOVASC,INSERM,SC7,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	KEE, F (corresponding author), QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,MONICA PROJECT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND.							CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; COLDITZ GA, 1991, AM J CARDIOL, V67, P933, DOI 10.1016/0002-9149(91)90163-F; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FLEISS JL, 1987, STATISTICAL METHODS; HELLER RF, 1983, J EPIDEMIOL COMMUN H, V37, P29, DOI 10.1136/jech.37.1.29; HERMANN N, 1985, AM J EPIDEMIOL, V121, P937; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KHAW KT, 1986, CIRCULATION, V74, P239, DOI 10.1161/01.CIR.74.2.239; KHOURY MJ, 1989, AM J EPIDEMIOL, V129, P183, DOI 10.1093/oxfordjournals.aje.a115107; KHOURY MJ, 1990, EPIDEMIOL REV, V12, P41, DOI 10.1093/oxfordjournals.epirev.a036061; LAUER RM, 1991, CIRCULATION, V84, P1445, DOI 10.1161/01.CIR.84.3.1445; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MERTENS TE, 1993, LANCET, V342, P418, DOI 10.1016/0140-6736(93)92820-J; MYERS RH, 1990, AM HEART J, V120, P963, DOI 10.1016/0002-8703(90)90216-K; NAPIER JA, 1972, AM J PUBLIC HEALTH N, V62, P30, DOI 10.2105/AJPH.62.1.30; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; OLAV H, 1977, AM J EPIDEMIOL, V105, P192; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; PATTERSON CC, 1990, ULSTER MED J, V59, P177; PERKINS KA, 1986, AM J EPIDEMIOL, V124, P182, DOI 10.1093/oxfordjournals.aje.a114377; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; RISSANEN AM, 1984, ATHEROSCLEROSIS, V53, P37, DOI 10.1016/0021-9150(84)90103-5; RISSANEN AM, 1979, AM J CARDIOL, V44, P60, DOI 10.1016/0002-9149(79)90251-0; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; SINGER F, 1991, AM HEART J, V121, P947, DOI 10.1016/0002-8703(91)90222-4; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SNOWDEN CB, 1982, AM J EPIDEMIOL, V115, P217, DOI 10.1093/oxfordjournals.aje.a113293; TENKATE LP, 1982, AM J CARDIOL, V50, P945, DOI 10.1016/0002-9149(82)90400-3; THELLE DS, 1979, AM J EPIDEMIOL, V110, P708, DOI 10.1093/oxfordjournals.aje.a112851	32	120	120	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1528	1530		10.1136/bmj.307.6918.1528	http://dx.doi.org/10.1136/bmj.307.6918.1528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274922	Bronze, Green Published			2022-12-28	WOS:A1993ML86900021
J	PETTERSON, B; NELSON, KB; WATSON, L; STANLEY, F				PETTERSON, B; NELSON, KB; WATSON, L; STANLEY, F			TWINS, TRIPLETS, AND CEREBRAL-PALSY IN BIRTHS IN WESTERN-AUSTRALIA IN THE 1980S	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE BIRTHS; PERINATAL-MORTALITY; TRENDS; EPIDEMIOLOGY	Objectives-To examine the rate of cerebral palsy in twins and triplets in births from 1980 to 1989 in Western Australia and to identify factors associated with increase in risk. Design-Pluralities for all births in Western Australia were identified through the standardised midwives' notification system, and cases of cerebral palsy were identified from the Western Australian cerebral palsy register. Main outcome measures-Multiple births, cerebral palsy, excluding postneonatal cause. Results-The prevalence of cerebral palsy in triplets, of 28 per 1000 survivors to 1 year (95% confidence interval 11 to 63) exceeded that in twins (7.3; 5.2 to 10) and singletons (1.6; 1.4 to 1.8). Although twins and triplets were more likely than singletons to be low in birth weight, their risks of cerebral palsy if low in birth weight were similar. In contrast, in normal birthweight categories twins had a higher rate of cerebral palsy (4.2; 2.2 to 7.7) than singletons (1.1; 1.0 to 1.3). The prevalence of cerebral palsy was similar in twins of unlike sex pairs, all of whom are dizygotic, and in like sex pairs. A twin pair in which one member died in utero was at higher risk of cerebral palsy: 96 per 1000 twin pairs (36 to 218) compared with 12 (8.2 to 17) for twin pregnancies in which both survived. There was a similar but non-significant trend for death of one triplet to be associated with increased risk of cerebral palsy in the survivors of the set. Conclusion-Triplet pregnancies produced a child with cerebral palsy 47 times more often than singleton pregnancies did and twin pregnancies eight times more often. Eighty six per cent of cerebral palsy in multiple births was in twins. As multiple births are increasing mainly because of personal and medical decisions the increased risk of cerebral palsy in multiple births is of concern.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	PETTERSON, B (corresponding author), PRINCESS MARGARET HOSP CHILDREN,WESTERN AUSTRALIAN RES INST CHILD HLTH,POB BOX D184,PERTH,WA 6001,AUSTRALIA.							BAARLETT WM, 1972, STATISTICS W AUSTR D; Botting B, 1990, 3 4 MORE STUDY TRIPL; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BRESLOW NE, 1980, SCI PUBLICATIONS, V32; BUCKENS P, 1993, AM J OBSTET GYNECOL, V168, P937; FLEISS JL, 1980, STATISTICAL METHODS, P14; GEE V, 1992, PERINATAL STATISTICS; GRETHER JK, 1985, IN PRESS PEDIATRICS; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; KIELY JL, 1990, B NEW YORK ACAD MED, V66, P618; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LEVENE MI, 1991, ARCH DIS CHILD-FETAL, V66, P1, DOI 10.1136/adc.66.1_Spec_No.1; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; MCKIMMIE M, 1993, W ASUSTR, V17, P15; MORDEL N, 1992, J PERINAT MED, V20, P117, DOI 10.1515/jpme.1992.20.2.117; PETTERSON B, 1990, AM J MED GENET, V37, P346, DOI 10.1002/ajmg.1320370311; ROSENTHAL E, 1992, NY TIMES        0526; RYDHSTROM H, 1993, J REPROD MED, V38, P142; SCHELLER JM, 1992, AM J DIS CHILD, V146, P1110, DOI 10.1001/archpedi.1992.02160210112036; SPELLACY WN, 1990, OBSTET GYNECOL, V75, P168; STANLEY F J, 1985, Neuroepidemiology, V4, P146, DOI 10.1159/000110226; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1979, PERINATAL MORTALITY; STANLEY RJ, 1980, LIVEBIRTHS PERINATAL; TAFFEL SM, 1992, VITAL HLTH STAT, V21, P1; WEBB S, 1987, MED J AUSTRALIA, V147, P151, DOI 10.5694/j.1326-5377.1987.tb133330.x	27	254	260	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1239	1243		10.1136/bmj.307.6914.1239	http://dx.doi.org/10.1136/bmj.307.6914.1239			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281055	Bronze, Green Published			2022-12-28	WOS:A1993MH00100018
J	STONE, DH				STONE, DH			HOW TO DO IT - DESIGN A QUESTIONNAIRE	BRITISH MEDICAL JOURNAL			English	Article								The design of questionnaires is a craft which has been badly neglected by the medical profession. A questionnaire should be appropriate, intelligible, unambiguous, unbiased, capable of coping with all possible responses, satisfactorily coded, piloted, and ethical. The key steps in designing a questionnaire are to: decide what data you need, select items for inclusion, design the individual questions, compose the wording, design the layout and presentation, think about coding, prepare the first draft and pretest, pilot, and evaluate the form, and perform the survey. Despite the apparently complicated nature of the task, theoretical knowledge is no substitute for practical experience.			STONE, DH (corresponding author), UNIV GLASGOW,PUBL HLTH RES UNIT,1 LILYBANK GARDENS,GLASGOW G12 8RZ,SCOTLAND.							Bennett A. E., 1975, QUESTIONNAIRES MED G; Cartwright A, 1983, HLTH SURVEYS PRACTIC; EASTWOOD RP, 1940, SALES CONTROL QUANTI; Hulley S. B., 1988, DESIGNING CLIN RES; McDowell I, 1987, MEASURING HLTH GUIDE; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; Sudman Seymour, 1982, ASKING QUESTIONS PRA	7	119	122	7	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1264	1266		10.1136/bmj.307.6914.1264	http://dx.doi.org/10.1136/bmj.307.6914.1264			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281062	Green Published, Bronze			2022-12-28	WOS:A1993MH00100029
J	JAESCHKE, R; GUYATT, G; SACKETT, DL				JAESCHKE, R; GUYATT, G; SACKETT, DL			USERS GUIDES TO THE MEDICAL LITERATURE .3. HOW TO USE AN ARTICLE ABOUT A DIAGNOSTIC-TEST .A. ARE THE RESULTS OF THE STUDY VALID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE VERIFICATION; SELECTION BIAS; SUBJECT		MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University				Tugwell, Peter/0000-0001-5062-0556; Bass, Eric/0000-0001-9106-527X; Gerstein, Hertzel/0000-0001-8072-2836				BATES SE, 1991, ANN INTERN MED, V115, P623, DOI 10.7326/0003-4819-115-8-623; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; CHOI BCK, 1992, J CLIN EPIDEMIOL, V45, P581, DOI 10.1016/0895-4356(92)90129-B; GRAY R, 1984, MED DECIS MAKING, V4, P151, DOI 10.1177/0272989X8400400204; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P53; THOMSON DMP, 1969, P NATL ACAD SCI USA, V64, P161, DOI 10.1073/pnas.64.1.161; 1990, JAMA-J AM MED ASSOC, V263, P2753	11	925	951	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					389	391		10.1001/jama.271.5.389	http://dx.doi.org/10.1001/jama.271.5.389			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283589				2022-12-28	WOS:A1994MR98300036
J	LURIE, P; BISHAW, M; CHESNEY, MA; COOKE, M; FERNANDES, MEL; HEARST, N; KATONGOLEMBIDDE, E; KOETSAWANG, S; LINDAN, CP; MANDEL, J; MHLOYI, M; COATES, TJ				LURIE, P; BISHAW, M; CHESNEY, MA; COOKE, M; FERNANDES, MEL; HEARST, N; KATONGOLEMBIDDE, E; KOETSAWANG, S; LINDAN, CP; MANDEL, J; MHLOYI, M; COATES, TJ			ETHICAL, BEHAVIORAL, AND SOCIAL ASPECTS OF HIV VACCINE TRIALS IN DEVELOPING-COUNTRIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS VACCINES; CLINICAL-TRIALS; ISSUES; AFRICA; RESEARCHERS; PREVENTION	Issue.-Several investigators are preparing to conduct efficacy trials of human immunodeficiency virus (HIV) vaccines in the developing world. Failure to adequately address the unique ethical, behavioral, and social issues that surround vaccine testing in that setting will jeopardize the success of these trials and future acquired immunodeficiency syndrome (AIDS) research in the host nation. Description of the Project.-Twelve investigators from Africa, Asia, North America, and South America reviewed previous experience with HIV trials in developing countries and explored potential solutions to these issues. Conclusions.-Host country scientists, government officials, and media must be actively involved in all aspects of the trials. Minimum prerequisites for conducting the trial include the following: (1) researching vaccines active against developing world HIV isolates; (2) establishing and maintaining an adequate technological infrastructure; (3) assessing the feasibility of recruitment in countries where the existence of HIV may be denied; (4) designing methods to obtain informed consent from each individual subject, rather than exclusively from family members or community elders; (5) creating locally appropriate instruments to measure risk behavior; (6) identifying a behavioral intervention for placebo and treatment groups; (7) making available laboratory methods to distinguish between natural HIV infection and vaccine-induced seropositivity; and (8) guaranteeing that an effective vaccine is available free of charge to the placebo group and at affordable prices to other host country residents.	UNIV ADDIS ABABA,INST DEV RES,ADDIS ABABA,ETHIOPIA; FAMILY HLTH INT AIDSCAP,SAO PAULO,BRAZIL; UGANDA CANC INST,KAMPALA,UGANDA; MAHIDOL UNIV,SIRARAJ FAMILY HLTH RES CTR,BANGKOK 10700,THAILAND; UNIV ZIMBABWE,HARARE,ZIMBABWE	Addis Ababa University; Mahidol University; University of Zimbabwe	LURIE, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY ST,6TH FLOOR,SAN FRANCISCO,CA 94105, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459, T32MH019105] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 19105, MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AJAYI OO, 1980, J MED ETHICS, V6, P61, DOI 10.1136/jme.6.2.61; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ANKRAH EM, 1989, SOC SCI MED, V29, P265, DOI 10.1016/0277-9536(89)90275-X; BARRICK B, 1988, 4TH INT C AIDS STOCK; BARRY M, 1990, NEW ENGL J MED, V322, P201; BARRY M, 1992, NEW ENGL J MED, V327, P1103; BLOWER SM, 1993, 9TH INT C AIDS BERL; CHEYNE J, 1989, REV INFECT DIS S3, V11, P5617; CHRISTAKIS NA, 1988, HASTINGS CTR REP JUN, P31; COHEN J, 1991, SCIENCE, V251, P1312, DOI 10.1126/science.2003218; COHEN J, 1993, SCIENCE, V259, P752, DOI 10.1126/science.8430324; COHEN J, 1992, SCIENCE, V258, P883, DOI 10.1126/science.1439797; COHEN J, 1992, SCIENCE, V258, P536, DOI 10.1126/science.1411563; COHEN J, 1992, SCIENCE, V258, P211, DOI 10.1126/science.1411518; Enel Patricia, 1992, AIDS Public Policy J, V7, P50; ESPARZA J, 1993, 9TH INT C AIDS BERL; GRANT RM, 1992, 8TH INT C AIDS AMST; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; KATZENSTEIN DA, 1988, AIDS, V2, P151; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; KOFF WC, 1992, 8TH INT C AIDS AMST; KONOTEYAHULU FID, 1987, LANCET, V2, P206; LAMPTEY P, 1992, 8TH INT C AIDS AMST; LEBLOND RF, 1992, 8TH INT C AIDS AMST; Macklin R, 1986, Law Med Health Care, V14, P273; MARINER WK, 1989, AM J PUBLIC HEALTH, V79, P86, DOI 10.2105/AJPH.79.1.86; MARMOR M, 1993, 9 INT C AIDS BERL; MARWICK C, 1991, JAMA-J AM MED ASSOC, V265, P2648; MATTHEWS TJ, 1988, SCI AM, V4, P120; MELTON GB, 1988, AM PSYCHOL, V43, P573, DOI 10.1037/0003-066X.43.7.573; MERZ B, 1987, JAMA-J AM MED ASSOC, V258, P1433, DOI 10.1001/jama.258.11.1433; NDINYAACHOLA JO, 1991, E AFR MED J, V68, P735; OSBORN JE, 1992, 8 INT C AIDS AMST; Sabatier Renee, 1988, BLAMING OTHERS PREJU; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; SCHOEPF BG, 1991, SOC SCI MED, V33, P749, DOI 10.1016/0277-9536(91)90374-L; SERWADDA D, 1990, LANCET, V335, P842, DOI 10.1016/0140-6736(90)90946-3; SOUTEYRAND Y, 1992, 8TH INT C AIDS AMST; TACKET CO, 1990, J INFECT DIS, V161, P356, DOI 10.1093/infdis/161.2.356; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; VERMUND SH, 1992, 8 INT C AIDS AMST; WALTERS L, 1988, SCIENCE, V239, P597, DOI 10.1126/science.3340846; WINKELSTEIN W, 1992, AUG FUT HIV VACC SAN; 1991, ETHICAL CONDUCT AIDS; 1992, NIH GUIDE GRANTS CON, V21, P3; 1978, US DHEW OS780012 NAT; 1990, PRACTICAL TECHNICAL; 1989, STATEMENT CONSULTATI	49	70	70	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					295	301		10.1001/jama.271.4.295	http://dx.doi.org/10.1001/jama.271.4.295			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR221	8295289				2022-12-28	WOS:A1994MR22100026
J	BAUREN, G; WIESLANDER, L				BAUREN, G; WIESLANDER, L			SPLICING OF BALBIANI RING-1 GENE PREMESSENGER RNA OCCURS SIMULTANEOUSLY WITH TRANSCRIPTION	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; CHIRONOMUS-TENTANS; ELECTROPHORETIC SEPARATION; INTERVENING SEQUENCES; SITE SELECTION; INVITRO; POLYADENYLATION; VISUALIZATION; SPLICEOSOMES; LOCALIZATION	The 40 kb Balbiani ring 1 (BR1) gene is at a given moment transcribed by, on average, 120 RNA polymerases. Here we directly assay the excision of introns both in the nascent and in the released nucleoplasmic BR1 pre-mRNAs, isolated by microdissection. We show that intron 3, located 3 kb from the 5' end of the pre-mRNA, is excised simultaneous with transcription. Within 2.5 min of transcription time, 50% of the pre-mRNA molecules have lost the intron. Intron 4, located 600 bases from the polyadenylation site, is excised cotranscriptionally in 5%-10% of the molecules and after or during release to the nucleoplasm in the remaining molecules. Our results demonstrate that spliceosome assembly is a cotranscriptional process in vivo and that splicing may occur during transcription but also after completed transcription, depending on the position of the intron.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Wieslander, Lars/B-4670-2016	Wieslander, Lars/0000-0003-3271-6946				AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; DANEHOLT B, 1972, NATURE-NEW BIOL, V240, P229, DOI 10.1038/newbio240229a0; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1990, EUCARYOTIC NUCLEUS S, V2, P477; EDSTROM JE, 1978, CHROMOSOMA, V66, P33, DOI 10.1007/BF00285814; EGYHAZI E, 1975, P NATL ACAD SCI USA, V72, P947, DOI 10.1073/pnas.72.3.947; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HOOG C, 1986, NUCLEIC ACIDS RES, V14, P703, DOI 10.1093/nar/14.2.703; HUANG S, 1992, Current Biology, V2, P188, DOI 10.1016/0960-9822(92)90516-D; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KEOHAVONG P, 1982, NUCLEIC ACIDS RES, V10, P1215, DOI 10.1093/nar/10.4.1215; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; Lambert B, 1975, Methods Cell Biol, V10, P17, DOI 10.1016/S0091-679X(08)60728-1; LAMOND AI, 1993, CURR BIOL, V3, P62, DOI 10.1016/0960-9822(93)90154-G; LANG KM, 1987, MOL CELL BIOL, V7, P3428, DOI 10.1128/MCB.7.10.3428; LANG KM, 1985, EMBO J, V4, P1991, DOI 10.1002/j.1460-2075.1985.tb03882.x; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LEWIN B, 1980, CELL, V22, P324, DOI 10.1016/0092-8674(80)90340-2; LONNROTH A, 1992, EXP CELL RES, V199, P292, DOI 10.1016/0014-4827(92)90437-D; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARIMAN ECM, 1983, J MOL BIOL, V163, P239, DOI 10.1016/0022-2836(83)90005-0; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCKNIGHT SL, 1979, CELL, V17, P551; MICHAUD S, 1993, GENE DEV, V7, P10018; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PAULSSON G, 1992, J MOL BIOL, V225, P349, DOI 10.1016/0022-2836(92)90926-B; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; SAMBROOK J, 1989, MOL CLONING LABORATG; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; [No title captured]	65	240	242	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					183	192		10.1016/0092-8674(94)90182-1	http://dx.doi.org/10.1016/0092-8674(94)90182-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287477				2022-12-28	WOS:A1994MR49500016
J	LI, M; MOYLE, H; SUSSKIND, MM				LI, M; MOYLE, H; SUSSKIND, MM			TARGET OF THE TRANSCRIPTIONAL ACTIVATION FUNCTION OF PHAGE-LAMBDA CL-PROTEIN	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; SIGMA-70 SUBUNIT; POSITIVE CONTROL; PROMOTER RECOGNITION; PRM PROMOTER; REPRESSOR; MUTATIONS; INITIATION; SPECIFICITY	Activation of transcription initiation by the cl protein of phage lambda is thought to be mediated by a direct interaction between cl and RNA polymerase at the P(RM) promoter. Two negatively charged amino acid residues in the DNA binding domain of cl play a key role in activation, suggesting that these residues contact RNA polymerase. The subunit of RNA polymerase involved was identified by selecting polymerase mutants that restored the activation function of a mutant form of cl protein. Although previous studies suggest that several activators interact with the alpha subunit of RNA polymerase, the results here suggest that cl interacts with the sigma subunit. An arginine to histidine change near the carboxyl terminus of sigma specifically suppresses an aspartic acid to asparagine change in the activation region of cl. This finding supports the direct-contact model and suggests that a cluster of positively charged residues near the carboxyl terminus of sigma is the target of the negatively charged activation region of cl.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California					NIGMS NIH HHS [GM36811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; EBRIGHT R, UNPUB; FONG RSC, 1988, IN PRESS J MOL BIOL, V200, P735; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRANA D, 1985, GENETICS, V110, P1; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAYWARD RB, UNPUB; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOCHSCHILD A, UNPUB; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; HWANG JJ, 1988, J MOL BIOL, V200, P735, DOI 10.1016/0022-2836(88)90484-6; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEENER J, 1993, P NATL ACAD SCI USA, V90, P1751, DOI 10.1073/pnas.90.5.1751; MAKINO K, 1993, GENE DEV, V7, P149, DOI 10.1101/gad.7.1.149; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; Miller J.H., 1972, EXPT MOL GENETICS; PTASHNE M, 1992, GENETIC SWITCH GENE; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIEGELE DA, 1988, J MOL BIOL, V203, P29, DOI 10.1016/0022-2836(88)90088-5; SILVERSTONE AE, 1972, MOL GEN GENET, V118, P223, DOI 10.1007/BF00333459; SMITH HO, 1964, P NATL ACAD SCI USA, V52, P356, DOI 10.1073/pnas.52.2.356; TSAI SP, 1989, J GEN MICROBIOL, V135, P2561; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6	28	151	152	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					75	77		10.1126/science.8272867	http://dx.doi.org/10.1126/science.8272867			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272867				2022-12-28	WOS:A1994MQ30100032
J	SASAKI, YC; SUZUKI, Y; ISHIBASHI, T				SASAKI, YC; SUZUKI, Y; ISHIBASHI, T			FLUORESCENT X-RAY INTERFERENCE FROM A PROTEIN MONOLAYER	SCIENCE			English	Article							SURFACE	Fluorescent x-ray interference patterns have been observed from monolayers of both a metal-containing protein (ferritin) and a nonmetal-containing protein [bovine serum albumin (BSA)] bound on a gold substrate. These interference patterns have been used to determine structure data. The nonmetal-containing protein was first reacted with metal ions by means of a chelate compound to place the necessary chromophore in the molecule. The size of the ferritin core measured by a scanning electron microscope agrees with the value obtained from the x-ray interference experiments. In the BSA molecule, the measured interference fringe is consistent with the model in which the short axes of BSA molecules are perpendicular to the surface substrate.			SASAKI, YC (corresponding author), HITACHI LTD,ADV RES LAB,HATOYAMA,SAITAMA 35003,JAPAN.		SASAKI, Yuji/N-6880-2016	SASAKI, Yuji/0000-0003-3403-237X				BEDZYK MJ, 1989, PHYS REV LETT, V62, P1376, DOI 10.1103/PhysRevLett.62.1376; Born M., 1980, PRINCIPLES OPTICS EL, V6th, P55; CHATTERJ.A, 1965, J MOL BIOL, V11, P432, DOI 10.1016/S0022-2836(65)80068-7; FROMHERZ P, 1971, NATURE, V231, P267, DOI 10.1038/231267a0; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020-708X(82)90144-2; HUTTON JT, 1985, PHYS REV B, V31, P6420, DOI 10.1103/PhysRevB.31.6420; Kossel W, 1935, Z PHYS, V94, P139, DOI 10.1007/BF01330803; SASAKI Y, 1990, APPL PHYS A-MATER, V50, P397, DOI 10.1007/BF00323597; SASAKI YC, 1993, PHYS REV B, V48, P7724, DOI 10.1103/PhysRevB.48.7724; TOMIOKA Y, 1990, CHEM PHYS LETT, V174, P433, DOI 10.1016/S0009-2614(90)87175-Q; von Laue M, 1935, ANN PHYS-BERLIN, V23, P705	12	21	21	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					62	64		10.1126/science.8272866	http://dx.doi.org/10.1126/science.8272866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272866				2022-12-28	WOS:A1994MQ30100027
J	EGLESTON, CV; KELLY, HC; COPE, AR				EGLESTON, CV; KELLY, HC; COPE, AR			USE OF A TELEPHONE ADVICE LINE IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article											EGLESTON, CV (corresponding author), PETERBOROUGH DIST GEN HOSP,DEPT ACCID & EMERGENCY,PETERBOROUGH PE3 6DA,ENGLAND.							[Anonymous], 1992, GUIDELINES HANDLING; ISSACMAN DJ, 1992, PEDIATRICS, V89, P35; Knowles P J, 1984, J Emerg Nurs, V10, P283; MARKLUND B, 1990, FAM PRACT, V7, P184, DOI 10.1093/fampra/7.3.184; 1992, NHS ACCIDENT EMERGEN	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					31	31		10.1136/bmj.308.6920.31	http://dx.doi.org/10.1136/bmj.308.6920.31			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298351	Green Published			2022-12-28	WOS:A1994MQ09600027
J	GOODMAN, NW				GOODMAN, NW			PARADIGM, PARAMETER, PARALYSIS OF MIND	BRITISH MEDICAL JOURNAL			English	Article											GOODMAN, NW (corresponding author), UNIV BRISTOL, SOUTHMEAD HOSP, BRISTOL BS10 5NB, AVON, ENGLAND.							GREENBAUM S, 1988, GUIDE ENGLISH USAGE; GREGORY MW, 1992, NATURE, V360, P11, DOI 10.1038/360011a0; HAYAKAWA SI, 1971, PENGUIN MODERN GUIDE; Howard P., 1983, WEASEL WORDS; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Masterman Margaret, 1970, CRITICISM GROWTH KNO; SIMPSON JA, 1991, COMPACT OXFORD ENGLI; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	8	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1627	1629		10.1136/bmj.307.6919.1627	http://dx.doi.org/10.1136/bmj.307.6919.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292964	Bronze, Green Published			2022-12-28	WOS:A1993MN10700032
J	ROBBINS, AS; MANSON, JE; LEE, IM; SATTERFIELD, S; HENNEKENS, CH				ROBBINS, AS; MANSON, JE; LEE, IM; SATTERFIELD, S; HENNEKENS, CH			CIGARETTE-SMOKING AND STROKE IN A COHORT OF US MALE PHYSICIANS	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; CEREBROVASCULAR DISORDERS; PHYSICIANS; RISK FACTORS; ALCOHOL DRINKING	CORONARY HEART-DISEASE; RISK-FACTORS; ALCOHOL-CONSUMPTION; CEREBRAL-HEMORRHAGE; BLOOD-PRESSURE; MEN; MORTALITY; INFARCTION; COMMUNITY; SMOKERS	Objective: To examine the association between cigarette smoking and the risk for stroke in men. Design: Prospective cohort study. Setting: Participants in the Physicians' Health Study, a randomized trial of aspirin and beta-carotene among U.S. male physicians. Patients: 22 071 men, 40 to 84 years of age at entry, free from self-reported myocardial infarction, stroke, and transient ischemic attack; followed for an average of 9.7 years; and classified as never-smokers, current smokers, and former smokers based on self-report.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; [Anonymous], 1988, NEW ENGL J MED; ARONOW WS, 1987, J AM GERIATR SOC, V35, P1; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRETT GZ, 1968, BRIT MED J, V3, P82, DOI 10.1136/bmj.3.5610.82; CHOPRA JS, 1979, ACTA NEUROL SCAND, V60, P289; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1980, CIRCULATION, V62, P70; DAVIS JW, 1979, AM J MED SCI, V278, P139, DOI 10.1097/00000441-197909000-00004; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DYKEN ML, 1984, STROKE, V15, P1105; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; Kannel W B, 1992, Cardiovasc Clin, V22, P9; Kannel WB, 1971, STROKE, V2, P295, DOI 10.1161/01.STR.2.4.295; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KHAN HA, 1966, NATL CANCER I MONOGR, V19, P127; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; KONO S, 1985, J CANCER RES CLIN, V110, P161, DOI 10.1007/BF00402732; MANSON JE, 1990, AM J MED, V89, P772, DOI 10.1016/0002-9343(90)90220-8; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NOMURA A, 1974, STROKE, V5, P483, DOI 10.1161/01.STR.5.4.483; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; OSTFELD AM, 1974, AM J PUBLIC HEALTH, V64, P450, DOI 10.2105/AJPH.64.5.450; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; RENAUD S, 1984, CLIN PHARMACOL THER, V36, P389, DOI 10.1038/clpt.1984.193; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SELVIN S, 1991, STATISTICAL ANAL EPI, P318; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SIEFFERT GF, 1981, SURG FORUM, V32, P333; SMITH JR, 1978, NEW ENGL J MED, V298, P6, DOI 10.1056/NEJM197801052980102; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1992, MMWR MORB MORTAL WKL, V42, P230; 1992, 1993 HEART STROKE FA, P10; 1989, SAS SYSTEM RELEASE; [No title captured]	51	100	102	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					458	462		10.7326/0003-4819-120-6-199403150-00002	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311368				2022-12-28	WOS:A1994NB62500002
J	FIORE, MC; EPPS, RP; MANLEY, MW; ALDEN, ER; BECKETT, WS; BERGEISEN, L; BLUM, AM; DOWNING, JW; HAFLER, JP; LOBECK, CC; MATORY, WE; POMREHN, PR; WILKES, MS				FIORE, MC; EPPS, RP; MANLEY, MW; ALDEN, ER; BECKETT, WS; BERGEISEN, L; BLUM, AM; DOWNING, JW; HAFLER, JP; LOBECK, CC; MATORY, WE; POMREHN, PR; WILKES, MS			A MISSED OPPORTUNITY - TEACHING MEDICAL-STUDENTS TO HELP THEIR PATIENTS SUCCESSFULLY QUIT SMOKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; TOBACCO USE; PHYSICIANS; CESSATION; PREVENTION; ATTITUDES; PROGRAM; SCHOOLS		UNIV WISCONSIN, SCH MED, DEPT MED, GEN INTERNAL MED SECT, MADISON, WI USA; NCI, DIV CANC PREVENT & CONTROL, CANC CONTROL SCI PROGRAM, BETHESDA, MD 20892 USA; NCI, SMOKING TOBACCO & CANC PROGRAM, BETHESDA, MD USA; AMER ACAD PEDIAT, DEPT EDUC, WASHINGTON, DC USA; YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT USA; YALE UNIV, SCH MED, DEPT PUBL HLTH, NEW HAVEN, CT 06510 USA; ASSOC AMER MED COLL, WASHINGTON, DC USA; DOCTORS OUGHT CARE, HOUSTON, TX USA; HOWARD UNIV, COLL MED, ASSOC MED SCH PEDIAT, WASHINGTON, DC USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI USA; UNIV WISCONSIN, SCH MED, DEPT PREVENT MED, MADISON, WI USA; NCI, APPLICAT PREVENT & EARLY DETECT SECT, BETHESDA, MD USA; UNIV IOWA, COLL MED, IOWA CITY, IA USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Education; Yale University; Yale University; Yale University; Association of American Medical Colleges; Howard University; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	FIORE, MC (corresponding author), UNIV WISCONSIN, CTR TOBACCO RES & INTERVENT, SCH MED, ROOM 7575 MSC, 1300 UNIV AVE, MADISON, WI 53606 USA.							ALLEN SS, 1990, AM J PREV MED, V6, P28, DOI 10.1016/S0749-3797(18)31041-9; [Anonymous], 1993, MMWR-MORBID MORTAL W, V42, P854; BLUM A, 1980, JAMA-J AM MED ASSOC, V243, P739, DOI 10.1001/jama.243.8.739; BLUM A, 1985, NEW ENGL J MED, V312, P1712; Epps R P, 1990, J Fla Med Assoc, V77, P454; EPPS RP, 1991, PEDIATRICS, V88, P140; ERAKER SA, 1985, AM J MED, V78, P817, DOI 10.1016/0002-9343(85)90289-X; FIORE M, 1988, SMOKING HLTH 1987, P189; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GILPIN E, 1992, TOBACCO CONTROL, V0001; GINZEL KH, 1985, NY STATE J MED   JUL, P299; GLYNN TJ, 1990, NIH9093064 US DEP HL; GREENLAND P, 1988, PREV MED, V17, P700, DOI 10.1016/0091-7435(88)90089-8; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HORTON J, 1986, CANCER DETECT PREV, V9, P417; HULL AL, 1990, TEACH LEARN MED, V23, P157; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; OCKENE JK, 1991, J GEN INTERN MED, V8, P1; ORLEANS CT, 1985, ANNU REV MED, V36, P51; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; RICHARDS J, 1985, NEW ENGL J MED, V312, P1712; SCOTT CS, 1985, SOC SCI MED, V21, P299, DOI 10.1016/0277-9536(85)90105-4; SEGALL A, 1981, J MED EDUC, V56, P324; Shank J C, 1985, Fam Med, V17, P96; SHERIN K, 1982, POSTGRAD MED, V71, P99; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WELLS KB, 1984, MED CARE, V22, P360, DOI 10.1097/00005650-198404000-00007; YOUNG RL, 1990, J SCHOOL HEALTH, V60, P463, DOI 10.1111/j.1746-1561.1990.tb05979.x; 1993, WORLD NO TOBACCO DAY, P12; 1991, DOC NEWS VIEWS, V6, P5; 1993, MMWR MORB MORTAL WKL, V42, P645; 1979, PHS7950066 US DHEW P; 1993, MMWR MORB MORTAL WKL, V42, P230; 1987, JAMA-J AM MED ASSOC, V257, P1916; 1982, DHHS PHS8250179 US D	35	71	73	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					624	626		10.1001/jama.271.8.624	http://dx.doi.org/10.1001/jama.271.8.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301797				2022-12-28	WOS:A1994MW47700028
J	WANG, EH; TJIAN, R				WANG, EH; TJIAN, R			PROMOTER-SELECTIVE TRANSCRIPTIONAL DEFECT IN CELL-CYCLE MUTANT TS13 RESCUED BY HTAF(II)250	SCIENCE			English	Article							DNA-BINDING PROTEIN; TATA-LESS PROMOTER; TFIID COMPLEX; REPLICATION; GENE; PROGRESSION; EXPRESSION; COACTIVATORS; ACTIVATION; REQUIRES	The TAF(II)250 subunit of the human transcription factor IID (TFIID) rescues the temperature-sensitive hamster cell line ts13 and overcomes a G1 arrest. Investigation of the transcriptional properties of ts13 nuclear extracts in vitro showed that activation by the site-specific regulators Sp1 and Gal4VP16 is temperature sensitive in ts13 extracts, whereas basal transcription remains unaffected. This transcriptional defect can be rescued by purified human TFIID or by expression of wild-type TAF(II)250 in ts13 cells. Expression from the cyclin A but not c-fos promoter is temperature sensitive in these mutant cells. Thus, the mutation in TAF(II)250 appears to have gene-specific effects that may lead to the ts13 cell cycle phenotype.			WANG, EH (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; LIN YS, 1988, CELL, V54, P65; LIU HT, 1985, J BIOL CHEM, V260, P3269; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SEKIGUCHI T, COMMUNICATION; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WANG EG, UNPUB; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	32	151	154	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					811	814		10.1126/science.8303298	http://dx.doi.org/10.1126/science.8303298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303298				2022-12-28	WOS:A1994MV86600036
J	BROOKS, A; LITHGOW, GJ; JOHNSON, TE				BROOKS, A; LITHGOW, GJ; JOHNSON, TE			MORTALITY-RATES IN A GENETICALLY HETEROGENEOUS POPULATION OF CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							LIFE-SPAN	Age-specific mortality rates in isogenic populations of the nematode Caenorhabditis elegans increase exponentially throughout life. In genetically heterogeneous populations, age-specific mortality increases exponentially until about 17 days and then remains constant until the last death occurs at about 60 days. This period of constant age-specific mortality results from genetic heterogeneity. Subpopulations differ in mean life-span, but they all exhibit near exponential, albeit different, rates of increase in age-specific mortality. Thus, much of the observed heterogeneity in mortality rates later in life could result from genetic heterogeneity and not from an inherent effect of aging.	UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; UNIV COLORADO,DEPT PSYCHOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder				/0000-0001-7147-8237	NATIONAL INSTITUTE ON AGING [K04AG000369, R01AG010248, R01AG008332] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG10248, K04-AG00369, R01-AG08332] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROCK DB, 1990, HDB BIOL AGING, P3; BROOKS A, 1991, HEREDITY, V67, P19, DOI 10.1038/hdy.1991.60; Brooks A, UNPUB; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; Charlesworth B., 1994, EVOLUTION AGE STRUCT, V2nd ed, edited by C. Cannings, F. C. Hoppensteadt, and L. A. Segel.; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; FABIAN TJ, IN PRESS J GERONTOL; FABIAN TJ, UNPUB; FINCH CE, 1990, SCIENCE, V249, P902, DOI 10.1126/science.2392680; Finch CE, 1990, LONGEVITY SENESCENCE; FRIES JF, 1988, PERSPECT BIOL MED, V31, P407; Gavrilov L.A., 1991, BIOL LIFE SPAN QUANT; GOMPERTZ B, 1825, PHILOS T R SOC LON A, V57, P289; JOHNSON TE, 1988, EXP GERONTOL, V23, P281, DOI 10.1016/0531-5565(88)90031-9; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; Kirkwood T., 1985, HDB BIOL AGING, P2743; KOWALD A, 1993, SCIENCE, V260, P1664, DOI 10.1126/science.8503014; NORUSSIS MJ, 1990, SPSS PC PLUS ADV STA; NORUSSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; SACHER GA, 1977, HDB BIOL AGING, P582; Tabachnick B.G., 2019, USING MULTIVARIATE S, V7th; WITTEN M, 1988, MECH AGEING DEV, V46, P175, DOI 10.1016/0047-6374(88)90124-8; 1990, SAS STAT USERS GUIDE, V2, P936	27	145	153	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					668	671		10.1126/science.8303273	http://dx.doi.org/10.1126/science.8303273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303273				2022-12-28	WOS:A1994MU96400044
J	FULHORST, CF; HARDY, JL; ELDRIDGE, BF; PRESSER, SB; REEVES, WC				FULHORST, CF; HARDY, JL; ELDRIDGE, BF; PRESSER, SB; REEVES, WC			NATURAL VERTICAL TRANSMISSION OF WESTERN EQUINE ENCEPHALOMYELITIS VIRUS IN MOSQUITOS	SCIENCE			English	Article							CALIFORNIA; CULICIDAE; DIPTERA	The mechanism by which western equine encephalomyelitis (WEE) virus and other mosquito-borne alphaviruses (Togaviridae) survive during periods of vector inactivity is unknown. Recently, three strains of WEE virus were isolated from adult Aedes dorsalis collected as larvae from a salt marsh in a coastal region of California. This provides evidence of vertical transmission of WEE virus in mosquitoes in nature. Vertical transmission in Ae. dorsalis and closely related mosquito species may be an important mechanism for the maintenance of WEE virus in temperate regions in North America where horizontal transmission of the virus is seasonal.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616	University of California System; University of California Berkeley; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI003028, R01AI026154, R22AI003028] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-03028, AI-26154] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAMPBELL GL, 1991, AM J TROP MED HYG, V44, P244, DOI 10.4269/ajtmh.1991.44.244; CHAMBERLAIN R, 1961, ANNU REV ENTOMOL, V6, P371, DOI 10.1146/annurev.en.06.010161.002103; ELDRIDGE BF, 1991, J MED ENTOMOL, V28, P645, DOI 10.1093/jmedent/28.5.645; HARDY JL, 1987, AM J TROP MED HYG, V37, pS18, DOI 10.4269/ajtmh.1987.37.18S; HAYES RO, 1962, AM J HYG, V75, P183, DOI 10.1093/oxfordjournals.aje.a120242; KAY BH, 1982, AUST J EXP BIOL MED, V60, P339, DOI 10.1038/icb.1982.37; LINDSEY HS, 1976, J CLIN MICROBIOL, V4, P503; OVENDEN JR, 1984, J MED ENTOMOL, V21, P292, DOI 10.1093/jmedent/21.3.292; REEVES WC, 1990, EPIDEMIOLOGY CONTROL; Reisen W.K.M.T., 1988, ARBOVIRUSES EPIDEMIO, P89; ROSEN L, 1987, AM J TROP MED HYG, V37, pS69, DOI 10.4269/ajtmh.1987.37.69S; STONES PB, CITED INDIRECTLY; TIKASINGH E. S., 1966, AMER J TROP MED HYG, V15, P219	13	39	42	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					676	678		10.1126/science.8303276	http://dx.doi.org/10.1126/science.8303276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303276				2022-12-28	WOS:A1994MU96400047
J	STUDITSKY, VM; CLARK, DJ; FELSENFELD, G				STUDITSKY, VM; CLARK, DJ; FELSENFELD, G			A HISTONE OCTAMER CAN STEP AROUND A TRANSCRIBING POLYMERASE WITHOUT LEAVING THE TEMPLATE	CELL			English	Article							RNA-POLYMERASE; NUCLEOSOME CORE; CHROMATIN STRUCTURE; ELONGATION COMPLEXES; DNA-TEMPLATE; TRANSCRIPTION; GENE; DISPLACEMENT; RESOLUTION; EXPRESSION	The mechanism by which nucleosome cores are displaced and re-formed during transcription in vitro has been investigated. A nucleosome core was assembled on a short linear DNA template (227 bp) containing an SP6 RNA polymerase promoter and a nucleosome-positioning sequence. Transcription induced the translocation of the nucleosome core over 75 or 80 bp to two positions at the other end of the template, blocking the promoter. At low rNTP concentrations, transfer occurred only on the same template molecule, even in the presence of large excesses of competitor DNA. On a longer template (262 bp), nucleosome core position after transcription depended on its position before transcription. The data suggest that the octamer transfers without dissociation from DNA and provide strong evidence for a translocation mechanism in which DNA ahead of the polymerase uncoils from the octamer as the DNA behind coils around it. In this way, the octamer steps around the transcribing polymerase.			STUDITSKY, VM (corresponding author), NIAID,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Studitsky, Vasily/A-9382-2014					ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BROWN JE, 1986, NUCLEIC ACIDS RES, V14, P3521, DOI 10.1093/nar/14.8.3521; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; KAMAKAKA RT, 1990, CELL, V11, P1941; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHR D, 1983, NUCLEIC ACIDS RES, V11, P6755, DOI 10.1093/nar/11.19.6755; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NAM SC, 1988, J BIOL CHEM, V263, P18123; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; STEIN AD, 1977, P NATL ACAD SCI USA, V74, P2480; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	42	201	204	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					371	382		10.1016/0092-8674(94)90343-3	http://dx.doi.org/10.1016/0092-8674(94)90343-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293470				2022-12-28	WOS:A1994MU67800019
J	KUBAN, KCK; LEVITON, A				KUBAN, KCK; LEVITON, A			CEREBRAL-PALSY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BIRTH-WEIGHT INFANTS; CYSTIC PERIVENTRICULAR LEUKOMALACIA; PRETERM INFANTS; INTRAVENTRICULAR HEMORRHAGE; CRANIAL ULTRASOUND; WESTERN-AUSTRALIA; GESTATIONAL-AGE; INTRAPARTUM ASPHYXIA; MOTOR ABNORMALITIES; INTRAUTERINE GROWTH		CHILDRENS HOSP MED CTR,NEUROEPIDEMIOL UNIT,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				Kuban, Karl/0000-0001-5299-3567	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027306] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27306] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSU F, 1990, DEV MED CHILD NEUROL, V32, P661; BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P386, DOI 10.1001/archneur.1962.04210050022004; BEDRICK AD, 1989, AM J DIS CHILD, V143, P1139, DOI 10.1001/archpedi.1989.02150220027014; BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BENNETT FC, 1981, AM J DIS CHILD, V135, P732, DOI 10.1001/archpedi.1981.02130320046016; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR E, 1985, DEV MED CHILD NEUROL, V27, P615; BLAIR E, 1982, DEV MED CHILD NEUROL, V24, P575; Blair E, 1988, J PEDIATR, V113, P420; BOZYNSKI MEA, 1990, DEV MED CHILD NEUROL, V32, P575; BRUN A, 1979, EUR J PEDIATR, V131, P93, DOI 10.1007/BF00447471; BRYCE R L, 1985, Neuroepidemiology, V4, P24, DOI 10.1159/000110211; BUNDEY S, 1991, AM J HUM GENET, V48, P1214; CHIAMULERA C, 1990, PSYCHOPHARMACOLOGY, V102, P551, DOI 10.1007/BF02247140; COHEN ME, 1981, ANN NEUROL, V9, P353, DOI 10.1002/ana.410090407; Collier J S, 1924, Proc R Soc Med, V17, P1; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COORSSEN EA, 1991, DEV MED CHILD NEUROL, V33, P730; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; COX AD, 1992, DEV MED CHILD NEUROL, V34, P1037; DEREUCK J, 1972, ARCH NEUROL-CHICAGO, V27, P229, DOI 10.1001/archneur.1972.00490150037007; DEVRIES LS, 1988, AM J DIS CHILD, V142, P732, DOI 10.1001/archpedi.1988.02150070046023; DEVRIES LS, 1985, LANCET, V2, P137; DOWDING VM, 1988, IRISH MED J, V81, P25; DUBOWITZ LMS, 1985, ARCH DIS CHILD, V60, P349, DOI 10.1136/adc.60.4.349; EMOND A, 1989, ARCH DIS CHILD, V64, P848, DOI 10.1136/adc.64.6.848; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; ESPINOZA MI, 1991, AM J OBSTET GYNECOL, V164, P1582, DOI 10.1016/0002-9378(91)91440-8; EVANS P, 1985, ARCH DIS CHILD, V60, P940, DOI 10.1136/adc.60.10.940; EVANS PM, 1990, ARCH DIS CHILD, V65, P1329, DOI 10.1136/adc.65.12.1329; FAZZI E, 1991, ITAL J NEUROL SCI, V12, P199, DOI 10.1007/BF02337034; FELDMAN HM, 1990, PEDIATR NEUROL, V6, P296, DOI 10.1016/0887-8994(90)90020-2; FOLEY J, 1992, ACTA PAEDIATR, V81, P57, DOI 10.1111/j.1651-2227.1992.tb12079.x; FORD GW, 1990, AM J PERINAT, V7, P178, DOI 10.1055/s-2007-999475; FORD LM, 1990, PEDIATR NEUROL, V6, P363, DOI 10.1016/0887-8994(90)90001-H; FREEMAN JM, 1988, PEDIATRICS, V82, P240; GARFINKEL E, 1988, AM J PERINAT, V5, P214, DOI 10.1055/s-2007-999688; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GILLES FH, 1969, J NEUROL NEUROSUR PS, V32, P404, DOI 10.1136/jnnp.32.5.404; GOLDSTEIN RB, 1989, J CLIN ULTRASOUND, V17, P553, DOI 10.1002/jcu.1870170803; GOULD SJ, 1987, J PATHOL, V151, P197, DOI 10.1002/path.1711510307; GRAZIANI LJ, 1992, PEDIATRICS, V89, P229; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; GRUNNET ML, 1979, ARCH PATHOL LAB MED, V103, P6; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1982, DEV MED CHILD NEUROL, V24, P13; HALLUM A, 1993, DEV MED CHILD NEUROL, V35, P24; HANSEN NB, 1989, J DEV BEHAV PEDIATR, V10, P129; HENSLEIGH PA, 1986, AM J OBSTET GYNECOL, V154, P978, DOI 10.1016/0002-9378(86)90732-5; HOPE PL, 1988, DEV MED CHILD NEUROL, V30, P457; HUGHES I, 1992, DEV MED CHILD NEUROL, V34, P80; IIDA K, 1992, PEDIATR NEUROL, V8, P205, DOI 10.1016/0887-8994(92)90069-B; ILLINGWORTH RS, 1985, BRIT J OBSTET GYNAEC, V92, P122, DOI 10.1111/j.1471-0528.1985.tb01063.x; JARVIS SN, 1985, ARCH DIS CHILD, V60, P1113, DOI 10.1136/adc.60.12.1113; JOHNSON A, 1989, COMMUNITY MED, V11, P352; KADOI N, 1992, No To Hattatsu, V24, P152; KITCHEN WH, 1990, AM J PERINAT, V7, P60, DOI 10.1055/s-2007-999448; KOCH B, 1980, DEV MED CHILD NEUROL, V22, P595; KOKKONEN J, 1991, DEV MED CHILD NEUROL, V33, P1095; KRAGELOHMANN I, 1992, NEUROPEDIATRICS, V23, P46, DOI 10.1055/s-2008-1071311; KRISHNAMOORTHY KS, 1990, PEDIATRICS, V85, P1027; KYLLERMAN M, 1982, ACTA PAEDIATR SCAND, V71, P543, DOI 10.1111/j.1651-2227.1982.tb09472.x; LEGIDO A, 1991, PEDIATRICS, V88, P583; LEVENE MI, 1990, ARCH DIS CHILD, V65, P469, DOI 10.1136/adc.65.5.469; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P553; LEVY SR, 1985, ANN NEUROL, V17, P366, DOI 10.1002/ana.410170411; Little W, 1843, LANCET, P318, DOI 10.1016/S0140-6736(02)73824-5; LOW JA, 1986, AM J OBSTET GYNECOL, V155, P750, DOI 10.1016/S0002-9378(86)80013-8; LOW JA, 1990, AM J OBSTET GYNECOL, V162, P977, DOI 10.1016/0002-9378(90)91299-R; LUI K, 1990, DEV MED CHILD NEUROL, V32, P882; Lumley J, 1988, Paediatr Perinat Epidemiol, V2, P299, DOI 10.1111/j.1365-3016.1988.tb00223.x; LUTHY DA, 1987, AM J OBSTET GYNECOL, V157, P676, DOI 10.1016/S0002-9378(87)80027-3; Madsen H, 1991, Ugeskr Laeger, V153, P2610; MENT LR, 1984, ANN NEUROL, V16, P559, DOI 10.1002/ana.410160506; MILLER G, 1988, ARCH DIS CHILD, V63, P1260, DOI 10.1136/adc.63.10.1260; MOLTENI B, 1987, NEUROPEDIATRICS, V18, P75, DOI 10.1055/s-2008-1052456; MONSETCOUCHARD M, 1988, NEUROPEDIATRICS, V19, P124, DOI 10.1055/s-2008-1052415; MUTCH L, 1992, DEV MED CHILD NEUROL, V34, P547; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; Nelson K B, 1978, Adv Neurol, V19, P421; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1982, PEDIATRICS, V69, P529; NELSON KB, 1987, AM J DIS CHILD, V141, P1333, DOI 10.1001/archpedi.1987.04460120099045; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; OKA A, 1993, J NEUROSCI, V13, P1441; Ounsted M, 1987, Paediatr Perinat Epidemiol, V1, P130, DOI 10.1111/j.1365-3016.1987.tb00098.x; PALMER P, 1982, ARCH DIS CHILD, V57, P748, DOI 10.1136/adc.57.10.748; PANETH N, 1990, J PEDIATR-US, V116, P975, DOI 10.1016/S0022-3476(05)80664-X; PANETH N, 1986, PEDIATR ANN, V15, P191, DOI 10.3928/0090-4481-19860301-05; PANETH N, 1986, PEDIATR ANN, V15, P194; PANETH N, 1986, PEDIATR ANN, V15, P197; PANETH N, 1984, EPIDEMIOLOGY CEREBRA, P46; PERLMAN JM, 1987, PEDIATRICS, V80, P705; PETTERSON B, 1993, DEV MED CHILD NEUROL, V35, P202; PETTERSON B, 1990, AM J MED GENET, V37, P346, DOI 10.1002/ajmg.1320370311; PHAROAH POD, 1989, ARCH DIS CHILD, V64, P1013, DOI 10.1136/adc.64.7.1013; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1971, LANCET, V1, P308; PHAROAH POD, 1987, ARCH DIS CHILD, V62, P1035, DOI 10.1136/adc.62.10.1035; PIDCOCK FS, 1990, J PEDIATR-US, V116, P417, DOI 10.1016/S0022-3476(05)82836-7; Plochl E, 1991, Padiatr Padol, V26, P97; RANTAKALLIO P, 1987, EARLY HUM DEV, V15, P75, DOI 10.1016/0378-3782(87)90040-5; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; RIIKONEN RS, 1992, PEDIATR NEUROL, V8, P37, DOI 10.1016/0887-8994(92)90050-9; ROBERTS CJ, 1969, BRIT J PREV SOC MED, V23, P128; RUMEAUROUQUETTE C, 1992, INT J EPIDEMIOL, V21, P359, DOI 10.1093/ije/21.2.359; RYDHSTROM H, 1990, AM J OBSTET GYNECOL, V163, P528, DOI 10.1016/0002-9378(90)91190-N; SALIBA E, 1990, ARCH DIS CHILD-FETAL, V65, P1033, DOI 10.1136/adc.65.10_Spec_No.1033; SCHENKROOTLIEB AJF, 1992, DEV MED CHILD NEUROL, V34, P473; SCHER MS, 1991, PEDIATRICS, V88, P898; SCRUTTON D, 1992, DEV MED CHILD NEUROL, V34, P833; SHANKARAN S, 1989, J PEDIATR-US, V114, P109, DOI 10.1016/S0022-3476(89)80616-X; SHORTLAND D, 1988, J PERINAT MED, V16, P241, DOI 10.1515/jpme.1988.16.3.241; SHY KK, 1990, NEW ENGL J MED, V322, P588, DOI 10.1056/NEJM199003013220904; SPIERS PS, 1982, DEV MED CHILD NEUROL, V24, P20; Stanley F J, 1992, Paediatr Perinat Epidemiol, V6, P298, DOI 10.1111/j.1365-3016.1992.tb00769.x; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STANLEY FJ, 1982, DEV MED CHILD NEUROL, V24, P93; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P740; STEWART AL, 1983, ARCH DIS CHILD, V58, P598, DOI 10.1136/adc.58.8.598; SUTHERLAND GR, 1988, AM J MED GENET, V30, P493, DOI 10.1002/ajmg.1320300152; TAMISARI L, 1986, HELV PAEDIATR ACTA, V41, P399; TAUDORF K, 1986, NEUROPEDIATRICS, V17, P19, DOI 10.1055/s-2008-1052493; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; TROUNCE JQ, 1988, ARCH DIS CHILD, V63, P17, DOI 10.1136/adc.63.1.17; TRUWIT CL, 1992, AM J NEURORADIOL, V13, P67; UVEBRANT P, 1992, ACTA PAEDIATR, V81, P407, DOI 10.1111/j.1651-2227.1992.tb12259.x; VANBOGAERT P, 1992, NEURORADIOLOGY, V34, P52, DOI 10.1007/BF00588433; VANNUCCI RC, 1990, PEDIATRICS, V85, P961; VEELKEN N, 1983, NEUROPEDIATRICS, V14, P20, DOI 10.1055/s-2008-1059548; VOHR BR, 1989, J PEDIATR-US, V115, P296, DOI 10.1016/S0022-3476(89)80089-7; VOHR BR, 1990, J PEDIATR, V116, P496; VOLPE JJ, 1992, AM J NEURORADIOL, V13, P79; VONWENDT L, 1985, ANN CLIN RES, V17, P156; VOORHIES TM, 1984, J PEDIATR-US, V105, P92, DOI 10.1016/S0022-3476(84)80370-4; WATKINS AMC, 1989, EARLY HUM DEV, V19, P103, DOI 10.1016/0378-3782(89)90120-5; WEINDLING AM, 1985, BRIT J OBSTET GYNAEC, V92, P1218, DOI 10.1111/j.1471-0528.1985.tb04865.x; WEISGLASKUPERUS N, 1992, EARLY HUM DEV, V31, P131, DOI 10.1016/0378-3782(92)90040-N; WHITAKER A, 1990, J DEV BEHAV PEDIATR, V11, P253; WIKLUND LM, 1991, DEV MED CHILD NEUROL, V33, P512; YOKOCHI K, 1991, DEV MED CHILD NEUROL, V33, P18	146	456	466	0	37	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					188	195		10.1056/NEJM199401203300308	http://dx.doi.org/10.1056/NEJM199401203300308			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264743				2022-12-28	WOS:A1994MQ86300008
J	SCHULZ, VP; ZAKIAN, VA				SCHULZ, VP; ZAKIAN, VA			THE SACCHAROMYCES PIF1 DNA HELICASE INHIBITS TELOMERE ELONGATION AND DE-NOVO TELOMERE FORMATION	CELL			English	Article							MITOCHONDRIAL-DNA; BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; CHROMATIN STRUCTURE; YEAST TELOMERES; CHROMOSOME LOSS; CEREVISIAE; RAP1; RECOMBINATION; MUTANTS	A screen to detect yeast mutants that frequently lost expression of subtelomeric genes identified two mutations in PIF1, a gene known to encode a 5' to 3' DNA helicase. The loss of expression of subtelomeric genes in pif1 cells was due to deletion of the subtelomeric regions of the chromosomes and the generation of new telomeres at proximal sites. In pif1 mutants, de novo telomere formation usually occurred at sites with very little homology to telomeric DNA. De novo telomere formation after HO-induced chromosome breakage also occurred at elevated frequencies in pif1 cells. Moreover, mutations in PIF1 caused all telomeres to lengthen. These results suggest that the PIF1 helicase is an inhibitor of both de novo telomere formation and telomere elongation.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	SCHULZ, VP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.			Schulz, Vincent/0000-0001-6333-4284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043265, R01GM026938, R37GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43265, GM26938] Funding Source: Medline; PHS HHS [G0057] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DUTCHER SK, 1981, MOL CELL BIOL, V1, P245, DOI 10.1128/MCB.1.3.245; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARTWELL LH, 1985, GENETICS, V110, P381; HENIKOFF S, 1990, METHOD ENZYMOL, V183, P111; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; PANASENKO SM, 1977, SCIENCE, V196, P187, DOI 10.1126/science.322281; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, GENETICS, V127, P61; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	57	293	297	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					145	155		10.1016/0092-8674(94)90179-1	http://dx.doi.org/10.1016/0092-8674(94)90179-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287473				2022-12-28	WOS:A1994MR49500013
J	GORRIE, M; BEAMAN, M; NICHOLLS, A; BACKWELL, P				GORRIE, M; BEAMAN, M; NICHOLLS, A; BACKWELL, P			ALLOPURINOL INTERACTION WITH CYCLOSPORINE	BRITISH MEDICAL JOURNAL			English	Letter											GORRIE, M (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.							STEVENS SL, 1992, SOUTHERN MED J, V85, P1265, DOI 10.1097/00007611-199212000-00032	1	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					113	113		10.1136/bmj.308.6921.113c	http://dx.doi.org/10.1136/bmj.308.6921.113c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298381	Green Published			2022-12-28	WOS:A1994MR17300020
J	MONTMAYEUR, JP; BORRELLI, E				MONTMAYEUR, JP; BORRELLI, E			TARGETING OF G-ALPHA(I2) TO THE GOLGI BY ALTERNATIVE SPLICED CARBOXYL-TERMINAL REGION	SCIENCE			English	Article							GTP-BINDING PROTEINS; SENSITIVE G-PROTEIN; SIGNAL TRANSDUCTION; BREFELDIN-A; BETA-COP; MEMBRANES; CELLS; TRANSPORT; APPARATUS; GENE	Heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) may participate pate in membrane traffic events. A complementary DNA (cDNA) was isolated from a mouse pituitary cDNA library that corresponded to an alternatively spliced form of the gene encoding the G protein alpha subunit Galpha(i2). The cDNA was identical to that encoding Galpha(i2) except that the region encoding for the carboxyl-terminal 24 amino acids was replaced by a longer region encoding 35 amino acids that have no sequence similarity with Galpha(i2) or other members of the G protein family. This alternative spliced product and the corresponding protein (sG(i2)) were present in several tissues. Specific antibodies revealed that sG(i2) was localized in the Golgi apparatus, suggesting a role in membrane transport. Thus, alternative splicing may generate from a single gene two G protein alpha subunits with differential cellular localization and function.	FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Montmayeur, Jean-Pierre R/A-5723-2009; Borrelli, Emiliana/M-8994-2018	Montmayeur, Jean-Pierre/0000-0002-0942-1114				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MONTMAYEUR JP, UNPUB; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P4536; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681	35	60	60	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					95	98		10.1126/science.8272874	http://dx.doi.org/10.1126/science.8272874			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272874				2022-12-28	WOS:A1994MQ30100039
J	SIGURGEIRSSON, B; AGNARSSON, BA; LINDELOF, B				SIGURGEIRSSON, B; AGNARSSON, BA; LINDELOF, B			RISK OF LYMPHOMA IN PATIENTS WITH DERMATITIS-HERPETIFORMIS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To provide accurate estimates of the risk of lymphoma in patients with dermatitis herpetiformis. Design-Comparison of observed and expected incidence of cancer in patients with dermatitis herpetiformis. Subjects-976 patients aged 4 to 97 years with no clinical signs of coeliac disease who were admitted to hospital between 1963 and 1983. Setting-Data from Swedish Cancer Registry. Main outcome measures-Incidence and type of cancer. Results-106 cancers were diagnosed in 94 patients. The relative risk was 1-4 (95% confidence interval 1.1 to 1.7) in male patients and 1.2 (0.8 to 1.7) in female patients. When the individual cancer sites were analysed a significant risk was found only for malignant, non-Hodgkin's lymphoma in male patients, with a relative risk of 5.4 (2.2 to 11.1). Conclusions-The risk of lymphoma is greater in male patients with dermatitis herpetiformis, and this calls for increased surveillance in these patients.	UNIV HOSP ICELAND,DEPT PATHOL,REYKJAVIK,ICELAND; KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN	Landspitali National University Hospital; Karolinska Institutet; Karolinska University Hospital			Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				BUCKLEY DB, 1983, CLIN EXP DERMATOL, V8, P477, DOI 10.1111/j.1365-2230.1983.tb01815.x; CHRISTENSEN OB, 1986, DERMATOLOGICA, V173, P271, DOI 10.1159/000249270; DAVIES MG, 1978, Q J MED, V186, P221; FREEMAN HJ, 1986, GASTROENTEROLOGY, V90, P2008, DOI 10.1016/0016-5085(86)90275-1; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; GAWKRODGER DJ, 1984, GUT, V25, P151, DOI 10.1136/gut.25.2.151; GJONE E, 1970, BMJ-BRIT MED J, V1, P610, DOI 10.1136/bmj.1.5696.610; JENKINS D, 1983, J AM ACAD DERMATOL, V9, P252, DOI 10.1016/S0190-9622(83)70134-9; LEONARD JN, 1983, BRIT MED J, V286, P16, DOI 10.1136/bmj.286.6358.16; MATTSSON B, 1984, CANCER REGISTRATION; OFARRELLY C, 1986, BRIT MED J, V293, P908, DOI 10.1136/bmj.293.6552.908; REUNALA T, 1982, ACTA DERM-VENEREOL, V62, P343; REUNALA TL, 1992, CLIN DERMATOL, V9, P369; SIGURGEIRSSON B, 1991, COMPUT METH PROG BIO, V35, P193, DOI 10.1016/0169-2607(91)90121-9; 1960, CANCER INCIDENCE SWE	15	62	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					13	15		10.1136/bmj.308.6920.13	http://dx.doi.org/10.1136/bmj.308.6920.13			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298344	Green Published			2022-12-28	WOS:A1994MQ09600021
J	BARKER, DJP; MARTYN, CN; OSMOND, C; HALES, CN; FALL, CHD				BARKER, DJP; MARTYN, CN; OSMOND, C; HALES, CN; FALL, CHD			GROWTH IN-UTERO AND SERUM-CHOLESTEROL CONCENTRATIONS IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							INFANT GROWTH; FETAL; LIPOPROTEINS; METABOLISM; CHILDREN; PLASMA; DIET; AGE	Objective-To see whether reduced rates of fetal growth are related to raised serum cholesterol concentrations in adult life. Design-Follow up study of men and women whose size at birth had been recorded. Setting-Jessop and Northern General Hospitals, Sheffield. Subjects-219 men and women born in the Jessop Hospital during 1939-40. Main outcome measures-Serum concentrations of total cholesterol, low density lipoprotein cholesterol, and apolipoprotein B. Results-Men and women who had had a small abdominal circumference at birth had raised serum concentrations of total and low density lipoprotein cholesterol and apolipoprotein B. This was independent of the duration of gestation. Serum concentrations of total cholesterol fell by 0.25 mmol/l (95% confidence interval 0.09 to 0.42) with each 1 in (2-54 cm) increase in abdominal circumference. The corresponding figure for serum low density lipoprotein cholesterol was 0.26 mmol/l (0.11 to 0.42) and for serum apolipoprotein B 0.04 g/l (0.02 to 0.07). Small head and chest circumferences at birth and short length were each associated with raised serum low density lipoprotein cholesterol concentrations but the trends disappeared in a simultaneous regression with abdominal circumference at birth. The association between abdominal circumference at birth and low density lipoprotein cholesterol concentration was independent of social class, current body weight, cigarette smoking, and alcohol consumption. Conclusion-Raised serum cholesterol concentrations in adult life are associated with impaired growth during late gestation, when fetal undernutrition has a disproportionate effect on liver growth. Impaired liver growth may permanently alter low density lipoprotein cholesterol metabolism.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P165, DOI 10.1111/j.1651-2227.1979.tb04983.x; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BHATNAGAR D, 1991, ANN CLIN BIOCHEM, V28, P427, DOI 10.1177/000456329102800501; CAMPBELL S, 1977, BRIT J OBSTET GYNAEC, V84, P165, DOI 10.1111/j.1471-0528.1977.tb12550.x; CARR BR, 1982, J CLIN ENDOCR METAB, V55, P447, DOI 10.1210/jcem-55-3-447; DICKE JM, 1987, CLIN OBSTETRICS, P421; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gruenwald P, 1974, CIBA F S, V27, P3; HAHN P, 1973, J NUTR, V103, P690, DOI 10.1093/jn/103.5.690; HAHN P, 1989, ATHEROSCLEROSIS PEDI, P155; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HASSAN AS, 1982, AM J CLIN NUTR, V35, P546, DOI 10.1093/ajcn/35.3.546; INNIS SM, 1983, J NUTR, V113, P2464, DOI 10.1093/jn/113.12.2464; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LABARTHE DR, 1991, ANNU REV PUBL HEALTH, V12, P519, DOI 10.1146/annurev.pu.12.050191.002511; LEWIS B, 1983, BMJ-BRIT MED J, V287, P1161, DOI 10.1136/bmj.287.6400.1161; LIE AF, 1976, CLIN CHEM, V22, P11627; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001; MCNAMARA DJ, 1972, J BIOL CHEM, V247, P5805; MOTT GE, 1990, J NUTR, V120, P243, DOI 10.1093/jn/120.3.243; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; SPORIK R, 1991, ARCH DIS CHILD, V66, P134, DOI 10.1136/adc.66.1.134; WALD NJ, 1992, CORONARY HEART DIS E, P358; 1986, LANCET, V2, P991	31	462	476	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1524	1527		10.1136/bmj.307.6918.1524	http://dx.doi.org/10.1136/bmj.307.6918.1524			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274921	Green Published, Bronze			2022-12-28	WOS:A1993ML86900020
J	BUSCH, ORC; HOP, WCJ; VANPAPENDRECHT, MAWH; MARQUET, RL; JEEKEL, J				BUSCH, ORC; HOP, WCJ; VANPAPENDRECHT, MAWH; MARQUET, RL; JEEKEL, J			BLOOD-TRANSFUSIONS AND PROGNOSIS IN COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-GROWTH; RECURRENCE; DEFENSES; SURVIVAL; CELLS; COLON	Background. Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported, Methods. We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group were required to donate two units of blood before surgery. Results. A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those in the autologous-transfusion group had no recurrence of colorectal cancer at four years (P = 0.93). We also found that the risk of recurrence was significantly increased in patients who received blood transfusions, either allogeneic or autologous, as compared with patients who did not require transfusions; the relative rates of recurrence were 2.1 (P = 0.01) and 1.8 (P = 0.04), respectively; these rates did not differ significantly from each other. Conclusions. The use of autologous blood as compared with allogeneic blood for transfusion does not improve the prognosis in patients with colorectal cancer. Regardless of their type, transfusions are associated with poor prognosis, probably because of the circumstances that necessitate them.	UNIV HOSP ROTTERDAM DIJKZIGT,DEPT SURG,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam			Busch, Olivier/AAC-3650-2020					BENTZEN SM, 1990, EUR J CANCER, V26, P457, DOI 10.1016/0277-5379(90)90016-M; BLUMBERG N, 1989, TRANSFUSION, V29, P236, DOI 10.1046/j.1537-2995.1989.29389162731.x; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; BURROWS L, 1982, LANCET, V2, P662; COX DR, 1972, J R STAT SOC B, V34, P187; FRANCIS DMA, 1991, BRIT J SURG, V78, P1420, DOI 10.1002/bjs.1800781205; FRANCIS DMA, 1987, SURGERY, V102, P485; FRANKISH PD, 1985, BRIT MED J, V290, P1827, DOI 10.1136/bmj.290.6484.1827-b; GANTT CL, 1981, LANCET, V2, P363; HEISS MM, 1992, P AN M AM SOC CLIN, V11, P172; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; JEEKEL J, 1982, EUR SURG RES, V14, P124; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; NATHANSON SD, 1985, ARCH SURG-CHICAGO, V120, P734; NESS PM, 1992, TRANSFUSION, V32, P31, DOI 10.1046/j.1537-2995.1992.32192116429.x; SINGH SK, 1987, EUR J CANCER CLIN ON, V23, P1537, DOI 10.1016/0277-5379(87)90097-6; SINGH SK, 1987, TRANSPLANT P, V19, P1473; SINGH SK, 1988, BRIT J SURG, V75, P377, DOI 10.1002/bjs.1800750427; TARTTER PI, 1988, TRANSPLANT P, V20, P1108; TAYLOR RMR, 1988, BRIT J SURG, V75, P1049, DOI 10.1002/bjs.1800751102; TURNBULL RB, 1967, ANN SURG, V166, P420; VANPABST WPV, 1988, EUR J CANCER CLIN ON, V24, P741, DOI 10.1016/0277-5379(88)90309-4; VANPAPENDRECHT MAWH, 1991, NETH J SURG, V43, P85; VANPAPENDRECHT MAWH, 1992, VOX SANG, V62, P102; WAYMACK JP, 1988, J SURG ONCOL, V39, P159; WEIDEN PL, 1987, CANCER-AM CANCER SOC, V60, P870, DOI 10.1002/1097-0142(19870815)60:4<870::AID-CNCR2820600425>3.0.CO;2-0; 1986, JAMA-J AM MED ASSOC, V256, P2378	27	465	469	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1372	1376		10.1056/NEJM199305133281902	http://dx.doi.org/10.1056/NEJM199305133281902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8292113				2022-12-28	WOS:A1993LB49500002
J	SHANNON, KM; OCONNELL, P; MARTIN, GA; PADERANGA, D; OLSON, K; DINNDORF, P; MCCORMICK, F				SHANNON, KM; OCONNELL, P; MARTIN, GA; PADERANGA, D; OLSON, K; DINNDORF, P; MCCORMICK, F			LOSS OF THE NORMAL NF1 ALLELE FROM THE BONE-MARROW OF CHILDREN WITH TYPE-1 NEUROFIBROMATOSIS AND MALIGNANT MYELOID DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; POLYMORPHIC CDNA PROBE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MYELODYSPLASTIC SYNDROMES; CHILDHOOD MONOSOMY-7; RAS P21; GENE; LEUKEMIA; MUTATIONS; PROTEIN	Background. Children with type 1 neurofibromatosis (NF-1) are at increased risk for malignant myeloid disorders. Analysis of the NF-1 gene (NF1) suggests that the function of its product, neurofibromin, is reduced in affected persons and that NF1 belongs to the tumor-suppressor class of recessive cancer genes. This model is consistent with evidence that neurofibromin accelerates the intrinsic guanosine triphosphate-hydrolyzing activity of the Ras family of regulatory proteins. Loss of constitutional heterozygosity has not been reported in the benign tumors associated with NF-1, however, and has only been detected in a few malignant neural-crest tumors and in some tumor-derived cell lines. Methods. We studied DNA extracted from the bone marrow of 11 children with NF-1 in whom malignant myeloid disorders developed and from parental leukocytes. We used a series of polymorphic markers within and near NF1 to determine whether leukemogenesis was associated with structural alterations of the gene. Results. Bone marrow samples from five patients showed loss of heterozygosity. In each case, the NF1 allele was inherited from a parent with NF-1 and the normal allele was deleted. Conclusions. These data provide evidence that NF1 may function as a tumor-suppressor allele in malignant myeloid diseases in children with NF-1 and that neurofibromin is a regulator of Ras in early myelopoiesis.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78284 USA; ONYX PHARMACEUT, RICHMOND, CA USA; CHILDRENS NATL MED CTR, WASHINGTON, DC 20010 USA	University of Texas System; University of Texas Health San Antonio; Children's National Health System	SHANNON, KM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, RM U-432, SAN FRANCISCO, CA 94143 USA.							ANDERSEN LB, 1993, HUM MOL GENET, V2, P1083, DOI 10.1093/hmg/2.7.1083-a; ANDERSEN LB, 1991, NUCLEIC ACIDS RES, V19, P3754, DOI 10.1093/nar/19.13.3754; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; ANDERSEN LB, 1991, NUCLEIC ACIDS RES, V19, P197, DOI 10.1093/nar/19.1.197-a; BADER JL, 1978, J PEDIATR-US, V92, P925, DOI 10.1016/S0022-3476(78)80362-X; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CASTROMALASPINA H, 1984, CANCER, V54, P675, DOI 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EMANUEL PD, 1991, BLOOD, V77, P925; FONG C, 1987, CANCER GENET CYTOGEN, V28, P55, DOI 10.1016/0165-4608(87)90354-2; FREEDMAN MH, 1992, BRIT J HAEMATOL, V80, P40, DOI 10.1111/j.1365-2141.1992.tb06398.x; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GADNER H, 1992, HEMATOL ONCOL CLIN N, V6, P655, DOI 10.1016/S0889-8588(18)30334-4; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LUBBERT M, 1992, ONCOGENE, V7, P263; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NEUBAUER A, 1991, BLOOD, V77, P594; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHANNON KM, 1989, J CLIN INVEST, V84, P984, DOI 10.1172/JCI114262; SHANNON KM, 1992, BLOOD, V79, P1311; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VOGELSTEIN B, 1990, GENE CHROMOSOME CANC, V2, P159, DOI 10.1002/gcc.2870020212; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISS K, 1987, LEUKEMIA, V1, P97; XU GF, 1991, NUCLEIC ACIDS RES, V19, P3764, DOI 10.1093/nar/19.13.3764; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	42	346	354	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					597	601		10.1056/NEJM199403033300903	http://dx.doi.org/10.1056/NEJM199403033300903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302341	Bronze			2022-12-28	WOS:A1994MY57300003
J	KENFORD, SL; FIORE, MC; JORENBY, DE; SMITH, SS; WETTER, D; BAKER, TB				KENFORD, SL; FIORE, MC; JORENBY, DE; SMITH, SS; WETTER, D; BAKER, TB			PREDICTING SMOKING CESSATION - WHO WILL QUIT WITH AND WITHOUT THE NICOTINE PATCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOBACCO WITHDRAWAL; SELF-QUITTERS; FOLLOW-UP; DEPENDENCE; RELAPSE; INTERVENTION; ABSTINENCE; SYMPTOMS	Objective.-To identify predictors of smoking cessation success or failure with and without transdermal nicotine patch treatment. Design.-Two independent randomized, double-blind, placebo-controlled studies using the nicotine patch assessing outcome at the end of treatment and at 6-month follow-up; each study used a different mode of adjuvant counseling. Patients.-Subjects were daily smokers (greater than or equal to 15 cigarettes per day), aged 21 to 65 years with expired air carbon monoxide levels of at least 10 ppm, and motivated to quit. Eighty-eight subjects participated in study 1, and 112 subjects participated in study 2. Intervention.-Study 1 consisted of 8 weeks of 22-mg nicotine patch therapy with intensive group counseling. Study 2 consisted of 4 weeks of 22-mg nicotine patch therapy and 2 weeks of 11-mg nicotine patch therapy with brief individual counseling. Main Outcome Measures.-The prediction of smoking cessation (at end of treatment and after 6 months) based on pretreatment and intratreatment measures in smokers using active or placebo nicotine patches. Results.-Pretreatment markers, such as the Fagerstrom Tolerance Questionnaire score, number of cigarettes smoked per day, years smoked, expired air carbon monoxide level, or baseline blood nicotine and cotinine levels, showed no consistent relationship with successful smoking cessation across both studies. Of the intratreatment markers examined, withdrawal severity and nicotine replacement levels also were not consistently predictive of cessation success. However, any smoking during the second week of treatment was a consistent and powerful predictor of failure at the end of treatment and after 6 months. Among active nicotine patch patients who smoked at all during week 2 after quitting, 83% and 97% (studies 1 and 2, respectively) were smoking at 6-month follow-up. Conversely, abstinence during the second week of treatment predicted successful smoking cessation. Among active nicotine patch patients who were totally abstinent during week 2 after quitting, 46% and 41% (studies 1 and 2, respectively) were abstinent at 6-month follow-up. Of all nicotine patch patients in both studies who were smoking at 6-month follow-up, 74% began smoking during week 1 or 2. Among all placebo patch patients who were smoking at 6-month follow-up, 86% began smoking during week 1 or 2. Conclusions.-Smoking status (abstinent or smoking) during the first 2 weeks of nicotine patch therapy, particularly week 2, was highly correlated with clinical outcome and can serve as a powerful predictor of smoking cessation. Early smoking behavior also predicted outcome among placebo patch users. Traditional measures of dependence are not consistently predictive of cessation success. Clinicians are advised to emphasize the importance of total abstinence after a quit attempt and to follow-up with patients within the first 2 weeks of quitting; smoking during this critical time should be assessed and treatment may be altered as appropriate.	UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED,GEN INTERNAL MED SECT,MADISON,WI; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI; UNIV WISCONSIN,DEPT PSYCHOL,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Wetter, David/0000-0002-6366-0108; Smith, Stevens/0000-0002-6824-2829				ABELIN T, 1989, LANCET, V1, P7; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BRANDON TH, 1987, J CONSULT CLIN PSYCH, V55, P780, DOI 10.1037/0022-006X.55.5.780; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1991, JAMA-J AM MED ASSOC, V266, P3183, DOI 10.1001/jama.266.22.3183; FIORE MC, IN PRESS CHEST; GARVEY AJ, 1992, ADDICT BEHAV, V17, P367, DOI 10.1016/0306-4603(92)90042-T; HALL SM, 1990, J CONSULT CLIN PSYCH, V58, P175, DOI 10.1037/0022-006X.58.2.175; HORWITZ MB, 1985, ADDICT BEHAV, V10, P29, DOI 10.1016/0306-4603(85)90050-4; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HUGHES JR, 1992, J CONSULT CLIN PSYCH, V60, P689, DOI 10.1037/0022-006X.60.5.689; HURT RD, 1993, CLIN PHARMACOL THER, V54, P98, DOI 10.1038/clpt.1993.117; KILLEN JD, 1992, J CONSULT CLIN PSYCH, V60, P797, DOI 10.1037/0022-006X.60.5.797; LANDO HA, 1992, AM J PUBLIC HEALTH, V82, P41, DOI 10.2105/AJPH.82.1.41; ORLEANS CT, 1993, NICOTINE ADDICTION P, P145; PINTO RP, 1987, ADDICT BEHAV, V12, P371, DOI 10.1016/0306-4603(87)90052-9; RUSSELL MA, 1988, NICOTINE REPLACEMENT, P64; TIFFANY ST, 1988, ASSESSMENT TREATMENT, P238; WEST DW, 1977, AM J PUBLIC HEALTH, V67, P536, DOI 10.2105/AJPH.67.6.536; ZELMAN DC, 1992, J CONSULT CLIN PSYCH, V60, P943, DOI 10.1037/0022-006X.60.6.943; 1991, JAMA-J AM MED ASSOC, V266, P3133	22	370	372	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					589	594		10.1001/jama.271.8.589	http://dx.doi.org/10.1001/jama.271.8.589			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW477	8301790				2022-12-28	WOS:A1994MW47700021
J	MOLITERNO, DJ; WILLARD, JE; LANGE, RA; NEGUS, BH; BOEHRER, JD; GLAMANN, DB; LANDAU, C; ROSSEN, JD; WINNIFORD, MD; HILLIS, LD				MOLITERNO, DJ; WILLARD, JE; LANGE, RA; NEGUS, BH; BOEHRER, JD; GLAMANN, DB; LANDAU, C; ROSSEN, JD; WINNIFORD, MD; HILLIS, LD			CORONARY-ARTERY VASOCONSTRICTION INDUCED BY COCAINE, CIGARETTE-SMOKING, OR BOTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRANASAL COCAINE; NICOTINE; DISEASE; DIMENSIONS; TERM	Background. In humans, the use of cocaine and cigarette smoking each increases the heart's metabolic need for oxygen but may also decrease the supply of oxygen. As cocaine abuse has proliferated, cocaine-associated chest pain, myocardial infarction, and sudden death have occurred, especially among smokers. We assessed the influence of intranasal cocaine and cigarette smoking, alone and together, on myocardial oxygen demand and coronary arterial dimensions in subjects with and subjects without coronary atherosclerosis. Methods. In 42 smokers (28 men and 14 women; age, 34 to 79 years; 36 with angiographically demonstrable coronary artery disease), we measured the product of the heart rate and systolic arterial pressure (rate-pressure product) and coronary arterial diameters before and after intranasal cocaine at a dose of 2 mg per kilogram of body weight (n = 6), one cigarette (n = 12), or intranasal cocaine at a dose of 2 mg per kilogram followed by one cigarette (n = 24). Results. No patient had chest pain or ischemic electrocardiographic changes after cocaine use or smoking. The mean (+/-SE) rate-pressure product increased by 11+/-2 percent after cocaine use (n = 30, P<0.001), by 12+/-4 percent after one cigarette (n = 12, P = 0.021), and by 45+/-5 percent after both cocaine use and smoking (n = 24, P<0.001). As compared with base-line measurements, the diameters of nondiseased coronary arterial segments decreased on average by 7+/-1 percent after cocaine use (P<0.001), by 7+/-1 percent after smoking (P<0.001), and by 6+/-2 percent after cocaine use and smoking (P<0.001). The diameters of diseased segments decreased by 9+/-2 percent after cocaine use (n = 18, P<0.001), by 5+/-5 percent after smoking (n = 12, P = 0.322), and by 19+/-4 percent after cocaine use and smoking (n = 12, P<0.001). The increase in the rate-pressure product and the decrease in the diameters of diseased segments caused by cocaine use and smoking together were greater (P<0.001 and P = 0.037, respectively) than the changes caused by either alone. Conclusions. The deleterious effects of cocaine on myocardial oxygen supply and demand are exacerbated by concomitant cigarette smoking. This combination substantially increases the metabolic requirement of the heart for oxygen but simultaneously decreases the diameter of diseased coronary arterial segments.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV CARDIOVASC,DALLAS,TX 75235; UNIV IOWA,DEPT INTERNAL MED,DIV CARDIOVASC,IOWA CITY,IA 52242	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa			Lange, Richard/AAM-9594-2021	Rossen, James/0000-0001-7287-7088				BOEHRER JD, 1992, J AM COLL CARDIOL, V20, P90, DOI 10.1016/0735-1097(92)90142-A; BROGAN WC, 1992, ANN INTERN MED, V116, P556, DOI 10.7326/0003-4819-116-7-556; BROGAN WC, 1991, J AM COLL CARDIOL, V18, P581, DOI 10.1016/0735-1097(91)90617-I; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; KLEIN LW, 1984, J AM COLL CARDIOL, V3, P879, DOI 10.1016/S0735-1097(84)80344-7; KUHN FE, 1990, J AM COLL CARDIOL, V16, P1481, DOI 10.1016/0735-1097(90)90396-7; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, ANN INTERN MED, V112, P897, DOI 10.7326/0003-4819-112-12-897; MAOUAD J, 1986, CATHETER CARDIO DIAG, V12, P366, DOI 10.1002/ccd.1810120603; MINOR RL, 1991, ANN INTERN MED, V115, P797, DOI 10.7326/0003-4819-115-10-797; MOREYRA AE, 1992, AM HEART J, V124, P392, DOI 10.1016/0002-8703(92)90603-S; NICOD P, 1984, J AM COLL CARDIOL, V4, P964, DOI 10.1016/S0735-1097(84)80058-3; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; RABINOWITZ BD, 1979, CIRCULATION, V60, P752, DOI 10.1161/01.CIR.60.4.752; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; REINDERS JH, 1986, ARTERIOSCLEROSIS, V6, P15, DOI 10.1161/01.ATV.6.1.15; SONNENFELD T, 1980, BRIT J PHARMACOL, V71, P609, DOI 10.1111/j.1476-5381.1980.tb10980.x; THOMAS CB, 1956, ANN INTERN MED, V44, P874, DOI 10.7326/0003-4819-44-5-874; WINER BJ, 1971, STATISTICAL PRINCIPL, P185; ZIMMERMAN M, 1987, ATHEROSCLEROSIS, V63, P33, DOI 10.1016/0021-9150(87)90079-7; 1988, DHHS ADM881584 PUBL	22	193	207	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					454	459		10.1056/NEJM199402173300702	http://dx.doi.org/10.1056/NEJM199402173300702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289850				2022-12-28	WOS:A1994MW48000002
J	CHARLTON, R				CHARLTON, R			FAMILY MEDICINE TO THE FORE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					486	486		10.1001/jama.271.7.486	http://dx.doi.org/10.1001/jama.271.7.486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301744				2022-12-28	WOS:A1994MV42300001
J	KLIMASAUSKAS, S; KUMAR, S; ROBERTS, RJ; CHENG, XD				KLIMASAUSKAS, S; KUMAR, S; ROBERTS, RJ; CHENG, XD			HHAL METHYLTRANSFERASE FLIPS ITS TARGET BASE OUT OF THE DNA HELIX	CELL			English	Article							COLI THYMIDYLATE SYNTHASE; CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; DETERMINES METHYLATION; DIFFRACTION ANALYSIS; RECOGNIZING DOMAINS; MAMMALIAN NUCLEI; MISMATCH REPAIR; GENE-EXPRESSION; MECHANISM		NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915; INST BIOTECHNOL FERMENTAS,VILNIUS 232028,LITHUANIA		KLIMASAUSKAS, S (corresponding author), COLD SPRING HARBOR LAB,WM KECK STRUCT BIOL LAB,COLD SPRING HARBOR,NY 11724, USA.		Klimasauskas, Saulius/M-3053-2016; Kumar, Sanjay/AAO-2593-2021	Klimasauskas, Saulius/0000-0002-1395-2030; Roberts, Richard/0000-0002-4348-0169	NIGMS NIH HHS [GM46127, GM49245] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049245, R01GM046127] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1990, ACTA CRYSTALLOGR B, V46, P195, DOI 10.1107/S0108768189012607; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRAVES KL, 1992, BIOCHEMISTRY-US, V31, P10315, DOI 10.1021/bi00157a020; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEINEMANN U, 1992, EMBO J, V11, P1931, DOI 10.1002/j.1460-2075.1992.tb05246.x; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU L, 1992, BIOCHEMISTRY-US, V31, P5100, DOI 10.1021/bi00137a002; MANN MB, 1979, P C TRANSMETHYLATION, P483; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; ROBERTS RJ, 1976, J MOL BIOL, V103, P199, DOI 10.1016/0022-2836(76)90060-7; ROBERTS RJ, 1993, IN PRESS NUCLEASES; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WU JC, 1987, J BIOL CHEM, V262, P4778; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319	65	889	914	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					357	369		10.1016/0092-8674(94)90342-5	http://dx.doi.org/10.1016/0092-8674(94)90342-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293469				2022-12-28	WOS:A1994MU67800018
J	ROBINSON, BH; HAAS, DA; MAILER, C				ROBINSON, BH; HAAS, DA; MAILER, C			MOLECULAR-DYNAMICS IN LIQUIDS - SPIN-LATTICE RELAXATION OF NITROXIDE SPIN LABELS	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; SATURATION-RECOVERY; MOTION	Time domain pulsed saturation recovery and electron-electron double resonance spectroscopies were used to measure the spin-lattice relaxation rates of the electron and the nitrogen nucleus in nitroxide spin labels in liquids. The rotational correlation time range covered is from picoseconds to milliseconds. These rates are quantitatively explained by isotropic rotational Brownian dynamics, which modulate the interactions between the electron spin and the molecular angular momentum; the nitrogen and electron spins; and the solvent protons with both the electron and the nitrogen spins. This solves a 20-year-old problem that has limited scientific applications of nitroxides.			ROBINSON, BH (corresponding author), UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195, USA.				NIGMS NIH HHS [GM-32681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, pCH8; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ATKINS PW, 1966, J CHEM PHYS, V44, P169, DOI 10.1063/1.1726440; BEECHAM M, 1991, FLUORESCENCE SPECTRO, V2, pCH5; Berliner L., 1989, BIOL MAGNETIC RESONA, V8; Berliner L., 1976, SPIN LABELING THEORY, V1; Berliner L. J., 1979, SPIN LABELING THEORY, V2; BLUMBERG WE, 1960, PHYS REV, V119, P79, DOI 10.1103/PhysRev.119.79; FAJER P, 1986, BIOPHYS J, V50, P1195, DOI 10.1016/S0006-3495(86)83562-7; FEIX JB, 1984, BIOCHEMISTRY-US, V23, P2293, DOI 10.1021/bi00305a032; FREED JH, 1979, MULTIPLE ELECTRON RE, P112; HAAS DA, 1993, BIOPHYS J, V64, P594, DOI 10.1016/S0006-3495(93)81418-8; HAAS DA, 1993, J PHYS CHEM-US, V97, P2914, DOI 10.1021/j100114a014; HAAS DA, 1993, THESIS U WASHINGTON; HORNAK JP, 1983, CHEM PHYS LETT, V101, P115, DOI 10.1016/0009-2614(83)87353-9; HUBBARD PS, 1963, PHYS REV, V131, P1155, DOI 10.1103/PhysRev.131.1155; HUISJEN M, 1974, REV SCI INSTRUM, V45, P669, DOI 10.1063/1.1686710; HUNT BI, 1966, P PHYS SOC LOND, V88, P513, DOI 10.1088/0370-1328/88/2/321; HWANG JS, 1975, J PHYS CHEM-US, V79, P489, DOI 10.1021/j100572a017; HYDE JS, 1984, CHEM PHYS LETT, V110, P621, DOI 10.1016/0009-2614(84)85474-3; HYDE JS, 1979, SPIN LABELING, V2, pCH1; LARSEN DW, 1984, J PHYS CHEM-US, V88, P4015, DOI 10.1021/j150662a031; MAILER C, 1992, B MAGN RESON, V14, P30; MILLER C, 1991, J MAGN RESON, V91, P475; PERCIVAL PW, 1976, J MAGN RESON, V23, P249, DOI 10.1016/0022-2364(76)90206-7; Reuben, 1989, BIOL MAGN RESON, P399; ROBINSON BH, 1992, J CHEM PHYS, V96, P2609, DOI 10.1063/1.462869; ROBINSON BH, 1993, 35TH EPR S MOUNT INT; ROBINSON BH, 1985, EPR ADV EPR STUDIES, P192; SARNA T, 1978, J CHEM PHYS, V69, P1945, DOI 10.1063/1.436833; SUGANO T, 1987, THESIS U WASHINGTON, P283; TORREY HC, 1953, PHYS REV, V92, P962, DOI 10.1103/PhysRev.92.962; YIN JJ, 1992, 34TH EPR S ROCK MOUN	34	130	130	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					490	493		10.1126/science.8290958	http://dx.doi.org/10.1126/science.8290958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290958				2022-12-28	WOS:A1994MT96600024
J	HABER, DA; PARK, S; MAHESWARAN, S; ENGLERT, C; RE, GG; HAZENMARTIN, DJ; SENS, DA; GARVIN, AJ				HABER, DA; PARK, S; MAHESWARAN, S; ENGLERT, C; RE, GG; HAZENMARTIN, DJ; SENS, DA; GARVIN, AJ			WT1-MEDIATED GROWTH SUPPRESSION OF WILMS-TUMOR CELLS EXPRESSING A WT1 SPLICING VARIANT	SCIENCE			English	Article							GENOMIC STRUCTURE; GENE WT1; RB GENE; FORM; TUMORIGENICITY; TRANSFORMATION; CHROMOSOME-11; PROTEIN; BINDING; FOSB	A human Wilms tumor cell line (RM1) was developed to test the tumor suppressor activity of WT1, a zinc finger transcription factor that is expressed in the developing human kidney and is mutationally inactivated in a subset of Wilms tumors. Transfection of each of four wild-type WT1 isoforms suppressed the growth of RM1 cells. The endogenous WT1 transcript in these cells was devoid of exon 2 sequences, a splicing alteration that was also detected in varying amounts in all Wilms tumors tested but not in normal kidney. Production of this abnormal transcript, which encodes a functionally altered protein, may represent a distinct mechanism for inactivating WT1 in Wilms tumors.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	Harvard University; Harvard Medical School; Medical University of South Carolina	HABER, DA (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BOSTON,MA 02129, USA.			Englert, Christoph/0000-0002-5931-3189	NCI NIH HHS [CA37887, CA58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058596, R01CA037887, R23CA037887, R37CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAZENMARTIN D, UNPUB; HAZENMARTIN DJ, 1993, AM J PATHOL, V142, P893; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PARK S, 1993, CANCER RES, V53, P4757; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PARK S, IN PRESS NATURE GENE; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	30	173	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2057	2059		10.1126/science.8266105	http://dx.doi.org/10.1126/science.8266105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266105				2022-12-28	WOS:A1993MN10800045
J	SHAW, A; MCREE, DE; VACQUIER, VD; STOUT, CD				SHAW, A; MCREE, DE; VACQUIER, VD; STOUT, CD			THE CRYSTAL-STRUCTURE OF LYSIN, A FERTILIZATION PROTEIN	SCIENCE			English	Article							ABALONE; SPERMATOZOA; DOMAIN	Lysin, a protein from abalone sperm, creates a hole in the envelope of the egg, permitting the sperm to pass through the envelope and fuse with the egg. The structure of lysin, refined at 1.9 angstroms resolution, reveals an alpha-helical, amphipathic molecule. The surface of the protein exhibits three features: two tracks of basic residues that span the length of the molecule, a solvent-exposed cluster of aromatic and aliphatic amino acids, and an extended amino-terminal hypervariable domain that is species-specific. The structure suggests possible mechanisms of action.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, CTR MARINE BIOMED & BIOTECHNOL, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; Scripps Institution of Oceanography					NICHD NIH HHS [HD12986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012986, R37HD012986] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAGINSKY ML, 1990, J BIOL CHEM, V265, P4958; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; HONG KL, 1986, BIOCHEMISTRY-US, V25, P543, DOI 10.1021/bi00351a004; HOWARD AJ, 1985, METHODS ENZYMOLOGY A, V114, pCH28; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LEWIS CA, 1982, DEV BIOL, V92, P227, DOI 10.1016/0012-1606(82)90167-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; VACQUIER VD, 1990, P NATL ACAD SCI USA, V87, P5792, DOI 10.1073/pnas.87.15.5792; VACQUIER VD, IN PRESS ZYGOTE; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	18	57	61	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1864	1867		10.1126/science.8266073	http://dx.doi.org/10.1126/science.8266073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266073				2022-12-28	WOS:A1993MM51100033
J	MOORE, L; DALZIEL, M				MOORE, L; DALZIEL, M			MAKING THE INTERNAL MARKET WORK - A CASE FOR MANAGED CHANGE	BRITISH MEDICAL JOURNAL			English	Article							OPEN-ANGLE GLAUCOMA; DIABETIC-RETINOPATHY	The internal market in the NHS is meant to ensure that provider units compete on the basis of price and quality and that money follows patients into efficient units. But the example of what happened to one local ophthalmology unit suggests what may go wrong when entrepreneurial activity is applied in a market that does not work perfectly. In 1991-2 the unit had a high workload but also comparatively high prices (because of crude pricing in the local hospital); because of pressure of work the waiting times lengthened and general practitioners increasingly complained about the service. The staff in the unit reopened a longstanding debate about the need for a third consultant ophthalmologist, but neither the purchasers (including fundholders) nor the provider unit were able to fund the post. Fundholders in a neighbouring district, however, together with that district health authority, decided to place their contracts elsewhere for the following year. Although the withdrawal of contracts jeopardised the clinical and financial viability of the ophthalmic unit, patients continued to use the service. When general practitioners in the district realised that their local service might collapse they pressed to keep the service open. The fundholders and the host purchaser finally agreed to fund a third consultant and drew up standards for the service. As a result the waiting times fell and the service is now described as ''excellent.'' Short term market decisions may have unforseen long term implications for services to patients. This needs to be addressed as part of the evolution of the reformed NHS.	HILLINGDON HLTH AGCY,UXBRIDGE UB8 3PL,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								[Anonymous], 1990, SHORT CUT BETTER SER; DOBSON J, 1993, HLTH SERVICE J, V103, P3; DOWIE R, 1991, PATTERNS HOSPITAL ME; HAM C, 1992, BMJ, V305, P131; HARRIES U, 1992, ANAL ROUTINELY COLLE; KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; ROSENTHAL RA, 1992, BMJ, V305, P904; SALTER B, 1992, HLTH SERVICE J, V102, P230; THOMAS HF, 1992, BRIT MED J, V305, P536, DOI 10.1136/bmj.305.6853.536; TOMLIN Z, 1993, HLTH SERVICE J, V103, P13; 1993, MAKING LONDON BETTER; 1991, PATIENTS CHARTER; 1991, HOSPITAL EYE SERVICE; 1990, NHS REFORMS 1ST 6 MO; 1993, HOSPITAL DOCTORS TRA; 1991, PUBLIC HLTH SERVICE; 1992, FINANCIAL SURVEY 199; 1987, COMPENDIUM HLTH STAT	19	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1270	1272		10.1136/bmj.307.6914.1270	http://dx.doi.org/10.1136/bmj.307.6914.1270			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281064	Green Published, Bronze			2022-12-28	WOS:A1993MH00100032
J	GELLERT, GA; WAGNER, GA; MAXWELL, RM; MOORE, D; FOSTER, L				GELLERT, GA; WAGNER, GA; MAXWELL, RM; MOORE, D; FOSTER, L			LEAD-POISONING AMONG LOW-INCOME CHILDREN IN ORANGE-COUNTY, CALIFORNIA - A NEED FOR REGIONALLY DIFFERENTIATED POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To estimate the prevalence of elevated lead levels among children in Orange County, California, and to evaluate the appropriateness of a universal pediatric blood lead screening policy in this community. Design.-Venous blood lead testing was conducted and results were analyzed according to seven blood lead strata ranging from less than 0.50 mumol/L (10 mug/dL) to 3.35 mumol/L (70 mug/dL) or higher. A cost analysis of the lead-testing program in Orange County was conducted. Setting.-Children meeting poverty eligibility criteria and attending the Child Health and Disability Prevention Program, the state's implementation of the federal Early and Periodic Screening, Diagnosis and Treatment (EPSDT) services program. Participants.-A total of 5115 Orange County children between 12 and 72 months of age using EPSDT services from March through December 1992. Main Outcome Measures.-Blood lead levels and associated costs of the testing program stratified by level of blood lead elevation. Results.-Blood lead levels of 0.50 mumol/L (10 mug/dL) or higher were found in 371 children (7.25%; 95% confidence interval, 6.66% to 7.85%), but only six children (0.12%; 95% confidence interval, 0.04% to 0.20%) had elevations greater than 1.20 mumol/L (25 mug/dL). Five children (83.3%) had histories of lead consumption unrelated to ingestion of lead-containing paint but related to the use of lead-containing folk remedies and cooking utensils. Costs for detection of children with blood levels elevated to 0.50 mumol/L (10 mug/dL) or higher was $310 per child and for levels of 1.20 mumol/L (25 mug/dL) or higher was $19 139 per child. Conclusions.-These data suggest that lead poisoning is not a major public health problem among Orange County children and detection of infrequent cases would involve a high cost per child. In jurisdictions with newer housing, initial screening for a history of possible lead exposure alone may offer reasonable efficacy that is cost-effective. The scope of lead-testing programs should be determined according to local needs and conditions.	ORANGE CTY HLTH CARE AGCY,SANTA ANA,CA									[Anonymous], 1991, PREVENTING LEAD POIS; 1992, MANAGEMENT SUMMARY R; 1980, SELECTED POPULATIO B, V5; 1991, 9110 DEP HLTH SERV C; 1992, MMWR MORB MORTAL WKL, V41, P291; 1991, 9111 DEP HLTH SERV C	6	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					69	71		10.1001/jama.270.1.69	http://dx.doi.org/10.1001/jama.270.1.69			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8305000				2022-12-28	WOS:A1993LK36600026
J	BARNARD, MJ; LINTER, SPK				BARNARD, MJ; LINTER, SPK			FORTNIGHTLY REVIEW - ACUTE CIRCULATORY SUPPORT	BRITISH MEDICAL JOURNAL			English	Article							CONGESTIVE HEART-FAILURE; REGIONAL BLOOD-FLOW; CARDIOGENIC-SHOCK; CARDIAC-OUTPUT; ORAL MILRINONE; DOBUTAMINE; THERAPY; DOPAMINE; COMBINATION; RECEPTOR	Numerous drugs can increase cardiac output, thereby improving tissue oxygen delivery, but often they do this at the expense of increasing myocardial oxygen demand. This may be critical when cardiac function is substantially impaired or ischaemia is the precipitating cause. Using polypharmacy to substantially improve cardiovascular status requires detailed knowledge of the pharmacodynamics and interactions of the available agents so that they may be tailored to the individual patient. In some settings combinations of inotropes and vasodilators may be desirable to minimise cardiac workload. In other instances vasopressors may be necessary to urgently restore a minimum perfusion pressure. This paper reviews the use of this group of drugs as well as the mechanical assist devices that may be used when drugs fail.			BARNARD, MJ (corresponding author), HAREFIELD HOSP,HAREFIELD UB9 6JH,MIDDX,ENGLAND.							ALDERMAN JD, 1987, J AM COLL CARDIOL, V9, P524, DOI 10.1016/S0735-1097(87)80044-X; [Anonymous], 1992, PULSE; BASS AS, 1990, J PHARMACOL EXP THER, V253, P798; Bianchi J J, 1992, ASAIO J, V38, pM143, DOI 10.1097/00002480-199207000-00005; BINKLEY PF, 1991, CIRCULATION, V84, P1210, DOI 10.1161/01.CIR.84.3.1210; BOLDT J, 1992, BRIT J ANAESTH, V64, P45; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; COLUCCI WS, 1991, AM HEART J, V121, P1945, DOI 10.1016/0002-8703(91)90829-7; CURFMAN GD, 1991, NEW ENGL J MED, V325, P1509, DOI 10.1056/NEJM199111213252111; DAGE RC, 1990, CARDIOLOGY, V77, P2, DOI 10.1159/000174664; DAMBRA MN, 1985, J THORAC CARDIOV SUR, V89, P567; Daniel M A, 1991, ASAIO Trans, V37, pM423; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DIBIANCO R, 1991, AM HEART J, V121, P1871, DOI 10.1016/0002-8703(91)90078-V; FARRAR DJ, 1993, ANN THORAC SURG, V55, P276, DOI 10.1016/0003-4975(93)90537-R; FOEX P, 1990, ANESTHESIOLOGY HEART; FRANCIS GS, 1991, AM HEART J, V6, P1875; FRY ETA, 1992, CORONARY ARTERY DIS, V3, P774, DOI 10.1097/00019501-199209000-00002; Ghosh S, 1991, J Cardiothorac Vasc Anesth, V5, P382, DOI 10.1016/1053-0770(91)90166-Q; GILLESPIE TA, 1977, AM J CARDIOL, V39, P588, DOI 10.1016/S0002-9149(77)80170-7; GOLDSTEIN RA, 1985, EUR HEART J, V56, pB25; GRAY P A, 1990, Intensive Care Medicine, V16, pA149; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HAJJAR RJ, 1991, CARDIOVASC DRUG THER, V5, P961, DOI 10.1007/BF00143520; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HAUSEN B, 1992, J CARDIOVASC PHARM, V19, P299, DOI 10.1097/00005344-199203000-00001; HINES R, 1990, J CARDIOTHORACIC S5, V4, P29; JASKI BE, 1988, AM J CARDIOL, V62, pC63, DOI 10.1016/S0002-9149(88)80070-5; Johnson K E, 1992, ASAIO J, V38, pM486, DOI 10.1097/00002480-199207000-00082; Kantrowitz A, 1992, ASAIO J, V38, pM617, DOI 10.1097/00002480-199207000-00110; Kantrowitz A, 1968, JAMA-J AM MED ASSOC, V203, P135; KAPLAN JA, 1990, J CARDIOTHORACIC S1, V4, P27; KAPOOR A, 1991, CARDIOMYOPATHIES HEA; KONSTAM MA, 1986, AM J CARDIOL, V57, P242, DOI 10.1016/0002-9149(86)90899-4; LARACH DR, 1990, PRACTICE CARDIAC ANE; LEIER CV, 1988, AM J CARDIOL, V62, pE86, DOI 10.1016/S0002-9149(88)80019-5; LEIER CV, 1988, AM J CARDIOL, V62, P94, DOI 10.1016/0002-9149(88)91371-9; LEIER CV, 1992, AM J CARDIOL, V69, pG120; LEIER CV, 1991, AM HEART J, V6, P1866; LEMMER JH, 1984, ANN THORAC SURG, V38, P108, DOI 10.1016/S0003-4975(10)62215-1; Liska M B, 1992, ASAIO J, V38, P804; LOLLGEN H, 1990, CRIT CARE MED, V18, pS56; Maccioli G A, 1988, J Cardiothorac Anesth, V2, P365, DOI 10.1016/0888-6296(88)90320-1; MARKS JD, 1992, J HEART LUNG TRANSPL, V11, P117; MCCARTHY PM, 1991, J THORAC CARDIOV SUR, V102, P578; MILLER LW, 1991, AM HEART J, V121, P1887, DOI 10.1016/0002-8703(91)90081-R; Moore C H, 1992, ASAIO J, V38, pM627, DOI 10.1097/00002480-199207000-00112; MULCAHY D, 1993, BRIT MED J, V306, P98, DOI 10.1136/bmj.306.6870.98; MURALI S, 1991, AM HEART J, V112, P1375; MURPHY MB, 1990, CRIT CARE MED, V18, pS14; MURPHY MB, 1990, J CARDIOTHERACIC S1, V4, P23; NOUIRA S, 1990, AM REV RESPIR DIS S, V14, pA139; OLSEN KH, 1988, CHEST, V94, P503, DOI 10.1378/chest.94.3.503; OTT RA, 1990, ASAIO T, V6, P792; PACKER M, 1992, AM J CARDIOL, V69, pG150, DOI 10.1016/0002-9149(92)91263-4; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PAE WE, 1993, ANN THORAC SURG, V55, P295, DOI 10.1016/0003-4975(93)90540-X; PENNINGTON DG, 1990, T AM SOC ART INT ORG, V36, pM126; PINSKY MR, 1983, J APPL PHYSIOL, V54, P950, DOI 10.1152/jappl.1983.54.4.950; PITT B, 1992, CURR OPIN CARDIOL, V7, P404, DOI 10.1097/00001573-199206000-00008; Poirier V, 1990, ASAIO Trans, V36, P787, DOI 10.1097/00002480-199010000-00001; PUCEAT M, 1992, TRENDS PHARMACOL SCI, V13, P263, DOI 10.1016/0165-6147(92)90080-P; Reedy J E, 1992, ASAIO J, V38, pM151, DOI 10.1097/00002480-199207000-00007; REEDY JE, 1992, J HEART LUNG TRANSPL, V11, P246; REITHMANN C, 1989, EUR J PHARM-MOLEC PH, V172, P211, DOI 10.1016/0922-4106(89)90051-5; ROBINSON RJS, 1987, J CARDIOTHORACIC ANE, V3, P229; ROYSTER RL, 1990, J CARDIOTHORACIC ANE, V4, P17; RUFFOLO RR, 1981, J PHARMACOL EXP THER, V219, P447; SCHAER GL, 1985, CRIT CARE MED, V13, P492, DOI 10.1097/00003246-198506000-00011; SHOEMAKER WC, 1991, CRIT CARE MED, V19, P672, DOI 10.1097/00003246-199105000-00014; TANAKA K, 1992, ARTIF ORGANS, V16, P182; TUTTLE RR, 1977, CIRC RES, V41, P357, DOI 10.1161/01.RES.41.3.357; URETSKY BF, 1987, CHEST, V92, P657, DOI 10.1378/chest.92.4.657; URETSKY BF, 1991, AM HEART J, V6, P1879; VANTRIGT P, 1984, CIRCULATION, V70, P112; VINCENT JL, 1992, CRIT CARE MED, V20, P1102, DOI 10.1097/00003246-199208000-00006; VINCENT JL, 1990, CARDIOLOGY, V77, P21, DOI 10.1159/000174667; VINCENT JL, 1991, AM HEART J, V121, P1859, DOI 10.1016/0002-8703(91)90076-T	78	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					35	41		10.1136/bmj.307.6895.35	http://dx.doi.org/10.1136/bmj.307.6895.35			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8267717	Green Published, Bronze			2022-12-28	WOS:A1993LL36900028
J	FISHER, B; COSTANTINO, J; REDMOND, C; FISHER, E; MARGOLESE, R; DIMITROV, N; WOLMARK, N; WICKERHAM, DL; DEUTSCH, M; ORE, L; MAMOUNAS, E; POLLER, W; KAVANAH, M				FISHER, B; COSTANTINO, J; REDMOND, C; FISHER, E; MARGOLESE, R; DIMITROV, N; WOLMARK, N; WICKERHAM, DL; DEUTSCH, M; ORE, L; MAMOUNAS, E; POLLER, W; KAVANAH, M			LUMPECTOMY COMPARED WITH LUMPECTOMY AND RADIATION-THERAPY FOR THE TREATMENT OF INTRADUCTAL BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOTAL MASTECTOMY; CARCINOMA; IRRADIATION; DISSECTION; MODELS	Background and Methods. Women with ductal carcinoma in situ have been treated both by lumpectomy and by lumpectomy followed by radiation therapy, but the benefit of combined therapy is uncertain. A group of 818 women with ductal carcinoma in situ were randomly assigned to undergo lumpectomy or lumpectomy followed by breast irradiation (50 Gy). Sufficient tissue was removed that the margins of the resected specimens were histologically tumor-free. The mean duration of follow-up was 43 months (range, 11 to 86). The principal end point of the study was event-free survival, as defined by the presence of no new ipsilateral or contralateral breast cancers, regional or distant metastases, or other cancers and by no deaths from causes other than cancer. Results. Five-year event-free survival was better in the women who received breast irradiation (84.4 percent, vs. 73.8 percent for the women treated by lumpectomy alone; P = 0.001). The improvement was due to a reduction in the occurrence of second ipsilateral breast cancers; the incidence of each of the other events was similar in the two groups. Of 391 women treated by lumpectomy alone, ipsilateral breast cancer developed in 64 (16.4 percent); it was noninvasive in 32 and invasive in the remaining 32. Of 399 women treated with lumpectomy and breast irradiation, ipsilateral breast cancer developed in 28 (7.0 percent) noninvasive in 20 and invasive in 8). The five-year cumulative incidence of second cancers in the ipsilateral breast was reduced by irradiation from 10.4 percent to 7.5 percent for noninvasive cancers and from 10.5 percent to 2.9 percent for invasive cancers (P = 0.055 and P<0.001, respectively). Conclusions. Breast irradiation after lumpectomy is more appropriate than lumpectomy alone for women with localized ductal carcinoma in situ.			FISHER, B (corresponding author), NATL SURG ADJUVANT BREAST & BOWEL PROJECT HEADQUAR, RM 914, SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Poller, Wolfgang/AAB-2185-2021					ASHIKARI R, 1971, CANCER, V28, P1182, DOI 10.1002/1097-0142(1971)28:5<1182::AID-CNCR2820280515>3.0.CO;2-H; BROWN PW, 1976, ARCH SURG-CHICAGO, V111, P1063; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1985, WORLD J SURG, V9, P692, DOI 10.1007/BF01655182; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P284; KORN EL, 1992, STAT MED, V11, P813, DOI 10.1002/sim.4780110611; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; RECHT A, 1985, J CLIN ONCOL, V3, P1339, DOI 10.1200/JCO.1985.3.10.1339; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; SILVERSTEIN MJ, 1987, CANCER, V59, P1819, DOI 10.1002/1097-0142(19870515)59:10<1819::AID-CNCR2820591023>3.0.CO;2-V; STOMPER PC, 1992, AM J ROENTGENOL, V159, P483, DOI 10.2214/ajr.159.3.1323923; ZAFRANI B, 1986, CANCER, V57, P1299, DOI 10.1002/1097-0142(19860401)57:7<1299::AID-CNCR2820570708>3.0.CO;2-B; 1992, NCI MONOGRAPHS, V11, P105	21	549	560	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1581	1586		10.1056/NEJM199306033282201	http://dx.doi.org/10.1056/NEJM199306033282201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8292119				2022-12-28	WOS:A1993LE28900001
J	WELCH, HG; MILLER, ME; WELCH, WP				WELCH, HG; MILLER, ME; WELCH, WP			PHYSICIAN PROFILING - AN ANALYSIS OF INPATIENT PRACTICE PATTERNS IN FLORIDA AND OREGON	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESOURCE USE; HEALTH-CARE; COST	Background. Physician profiling is a method of cost control that focuses on patterns of care instead of on specific clinical decisions. It is one cost-control method that takes into account physicians' desire to curb the intrusion of administrative mechanisms into the clinical encounter. To provide a concrete example of profiling, we analyzed the inpatient practice patterns of physicians in Florida and Oregon. Methods. Data for 1991 from Medicare's National Claims History File were used to profile 12,720 attending physicians in Florida and 2589 in Oregon. For each attending physician, we determined the total relative value of all physicians' services delivered during each patient's hospital stay. Relative value was measured in relative-value units (RVUs), according to the resource-based relative-value scale used by Medicare in determining payments to physicians. The mean number of RVUs per admission was then adjusted for the physician's case mix according to the patients' assigned diagnosis-related groups. The influence of the physician's specialty and of selected types of services (such as imaging and endoscopy) was also examined. Results. Florida physicians used markedly more resources, on average, than their colleagues in Oregon (46 vs. 30 case-mix-adjusted RVUs per admission). The difference was apparent for all specialties and all types of service. To illustrate the profiling data potentially available to the medical staffs of individual hospitals, we examined specific data on individual attending physicians and for various types of service for three hospitals' staffs. Despite similar overall profiles that fell below the national mean, each staff had a different practice pattern and would require different efforts to improve efficiency. Conclusions. In an effort to encourage further debate, we have described one method of physician profiling. Profiling data help identify and characterize differences in practice style to which individual physicians or hospital staffs can respond. Because profiling is not based on rigid rules, it is a cost-containment strategy that can easily accommodate legitimate exceptions; it is therefore preferable to methods in which the appropriateness of each clinical decision is judged separately.	DARTMOUTH COLL,SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH; URBAN INST,WASHINGTON,DC 20037	Dartmouth College; Urban Institute	WELCH, HG (corresponding author), VET AFFAIRS MED CTR,VA OUTCOMES GRP 111B,WHITE RIVER JCT,VT 05009, USA.							BENNETT L, 1993, BUSINESS HLTH    MAR, P20; BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P687, DOI 10.1001/jama.267.5.687; DAY K, 1993, WASHINGTON POST 0606, pH1; DAY K, 1993, WASHINGTON POST 0606, pH6; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Feinglass J, 1987, NLN Publ, P99; FINDLAY S, 1993, BUSINESS HLTH    APR, P58; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; IEZZONI LI, 1988, MED CARE, V26, P1068, DOI 10.1097/00005650-198811000-00005; Keller R B, 1990, Qual Assur Health Care, V2, P69; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; Lee P R, 1992, J Insur Med, V24, P179; MCMAHON LF, 1986, MED CARE, V24, P388, DOI 10.1097/00005650-198605000-00002; MILLER ME, 1993, 621001 URB I WORK PA; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; Scott HD, 1992, ANN INTERN MED, V117, P511, DOI 10.7326/0003-4819-117-6-511; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WELCH WP, 1993, 621002 URB I WORK PA; 1992, MAY C PROF WASH	22	77	77	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					607	612		10.1056/NEJM199403033300906	http://dx.doi.org/10.1056/NEJM199403033300906			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302344	Bronze			2022-12-28	WOS:A1994MY57300006
J	DEWEY, KG; LOVELADY, CA; NOMMSENRIVERS, LA; MCCRORY, MA; LONNERDAL, B				DEWEY, KG; LOVELADY, CA; NOMMSENRIVERS, LA; MCCRORY, MA; LONNERDAL, B			A RANDOMIZED STUDY OF THE EFFECTS OF AEROBIC EXERCISE BY LACTATING WOMEN ON BREAST-MILK VOLUME AND COMPOSITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROLACTIN; TESTOSTERONE; ADAPTATION; RUNNERS; GROWTH; MUSCLE	Background. The potential risks and benefits of regular exercise during lactation have not been adequately evaluated. We investigated whether regular aerobic exercise had any effects on the volume or composition of breast milk. Methods. Six to eight weeks post partum, 33 sedentary women whose infants were being exclusively breastfed were randomly assigned to an exercise group (18 women) or a control group (15 women). The exercise program consisted of supervised aerobic exercise (at a level of 60 to 70 percent of the heart-rate reserve) for 45 minutes per day, 5 days per week, for 12 weeks. Energy expenditure, dietary intake, body composition, and the volume and composition of breast milk were assessed at 6 to 8, 12 to 14, and 18 to 20 weeks post partum. Maximal oxygen uptake and the plasma prolactin response to nursing were assessed at 6 to 8 and 18 to 20 weeks. Results. The women in the exercise group expended about 400 kcal per day during the exercise sessions but compensated for this energy expenditure with a higher energy intake than that recorded by the control women (mean [+/-SD] intake, 2497+/-436 vs 2168+/-328 kcal per day at 18 to 20 weeks; P < 0.05). Maximal oxygen uptake increased by 25 percent in the exercising women but by only 5 percent in the control women (P < 0.001). There were no significant differences between the two groups in maternal body weight or fat loss, the volume or composition of the breast milk, the infant's weight gain, or maternal prolactin levels during the 12-week study. Conclusions. In this study, aerobic exercise performed four or five times per week beginning six to eight weeks post partum had no adverse effect on lactation and significantly improved the cardiovascular fitness of the mothers.	UNIV N CAROLINA,DEPT FOOD NUTR & FOOD SERV MANAGEMENT,GREENSBORO,NC	University of North Carolina; University of North Carolina Greensboro	DEWEY, KG (corresponding author), UNIV CALIF DAVIS,DEPT NUTR,DAVIS,CA 95616, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024112] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24112] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BJORNTORP P, 1970, METABOLIS, V19, P631, DOI 10.1016/0026-0495(70)90020-X; BRISSON GR, 1980, HORM METAB RES, V12, P201, DOI 10.1055/s-2007-996242; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DEWEY KG, 1991, J PEDIATR-US, V119, P538, DOI 10.1016/S0022-3476(05)82401-1; DEWEY KG, 1993, PEDIATRICS, V91, P514; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOLDBERG GR, 1988, EUR J CLIN NUTR, V42, P137; HALE RW, 1983, AM J OBSTET GYNECOL, V146, P550, DOI 10.1016/0002-9378(83)90801-3; HAMBRAEUS L, 1976, ANAL BIOCHEM, V72, P78, DOI 10.1016/0003-2697(76)90508-X; HENRIKSSON J, 1977, J PHYSIOL-LONDON, V270, P661, DOI 10.1113/jphysiol.1977.sp011974; ISSEKUTZ B, 1966, FED PROC, V25, P1415; KARASAWA K, 1981, J NUTR SCI VITAMINOL, V27, P333, DOI 10.3177/jnsv.27.333; LAMB RC, 1979, J DAIRY SCI, V62, P1791, DOI 10.3168/jds.S0022-0302(79)83498-0; LOVELADY CA, 1993, AM J CLIN NUTR, V57, P512, DOI 10.1093/ajcn/57.4.512; LOVELADY CA, 1990, AM J CLIN NUTR, V52, P103, DOI 10.1093/ajcn/52.1.103; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P65; SHANGOLD MM, 1981, FERTIL STERIL, V35, P699; Siri W., 1961, TECHNIQUES MEASURING, P223; SPURR GB, 1988, AM J CLIN NUTR, V48, P552, DOI 10.1093/ajcn/48.3.552; TREADWAY JL, 1986, AM J CLIN NUTR, V44, P481, DOI 10.1093/ajcn/44.4.481; WALLACE JP, 1992, PEDIATRICS, V89, P1245; 1991, NUTRITION LACTATION; 1987, SAS PC SOFTWARE VERS; 1991, GUIDELINES EXERCISE	26	118	125	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					449	453		10.1056/NEJM199402173300701	http://dx.doi.org/10.1056/NEJM199402173300701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289849				2022-12-28	WOS:A1994MW48000001
J	MULROW, CD; GERETY, MB; KANTEN, D; CORNELL, JE; DENINO, LA; CHIODO, L; AGUILAR, C; ONEIL, MB; ROSENBERG, J; SOLIS, RM				MULROW, CD; GERETY, MB; KANTEN, D; CORNELL, JE; DENINO, LA; CHIODO, L; AGUILAR, C; ONEIL, MB; ROSENBERG, J; SOLIS, RM			A RANDOMIZED TRIAL OF PHYSICAL REHABILITATION FOR VERY FRAIL NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION GROUPS; LONG-TERM CARE; IMPACT; MUSCLE; EFFICACY; THERAPY; UNIT	Background.-Past studies suggest multidisciplinary interventions that include physical therapy (PT) can improve function of nursing home residents. This trial specifically evaluates effects of PT for frail long-stay nursing home residents. Design.-Randomized, controlled trial. Setting.-One academic nursing home and eight community nursing homes. Patients.-A total of 194 elderly nursing home residents dependent in at least two activities of daily living residing in the nursing home for at least 3 months. Interventions.-Patients were randomized to individually tailored one-on-one PT sessions or friendly visits (FVs) three times a week for 4 months. Physical therapy included range-of-motion, strength, balance, transfer, and mobility exercises. Main Outcome Measures.-Performance-based physical function assessed by the Physical Disability Index; self-perceived health status assessed with the Sickness Impact Profile; observer-reported activities of daily living; and falls. Results.-Eighty-nine percent and 92% of PT and FV sessions, respectively, were attended; 5% and 9% of subjects dropped out in the PT group and FV group, respectively. Compared with the FV group, the PT group experienced no significant improvements in overall Physical Disability Index, Sickness Impact Profile, or activities of daily living scores. A 15.5% improvement in the mobility subscale of the Physical Disability Index was seen (95% confidence interval [CI], 6.4% to 24.7%); no benefits in range-of-motion, strength, or balance subscales were found. Compared with the FV group, the PT group used assistive devices for bed mobility tasks less often (P=.06) and were less likely to use assistive devices and wheelchairs for locomotion (P<.005). There were 79 falls in the PT group vs 60 falls in the FV group (P=.11). Charge for the 4-month PT program was $1220 per subject (95% CI, $412 to $1832). Conclusion.-This standardized physical therapy program provided modest mobility benefits for very frail long-stay nursing home residents with physical disability due to multiple comorbid conditions.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	MULROW, CD (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,2400 MERTON MINTER BLVD,SAN ANTONIO,TX 78284, USA.				NIA NIH HHS [UO1AG09117] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG009117] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Applegate W B, 1987, Clin Geriatr Med, V3, P145; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOCK RD, 1975, MULTIVARIATE STATIST; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; CHIODO LK, 1992, PHYS THER, V72, P168, DOI 10.1093/ptj/72.3.168; COHEN MA, 1986, MED CARE, V12, P1161; COONEY LM, 1985, MED CARE, V23, P123, DOI 10.1097/00005650-198502000-00003; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P181; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIES BE, 1985, MED CARE, V23, P110, DOI 10.1097/00005650-198502000-00002; GERETY MB, 1993, J GERONTOL, V48, pM33, DOI 10.1093/geronj/48.2.M33; GORDON BE, 1960, J CHRONIC EDIS, V15, P311; GRIMALDI PL, 1987, CASE MIX PAYMENT SYS; HADLEY EC, 1993, GERONTOLOGIST, V33, P204; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HUGHES SL, 1984, MED CARE, V22, P460, DOI 10.1097/00005650-198405000-00010; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JIROVEC MM, 1991, INT J NURS STUD, V28, P145, DOI 10.1016/0020-7489(91)90004-M; KANTEN DN, 1993, J AM GERIATR SOC, V41, P662, DOI 10.1111/j.1532-5415.1993.tb06741.x; KAPLAN J, 1975, GERONTOLOGIST, V15, P393, DOI 10.1093/geront/15.5_Part_1.393; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LEMKE S, 1986, J GERONTOL, V41, P268, DOI 10.1093/geronj/41.2.268; LI L, 1993, J AM GERIATR SOC, V41, pSA29; LIEM PH, 1986, J GERONTOL, V41, P44, DOI 10.1093/geronj/41.1.44; MARINO M, 1982, AM J SPORT MED, V10, P360, DOI 10.1177/036354658201000608; MCMURDO MET, 1993, AGE AGEING, V22, P11, DOI 10.1093/ageing/22.1.11; MULROW CD, 1993, J AM GERIATR SOC, V41, P326, DOI 10.1111/j.1532-5415.1993.tb06712.x; Murtaugh C M, 1988, Health Serv Res, V23, P467; ONEIL MB, 1992, PHYS THER, V72, P596, DOI 10.1093/ptj/72.8.596; PARRY F, 1982, J AM GERIATR SOC, V31, P482; ROTHMAN ML, 1989, MED CARE, V27, pS157, DOI 10.1097/00005650-198903001-00013; RUBENSTEIN LV, 1992, PHYS THER, V72, P173, DOI 10.1093/ptj/72.3.173; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; SAUVAGE LR, 1992, AM J PHYS MED REHAB, V71, P333, DOI 10.1097/00002060-199212000-00005; SCHUMAN JE, 1980, ARCH PHYS MED REHAB, V61, P310; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SMITH DW, 1987, MED CARE, V25, P120, DOI 10.1097/00005650-198702000-00005; WEILAND D, 1986, JAMA-J AM MED ASSOC, V255, P2622; 1988, RED BOOK ANN PHARM R; 1987, SAS STAT GUIDE PERSO	41	200	200	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					519	524		10.1001/jama.271.7.519	http://dx.doi.org/10.1001/jama.271.7.519			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV423	8301766				2022-12-28	WOS:A1994MV42300034
J	NEWMAN, LJ; PLATTSMILLS, TAE; PHILLIPS, CD; HAZEN, KC; GROSS, CW				NEWMAN, LJ; PLATTSMILLS, TAE; PHILLIPS, CD; HAZEN, KC; GROSS, CW			CHRONIC SINUSITIS - RELATIONSHIP OF COMPUTED TOMOGRAPHIC FINDINGS TO ALLERGY, ASTHMA, AND EOSINOPHILIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAXILLARY SINUSITIS; CHILDREN; SINUSES; SURGERY; BACTERIOLOGY; DISEASE	Objective.-To develop a technique for evaluating the severity of chronic sinus disease and to examine the correlation with allergy, asthma, and eosinophilia. Design.-A survey of 104 patients undergoing surgery for chronic sinusitis. Setting.-A university hospital ear, nose, and throat clinic. Patients.-A referral population of adult patients being scheduled for endoscopic sinus surgery was eligible; 104 completed questionnaires and agreed to participate. Main Outcome Measures.-Computed tomographic scans were reviewed and scored for extent of disease. Serum samples were assayed for total IgE and specific IgE antibodies to common inhalant allergens. Peripheral blood samples were analyzed for total eosinophil count. Surgical biopsy specimens were examined for eosinophilia and cultured for bacteria and fungi. Results.-Extensive disease was present in 39% of subjects and correlated well with asthma, specific IgE antibodies, and eosinophilia, but not with elevated total IgE. Among patients with peripheral eosinophilia, 87% had extensive disease. All cultures grew aerobic bacteria; anaerobes and fungi were uncommon. Conclusions.-We present a system for quantitation of disease extent using computed tomographic scans of patients with chronic sinusitis. The well-accepted associations of chronic sinusitis with asthma and allergy appear to be restricted to the group with extensive disease. The presence of peripheral eosinophilia in patients with sinusitis indicates a high likelihood of extensive disease.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT OTOLARYNGOL,CHARLOTTESVILLE,VA 22903	University of Virginia; University of Virginia; University of Virginia; University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-30840, AI-20562] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT A, 1987, MULTIVARIATE INTERPR, P76; Balows A, 1991, MANUAL CLIN MICROBIO; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KANAI N, IN PRESS AM REV RESP; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; MINGS R, 1988, AM J RHINOL, V71, P123; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SHAPIRO ED, 1982, J INFECT DIS, V146, P589, DOI 10.1093/infdis/146.5.589; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; VAN DISHOECK H A, 1957, Pract Otorhinolaryngol (Basel), V19, P502; VANDISHOECK HAE, 1961, ADV OTORHINOLARYNGOL, V10, P1; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731; 1990, 901261 US DEP HLTH H	25	260	269	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					363	367		10.1001/jama.271.5.363	http://dx.doi.org/10.1001/jama.271.5.363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283586				2022-12-28	WOS:A1994MR98300031
J	ALLSHIRE, RC; JAVERZAT, JP; REDHEAD, NJ; CRANSTON, G				ALLSHIRE, RC; JAVERZAT, JP; REDHEAD, NJ; CRANSTON, G			POSITION EFFECT VARIEGATION AT FISSION YEAST CENTROMERES	CELL			English	Article							MATING-TYPE LOCI; NONHISTONE CHROMOSOMAL PROTEIN; SATELLITE DNA-SEQUENCES; TRANSFER-RNA GENES; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; HETEROCHROMATIN; TRANSCRIPTION	Chromatin structure at Schizosaccharomyces pombe centromeres is unusual. The insertion of the ura4 gene within these centromeres resulted in genetically identical cells mosaic for its expression. Placement of the ade6 gene within cen1 or cen3 resulted in red-white sectored colonies, demonstrating the instability of gene expression. The occurrence of pink colonies implied that intermediate levels of repression were established. Repression of both genes within centromeres was temperature sensitive. The chromatin structure of the ura4 gene at centromeres was altered, suggesting that the unusual chromatin encroaches into the gene and inhibits normal expression. These repressive effects at S. pombe centromeres resemble the classical phenomenon of position effect variegation imposed by Drosophila heterochromatin on nearby genes. However, since the epigenetic states can be set at intermediate levels of expression, a purely euchromatin-heterochromatin dichotomy does not apply. A model for the epigenetic regulation of genes placed within S. pombe centromeres is presented.			ALLSHIRE, RC (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.			Allshire, Robin/0000-0002-8005-3625	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARIGOZZI C, 1966, EXP CELL RES, V43, P231, DOI 10.1016/0014-4827(66)90399-5; BISHOP CP, 1992, GENETICS, V132, P1063; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; Demerec M, 1940, GENETICS, V25, P618; DIMITRI P, 1989, GENETICS, V122, P793; EGEL R, 1984, CURR GENET, V8, P199, DOI 10.1007/BF00417816; EISSENBERG JC, 1992, GENETICS, V131, P345; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gowen JW, 1933, SCIENCE, V77, P312, DOI 10.1126/science.77.1995.312; Gowen JW, 1934, GENETICS, V19, P0189; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HARTMANN.IJ, 1967, GENET RES, V10, P143, DOI 10.1017/S0016672300010880; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HENIKOFF S, 1979, GENETICS, V93, P105; HILLIKER AJ, 1980, CELL, V21, P607, DOI 10.1016/0092-8674(80)90424-9; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KUHN RM, 1991, P NATL ACAD SCI USA, V88, P1306, DOI 10.1073/pnas.88.4.1306; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Miklos GLG, 1985, MOL EVOLUTIONARY GEN, P241; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; REUTER G, 1982, CHROMOSOMA, V85, P539, DOI 10.1007/BF00327349; Sambrook J, 1989, MOL CLONING LABORATO; Schultz J, 1936, P NATL ACAD SCI USA, V22, P27, DOI 10.1073/pnas.22.1.27; SINCLAIR DAR, 1983, MOL GEN GENET, V191, P326, DOI 10.1007/BF00334834; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SPOFFORD JB, 1967, GENETICS, V57, P751; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; SPRADLING AC, 1990, GENETICS, V126, P779; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TAKAHASHI K, 1991, J MOL BIOL, V218, P13, DOI 10.1016/0022-2836(91)90867-6; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TARTOF KD, 1990, DEVELOPMENT, P35; TARTOF KD, 1989, DEV GENET, V10, P162, DOI 10.1002/dvg.1020100306; THON G, 1992, GENETICS, V131, P287; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	62	279	284	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					157	169		10.1016/0092-8674(94)90180-5	http://dx.doi.org/10.1016/0092-8674(94)90180-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287474				2022-12-28	WOS:A1994MR49500014
J	BRONSTHER, O; FUNG, JJ; IZAKIS, A; VANTHIEL, D; STARZL, TE				BRONSTHER, O; FUNG, JJ; IZAKIS, A; VANTHIEL, D; STARZL, TE			PRIORITIZATION AND ORGAN DISTRIBUTION FOR LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY BILIARY-CIRRHOSIS; EXTENDED PRESERVATION		UNIV PITTSBURGH,MED CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUELMAGD KM, 1993, SURG GYNECOL OBSTET, V177, P335; DELMONICO FL, 1992, ARCH SURG-CHICAGO, V127, P579; DICKSON ER, 1992, GASTROENTEROLOGY, V103, P1893, DOI 10.1016/0016-5085(92)91449-E; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HENDERSON JM, 1992, ANN SURG, V216, P248, DOI 10.1097/00000658-199209000-00004; KALAYOGLU M, 1988, LANCET, V1, P617; MARKUS BH, 1989, NEW ENGL J MED, V320, P1709, DOI 10.1056/NEJM198906293202602; MUTO P, IN PRESS TRANSPLANTA; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1982, HEPATOLOGY, V2, P614; STARZL TE, 1988, TRANSPLANT P S1, V20, P5131; TODO S, 1989, JAMA-J AM MED ASSOC, V261, P711, DOI 10.1001/jama.261.5.711; VANTHIEL D, IN PRESS AM J GASTRO; 1984, HEPATOLOGY S, V4, pS1	15	40	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					140	143		10.1001/jama.271.2.140	http://dx.doi.org/10.1001/jama.271.2.140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264069	Green Accepted			2022-12-28	WOS:A1994MQ08300024
J	NELLIST, M; JANSSEN, B; BROOKCARTER, PT; HESSELINGJANSSEN, ALW; MAHESHWAR, MM; VERHOEF, S; VANDENOUWELAND, AMW; LINDHOUT, D; EUSSEN, B; CORDEIRO, I; SANTOS, H; HALLEY, DJJ; SAMPSON, JR; WARD, CJ; PERAL, B; THOMAS, S; HUGHES, J; HARRIS, PC; ROELFSEMA, JH; SARIS, JJ; SPRUIT, L; PETERS, DJM; DAUWERSE, JG; BREUNING, MH				NELLIST, M; JANSSEN, B; BROOKCARTER, PT; HESSELINGJANSSEN, ALW; MAHESHWAR, MM; VERHOEF, S; VANDENOUWELAND, AMW; LINDHOUT, D; EUSSEN, B; CORDEIRO, I; SANTOS, H; HALLEY, DJJ; SAMPSON, JR; WARD, CJ; PERAL, B; THOMAS, S; HUGHES, J; HARRIS, PC; ROELFSEMA, JH; SARIS, JJ; SPRUIT, L; PETERS, DJM; DAUWERSE, JG; BREUNING, MH			IDENTIFICATION AND CHARACTERIZATION OF THE TUBEROUS SCLEROSIS GENE ON CHROMOSOME-16	CELL			English	Article							POLYCYSTIC KIDNEY-DISEASE; LOCUS; HETEROGENEITY; SEQUENCES; MARKER; SITES; DNA; PHOSPHORYLATION; RETINOBLASTOMA; RECOMBINATION	Tuberous sclerosis (TSC) is an autosomal dominant multisystem disorder with loci assigned to chromosomes 9 and 16. Using pulsed-field gel electrophoresis (PFGE), we identified five TSC-associated deletions at 16p13.3. These were mapped to a 120 kb region that was cloned in cosmids and from which four genes were isolated. One gene, designated TSC2, was interrupted by all five PFGE deletions, and closer examination revealed several intragenic mutations, including one de novo deletion. In this case, Northern blot analysis identified a shortened transcript, while reduced expression was observed in another TSC family, confirming TSC2 as the chromosome 16 TSC gene. The 5.5 kb TSC2 transcript is widely expressed, and its protein product, tuberin, has a region of homology to the GTPase-activating protein GAP3.	UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3015 GE ROTTERDAM, NETHERLANDS; HOSP SANTA MARIA, GENET UNIT, P-1699 LISBON, PORTUGAL; ERASMUS UNIV ROTTERDAM, HOSP DIJKZIGT, 3015 GE ROTTERDAM, NETHERLANDS; JOHN RADCLIFFE HOSP, INST MOLEC MED, MRC, MOLEC HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND; LEIDEN UNIV, INST HUMAN GENET, 2333 AL LEIDEN, NETHERLANDS	Cardiff University; Erasmus University Rotterdam; Universidade de Lisboa; Hospital Santa Maria; Erasmus University Rotterdam; Erasmus MC; University of Oxford; Leiden University; Leiden University - Excl LUMC			Peters, Dorien/AFH-8507-2022; Lindhout, Dick/AAH-5765-2019; Peral, Belén/F-4562-2015	Peters, Dorien/0000-0001-6974-7143; Peral, Belén/0000-0003-4984-4020	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGAZALI LI, 1989, J MED GENET, V26, P694, DOI 10.1136/jmg.26.11.694; BERNSTEIN J, 1974, Birth Defects Original Article Series, V10, P35; BERNSTEIN J, 1991, ANN NY ACAD SCI, V615, P36; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P2185, DOI 10.1073/pnas.76.5.2185; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRYER AE, 1990, J MED GENET, V27, P217, DOI 10.1136/jmg.27.4.217; FRYER AE, 1987, LANCET, V1, P659; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GERMINO GG, 1993, KIDNEY INT       S39, V43, P20; GLASS DB, 1986, J BIOL CHEM, V261, P2987; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1993, AM J HUM GENET, V53, P244; HAINES JL, 1991, AM J HUM GENET, V49, P764; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HARRIS PC, 1991, LANCET, V338, P1484, DOI 10.1016/0140-6736(91)92300-Q; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; JANSSEN LAJ, 1991, ANN NY ACAD SCI, V615, P306; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KKWIATKOWSKI DJ, 1993, CELL GENET, V64, P94; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NELLIST M, 1993, J MED GENET, V30, P224, DOI 10.1136/jmg.30.3.224; NORTHRUP H, 1992, AM J HUM GENET, V51, P709; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RACK KA, 1993, AM J HUM GENET, V52, P987; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROYLE NJ, 1992, NUCLEIC ACIDS RES, V20, P1164, DOI 10.1093/nar/20.5.1164; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SAMPSON JR, 1989, J MED GENET, V26, P511, DOI 10.1136/jmg.26.8.511; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SMITH M, 1993, AM J HUM GENET, V53, P366; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; THOMPSON AD, 1992, GENOMICS, V13, P402, DOI 10.1016/0888-7543(92)90260-Y; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; van der Hoeve J., 1933, J BELGE NEUROLOGICAL, V33, P752; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; [No title captured]; [No title captured]	60	1239	1263	1	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1305	1315						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269512				2022-12-28	WOS:A1993MP86900010
J	BLACK, D				BLACK, D			DEPRIVATION AND HEALTH	BRITISH MEDICAL JOURNAL			English	Article																		BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111; BOYS RJ, 1991, BMJ-BRIT MED J, V303, P879, DOI 10.1136/bmj.303.6807.879; MARMOT MG, 1984, LANCET, V1, P1003; RUSKIN J, 1965, SESAME AND LILIES; TOWNSEND P, 1976, EQUALITIES INEQUALIT; Whitehead M, 1992, INEQUALITIES HLTH BL; 1978, HLTH SERVICES DEV CO	7	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1630	1631		10.1136/bmj.307.6919.1630	http://dx.doi.org/10.1136/bmj.307.6919.1630			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292965	Green Published, Bronze			2022-12-28	WOS:A1993MN10700033
J	LINDGREN, S; BOHLIN, AB; FORSGREN, M; ARNEBORN, M; OTTENBLAD, C; LIDMAN, K; ANZEN, B; VONSYDOW, M; BOTTIGER, M				LINDGREN, S; BOHLIN, AB; FORSGREN, M; ARNEBORN, M; OTTENBLAD, C; LIDMAN, K; ANZEN, B; VONSYDOW, M; BOTTIGER, M			SCREENING FOR HIV-1 ANTIBODIES IN PREGNANCY - RESULTS FROM THE SWEDISH NATIONAL PROGRAM	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDBEARING WOMEN; INFECTION; TRANSMISSION; PREVALENCE; TYPE-1; SEROPREVALENCE; KNOWLEDGE; CONTINUE; NEWBORNS	Objective-To determine the effectiveness of a national screening programme for HIV infection in pregnant women. Design-Observational study. Subjects-All pregnant women presenting to antenatal or abortion clinics. Setting-Sweden, September 1987 to December 1991. Main outcome measures-Number and characteristics of infected women. Results-By the end of the study period 510000 tests had been performed and 54 women with HIV infection identified (1.06/10000). Of the 33 women identified in Stockholm, 14 women (4.4/10000) had attended abortion clinics and 19 antenatal clinics (1.8/10000; p < 0.05). Three women had been intravenous drug users, one was infected through a blood transfusion, and 50 were probably infected sexually. Of the 20 women who attended antenatal clinics early enough to allow an abortion, 12 continued with their pregnancies. Conclusions-Testing of all women, not just those perceived to be at risk, probably contributed to the high uptake of HIV testing. With high uptake such screening provides valuable data on spread of HIV in the heterosexual population and presents opportunity for preventing transmission of HIV to children and partners.	STOCKHOLM CTY COUNCIL,DEPT CLIN VIROL,CENT MICROBIOL LAB,S-10726 STOCKHOLM,SWEDEN; NATL BACTERIOL LAB,DEPT EPIDEMIOL,S-10521 STOCKHOLM,SWEDEN; DANDERYD HOSP,S-18288 DANDERYD,SWEDEN	Stockholm County Council; Danderyds Hospital	LINDGREN, S (corresponding author), HUDDINGE HOSP,FAMILY SOCIAL CLIN,S-14186 HUDDINGE,SWEDEN.							ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BARBACCI M, 1991, LANCET, V337, P7509; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLAXHULT A, IN PRESS AIDS; BOYD KM, 1990, J MED ETHICS, V16, P173, DOI 10.1136/jme.16.4.173; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GAINES H, 1987, LANCET, V1, P1249; GOLDBERG DJ, 1992, BMJ-BRIT MED J, V304, P1082, DOI 10.1136/bmj.304.6834.1082; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HULL HF, 1988, JAMA-J AM MED ASSOC, V260, P935, DOI 10.1001/jama.260.7.935; JOHNSTONE FD, 1990, BRIT MED J, V300, P23, DOI 10.1136/bmj.300.6716.23; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LARSSON G, 1990, AIDS Care, V2, P223, DOI 10.1080/09540129008257734; LARSSON G, 1987, J ADV NURS, V12, P441; Larsson G, 1988, Lakartidningen, V85, P332; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MITCHELL J, 1990, PEDIATRIC AIDS HIF I, V1, P78; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; SHERR L, 1991, HIV AIDS MOTHERS BAB, P57; TAPPIN DM, 1991, LANCET, V337, P1565; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WENSTROM KD, 1989, OBSTET GYNECOL, V74, P558; 1991, EPIDAKTUELLT, V14, P6; 1987, SOCIALSTYRELSENS FOR, V22, P1; 1991, LANCET, V337, P253	31	52	52	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1447	1451		10.1136/bmj.307.6917.1447	http://dx.doi.org/10.1136/bmj.307.6917.1447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281085	Green Published, Bronze			2022-12-28	WOS:A1993MK79700018
J	ROONEY, C; BERAL, V; MACONOCHIE, N; FRASER, P; DAVIES, G				ROONEY, C; BERAL, V; MACONOCHIE, N; FRASER, P; DAVIES, G			CASE-CONTROL STUDY OF PROSTATIC-CANCER IN EMPLOYEES OF THE UNITED-KINGDOM-ATOMIC-ENERGY-AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							NUCLEAR-FUELS; MORTALITY; WORKERS; FACILITY	Objective-To investigate the relation between risk of prostatic cancer and occupational exposures, especially to radionuclides, in employees of the United Kingdom Atomic Energy Authority. Design-Case-control study of men with prostatic cancer and matched controls. Information about sociodemographic factors and exposures to radionuclides and other substances was abstracted and classified for each subject from United Kingdom Atomic Energy Authority records without knowledge of who had cancer. Subjects-136 men with prostatic cancer diagnosed between 1946 and 1986 and 404 matched controls, all employees of United Kingdom Atomic Energy Authority. Main outcome measures-Documented or possible contamination with specific radionuclides. Results-Risk of prostatic cancer was significantly increased in men who were internally contaminated with or who worked in environments potentially contaminated by tritium, chromium-51, iron-59, cobalt-60, or zinc-65. Internal contamination with at least one of the five radionuclides was detected in 14 men with prostatic cancer (10%) and 12 controls (3%) (relative risk 5.32 (95% confidence interval 1.87 to 17.24). Altogether 28 men with prostatic cancer (21%) and 46 controls (11%) worked in environments potentially contaminated by at least one of the five radionuclides (relative risk 2.36 (1.26 to 4.43)); about two thirds worked at heavy water reactors (19 men with prostatic cancer and 32 controls (relative risk 2.13 (1.00 to 4.52)). Relative risk of prostatic cancer increased with increasing duration of work in places potentially contaminated by these radionuclides and with increasing level of probable contamination. Prostatic cancer was not associated with exposure to plutonium, uranium, cadmium, boron, beryllium, or organic or inorganic chemicals. Conclusions-Risk of prostatic cancer risk was increased in United Kingdom Atomic Energy Authority workers who were occupationally exposed to tritium, C-51, Fe-59, Co-60, or Zn-65. Exposure to these radionuclides was infrequent, and their separate effects could not be evaluated.	RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL MONITORING UNIT,LONDON WC1E 7HT,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine								BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BRESLOW NE, 1980, IARC SCI PUBLICATION, V82; BYAR DP, 1969, INVEST UROL, V7, P57; BYAR DP, 1974, MALE ACCESSORY SEX O, P161; COSTELLO LC, 1991, PROSTATE, V18, P25, DOI 10.1002/pros.2990180104; CRAGLE DL, 1988, AM J IND MED, V14, P379, DOI 10.1002/ajim.4700140404; FRASER P, 1993, BRIT J CANCER, V67, P615, DOI 10.1038/bjc.1993.113; FRASER P, 1985, BRIT MED J, V291, P435, DOI 10.1136/bmj.291.6493.435; GILBERT ES, 1989, HEALTH PHYS, V56, P11, DOI 10.1097/00004032-198901000-00001; GILBERT ES, 1979, RADIAT RES, V79, P122, DOI 10.2307/3575027; MARTIN MJ, 1970, RADIOACTIVE ATOMS AU; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; SCHROEDER HA, 1967, J CHRON DIS, V20, P179, DOI 10.1016/0021-9681(67)90002-1; SHIMIZU Y, 1987, RAD EFFECTS RES F TE, V12, P1; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; THUN MJ, 1985, J NATL CANCER I, V74, P325; WILKINSON GS, 1987, AM J EPIDEMIOL, V125, P231, DOI 10.1093/oxfordjournals.aje.a114523; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; 1985, LANCET, V2, P533; 1990, EGRET EPIDEMIOLOGICA	21	60	63	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1391	1397		10.1136/bmj.307.6916.1391	http://dx.doi.org/10.1136/bmj.307.6916.1391			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274891	Green Published, Bronze			2022-12-28	WOS:A1993MK42000020
J	WORCESTER, MC; HARE, DL; OLIVER, RG; REID, MA; GOBLE, AJ				WORCESTER, MC; HARE, DL; OLIVER, RG; REID, MA; GOBLE, AJ			EARLY PROGRAMS OF HIGH AND LOW-INTENSITY EXERCISE AND QUALITY-OF-LIFE AFTER ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							SCALE	Objective-To determine whether a group programme of light exercise could improve quality of life in patients after acute myocardial infarction to the same extent as a high intensity exercise training programme. Setting-Australian teaching hospital. Patients-224 men from a consecutive series of 339 men under 70 admitted to a coronary care unit with transmural acute myocardial infarction. Intervention-Patients were randomly allocated in hospital to a group programme lasting eight weeks of either high intensity exercise training or light exercise. Main outcome measures-Physical working capacity based on metabolic equivalents achieved from treadmill exercise tests at entry, after 11 weeks, and after one year. Quality of life based on self report scores of anxiety, depression, denial, and wellbeing and interview assessments of activities and psychosocial adjustment at entry, after four months, and after one year. Results-The two groups were well matched at entry. At 11 weeks the mean results of treadmill testing were 10.7 (95% confidence interval 10.20 to 11.20) metabolic equivalents for exercise training and 9.7 (9.26 to 10.14) for light exercise (t=2.85, df=181, p=0.005). Apart from this small temporary benefit in mean physical working capacity, there were no significant differences between groups. Improvement in occupational adjustment score from baseline to four months was greater after exercise training than after light exercise, but at one year repeated measures analysis of variance showed no significant effects of treatment or interaction between treatment and time point. Conclusion-The effects on quality of life of a low cost programme of light exercise are similar to those obtained from a high intensity exercise training programme.	AUSTIN HOSP,DEPT CARDIOL,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	WORCESTER, MC (corresponding author), HEART RES CTR,POB 607,CARLTON,VIC 3053,AUSTRALIA.			Hare, David Linley/0000-0001-9554-6556				BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLUMENTHAL JA, 1988, AM J CARDIOL, V61, P26, DOI 10.1016/0002-9149(88)91298-2; BLUMENTHAL JA, 1988, J CARDIOPULM REHABIL, V8, P183, DOI DOI 10.1097/00008483-198805000-00003; Broom L, 1977, INVESTIGATING SOCIAL; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; BRUCE RA, 1974, CONTROVERSY INTERNAL, V2; CLAUSEN JP, 1969, CIRCULATION, V40, P143, DOI 10.1161/01.CIR.40.2.143; DEBUSK RF, 1979, AM J CARDIOL, V44, P1223, DOI 10.1016/0002-9149(79)90433-8; DIMSDALE JE, 1982, AM J PSYCHIAT, V139, P1477; EWART CK, 1983, AM J CARDIOL, V51, P1077; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FOLSTEIN MF, 1973, PSYCHOL MED, V3, P479, DOI 10.1017/S0033291700054283; GOBLE AJ, 1991, BRIT HEART J, V65, P126; GURLAND BJ, 1972, ARCH GEN PSYCHIAT, V27, P259; HACKETT TP, 1974, J PSYCHOSOM RES, V18, P93, DOI 10.1016/0022-3999(74)90072-5; Inc S. P. S. S., 1988, SPSS X USERS GUIDE; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; Laughlin, 1976, HDB IPAT DEPRESSION; MAYOU R, 1978, J PSYCHOSOM RES, V22, P447, DOI 10.1016/0022-3999(78)90068-5; NORRIS RM, 1969, LANCET, V1, P274; NORRIS RM, 1970, LANCET, V2, P485; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Prineas R., 1982, MINNESOTA CODE MANUA; SAETERHAUG A, 1989, J CARDIOPULM REHABIL, V7, P268; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; STERN MJ, 1976, J CHRON DIS, V29, P513, DOI 10.1016/0021-9681(76)90015-1; TAYLOR CB, 1986, J PSYCHOSOM RES, V30, P581, DOI 10.1016/0022-3999(86)90031-0; WEISSMAN MM, 1975, ARCH GEN PSYCHIAT, V32, P357; WIKLUND I, 1984, J PSYCHOSOM RES, V28, P309, DOI 10.1016/0022-3999(84)90053-9; WOLK MJ, 1972, CIRCULATION, V45, P1125, DOI 10.1161/01.CIR.45.5.1125; 1959, WHO TECH REP SER, V168, P25; 1979, CIRCULATION, V59, P1084	33	38	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1244	1247		10.1136/bmj.307.6914.1244	http://dx.doi.org/10.1136/bmj.307.6914.1244			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MH001	8281056	Bronze, Green Published			2022-12-28	WOS:A1993MH00100019
J	MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S				MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S			GENERAL-PRACTICE FUNDHOLDING - OBSERVATIONS ON PRESCRIBING PATTERNS AND COSTS USING THE DEFINED DAILY DOSE METHOD	BRITISH MEDICAL JOURNAL			English	Article							BUDGET	Objective-To compare prescribing patterns between a group of fundholding practices and a group of non-fundholding practices in north east Scotland using a method which provides more accurate statements about volumes prescribed than standard NHS statistics. Design-The pharmacy practice division of the National Health Service in Scotland provided data for selected British National Formulary sections over two years. Each prescription issued was converted using the World Health Organisation ''defined daily dose'' mechanism. Setting-Six fundholding groups (nine practices) in Grampian and Tayside regions and six non-fundholding practices in Grampian. Results-During the past two years both fund-holding and control practices reduced the volume of their prescribing for the classes of drug analysed. The unit costs of drugs in some classes, however, rose substantially, contributing to higher costs per patient. The unit costs rose more in the control practices (24%) than in the fundholding practices (11% in Tayside, 16% in Grampian). Conclusion-The use of defined daily doses helped identify cost and volume trends in specific areas of prescribing in fundholding and control practices. The basis on which funds are set needs improving, and defined daily doses may prove useful for setting volume targets within drug classes for all practices, whether fundholding or not.	LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,SCOTLAND		MAXWELL, M (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102; WUATT TD, 1990, BMJ, V300, P441; 1986, NORDIC STATISTICS 1; 1989, WORKING PATIENTS; 1985, NORDIC STATISTICS 3; 1991, GUIDELINES DEFINED D; 1990, FUNDING GENERAL PRAC; 1985, NORDIC STATISTICS 2; 1993, TREATMENT DEPRESSION	18	115	117	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1190	1194		10.1136/bmj.307.6913.1190	http://dx.doi.org/10.1136/bmj.307.6913.1190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8305075	Bronze, Green Published			2022-12-28	WOS:A1993MF82400027
J	MCKENNEY, JM; PROCTOR, JD; HARRIS, S; CHINCHILI, VM				MCKENNEY, JM; PROCTOR, JD; HARRIS, S; CHINCHILI, VM			A COMPARISON OF THE EFFICACY AND TOXIC EFFECTS OF SUSTAINED-RELEASE VS IMMEDIATE-RELEASE NIACIN IN HYPERCHOLESTEROLEMIC PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; FULMINANT HEPATIC-FAILURE; CORONARY-ARTERY DISEASE; NICOTINIC-ACID; CRYSTALLINE NIACIN; THERAPY; ATHEROSCLEROSIS; REGRESSION; MECHANISM; BENEFIT	Objective.-To compare escalating doses of immediate-release (IR) and sustained-release (SR) niacin for effectiveness in reducing levels of low-density lipoprotein cholesterol and triglycerides and increasing levels of high-density lipoprotein cholesterol, and for the occurrence of adverse reactions, especially hepatotoxicity. Design.-Randomized, double-blind, parallel comparison of IR and SR niacin administered sequentially at 500, 1000, 1500, 2000, and 3000 mg/d, each for 6 weeks. Setting.-Cholesterol research center. Patients.-Forty-six adults, 23 in each group, with low-density lipoprotein cholesterol levels greater than 4.14 mmol/l (160 mg/dL) after 1 month of a step 1 National Cholesterol Education Program diet. Outcome Measures.-Fourteen-hour fasting lipid and lipoprotein cholesterol levels, results of clinical laboratory tests, a symptom questionnaire, and withdrawal rates. Results.-The SR niacin lowered low-density lipoprotein cholesterol levels significantly more than IR niacin did at the dosage of 1500 mg/d and above, while IR niacin increased high-density lipoprotein cholesterol levels significantly more than SR niacin did at all dosage levels. The reduction in triglyceride levels was similar with IR and SR niacin. Nine (39%) of the 23 patients assigned to the IR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were vasodilatory symptoms, fatigue, and acanthosis nigricans. Eighteen (78%) of the 23 patients assigned to the SR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were gastrointestinal tract symptoms, fatigue, and increases in levels of liver aminotransferases, often with symptoms of hepatic dysfunction. None of the patients taking IR niacin developed hepatoxic effects, while 12 (52%) of the 23 patients taking SR niacin did. Conclusion.-The SR form of niacin is hepatotoxic and should be restricted from use. The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,SCH MED,RICHMOND,VA 23298; BAPTIST MED CTR,LITTLE ROCK,AR; PENN STATE UNIV,COLL MED,HERSHEY,PA	Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	MCKENNEY, JM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,SCH PHARM,RICHMOND,VA 23298, USA.		Adiels, Martin/C-9278-2011					ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; [Anonymous], 1988, CLIN CHEM, V34, P193; BERGE KG, 1961, AM J MED, V31, P24, DOI 10.1016/0002-9343(61)90221-2; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN BG, 1989, CIRCULATION S2, V80, P266; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; CHRISTENSEN N, 1961, JAMA-J AM MED ASSOC, V177, P546, DOI 10.1001/jama.1961.03040340010003; CLEMENTZ GL, 1987, J CLIN GASTROENTEROL, V9, P582, DOI 10.1097/00004836-198710000-00022; DALTON TA, 1992, AM J MED, V93, P102, DOI 10.1016/0002-9343(92)90689-9; EINSTEIN N, 1975, AM J DIG DIS, V20, P282, DOI 10.1007/BF01070732; ETCHASON JA, 1991, MAYO CLIN PROC, V66, P23, DOI 10.1016/S0025-6196(12)61171-9; FERENCHICK G, 1989, AM J MED SCI, V298, P191, DOI 10.1097/00000441-198909000-00009; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROST PH, 1991, ANN INTERN MED, V114, P1065, DOI 10.7326/0003-4819-114-12-1065_1; GOLDSTEIN MR, 1988, AM J MED, V85, P881; HENKIN Y, 1990, JAMA-J AM MED ASSOC, V264, P241, DOI 10.1001/jama.264.2.241; HENKIN Y, 1991, AM J MED, V91, P289; HODIS HN, 1990, JAMA-J AM MED ASSOC, V264, P181, DOI 10.1001/jama.1990.03450020033012; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KEENAN JM, 1991, J AM GERIATR SOC, V40, P12; KING JM, 1991, ARTERIOSCLEROSIS, V11, pA1519; KNAPP TRF, 1991, DICP ANN PHARMAC, V25, P253; KNOPP R, 1991, ANN INTERN MED, V111, P769; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LAVIE CJ, 1992, AM J CARDIOL, V69, P1083, DOI 10.1016/0002-9149(92)90868-Y; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; MORRISON DF, 1976, MULTIVARIATE STATIST, P102; MULLIN GE, 1989, ANN INTERN MED, V111, P253, DOI 10.7326/0003-4819-111-3-253; PALUMBO PJ, 1991, MAYO CLIN PROC, V66, P112, DOI 10.1016/S0025-6196(12)61180-X; PATTERSON DJ, 1983, SOUTHERN MED J, V76, P239, DOI 10.1097/00007611-198302000-00023; RADER JI, 1992, AM J MED, V92, P77, DOI 10.1016/0002-9343(92)90018-7; REMMELL PS, 1980, J AM DIET ASSOC, V76, P351; SUPERKO HR, 1992, ATHEROSCLEROSIS, V95, P69, DOI 10.1016/0021-9150(92)90177-I; TORNVALL P, 1990, ATHEROSCLEROSIS, V84, P219, DOI 10.1016/0021-9150(90)90094-Y; WOOLSON RF, 1987, ANAL BIOMEDICAL DATA, P161; 1975, JAMA-J AM MED ASSOC, V231, P360; 1974, MANUAL LABORATORY OP, V1, P56; 1993, JAMA-J AM MED ASSOC, V269, P3015	43	233	240	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					672	677		10.1001/jama.271.9.672	http://dx.doi.org/10.1001/jama.271.9.672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309029				2022-12-28	WOS:A1994MX57000027
J	FERRER, M; TORRES, A; GONZALEZ, J; DELABELLACASA, JP; ELEBIARY, M; ROCA, M; GATELL, JM; RODRIGUEZROISIN, R				FERRER, M; TORRES, A; GONZALEZ, J; DELABELLACASA, JP; ELEBIARY, M; ROCA, M; GATELL, JM; RODRIGUEZROISIN, R			UTILITY OF SELECTIVE DIGESTIVE DECONTAMINATION IN MECHANICALLY VENTILATED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, ARTIFICIAL; GROSS INFECTION; PNEUMONIA; DECONTAMINATION; DIGESTIVE SYSTEM	PROTECTED SPECIMEN BRUSH; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; QUANTITATIVE CULTURE TECHNIQUES; NOSOCOMIAL BACTERIAL PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; MULTIPLE TRAUMA PATIENTS; GRAM-NEGATIVE BACILLI; DOUBLE-BLIND; INTUBATED PATIENTS	Objective: To assess selective digestive decontamination for preventing nosocomial pneumonia and mortality in mechanically ventilated patients. Design: Prospective, randomized, placebo-controlled, double-blind study. Setting: Respiratory intensive care unit of a 1000-bed teaching hospital. Patients: 80 patients receiving mechanical ventilation for more than 72 hours. Interventions: Patients received selective digestive decontamination using polymyxin E, tobramycin, and amphotericin B through a nasogastric tube and also topically in the oropharynx; control patients received placebo. All patients received intravenous cefotaxime for 4 days or other systemic antibiotics if required. Measurements: Bacteriologic surveillance (three times a week) was done by quantitatively culturing tracheal aspirates, pharyngeal swabs, and gastric juice. The diagnosis of pneumonia was based on quantitative cultures of protected specimen brush samples (greater than or equal to 10(3) CFU/mL [colony forming units/mL]) or bronchoalveolar lavage fluid (greater than or equal to 10(4) CFU/mL) and autopsy findings. Results: Bronchial, oropharyngeal, and gastric colonization by gram-negative bacilli and Candida species was lower in the selective digestive decontamination group compared with the placebo group. Nonsignificant differences were found in the incidence of nosocomial infections (28% compared with 37%; odds ratio, 0.66; 95% Cl, 0.35 to 1.25) and nosocomial pneumonia (18% compared with 24%; odds ratio, 0.7; Cl, 0.33 to 1.46) and in the crude mortality rate (31% compared with 27%; odds ratio, 1.21; Cl, 0.63 to 2.34) when comparing digestive decontamination with placebo, respectively. Conclusions: Selective digestive decontamination in our mechanically ventilated patients significantly decreased the colonization rate of gram-negative bacilli and of Candida species but not of Staphylococcus aureus. It did not decrease the incidence of nosocomial pneumonia, mortality, length of stay, or the duration of mechanical ventilation.	UNIV BARCELONA, HOSP CLIN, SERV PNEUMOL, E-08036 BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona			Gatell, Jose M/ABC-3607-2020; Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ferrer, Miguel/0000-0001-8171-6673				AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; Balows A, 1991, MANUAL CLIN MICROBIO; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BLAIR P, 1991, SURGERY, V110, P303; BROWN RB, 1985, CRIT CARE MED, V13, P472, DOI 10.1097/00003246-198506000-00006; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CHANDRASEKAR PH, 1986, CRIT CARE MED, V14, P508, DOI 10.1097/00003246-198605000-00017; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CHASTRE J, 1988, AM J MED, V85, P499; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; DASCHNER F, 1985, INTENS CARE MED, V11, P284, DOI 10.1007/BF00273537; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GASTINNE H, 1991, INTENS CARE MED, V17, P215, DOI 10.1007/BF01709880; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HARTENAUER U, 1991, CRIT CARE MED, V19, P463, DOI 10.1097/00003246-199104000-00003; Hunefeld G, 1989, Anaesthesiol Reanim, V14, P131; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KONRAD F, 1989, ANAESTHESIST, V38, P99; LEDINGHAM IM, 1988, LANCET, V1, P785; LIBERATI A, 1992, REANIMATION URGENCES, V1, P521; LOIRAT P, 1992, INTENS CARE MED, V18, P182, DOI 10.1007/BF01709246; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MCCLELLAND P, 1990, CRIT CARE MED, V18, P935, DOI 10.1097/00003246-199009000-00006; MURRAY AE, 1991, BAILLIERE CLIN ANAES, V5, P1, DOI 10.1016/S0950-3501(05)80202-8; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; Sydow M, 1990, Anasth Intensivther Notfallmed, V25, P416, DOI 10.1055/s-2007-1001091; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TORRES A, 1989, AM REV RESPIR DIS, V140, P306, DOI 10.1164/ajrccm/140.2.306; TORRES A, 1993, AM REV RESPIR DIS, V147, P952, DOI 10.1164/ajrccm/147.4.952; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; WUNDERINK RG, 1992, CHEST, V101, P458, DOI 10.1378/chest.101.2.458; ZOBEL G, 1991, CRIT CARE MED, V19, P1242, DOI 10.1097/00003246-199110000-00005	50	98	104	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					389	395		10.7326/0003-4819-120-5-199403010-00006	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304656				2022-12-28	WOS:A1994MY49700006
J	GERBER, HP; SEIPEL, K; GEORGIEV, O; HOFFERER, M; HUG, M; RUSCONI, S; SCHAFFNER, W				GERBER, HP; SEIPEL, K; GEORGIEV, O; HOFFERER, M; HUG, M; RUSCONI, S; SCHAFFNER, W			TRANSCRIPTIONAL ACTIVATION MODULATED BY HOMOPOLYMERIC GLUTAMINE AND PROLINE STRETCHES	SCIENCE			English	Article							FRAGILE-X SYNDROME; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; HUMAN-DISEASE; MUTATIONS; SEQUENCE; GENE; ANTENNAPEDIA; EXPRESSION	Many transcription factors contain proline- or glutamine-rich activation domains. Here it is shown that simple homopolymeric stretches of these amino acids can activate transcription when fused to the DNA binding domain of GAL4 factor. In vitro, activity increased with polymer length, whereas in cell transfection assays maximal activity was achieved by 10 to 30 glutamines or about 10 prolines. Similar results were obtained when glutamine stretches were placed within a [GAL4]-VP16 chimeric protein. Because these stretches are encoded by rapidly evolving triplet repeats (microsatellites), they may be the main cause for modulation of transcription factor activity and thus result ir subtle or overt genomic effects.	UNIV ZURICH,INST MOLEK BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Seipel, Katja/0000-0003-3128-1573				BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GERBER HJ, UNPUB; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; Group T. H. D. C. R., 1993, CELL, V72, P971, DOI [10.1016/0092-8674(93)90585-E8458085, DOI 10.1016/0092-8674(93)90585-E8458085]; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORREMOLLE A, 1993, HUM MOL GENET, V2, P1475, DOI 10.1093/hmg/2.9.1475; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROSS GA, 1993, TRENDS NEUROSCI, V16, P254; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; ZUHLKE C, 1993, HUM MOL GENET, V2, P1367	24	513	530	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					808	811		10.1126/science.8303297	http://dx.doi.org/10.1126/science.8303297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303297				2022-12-28	WOS:A1994MV86600035
J	LO, TS; OKADA, M				LO, TS; OKADA, M			PORCELAIN GALLBLADDER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LO, TS (corresponding author), NAGOYA TOKUSHUKAI HOSP,NAGOYA,AICHI 487,JAPAN.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					402	402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284006				2022-12-28	WOS:A1994MV27900006
J	ARCA, M; VEGA, GL; GRUNDY, SM				ARCA, M; VEGA, GL; GRUNDY, SM			HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN - METABOLIC DEFECTS AND RESPONSE TO LOW-DOSE LOVASTATIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DENSITY LIPOPROTEIN METABOLISM; COA REDUCTASE INHIBITORS; CARDIOVASCULAR MORTALITY; ALCOHOL-CONSUMPTION; SERUM-CHOLESTEROL; APOLIPOPROTEIN-B; RISK FACTOR; ESTROGEN; FRAMINGHAM	Objective.-To determine the metabolic mechanisms underlying hypercholesterolemia in postmenopausal women and to determine whether a low dose of lovastatin will correct this abnormality. Design.-In the first part of the study, turnover rates of autologous low-density lipoprotein (LDL) were measured in hypercholesterolemic and control women. In the second part, hypercholesterolemic women participated in a placebo-controlled, randomized, double-blind study using lovastatin as the therapeutic agent. Setting.-The General Clinical Research Center of the University of Texas Southwestern Medical Center, Dallas, utilizing inpatient and outpatient facilities, and the Veterans Affairs Medical Center, Dallas, Tex. Patients.-For the LDL turnover study, 26 postmenopausal women with moderate hypercholesterolemia (mean+/-SD LDL cholesterol, 4.78+/-0.59 mmol/L [185 +/-23 mg/dL]) and 13 postmenopausal women with normal levels of plasma lipids and lipoproteins (mean+/-SD LDL cholesterol, 3.31+/-0.39 mmol/L [128+/-15 mg/dL]) were studied. Sixteen postmenopausal women participated in the drug study. Interventions.-In the drug study, patients received blindly both lovastatin (10 mg/d) and placebo. Main Outcome Measures.-In the first study, kinetic parameters of LDL metabolism; in the second study, response in lipids and lipoproteins to lovastatin therapy. Results.-In the LDL turnover study, mean (+/-SD) input (production) rates for LDL apolipoprotein B (apo B) were similar for hypercholesterolemic women and control women (12.4 [+/-3.2] mg/kg per day and 11.1 [+/-2.21 mg/kg per clay, respectively). In contrast, mean (+/-SD) fractional catabolic rates for LDL apo B in hypercholesterolemic women (0.29 [+/-0.04]pools per day) were significantly lower than those in normolipidemic women (0.35 [+/-0.03] pools per day). In the drug trial, lovastatin therapy reduced mean (+/-SD) total cholesterol and LDL cholesterol from 7.03 (+/-1.16) mmol/L (272 [+/-45] mg/dL) and 4.42 (+/-0.80) mmol/L (171 [+/-31] mg/dL, respectively, to 5.70 (+/-1.03) mmol/L (221 [+/-40] mg/dL) and 3.46 (+/-0.85) mmol/L (134 [+/-33] mg/dL). Conclusions.-The turnover data suggest that hypercholesterolemia in postmenopausal women is primarily attributable to a reduced activity of LDL receptors. In accord, the hypercholesterolemia in these women was effectively lowered by low doses of lovastatin. Thus, a low dose of lovastatin appears highly effective for treatment of moderate hypercholesterolemia in most postmenopausal women, presumably because it reverses the reduction in LDL receptor activity associated with menopause.	UNIV TEXAS,SW MED CTR,CTR HUMAN NUTR,5323 HARRY HINES BLVD,DALLAS,TX 75235; VET AFFAIRS MED CTR,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT CLIN NUTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNA MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				ARCA, Marcello/0000-0003-3786-0883				ALBERS JJ, 1978, LIPIDS, V13, P926, DOI 10.1007/BF02533852; [Anonymous], 1993, ARCH INTERN MED, V153, P1079; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BERMAN M, 1983, CONSAAM USERS GUIDE; BRADFORD RH, 1993, ANN INTERN MED, V118, P850, DOI 10.7326/0003-4819-118-11-199306010-00004; BRUNNER D, 1987, AM J CARDIOL, V59, P1271, DOI 10.1016/0002-9149(87)90903-9; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CAULEY JA, 1983, ATHEROSCLEROSIS, V49, P31, DOI 10.1016/0021-9150(83)90005-9; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; ENDO A, 1992, J LIPID RES, V33, P1569; ERIKSSON M, 1989, J CLIN INVEST, V84, P802, DOI 10.1172/JCI114239; FARHRAEUS L, 1983, J ENDOCRINOL METAB, V56, P797; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRANFONE A, 1992, METABOLISM, V41, P1193, DOI 10.1016/0026-0495(92)90008-X; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HOBBS HH, 1992, HUM MUTAT, V1, P455; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; INNERARITY TL, 1990, J LIPID RES, V31, P1337; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JENSEN J, 1986, BRIT J OBSTET GYNAEC, V93, P613, DOI 10.1111/j.1471-0528.1986.tb08035.x; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KANNEL WB, 1987, FRAMINGHAM STUDY; KANNEL WB, 1983, AM J CARDIOL, V52, P96; KHAW KT, 1986, CIRCULATION, V74, P239, DOI 10.1161/01.CIR.74.2.239; KRAUSS RM, 1988, AM J OBSTET GYNECOL, V158, P1606, DOI 10.1016/0002-9378(88)90198-6; LE NA, 1984, J LIPID RES, V25, P1387; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LINDGREN FT, 1972, QUANTITATION COMPOSI, P181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; MANIAHS T, 1989, MOL CLONING LABORATO; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; Markwell M A, 1981, Methods Enzymol, V72, P296; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ROESCHLA.P, 1974, Z KLIN CHEM KLIN BIO, V12, P226; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER J, 1992, MULTIPLE RISK FACTOR, P19; Stamler J, 1992, CORONARY HEART DIS E, P35; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOM TJ, 1987, CORONARY HEART DISEA, P31; VEGA GL, 1991, CIRCULATION, V84, P118, DOI 10.1161/01.CIR.84.1.118; VEGA GL, 1993, ARTERIOSCLER THROMB, V13, P579, DOI 10.1161/01.ATV.13.4.579; VEGA GL, 1986, J CLIN INVEST, V78, P1410, DOI 10.1172/JCI112729; VEGA GL, 1985, J LIPID RES, V26, P115; VEGA GL, 1985, JAMA-J AM MED ASSOC, V253, P2398, DOI 10.1001/jama.253.16.2398; [No title captured]; 1978, AM HEART ASS MONOGRA, V60; 1993, JAMA-J AM MED ASSOC, V269, P3015	57	56	57	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					453	459		10.1001/jama.271.6.453	http://dx.doi.org/10.1001/jama.271.6.453			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295321				2022-12-28	WOS:A1994MU49100033
J	VONBOEHMER, H				VONBOEHMER, H			POSITIVE SELECTION OF LYMPHOCYTES	CELL			English	Review							T-CELL-RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; GERMINAL-CENTERS; GENE-EXPRESSION; PRE-B; HISTOCOMPATIBILITY ANTIGENS; THYMOCYTE DEVELOPMENT; NEGATIVE SELECTION; ALLELIC EXCLUSION		FAC NECKER ENFANTS MALAD,F-75743 PARIS 15,FRANCE	UDICE-French Research Universities; Universite Paris Cite	VONBOEHMER, H (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.							ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ANDERSON G, 1993, NATURE, V262, P330; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; CASANOVA JL, 1991, J EXP MED, V174, P1371, DOI 10.1084/jem.174.6.1371; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CLARK MR, 1992, J IMMUNOL, V149, P2857; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; GRANDIEN A, 1991, INT IMMUNOL, V3, P67, DOI 10.1093/intimm/3.1.67; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P610, DOI 10.1016/0167-5699(93)90201-U; GROETTRUP M, 1993, THESIS U BASEL BASEL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISELOW P, 1988, NATURE, V333, P742; KISELOW P, 1988, NATURE, V335, P730; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOURILSKY P, 1989, COLD SH Q B, V54, P93; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PAWLOWSKI T, 1993, NATURE, V364, P642, DOI 10.1038/364642a0; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAIPING FL, 1991, CELL, V65, P443; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS U, 1992, EUR J IMMUNOL, V22, P511, DOI 10.1002/eji.1830220233; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	89	531	532	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					219	228		10.1016/0092-8674(94)90330-1	http://dx.doi.org/10.1016/0092-8674(94)90330-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293460				2022-12-28	WOS:A1994MU67800006
J	WEIS, K; RAMBAUD, S; LAVAU, C; JANSEN, J; CARVALHO, T; CARMOFONSECA, M; LAMOND, A; DEJEAN, A				WEIS, K; RAMBAUD, S; LAVAU, C; JANSEN, J; CARVALHO, T; CARMOFONSECA, M; LAMOND, A; DEJEAN, A			RETINOIC ACID REGULATES ABERRANT NUCLEAR-LOCALIZATION OF PML-RAR-ALPHA IN ACUTE PROMYELOCYTIC LEUKEMIA-CELLS	CELL			English	Article							THYROID-HORMONE; RECEPTOR-ALPHA; T(15-17) TRANSLOCATION; SIGNALING PATHWAYS; RESPONSE ELEMENTS; MAMMALIAN NUCLEI; CDNA CLONING; COILED BODY; RXR-BETA; GENE	Acute promyelocytic leukemia (APL) is characterized by a specific t(15; 17) translocation that fuses the retinoic acid receptor alpha (RARalpha) to a novel gene product, PML. The involvement of RARalpha is particularly intriguing in view of the efficient therapeutic effect of retinoic acid (RA) in this disease. In this report, we show that PML is specifically localized within a discrete subnuclear compartment corresponding to nuclear bodies recognized by patient autoimmune sera. In APL cells, the PML-RARalpha hybrid displays an abnormal localization and directs RXR and other nuclear antigens into aberrant structures that are tightly bound to chromatin. This suggests that the hybrid could exert a dominant negative effect by diverting a subset of proteins from their natural sites of action. Interestingly, treatment of APL cells with RA induces a complete relocalization of each of these proteins. We propose that the beneficial role of RA in promoting myeloid differentiation in APL might be related to its ability to restore a normal subnuclear organization.	INST PASTEUR,INSERM,U163,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS 15,FRANCE; FAC MED LISBON,INST HISTOL,P-1699 LISBON,PORTUGAL	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade de Lisboa	WEIS, K (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Dejean, Anne/L-5145-2018; Jansen, J.H./H-8054-2014; Weis, Karsten/F-5719-2011; Lavau, Catherine/Q-2928-2019	Jansen, J.H./0000-0001-9459-568X; Weis, Karsten/0000-0001-7224-925X; Carvalho Goncalves, Teresa/0000-0001-7061-8904; Lavau, Catherine/0000-0003-4800-1320; Lamond, Angus/0000-0001-6204-6045; Carmo-Fonseca, Maria/0000-0002-3402-7143				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUTEILLE M, 1974, CELL NUCLEUS, V1, P5; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREITMAN TR, 1981, BLOOD, V57, P1000; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUFFO TH, 1992, EMBO J, V11, P1409; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOEFFLER HP, 1985, CHRONIC ACUTE LEUKEM, P27; LAMOND AI, 1993, MOL BIOL REP, V18, P127, DOI 10.1007/BF00986767; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LANGANGER G, 1984, J CELL BIOL, V99, P1324, DOI 10.1083/jcb.99.4.1324; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	659	666	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					345	356		10.1016/0092-8674(94)90341-7	http://dx.doi.org/10.1016/0092-8674(94)90341-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293468				2022-12-28	WOS:A1994MU67800017
J	ROSENBAUM, DS; JACKSON, LE; SMITH, JM; GARAN, H; RUSKIN, JN; COHEN, RJ				ROSENBAUM, DS; JACKSON, LE; SMITH, JM; GARAN, H; RUSKIN, JN; COHEN, RJ			ELECTRICAL ALTERNANS AND VULNERABILITY TO VENTRICULAR ARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ST-SEGMENT ALTERNANS; MYOCARDIAL-INFARCTION; T-WAVE; SUDDEN-DEATH; FIBRILLATION; MORPHOLOGY	Background. Although electrical alternans (alternating amplitude from beat to beat on the electrocardiogram) has been associated with ventricular arrhythmias in many clinical settings, its physiologic importance and prognostic implications remain unknown. Methods. To test the hypothesis that electrical alternans is a marker of vulnerability to ventricular arrhythmias, we developed a technique to detect subtle alternation in the morphologic features of the electrocardiogram (which would not be detectable by visual inspection of the electrocardiogram). In a group of 83 patients referred for diagnostic electrophysiologic testing, we prospectively examined whether levels of alternans predicted vulnerability to arrhythmias as defined by the outcome of electrophysiologic testing and arrhythmia-free survival. Results. Sustained ventricular arrhythmias were induced during electrophysiologic testing in 32 of the patients (39 percent). In this group, low-level electrical alternans (a beat-to-beat change in amplitude of < 15 muV) was detected over a broad range of physiologic heart rates (from 95 to 150 beats per minute) and primarily involved the ST segment and the T wave (i.e., the phase of repolarization). Alternans during repolarization was a significant and independent predictor of inducible arrhythmias on electrophysiologic testing (sensitivity, 81 percent; specificity, 84 percent; relative risk, 5.2). Of 66 patients followed for up to 20 months, 13 had arrhythmic events. Alternans affecting the T wave and inducibility of ventricular arrhythmias were significant and essentially equivalent predictors of survival without arrhythmia (P<0.001). Actuarial survival without arrhythmia at 20 months was significantly lower among the patients with T-wave alternans (19 percent) than among the patients without T-wave alternans (94 percent). Conclusions. Electrical alternans affecting the ST segment and T wave is common among patients at increased risk for ventricular arrhythmias. Subtle electrical alternans on the electrocardiogram may serve as a noninvasive marker of vulnerability to ventricular arrhythmias.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02138	Case Western Reserve University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	ROSENBAUM, DS (corresponding author), CASE WESTERN RESERVE UNIV,DEPT BIOMED ENGN,WICKENDEN BLDG,RM 504,CLEVELAND,OH 44106, USA.				NHLBI NIH HHS [R01-HL39291] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039291] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM DR, 1984, J ELECTROCARDIOL, V17, P209, DOI 10.1016/S0022-0736(84)80057-6; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; CHENG TC, 1983, ARCH INTERN MED, V143, P1052, DOI 10.1001/archinte.143.5.1052; FEIGENBAUM H, 1966, CIRCULATION, V34, P611, DOI 10.1161/01.CIR.34.4.611; FRANK E, 1956, CIRCULATION, V13, P737, DOI 10.1161/01.CIR.13.5.737; GHANI MF, 1974, CHEST, V65, P695, DOI 10.1378/chest.65.6.695; Hamburger WW, 1936, J AMER MED ASSOC, V106, P902, DOI 10.1001/jama.1936.02770110018006; HELLERSTEIN HK, 1950, AM J PHYSIOL, V160, P366, DOI 10.1152/ajplegacy.1950.160.2.366; HIEJIMA K, 1976, BRIT HEART J, V38, P767; JOYAL M, 1984, AM J CARDIOL, V54, P915, DOI 10.1016/S0002-9149(84)80233-7; KALTER HH, 1948, NY STATE J MED, V1, P1164; KLEIMAN RB, 1988, AM J CARDIOL, V62, P528, DOI 10.1016/0002-9149(88)90649-2; KLEINFELD MJ, 1977, CIRCULATION, V55, P574, DOI 10.1161/01.CIR.55.4.574; KONTA T, 1990, CIRCULATION, V82, P2185, DOI 10.1161/01.CIR.82.6.2185; KUCHAR DL, 1986, CIRCULATION, V74, P1280, DOI 10.1161/01.CIR.74.6.1280; LEBRETT K, 1990, THESIS MIT; LEPESCHKIN E, 1950, Cardiologia, V16, P278, DOI 10.1159/000164958; Lewis T, 1910, Q J MED, V4, P141; NEARING BD, 1991, SCIENCE, V252, P437, DOI 10.1126/science.2017682; PULETTI M, 1980, J ELECTROCARDIOL, V13, P297, DOI 10.1016/S0022-0736(80)80035-5; RAEDER EA, 1992, NEW ENGL J MED, V326, P271; REDDY CVR, 1984, AM J CARDIOL, V53, P390, DOI 10.1016/0002-9149(84)90487-9; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; ROSENBAUM DS, 1991, CIRCULATION, V84, P1333, DOI 10.1161/01.CIR.84.3.1333; SALERNO JA, 1986, EUR HEART J, V7, P63; SCHWARTZ PJ, 1975, AM HEART J, V89, P45, DOI 10.1016/0002-8703(75)90008-3; SHIMONI Z, 1984, AM J CARDIOL, V54, P920, DOI 10.1016/S0002-9149(84)80236-2; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; USHER BW, 1972, AM HEART J, V83, P459, DOI 10.1016/0002-8703(72)90035-X; WAYNE VS, 1983, CHEST, V83, P824, DOI 10.1378/chest.83.5.824; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1980, PROG CARDIOVASC DIS, V23, P99, DOI 10.1016/0033-0620(80)90007-9	32	887	922	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					235	241		10.1056/NEJM199401273300402	http://dx.doi.org/10.1056/NEJM199401273300402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272084	Bronze			2022-12-28	WOS:A1994MR49600002
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE - BUILDING MORALE THROUGH PERSONAL DEVELOPMENT .2.	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS	Once general practitioners have established themselves as principals it may seem there is little else to work for. Lack of stimulation may lead to demoralisation, and it is essential that they have other ways to continue to develop their careers. Meeting other doctors to discuss cases and problems and post-graduate education often help but many doctors want to take on extra roles. The options available include undergraduate teacher, tutor for post-graudate education, and participation in medical audit advisory groups, local medical committees, or royal college faculties. Some general practitioners work part time to allow them to fit in these activities. It may also be possible to obtain extended study leave or a sabbatical to broaden experience. Others even move practice to provide new challenges.										Allen I, 1992, PART TIME WORKING GE; ALLEN J, 1993, BRIT MED J, V307, P719, DOI 10.1136/bmj.307.6906.719; Balint M., 1986, DOCTOR HIS PATIENT I; EDWARDS PH, 1988, J ROY COLL GEN PRACT, V38, P61; FREELING P, 1991, BRIT MED J, V303, P61, DOI 10.1136/bmj.303.6793.61; GIBSON R, 1981, FAMILY DOCTOR; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; Hartley J. E., 1988, NICOT, P88; HELLER T, 1993, GENERAL PRACTIT 0709, P43; HOWIE JGR, 1992, BRIT J GEN PRACT, V42, P181; LIVINGSTONE A, 1990, BRIT MED J, V301, P708, DOI 10.1136/bmj.301.6754.708; MASHTA O, 1993, GENERAL PRACTIT 1023, P13; MUNSON S, 1992, MEDECONOMICS     JUL, P60; ODONNELL M, 1986, DOCTOR DOCTOR; RAWNSLEY K, 1985, BRIT MED J, V291, P922, DOI 10.1136/bmj.291.6500.922; RICHARDS C, 1991, BRIT MED J, V303, P827, DOI 10.1136/bmj.303.6806.827; Richards C., 1989, HLTH DOCTORS; RICHARDSON A, 1993, IMPACT AUDIT PRESCRI; ROBERTS J, 1993, PULSE           0911, P32; SAVAGE R, 1991, BRIT J GEN PRACT, V41, P311; SIDE CD, 1987, BRIT MED J, V294, P1265, DOI 10.1136/bmj.294.6582.1265; SNADDEN D, 1993, BRIT MED J, V306, P1740, DOI 10.1136/bmj.306.6894.1740; SNOWISE NG, 1992, BRIT MED J, V305, P398, DOI 10.1136/bmj.305.6850.398; TAYLOR GB, 1982, BRIT MED J, V285, P103; WARRY R, 1993, GENERAL PRACTIT 1008, P1; WYNNEJONES M, 1993, BRIT MED J, V307, P630; 1991, GENERAL MED PRACTITO; 1992, MEMBERS REFERENCE BO; 1991, FELLOWSHIP ASSESSMEN; 1993, GENERAL PRACTIO 1008, P16	31	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					114	116		10.1136/bmj.308.6921.114	http://dx.doi.org/10.1136/bmj.308.6921.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298384	Green Published			2022-12-28	WOS:A1994MR17300021
J	HIERONS, R				HIERONS, R			CHARCOT AND HIS VISITS TO BRITAIN	BRITISH MEDICAL JOURNAL			English	Article																		CHARCOT JM, 1874, LANCET, V2, P73; CHARCOTT JM, 1977, BMJ, V2, P314; EARNEST E, 1950, W MITCHELL NOVALIST, P241; FREUD EL, 1961, LETT S FREUD, V3, P11; FREUD EL, 1961, LETT S FREUD, V1, P7; FREUD S, 1966, STANDARD EDITION COM, V1, P9; GAMJEE A, 1878, BMJ, V2, P454; HERZ C, 1893, BMJ, V2, P1009; HERZ C, 1893, BMJ, V2, P858; HERZ C, 1893, BMJ, V2, P885; HERZ C, 1893, LANCET, V2, P885; HERZ C, 1893, LANCET, V2, P1273; MACCORMACK W, 1881, T INT MED C; MARIA P, 1925, REV NEUROL, V1, P736; Munthe A., 1929, STORY SAN MICHELE; OSLER W, 1893, J HOPKINS HOSP B, V4, P87; 1893, TIMES           1110	17	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1589	1591		10.1136/bmj.307.6919.1589	http://dx.doi.org/10.1136/bmj.307.6919.1589			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292949	Green Published, Bronze			2022-12-28	WOS:A1993MN10700012
J	WALKER, MC; SANDER, JWAS				WALKER, MC; SANDER, JWAS			CONSULTATIO-EPISTULAE - THE WAY FORWARD	BRITISH MEDICAL JOURNAL			English	Article									UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, LONDON WC1N 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust			Walker, Matthew C/C-1577-2008; Sander, Josemir W/C-1576-2008	Walker, Matthew C/0000-0002-0812-0352; Sander, Josemir W/0000-0001-6041-9661					0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1624	1625		10.1136/bmj.307.6919.1624	http://dx.doi.org/10.1136/bmj.307.6919.1624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292962	Green Published, Bronze			2022-12-28	WOS:A1993MN10700030
J	BELL, SP; KOBAYASHI, R; STILLMAN, B				BELL, SP; KOBAYASHI, R; STILLMAN, B			YEAST ORIGIN RECOGNITION COMPLEX FUNCTIONS IN TRANSCRIPTION SILENCING AND DNA-REPLICATION	SCIENCE			English	Article							MATING-TYPE LOCUS; SODIUM DODECYL-SULFATE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; CHROMOSOMAL ORIGIN; REPRESSION; ACTIVATION; SEPARATION; SEQUENCES; ELEMENTS	The genes encoding two of the subunits of the Saccharomyces cerevisiae origin recognition complex (ORC) have been isolated. Characterization of a temperature-sensitive mutation in the gene encoding the 72-kD subunit of ORC (ORC2) indicates that this protein complex functions early in the DNA replication process. Moreover, ORC derived from orc2ts cells is defective for DNA binding. Others have shown a defect in orc2ts cells in transcriptional silencing at the silent mating-type loci. Consistent with this finding, ORC specifically binds to each of the four mating-type silencers identified in yeast. These findings support the hypothesis that ORC acts as an initiator protein at yeast origins of DNA replication and suggest that ORC also functions in the determination of transcriptional domains.			BELL, SP (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Bell, Stephen/0000-0002-2876-610X; Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline; NIAID NIH HHS [AI20460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; Baker T, 1991, DNA REPLICATION, V2; BELL SG, UNPUB; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NEWLON CS, IN PRESS CURRENT OPI; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; VILLARREAL LP, 1991, MICROBIOL REV, V55, P512, DOI 10.1128/MMBR.55.3.512-542.1991; WOLFFE AP, 1991, J CELL SCI, V99, P201	38	378	383	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1844	1849		10.1126/science.8266072	http://dx.doi.org/10.1126/science.8266072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266072				2022-12-28	WOS:A1993MM51100027
J	NEALE, G				NEALE, G			CLINICAL ANALYSIS OF 100 MEDICOLEGAL CASES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To find the reasons for legal claims against hospital doctors. Design-Prospective analysis of requests for medical opinion submitted by solicitors during 1984-93 on legal claims against hospital doctors. Subjects-100 successive cases: 98 from the United Kingdom and two from the Republic of Ireland. Main outcome measures-Principal underlying causes of claims. Results-In 44 cases there was no serious clinical error. Of the 56 cases of clinical fault, seven were a failure of communication by doctors, 15 were an isolated error in otherwise good clinical management, 21 were errors that might not have occurred with better control of clinical practice (doctors exceeding their competence, poor clinical judgment, and poor teamwork), and 13 were major errors due to carelessness or incompetence. In 34 cases there was evidence of clinical fault that might escape clinical audit and medicolegal processes. Most of these legal claims have been or are likely to be withdrawn: only five plaintiffs have settled out of court, and 11 are pursuing their actions. Conclusions-To reduce the incidence of errors, hospital doctors should consult colleagues about difficult cases and specialists should maintain a broad interest in disease. The NHS clinical complaints procedure should be extended to cover potential claims, and serious cases should be subject to independent external assessment by experienced consultants.			NEALE, G (corresponding author), ADDENBROOKES NHS TRUST,CAMBRIDGE CB2 2QQ,ENGLAND.							BLACK N, 1990, LANCET, V335, P35, DOI 10.1016/0140-6736(90)90151-T; Buck N, 1987, REPORT CONFIDENTIAL; HAVARD J, 1992, MED SCI LAW, V32, P187, DOI 10.1177/002580249203200302; HAVARD JDJ, 1990, BRIT MED J, V300, P343, DOI 10.1136/bmj.300.6721.343; HAWKINS C, 1987, BRIT MED J, V295, P1533, DOI 10.1136/bmj.295.6612.1533; Rosenthal M.M., 1987, DEALING MED MALPRACT; Segest E, 1988, Med Law, V7, P141; SEGEST E, 1993, MED SCI LAW, V33, P41, DOI 10.1177/002580249303300108; SMITH R, 1990, BRIT MED J, V301, P620; VERE DW, 1988, ADVERSE DRUG REACT, V128, P480; 1993, BMJ, V307, P12; 1990, COMPENSATION ADVERSE; 1990, QUALITY MED CARE REP; 1993, HOSPITAL DOCTORS TRA; 1987, NO FAULT COMPENSATIO; 1993, BMJ, V306, P1711; 1991, UK REPORTS CONFIDENT	17	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1483	1487		10.1136/bmj.307.6917.1483	http://dx.doi.org/10.1136/bmj.307.6917.1483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281095	Bronze, Green Published			2022-12-28	WOS:A1993MK79700032
J	KINNERSLEY, P; WILKINSON, CE; SRINIVASAN, J				KINNERSLEY, P; WILKINSON, CE; SRINIVASAN, J			PNEUMOCOCCAL VACCINATION AFTER SPLENECTOMY - SURVEY OF HOSPITAL AND PRIMARY-CARE RECORDS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT GEN PRACTICE,CARDIFF CF4 4XN,S GLAM,WALES; LLANDOUGH HOSP,DEPT MED,PENARTH CF6 1XX,S GLAM,WALES	Cardiff University								AMMANN AJ, 1977, NEW ENGL J MED, V297, P897, DOI 10.1056/NEJM197710272971701; [Anonymous], MMWR MORB MORTAL WKL; SIDDINS M, 1990, AUST NZ J SURG, V60, P183, DOI 10.1111/ans.1990.60.3.183; 1990, DRUG THER B, V28, P31; 1992, IMMUNISATION INFECTI	5	41	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1398	1399		10.1136/bmj.307.6916.1398	http://dx.doi.org/10.1136/bmj.307.6916.1398			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274893	Green Published			2022-12-28	WOS:A1993MK42000022
J	APRILL, BS; DRAKE, AJ; LASSETER, DH; SHAKIR, KMM				APRILL, BS; DRAKE, AJ; LASSETER, DH; SHAKIR, KMM			SILENT ADRENAL NODULES IN VON HIPPEL-LINDAU DISEASE SUGGEST PHEOCHROMOCYTOMA	ANNALS OF INTERNAL MEDICINE			English	Note							CLONIDINE		NATL NAVAL MED CTR, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, BETHESDA, MD 20889 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD USA	Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA								ELLIOTT WJ, 1988, AM J MED, V84, P419, DOI 10.1016/0002-9343(88)90261-6; GLUSHIEN AS, 1953, AM J MED, V14, P318, DOI 10.1016/0002-9343(53)90043-6; GROSSMAN E, 1991, HYPERTENSION, V17, P733, DOI 10.1161/01.HYP.17.6.733; LUDMERER KM, 1981, AM J MED, V71, P287; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; SHAPIRO B, 1985, J NUCL MED, V26, P576; SIQUEIRAFILHO AG, 1975, ARCH INTERN MED, V135, P1227, DOI 10.1001/archinte.135.9.1227; 1991, NEW ENGL J MED, V324, P1119	8	36	36	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					485	487		10.7326/0003-4819-120-6-199403150-00006	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311371				2022-12-28	WOS:A1994NB62500006
J	CHERIAN, T; STEINHOFF, MC; HARRISON, LH; ROHN, D; MCDOUGAL, LK; DICK, J				CHERIAN, T; STEINHOFF, MC; HARRISON, LH; ROHN, D; MCDOUGAL, LK; DICK, J			A CLUSTER OF INVASIVE PNEUMOCOCCAL DISEASE IN YOUNG-CHILDREN IN CHILD-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESISTANT STREPTOCOCCUS-PNEUMONIAE	Objective.-To investigate a cluster of invasive pneumococcal disease in children 8 to 26 months of age, using standard microbiological procedures and ribosomal DNA gene-restriction patterns to characterize the outbreak strain. Design.-Outbreak investigation. Setting.-A family child-care home with six children in Baltimore, Md. Results.-During an 8-day period, three of the six children in the family child-care home had febrile illnesses with pneumococcal bacteremia, and a fourth had purulent pneumococcal conjunctivitis. Type 12F Streptococcus pneumoniae was isolated from the four ill children and from the nasopharynges of the two healthy children. Ribotyping revealed all outbreak isolates had an identical ribotype pattern. Administration of rifampin to the children did not eradicate carriage of the organism. Conclusions.-Our data demonstrate that child care provides an opportunity for outbreak of invasive pneumococcal disease in young child ren. This observation suggests a need for increased alertness for clusters of pneumococcal disease in young children in child-care facilities and underscores the necessity for a pneumococcal vaccine that is effective in infants and young children.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,CTR IMMUNIZAT RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT LAB MED,BALTIMORE,MD 21205; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD; NATL CTR INFECT DIS,HOSP INFECT PROGRAM,NOSOCOMIAL PATHOGENS LAB BRANCH,ATLANTA,GA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA								AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; DOYLE MG, 1992, PEDIATR INFECT DIS J, V11, P831, DOI 10.1097/00006454-199210000-00005; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; Holle HA, 1940, NEW ENGL J MED, V223, P887, DOI 10.1056/NEJM194011282232203; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KOORNHOF HJ, 1979, MICROBIOLOGY 1979, P286; LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; OSTERHOLM MT, 1990, SEMIN PEDIATR INFECT, V1, P222; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER M, 1991, 31ST INT C ANT AG CH; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; RIEDO F, 1991, 31ST INT C ANT AG CH; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; STEINHOFF MC, IN PRESS PEDIATR INF; Strom A, 1932, J INFECT DIS, V50, P430, DOI 10.1093/infdis/50.5-6.430; 1990, M7A2 NAT COMM CLIN L; 1991, REPORT COMMITTEE INF, P373; 1989, MMWR MORB MORTAL WKL, V38, P733	22	84	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					695	697		10.1001/jama.271.9.695	http://dx.doi.org/10.1001/jama.271.9.695			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309033				2022-12-28	WOS:A1994MX57000031
J	LEE, ST; NICHOLLS, RD; BUNDEY, S; LAXOVA, R; MUSARELLA, M; SPRITZ, RA				LEE, ST; NICHOLLS, RD; BUNDEY, S; LAXOVA, R; MUSARELLA, M; SPRITZ, RA			MUTATIONS OF THE P-GENE IN OCULOCUTANEOUS ALBINISM, OCULAR ALBINISM, AND PRADER-WILLI-SYNDROME PLUS ALBINISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA	Background. Type II (tyrosinase-positive) oculocutaneous albinism is an autosomal recessive disorder that has recently been mapped to chromosome segment 15q11-q13. The frequency of this disorder is greatly increased in patients with Prader-Willi or Angelman syndrome, both of which involve deletions of chromosome 15q. The P protein is a transmembrane polypeptide that may transport small molecules such as tyrosine, the precursor of melanin. The P gene is located in chromosome segment 15q11-q13. Methods. We studied the tyrosinase and P genes in three patients with type II oculocutaneous albinism, one of whom also had Prader-Willi syndrome, and in one patient with a milder syndrome known as autosomal recessive ocular albinism. Individual exons of these genes were amplified from the DNA of each patient by the polymerase chain reaction and screened for mutations by simultaneous analyses of single-stranded conformation polymerphisms and heteroduplexes and subsequent DNA sequencing. Results. Mutations of the P gene were identified in ail four patients. These included one frame shift, three missense mutations that result in amino acid substitutions, and one mutation that affects RNA splicing. The patient with Prader-Willi syndrome plus albinism had a typical deletion of the paternal chromosome 15, rendering him hemizygous for a maternally inherited mutant allele of the P gene. The child with ocular albinism was heterozygous for two different mutations in the P gene. Conclusions. Abnormalities of the P gene are associated with a wide range of clinical phenotypes, including type It oculocutaneous albinism, albinism associated with the Prader-Willi syndrome, and at least some cases of autosomal recessive ocular albinism.	UNIV WISCONSIN, DEPT MED GENET, GENET LAB 317, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT GENET, CLEVELAND, OH 44106 USA; UNIV BIRMINGHAM, BIRMINGHAM MATERN HOSP, DEPT PEDIAT & CHILD HLTH, BIRMINGHAM, ENGLAND; HOSP SICK CHILDREN, DEPT OPHTHALMOL, TORONTO, ON, CANADA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; University of Birmingham; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Lee, Seung-Taek/0000-0001-7300-9784	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-39892] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUTLER MG, 1989, AM J HUM GENET, V45, P140; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; LUDOWESE CJ, 1991, CLIN GENET, V40, P194; NICHOLLS RD, 1993, AM J MED GENET, V46, P16, DOI 10.1002/ajmg.1320460106; ODONNELL FE, 1978, ARCH OPHTHALMOL-CHIC, V96, P1621, DOI 10.1001/archopht.1978.03910060255013; OTT J, 1974, AM J HUM GENET, V26, P588; RAMSAY M, 1992, AM J HUM GENET, V51, P879; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; ROSE NC, 1992, AM J MED GENET, V42, P700, DOI 10.1002/ajmg.1320420515; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCIALFA AC, 1972, AM J OPHTHALMOL, V73, P943, DOI 10.1016/0002-9394(72)90464-3; SPRITZ RA, 1992, AM J HUM GENET, V51, P1058; SPRITZ RA, 1993, SEMIN DERMATOL, V12, P167; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; Witkop C J Jr, 1985, Clin Dermatol, V3, P70; WITKOP CJ, 1989, METABOLIC BASIS INHE, V2, P2905	18	163	165	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					529	534		10.1056/NEJM199402243300803	http://dx.doi.org/10.1056/NEJM199402243300803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302318	Bronze			2022-12-28	WOS:A1994MX43600003
J	FOLEY, TP; ABBASSI, V; COPELAND, KC; DRAZNIN, MB				FOLEY, TP; ABBASSI, V; COPELAND, KC; DRAZNIN, MB			HYPOTHYROIDISM CAUSED BY CHRONIC AUTOIMMUNE-THYROIDITIS IN VERY YOUNG INFANTS - BRIEF REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							AUTOANTIBODIES; DIARRHEA		UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA; GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,WASHINGTON,DC 20007; UNIV VERMONT,COLL MED,DEPT PEDIAT,BURLINGTON,VT; MICHIGAN STATE UNIV,KALAMAZOO CTR MED STUDIES,DEPT PEDIAT,KALAMAZOO,MI	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Georgetown University; University of Vermont; Michigan State University; Michigan State University Hospital	FOLEY, TP (corresponding author), CHILDRENS HOSP PITTSBURGH,3705 5TH AVE,PITTSBURGH,PA 15213, USA.				NCRR NIH HHS [RR 0084] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABBASSI V, 1980, J PEDIATR-US, V97, P259, DOI 10.1016/S0022-3476(80)80488-4; BLIZZARD RM, 1960, NEW ENGL J MED, V263, P327, DOI 10.1056/NEJM196008182630702; BODE HH, 1978, PEDIATRICS, V62, P13; DEZEGHER F, 1992, ACTA PAEDIATR, V81, P274, DOI 10.1111/j.1651-2227.1992.tb12223.x; FOLEY TP, 1987, J PEDIATR-US, V110, P378, DOI 10.1016/S0022-3476(87)80498-5; FOLEY TP, 1991, ADV EXP MED BIOL, V299, P209; FOLEY TP, WILKINS DIAGNOSIS TR; Greulich WW., 1959, CALIF MED, V91, P53; GRUTERS A, 1992, PEDIATR ANN, V21, P18; LAFRANCHI S, 1992, PEDIATR ANN, V21, P32; LAFRANCHI SH, 1985, PEDIATRICS, V76, P734; MATSUURA N, 1980, NEW ENGL J MED, V303, P738, DOI 10.1056/NEJM198009253031306; OSTERGAARD GZ, 1989, HORM RES, V31, P190, DOI 10.1159/000181114; PHILLIPS D, 1990, J CLIN ENDOCR METAB, V70, P742, DOI 10.1210/jcem-70-3-742; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; ROVET JF, 1990, PSYCHONEUROENDOCRINO, P273; SAVAGE MO, 1985, J PEDIATR GASTR NUTR, V4, P187, DOI 10.1097/00005176-198504000-00006; TAKASU N, 1992, NEW ENGL J MED, V326, P513, DOI 10.1056/NEJM199202203260803	18	35	37	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					466	468		10.1056/NEJM199402173300704	http://dx.doi.org/10.1056/NEJM199402173300704			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289852	Bronze			2022-12-28	WOS:A1994MW48000004
J	BENCHETRIT, E				BENCHETRIT, E			SAVED BY A TEST RESULT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ENDOCARDITIS		HADASSAH UNIV HOSP,DEPT CLIN MICROB & INFECT DIS,JERUSALEM,ISRAEL	Hebrew University of Jerusalem	BENCHETRIT, E (corresponding author), HADASSAH UNIV HOSP,DIV MED,RHEUMATOL UNIT,POB 12000,JERUSALEM,ISRAEL.							HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Niles J L, 1993, Curr Opin Rheumatol, V5, P18; PAUKER SG, 1975, NEW ENGL J MED, V293, P229, DOI 10.1056/NEJM197507312930505; WAGNER J, 1991, LANCET, V337, P799, DOI 10.1016/0140-6736(91)91427-V; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WILSON WR, 1983, ANNU REV MED, V34, P413, DOI 10.1146/annurev.me.34.020183.002213	7	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					343	346		10.1056/NEJM199402033300509	http://dx.doi.org/10.1056/NEJM199402033300509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277956				2022-12-28	WOS:A1994MU48900009
J	MARCUARD, SP; ALBERNAZ, L; KHAZANIE, PG				MARCUARD, SP; ALBERNAZ, L; KHAZANIE, PG			OMEPRAZOLE THERAPY CAUSES MALABSORPTION OF CYANOCOBALAMIN (VITAMIN-B12)	ANNALS OF INTERNAL MEDICINE			English	Article							INTRINSIC-FACTOR SECRETION; PROTEIN-BOUND VITAMIN-B12; GASTRIC-ACID SECRETION; SUBSTITUTED BENZIMIDAZOLES; COBALAMIN ABSORPTION; CIMETIDINE; RANITIDINE; INHIBITION	Objective: To evaluate protein-bound cyanocobalamin (vitamin B-12) absorption before and after omeprazole (Prilosec) therapy in healthy male volunteers. Design: Clinical trial in which each volunteer served as his own control. Setting: Outpatient department of a university medical center. Participants: Ten healthy, male volunteers 22 to 50 years old. Intervention: Each participant had a modified Schilling test (protein-bound cyanocobalamin) and a gastric analysis, as well as measurements of serum vitamin B-12, gastrin, and folate levels. Five patients were then randomly assigned to take either 20 mg or 40 mg of omeprazole daily. After 2 weeks of omeprazole therapy, these tests were repeated. Measurements: The modified Schilling test, gastric analysis, serum gastrin level, folate level, and cyanocobalamin level. Results: At the end of the 2-week treatment period, cyanocobalamin absorption decreased from 3.2% to 0.9% (P = 0.031) in participants receiving 20 mg of omeprazole daily. In patients taking 40 mg of omeprazole daily, cyanocobalamin absorption decreased from 3.4% to 0.4% (P <. 0.05). Conclusions: Omeprazole therapy acutely decreased cyanocobalamin absorption in a dose-dependent manner.	E CAROLINA UNIV, SCH MED, DEPT CLIN PATHOL & DIAGNOST MED, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University	MARCUARD, SP (corresponding author), E CAROLINA UNIV, SCH MED, DEPT MED, GASTROENTEROL SECT, GREENVILLE, NC 27858 USA.							BELAICHE J, 1983, GASTROEN CLIN BIOL, V7, P381; BELAICHE J, 1983, DIGEST DIS SCI, V28, P667, DOI 10.1007/BF01299929; DOSCHERHOLMEN A, 1973, GASTROENTEROLOGY, V64, P913; FELLENIUS E, 1981, NATURE, V290, P159, DOI 10.1038/290159a0; FELLENIUS E, 1982, AM J PHYSIOL, V243, pG505, DOI 10.1152/ajpgi.1982.243.6.G505; FESTEN HPM, 1989, ALIMENT PHARM THERAP, V3, P375; FORTE JG, 1977, GASTROENTEROLOGY, V73, P921; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HERBERT V, 1984, T ASSOC AM PHYSICIAN, V97, P161; HERBERT V, 1988, ARCH INTERN MED, V148, P1705, DOI 10.1001/archinte.148.8.1705; HERZLICH B, 1984, AM J GASTROENTEROL, V79, P489; HERZLICH B, 1986, AM J GASTROENTEROL, V81, P678; KEMP J A, 1992, Gastroenterology, V102, pA560; KING CE, 1979, DIGEST DIS SCI, V24, P397, DOI 10.1007/BF01297127; KITTANG E, 1987, SCAND J GASTROENTERO, V22, P156, DOI 10.3109/00365528708991873; KITTANG E, 1985, GUT, V26, P594, DOI 10.1136/gut.26.6.594; KOOP H, 1992, J CLIN GASTROENTEROL, V14, P288, DOI 10.1097/00004836-199206000-00005; KOOP H, 1992, ALIMENT PHARM THERAP, V6, P399; LANZON-MILLER S, 1987, Alimentary Pharmacology and Therapeutics, V1, P239; LEE GR, 1993, WINTROBES CLIN HEMAT, P745; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; MARCUARD SP, 1989, DIGEST DIS SCI, V34, P1238, DOI 10.1007/BF01537272; MATON PN, 1989, GASTROENTEROLOGY, V97, P827, DOI 10.1016/0016-5085(89)91485-6; MOHAMMED R, 1981, CLIN THER, V4, P118; NEALE G, 1990, GUT, V31, P59, DOI 10.1136/gut.31.1.59; SACCOMANI G, 1979, J CELL BIOL, V83, P271, DOI 10.1083/jcb.83.2.271; SALOM IL, 1982, SCAND J GASTROENTERO, V17, P129, DOI 10.3109/00365528209181056; STEINBERG WM, 1980, DIGEST DIS SCI, V25, P188, DOI 10.1007/BF01308137; STREETER AM, 1982, DIGEST DIS SCI, V27, P13, DOI 10.1007/BF01308115; STREETER AM, 1974, AM J SURG, V128, P340, DOI 10.1016/0002-9610(74)90169-X; SUTER PM, 1991, GASTROENTEROLOGY, V101, P1039, DOI 10.1016/0016-5085(91)90731-Y; WALLMARK B, 1983, AM J PHYSIOL, V245, pG64, DOI 10.1152/ajpgi.1983.245.1.G64; YALE CE, 1993, AM J HEMATOL, V42, P63, DOI 10.1002/ajh.2830420113; YEOMANS ND, 1982, BRIT MED J, V285, P264, DOI 10.1136/bmj.285.6337.264	34	182	192	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					211	215		10.7326/0003-4819-120-3-199402010-00006	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273984				2022-12-28	WOS:A1994MU30300006
J	MIYATA, T; YAMADA, N; IIDA, Y; NISHIMURA, J; TAKEDA, J; KITANI, T; KINOSHITA, T				MIYATA, T; YAMADA, N; IIDA, Y; NISHIMURA, J; TAKEDA, J; KITANI, T; KINOSHITA, T			ABNORMALITIES OF PIG-A TRANSCRIPTS IN GRANULOCYTES FROM PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANCHORED PROTEINS; CELLS; BIOSYNTHESIS; EXPRESSION; DEFICIENT	Background. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder in which there is a deficiency in the synthesis by hematopoietic cells of the glycosyl-phosphatidylinositol molecules that anchor proteins to the cell membrane. Recently, we demonstrated that a gene termed PIG-A (for phosphatidylinositol glycan class A), a component of glycosyl-phosphatidylinositol biosynthesis, was responsible for PNH in two patients. The present study was undertaken to elucidate whether PIG-A is the gene responsible for all cases of PNH and to characterize further the somatically acquired abnormalities of this gene. Methods. We studied granulocytes from 15 patients with PNH. The cell content of CD55 and CD59 was assessed by fluorescence-activated flow cytometry. PIG-A transcripts were reverse-transcribed, amplified by the polymerase chain reaction, and cloned into plasmids. The structure of the cloned complementary DNA was analyzed by nucleotide sequencing, and its function was assessed on the basis of its ability to restore to normal the abnormal phenotype of a PIG-A-deficient cell line after transfection. Results. Three patients had size abnormalities of PIG-A transcripts with different patterns, and in one patient a very low level of the PIG-A transcript was found. Eleven patients had transcripts of normal size, but the transfection assay revealed that in each patient some of them were nonfunctional. The percentage of nonfunctional PIG-A transcripts was correlated with the percentage of affected granulocytes (P<0.001). Sequence analysis demonstrated somatic mutations in two of the patients. Conclusions. PIG-A is the gene responsible for PNH in all patients studied to date.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT INTERNAL MED,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,BRANCH HOSP,DEPT INTERNAL MED,NAGOYA,AICHI 466,JAPAN	Osaka University; Osaka University; Nagoya University			Kinoshita, Taroh/C-7353-2009; Miyata, Toshio/A-4872-2010					ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; HILLMEN P, 1993, BLOOD, V81, P193; HJIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; MAHONEY JF, 1992, BLOOD, V79, P1400; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ROSSE WF, 1989, BLOOD REV, V3, P192, DOI 10.1016/0268-960X(89)90016-7; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; UEDA E, 1992, INT IMMUNOL, V4, P1263, DOI 10.1093/intimm/4.11.1263	18	205	207	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					249	255		10.1056/NEJM199401273300404	http://dx.doi.org/10.1056/NEJM199401273300404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272086	Bronze			2022-12-28	WOS:A1994MR49600004
J	WEST, SC				WEST, SC			THE PROCESSING OF RECOMBINATION INTERMEDIATES - MECHANISTIC INSIGHTS FROM STUDIES OF BACTERIAL PROTEINS	CELL			English	Review							ESCHERICHIA-COLI RECA; SYNTHETIC HOLLIDAY JUNCTIONS; DNA-REPAIR; BRANCH MIGRATION; RUVB PROTEINS; RESOLUTION; CHI; ENDONUCLEASE; PURIFICATION; MUTANTS				WEST, SC (corresponding author), CLARE HALL LABS,IMPERIAL CANC RES FUND,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HYDE H, 1993, IN PRESS J BIOL CHEM; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; Lloyd RG, 1992, CURR OPIN GENET DEV, V2, P683, DOI 10.1016/S0959-437X(05)80127-3; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MENDONCA VM, 1993, J BACTERIOL, V175, P4641, DOI 10.1128/JB.175.15.4641-4651.1993; MESELSON M, 1972, J MOL BIOL, V71, P795, DOI 10.1016/0022-2828(72)90048-X; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Warner R .C., 1978, COLD SPRING HARB SYM, V43, P957; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P	51	96	99	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					9	15		10.1016/0092-8674(94)90168-6	http://dx.doi.org/10.1016/0092-8674(94)90168-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287483				2022-12-28	WOS:A1994MR49500002
J	THOMAS, DGT; KITCHEN, ND				THOMAS, DGT; KITCHEN, ND			MINIMALLY INVASIVE SURGERY .7. NEUROSURGERY	BRITISH MEDICAL JOURNAL			English	Article								The introduction of minimally invasive techniques has greatly improved results for intracranial neurosurgery. Stereotaxy and improved imaging techniques have reduced surgical trauma by allowing surgeons to plan the least damaging route to operative sites and by increasing surgical precision. Stereotaxy has also allowed brain biopsies to be taken from sites such as the brain stem, which were rarely sampled before because free hand biopsy was so dangerous. Brain tumours can now be treated by interstitial radiotherapy-stereotactic insertion of catheters into the lesion for loading of radioactive iodine or radiosurgery-focusing of intense beams of radiation on lesions without needing surgical incisions. Endoscopic neurosurgery can be used to reach cavities such as the ventricular system or cystic tumours. With interventional neuroradiology fine catheters can be introduced into most vessels in the cranium for embolisation or dilatation. The development of augmentative functional neurosurgery means that movement disorders, epilepsy, and intractable pain can be treated with implanted neurostimulating electrodes. Future developments will probably include frameless stereotaxy, when the rigid attachment of stereotactic apparatus to the patient's head can be dispensed with, and at least partial automation of procedures such brain biopsy.	INST NEUROL,GOUGH COOPER DEPT NEUROL SURG,LONDON WC1N 3BG,ENGLAND	University of London; University College London								BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; Griffith H B, 1986, Adv Tech Stand Neurosurg, V14, P2; GUTHRIE B L, 1990, Stereotactic and Functional Neurosurgery, V54-55, P497; GUTIN PH, 1984, J NEUROSURG, V60, P61, DOI 10.3171/jns.1984.60.1.0061; HELLWIG D, 1992, MINIMALLY INVASIVE N, P63; LEE T, 1991, British Journal of Neurosurgery, V5, P331, DOI 10.3109/02688699109002859; LUXTON G, 1993, NEUROSURGERY, V32, P241, DOI 10.1227/00006123-199302000-00014; NICHOLS DA, 1993, J NEUROSURG, V79, P1, DOI 10.3171/jns.1993.79.1.0001; REDFERN RM, 1993, STEREOTACTIC IMAGE D, P1; Siegfried J, 1991, Acta Neurochir Suppl (Wien), V52, P112	10	17	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					126	128		10.1136/bmj.308.6921.126	http://dx.doi.org/10.1136/bmj.308.6921.126			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298388	Green Published			2022-12-28	WOS:A1994MR17300025
J	SALAMAN, JR; GRIFFIN, PJA; ROSS, W; HAINES, J				SALAMAN, JR; GRIFFIN, PJA; ROSS, W; HAINES, J			LIFELINE WALES - EXPERIENCE WITH A COMPUTERIZED KIDNEY DONOR REGISTRY	BRITISH MEDICAL JOURNAL			English	Article											SALAMAN, JR (corresponding author), CARDIFF ROYAL INFIRM,DEPT SURG & TRANSPLANTAT,CARDIFF CF2 1SZ,S GLAM,WALES.							DEWHURST F W, 1987, Journal of Medical Systems, V11, P381, DOI 10.1007/BF00996352; GORE SM, 1992, BRIT MED J, V304, P349, DOI 10.1136/bmj.304.6823.349; RAINE AEG, 1992, NEPHROL DIAL TRANSPL, V7, P7; SMITH MAM, 1991, BMJ, V302, P1053; 1992, UKTSS1991 1992 UK TR	5	0	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					30	31		10.1136/bmj.308.6920.30	http://dx.doi.org/10.1136/bmj.308.6920.30			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298350	Green Published			2022-12-28	WOS:A1994MQ09600026
J	LESSER, CF; GUTHRIE, C				LESSER, CF; GUTHRIE, C			MUTATIONS IN U6 SNRNA THAT ALTER SPLICE-SITE SPECIFICITY - IMPLICATIONS FOR THE ACTIVE-SITE	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; U1 SNRNA; ASSEMBLY PATHWAY; YEAST; U2; SELECTION; CLEAVAGE; RIBONUCLEOPROTEIN	What determines the precise sites of cleavage in the two transesterification reactions of messenger RNA (mRNA) splicing is a major unsolved question. Mutation of the invariant G (guanosine) at position 5 of 5' splice sites in Saccharomyces cerevisiae introns activates cleavage at nearby aberrant sites. A genetic approach was used to test the hypothesis that a base-pairing interaction between the 5' splice site and the invariant ACAGAG sequence of U6 is a determinant of 5' splice site choice. Mutations in U6 or the intron (or both) that were predicted to stabilize the interaction suppressed aberrant cleavage and increased normal cleavage. In addition, a mutation in the ACAGAG sequence suppressed mutations of the 3' splice site dinucleotide. These data can fit a model for the spliceosomal active site comprised of a set of RNA-RNA interactions between the intron, U2 and U6.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED SCIENTIST TRAINING PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021119, R01GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRANK D, UNPUB; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; GUTHRIE CC, UNPUB; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; Johnson SL, 1991, THESIS U WASHINGTON; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LESSER C, UNPUB; LESSER CF, 1993, GENETICS, V133, P851; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PARKER R, 1987, CELL, V49, P220; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YU YT, IN PRESS CELL; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	45	266	268	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1982	1988		10.1126/science.8266093	http://dx.doi.org/10.1126/science.8266093			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266093				2022-12-28	WOS:A1993MN10800026
J	GILL, DBEC				GILL, DBEC			A COMMISSION OF LUNACY, MAD DOCTORS, AND HAPPY HUNTING	BRITISH MEDICAL JOURNAL			English	Article											GILL, DBEC (corresponding author), WARNEFORD HOSP,OXFORD,ENGLAND.							SURTEES R, 1854, HANDLEY CROSS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1603	1606		10.1136/bmj.307.6919.1603	http://dx.doi.org/10.1136/bmj.307.6919.1603			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292955	Bronze, Green Published			2022-12-28	WOS:A1993MN10700018
J	MANASEKI, S				MANASEKI, S			MONGOLIA - A HEALTH SYSTEM IN TRANSITION	BRITISH MEDICAL JOURNAL			English	Article											MANASEKI, S (corresponding author), ARROWE PK HOSP,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND.		Manaseki-Holland, Semira/AFX-1728-2022; Manaseki-Holland, Semira/I-7303-2017	Manaseki-Holland, Semira/0000-0001-5827-8855; Manaseki-Holland, Semira/0000-0001-5827-8855					0	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1609	1611		10.1136/bmj.307.6919.1609	http://dx.doi.org/10.1136/bmj.307.6919.1609			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292957	Bronze, Green Published			2022-12-28	WOS:A1993MN10700021
J	MARKBY, DW; ONRUST, R; BOURNE, HR				MARKBY, DW; ONRUST, R; BOURNE, HR			SEPARATE GTP-BINDING AND GTPASE-ACTIVATING DOMAINS OF A G-ALPHA-SUBUNIT	SCIENCE			English	Article							ADENYLATE-CYCLASE; ESCHERICHIA-COLI; G-PROTEIN; MOLECULAR-CLONING; TERMINAL DOMAIN; CHOLERA-TOXIN; RAS PROTEINS; WILD-TYPE; EF-TU; SITE	Most members of the guanosine triphosphatase (GTPase) superfamily hydrolyze guanosine triphosphate (GTP) quite slowly unless stimulated by a GTPase activating protein or GAP. The alpha subunits (Galpha) of the heterotrimeric G proteins hydrolyze GTP much more rapidly and contain an approximately 120-residue insert not found in other GTPases. Interactions between a Galpha insert domain and a Galpha GTP-binding core domain, both expressed as recombinant proteins, show that the insert acts biochemically as a GAP. The results suggest a general mechanism for GAP-dependent hydrolysis of GTP by other GTPases.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA54427] Funding Source: Medline; NIGMS NIH HHS [GM27800, 5F32-GM13918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800, F32GM013918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BENJAMIN D, UNPUB; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CREIGHTON TE, 1993, PROTEIN STRUCTURES M, P307; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ECCLESTON JF, 1985, J BIOL CHEM, V260, P6237; ELWELL ML, 1977, BIOCHIM BIOPHYS ACTA, V494, P367, DOI 10.1016/0005-2795(77)90166-0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; ITOH H, 1991, J BIOL CHEM, V266, P16226; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKBY DW, UNPUB; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers MD, 1987, TEXAS AGR EXPT STATI; VANDOP C, 1984, J BIOL CHEM, V259, P696; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	61	151	160	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1895	1901		10.1126/science.8266082	http://dx.doi.org/10.1126/science.8266082			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266082				2022-12-28	WOS:A1993MM51100043
J	EMSLIE, C; GRIMSHAW, J; TEMPLETON, A				EMSLIE, C; GRIMSHAW, J; TEMPLETON, A			DO CLINICAL GUIDELINES IMPROVE GENERAL-PRACTICE MANAGEMENT AND REFERRAL OF INFERTILE COUPLES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate guidelines for general practice management and referral of infertile couples. Guidelines were implemented with a disease specific reminder at the time of consultation (the guidelines were embedded within a structured infertility management sheet for each couple). Design-Pragmatic randomised controlled trial. Participating practices were randomised to a group that received the guidelines and a control group. Setting-82 general practices in Grampian region. Subjects-100 couples referred by general practitioners receiving the guideline and 100 couples referred by control general practitioners. Main outcome measure-Whether the general practitioner had taken a full sexual history and examined and investigated both partners appropriately. Results-Characteristics of patients referred by study and control general practitioners did not differ significantly at baseline. Compliance with the guidelines increased for all targeted activities. General practitioners in the study group were more likely to take a sexual history (for example, couples' use of fertile period, 85% v 69%, p < 0.01); examine both partners (female partner, 68% v 52%, p < 0.05; male partner 39% v 13%, p<0.01); and investigate both partners (day 21 progesterone, 72% v 41%, p < 0.001; semen analysis, 51% v 41%, p > 0.05). Improvements were greater when general practitioners used the disease specific reminder. Conclusion-Receiving guidelines led to improvements in the process of care of infertile couples within general practice. This effect was enhanced when the guidelines were embedded in a structured infertility management sheet for each couple.	UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen			Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				ARAL SO, 1983, JAMA-J AM MED ASSOC, V250, P2327, DOI 10.1001/jama.250.17.2327; EMMANUEL J, 1989, BRIT MED J, V299, P722, DOI 10.1136/bmj.299.6701.722; GRIMSHAW J, 1992, 13 U AB HLTH SERV RE; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; HELLIWELL PS, 1991, BRIT MED J, V302, P304, DOI 10.1136/bmj.302.6772.304; LILFORD R, 1992, BRIT MED J, V305, P1376, DOI 10.1136/bmj.305.6866.1376; LILFORD RJ, 1992, BMJ-BRIT MED J, V305, P1181, DOI 10.1136/bmj.305.6863.1181; MARINKER M, 1988, BRIT MED J, V297, P461, DOI 10.1136/bmj.297.6646.461; MCQUEEN D, 1989, STUDY LIFESTYLE HLTH; PURVES I, 1992, BRIT MED J, V305, P1364, DOI 10.1136/bmj.305.6865.1364-b; RUSSELL IT, 1992, HOSPITAL REFERRALS; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; TEMPLETON A, 1991, HUM REPROD, V6, P1391, DOI 10.1093/oxfordjournals.humrep.a137275; WIRTSCHAFTER DD, 1986, AM J DIS CHILD, V140, P791, DOI 10.1001/archpedi.1986.02140220073036; 1992, LANCET, V339, P1197; 1991, NHS OUTPATIENT SERVI; 1992, EFFECTIVE HLTH CARE, P1; 1992, INFERTILITY GUIDELIN	18	61	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1728	1731		10.1136/bmj.306.6894.1728	http://dx.doi.org/10.1136/bmj.306.6894.1728			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8280213	Green Published, Bronze			2022-12-28	WOS:A1993LK36700023
J	DAVIS, DL; DINSE, GE; HOEL, DG				DAVIS, DL; DINSE, GE; HOEL, DG			DECREASING CARDIOVASCULAR-DISEASE AND INCREASING CANCER AMONG WHITES IN THE UNITED-STATES FROM 1973 THROUGH 1987 - GOOD-NEWS AND BAD-NEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUSTRIALIZED COUNTRIES; TRENDS; MORTALITY; PERIOD; MODELS; RATES; AGE	Objective.-Trends in cancer mortality, cardiovascular mortality, and cancer incidence are assessed among US whites to determine whether aging of the population and smoking patterns completely account for increased cancer rates from 1973 through 1987. Design.-For mortality, percentage changes in age-specific rates were calculated. For cancer incidence, trends in age-specific rates across time periods and birth cohorts were assessed for several sites. Main Outcome Measures.-National US cardiovascular and cancer mortality rates and incidence rates for smoking-related cancer, breast cancer, and all other types of cancer in 1 0% of the US population covered by the National Cancer Institute's Surveillance, Epidemiology, and End Results Program were analyzed. Results.-From 1973 through 1987, cardiovascular mortality decreased 42% in the age group 0 to 54 years and decreased 33% in the age group 55 to 84 years; concurrently, cancer mortality decreased 17% in the younger group but increased 12% in the older group. By 1987, even though proportionally fewer people in the older age groups died, relatively more of them died of cancer. Men born in the 1940s had twice as much cancer as those born in 1888 through 1897 and more than twice as much cancer not linked to smoking; women born during this period had 50% and 30% more of these same cancers, respectively. Rates of smoking-related cancers in recent cohorts of women were five to six times greater than in those born in 1888 th rough 1897, while rates in men declined. Recent cohorts of women also had more than twice as much breast cancer as those born in 1888 through 1897. Conclusions.-In recent US birth cohorts, our model found that increases in cancer have occurred that are not solely linked to aging of the population and smoking patterns. In light of these results and similar findings in Sweden, changes in carcinogenic hazards in addition to smoking are likely to have occurred and need to be studied further.	NIEHS, STAT & BIOMATH BRANCH, RES TRIANGLE PK, NC 27709 USA; MED UNIV S CAROLINA, HOLLINGS CANC CTR, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT BIOMETRY & EPIDEMIOL, CHARLESTON, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical University of South Carolina; Medical University of South Carolina	DAVIS, DL (corresponding author), DEPT HLTH & HUMAN SERV, OFF ASSISTANT SECRETARY HLTH, 200 INDEPENDENCE AVE SW, WASHINGTON, DC 20201 USA.							ADAMI HO, 1993, LANCET, V341, P773, DOI 10.1016/0140-6736(93)90557-W; ADAMI HO, 1992, ACTA ONCOL, V31, P1; BAKER RJ, 1978, GLIM SYSTEM; BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; BRODER S, 1991, ORIGINS HUMAN CANNCE; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V100, P39, DOI 10.2307/3431519; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; HOEL DG, 1992, JNCI-J NATL CANCER I, V84, P313, DOI 10.1093/jnci/84.5.313; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LOPEZ AD, 1990, ANN NY ACAD SCI, V609, P58, DOI 10.1111/j.1749-6632.1990.tb32057.x; RIES LAG, 1990, NCI NIH902789 PUBL; 1982, HLTH CONSEQUENCES SM; 1991, CANCER FACTS FIGURES; 1991, NCI MONOGRAPH, V1	20	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					431	437		10.1001/jama.271.6.431	http://dx.doi.org/10.1001/jama.271.6.431			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295317				2022-12-28	WOS:A1994MU49100029
J	COHEN, C; PARRY, DAD				COHEN, C; PARRY, DAD			ALPHA-HELICAL COILED COILS - MORE FACTS AND BETTER PREDICTIONS	SCIENCE			English	Article							FIBROUS PROTEINS; HEPTAD REPEAT; TROPOMYOSIN; SPECTRIN; MOTIF		MASSEY UNIV, DEPT PHYS & BIOPHYS, PALMERSTON NORTH, NEW ZEALAND	Massey University	COHEN, C (corresponding author), BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017346, R37AR017346] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17346] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; WARD CW, 1980, AUST J BIOL SCI, V33, P449; WILEY DC, UNPUB; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	24	159	167	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					488	489		10.1126/science.8290957	http://dx.doi.org/10.1126/science.8290957			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290957				2022-12-28	WOS:A1994MT96600023
J	SCHUMAN, EM; MADISON, DV				SCHUMAN, EM; MADISON, DV			LOCALLY DISTRIBUTED SYNAPTIC POTENTIATION IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE; LASTING POTENTIATION; ARACHIDONIC-ACID; TRANSMISSION; INDUCTION; STIMULATION; ENHANCEMENT; MESSENGER; RELEASE	The long-lasting increase in synaptic strength known as long-term potentiation has been advanced as a potential physiological mechanism for many forms of both developmental and adult neuronal plasticity. In many models of plasticity, intercellular communication has been proposed to account for observations in which simultaneously active neurons are strengthened together. The data presented here indicate that long-term potentiation can be communicated between synapses on neighboring neurons by means of a diffusible messenger. This distributed potentiation provides a mechanism for the cooperative strengthening of proximal synapses and may underlie a variety of plastic processes in the nervous system.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University			Schuman, Erin M/D-6204-2011					ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BALLYK BA, 1992, J NEUROSCI RES, V33, P598, DOI 10.1002/jnr.490330412; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; COLLINGRIDGE GL, 1992, EXP PHYSIOL, V77, P771, DOI 10.1113/expphysiol.1992.sp003645; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GOODMAN CS, 1993, NEURON S, V10, P77; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TSENG GF, 1991, J NEUROSCI METH, V37, P121, DOI 10.1016/0165-0270(91)90122-G; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	37	301	303	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					532	536		10.1126/science.8290963	http://dx.doi.org/10.1126/science.8290963			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290963				2022-12-28	WOS:A1994MT96600037
J	SMITH, JC				SMITH, JC			HEDGEHOG, THE FLOOR PLATE, AND THE ZONE OF POLARIZING ACTIVITY	CELL			English	Review							CHICK WING BUD; RETINOIC ACID; LIMB				SMITH, JC (corresponding author), NATL INST MED RES,DEV BIOL LAB,RIDGEWAY,LONDON NW7 1AA,ENGLAND.			Smith, Jim/0000-0003-2413-9392				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FORBES AJ, 1993, IN PRESS DEVELOPME S, V119; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; NOJI S, 1991, NATURE, V350, P80; PLACZEK M, 1993, DEVELOPMENT, V117, P205; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; SMITH JC, 1978, NATURE, V272, P612, DOI 10.1038/272612a0; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	21	81	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					193	196		10.1016/0092-8674(94)90325-5	http://dx.doi.org/10.1016/0092-8674(94)90325-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293455				2022-12-28	WOS:A1994MU67800001
J	VIBERTI, G; MOGENSEN, CE; GROOP, LC; PAULS, JF; BONER, G; VANDYK, DJ; LUCAS, A; ROMERO, R; SALINAS, I; SANMARTI, A; BLOMQVIST, AC; EKSTRAND, A; KIRSI, VL; KOIVISTO, VA; GROOP, LC; GROOP, PH; ESCOBAR, F; JIMENEZ, FE; CAMPOSPASTOR, MM; MUNOZ, M; GOMEZ, M; MANGILI, R; POZZA, G; SPOTTI, D; HANSEN, KW; CHRISTIANSEN, JS; KLEIN, F; MOGENSEN, CE; VANDOORN, LG; SPOOREN, PFMJ; CRUICKSHANK, JK; JERVELL, J; PAUS, PN; COLLINS, A; WILLIAMS, G				VIBERTI, G; MOGENSEN, CE; GROOP, LC; PAULS, JF; BONER, G; VANDYK, DJ; LUCAS, A; ROMERO, R; SALINAS, I; SANMARTI, A; BLOMQVIST, AC; EKSTRAND, A; KIRSI, VL; KOIVISTO, VA; GROOP, LC; GROOP, PH; ESCOBAR, F; JIMENEZ, FE; CAMPOSPASTOR, MM; MUNOZ, M; GOMEZ, M; MANGILI, R; POZZA, G; SPOTTI, D; HANSEN, KW; CHRISTIANSEN, JS; KLEIN, F; MOGENSEN, CE; VANDOORN, LG; SPOOREN, PFMJ; CRUICKSHANK, JK; JERVELL, J; PAUS, PN; COLLINS, A; WILLIAMS, G			EFFECT OF CAPTOPRIL ON PROGRESSION TO CLINICAL PROTEINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS AND MICROALBUMINURIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLOMERULAR-FILTRATION RATE; ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; URINARY ALBUMIN; NEPHROPATHY; ENALAPRIL; TERM; PREVENTION; EXCRETION; PRESSURE	Objectives.-To study the effect of angiotensin converting enzyme inhibition on the rate of progression to clinical proteinuria and the rate of change of albumin excretion rates in patients with insulin-dependent diabetes mellitus and persistent microalbuminuria. Design and Setting.-Randomized, double-blind, placebo-controlled clinical trial of 2 years' duration at 12 hospital-based diabetes centers. Patients.-Ninety-two patients with insulin-dependent diabetes mellitus and persistent microalbuminuria but no hypertension. Intervention.-The patients were randomly allocated in blocks of two to receive either captopril, 50 mg, or placebo twice per day. Measurements.-Albumin excretion rate, blood pressure, glycosylated hemoglobin level, and fructosamine level every 3 months; urinary urea nitrogen excretion every 6 months; and glomerular filtration rate every 12 months. Results.-Twelve patients receiving placebo and four receiving captopril progressed to clinical proteinuria, defined as an albumin excretion rate persistently greater than 200 mug/min and at least a 30% increase from baseline (P=.05). The probability of progression to clinical proteinuria was significantly reduced by captopril therapy (P=.03 by log-rank test Albumin excretion rate rose from a geometric mean (95% confidence interval) of 52 (39 to 68) to 76 (47 to 199) mug/min in the placebo group but fell from 52 (41 to 65) to 41 (28 to 60) mug/min in the captopril group, a significant difference (P<.01). Mean blood pressure was similar at baseline in the two groups and remained unchanged in the placebo group but fell significantly, by 3 to 7 mm Hg, in the captopril group. Glycosylated hemoglobin levels and glomerular filtration rate remained stable in the two groups. Conclusions.-Captopril therapy significantly impeded progression to clinical proteinuria and prevented the increase in albumin excretion rate in nonhypertensive patients with insulin-dependent diabetes mellitus and persistent microalbuminuria.	BRISTOL MYERS SQUIBB CO,PRINCETON,NJ; AARHUS UNIV,AARHUS KOMMUNE HOSP,DK-8000 AARHUS,DENMARK; UNIV HELSINKI,CENT HOSP,SF-00100 HELSINKI 10,FINLAND; BEILINSON MED CTR,IL-49100 PETAH TIQWA,ISRAEL; HOSP GERMANS TRIAS I PUJOL,BADALONA,SPAIN; UNIV HELSINKI,CENT HOSP,SF-00100 HELSINKI 10,FINLAND; HOSP UNIV GRANADA,GRANADA,SPAIN; IST SCI SAN RAFFAELE,MILAN,ITALY; AARHUS UNIV,AARHUS KOMMUNE HOSP,DK-8000 AARHUS,DENMARK; MARIA ZIEKENHUIS TILBURG,TILBURG,NETHERLANDS; MED SPECTRUM TWENTE,ENSCHEDE,NETHERLANDS; NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; NATL HOSP NORWAY,OSLO 1,NORWAY; SENTRALSYKEHOSET & AKERSHUS,NORD BYHAGEN,NORWAY; WATFORD DIST GEN HOSP,WATFORD,ENGLAND	Bristol-Myers Squibb; Aarhus University; University of Helsinki; Helsinki University Central Hospital; Rabin Medical Center; Hospital Germans Trias i Pujol; University of Helsinki; Helsinki University Central Hospital; University of Granada; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Aarhus University; Medical Spectrum Twente; Imperial College London; University of Oslo; National Hospital Norway; Watford General Hospital	VIBERTI, G (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,4TH FLOOR,HUNTS HOUSE,LONDON SE1 9RT,ENGLAND.							ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BRICHARD SM, 1989, DIABETES METAB, V16, P30; CHANTLER C, 1969, CLIN SCI, V37, P169; CHRISTENSEN CK, 1985, HYPERTENSION, V7, P109; COHEN D, 1987, BRIT MED J, V294, P795, DOI 10.1136/bmj.294.6575.795; COOPER ME, 1989, DIABETOLOGIA, V32, P326, DOI 10.1007/BF00265552; FAWDRY RM, 1985, EUR J NUCL MED, V11, P7, DOI 10.1007/BF00440953; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FOGO A, 1988, J CLIN INVEST, V82, P322, DOI 10.1172/JCI113590; HUNSICKER L, 1993, DIABETES S1, V2, pA98; INSUA A, 1988, POSTGRAD MED J, V64, P59; KEANE WF, 1985, LAB INVEST, V52, P599; KEARNEY EM, 1987, J CLIN PATHOL, V40, P465, DOI 10.1136/jcp.40.4.465; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MAYER TK, 1983, CLIN CHIM ACTA, V127, P147, DOI 10.1016/S0009-8981(83)80002-3; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1971, SCAND J CLIN LAB INV, V28, P91, DOI 10.3109/00365517109090667; MOGENSEN CE, 1992, DIABETES CARE, V15, P1992; MORELLI E, 1990, DIABETES, V39, P76, DOI 10.2337/diabetes.39.1.76; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PINTO JR, 1990, KIDNEY INT, V37, P516; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; ROSSING P, 1992, Journal of the American Society of Nephrology, V3, P338; Striker Gary E., 1991, Journal of Diabetic Complications, V5, P51, DOI 10.1016/0891-6632(91)90014-G; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1979, NEW ENGL J MED, V300, P638, DOI 10.1056/NEJM197903223001202; YOSHIDA Y, 1989, KIDNEY INT, V36, P626, DOI 10.1038/ki.1989.239; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; 1991, BMJ, V302, P210; SAS P229 I INC TECHN, pCH16	39	551	561	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					275	279		10.1001/jama.271.4.275	http://dx.doi.org/10.1001/jama.271.4.275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295285				2022-12-28	WOS:A1994MR22100022
J	MOSER, KM; FEDULLO, PF; LITTEJOHN, JK; CRAWFORD, R				MOSER, KM; FEDULLO, PF; LITTEJOHN, JK; CRAWFORD, R			FREQUENT ASYMPTOMATIC PULMONARY-EMBOLISM IN PATIENTS WITH DEEP VENOUS THROMBOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VEIN THROMBOSIS; LUNG-SCAN	Objective.-To determine the frequency of pulmonary embolism in patients admitted for treatment of deep venous thrombosis. Design.-An open, multicenter, dose-ranging study to assess the safety and pharmacokinetic characteristics of tissue-type plasminogen activator in deep venous thrombosis and pulmonary embolism. Perfusion and ventilation lung scans, chest roentgenograms, and venograms (in deep venous thrombosis) or pulmonary angiograms (in pulmonary embolism) were obtained before and 24 hours after inception of therapy. Heparin therapy was then administered. Settings.-Five tertiary-care hospitals. Patients.-All patients with suspected deep venous thrombosis or pulmonary embolism seen from August 1987 through November 1988 entered the study if they met inclusion criteria and if the diagnosis was confirmed by venogram (deep venous thrombosis) or pulmonary angiogram (pulmonary embolism). Interventions.-All patients received tissue-type plasminogen activator followed by intravenous heparin therapy. Main Outcome Measures.-The primary measure was the frequency of pulmonary embolism in patients with deep venous thrombosis who had no symptoms of pulmonary embolism. This was not the original purpose of the study but emerged as an important finding as the data were analyzed. Results.-Nearly 40% of patients with deep venous thrombosis who had no symptoms of pulmonary embolism had evidence of pulmonary embolism based on ventilation-perfusion scan and chest roentgenogram findings. Conclusions.-Because all of those considered to have embolism had so-called high-probability scan results, the frequency of embolism reported likely represents the minimum incidence of pulmonary embolism in patients with deep venous thrombosis who have no embolic symptoms. These data emphasize that venous thromboembolism is one disorder.	BURROUGHS WELLCOME CO,DIV CLIN RES,RES TRIANGLE PK,NC 27709	Burroughs Wellcome Fund	MOSER, KM (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SCH MED,DEPT MED,DIV PULM & CRIT CARE,PULM VASC SERV,200 W ARBOR DR,SAN DIEGO,CA 92103, USA.							BYRNE JJ, 1952, AM J SURG, V83, P47, DOI 10.1016/0002-9610(52)90157-8; DORFMAN GS, 1987, AM J RADIOL, V1487, P263; HUISMAN MV, 1989, CHEST, V95, P948; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KISTNER RL, 1972, AM J SURG, V124, P169, DOI 10.1016/0002-9610(72)90009-8; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MONREAL M, 1989, J CARDIOVASC SURG, V30, P104; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; OLMAN MA, 1990, CHEST, V98, P1430, DOI 10.1378/chest.98.6.1430; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SHORT DS, 1952, BRIT MED J, V1, P790, DOI 10.1136/bmj.1.4762.790; 1990, JAMA-J AM MED ASSOC, V263, P2753	13	275	293	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					223	225		10.1001/jama.271.3.223	http://dx.doi.org/10.1001/jama.271.3.223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277550				2022-12-28	WOS:A1994MQ64500037
J	BANERJEE, A; DUBNAU, E; QUEMARD, A; BALASUBRAMANIAN, V; UM, KS; WILSON, T; COLLINS, D; DELISLE, G; JACOBS, WR				BANERJEE, A; DUBNAU, E; QUEMARD, A; BALASUBRAMANIAN, V; UM, KS; WILSON, T; COLLINS, D; DELISLE, G; JACOBS, WR			INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS	SCIENCE			English	Article							MYCOLIC ACID SYNTHESIS; ESCHERICHIA-COLI; RESISTANCE; AURUM; CHEMOTHERAPY; TRIMETHOPRIM; MECHANISMS; SMEGMATIS; EXTRACTS	Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis. The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, 1300 MORRIS PK, BRONX, NY 10461 USA; MINIST AGR & FISHERIES, WALLACEVILLE ANIM RES CTR, UPPER HUTT, NEW ZEALAND	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; AgResearch - New Zealand				Jacobs, William/0000-0003-3321-3080; Quemard, Annaik/0000-0002-5545-3424	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27160, UO1AI30189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balasubramanian V., UNPUB; Banerjee A., UNPUB; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BEGGS WH, 1970, AM REV RESPIR DIS, V102, P94; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; BESLILE JT, 1991, J BACTERIOL, V173, P6991; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; Brennan P J, 1970, Ir J Med Sci, V3, P371, DOI 10.1007/BF02956904; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COHN ML, 1954, AM REV TUBERC PULM, V70, P641; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOPINATHAN KP, 1981, CURR SCI INDIA, V50, P216; GREY D, 1979, CHEMOTHERAPY, V25, P147, DOI 10.1159/000237834; GRUMBACH F, 1961, Rev Tuberc Pneumol (Paris), V25, P1365; HOK TT, 1964, AM REV RESPIR DIS, V90, P468; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KALPANA GV, 1991, P NATL ACAD SCI USA, V88, P5433, DOI 10.1073/pnas.88.12.5433; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; Lefford M J, 1966, Tubercle, V47, P198, DOI 10.1016/S0041-3879(66)80036-3; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V69, P471; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; MURRAY CJL, 1990, B INT UNION TUBER, V65, P24; NAG DK, 1988, GENE, V64, P135, DOI 10.1016/0378-1119(88)90487-8; OFFE HA, 1952, Z NATURFORSCH B, V7, P462; PANSY F, 1952, AM REV TUBERC PULM, V65, P761; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; RABUSSAY D, 1969, FEBS LETT, V5, P104, DOI 10.1016/0014-5793(69)80305-4; SAROJA D, 1973, ANTIMICROB AGENTS CH, V4, P643, DOI 10.1128/AAC.4.6.643; SMALL PM, COMMUNICATION; SMALL PM, 1966, TUBERCLE, V47, P109; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; THEN RL, 1982, REV INFECT DIS, V4, P261; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WILSON T, UNPUB; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; 1991, PROGRAM MANUAL GCG P	52	1139	1212	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	1994	263	5144					227	230		10.1126/science.8284673	http://dx.doi.org/10.1126/science.8284673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284673				2022-12-28	WOS:A1994MQ87900035
J	HALE, D; ALDEEN, W; CARROLL, K				HALE, D; ALDEEN, W; CARROLL, K			DIARRHEA ASSOCIATED WITH CYANOBACTERIALIKE BODIES IN AN IMMUNOCOMPETENT HOST - AN UNUSUAL EPIDEMIOLOGIC SOURCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORGANISM	Objective.-To describe a patient who developed diarrhea secondary to Cyanobacterialike bodies (CLBs) after exposure to contaminated water in his home. Design.-Case report. Setting.-General community. Patient.-Healthy, elderly man. Intervention.-None, self-limited illness. Results.-The patient's clinical course was consistent with illness caused by CLBs. Cyanobacterialike bodies were recovered from the patient's stool sample and the contaminated water to which he was exposed. Conclusion.-Internists and laboratory technicians should be aware of CLBs as a cause of protracted diarrhea in the community.	UNIV UTAH,MED CTR,DEPT PATHOL,5C130 SOM,50 N MED CTR DR,SALT LAKE CITY,UT 84132; UNIV UTAH,MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132; ASSOCIATED REG & UNIV PATHOLOGISTS,SALT LAKE CITY,UT	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah								Herwaldt B L, 1991, MMWR CDC Surveill Summ, V40, P1; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PETERS CS, 1991, 91ST GEN M AM SOC MI; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; 1991, MMWR MORB MORTAL WKL, V40, P325	7	29	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					144	145		10.1001/jama.271.2.144	http://dx.doi.org/10.1001/jama.271.2.144			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264070				2022-12-28	WOS:A1994MQ08300025
J	ADELSON, EH				ADELSON, EH			PERCEPTUAL ORGANIZATION AND THE JUDGMENT OF BRIGHTNESS	SCIENCE			English	Article							LIGHTNESS	The perceived brightness of a gray patch depends on the surrounding context. For example, a medium-gray patch appears darker when placed on a bright background and brighter when placed on a dark background. Models to explain these effects are usually based on simple low-level mechanisms. A new set of brightness illusions cannot be explained by such models. In these illusions, the brightness percept is strongly influenced by the perceptual organization of the stimuli. Simple modifications of the stimuli that should have little effect on low-level mechanisms greatly alter the strength of the illusion. These effects may be ascribed to more complex mechanisms occurring later in the visual system.	MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	ADELSON, EH (corresponding author), MIT, MEDIA LAB, CAMBRIDGE, MA 02139 USA.			Sanchez-Fernandez, Gregorio Esteban/0000-0002-6059-7182				ADELSON EH, 1991, CHANNELS IN THE VISUAL NERVOUS SYSTEM : NEUROPHYSIOLOGY, PSYCHOPHYSICS AND MODELS, P195; [Anonymous], 1974, COMPUT VISION GRAPH, DOI DOI 10.1016/0146-664X(74)90022-7; AREND LE, 1987, J OPT SOC AM A, V4, P2281, DOI 10.1364/JOSAA.4.002281; Barrow H., 1978, COMPUT VIS SYST, V2, P2; Cornsweet T., 1970, VISUAL PERCEPTION; Evans Ralph M., 1948, INTRO COLOR; GILCHRIST A, 1983, PERCEPT PSYCHOPHYS, V33, P425, DOI 10.3758/BF03202893; GILCHRIST AL, 1977, SCIENCE, V195, P185, DOI 10.1126/science.831266; KERSTEN D, 1991, COMPUTATIONAL MODELS; KNILL DC, 1991, NATURE, V351, P228, DOI 10.1038/351228a0; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; Sinha P., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P156, DOI 10.1109/ICCV.1993.378224	13	358	361	4	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2042	2044		10.1126/science.8266102	http://dx.doi.org/10.1126/science.8266102			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266102				2022-12-28	WOS:A1993MN10800041
J	GODLEE, F				GODLEE, F			WALKING ACROSS ANTARCTICA	BRITISH MEDICAL JOURNAL			English	Article																		STROUD M, 1993, SHADOWS WASTELAND CR	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1599	1601		10.1136/bmj.307.6919.1599	http://dx.doi.org/10.1136/bmj.307.6919.1599			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292953	Green Published, Bronze			2022-12-28	WOS:A1993MN10700016
J	OBRIEN, PMS				OBRIEN, PMS			FORTNIGHTLY REVIEW - HELPING WOMEN WITH PREMENSTRUAL-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMS; DANAZOL; FLUOXETINE; CYCLICITY; TENSION				OBRIEN, PMS (corresponding author), KEELE UNIV,SCH POSTGRAD MED,ACAD DEPT OBSTET & GYNAECOL,STOKE ON TRENT ST4 6SD,ENGLAND.							BACKSTROM T, 1992, CONTRACEPTION, V46, P253, DOI 10.1016/0010-7824(92)90006-F; BACKSTROM T, 1992, CLIN OBSTET GYNECOL, V35, P612, DOI 10.1097/00003081-199209000-00021; CASSON P, 1990, AM J OBSTET GYNECOL, V162, P99, DOI 10.1016/0002-9378(90)90830-Z; Dalton K., 1984, PREMENSTRUAL SYNDROM; DEENY M, 1991, POSTGRAD MED J, V67, P450, DOI 10.1136/pgmj.67.787.450; DERZKO CM, 1990, J REPROD MED, V35, P97; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; GOODALE IL, 1990, OBSTET GYNECOL, V75, P649; HALBREICH U, 1991, FERTIL STERIL, V56, P1066; HELLBERG D, 1991, INT J GYNECOL OBSTET, V34, P243, DOI 10.1016/0020-7292(91)90357-B; HUSSAIN SY, 1992, GYNECOL ENDOCRINOL, V6, P57, DOI 10.3109/09513599209081007; HUSSAIN SY, 1993, THESIS U LONDON LOND; JOHNSON SR, 1992, CLIN OBSTET GYNECOL, V35, P637, DOI 10.1097/00003081-199209000-00023; KHOO SK, 1990, MED J AUSTRALIA, V153, P189, DOI 10.5694/j.1326-5377.1990.tb136857.x; KLEIJNEN J, 1990, BRIT J OBSTET GYNAEC, V97, P847, DOI 10.1111/j.1471-0528.1990.tb02582.x; LEATHER AT, 1993, OBSTET GYNECOL, V82, P104; LEFLER HT, 1992, J REPROD MED, V37, P596; MENKES DB, 1992, BRIT MED J, V305, P346, DOI 10.1136/bmj.305.6849.346; METCALF MG, 1989, J PSYCHOSOM RES, V33, P281, DOI 10.1016/0022-3999(89)90019-6; METCALF MG, 1992, J PSYCHOSOM RES, V36, P569, DOI 10.1016/0022-3999(92)90042-Z; METCALF MG, 1991, J PSYCHOSOM RES, V35, P555, DOI 10.1016/0022-3999(91)90050-X; MORTOLA JF, 1991, J ENDOCRINOL METAB, V72, pAF252; MUSE K, 1992, CLIN OBSTET GYNECOL, V35, P658, DOI 10.1097/00003081-199209000-00024; OBRIEN PMS, 1990, OMEGA 6 ESSENTIAL FA, P523; OBRIEN PMS, 1987, PREMENSTRUAL SYNDROM; RAPKIN AJ, 1992, CLIN OBSTET GYNECOL, V35, P629, DOI 10.1097/00003081-199209000-00022; WALKER A, 1990, PSYCHOSOM MED, V52, P86, DOI 10.1097/00006842-199001000-00007; WATSON NR, 1989, LANCET, V2, P730, DOI 10.1016/S0140-6736(89)90784-8; WATSON NR, 1990, GYNECOL ENDOCRINOL, V4, P99, DOI 10.3109/09513599009012326; WOOD SH, 1992, OBSTET GYNECOL, V80, P339	30	45	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1471	1475		10.1136/bmj.307.6917.1471	http://dx.doi.org/10.1136/bmj.307.6917.1471			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281092	Bronze, Green Published			2022-12-28	WOS:A1993MK79700029
J	BENGTSSON, C; BJORKELUND, C; LAPIDUS, L; LISSNER, L				BENGTSSON, C; BJORKELUND, C; LAPIDUS, L; LISSNER, L			ASSOCIATIONS OF SERUM-LIPID CONCENTRATIONS AND OBESITY WITH MORTALITY IN WOMEN - 20 YEAR FOLLOW-UP OF PARTICIPANTS IN PROSPECTIVE POPULATION STUDY IN GOTHENBURG, SWEDEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK; FRAMINGHAM; DEATH; PHASE	Objective-To examine association of different measures of serum lipid concentr Design-Prospective observational study initiated in 1968-9, follow up examination after 12 years, and follow up study based on death certificates after 20 years. Setting-Gothenburg, Sweden. Subjects-1462 randomly selected women aged 38-60 at start of study. Main outcome measures-Total mortality and death from myocardial infarction as predicted by serum cholesterol and triglyceride concentrations, body mass index, and ratio of circumference of waist to circumference of hips. Results-170 women died during follow up, 26 from myocardial infarction. Serum triglyceride concentration and waist:hip ratio were significantly associated with both end points (relative risk of total mortality for highest quarter of triglyceride concentration v lower three quarters 1.86 (95% confidence interval 1.30 to 2.67); relative risk for waist:hip ratio 1.67 (1.18 to 2.36)). These associations remained after adjustment for background variables. Serum cholesterol concentration and body mass index were initially associated with death from myocardial infarction, but association was lost after adjustment for background variables. Serum triglyceride concentration and waist:hip ratio were independently predictive of both end points (logistic regression coefficient for total mortality for triglyceride 0.514 (SE 0.150), p=0.0006; coefficient for waist:hip ratio 7.130 (1.92), p=0.0002) whereas the other two risk factors were not (coefficient for total mortality for cholesterol concentration -0.102 (0.079), p=0.20; coefficient for body mass index -0.051 (0.027), p=0.05). Conclusions-Lipid risk profile appears to be different in men and women given that serum triglyceride concentration was an independent risk factor for mortality while serum cholesterol concentration was not. Consistent with previous observations in men, localisation of adipose tissue was more important than obesity per se as risk factor in women.	GOTHENBURG UNIV, DEPT PRIMARY HLTH CARE, S-41124 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT MED, S-41124 GOTHENBURG, SWEDEN	University of Gothenburg; University of Gothenburg								BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND     S, P549; BOTTIGER LE, 1982, ACTA MED SCAND, V211, P437; BRADLEY PJ, 1982, INT J OBESITY, V6, P43; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; HARTZ A, 1990, INT J OBESITY, V14, P657; JOHANSSON S, 1988, ARTERIOSCLEROSIS, V8, P742, DOI 10.1161/01.ATV.8.6.742; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1984, PREV MED, V13, P141, DOI 10.1016/0091-7435(84)90047-1; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEVINE JB, 1964, CLIN CHIM ACTA, V10, P381, DOI 10.1016/0009-8981(64)90073-7; LOFLAND HB, 1964, ANAL BIOCHEM, V9, P393, DOI 10.1016/0003-2697(64)90199-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; THOMPSON CJ, 1991, ARTERIOSCLER THROMB, V11, P327, DOI 10.1161/01.ATV.11.2.327; 1983, SPRI122 SWED PLANN R	19	117	121	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1993	307	6916					1385	1388		10.1136/bmj.307.6916.1385	http://dx.doi.org/10.1136/bmj.307.6916.1385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274890	Green Published, Bronze			2022-12-28	WOS:A1993MK42000018
J	LOWRY, WS; ATKINSON, RJ				LOWRY, WS; ATKINSON, RJ			TUMOR-SUPPRESSOR GENES AND RISK OF METASTASIS IN OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article											LOWRY, WS (corresponding author), QUEENS UNIV BELFAST,DEPT ONCOL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							ANDERSON MC, 1987, OVARIAN CANCERS WAY, P63; ECCLES DM, 1992, ONCOGENE, V7, P2069	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					542	542		10.1136/bmj.307.6903.542	http://dx.doi.org/10.1136/bmj.307.6903.542			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8267754	Green Published, Bronze			2022-12-28	WOS:A1993LV18000019
J	RAE, P; FARRAR, J; BECKETT, G; TOFT, A				RAE, P; FARRAR, J; BECKETT, G; TOFT, A			FORTNIGHTLY REVIEW - ASSESSMENT OF THYROID STATUS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							THYROTROPIN-RELEASING-HORMONE; FREE-THYROXINE; ANALOG RADIOIMMUNOASSAY; FUNCTION TESTS; ILLNESS; ASSAY; TSH; TRIIODOTHYRONINE; DIALYSIS; DISEASE		UNIV EDINBURGH,ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT CLIN BIOCHEM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh				Farrar, Jeremy/0000-0002-2700-623X				BACCI V, 1982, J CLIN ENDOCR METAB, V54, P1229, DOI 10.1210/jcem-54-6-1229; BECKETT GJ, 1991, ANN CLIN BIOCHEM, V28, P335, DOI 10.1177/000456329102800404; BECKPECCOZ P, 1985, LANCET, V1, P1456; BORST GC, 1983, J CLIN ENDOCR METAB, V57, P380, DOI 10.1210/jcem-57-2-380; CARADOCDAVIES TH, 1988, NEW ZEAL MED J, V101, P662; CHOPRA IJ, 1985, J CLIN ENDOCR METAB, V60, P980, DOI 10.1210/jcem-60-5-980; DANFORTH E, 1986, THYROID HORMONE META, P335; DAVIS PJ, 1979, CLIN ENDOCRINOL META, V8, P602; EHRMANN DA, 1989, ARCH INTERN MED, V149, P369; EKINS R, 1987, CLIN CHEM, V3, P2137; ENGLER D, 1987, J CLIN ENDOCR METAB, V46, P77; FABER J, 1987, J CLIN ENDOCR METAB, V65, P315, DOI 10.1210/jcem-65-2-315; GOW SM, 1986, CLIN CHIM ACTA, V158, P49, DOI 10.1016/0009-8981(86)90115-4; GRIFFIN JE, 1985, AM J MED SCI, V289, P76, DOI 10.1097/00000441-198502000-00008; GRIFFIN JE, 1990, AM J MED SCI, V299, P334, DOI 10.1097/00000441-199005000-00009; HAVARD CWH, 1981, CLIN ENDOCRINOL META, V10, P163, DOI 10.1016/S0300-595X(81)80043-6; HAY ID, 1989, DIAGNOSTIC METHODS C, P39; HELENIUS T, 1983, CLIN CHEM, V29, P816; Kaptein EM, 1986, THYROID HORMONE META, P297; LIEWENDAHL K, 1984, CLIN CHEM, V30, P760; MORI T, 1987, CLIN ENDOCRINOL, V27, P1, DOI 10.1111/j.1365-2265.1987.tb00833.x; MORLEY JE, 1981, ENDOCR REV, V2, P396, DOI 10.1210/edrv-2-4-396; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PIKETTY ML, 1987, CLIN CHEM, V33, P1237; RE RN, 1976, J CLIN ENDOCR METAB, V43, P338, DOI 10.1210/jcem-43-2-338; SNYDER PJ, 1972, J CLIN ENDOCR METAB, V34, P380, DOI 10.1210/jcem-34-2-380; SPENCER C, 1987, CLIN CHEM, V33, P1391; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; STOCKIGT JR, 1983, CLIN CHEM, V29, P1408; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TOFT AD, 1987, BJM, V295, P503; 1989, LANCET, V1, P1176	32	46	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					177	180		10.1136/bmj.307.6897.177	http://dx.doi.org/10.1136/bmj.307.6897.177			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8280215	Bronze, Green Published			2022-12-28	WOS:A1993LN18400025
J	SCHACHMAN, HK				SCHACHMAN, HK			WHAT IS MISCONDUCT IN SCIENCE	SCIENCE			English	Article											SCHACHMAN, HK (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,WM STANLEY HALL,BERKELEY,CA 94720, USA.							ANDERSON RM, 1989, AAAS AM BAR ASS NATI; BUZZELLI DE, 1993, SCIENCE, V259, P584, DOI 10.1126/science.8430300; GUNSALUS CK, 1992, FEB ANN M AM ASS ADV; HAMILTON DP, 1992, SCIENCE, V255, P1345, DOI 10.1126/science.255.5050.1345; HANSEN KD, 1991, FASEB J, V5, P2512, DOI 10.1096/fasebj.5.11.1868976; MARSHALL E, 1993, SCIENCE, V259, P592, DOI 10.1126/science.8430304; 1993, FEB SIGM XI FOR ETH; 1992, 6TH ANN S PROT SOC S; 1992, RESPONSIBLE SCI ENSU, V1	9	34	36	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					148	&		10.1126/science.8305005	http://dx.doi.org/10.1126/science.8305005			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8305005				2022-12-28	WOS:A1993LL59600014
J	SINGH, N; YU, VL; MIELES, L; WAGENER, MM; MINER, RC; GAYOWSKI, T				SINGH, N; YU, VL; MIELES, L; WAGENER, MM; MINER, RC; GAYOWSKI, T			HIGH-DOSE ACYCLOVIR COMPARED WITH SHORT-COURSE PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						GANCYCLOVIR; ACYCLOVIR; CYTOMEGALOVIRUSES; LIVER TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS	MARROW TRANSPLANTATION; RENAL-TRANSPLANTATION; VIRUS INFECTION; RESISTANCE; REJECTION; REGIMENS; OKT3	Objective: To assess the efficacy of high-dose oral acyclovir therapy compared with preemptive, short-course ganciclovir therapy (administered only if cytomegalovirus [CMV] shedding occurred) to prevent CMV disease in liver transplant recipients. Design: A randomized controlled trial. Setting: Liver transplant center at a university-affiliated Veterans Affairs Medical Center. Patients: 47 consecutive patients having liver transplantation. Intervention: Patients were stratified by their CMV antibody status and the CMV antibody status of the donor and were randomly assigned to one of two treatment groups. Surveillance cultures for CMV (buffy coat and urine) were done every 2 to 4 weeks for 24 weeks in all patients. One group received high-dose oral acyclovir (800 mg four times daily). The experimental group received no acyclovir, but if surveillance cultures were positive, ganciclovir (5 mg/kg intravenously twice daily) was administered for 7 days. Measurements: Cytomegalovirus shedding and CMV disease were measured in the two groups. Results: Cytomegalovirus shedding before the onset of CMV disease occurred in 25% (6 of 24) of patients in the acyclovir group compared with 22% (5 of 23) in the experimental group. Cytomegalovirus disease developed in 29% (7 of 24) of the acyclovir group and in 4% (1 of 23) of the experimental group (P < 0.05). No hematologic toxicity occurred with ganciclovir. Conclusion: Oral acyclovir is ineffective prophylaxis against CMV in liver transplant recipients. Pre-emptive, short-course ganciclovir therapy in patients with CMV shedding was well tolerated and provided effective prophylaxis against subsequent CMV disease; this protocol targets the patients at risk for CMV disease and minimizes toxicity and expense.	VET AFFAIRS MED CTR, INFECT DIS SECT, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA USA; UNIV CALIF SAN FRANCISCO, MT ZION MED CTR, SAN FRANCISCO, CA 94120 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion								BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; CERRINA J, 1991, 5TH C EUR SOC ORG TR; Child C G, 1964, Major Probl Clin Surg, V1, P1; CHITWOOD K, 1992, 32ND INT C ANT AG CH; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; FREISE CE, 1991, TRANSPLANT P, V23, P1498; GEORGE MJ, 1992, 32ND INT C ANT AG CH; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; MARTIN M, 1992, 14TH P INT C TRANSPL; MCCARTHY M, 1991, Journal of the American Society of Nephrology, V2, P807; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MIELES LA, 1991, TRANSPLANT P, V23, P3016; OGRADY JG, 1988, LANCET, V2, P302; OH CS, 1988, TRANSPLANTATION, V45, P68, DOI 10.1097/00007890-198801000-00016; PAN SH, 1992, TRANSPLANT P, V24, P1466; RAND KH, 1978, NEW ENGL J MED, V298, P951, DOI 10.1056/NEJM197804272981705; RUBIN RH, 1991, NEW ENGL J MED, V324, P1057, DOI 10.1056/NEJM199104113241509; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SINGH N, 1988, J INFECT DIS, V158, P124, DOI 10.1093/infdis/158.1.124; SNYDMAN DR, 1991, 31ST INT C ANT AG CH; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WONG T, 1991, ANN INTERN MED, V115, P68, DOI 10.7326/0003-4819-115-1-68_1	29	165	167	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					375	381		10.7326/0003-4819-120-5-199403010-00004	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304654				2022-12-28	WOS:A1994MY49700004
J	OHYA, Y; BOTSTEIN, D				OHYA, Y; BOTSTEIN, D			DIVERSE ESSENTIAL FUNCTIONS REVEALED BY COMPLEMENTING YEAST CALMODULIN MUTANTS	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PEPTIDE COMPLEX; CELL-GROWTH; MUTATIONS; PROTEIN; MITOSIS; MYOSIN; CYCLE; GENE	Calmodulin, a cytoplasmic calcium-binding protein, is indispensable for eukaryotic cell growth. Examination of 14 temperature-sensitive yeast mutants bearing one or more phenylalanine to alanine substitutions in the single essential calmodulin gene of yeast (CMD1) revealed diverse essential functions. Mutations could be classified into four intragenic complementation groups. Each group showed different characteristic functional defects in actin organization, calmodulin localization, nuclear division, or bud emergence. Phenylalanine residues implicated in calmodulin localization and nuclear division are located in the amino-terminal half of the protein, whereas those implicated in actin organization and bud emergence are located in the carboxyl-terminal half.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	Stanford University					NIGMS NIH HHS [GM46888, GM46406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046888, R01GM046406, R37GM046406] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; BIGELIS R, 1977, ICN UCLA S MOL CELL, V8, P179; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; DAVIS TN, 1992, CELL CALCIUM, V13, P435, DOI 10.1016/0143-4160(92)90056-X; DAVIS TN, 1992, J CELL BIOL, V118, P607, DOI 10.1083/jcb.118.3.607; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FINK GR, 1966, GENETICS, V53, P445; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; MATTHIES HJ, 1993, J BIOL CHEM, V268; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER HC, 1993, J BIOL CHEM, V268; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OHYA Y, 1992, CELL CALCIUM, V13, P445, DOI 10.1016/0143-4160(92)90057-Y; OHYA Y, UNPUB; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; REHAKRANTZ LJ, 1990, GENETICS, V124, P213; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; SCHLESINGER MJ, 1963, COLD SPRING HARB SYM, V28, P539, DOI 10.1101/SQB.1963.028.01.072; STAROVASNIK MA, 1993, BIOCHEMISTRY-US, V32, P3261, DOI 10.1021/bi00064a008; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; SUN GH, 1992, PROTOPLASMA, V166, P110, DOI 10.1007/BF01320150	30	132	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					963	966		10.1126/science.8310294	http://dx.doi.org/10.1126/science.8310294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310294				2022-12-28	WOS:A1994MX16500034
J	FIELDING, JE; CUMBERLAND, WG; PETTITT, L				FIELDING, JE; CUMBERLAND, WG; PETTITT, L			IMMUNIZATION STATUS OF CHILDREN OF EMPLOYEES IN A LARGE CORPORATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEASLES; OPPORTUNITIES; BENEFITS; VACCINE; RISKS; COSTS	Objective.-To assess immunization levels for children of employees of a large corporation. Design.-A mail survey of a random sample of employees on the immunization history of one child per family. Setting.-US employees of Johnson & Johnson. Participants.-1500 employees with children born between 1984 and 1991. Main Outcome Measures.-Coverage rates for recommended vaccines at different ages up to 6 years. Main Results.-Only 45.2% and 55.3% of the study children at ages 2 and 6 years were current for all recommended immunizations (65.1% and 70.3%, respectively, excluding the Haemophilus influenzae type b vaccine). Using the minimum standard required by many states for school entry, the coverage level at age 6 years was 90.4%. Factors associated with higher immunization rates at age 2 years were the corporate health plan (choices), higher pay level, greater parental formal education, white race, and knowing when to initiate immunization. Lower immunization rates at age 2 years were associated with delayed receipt of the first dose of diphtheria, tetanus, and pertussis vaccine, use of city or county clinics, employee-reported barriers of difficulty leaving work, and provider access problems, but not cost of services. After adjusting for the effects of other variables through logistic regression, race, pay level, and plan choice were no longer significant. Modeling with the remaining variables predicted rates of adequate immunization at age 2 years from 15% to 81%. Conclusion.-Even in this relatively affluent group with good insurance (including immunizations), preschool immunization rates did not reach public health goals. Changing modifiable factors, such as knowing when to initiate immunization, enabling parents to leave work more easily, and improving provider access, might improve preschool immunization rates.	UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT BIOSTAT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; JOHNSON & JOHNSON, DEPT HLTH POLICY ANAL & PLANNING, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johnson & Johnson; Johnson & Johnson USA	FIELDING, JE (corresponding author), UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA.							BOBO JK, 1993, PEDIATRICS, V91, P308; CURTIS R, 1991, POLICY B REPORT EMPL; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; FARIZO KM, 1992, PEDIATRICS, V89, P589; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; HINMAN AR, 1990, PEDIATRICS, V86, P1064; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; KOPLAN JP, 1982, AM J DIS CHILD, V136, P362, DOI 10.1001/archpedi.1982.03970400080021; KOPLAN JP, 1979, NEW ENGL J MED, V301, P906, DOI 10.1056/NEJM197910253011703; LIU JTY, 1992, MED CHILDHOOD IMMUNI, P1; MARKS JS, 1979, PEDIATRICS, V64, P304; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1991, MMWR MORB MORTAL WKL, V40, P369; 1990, MMWR MORB MORTAL WKL, V39, P317; 1990, MMWR MORB MORTAL WKL, V39, P325; 1990, PHS9150212 US DEP HL, P521; 1992, MMWR MORB MORTAL WKL, V41, P668; 1992, STATE IMMUNIZATION R, P1; 1992, MMWR MORB MORTAL WKL, V41, P103; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, MMWR41SS6 CENT DIS C, P1; 1991, MMWR40RR1 CENT DIS C, P1; 1993, B US DEP LABOR, V2422; 1991, REPORT COMMITTEE INF, P10; 1992, MMWR MORB MORTAL WKL, V40, P888	27	66	67	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					525	530		10.1001/jama.271.7.525	http://dx.doi.org/10.1001/jama.271.7.525			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301767				2022-12-28	WOS:A1994MV42300035
J	DEFIJTER, CWH; OE, LP; NAUTA, JJP; VANDERMEULEN, J; VERBRUGH, HA; VERHOEF, J; DONKER, AJM				DEFIJTER, CWH; OE, LP; NAUTA, JJP; VANDERMEULEN, J; VERBRUGH, HA; VERHOEF, J; DONKER, AJM			CLINICAL EFFICACY AND MORBIDITY ASSOCIATED WITH CONTINUOUS CYCLIC COMPARED WITH CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEAL DIALYSIS, CONTINUOUS CYCLIC; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PERITONITIS	CAPD; HEMODIALYSIS; EXPERIENCE; MULTICENTER; PATIENT; RATES; CCPD	Objective: To assess the clinical efficacy and morbidity of continuous cyclic peritoneal dialysis compared with continuous ambulatory peritoneal dialysis with a Y-connector as renal replacement therapy. Design: Prospective, randomized study. Setting: University hospital. Patients: All new patients with end-stage renal failure consecutively entering the dialysis program from January 1988 through July 1991 were randomly assigned to receive continuous ambulatory peritoneal dialysis with a Y-connector or continuous cyclic peritoneal dialysis and were followed prospectively. Measurements: Patient and technique survival, dialysis adequacy, and (infectious) morbidity. Results: Forty-one patients (median age, 56 years; range, 18 to 86 years) started continuous ambulatory peritoneal dialysis with a Y-connector (follow-up, 688 patient-months), and 41 patients (median age, 54 years; range 21 to 76 years) started continuous cyclic peritoneal dialysis (follow-up, 723 patient-months). The two groups showed no significant differences in adequacy of dialysis (as assessed by blood pressure control and laboratory and neurologic variables) and patient or technique survival. Renal transplant was the primary reason for discontinuing the assigned dialysis technique in both groups. The average number of hospitalizations per patient-year was 1.0 using continuous ambulatory peritoneal dialysis with a Y-connector and 0.6 per patient-year using continuous cyclic peritoneal dialysis (P = 0.02), with a mean duration of 10.8 and 9.6 days per admission, respectively (not significant). Peritonitis occurred significantly less often in those receiving continuous cyclic peritoneal dialysis (0.94 compared with 0.51 episodes per patient-year; P = 0.03). No difference in causative pathogens was observed. Exit site infection rate was 0.38 episodes per patient-year in both groups. Conclusion: In an unselected patient group, continuous cyclic peritoneal dialysis was accompanied by significantly lower rates of peritonitis and dialysis-related hospital admission, whereas it was as effective as continuous ambulatory peritoneal dialysis with a Y-connector for patient and technique survival.	STATE UNIV UTRECHT HOSP,DEPT MICROBIOL,3584 CK UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center	DEFIJTER, CWH (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,DIV NEPHROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.							ABRAHAM G, 1988, PERITON DIALYSIS INT, V8, P211; [Anonymous], 1989, PERIT DIAL INT, V9, P159; BOEN ST, 1962, ASAIO T, V8, P256; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; BUNCHMAN TE, 1987, PERITON DIALYSIS INT, V7, P237; Cavoretto C A, 1983, Nephrol Nurse, V5, P33; DEFIJTER CWH, 1992, KIDNEY INT, V42, P947, DOI 10.1038/ki.1992.371; DIAZBUXO JA, 1989, PERITON DIALYSIS INT, V9, P9; DIAZBUXO JA, 1981, ARTIF ORGANS, V5, P157, DOI 10.1111/j.1525-1594.1981.tb03978.x; DIAZBUXO JA, 1985, KIDNEY INT       S17, V28, pS26; DOMOTO DT, 1989, ADV PERIT D, V5, P212; DUNN OJ, 1974, APPLIED STATISTICS A, P236; GOKAL R, 1989, J NEPHROL, V2, P95; HOLLEY JL, 1990, AM J KIDNEY DIS, V16, P133, DOI 10.1016/S0272-6386(12)80567-1; HOWARD RL, 1990, AM J KIDNEY DIS, V16, P469, DOI 10.1016/S0272-6386(12)80061-8; HUME R, 1971, J CLIN PATHOL, V24, P234, DOI 10.1136/jcp.24.3.234; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESHAVIAH PR, 1989, PERITON DIALYSIS INT, V9, P257; KREDIET RT, 1990, NETH J MED, V37, P215; LEVY M, 1990, PERITON DIALYSIS INT, V10, P263; LITTLE JA, 1987, STATISTICAL ANAL MIS, P195; LUPO A, 1988, ADV CONTINUOUS AMBUL, V4, P101; LUZAR MA, 1989, PERITON DIALYSIS INT, V9, P169; MAIORCA R, 1991, PERITON DIALYSIS INT, V11, P118; MAIORCA R, 1983, LANCET, V2, P642; MATTERN WD, 1988, CLIN NEPHROL, V30, pS49; NOLPH KD, 1991, AM J KIDNEY DIS, V17, P154, DOI 10.1016/S0272-6386(12)81121-8; NOLPH KD, 1988, DIALYSIS TRANSPLANT, V17, P457; OREOPOULOS DG, 1986, PERITON DIALYSIS B, V6, P2; POPOVICH RP, 1976, ABSTR AM SOC ART INT, V5, P64; PORT FK, 1992, KIDNEY INT, V42, P967, DOI 10.1038/ki.1992.375; PRICE CG, 1981, AM J NEPHROL, V1, P97, DOI 10.1159/000166501; ROCCO MV, 1985, PERITON DIALYSIS B, V5, P171; Rottembourg J, 1987, ADV CONTINUOUS AMBUL, P107; SCALAMOGNA A, 1990, NEPHRON, V55, P24, DOI 10.1159/000185913; SERKES KD, 1990, PERITON DIALYSIS INT, V10, P15; STRAUSS FG, 1991, ADV PERIT D, V7, P193; Suki W N, 1986, ASAIO Trans, V32, P572, DOI 10.1097/00002480-198609000-00041; VERGER C, 1987, PERIT DIAL B S, V7, pS82; VIGLINO G, 1989, PERITON DIALYSIS INT, V9, P165; WALLS J, 1981, ADV PERITONEAL DIALY, P141	41	100	104	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					264	271		10.7326/0003-4819-120-4-199402150-00002	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291819				2022-12-28	WOS:A1994MW10300002
J	POPE, AM				POPE, AM			ENVIRONMENTAL MEDICINE AND THE MEDICAL-SCHOOL CURRICULUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					417	417		10.1001/jama.271.6.417	http://dx.doi.org/10.1001/jama.271.6.417			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295300				2022-12-28	WOS:A1994MU49100003
J	BURHANS, WC; HUBERMAN, JA				BURHANS, WC; HUBERMAN, JA			DNA-REPLICATION ORIGINS IN ANIMAL-CELLS - A QUESTION OF CONTEXT	SCIENCE			English	Editorial Material							DIHYDROFOLATE-REDUCTASE DOMAIN; EGG EXTRACTS; CHO CELLS; PLASMID; LOCUS; SEQUENCE				BURHANS, WC (corresponding author), NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.							ARIIZUMI K, 1993, P NATL ACAD SCI USA, V90, P3695, DOI 10.1073/pnas.90.8.3695; BERBERICH S, 1993, DNA CELL BIOL, V12, P703, DOI 10.1089/dna.1993.12.703; BIAMONTI G, 1992, CHROMOSOMA, V102, pS24, DOI 10.1007/BF02451782; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; GILBERT DM, IN PRESS COLD SPRING; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; IGUCHIARIGA SMM, 1993, BIOCHIM BIOPHYS ACTA, V1172, P73, DOI 10.1016/0167-4781(93)90271-E; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; LEU TH, 1989, MOL CELL BIOL, V9, P523, DOI 10.1128/MCB.9.2.523; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; ORRWEAVER TL, 1991, BIOESSAYS, V13, P97, DOI 10.1002/bies.950130302; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SHINOMIYA T, 1991, NUCLEIC ACIDS RES, V19, P3935, DOI 10.1093/nar/19.14.3935; SHINOMIYA T, 1993, MOL CELL BIOL, V13, P4098, DOI 10.1128/MCB.13.7.4098; STILLMAN B, 1993, NATURE, V366, P506, DOI 10.1038/366506a0; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; VIRTAPEARLMAN VJ, 1993, MOL CELL BIOL, V13, P5931, DOI 10.1128/MCB.13.10.5931; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P258, DOI 10.1016/0167-4781(93)90194-I	34	35	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					639	640		10.1126/science.8303270	http://dx.doi.org/10.1126/science.8303270			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303270				2022-12-28	WOS:A1994MU96400035
J	WOLRAICH, ML; LINDGREN, SD; STUMBO, PJ; STEGINK, LD; APPELBAUM, MI; KIRITSY, MC				WOLRAICH, ML; LINDGREN, SD; STUMBO, PJ; STEGINK, LD; APPELBAUM, MI; KIRITSY, MC			EFFECTS OF DIETS HIGH IN SUCROSE OR ASPARTAME ON THE BEHAVIOR AND COGNITIVE PERFORMANCE OF CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERACTIVE BOYS; AMINO-ACIDS; PHENYLKETONURIA; INGESTION; ADULTS	Background. Both dietary sucrose and the sweetener aspartame have been reported to produce hyperactivity and other behavioral problems in children. Methods. We conducted a double-blind controlled trial with two groups of children: 25 normal preschool children (3 to 5 years of age), and 23 school-age children (6 to 10 years) described by their parents as sensitive to sugar. The children and their families followed a different diet for each of three consecutive three-week periods. One diet was high in sucrose with no artificial sweeteners, another was low in sucrose and contained aspartame as a sweetener, and the third was low in sucrose and contained saccharin (placebo) as a sweetener. All the diets were essentially free of additives, artificial food coloring, and preservatives. The children's behavior and cognitive performance were evaluated weekly. Results. The preschool children ingested a mean (+/-SD) of 5600+/-2100 mg of sucrose per kilogram of body weight per day while on the sucrose diet, 38+/-13 mg of aspartame per kilogram per day while on the aspartame diet, and 12+/-4.5 mg of saccharin per kilogram per day while on the saccharin diet. The school-age children considered to be sensitive to sugar ingested 4500+/-1200 mg of sucrose per kilogram, 32+/-8.9 mg of aspartame per kilogram, and 9.9+/-3.9 mg of saccharin per kilogram, respectively. For the children described as sugar-sensitive, there were no significant differences among the three diets in any of 39 behavioral and cognitive variables. For the preschool children, only 4 of the 31 measures differed significantly among the three diets, and there was no consistent pattern in the differences that were observed. Conclusions. Even when intake exceeds typical dietary levels, neither dietary sucrose nor aspartame affects children's behavior or cognitive function.	VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37240; VANDERBILT UNIV,DEPT PSYCHOL & HUMAN DEV,NASHVILLE,TN 37240; UNIV IOWA,COLL MED,CLIN RES CTR,IOWA CITY,IA 52242	Vanderbilt University; Vanderbilt University; University of Iowa					NCRR NIH HHS [RR59] Funding Source: Medline; NICHD NIH HHS [HD24751] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024751] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAMS IJ, 1986, 1986 P INT ASP WORKS; [Anonymous], 1984, WIDE RANGE ACHIEVEME; BAKER H, 1975, P49; Barkley R. A., 1998, ATTENTION DEFICIT HY, V2nd; COSTELLO A, 1985, TESTING NIMH DIAGNOS; CROOK WG, 1975, PEDIATR CLIN N AM, V22, P227; ELSAS LJ, 1988, DIETARY PHENYLALANIN, P187; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; GOLDMAN JA, 1986, J ABNORM CHILD PSYCH, V14, P565, DOI 10.1007/BF01260524; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; KNIGHTS RM, 1968, PERCEPT MOTOR SKILL, V26, P643, DOI 10.2466/pms.1968.26.2.643; Levy Harvey L., 1993, Pediatric Research, V33, p130A; Lindgren S.D., 1987, ADV BEHAV ASSESSMENT, V3, P57; LINDGREN SD, 1991, PEDIATRIC ASSESSMENT; LINDGREN SD, 1992, J AM ACAD SCHILD ADO, V31, P197; MILICH R, 1986, CLIN PSYCHOL REV, V6, P493, DOI 10.1016/0272-7358(86)90034-6; OBRIEN D, 1968, LABORATORY MANUAL PE, P114; PARDRIDGE WM, 1986, JAMA-J AM MED ASSOC, V256, P2678, DOI 10.1001/jama.256.19.2678; Pelham W. E., 1987, ADV BEHAVIORAL ASSES, V3, P3; PORRINO LJ, 1983, ARCH GEN PSYCHIAT, V40, P681; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; ROBERTS MA, 1990, J ABNORM CHILD PSYCH, V18, P131, DOI 10.1007/BF00910726; ROBERTS MA, 1981, J ABNORM CHILD PSYCH, V9, P371, DOI 10.1007/BF00916841; Roe JH, 1943, J BIOL CHEM, V147, P399; ROURKE BP, 1973, J CONSULT CLIN PSYCH, V41, P128, DOI 10.1037/h0035613; STEGINK LD, 1985, AM J CLIN NUTR, V42, P220, DOI 10.1093/ajcn/42.2.220; STEGINK LD, 1991, AM J CLIN NUTR, V53, P670, DOI 10.1093/ajcn/53.3.670; SWANSON JM, 1980, TREATMENT HYPERACTIV, P131; ULLMANN RK, 1984, PSYCHOPHARMACOL BULL, V20, P160; WAISBREN SE, 1984, J PEDIATR-US, V105, P955, DOI 10.1016/S0022-3476(84)80088-8; WENDER E, 1991, DIET BEHAVIOR, P65; Winer BJ, 1991, STATISTICAL PRINCIPL; WOLFNOVAK LC, 1990, METABOLISM, V39, P391, DOI 10.1016/0026-0495(90)90254-A; WOLRAICH ML, 1988, DIETARY PHENYLALANIN, P201; WURTMAN RJ, 1983, NEW ENGL J MED, V309, P429; 1974, WECHSLER INTELLIGENC; 1967, WECHSLER PRESCHOOL P; 1989, RECOMMENDED DIETARY; 1976, 75F0355 FOOD DRUG AD, V103	39	161	163	1	94	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					301	307		10.1056/NEJM199402033300501	http://dx.doi.org/10.1056/NEJM199402033300501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU489	8277950	Bronze			2022-12-28	WOS:A1994MU48900001
J	DANCIS, A; YUAN, DS; HAILE, D; ASKWITH, C; EIDE, D; MOEHLE, C; KAPLAN, J; KLAUSNER, RD				DANCIS, A; YUAN, DS; HAILE, D; ASKWITH, C; EIDE, D; MOEHLE, C; KAPLAN, J; KLAUSNER, RD			MOLECULAR CHARACTERIZATION OF A COPPER TRANSPORT PROTEIN IN SACCHAROMYCES-CEREVISIAE - AN UNEXPECTED ROLE FOR COPPER IN IRON TRANSPORT	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEINS; FERRIC REDUCTASE; SHUTTLE VECTORS; YEAST; METALLOTHIONEIN; CERULOPLASMIN; RESISTANCE; SEQUENCE; SYSTEM	We report the identification and characterization of CTR1, a gene in the yeast S. cerevisiae that encodes a multispanning plasma membrane protein specifically required for high affinity copper transport into the cell. The predicted protein contains a methionine- and serine-rich domain that includes 11 examples of the sequence Met-X2-Met, a motif noted in proteins involved in bacterial copper metabolism. CTR1 mutants and deletion strains have profound deficiency in ferrous iron uptake, thus revealing a requirement for copper in mediating ferrous transport into the cell. Genetic evidence suggests that the target for this requirement is the FET3 gene (detailed in a companion study), predicted to encode a copper-containing protein that acts as a cytosolic ferro-oxidase. These findings provide an unexpected mechanistic link between the uptake of copper and iron.	UNIV UTAH, COLL MED, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM & MOLEC BIOL, DULUTH, MN 55812 USA; NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA	Utah System of Higher Education; University of Utah; University of Minnesota System; University of Minnesota Duluth; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	DANCIS, A (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Cammack R, 1990, IRON TRANSPORT STORA, P17; CAROLINE D, 1987, NUCLEIC ACIDS RES, V15, P4655; CARTWRIGHT GE, 1956, BLOOD, V11, P143, DOI 10.1182/blood.V11.2.143.143; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; COOPER T, 1982, MOL BIOL YEAST SACCH, P436; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GATIGNOL A, 1990, GENE, V91, P35, DOI 10.1016/0378-1119(90)90159-O; GUBLER CJ, 1952, BLOOD, V7, P1075, DOI 10.1182/blood.V7.11.1075.1075; Halliwell B, 1988, FREE RADICALS BIOL M; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Karlin K.D., 1993, BIOINORGANIC CHEM CO; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAHEY ME, 1952, BLOOD, V7, P1053, DOI 10.1182/blood.V7.11.1053.1053; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LIN CM, 1990, J BIOL CHEM, V265, P9194; LINDER MC, 1991, BIOCH COPPER, P1; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1989, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Solomon E. P., 1993, BIOINORGANIC CHEM CO; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215; [No title captured]	43	566	579	0	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					393	402		10.1016/0092-8674(94)90345-X	http://dx.doi.org/10.1016/0092-8674(94)90345-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293472				2022-12-28	WOS:A1994MU67800021
J	NOSSAL, GJV				NOSSAL, GJV			NEGATIVE SELECTION OF LYMPHOCYTES	CELL			English	Review							T-CELL-RECEPTOR; HISTOCOMPATIBILITY COMPLEX ANTIGENS; FUNCTIONAL CLONAL DELETION; B-CELLS; TRANSGENIC MICE; SELF-TOLERANCE; IMMUNOLOGICAL-TOLERANCE; PRIMARY IMMUNIZATION; VIRUS-INFECTION; INDUCTION				NOSSAL, GJV (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.				NIAID NIH HHS [AI-03958] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI003958] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; ERIS JM, 1994, IN PRESS P NATL ACAD; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FULCHER DA, 1994, IN PRESS J EXP MED; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOOD MF, 1983, P NATL ACAD SCI-BIOL, V80, P3045, DOI 10.1073/pnas.80.10.3045; GOODNOW CC, 1991, NATURE, V352, P532, DOI 10.1038/352532a0; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HAMMERLING GJ, 1993, IMMUNOL REV, V133, P93, DOI 10.1111/j.1600-065X.1993.tb01511.x; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HEATH WR, 1993, J EXP MED, V178, P1807, DOI 10.1084/jem.178.5.1807; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HODGKIN PD, 1991, J IMMUNOL, V147, P3696; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARVELAS M, 1992, P NATL ACAD SCI USA, V89, P3150, DOI 10.1073/pnas.89.7.3150; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MAMULA MJ, 1993, J EXP MED, V177, P567, DOI 10.1084/jem.177.2.567; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MAMULA MJ, 1993, IN PRESS J IMMUNOL; METCALF ES, 1977, J IMMUNOL, V118, P2111; MILLER JFAP, 1993, IMMUNOL REV, V133, P131, DOI 10.1111/j.1600-065X.1993.tb01514.x; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJ, 1971, ANTIGENS LYMPHOID CE; NOSSAL GJV, 1989, P NATL ACAD SCI USA, V86, P4679, DOI 10.1073/pnas.86.12.4679; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; NOSSAL GJV, 1975, J EXP MED, V141, P904; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; NOSSAL GJV, 1981, P NATL ACAD SCI-BIOL, V78, P3844, DOI 10.1073/pnas.78.6.3844; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; NOSSAL GJV, 1990, P NATL ACAD SCI USA, V87, P1615, DOI 10.1073/pnas.87.4.1615; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIKE BE, 1981, J IMMUNOL, V126, P89; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1992, CURR OPIN IMMUNOL, V4, P140, DOI 10.1016/0952-7915(92)90003-W; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; VONBOEHMER H, 1984, EUR J IMMUNOL, V14, P1048, DOI 10.1002/eji.1830141116; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J	67	720	736	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					229	239		10.1016/0092-8674(94)90331-X	http://dx.doi.org/10.1016/0092-8674(94)90331-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293461				2022-12-28	WOS:A1994MU67800007
J	BOTEROVELEZ, M; CURTIS, JJ; WARNOCK, DG				BOTEROVELEZ, M; CURTIS, JJ; WARNOCK, DG			LIDDLES SYNDROME REVISITED - A DISORDER OF SODIUM-REABSORPTION IN THE DISTAL TUBULE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CLINICAL SPECTRUM; ALDOSTERONE		UNIV ALABAMA,DEPT MED,DIV NEPHROL,UAB STN,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR NEPHROL RES & TRAINING,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,BIRMINGHAM,AL; UNIV ALABAMA,DEPT PHYSIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,GEN CLIN RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCRR NIH HHS [5 M01 RR00032] Funding Source: Medline; NIDDK NIH HHS [P50-DK39258] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039258] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; GARDNER JD, 1971, J CLIN INVEST, V50, P2253, DOI 10.1172/JCI106722; GUTHRIE GP, 1983, J CLIN ENDOCR METAB, V56, P87, DOI 10.1210/jcem-56-1-87; KOTCHEN TA, 1982, J CLIN ENDOCR METAB, V54, P808, DOI 10.1210/jcem-54-4-808; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; NAKADA T, 1987, J UROLOGY, V137, P636, DOI 10.1016/S0022-5347(17)44161-9; NIESZPOREK T, 1989, International Urology and Nephrology, V21, P233, DOI 10.1007/BF02550813; PRATT JH, 1989, NEW ENGL J MED, V321, P1152, DOI 10.1056/NEJM198910263211703; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; RODRIGUEZ JA, 1981, T ASSOC AM PHYSICIAN, V94, P172; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; STANEK B, 1987, CLIN NEPHROL, V28, P186; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; WANG C, 1981, J CLIN ENDOCR METAB, V52, P1027, DOI 10.1210/jcem-52-5-1027	17	284	297	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					178	181		10.1056/NEJM199401203300305	http://dx.doi.org/10.1056/NEJM199401203300305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264740	Bronze			2022-12-28	WOS:A1994MQ86300005
J	ABELIOVICH, A; CHEN, C; GODA, Y; SILVA, AJ; STEVENS, CF; TONEGAWA, S				ABELIOVICH, A; CHEN, C; GODA, Y; SILVA, AJ; STEVENS, CF; TONEGAWA, S			MODIFIED HIPPOCAMPAL LONG-TERM POTENTIATION IN PKC-GAMMA-MUTANT MICE	CELL			English	Article							PROTEIN-KINASE-C; INDUCTION; EXPRESSION; CALMODULIN; LTP; CA1; TRANSMISSION; MAINTENANCE; ACTIVATION; CURRENTS	Calcium-phospholipid-dependent protein kinase (PKC) has long been suggested to play an important role in modulating synaptic efficacy. We have created a strain of mice that lacks the gamma subtype of PKC to evaluate the significance of this brain-specific PKC isozyme in synaptic plasticity. Mutant mice are viable, develop normally, and have synaptic transmission that is indistinguishable from wild-type mice. Long-term potentiation (LTP), however, is greatly diminished in mutant animals, while two other forms of synaptic plasticity, long-term depression and paired-pulse facilitation, are normal. Surprisingly, when tetanus to evoke LTP was preceded by a low frequency stimulation, mutant animals displayed apparently normal LTP. We propose that PKCgamma is not part of the molecular machinery that produces LTP but is a key regulatory component.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute	ABELIOVICH, A (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021; Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020	Silva, Alcino/0000-0002-1587-4558; Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [5 RO1 NS 12961-17] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BENARI Y, 1992, TRENDS NEUROSCI, V15, P333, DOI 10.1016/0166-2236(92)90049-E; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUANG FL, 1988, J NEUROSCI, V8, P4734; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; JAHR CE, 1990, J NEUROSCI, V10, P3178; KLANN E, 1991, J BIOL CHEM, V266, P24253; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REYMANN KG, 1968, BRAIN RES, V463, P388; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SAE K, 1988, J NEUROSCI, V8, P3850; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	32	407	415	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1253	1262		10.1016/0092-8674(93)90613-U	http://dx.doi.org/10.1016/0092-8674(93)90613-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269509				2022-12-28	WOS:A1993MP86900005
J	SONTHEIMER, EJ; STEITZ, JA				SONTHEIMER, EJ; STEITZ, JA			THE U5 AND U6 SMALL NUCLEAR RNAS AS ACTIVE-SITE COMPONENTS OF THE SPLICEOSOME	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SELF-SPLICING INTRONS; GROUP-I INTRONS; RIBONUCLEOPROTEIN-PARTICLES; MUTATIONAL ANALYSIS; CATALYTIC CORE; HELA-CELLS; P-SITE; YEAST	Five small nuclear RNAs (U1, U2, U4, U5, and U6) participate in precursor messenger RNA (pre-mRNA) splicing. To probe their interactions within the active center of the mammalian spliceosome, substrates containing a single photoactivatable 4-thiouridine residue adjacent to either splice site were synthesized, and crosslinks were induced during the course of in vitro splicing. An invariant loop sequence in U5 small nuclear RNA contacts exon 1 before and after the first step of splicing because a crosslink between U5 and the last residue of exon 1 appeared in the pre-mRNA and then in the cutoff exon 1 intermediate. Both of these crosslinked species could undergo subsequent splicing, indicating that the crosslinks reflect afunctional interaction that is maintained through both reaction steps. The same U5 loop aligns the two exons for ligation since the first residue of exon 2 also became crosslinked to U5 in the lariat intermediate. An invariant sequence in U6 RNA became crosslinked to the conserved second position of the intron within both the lariat intermediate and the lariat intron product. On the basis of these results, several conformational arrangements of small nuclear RNAs within the spliceosomal active center can be distinguished, and additional mechanistic parallels between the spliceosome and self-splicing introns can be drawn.	YALE UNIV, SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06536 USA	Howard Hughes Medical Institute; Yale University				Sontheimer, Erik/0000-0002-0881-0310	NIGMS NIH HHS [GM26514] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CORTES JJ, IN PRESS EMBO J; DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DENMAN R, 1988, NUCLEIC ACIDS RES, V16, P165, DOI 10.1093/nar/16.1.165; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MARCINIEC TE, COMMUNICATION; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKASHIMA K, 1980, NATURE, V286, P226, DOI 10.1038/286226a0; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; Smith Coby, UNPUB; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1992, MOL CELL BIOL, V12, P734, DOI 10.1128/MCB.12.2.734; SONTHEIMER EJ, UNPUB; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, IN PRESS P NATL ACAD; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YU YT, IN PRESS CELL; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; [No title captured]	66	318	344	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					1989	1996		10.1126/science.8266094	http://dx.doi.org/10.1126/science.8266094			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266094				2022-12-28	WOS:A1993MN10800027
J	KIRSCH, J; WOLTERS, I; TRILLER, A; BETZ, H				KIRSCH, J; WOLTERS, I; TRILLER, A; BETZ, H			GEPHYRIN ANTISENSE OLIGONUCLEOTIDES PREVENT GLYCINE RECEPTOR CLUSTERING IN SPINAL NEURONS	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; GAMMA-AMINOBUTYRIC ACID; MONOCLONAL-ANTIBODIES; POSTSYNAPTIC MEMBRANE; CENTRAL SYNAPSES; PROTEIN; TUBULIN; LOCALIZATION; POLYPEPTIDE; COMPLEX	EACH neuron in the mammalian brain carries many postsynaptic membrane specializations containing high densities of receptors that mediate signal transduction upon neurotransmitter release from the apposed nerve terminal1. Little is known about the mechanisms by which receptors are transported to and anchored at postsynaptic sites, but extracellular2 as well as intracellular3 components may be involved. Ultrastructural studies have shown that the peripheral membrane protein gephyrin4, Which co-purifies with the postsynaptic inhibitory glycine receptor (GlyR) upon affinity chromatography5,6, is situated on the cytoplasmic face of glycinergic postsynaptic membranes7-9. Moreover, gephyrin binds with high affinity to polymerized tubulin and has been postulated to link the GlyR to the subsynaptic cytoskeleton10. Here we report that treatment of rat spinal neurons in culture with gephyrin antisense oligonucleotides prevents the formation of GlyR clusters in the dendritic plasma membrane. Thus, gephyrin is essential for localizing the GlyR to presumptive postsynaptic plasma membrane specializations.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY; INST PASTEUR,DEPT BIOTECHNOL,INSERM,U261,F-750 PARIS 15,FRANCE	Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm)				TRILLER, Antoine/0000-0002-7530-1233				ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BLOCH RJ, 1986, J CELL BIOL, V102, P1447, DOI 10.1083/jcb.102.4.1447; BLOMBERG F, 1977, J CELL BIOL, V74, P204, DOI 10.1083/jcb.74.1.204; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BRIDGMAN PC, 1989, J CELL BIOL, V105, P1829; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; HIROKAWA N, 1982, J NEUROCYTOL, V11, P487, DOI 10.1007/BF01257990; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; JASMIN BJ, 1991, J NATURE, V344, P673; KIRSCH J, 1993, EUR J NEUROSCI, V5, P1109, DOI 10.1111/j.1460-9568.1993.tb00965.x; KIRSCH J, 1990, J NEUROCHEM, V55, P1031, DOI 10.1111/j.1471-4159.1990.tb04593.x; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, BRAIN RES, V621, P301, DOI 10.1016/0006-8993(93)90120-C; LAROCHELLE WJ, 1990, J NEUROSCI, V10, P3460; MCMAHAN UJ, 1989, DEV NEUROSCI-BASEL, V11, P227, DOI 10.1159/000111903; NGHIEM HO, 1983, P NATL ACAD SCI-BIOL, V80, P6403, DOI 10.1073/pnas.80.20.6403; NICOLA MA, 1992, NEUROSCI LETT, V138, P173, DOI 10.1016/0304-3940(92)90499-W; PETERS A, 1992, FINE STRUCTURE NERVO; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; STEPHENS RE, 1986, BIOL CELL, V57, P95, DOI 10.1111/j.1768-322X.1986.tb00467.x; TRILLER A, 1987, J CELL BIOL, V104, P947, DOI 10.1083/jcb.104.4.947; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WALKER JH, 1984, EMBO J, V3, P2287, DOI 10.1002/j.1460-2075.1984.tb02127.x	30	368	377	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					745	748		10.1038/366745a0	http://dx.doi.org/10.1038/366745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264797				2022-12-28	WOS:A1993MN26400029
J	UYEDA, TQP; SPUDICH, JA				UYEDA, TQP; SPUDICH, JA			A FUNCTIONAL RECOMBINANT MYOSIN-II LACKING A REGULATORY LIGHT-CHAIN BINDING-SITE	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; HEAVY-CHAIN; ELECTRON-MICROSCOPY; MUSCLE-CONTRACTION; NONMUSCLE MYOSIN; ACTIN-FILAMENTS; SCALLOP MYOSIN; PHOSPHORYLATION; GENE; SUBFRAGMENT-1	Myosin II, which converts the energy of adenosine triphosphate hydrolysis into the movement of actin filaments, is a hexamer of two heavy chains, two essential light chains, and two regulatory light chains (RLCs). Dictyostelium myosin II is known to be regulated in vitro by phosphorylation of the RLC. Cells in which the wild-type myosin II heavy chain was replaced with a recombinant form that lacks the binding site for RLC carried out cytokinesis and almost normal development, processes known to be dependent on functional myosin II. Characterization of the purified recombinant protein suggests that a complex of RLC and the RLC binding site of the heavy chain plays an inhibitory role for adenosine triphosphatase activity and a structural role for the movement of myosin along actin.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University					NIGMS NIH HHS [GM46551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046551, R01GM046551] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLEY SA, 1986, EUR J CELL BIOL, V42, P10; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHISHOLM RL, 1993, MAY INT DICT M NOORD; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COOKE R, 1984, CONTRACTILE MECHANIS, P413; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOSOYA H, 1991, J BIOL CHEM, V266, P22173; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MERINO E, 1992, BIOTECHNIQUES, V12, P508; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPEL KM, UNPUB; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SPUDICH JA, 1989, CELL REGUL, V1, P11; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; UYEDA TQP, UNPUB; VALE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6775, DOI 10.1073/pnas.81.21.6775; VIBERT P, 1982, J MOL BIOL, V157, P299, DOI 10.1016/0022-2836(82)90236-4; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WAKABAYASHI K, 1993, BIOCHEMISTRY-US, V32, P2455; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701	54	114	114	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1867	1870		10.1126/science.8266074	http://dx.doi.org/10.1126/science.8266074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266074				2022-12-28	WOS:A1993MM51100034
J	NICHOLSON, DA; DRISCOLL, PA				NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE ABDOMEN .2.	BRITISH MEDICAL JOURNAL			English	Article											NICHOLSON, DA (corresponding author), SALFORD HOSP,SALFORD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1410	1414		10.1136/bmj.307.6916.1410	http://dx.doi.org/10.1136/bmj.307.6916.1410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274897	Green Published, Bronze			2022-12-28	WOS:A1993MK42000027
J	FRENCH, J				FRENCH, J			THE LONG-TERM THERAPEUTIC MANAGEMENT OF EPILEPSY	ANNALS OF INTERNAL MEDICINE			English	Review							COMPLEX-PARTIAL SEIZURES; ACID HEPATIC FATALITIES; TONIC CLONIC SEIZURES; CARBAMAZEPINE NEUROTOXICITY; CEREBELLAR DEGENERATION; INTRACTABLE EPILEPSY; HYSTERICAL SEIZURES; PHENYTOIN THERAPY; DRUG-INTERACTIONS; SODIUM VALPROATE	Objective: To provide a rational strategy for the evaluation and long-term management of epilepsy. Data Sources: Articles written between 1964 and 1993, obtained from a MEDLINE search on epilepsy-related topics as well as from the author's personal files, major reference books on antiepileptic drugs, and references identified from these books. Study Selection: Articles were selected if they contained well-documented information comparing antiepileptic drugs, represented controlled clinical trials, or were considered ''key'' articles of clinical relevance. Data Synthesis: Epilepsy is a chronic condition requiring careful long-term management. The treatment is complex, involving classification and diagnosis, selection and monitoring of the appropriate antiepileptic agent, and evaluation of the chosen drug's side effects and drug interactions. Because these side effects increase when drugs are combined, monotherapy is recommended. Long-term management issues and optimal drug selection differ from patient to patient. If seizures are not controlled by medication, the patient may have been misdiagnosed or misclassified. Noncompliance, a major cause of apparent unresponsiveness to treatment, should also be ruled out. Recognizing that current therapy is not ideal for many patients, new pharmacologic and surgical therapies are briefly discussed. Conclusions: Physicians can pursue a rational strategy for the management of epilepsy if they understand the risks and benefits of various pharmacologic and therapeutic options and if they maintain open lines of communication with the patient.	UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	FRENCH, J (corresponding author), GRAD HOSP PHILADELPHIA, CTR COMPREHENS EPILEPSY, DEPT NEUROL, 1 GRAD PLAZA, 1800 LOMBARD ST, PHILADELPHIA, PA 19146 USA.		French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027				AGUWA CN, 1990, CURR THER RES CLIN E, V47, P990; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; [Anonymous], 1990, Lancet, V335, P1114; BOOKER HE, 1982, ANTIEPILEPTIC DRUGS, P341; BOURGEOIS B, 1987, EPILEPSIA, V28, pS8, DOI 10.1111/j.1528-1157.1987.tb05769.x; BRODIE MJ, 1986, BRIT MED J, V292, P1170, DOI 10.1136/bmj.292.6529.1170-a; BROWNE TR, 1983, NEUROLOGY, V33, P414, DOI 10.1212/WNL.33.4.414; BROWNE TR, 1973, EPILEPSIA, V14, P277, DOI 10.1111/j.1528-1157.1973.tb03965.x; BROWNE TR, 1975, NEUROLOGY, V25, P515, DOI 10.1212/WNL.25.6.515; BROWNE TR, 1983, EPILEPSY DIAGNOSIS M, P254; CASCINO GD, 1990, MAYO CLIN PROC, V65, P1578, DOI 10.1016/S0025-6196(12)62193-4; CHADWICK DW, 1987, EPILEPSIA, V28, pS12, DOI 10.1111/j.1528-1157.1987.tb05766.x; CHRISTIANSEN C, 1974, ACTA NEUROL SCAND, V50, P631; COHEN RJ, 1982, ANN NEUROL, V11, P391, DOI 10.1002/ana.410110413; COKER SB, 1995, MED TREATMENT EPILEP, P389; COVANIS A, 1982, EPILEPSIA, V23, P693, DOI 10.1111/j.1528-1157.1982.tb05085.x; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; CRAMER JA, 1991, PATIENT COMPLIANCE M, P134; CRITCHLEY EMR, 1976, J NEUROL NEUROSUR PS, V39, P498, DOI 10.1136/jnnp.39.5.498; DALTON MJ, 1986, EPILEPSIA, V27, P553, DOI 10.1111/j.1528-1157.1986.tb03583.x; DESAI BT, 1982, ARCH NEUROL-CHICAGO, V39, P202, DOI 10.1001/archneur.1982.00510160008002; DINESEN H, 1984, ACTA NEUROL SCAND, V70, P65; DODRILL CB, 1991, NEUROLOGY, V41, P141, DOI 10.1212/WNL.41.1.141; DOWSE R, 1991, S AFR MED J, V80, P550; DREIFUSS FE, 1987, NEUROLOGY, V37, P379, DOI 10.1212/WNL.37.3.379; DREIFUSS FE, 1989, NEUROLOGY, V39, P201, DOI 10.1212/WNL.39.2.201; DREIFUSS FE, 1987, SURGICAL TREATMENT E, P31; Dupuis R E, 1991, AACN Clin Issues Crit Care Nurs, V2, P639; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; FRASER DG, 1980, CLIN PHARMACOL THER, V27, P165, DOI 10.1038/clpt.1980.25; GALLAGHER BB, 1973, NEUROLOGY, V23, P145, DOI 10.1212/WNL.23.2.145; GALLAGHER BB, 1992, MED TREATMENT EPILEP, V357, P62; GALLASSI R, 1988, ARCH NEUROL-CHICAGO, V45, P892, DOI 10.1001/archneur.1988.00520320082020; GASTAUT H, 1985, J CLIN NEUROPHYSIOL, V2, P313, DOI 10.1097/00004691-198510000-00001; GHATAK NR, 1976, NEUROLOGY, V26, P818, DOI 10.1212/WNL.26.9.818; GILMAN ME, 1983, CLIN PHARMACY, V2, P258; GRAF WD, 1987, EPILEPSIA, V28, P606; GRAM L, 1989, ANTIEPILEPTIC DRUGS, P555; GRASELA TH, 1985, DEV PHARMACOL THERAP, V8, P374, DOI 10.1159/000457062; GRAVES NM, 1991, DICP ANN PHARMAC, V25, P978, DOI 10.1177/106002809102500913; GUGGENHEIM MA, 1987, ANN NEUROL, V22, P412; HAHN TJ, 1976, DRUGS, V12, P201, DOI 10.2165/00003495-197612030-00003; HANSEN JM, 1979, ACTA MED SCAND, P106; HANSON JW, 1976, J PEDIATR-US, V89, P662, DOI 10.1016/S0022-3476(76)80414-3; HART RG, 1982, ANN NEUROL, V11, P309, DOI 10.1002/ana.410110312; HEMPEL E, 1976, DRUGS, V12, P442, DOI 10.2165/00003495-197612060-00003; HOSKING G, 1989, 4TH INT S SOD VALPR, P71; HYMAN NM, 1979, NEUROLOGY, V29, P1177, DOI 10.1212/WNL.29.8.1177; JANZ D, 1975, EPILEPSIA, V16, P159, DOI 10.1111/j.1528-1157.1975.tb04732.x; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; JAWAD S, 1987, EPILEPSY RES, V1, P194, DOI 10.1016/0920-1211(87)90041-6; JEAVONS PM, 1982, ANTIEPILEPTIC DRUGS, P601; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KAY L, 1985, BRIT J CLIN PHARMACO, V20, P323, DOI 10.1111/j.1365-2125.1985.tb05071.x; KELLY TE, 1984, AM J MED GENET, V19, P413, DOI 10.1002/ajmg.1320190302; KERNEN T, 1983, CHRONIC TOXICITY ANT, P201; KEYSER A, 1990, PHARM WEEKBLAD, V12, P145, DOI 10.1007/BF01970155; KING DW, 1982, NEUROLOGY, V32, P18, DOI 10.1212/WNL.32.1.18; KOTAGAL P, 1992, MED TREATMENT EPILEP, P225; KRASINSKI K, 1982, PEDIATR INFECT DIS J, V1, P232, DOI 10.1097/00006454-198207000-00008; KUTT H, 1985, RECENT ADV EPILEPSY, P183; KUTT H, 1989, ANTIEPILEPTIC DRUGS, P313; KUTT H, 1989, ANTIEPILEPTIC DRUGS, P533; Lairy C, 1964, REV NEUROL, V110, P225; LEPPIK IE, 1990, POSTGRAD MED, V88, P253, DOI 10.1080/00325481.1990.11716375; LEPPIK IE, 1992, MED TREATMENT EPILEP, P655; LEPPIK IE, 1989, ANTIEPILEPTIC DRUGS, P983; LESSER RP, 1984, NEUROLOGY, V34, P707, DOI 10.1212/WNL.34.6.707; LEVINE M, 1985, NEUROLOGY, V35, P562, DOI 10.1212/WNL.35.4.562; LEVY R, 1989, ANTIEPILEPTIC DRUGS; LINDHOUT D, 1984, LANCET, V2, P396; LOISEAU P, 1989, ANTIEPILEPTIC DRUGS, P533; LOTT RS, 1988, APPL THER, P1369; MACPHEE GJA, 1986, LANCET, V1, P700; MARSAN CA, 1970, EPILEPSIA, V11, P361, DOI 10.1111/j.1528-1157.1970.tb03903.x; Mattson R H, 1988, Am J Med, V84, P23, DOI 10.1016/0002-9343(88)90053-8; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1990, SEMIN NEUROL, V10, P406, DOI 10.1055/s-2008-1063985; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MEADOR KJ, 1990, NEUROLOGY, V40, P391, DOI 10.1212/WNL.40.3_Part_1.391; MIHALY GW, 1979, EUR J CLIN PHARMACOL, V16, P23, DOI 10.1007/BF00644962; MONKS A, 1978, BRIT J CLIN PHARMACO, V6, P487, DOI 10.1111/j.1365-2125.1978.tb00871.x; MORRIS HH, 1984, CLEVELAND CLIN Q, V51, P255, DOI 10.3949/ccjm.51.2.255; MURPHY MJ, 1981, LANCET, V1, P41; OLESEN OV, 1967, ARCH NEUROL-CHICAGO, V16, P642, DOI 10.1001/archneur.1967.00470240080011; PAINTER MJ, 1989, ANTIEPILEPTIC DRUGS, P329; Pedley TA, 1992, MED TREATMENT EPILEP, P3; PENRY JK, 1986, EPILEPSY DIAGNOSIS M, P14; PERUCCA E, 1982, CLIN PHARMACOKINET, V7, P57, DOI 10.2165/00003088-198207010-00004; Phenytoin Leppik I., 1992, MED TREATMENT EPILEP, P279; PIPPENGER CE, 1984, CLEVELAND CLIN Q, V51, P241, DOI 10.3949/ccjm.51.2.241; PORTER RJ, 1988, CURR OPIN NEUROL NEU, V1, P206; PUGH CB, 1991, CLIN PHARMACY, V10, P335; RAMANI V, 1982, ARCH NEUROL-CHICAGO, V39, P78, DOI 10.1001/archneur.1982.00510140012003; RESOR SR, 1992, MED TREATMENT EPILEP; REYNOLDS EH, 1983, LANCET, V2, P952; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; ROBERTSON MM, 1988, RECENT ADV EPILEPSY, P63; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; ROTH HP, 1978, CLIN PHARMACOL THER, V23, P361; ROWAN AJ, 1979, NEUROLOGY, V29, P1450, DOI 10.1212/WNL.29.11.1450; ROWAN AJ, 1988, RECENT ADV EPILEPSY, P63; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; SALINSKY M, 1987, EPILEPSIA, V28, P331, DOI 10.1111/j.1528-1157.1987.tb03652.x; SATO S, 1989, ANTIEPILEPTIC DRUGS, P765; SCHMIDT B, 1989, ANTIEPILEPTIC DRUGS, P925; SCHMIDT D, 1983, EPILEPSIA, V24, P368, DOI 10.1111/j.1528-1157.1983.tb04900.x; SCHMIDT D, 1982, J NEUROL NEUROSUR PS, V45, P1119, DOI 10.1136/jnnp.45.12.1119; SCHMIDT D, 1984, EPILEPSIA, V25, pS44, DOI 10.1111/j.1528-1157.1984.tb05636.x; SCHMIDT D, 1992, MED TREATMENT EPILEP, P293; SELHORST JB, 1972, ARCH NEUROL-CHICAGO, V27, P453, DOI 10.1001/archneur.1972.00490170085012; Sherwin A. L., 1989, ANTIEPILEPTIC DRUGS, P685; SHIELDS WD, 1983, NEUROLOGY, V33, P1487, DOI 10.1212/WNL.33.11.1487; SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8; SKOVSTED L, 1976, ACTA MED SCAND, V199, P513; SMITH DB, 1987, EPILEPSIA, V28, pS50, DOI 10.1111/j.1528-1157.1987.tb05778.x; SMITH DB, 1990, EPILEPSY CURRENT APP, P111; TAYLOR DC, 1972, EPILEPSIA, V13, P727, DOI 10.1111/j.1528-1157.1972.tb05160.x; TRIMBLE MR, 1983, ANTIEPILEPTIC DRUG T, P201; TROUPIN AS, 1992, MED TREATMENT EPILEP, P399; UTHMANN BM, 1992, MED TREATMENT EPILEP, P379; VALSALAN VC, 1982, BRIT MED J, V285, P261, DOI 10.1136/bmj.285.6337.261; VINING EPG, 1987, EPILEPSIA, V28, pS18, DOI 10.1111/j.1528-1157.1987.tb05767.x; WALLACE SJ, 1990, DEV MED CHILD NEUROL, V32, P923; WARNER T, 1992, EPILEPSY RES, V11, P147, DOI 10.1016/0920-1211(92)90049-Y; WITMER DR, 1984, DRUG INTEL CLIN PHAR, V18, P483, DOI 10.1177/106002808401800607; YU YL, 1986, POSTGRAD MED J, V62, P231, DOI 10.1136/pgmj.62.725.231; ZITELLI BJ, 1987, CLIN PEDIATR, V26, P117, DOI 10.1177/000992288702600302	129	44	44	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					411	422		10.7326/0003-4819-120-5-199403010-00010	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304660				2022-12-28	WOS:A1994MY49700010
J	MOURANI, S; DOBBS, SM; GENTA, RM; TANDON, AK; YOFFE, B				MOURANI, S; DOBBS, SM; GENTA, RM; TANDON, AK; YOFFE, B			HEPATITIS A VIRUS-ASSOCIATED CHOLECYSTITIS	ANNALS OF INTERNAL MEDICINE			English	Note							A INFECTION; LIVER		VET AFFAIRS MED CTR, DEPT MED, DIV DIGEST DIS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; BIOGENEX LABS, SAN RAMON, CA 94583 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine								BLACK MM, 1992, J TROP MED HYG, V95, P73; FAGAN E, 1990, J MED VIROL, V30, P131, DOI 10.1002/jmv.1890300210; GORDON SC, 1984, ANN INTERN MED, V101, P635, DOI 10.7326/0003-4819-101-5-635; HERMIER M, 1985, ARCH FR PEDIATR, V42, P525; KARAYIANNIS P, 1986, J MED VIROL, V18, P261, DOI 10.1002/jmv.1890180308; LEMON SM, 1985, NEW ENGL J MED, V313, P1059, DOI 10.1056/NEJM198510243131706; MATHIESEN LR, 1978, J INFECT DIS, V138, P369, DOI 10.1093/infdis/138.3.369; MAUDGAL DP, 1984, DIGEST DIS SCI, V29, P257, DOI 10.1007/BF01296260; SHIMIZU YK, 1982, INFECT IMMUN, V36, P320, DOI 10.1128/IAI.36.1.320-324.1982; TAYLOR GM, 1992, HEPATOLOGY, V16, P642, DOI 10.1002/hep.1840160306	10	60	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					398	400		10.7326/0003-4819-120-5-199403010-00008	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304658				2022-12-28	WOS:A1994MY49700008
J	DITUNNO, JF; FORMAL, CS				DITUNNO, JF; FORMAL, CS			CHRONIC SPINAL-CORD INJURY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRESSURE SORES; CONTROLLED TRIAL; DRUG-THERAPY; SPASTICITY; MANAGEMENT; OSTEOMYELITIS; SATISFACTION; PREVENTION; RECOVERY; OUTCOMES		REG SPINAL CORD INJURY CTR DELAWARE VALLEY, PHILADELPHIA, PA USA; MAGEE MEM REHABILITAT CTR, PHILADELPHIA, PA USA		DITUNNO, JF (corresponding author), THOMAS JEFFERSON UNIV HOSP, JEFFERSON MED COLL, DEPT REHABIL MED, 111 S 11TH ST, PHILADELPHIA, PA 19107 USA.							[Anonymous], 1992, J Am Paraplegia Soc, V15, P194; BALAZY TE, 1992, CLIN J PAIN, V8, P102, DOI 10.1097/00002508-199206000-00007; BAROLAT G, 1989, NEUROSURG STATE ART, V4, P365; BLACK JM, 1987, NURS CLIN N AM, V22, P429; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P751; Chancellor M B, 1992, Semin Urol, V10, P83; Colachis S C 3rd, 1992, J Am Paraplegia Soc, V15, P171; Cushing Harvey, 1927, MED DEP US ARMY WORL, P749; DAVIDOFF G, 1991, PARAPLEGIA, V29, P17, DOI 10.1038/sc.1991.3; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; DEVIVO MJ, 1991, WESTERN J MED, V154, P602; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; DEVIVO MJ, 1990, PARAPLEGIA, V28, P545, DOI 10.1038/sc.1990.74; DEWIRE DM, 1992, J UROLOGY, V147, P1069, DOI 10.1016/S0022-5347(17)37472-4; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; EAGLSTEIN WH, 1991, PROG CLIN BIOL RES, V365, P257; FORMAL C, 1992, PHYS MED REH CLIN N, V3, P783; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P255; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; LANIG IS, 1992, PHYS MED REH CLIN N, V3, P725; LEWIS VL, 1988, PLAST RECONSTR SURG, V81, P229, DOI 10.1097/00006534-198802000-00016; MAYNARD FM, 1990, ARCH PHYS MED REHAB, V71, P566; MENTER RR, 1992, PHYS MED REH CLIN N, V3, P879; MERRITT JL, 1981, MAYO CLIN PROC, V56, P614; MILLER LS, 1975, ARCH PHYS MED REHAB, V56, P405; MORRISON WB, 1993, RADIOLOGY, V189, P251, DOI 10.1148/radiology.189.1.8204132; NASO F, 1992, PHYS MED REH CLIN N, V3, P741; PATTERSON DR, 1993, NEW ENGL J MED, V328, P506, DOI 10.1056/NEJM199302183280712; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENTLAND B, 1993, LANCET, V341, P413, DOI 10.1016/0140-6736(93)93000-Q; POPE AM, 1991, DISABILITY AM NATION; RAGNARSSON KT, 1992, PHYS MED REH CLIN N, V23, P853; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; ROBSON MC, 1992, LANCET, V339, P23, DOI 10.1016/0140-6736(92)90143-Q; RUSH PJ, 1989, SEMIN ARTHRITIS RHEU, V19, P77, DOI 10.1016/0049-0172(89)90052-8; SIOSTEEN A, 1990, PARAPLEGIA, V28, P285; Sipski M.L., 1992, PHYS MED REH CLIN N, V3, P811, DOI [10.1016/S1047-9651(18)30619-3, DOI 10.1016/S1047-9651(18)30619-3]; STAAS WE, 1991, WESTERN J MED, V154, P539; STAAS WE, 1992, PHYS MED REH CLIN N, V3, P699; STAAS WE, 1989, CRIT REV PHYS REHABI, V1, P11; STOOVER SL, 1986, SPINAL CORD INJURY F; STOVER SL, 1991, NEUROL CLIN, V9, P741, DOI 10.1016/S0733-8619(18)30277-9; SUGARMAN B, 1983, ARCH INTERN MED, V143, P683, DOI 10.1001/archinte.143.4.683; TASKER RR, 1992, J NEUROSURG, V77, P373, DOI 10.3171/jns.1992.77.3.0373; UMBACH I, 1991, PARAPLEGIA, V29, P219, DOI 10.1038/sc.1991.32; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; WOOLSEY RM, 1991, NEUROL CLIN, V9, P797, DOI 10.1016/S0733-8619(18)30280-9; WYNDAELE JJ, 1990, PARAPLEGIA, V28, P146, DOI 10.1038/sc.1990.18; YOUNG RR, 1988, ANN NY ACAD SCI, V531, P146, DOI 10.1111/j.1749-6632.1988.tb31820.x; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96; 1991, LANCET, V337, P1010; 1992, STANDARDS NEUROLOGIC; 1992, DHHS AHCPR920047 DEP, P22	57	110	111	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					550	556		10.1056/NEJM199402243300808	http://dx.doi.org/10.1056/NEJM199402243300808			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302323				2022-12-28	WOS:A1994MX43600008
J	WEISSMAN, NJ; WEYMAN, AE				WEISSMAN, NJ; WEYMAN, AE			CORONARY ATHERECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WEISSMAN, NJ (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					539	539						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302320				2022-12-28	WOS:A1994MX43600005
J	GAGLIARDINI, V; FERNANDEZ, PA; LEE, RKK; DREXLER, HCA; ROTELLO, RJ; FISHMAN, MC; YUAN, J				GAGLIARDINI, V; FERNANDEZ, PA; LEE, RKK; DREXLER, HCA; ROTELLO, RJ; FISHMAN, MC; YUAN, J			PREVENTION OF VERTEBRATE NEURONAL DEATH BY THE CRMA GENE	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-PRECURSOR; RNA-SYNTHESIS; BCL-2; INTERLEUKIN-1; EXPRESSION; SURVIVAL	Interleukin-1beta converting enzyme (ICE) is a mammalian homolog of CED-3, a protein required for programmed cell death in the nematode Caenorhabditis elegans. The activity of ICE can be specifically inhibited by the product of crmA, a cytokine response modifier gene encoded by cowpox virus. Microinjection of the crmA gene into chicken dorsal root ganglion neurons was found to prevent cell death induced by deprivation of nerve growth factor. Thus, ICE is likely to participate in neuronal death in vertebrates.	MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, 149 13TH ST, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Drexler, Hannes/AAI-3449-2020	Gagliardini, Valeria/0000-0001-9471-0764				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; DAVIES AM, 1987, DEVELOPMENT, V101, P185; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GAGLIARDINI V, UNPUB; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MAYAWAKI A, 1990, NEURON, V5, P1114; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	21	631	679	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	1994	263	5148					826	828		10.1126/science.8303301	http://dx.doi.org/10.1126/science.8303301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303301				2022-12-28	WOS:A1994MV86600041
J	FERBER, I; SCHONRICH, G; SCHENKEL, J; MELLOR, AL; HAMMERLING, GJ; ARNOLD, B				FERBER, I; SCHONRICH, G; SCHENKEL, J; MELLOR, AL; HAMMERLING, GJ; ARNOLD, B			LEVELS OF PERIPHERAL T-CELL TOLERANCE INDUCED BY DIFFERENT DOSES OF TOLEROGEN	SCIENCE			English	Article							TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; INDUCTION; ANTIGEN; THYMOCYTES; EXPRESSION; RECEPTORS; MECHANISM; PROTEIN	Antigen-specific immunosuppression requires an understanding of the parameters that control peripheral T cell tolerance. A liver-specific inducible promoter was used to drive the expression of the major histocompatibility complex antigen K(b) in transgenic mice. Minute amounts of K(b), expressed exclusively on hepatocytes, induced tolerance by partial down-regulation of the T cell receptor (TCR) on the self-reactive CD8+ cells. Contact of these tolerant T cells with high concentrations of K(b) after induction led to complete down-regulation of TCR. Thus, tolerant T cells are susceptible to further tolerogenic signals and reach different levels of tolerance depending on antigen dose.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT SOMAT GENET, TUMOR IMMUNOL PROGRAM, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; NATL INST MED RES, DIV MOLEC IMMUNOL, LONDON NW7 1AA, ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; MRC National Institute for Medical Research				Schonrich, Gunther/0000-0002-5346-5704				ADORINI L, 1993, IMMUNOL TODAY, V14, P285, DOI 10.1016/0167-5699(93)90047-O; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FIELDS LE, 1992, P NATL ACAD SCI USA, V89, P5730, DOI 10.1073/pnas.89.13.5730; GEIGER T, 1992, P NATL ACAD SCI USA, V89, P2985, DOI 10.1073/pnas.89.7.2985; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HUA C, 1986, J IMMUNOL, V136, P1937; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAST WM, 1988, EUR J IMMUNOL, V18, P2105; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KUBO RT, 1989, J IMMUNOL, V142, P2736; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIMPSON SJ, 1993, INT IMMUNOL, V5, P189, DOI 10.1093/intimm/5.2.189; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	25	205	208	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					674	676		10.1126/science.8303275	http://dx.doi.org/10.1126/science.8303275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303275				2022-12-28	WOS:A1994MU96400046
J	REBAR, EJ; PABO, CO				REBAR, EJ; PABO, CO			ZINC-FINGER PHAGE - AFFINITY SELECTION OF FINGERS WITH NEW DNA-BINDING SPECIFICITIES	SCIENCE			English	Article							RECOGNITION; PROTEIN; SEQUENCES; DOMAINS	A phage display system was developed and used to select zinc finger proteins with altered DNA-binding specificities. The three zinc fingers of the Zif268 protein were expressed on the surface of filamentous phage, and a library of variants was prepared by randomizing critical amino acids in the first zinc finger. Affinity selections, using DNA sites with base changes in the region recognized by the first finger, yielded Zif268 variants that bound tightly and specifically to the new sites. This phage system provides a tool for the study of protein-DNA interactions and may offer a general method for selecting zinc finger proteins that recognize desired target sites on double-stranded DNA.			REBAR, EJ (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; HOESS RH, 1993, CURR OPIN STRUCT BIO, V217, P228; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON A, IN PRESS BIOCHEMISTR; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228	16	364	477	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					671	673		10.1126/science.8303274	http://dx.doi.org/10.1126/science.8303274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303274				2022-12-28	WOS:A1994MU96400045
J	WONG, LJC; CRAIGEN, WJ; OBRIEN, WE				WONG, LJC; CRAIGEN, WJ; OBRIEN, WE			POSTPARTUM COMA AND DEATH DUE TO CARBAMOYL-PHOSPHATE SYNTHETASE-I DEFICIENCY	ANNALS OF INTERNAL MEDICINE			English	Note							HYPERAMMONEMIA				WONG, LJC (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.							ARASHIMA S, 1972, TOHOKU J EXP MED, V107, P143, DOI 10.1620/tjem.107.143; ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BATSHAW M, 1975, NEW ENGL J MED, V292, P1085, DOI 10.1056/NEJM197505222922101; Brusilow S.W., 1989, METABOLIC BASIS INHE, P629; GELEHRTER TD, 1974, NEW ENGL J MED, V290, P430, DOI 10.1056/NEJM197402212900804; KLINE JJ, 1981, AM J DIS CHILD, V135, P437, DOI 10.1001/archpedi.1981.02130290035013; LO WD, 1993, AM J DIS CHILD, V147, P267, DOI 10.1001/archpedi.1993.02160270029012; MANTAGOS S, 1978, ARCH DIS CHILD, V53, P230, DOI 10.1136/adc.53.3.230; MCREYNOLDS JW, 1981, AM J HUM GENET, V33, P345; Nuzum CT, 1976, UREA CYCLE, P325; WILSON RG, 1977, AUST PAEDIATR J, V13, P119	11	38	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					216	217		10.7326/0003-4819-120-3-199402010-00007	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273985				2022-12-28	WOS:A1994MU30300007
J	CLARKSON, TB; PRICHARD, RW; MORGAN, TM; PETRICK, GS; KLEIN, KP				CLARKSON, TB; PRICHARD, RW; MORGAN, TM; PETRICK, GS; KLEIN, KP			REMODELING OF CORONARY-ARTERIES IN HUMAN AND NONHUMAN-PRIMATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPICARDIAL ECHOCARDIOGRAPHY; ATHEROSCLEROSIS	Objective.-To compare coronary artery remodeling (compensatory enlargement) in human and nonhuman primates. Design.-Coronary artery data were analyzed retrospectively for 416 nonhuman primates and 100 men and women. Setting.-The monkeys had been in experiments involving diet-induced coronary artery atherosclerosis. The human hearts were obtained from the North Carolina Baptist Hospital, Winston-Salem, and age greater than 25 years was the only criterion. Patients and Other Participants.-The left anterior descending coronary arteries from 100 humans, 328 cynomolgus monkeys, and 88 male rhesus monkeys were used. Interventions.-None; this was a cross-sectional observational study. Main Outcome Measures.-Coronary artery size, lumen area, and plaque size. In the humans, we also examined demographic characteristics (ethnicity, sex, and history of hypertension) and pathologic criteria (eccentricity or concentricity of plaque area). Results.-On average, lumen size remained unaffected by plaque size. Lumen size was variable and could not be predicted by traditional risk factors for coronary heart disease. However, lack of compensation (decreased lumen size as plaques enlarged) and history of coronary heart disease were significantly correlated. Conclusions.-The similarity of remodeling in human and nonhuman primates suggests that the process has general biologic significance. Lack of remodeling may be a major determinant of whether a person with coronary artery atherosclerosis develops its complications.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, COMPARAT MED CLIN RES CTR, DEPT PATHOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, COMPARAT MED CLIN RES CTR, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	CLARKSON, TB (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, COMPARAT MED CLIN RES CTR, DEPT COMPARAT MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NHLBI NIH HHS [HL14164, HV53029] Funding Source: Medline; NICHD NIH HHS [N01 HD82827] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV053029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOND MG, 1981, ARTERY, V9, P21; BOND MG, 1982, CLIN DIAGNOSIS ATHER, P435; CLARKSON TB, 1984, EXP MOL PATHOL, V41, P96, DOI 10.1016/0014-4800(84)90011-X; CLARKSON TB, 1980, ATHEROSCLEROSIS, V5, P739; CLARKSON TB, 1984, REGRESSION ATHEROSCL, P43; GERTLER NM, 1954, CORONARY HEART DISEA; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOLDBERG HL, 1983, AM J CARDIOL, V51, P434, DOI 10.1016/S0002-9149(83)80075-7; GREGG DE, 1980, NEW ENGL J MED, V303, P1404, DOI 10.1056/NEJM198012113032406; KEOHANE SG, 1988, ATHEROSCLEROSIS, V69, P103, DOI 10.1016/0021-9150(88)90002-0; MANN GV, 1972, AM J EPIDEMIOL, V95, P26, DOI 10.1093/oxfordjournals.aje.a121365; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MCPHERSON DD, 1991, J AM COLL CARDIOL, V17, P79, DOI 10.1016/0735-1097(91)90707-G; MCPHERSON DD, 1992, J AM COLL CARDIOL, V19, P593, DOI 10.1016/S0735-1097(10)80278-5; MOISE A, 1985, AM J CARDIOL, V56, P30, DOI 10.1016/0002-9149(85)90561-2; ROBERTSON WB, 1968, LAB INVEST, V18, P538; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; STRONG JP, 1962, AM J PATHOL, V40, P37; WILENS SL, 1966, J AMER MED ASSOC, V198, P1325, DOI 10.1001/jama.198.13.1325; WISSLER RW, 1983, AM J CARDIOL, V52, pA2; WISSLER RW, 1985, ANN NY ACAD SCI, V454, P9, DOI 10.1111/j.1749-6632.1985.tb11840.x; YOUNG W, 1960, AM J CARDIOL, V6, P288, DOI 10.1016/0002-9149(60)90317-9	23	203	213	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					289	294		10.1001/jama.271.4.289	http://dx.doi.org/10.1001/jama.271.4.289			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295288				2022-12-28	WOS:A1994MR22100025
J	CANE, DE				CANE, DE			POLYKETIDE BIOSYNTHESIS - MOLECULAR RECOGNITION OR GENETIC PROGRAMMING	SCIENCE			English	Editorial Material							STREPTOMYCES-COELICOLOR A3(2); MACROLIDE BIOSYNTHESIS; SACCHAROPOLYSPORA-ERYTHRAEA; CHAIN-ELONGATION; ANTIBIOTIC ACTINORHODIN; ERYTHROMYCIN; SYNTHASE; ORGANIZATION				CANE, DE (corresponding author), BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912, USA.							CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1993, J AM CHEM SOC, V115, P527, DOI 10.1021/ja00055a024; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1986, J AM CHEM SOC, V108, P4957, DOI 10.1021/ja00276a042; CANE DE, 1991, TETRAHEDRON LETT, V32, P5457, DOI 10.1016/0040-4039(91)80057-D; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CELMER W D, 1971, Pure and Applied Chemistry, V28, P413, DOI 10.1351/pac197128040413; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; OHAGAN D, 1992, NAT PROD REP, V9, P447, DOI 10.1039/np9920900447; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; SIMPSON TJ, 1984, NAT PROD REP, V1, P281, DOI 10.1039/np9840100281; SIMPSON TJ, 1985, NAT PROD REP, V2, P321, DOI 10.1039/np9850200321; SIMPSON TJ, 1987, NAT PROD REP, V4, P339, DOI 10.1039/np9870400339; SIMPSON TJ, 1991, NAT PROD REP, V8, P573, DOI 10.1039/np9910800573; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	27	27	28	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					338	340		10.1126/science.8278806	http://dx.doi.org/10.1126/science.8278806			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278806				2022-12-28	WOS:A1994MT03400023
J	KHABBAZ, RF; HENEINE, W; GEORGE, JR; PAREKH, B; ROWE, T; WOODS, T; SWITZER, WM; MCCLURE, HM; MURPHEYCORB, M; FOLKS, TM				KHABBAZ, RF; HENEINE, W; GEORGE, JR; PAREKH, B; ROWE, T; WOODS, T; SWITZER, WM; MCCLURE, HM; MURPHEYCORB, M; FOLKS, TM			INFECTION OF A LABORATORY WORKER WITH SIMIAN IMMUNODEFICIENCY VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MACAQUE MONKEYS; SOOTY MANGABEY; RHESUS-MONKEYS; NEF GENE; RETROVIRUS; DISEASE; INVITRO; HIV-2; AIDS; REPLICATION		CTR DIS CONTROL,LAB INVEST BRANCH,DIV HIV AIDS,ATLANTA,GA 30333; EMORY UNIV,YERKES REG PRIMATE RES CTR,ATLANTA,GA 30322; TULANE UNIV,DELTA REG PRIMATE RES CTR,COVINGTON,LA 70433	Centers for Disease Control & Prevention - USA; Emory University; Tulane University	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,RETROVIRUS DIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,MAILSTOP G-03,ATLANTA,GA 30333, USA.		Rowe, Thomas/AAW-4899-2020	PAREKH, BHARAT/0000-0002-1088-4263	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164, P51RR000165] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00165, RR00164] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; FULTZ PN, 1986, P NATL ACAD SCI USA, V83, P5286, DOI 10.1073/pnas.83.14.5286; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; HIRSCH VM, 1990, VACCINES 90, P379; HIRSCH VM, 1991, J INFECT DIS, V163, P976, DOI 10.1093/infdis/163.5.976; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HIRSCH VM, 1989, NATURE, V341, P573, DOI 10.1038/341573a0; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KHABBAZ RF, 1992, LANCET, V340, P271, DOI 10.1016/0140-6736(92)92358-M; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; MCCLURE HM, 1989, VET IMMUNOL IMMUNOP, V21, P13, DOI 10.1016/0165-2427(89)90126-8; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; MYERS G, 1993, HUMAN RETROVIRUSES A; OHTA Y, 1988, INT J CANCER, V41, P115, DOI 10.1002/ijc.2910410121; SIMON F, 1992, 8TH INT C AIDS 3RD S, V2, pA23; TSUJIMOTO H, 1988, J VIROL, V62, P4044, DOI 10.1128/JVI.62.11.4044-4050.1988; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277; 1988, MMWR MORB MORTAL WKL, V37, P699; 1992, MMWR MORB MORTAL WKL, V41, P814; 1988, MMWR MORB MORTAL WKL, V37, P693	28	104	109	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					172	177		10.1056/NEJM199401203300304	http://dx.doi.org/10.1056/NEJM199401203300304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264739				2022-12-28	WOS:A1994MQ86300004
J	HINZ, U; GIEBEL, B; CAMPOSORTEGA, JA				HINZ, U; GIEBEL, B; CAMPOSORTEGA, JA			THE BASIC-HELIX-LOOP-HELIX DOMAIN OF DROSOPHILA LETHAL OF SCUTE PROTEIN IS SUFFICIENT FOR PRONEURAL FUNCTION AND ACTIVATES NEUROGENIC GENES	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; X-A RATIO; ACHAETE-SCUTE; SEX DETERMINATION; DNA-BINDING; LATERAL INHIBITION; ENHANCER DETECTION; MOLECULAR ANALYSIS; WING DISK	The development of most epidermal sensory organs in Drosophila is controlled by achaete and scute, two of the genes of the achaete-scute complex (AS-C). The genes of the AS-C encode members of the basic-helix-loop-helix (bHLH) class of transcriptional regulators, and their activity defines proneural cell clusters in the imaginal discs from which sensory organ mother cells are singled out by a process of lateral inhibition. Ectopic expression of lethal of scute, another member of the AS-C, normally dispensable for sensory organ development in the adult, promotes this process independently of the activity of the other AS-C genes. This demonstrates a high degree of functional redundancy of the products of the AS-C. Furthermore, neurogenic genes are activated in ectopic proneural clusters, allowing development of epidermal progenitor cells. Finally, the bHLH domain is necessary and sufficient to mediate the proneural function, to activate neurogenic genes, and to allow lateral inhibition.			HINZ, U (corresponding author), UNIV COLOGNE, INST ENTWICKLUNGSBIOL, D-50923 COLOGNE, GERMANY.		Giebel, Bernd/AAH-1083-2021	Giebel, Bernd/0000-0003-2446-948X				ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; Bryant P.J., 1978, P230; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CAMPOSORTEGA JA, 1992, ROUX ARCH DEV BIOL, V201, P1, DOI 10.1007/BF00188770; CAMPOSORTEGA JA, 1993, IN PRESS DEV DROSOPH; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECELIS JF, 1991, ROUX ARCH DEV BIOL, V200, P64, DOI 10.1007/BF00637186; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KNUST E, 1992, GENETICS, V132, P505; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEYNS L, 1989, ROUX ARCH DEV BIOL, V198, P227, DOI 10.1007/BF00375909; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; MARTINBERMUDO MD, 1993, DEVELOPMENT, V118, P1003; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; ROBERTSON HM, 1988, GENETICS, V118, P461; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467	78	284	285	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					77	87		10.1016/0092-8674(94)90174-0	http://dx.doi.org/10.1016/0092-8674(94)90174-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287481				2022-12-28	WOS:A1994MR49500008
J	MA, K; INGLIS, JD; SHARKEY, A; BICKMORE, WA; HILL, RE; PROSSER, EJ; SPEED, RM; THOMSON, EJ; JOBLING, M; TAYLOR, K; WOLFE, J; COOKE, HJ; HARGREAVE, TB; CHANDLEY, AC				MA, K; INGLIS, JD; SHARKEY, A; BICKMORE, WA; HILL, RE; PROSSER, EJ; SPEED, RM; THOMSON, EJ; JOBLING, M; TAYLOR, K; WOLFE, J; COOKE, HJ; HARGREAVE, TB; CHANDLEY, AC			A Y-CHROMOSOME GENE FAMILY WITH RNA-BINDING PROTEIN HOMOLOGY - CANDIDATES FOR THE AZOOSPERMIA FACTOR AZF CONTROLLING HUMAN SPERMATOGENESIS	CELL			English	Article							UBIQUITIN-ACTIVATING ENZYME-E1; DROSOPHILA-MELANOGASTER; RECOGNITION MOTIF; SEQUENCE-ANALYSIS; LONG ARM; LOCALIZATION; EXPRESSION; CLONING; NUCLEAR; DOMAIN	We have previously mapped the human azoospermia factor to a deletion in Y chromosome interval 6 (subinterval XII-XIV). We now report the isolation and characterization of a gene family located within this deletion. Analysis of the predicted protein products suggests a possible role in RNA processing or translational control during early spermatogenesis. The Y chromosome RNA recognition motif (YRRM) family includes a minimum of three members expressed specifically in the testis. Interphase in situ results and Southern blot analysis indicate that several further YRRM sequences map within interval 6. Several mammalian species show Y chromosome conservation of YRRM sequences. We have detected deletions of YRRM sequences in two oligospermic patients with no previously detectable mutation.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,GALTON LAB,LONDON NW1 2HE,ENGLAND; WESTERN GEN HOSP,DEPT UROL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT SURG UROL,EDINBURGH EH4 2XU,SCOTLAND	University of Leicester; University of London; University College London; University of Edinburgh; University of Edinburgh	MA, K (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Bickmore, Wendy A/C-7314-2013; Sharkey, Andrew M/H-7015-2013	Bickmore, Wendy A/0000-0001-6660-7735; Sharkey, Andrew M/0000-0002-5072-7748; Jobling, Mark/0000-0002-8061-1308				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; ARNEMANN J, 1991, GENOMICS, V11, P108, DOI 10.1016/0888-7543(91)90107-P; BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CHANDLEY AC, 1989, J MED GENET, V26, P145, DOI 10.1136/jmg.26.3.145; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Hargreave TB, 1990, MANAGEMENT MALE INFE, P2; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; JAKUBICZKA S, 1993, GENOMICS, V17, P732, DOI 10.1006/geno.1993.1394; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REILLY AJ, 1992, HUM MOL GENET, V1, P379; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARA A, 1987, 12TH P WORLD C FERT, V4, P91; SINNOTT P, 1990, P NATL ACAD SCI USA, V87, P2107, DOI 10.1073/pnas.87.6.2107; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TAYLOR K, 1991, CYTOGENET CELL GENET, V58, P2096; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; WANG MY, 1992, NUCLEIC ACIDS RES, V20, P3519, DOI 10.1093/nar/20.13.3519; Zhang Julie S., 1992, Human Molecular Genetics, V1, P717, DOI 10.1093/hmg/1.9.717	43	448	488	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1287	1295		10.1016/0092-8674(93)90616-X	http://dx.doi.org/10.1016/0092-8674(93)90616-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269511				2022-12-28	WOS:A1993MP86900008
J	TURNER, R				TURNER, R			BIG-BROTHER IS LOOKING AFTER YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article											TURNER, R (corresponding author), E RIDING HLTH,KINGSTON HULL HU10 6DT,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1623	1624		10.1136/bmj.307.6919.1623	http://dx.doi.org/10.1136/bmj.307.6919.1623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292961	Green Published, Bronze			2022-12-28	WOS:A1993MN10700029
J	KONDO, M; TAKESHITA, T; ISHII, N; NAKAMURA, M; WATANABE, S; ARAI, K; SUGAMURA, K				KONDO, M; TAKESHITA, T; ISHII, N; NAKAMURA, M; WATANABE, S; ARAI, K; SUGAMURA, K			SHARING OF THE INTERLEUKIN-2 (IL-2) RECEPTOR GAMMA-CHAIN BETWEEN RECEPTORS FOR IL-2 AND IL-4	SCIENCE			English	Article							T-CELLS; BETA-CHAIN; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; B-CELLS; GM-CSF; GENERATION; DEFICIENT; MOLECULE; SUBUNIT	The gamma chain of the interleukin-2 (IL-2) receptor is an indispensable subunit for IL-2 binding and intracellular signal transduction. A monoclonal antibody to the gamma chain, TUGm2, inhibited IL-2 binding to the functional IL-2 receptors and also inhibited IL-4-induced cell growth and the high-affinity binding of IL-4 to the CTLL-2 mouse T cell line. Another monoclonal antibody, TUGm3, which reacted with the gamma chain cross-linked with IL-2, also immunoprecipitated the gamma chain when cross-linked with IL-4. These results suggest that the IL-2 receptor gamma chain is functionally involved in the IL-4 receptor complex.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,TOKYO 108,JAPAN	Tohoku University; University of Tokyo			Takeshita, Toshikazu/AAL-1382-2021	Ishii, Naoto/0000-0002-0549-8245				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KONDO M, UNPUB; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; LEE HK, 1990, J IMMUNOL, V144, P3431; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGA T, 1993, FASEB J, V7, P3387; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA T, 1991, J IMMUNOL, V147, P2222; TANAKA Y, 1990, INT J CANCER, V46, P675, DOI 10.1002/ijc.2910460421; TATENO M, 1984, J EXP MED, V159, P1105, DOI 10.1084/jem.159.4.1105; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	32	774	814	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1874	1877		10.1126/science.8266076	http://dx.doi.org/10.1126/science.8266076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266076				2022-12-28	WOS:A1993MM51100036
J	BANTA, HD				BANTA, HD			MINIMALLY INVASIVE SURGERY - IMPLICATIONS FOR HOSPITALS, HEALTH-WORKERS, AND PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							CHOLECYSTECTOMY; LAPAROSCOPY	Minimally invasive surgery is one of the great innovations of health care in the 20th century. It promises to revolutionise surgery by allowing many more operations to be performed with minimal hospitalisation. Pressure from patients has caused many techniques to spread rapidly before they have been adequately assessed. This must be resisted, and policy makers must pay more attention to minimally invasive surgery to ensure that good assessments are made. The widespread use of minimally invasive techniques has important implications for hospitals and health workers. As more patients are treated on an outpatient basis, fewer hospital beds will be needed, and traditional operating rooms will have to adapt to a greater turnover of patients. Surgeons will have to acquire new operating skills, possibly requiring formal training and accreditation, and, as different specialties fight for control of new technologies, surgery may eventually be merged with internal medicine so that specialists will deal with organ systems. Postoperative care will have to be carried out in the community rather than in hospitals, and policy makers will need to reorganise their health systems to cope with these developments.			BANTA, HD (corresponding author), TNO,HLTH RES CTR MED TECHNOL,ZERNIKEDREEF 9,2300 AK LEIDEN,NETHERLANDS.							BANTA HD, 1992, MINIM INVASIV THER, V1, P189; BANTA HD, 1991, BUDGET IS BLIND CASE; BERGSTROM R, 1984, CLIN ORTHOP RELAT R, V184, P133; BURN JMB, 1979, ANAESTHESIA, V34, P790, DOI 10.1111/j.1365-2044.1979.tb06413.x; COOK AS, 1991, FERTIL STERIL, V55, P663; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; GADACZ TR, 1990, SURG CLIN N AM, V70, P1249; GOODMAN MP, 1989, J GYNECOL SURG, V5, P353, DOI 10.1089/gyn.1989.5.353; HAMBERG P, 1984, J BONE JOINT SURG BR, V66, P189, DOI 10.1302/0301-620X.66B2.6546759; HOLAHAN T, 1991, LANCET, V338, P801; NORTHMOREBALL MD, 1982, CLIN ORTHOP RELAT R, V167, P34; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; REDDICK EJ, 1990, AM J SURG, V160, P485, DOI 10.1016/S0002-9610(05)81009-8; TAVMERGEN EN, 1990, ZBL GYNAKOL, V112, P1405; VONDELING H, 1993, HEALTH POLICY, V23, P67, DOI 10.1016/0168-8510(93)90007-C; VROLIJK H, 1988, EINDE STENEN TIJDPER; WHITWORTH CM, 1988, SURG GYNECOL OBSTET, V167, P187; 1990, ROLE LAPAROSCOPIC CH; 1987, ADVICES INZAKE DAGVE; 1987, HLTH TECHNOLOGY, V1, P91; 1992, ASSESSING EFFECTS HL; 1991, JAMA-J AM MED ASSOC, V265, P1585; 1991, NEW ENGL J MED, V302, P30	23	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1546	1549		10.1136/bmj.307.6918.1546	http://dx.doi.org/10.1136/bmj.307.6918.1546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274927	Bronze, Green Published			2022-12-28	WOS:A1993ML86900027
J	DEMARCO, P; DAIN, C; LOCKWOOD, T; ROLAND, M				DEMARCO, P; DAIN, C; LOCKWOOD, T; ROLAND, M			HOW VALUABLE IS FEEDBACK OF INFORMATION ON HOSPITAL REFERRAL PATTERNS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; RATES	Objectives-To determine general practitioners' responses to and explanations for variation in rates of referral to hospital and how feedback of data on rates of referral could be used to facilitate practices in auditing their own referral behaviour. Design-Visits by audit facilitators to general practices after feedback of details of rates of referral to hospital derived from annual reports in general practice. Setting-92 general practices in East Anglia. Results-General practitioners judged that access to specialist care, the individual skill of general practitioners, patient demand, and fear of litigation were major determinants of referral behaviour. Because there was widespread scepticism about the accuracy of the data on which the feedback was based and because there is no clear relation between rates of referral and quality of care, it was extremely difficult to encourage doctors to use the feedback as a basis for auditing their own hospital referrals. Conclusion-If general practitioners are to contribute meaningfully to monitoring future changes in referral patterns it will be essential to develop reliable information systems in which doctors have confidence. Furthermore, audits need to be based on analysis of clinical cases rather than on rates of referral.	UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND	University of Manchester								COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; COULTER A, 1992, HOSPITAL REFERRALS, P150; COULTER A, 1991, GP REFERRALS HOSPITA; DOWIE R, 1983, GENERAL PRACTITIONER; KENNEDY F, 1993, J PUBLIC HEALTH MED, V15, P83, DOI 10.1093/oxfordjournals.pubmed.a042824; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; MADELEY RJ, 1990, J PUBLIC HEALTH MED, V12, P22, DOI 10.1093/oxfordjournals.pubmed.a042501; MCCORMICK A, 1990, MORBIDITY STATISTICS; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; ROLAND M, 1988, BRIT MED J, V297, P599, DOI 10.1136/bmj.297.6648.599; ROLAND M, 1992, HOSP REFERRALS, P136; ROLAND M, 1992, REFERRALS MED OUTPAT, P33; ROLAND MO, 1990, BRIT MED J, V301, P98, DOI 10.1136/bmj.301.6743.98; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160; WILKIN D, 1992, HOSPITAL REFERRALS, P76	18	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1465	1466		10.1136/bmj.307.6917.1465	http://dx.doi.org/10.1136/bmj.307.6917.1465			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281090	Green Published, Bronze			2022-12-28	WOS:A1993MK79700026
J	BRATTEBO, G; WISBORG, T; SOLHEIM, K; OYEN, N				BRATTEBO, G; WISBORG, T; SOLHEIM, K; OYEN, N			PUBLIC-OPINION ON DIFFERENT APPROACHES TO TEACHING INTUBATION TECHNIQUES	BRITISH MEDICAL JOURNAL			English	Article							SKILLS		ULLEVAL UNIV HOSP,DEPT SURG,N-0407 OSLO,NORWAY; UNIV BERGEN,HAUKELAND UNIV HOSP,MED INFORMAT & STAT SECT,N-5021 BERGEN,NORWAY	University of Oslo; University of Bergen; Haukeland University Hospital	BRATTEBO, G (corresponding author), HAMMERFEST HOSP,DEPT ANAESTHESIA & INTENS CARE,N-9601 HAMMERFEST,NORWAY.		Wisborg, Torben/H-5126-2011	Wisborg, Torben/0000-0002-7213-8012; Brattebo, Guttorm/0000-0002-7124-5641				BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BRATTEBO G, 1990, Tidsskrift for den Norske Laegeforening, V110, P1380; NELSON MS, 1990, ANN EMERG MED, V19, P333, DOI 10.1016/S0196-0644(05)82058-X; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; TONKS A, 1992, BRIT MED J, V305, P332	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1256	1257		10.1136/bmj.307.6914.1256	http://dx.doi.org/10.1136/bmj.307.6914.1256			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281059	Green Published, Bronze			2022-12-28	WOS:A1993MH00100023
J	ADAMS, J; TRENT, R; RAWLES, J				ADAMS, J; TRENT, R; RAWLES, J			EARLIEST ELECTROCARDIOGRAPHIC EVIDENCE OF MYOCARDIAL-INFARCTION - IMPLICATIONS FOR THROMBOLYTIC TREATMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-CRITERIA	Objectives-To determine the incidence of the earliest electrocardiographic changes in patients with suspected myocardial infarction and their sensitivity and specificity for predicting the final diagnosis of acute myocardial infarction. Design-Retrospective study of paired electrocardiograms recorded at home and on admission to hospital. Setting-29 rural practices in Grampian and teaching hospitals in Aberdeen. Patients-137 patients participating in the early anistreplase trial in the Grampian region, who received placebo at home and for whom paired electrocardiograms were available. Main outcome measures-Classified electrocardiographic abnormalities and diagnosis at discharge. Results-Electrocardiograms were recorded immediately before injection of placebo at home and anistreplase in hospital at median times of 110 and 240 minutes after the onset of symptoms. Definite or probable myocardial infarction was later confirmed in 93 (68%) patients. Of these, 66 (71%) had the same findings on both electrocardiograms of either ST elevation, bundle branch block, or a non-specific abnormality, while 27 (29%) showed a major change of classification between home and hospital recordings; 21 (23%) had ST elevation or bundle branch block on only one of the paired recordings. Although ST elevation was the commonest abnormality in the 93 patients with myocardial infarction, in only 51 was it recorded at home (sensitivity 55%) and in 49 on admission (sensitivity 53%). Of 57 patients with ST elevation at home, six did not have infarction (specificity 86%), while of 51 with ST elevation on admission, two did not have infarction (specificity 95%). Conclusions-Elevation of the ST segment is a transient electrocardiographic abnormality that has high specificity but low sensitivity for predicting the diagnosis of acute myocardial infarction; it is an unsatisfactory precondition for giving thrombolytic treatment to patients with suspected acute myocardial infarction.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT CARDIAC, ABERDEEN AB9 2ZB, SCOTLAND	University of Aberdeen; University of Aberdeen								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BAUGHMAN KL, 1981, CIRCULATION, V63, P317, DOI 10.1161/01.CIR.63.2.317; BERGMANN SR, 1982, AM J MED, V73, P573, DOI 10.1016/0002-9343(82)90338-2; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CHAMBERLAIN DA, 1992, MED PUBLISHING F SER, V31, P17; ESSEN RV, 1979, CIRCULATION, V59, P105, DOI 10.1161/01.CIR.59.1.105; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GIBSON RS, 1982, CIRCULATION, V66, P732, DOI 10.1161/01.CIR.66.4.732; KLAINMAN E, 1987, J ELECTROCARDIOL, V20, P98, DOI 10.1016/S0022-0736(87)80098-5; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; QUYYUMI AA, 1986, LANCET, V1, P347; RAWLES JM, 1992, CORONARY ARTERY DIS, V3, P1153; REID DS, 1971, BRIT HEART J, V33, P370; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; SCHWEITZER P, 1990, AM HEART J, V119, P642, DOI 10.1016/S0002-8703(05)80288-1; SELWYN AP, 1978, BRIT HEART J, V40, P383; SHORT D, 1970, BRIT HEART J, V32, P6; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; WILCOX RG, 1992, MED PUBLISHING F SER, V31, P9; YUSUF S, 1984, EUR HEART J, V5, P690, DOI 10.1093/oxfordjournals.eurheartj.a061728; ZMYSLINSKI RW, 1979, AM J CARDIOL, V43, P29, DOI 10.1016/0002-9149(79)90040-7	23	67	69	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	1993	307	6901					409	413		10.1136/bmj.307.6901.409	http://dx.doi.org/10.1136/bmj.307.6901.409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8267742	Green Published, Bronze			2022-12-28	WOS:A1993LR89500014
J	LURIE, N; CHRISTIANSON, J; FINCH, M; MOSCOVICE, I				LURIE, N; CHRISTIANSON, J; FINCH, M; MOSCOVICE, I			THE EFFECTS OF CAPITATION ON HEALTH AND FUNCTIONAL STATUS OF THE MEDICAID ELDERLY - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							FEE-FOR-SERVICE; MAINTENANCE-ORGANIZATIONS; AMBULATORY CARE; PREPAID; QUALITY; PLANS	Purpose: To determine the effect on health and functional status outcomes of enrollment of noninstitutionalized elderly Medicaid recipients in prepaid plans compared with traditional fee-for-service Medicaid. Design: A randomized controlled trial. Beneficiaries were randomly assigned to prepaid care in one of seven capitated health plans compared with fee-for-service care. Only the Medicaid portion of their care was capitated. Patients were followed for 1 year. Setting: The Medicaid Demonstration Project in Hennepin County, Minnesota, which includes Minneapolis. Patients: 800 Medicaid beneficiaries who were 65 years or older at the beginning of the evaluation. Beneficiaries were interviewed at baseline (time 1) and 1 year later (time 2). Ninety-six percent of beneficiaries were available for follow-up interviews at time 2. Main Outcome Measures: General health status, physical functioning, mental health status, activities of daily living, instrumental activities of daily living, corrected visual acuity, and blood pressure and glycosylated hemoglobin measurements for hypertensive and diabetic persons, respectively. Results:There were no differences between prepaid and fee-for-service groups in the number of deaths (20 compared with 24, P > 0.2), the proportion in fair or poor health (56.5% compared with 59.7%, P > 0.2), physical functioning, activities of daily living, visual acuity, or blood pressure or diabetic control. Patients in the prepaid group reported a trend toward better general health rating scores (10.2 compared with 9.8, P = 0.06) and well-being scores (10.0 compared with 9.7, P = 0.07) than patients in the fee-for-service group. The difference in the likelihood of a patient in the prepaid group having a physician visit relative to the fee-for-service group was -16.5% (adjusted odds ratio, 0.46; 95% CI, 0.29 to 0.74) and for an inpatient visit was -11.2% (adjusted odds ratio, 0.55; CI, 0.32 to 0.94). Conclusions: There was no evidence of harmful effects of enrolling elderly Medicaid patients in prepaid plans, at least in the short run. Whether these findings also apply to settings in which health maintenance organizations are formed exclusively for Medicaid patients should be studied further.	UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, INST HLT SERV RES, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	LURIE, N (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.		Finch, Michael/AAN-7772-2021	Finch, Michael/0000-0001-7770-1102				[Anonymous], 1948, CONSTITUTION WHO; BATES EW, 1988, MED CARE, V26, P488, DOI 10.1097/00005650-198805000-00005; Bindman A B, 1993, Fam Med, V25, P114; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; CAREY TS, 1990, ARCH INTERN MED, V150, P2369, DOI 10.1001/archinte.150.11.2369; CHRISTIANSON J, 1987, SEP P NAT I MENT HLT; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; FREEBORN DK, 1990, MED CARE, V28, P527, DOI 10.1097/00005650-199006000-00005; KANE RA, 1985, ADM851384 USDHHS; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P640, DOI 10.2105/AJPH.79.5.640; LURIE N, 1992, JAMA-J AM MED ASSOC, V267, P3300, DOI 10.1001/jama.267.24.3300; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RETCHIN SM, 1991, AM J MED, V90, P236; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; STEWART AL, 1982, CONSTRUCTION SCORING; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WARE JE, 1986, LANCET, V1, P1017; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1976, HRP0015709 ANN REP; 1992, MED HLTH PERSPECTIVE	28	64	64	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					506	511		10.7326/0003-4819-120-6-199403150-00010	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311374				2022-12-28	WOS:A1994NB62500010
J	ROSTOKER, G; DESVAUXBELGHITI, D; PILATTE, Y; PETITPHAR, M; PHILIPPON, C; DEFORGES, L; TERZIDIS, H; INTRATOR, L; ANDRE, C; ADNOT, S; BONIN, P; BIERLING, P; REMY, P; LAGRUE, G; LANG, P; WEIL, B				ROSTOKER, G; DESVAUXBELGHITI, D; PILATTE, Y; PETITPHAR, M; PHILIPPON, C; DEFORGES, L; TERZIDIS, H; INTRATOR, L; ANDRE, C; ADNOT, S; BONIN, P; BIERLING, P; REMY, P; LAGRUE, G; LANG, P; WEIL, B			HIGH-DOSE IMMUNOGLOBULIN THERAPY FOR SEVERE IGA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA	ANNALS OF INTERNAL MEDICINE			English	Article						PURPURA, SCHONLEIN-HENOCH; GLOMERULONEPHRITIS, IGA; PROTEINURIA; HEMATURIA	CHRONIC-RENAL-FAILURE; IMMUNE-COMPLEXES; GAMMA-GLOBULIN; INTRAVENOUS IMMUNOGLOBULIN; PRIMARY GLOMERULONEPHRITIS; NATURAL-HISTORY; LUPUS NEPHRITIS; A NEPHROPATHY; POLYMERIC IGA; SERUM	Objective: To determine if polyvalent IgG is promising therapy for severe IgA nephropathy. Design: Open prospective cohort study. Setting: Referral nephrology unit. Patients: 11 adult patients with severe IgA nephropathy (9 who had idiopathic disease and 2 who had Henoch-Schanlein purpura) and indicators of poor prognosis. Intervention: Patients were given high-dose immunoglobulins (2 g/kg each month) for 3 successive months, followed by intramuscular immunoglobulins (preparation content, 16.5%; 0.35 mL/kg every 15 days) for another 6 months. Measurements: Histologic changes were analyzed by comparing pre- and post-therapy renal biopsy specimens blindly, using an activity index (14-point scale), a sclerosis index (10-point scale), and a semiquantitative immunofluorescence test of immune deposits. Proteinuria, hematuria, leukocyturia, enzymuria, and global renal function (creatinine and polyfructosan clearances) were evaluated before and after intervention. Results: Proteinuria (median level before intervention, 5.20 g/d; median level after intervention, 2.25 g/d), hematuria, and leukocyturia decreased substantially. The decrease in glomerular filtration rate was greatly slowed or stopped (median rate of decline in glomerular filtration before, -3.78 mL/min per month; after, 0 mL/min per month). The histologic index of activity (median index before, 5; after, 2) and the staining intensity of glomerular IgA and C3 deposits also decreased. Immunoglobulin therapy was well tolerated. Conclusions: Immunoglobulin therapy may be effective in treating severe IgA nephropathy and protecting renal function. However, prospective controlled trials must confirm these preliminary results.	HOP HENRI MONDOR, INSERM, U139, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, HISTOL ANAT PATHOL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, BIOCHIM LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, BACTERIOL VIROL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, IMMUNOL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, EXPLORAT FONCTIONNELLES RENALES LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, CTR DEPT TRANFUS SANGUINE, F-94010 CRETEIL, FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	ROSTOKER, G (corresponding author), HOP HENRI MONDOR, SERV NEPHROL, 51 AVE GEN DE LATTRE DE TASSIGNY, F-94010 CRETEIL, FRANCE.		Rostoker, Guy/K-1432-2019; Pilatte, Yannick/N-4422-2018; Pilatte, Yannick/AAD-1943-2019	Rostoker, Guy/0000-0002-4383-3825; 				ALAMARTINE E, 1990, CLIN NEPHROL, V34, P45; ANDREOLI SP, 1989, PEDIATR NEPHROL, V3, P248, DOI 10.1007/BF00858524; BALLARDIE F, 1991, IMMUNOLOGY RENAL DIS, P183; BARANDUN S, 1986, CLIN USE INTRAVENOUS, P63; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BENE MC, 1983, J CLIN INVEST, V71, P1342, DOI 10.1172/JCI110886; BERGER J, 1969, TRANSPL P, V1, P939; CLARKSON A, 1993, IGA NEPHROPATHY 25TH, V104, P189; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAMICO G, 1987, Q J MED, V64, P709; DUNNILL MS, 1984, PATHOLOGICAL BASIS R, P112; DURANDY A, 1981, J CLIN INVEST, V67, P867, DOI 10.1172/JCI110104; EMANCIPATOR SN, 1990, KIDNEY INT, V38, P1216, DOI 10.1038/ki.1990.337; EMANCIPATOR SN, 1985, CLIN NEPHROL, V24, P161; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; GENKINS G, 1979, JPLASMAPHERESIS IMMU, P144; GONZALEZCABRERO J, 1987, CLIN EXP IMMUNOL, V68, P694; HAMMARSTROM L, 1992, CLIN APPLICATIONS IN, P117; HOGG RJ, 1985, AM J KIDNEY DIS, V5, P157; HORII Y, 1989, J IMMUNOL, V143, P3949; IMAI H, 1987, J IMMUNOL METHODS, V103, P239, DOI 10.1016/0022-1759(87)90295-X; ISAACS JD, 1990, NEPHROL DIAL TRANSPL, V5, P619, DOI 10.1093/ndt/5.8.619; JAYNE DRW, 1991, LANCET, V337, P1137, DOI 10.1016/0140-6736(91)92797-6; JULIAN B, 1992, IGA NEPHROPATHY 25TH, V104, P198; KIM M, 1992, AUGP INT S IGA NEPHR; LAGRUE G, 1975, J UROL NEPHROL, V81, P655; LAI KN, 1991, CLIN EXP IMMUNOL, V85, P240; LAI KN, 1987, AM J KIDNEY DIS, V10, P66, DOI 10.1016/S0272-6386(87)80014-8; LAI KN, 1986, CLIN NEPHROL, V26, P174; LAI KN, 1988, TRANSPLANT P, V20, P297; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; LIN CY, 1989, NEPHRON, V53, P303, DOI 10.1159/000185772; MAGIL AB, 1987, NEPHRON, V47, P246, DOI 10.1159/000184518; MANOHAR N, 1990, 11TH P INT C NEPHR T, pA105; MEILLET D, 1987, CLIN EXP IMMUNOL, V69, P142; MERSKEY C, 1966, BLOOD-J HEMATOL, V28, P1; MIYAKAWA S, 1986, Jikeikai Medical Journal, V33, P241; NYDEGGER U E, 1991, P27; ODONOGHUE DJ, 1991, J CLIN INVEST, V88, P1522, DOI 10.1172/JCI115462; OLIVIERA D, 1992, IMMUNOLOGICAL ASPECT, P87; PALLA R, 1991, CLIN NEPHROL, V35, P98; PECHADRE JC, 1977, REV EEG NEUROPHYSIOL, V7, P443, DOI 10.1016/S0370-4475(77)80049-X; REMUZZI G, 1987, KIDNEY INT, V32, P292, DOI 10.1038/ki.1987.206; ROSSI F, 1989, J IMMUNOL, V143, P4104; ROSTOKER G, 1991, NEPHRON, V59, P561, DOI 10.1159/000186644; ROSTOKER G, 1989, CLIN EXP IMMUNOL, V75, P30; ROSTOKER G, 1991, LANCET, V338, P54, DOI 10.1016/0140-6736(91)90043-O; ROSTOKER G, 1992, CLIN EXP IMMUNOL, V90, P305; SCHENA FP, 1990, AM J MED, V89, P209; SCHENA FP, 1989, CLIN EXP IMMUNOL, V77, P15; SCHWARTZ D, 1984, METHODES STATISTIQUE, P245; SCOTT MG, 1990, HUMAN IGG SUBCLASSES, P161; SINICO RA, 1986, J IMMUNOL, V137, P536; SUNDBLAD A, 1991, EUR J IMMUNOL, V21, P1155, DOI 10.1002/eji.1830210510; TOMINO Y, 1984, CLIN EXP IMMUNOL, V58, P42; van den Wall Bake A W, 1988, Clin Exp Immunol, V72, P321; WALDO FB, 1989, AM J KIDNEY DIS, V13, P55, DOI 10.1016/S0272-6386(89)80117-9; WALKER RG, 1990, CLIN NEPHROL, V34, P103; WALSER M, 1990, KIDNEY INT, V37, P1195, DOI 10.1038/ki.1990.103; WIENER E, 1990, HUMAN IGG SUBCLASSES, P135; WIGHT JP, 1992, NEPHROL DIAL TRANSPL, V7, P379; WOO KT, 1987, CLIN NEPHROL, V28, P304; YOSHIKAWA N, 1990, CLIN NEPHROL, V33, P160	63	122	128	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					476	484		10.7326/0003-4819-120-6-199403150-00005	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311370				2022-12-28	WOS:A1994NB62500005
J	CHREN, MM; LANDEFELD, CS				CHREN, MM; LANDEFELD, CS			PHYSICIANS BEHAVIOR AND THEIR INTERACTIONS WITH DRUG COMPANIES - A CONTROLLED-STUDY OF PHYSICIANS WHO REQUESTED ADDITIONS TO A HOSPITAL DRUG FORMULARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACEUTICAL REPRESENTATIVES; FREE LUNCH; DOCTORS; FACULTY; GIFTS	Objective.-It is controversial whether physicians' interactions with drug companies affect their behavior. To test the null hypothesis, that such interactions are not associated with physician behavior, we studied one behavior: requesting that a drug be added to a hospital formulary. Design.-Nested case-control study. Setting.-University hospital. Participants.-Full-time attending physicians. Case physicians were all 40 physicians who requested a formulary addition from January 1989 through October 1990. Control physicians were 80 randomly selected physicians who had not made requests. Main Exposure Measure.-Physician interactions with drug companies, as determined by survey of physicians (response rate, 88% [105/120]). Results.-Physicians who had requested that drugs be added to the formulary interacted with drug companies more often than other physicians; for example, they were more likely to have accepted money from companies to attend or speak at educational symposia or to perform research (odds ratio [OR], 5.1; 95% confidence interval [CI], 2.0 to 13.2). Furthermore, physicians were more likely than other physicians to have requested that drugs manufactured by specific companies be added to the formulary if they had met with pharmaceutical representatives from those companies (OR, 13.2; 95% CI, 4.8 to 36.3) or had accepted money from those companies (OR, 19.2; 95% CI, 2.3 to 156.9). These associations were consistent in multivariable analyses controlling for potentially confounding factors. Moreover, physicians were more likely to have requested formulary additions made by the companies whose pharmaceutical representatives they had met (OR, 4.9; 95% CI, 3.2 to 7.4) or from whom they had accepted money (OR, 1.7; 95% CI, 1.0 to 2.7) than they were to have requested drugs made by other companies. Conclusion.-Requests by physicians that drugs be added to a hospital formulary were strongly and specifically associated with the physicians' interactions with the companies manufacturing the drugs.	VET AFFAIRS MED CTR,DEPT MED,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,PROGRAM HLTH CARE RES,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; University Hospitals of Cleveland; Case Western Reserve University	CHREN, MM (corresponding author), VET AFFAIRS MED CTR,DEPT DERMATOL 11GW,10701 EAST BLVD,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMOWITZ PW, 1986, AM J HOSP PHARM, V43, P2834, DOI 10.1093/ajhp/43.11.2834; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BERMAN JL, 1990, ANN INTERN MED, V113, P900, DOI 10.7326/0003-4819-113-11-900_2; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; Bowman M A, 1988, J Contin Educ Health Prof, V8, P13, DOI 10.1002/chp.4750080104; BOWMAN MA, 1986, MOBIUS, V6, P66; BRICKER EM, 1989, NEW ENGL J MED, V320, P1690, DOI 10.1056/NEJM198906223202511; CASSEL CK, 1992, NEW ENGL J MED, V327, P1687; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; FLEISS JL, 1981, STATISTICAL METHODS, P64; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; KATZ AM, 1992, NEW ENGL J MED, V327, P1687; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUCKER TD, 1990, MED CARE, V28, P928, DOI 10.1097/00005650-199010000-00007; SCARPIN L, 1991, J GEN INTERN MED, V6, P181, DOI 10.1007/BF02598322; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; Wilkes Michael S, 1989, N Y Times Mag, P128; YASUDA SU, 1992, CLIN PHARMACOL THER, V52, P577, DOI 10.1038/clpt.1992.194; 1990, CLIN RES, V38, P239; 1989, SAS STAT USERS GUIDE, P2; 1990, ABMS COMPENDIUM CERT	26	294	296	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					684	689		10.1001/jama.271.9.684	http://dx.doi.org/10.1001/jama.271.9.684			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309031				2022-12-28	WOS:A1994MX57000029
J	MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J				MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J			THE INFLUENCE OF THE PROBABILITY OF SURVIVAL ON PATIENTS PREFERENCES REGARDING CARDIOPULMONARY-RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; HOSPITAL CARDIAC-ARREST; ADVANCE DIRECTIVES; ELDERLY OUTPATIENTS; MEDICAL-CARE; ATTITUDES; OUTCOMES; OLDER; PHYSICIANS; DECISIONS	Background. Studies suggest that a majority of elderly patients would want to undergo cardiopulmonary resuscitation (CPR) if they had a cardiac arrest. Yet few studies have examined their preferences after clinicians have informed them about the outcomes of CPR. Methods. To study older patients' preferences regarding CPR, we interviewed as many ambulatory patients as possible in one geriatrics practice in Denver from August 1, 1991, through July 31, 1992. Results. A total of 371 patients at least 60 years of age were eligible; 287 completed the interview (mean age, 77 years; range, 60 to 99). When asked about their wishes if they had cardiac arrest during an acute illness, 41 percent opted for CPR before learning the probability of survival to discharge. After learning the probability of survival (10 to 17 percent), 22 percent opted for CPR. Only 6 percent of patients 86 years of age or older opted for CPR under these conditions. When asked about a chronic illness in which the life expectancy was less than one year, 11 percent of the 287 patients opted for CPR before learning the. probability of survival to discharge. After teaming the probability of survival (0 to 5 percent), 5 percent said they would want CPR. Conclusions. Older patients readily understand prognostic information, which influences their preferences with respect to CPR. Most do not want to undergo CPR once a clinician explains the probability of survival after the procedure.	GEORGE WASHINGTON UNIV,DEPT HLTH CARE SCI,WASHINGTON,DC; GEORGE WASHINGTON UNIV,INTENS CARE UNIT RES UNIT,WASHINGTON,DC	George Washington University; George Washington University	MURPHY, DJ (corresponding author), PRESBYTERIAN ST LUKES MED CTR,SENIOR CITIZENS HLTH CTR,1801 HIGH ST,DENVER,CO 80218, USA.		Murphy, Denis J/ABC-1734-2020					APPLEBAUM GE, 1990, J AM GERIATR SOC, V38, P197, DOI 10.1111/j.1532-5415.1990.tb03490.x; AWOKE S, 1992, J AM GERIATR SOC, V40, P593, DOI 10.1111/j.1532-5415.1992.tb02109.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; COGEN R, 1992, ARCH INTERN MED, V152, P1885, DOI 10.1001/archinte.152.9.1885; COHENMANSFIELD J, 1992, GERONTOLOGIST, V32, P89, DOI 10.1093/geront/32.1.89; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DEGROSS JM, 1990, SOUTHERN MED J, V83, P733, DOI 10.1097/00007611-199007000-00001; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; JECKER NS, 1993, J CLIN ETHIC, V4, P16; Kielstein Rita, 1993, Kennedy Institute of Ethics Journal, V3, P303; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MALLOY TR, 1992, J AM GERIATR SOC, V40, P1255, DOI 10.1111/j.1532-5415.1992.tb03652.x; MICHELSON C, 1991, GERONTOLOGIST, V31, P358, DOI 10.1093/geront/31.3.358; MILLER DL, 1993, ARCH INTERN MED, V153, P1999, DOI 10.1001/archinte.153.17.1999; MILLER DL, 1992, ARCH INTERN MED, V152, P578, DOI 10.1001/archinte.152.3.578; MOWER MR, 1993, ARCH INTERN MED, V153, P375; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; QUILL TE, 1992, ARCH INTERN MED, V152, P569, DOI 10.1001/archinte.152.3.569; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TORIAN LV, 1992, ARCH INTERN MED, V152, P1659; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; TRIAN LV, 1992, ARCH INTERNMED, V152, P561; UHLMANN RF, 1989, WESTERN J MED, V150, P705; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; 1987, CRUNC STATISTICAL PA	45	439	443	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					545	549		10.1056/NEJM199402243300807	http://dx.doi.org/10.1056/NEJM199402243300807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX436	8302322				2022-12-28	WOS:A1994MX43600007
J	HURT, RD; DALE, LC; FREDRICKSON, PA; CALDWELL, CC; LEE, GA; OFFORD, KP; LAUGER, GG; MARUSIC, Z; NEESE, LW; LUNDBERG, TG				HURT, RD; DALE, LC; FREDRICKSON, PA; CALDWELL, CC; LEE, GA; OFFORD, KP; LAUGER, GG; MARUSIC, Z; NEESE, LW; LUNDBERG, TG			NICOTINE PATCH THERAPY FOR SMOKING CESSATION COMBINED WITH PHYSICIAN ADVICE AND NURSE FOLLOW-UP - ONE-YEAR OUTCOME AND PERCENTAGE OF NICOTINE REPLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOBACCO WITHDRAWAL; CONTROLLED TRIAL; QUIT SMOKING; DEPENDENCE; INTERVENTION; SYMPTOMS	Objective.-To determine the efficacy of a 22-mg nicotine patch combined with the National Cancer Institute program for physician advice and nurse follow-up in providing withdrawal symptom relief, 1-year smoking cessation outcome, and percentage of nicotine replacement. Design.-Randomized, double-blind, placebo-controlled trial. Subjects.-Two-hundred forty healthy volunteers who were smoking at least 20 cigarettes per day. Interventions.-Based on the National Cancer Institute program, subjects received smoking cessation advice from a physician. Follow-up and relapse prevention were provided by a study nurse during individual counseling sessions. Subjects were randomly assigned to 8 weeks of a 22-mg nicotine or placebo patch. Main Outcome Measures.-Abstinence from smoking was verified by expired air carbon monoxide levels. Withdrawal symptoms were recorded during patch therapy, and the percentage of nicotine replacement was calculated by dividing serum nicotine and cotinine levels at week 8 of patch therapy by levels obtained while smoking. Results.-Higher smoking cessation rates were observed in the active nicotine patch group at 8 weeks (46.7% vs 20%) (P<.001) and at 1 year (27.5% vs 14.2%) (P=.011). Higher smoking cessation rates were also observed in subjects assigned to the active patch who had lower serum levels of nicotine and cotinine at baseline, and withdrawal symptom relief was better in the active patch group compared with placebo. Conclusions.-Clinically significant smoking cessation can be achieved using nicotine patch therapy combined with physician intervention, nurse counseling, follow-up, and relapse prevention. Smokers with lower baseline nicotine and cotinine levels had better cessation rates, which provides indirect evidence that they had more adequate nicotine replacement with this fixed dose of transdermal nicotine than those smokers with higher baseline levels.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV THORAC DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN,CTR NICOTINE DEPENDENCE,JACKSONVILLE,FL; MAYO CLIN,DIV COMMUNITY INTERNAL MED,SCOTTSDALE,AZ	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	HURT, RD (corresponding author), MAYO CLIN & MAYO FDN,CTR NICOTINE DEPENDENCE,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; ABELIN T, 1989, LANCET, V1, P7; Beck A.T, 1978, BECK DEPRESSION INVE; BENOWITZ NL, 1991, BRIT J ADDICT, V86, P495; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; GLYNN TJ, 1987, ADM871447 US DEP HLT, V65, P70; GRITZ ER, 1991, BRIT J ADDICT, V86, P57; HALL SM, 1984, CLIN PHARMACOL THER, V35, P810, DOI 10.1038/clpt.1984.117; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HURT RD, 1992, MED CLIN N AM, V76, P495, DOI 10.1016/S0025-7125(16)30364-9; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; HURT RD, 1993, CLIN PHARMACOL THER, V54, P98, DOI 10.1038/clpt.1993.117; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; ROSE JE, 1985, CLIN PHARMACOL THER, V38, P450, DOI 10.1038/clpt.1985.203; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; WEST RJ, 1989, PSYCHOL MED, V19, P981, DOI 10.1017/S0033291700005705; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; 1987, DIAGNOSTIC STATISTIC; 1991, JAMA-J AM MED ASSOC, V266, P3133	24	187	189	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					595	600		10.1001/jama.271.8.595	http://dx.doi.org/10.1001/jama.271.8.595			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW477	8301791				2022-12-28	WOS:A1994MW47700022
J	WU, J; COHEN, LB; FALK, CX				WU, J; COHEN, LB; FALK, CX			NEURONAL-ACTIVITY DURING DIFFERENT BEHAVIORS IN APLYSIA - A DISTRIBUTED ORGANIZATION	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; CENTRAL NERVOUS-SYSTEM; ABDOMINAL-GANGLION; IDENTIFICATION; INTERNEURONS; LEECH; CALIFORNICA; MODULATION; MEDIATION; CIRCUITS	The active neuronal populations in the Aplysia abdominal ganglion during spontaneous and evoked behaviors were compared with the use of multineuronal optical measurements. In some preparations, more than 90 percent of the neurons activated during the reflex withdrawal of the gill also were activated during respiratory pumping and during small spontaneous gill contractions. Although the same neurons made action potentials in all three behaviors, the activity patterns were different. There was a substantial interaction between the neural substrates underlying evoked and spontaneous behaviors when they were made to occur together. If a gill withdrawal reflex was elicited a few seconds after a respiratory pumping episode, the evoked neuronal activity in most neurons was clearly altered. These results suggest that a distributed organization involving a large number of neurons may be responsible for generating the two behaviors. Different behaviors appear to be generated by altered activities of a single, large distributed network rather than by small dedicated circuits.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008437, T32NS007102] Funding Source: NIH RePORTER; NINDS NIH HHS [NS07102, NS08437] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEVIZOS A, 1989, J NEUROSCI, V9, P3058; BALDSSERA F, 1981, HDB PHYSL NERVOUS SY; BYME JH, 1980, J NEUROPHYSIOL, V43, P896; BYRNE JH, 1978, BRAIN RES, V143, P87, DOI 10.1016/0006-8993(78)90754-0; BYRNE JH, 1983, J NEUROPHYSIOL, V49, P491, DOI 10.1152/jn.1983.49.2.491; BYRNE JH, 1978, J NEUROPHYSIOL, V41, P418, DOI 10.1152/jn.1978.41.2.418; CAMHI JM, 1978, J COMP PHYSIOL, V128, P193, DOI 10.1007/BF00656852; CASH D, 1989, J NEUROBIOL, V20, P25, DOI 10.1002/neu.480200104; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; Cohen L B, 1986, Soc Gen Physiol Ser, V40, P71; COHEN T E, 1991, Society for Neuroscience Abstracts, V17, P1302; FALK C X, 1989, Society for Neuroscience Abstracts, V15, P1264; FALK CX, 1993, J NEUROSCI, V13, P4072; FROST WN, 1987, THESIS COLUMBIA U; GETTING PA, 1989, ANNU REV NEUROSCI, V12, P185, DOI 10.1146/annurev.neuro.12.1.185; GRINVALD A, 1980, BIOL BULL, V159, P484; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HEITLER WJ, 1985, J EXP BIOL, V114, P521; HENNIG RM, 1992, NEUROBIOLOGY MOTOR P, P105; HOOPER SL, 1989, SCIENCE, V244, P1587, DOI 10.1126/science.2740903; HOPFIELD JJ, 1986, SCIENCE, V233, P625, DOI 10.1126/science.3755256; KANDEL ER, 1967, J NEUROPHYSIOL, V30, P1352, DOI 10.1152/jn.1967.30.6.1352; Kaplan S. W., 1993, Society for Neuroscience Abstracts, V19, P16; KEIN J, 1992, NEUROBIOLOGY MOTOR P, P147; KOESTER J, 1989, J NEUROPHYSIOL, V62, P1113, DOI 10.1152/jn.1989.62.5.1113; KOESTER J, 1977, BRAIN RES, V121, P1, DOI 10.1016/0006-8993(77)90435-8; KRISTAN WB, 1988, EXPERIENTIA, V44, P383, DOI 10.1007/BF01940531; KUPFERMANN I, 1971, SCIENCE, V174, P1252, DOI 10.1126/science.174.4015.1252; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; NAKASHIMA M, 1992, IEEE T BIO-MED ENG, V39, P26, DOI 10.1109/10.108124; NICHOLLS JG, 1970, J PHYSIOL-LONDON, V209, P647, DOI 10.1113/jphysiol.1970.sp009184; Soffe S. R, 1992, NEUROBIOLOGY MOTOR P, P73; SYED NI, 1992, NEURON, V8, P767, DOI 10.1016/0896-6273(92)90097-W; TRUDEAU LE, 1992, J NEUROSCI, V12, P3838; TSAU Y, IN PRESS J NEUROSCI; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; WU JY, IN PRESS J NEUROSCI; ZECEVIC D, 1989, J NEUROSCI, V9, P3681	38	107	109	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	1994	263	5148					820	823		10.1126/science.8303300	http://dx.doi.org/10.1126/science.8303300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303300				2022-12-28	WOS:A1994MV86600039
J	JENSEN, DM; CHENG, S; KOVACS, TOG; RANDALL, G; JENSEN, ME; REEDY, T; FRANKL, H; MACHICADO, G; SMITH, J; SILPA, M; VANDEVENTER, G				JENSEN, DM; CHENG, S; KOVACS, TOG; RANDALL, G; JENSEN, ME; REEDY, T; FRANKL, H; MACHICADO, G; SMITH, J; SILPA, M; VANDEVENTER, G			A CONTROLLED-STUDY OF RANITIDINE FOR THE PREVENTION OF RECURRENT HEMORRHAGE FROM DUODENAL-ULCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLEEDING PEPTIC-ULCERS; HISTAMINE2-RECEPTOR ANTAGONISTS; MAINTENANCE TREATMENT; STANDARD THERAPY; CONTROLLED TRIAL; DRUG-THERAPY; CIMETIDINE; MULTICENTER; DISEASE; RELAPSE	Background. Hemorrhage is the most common complication of duodenal ulcer disease, but there is little information about the effectiveness and safety of long-term maintenance therapy with histamine H-2-receptor blockers. Methods. We conducted a double-blind study in patients with endoscopically documented hemorrhage from duodenal ulcers. Patients were randomly assigned to maintenance therapy with ranitidine (150 mg at night) or placebo and were followed for up to three years. Endoscopy was performed at base line (to document that the ulcers had healed), at exit from the study, and when a patient had persistent ulcer symptoms unrelieved by antacids or had gastrointestinal bleeding. Symptomatic relapses without bleeding were treated with ranitidine; if the ulcer healed within eight weeks, the patient resumed taking the assigned study medication. Results. The two groups were similar at entry, which usually occurred about three months after the index hemorrhage. After a mean follow-up of 61 weeks, 3 of the 32 patients treated with ranitidine had recurrent hemorrhage, as compared with 12 of the 33 given placebo (P<0.05). Half the episodes of recurrent bleeding were asymptomatic. One patient in the ranitidine group withdrew from the study because of asymptomatic thrombocytopenia during the first month. Conclusions. For patients whose duodenal ulcers heal after severe hemorrhage, long-term maintenance therapy with ranitidine is safe and reduces the risk of recurrent bleeding.	UNIV CALIF LOS ANGELES, CTR ULCER RES & EDUC, LOS ANGELES, CA 90024 USA; W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA USA; VALLEY MED CTR, VAN NUYS, CA USA; ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA; HIGHLAND HOSP, OAKLAND, CA USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Ochsner Health System			smith, james w/C-9922-2016		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033273] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 41301, AM 33273] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALSTEAD EM, 1983, GUT, V24, P418, DOI 10.1136/gut.24.5.418; BOYD EJS, 1984, SCAND J GASTROENTERO, V19, P394, DOI 10.1080/00365521.1984.12005741; CAPRIA A, 1987, INT J TISSUE REACT, V9, P439; DEBAS HT, 1991, TXB GASTROENTEROLOGY, V1, P1379; DIXON WJ, 1985, BMDP STATISTICAL SOF; ELASHOFF JD, 1983, J CLIN GASTROENTEROL, V5, P509, DOI 10.1097/00004836-198312000-00008; FELDMAN M, 1990, NEW ENGL J MED, V323, P1749; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; GOUGH KR, 1984, LANCET, V2, P659; JENSEN D M, 1990, Gastroenterology, V98, pA65; JENSEN D M, 1990, Gastroenterology, V98, pA5; JENSEN D M, 1989, Gastroenterology, V96, pA239; JENSEN DM, 1988, SCAND J GASTROENTERO, V23, P214, DOI 10.3109/00365528809099148; JENSEN DM, 1991, TXB GASTROENTEROLOGY, V2, P2618; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; KURATA JH, 1982, GASTROENTEROLOGY, V83, P1008; MURRAY WR, 1988, SCAND J GASTROENTERO, V23, P183, DOI 10.3109/00365528809103965; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SAMLOFF IM, 1982, GASTROENTEROLOGY, V82, P26; SILVIS SE, 1985, J CLIN GASTROENTEROL, V7, P482, DOI 10.1097/00004836-198512000-00008; SONNENBERG A, 1985, BRIT MED J, V290, P1185, DOI 10.1136/bmj.290.6476.1185; STRUM WB, 1986, ANN INTERN MED, V105, P757, DOI 10.7326/0003-4819-105-5-757; SWAIN CP, 1986, LANCET, V1, P1113; SWAIN CP, 1981, LANCET, V2, P1313; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; WADE AG, 1988, BMJ-BRIT MED J, V296, P971, DOI 10.1136/bmj.296.6627.971; WALAN A, 1987, SCAND J GASTROENTERO, V22, P397, DOI 10.3109/00365528708991481	27	102	104	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					382	386		10.1056/NEJM199402103300602	http://dx.doi.org/10.1056/NEJM199402103300602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284002	Bronze			2022-12-28	WOS:A1994MV27900002
J	WANG, L; JUJI, T; TOKUNAGA, K; TAKAHASHI, K; KUWATA, S; UCHIDA, S; TADOKORO, K; TAKAI, K				WANG, L; JUJI, T; TOKUNAGA, K; TAKAHASHI, K; KUWATA, S; UCHIDA, S; TADOKORO, K; TAKAI, K			BRIEF REPORT - POLYMORPHIC MICROSATELLITE MARKERS FOR THE DIAGNOSIS OF GRAFT-VERSUS-HOST DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRINUCLEOTIDE REPEAT POLYMORPHISM; BONE-MARROW TRANSPLANTATION; DINUCLEOTIDE REPEAT; IMMUNOCOMPETENT PATIENT; DNA POLYMORPHISMS; X-CHROMOSOME; TRANSFUSION; GENE; BLOOD; LOCUS		UNIV TOKYO, FAC MED, DEPT TRANSFUS MED & IMMUNOHEMATOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM & NUTR, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo	WANG, L (corresponding author), JAPANESE RED CROSS SOC, CTR CENT BLOOD, HIROO 4-1-31, SHIBUYA KU, TOKYO 150, JAPAN.							ARSURA EL, 1988, ARCH INTERN MED, V148, P1941, DOI 10.1001/archinte.148.9.1941; BLAZAR BR, 1985, BLOOD, V66, P1436; BOEHM CD, 1983, NEW ENGL J MED, V308, P1054, DOI 10.1056/NEJM198305053081803; BRUBAKER DB, 1986, HUM PATHOL, V17, P1085, DOI 10.1016/S0046-8177(86)80412-9; CAPON SM, 1991, ANN INTERN MED, V114, P1025, DOI 10.7326/0003-4819-114-12-1025; CASKEY CT, 1983, BANBURY REPORT SERIE, V14, P1; DROBYSKI W, 1989, BLOOD, V74, P2285; GINSBURG D, 1985, J CLIN INVEST, V75, P596, DOI 10.1172/JCI111736; HAUGE XY, 1991, NUCLEIC ACIDS RES, V19, P4308, DOI 10.1093/nar/19.15.4308-a; HUTZ MH, 1984, HUM GENET, V66, P217, DOI 10.1007/BF00286604; JUJI T, 1989, NEW ENGL J MED, V321, P56; KANTER MH, 1992, TRANSFUSION, V32, P323, DOI 10.1046/j.1537-2995.1992.32492263445.x; LALLOZ MRA, 1991, LANCET, V338, P207, DOI 10.1016/0140-6736(91)90348-S; LEITMAN SF, 1985, TRANSFUSION, V25, P293, DOI 10.1046/j.1537-2995.1985.25485273804.x; LITT M, 1989, AM J HUM GENET, V44, P397; LITT M, 1990, NUCLEIC ACIDS RES, V18, P4301, DOI 10.1093/nar/18.14.4301; ORKIN SH, 1983, PROG HEMATOL, V13, P49; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; PAGE D, 1982, P NATL ACAD SCI-BIOL, V79, P5352, DOI 10.1073/pnas.79.17.5352; PERKINS HA, 1992, TRANSFUSION, V32, P302, DOI 10.1046/j.1537-2995.1992.32492263440.x; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P4307, DOI 10.1093/nar/19.15.4307; POLYMEROPOULOS MH, 1990, NUCLEIC ACIDS RES, V18, P7468, DOI 10.1093/nar/18.24.7468-a; PROCHOWNIK EV, 1983, NEW ENGL J MED, V308, P1549, DOI 10.1056/NEJM198306303082601; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; TAKAHASHI K, 1991, TRANSFUS SCI, V12, P281, DOI 10.1016/0955-3886(91)90108-F; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; VONFLIEDNER V, 1982, AM J MED, V72, P951; WEBER JL, 1989, AM J HUM GENET, V44, P388; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754	31	47	50	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					398	401		10.1056/NEJM199402103300605	http://dx.doi.org/10.1056/NEJM199402103300605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284005	Bronze			2022-12-28	WOS:A1994MV27900005
J	JACKSON, MR; COHENDOYLE, MF; PETERSON, PA; WILLIAMS, DB				JACKSON, MR; COHENDOYLE, MF; PETERSON, PA; WILLIAMS, DB			REGULATION OF MHC CLASS-I TRANSPORT BY THE MOLECULAR CHAPERONE, CALNEXIN (P88, IP90)	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; ENDOPLASMIC-RETICULUM MEMBRANE; BINDING-PROTEIN; HISTOCOMPATIBILITY MOLECULES; SURFACE EXPRESSION; HLA-A; PEPTIDE; ANTIGEN; BETA-2-MICROGLOBULIN; EMPTY	Assembled class I histocompatibility molecules, consisting of heavy chain, beta2-microglobulin, and peptide ligand, are transported rapidly to the cell surface. In contrast, the intracellular transport of free heavy chains or peptide-deficient heavy chain-beta2-microglobulin heterodimers is impaired. A 90-kilodalton membrane-bound chaperone of the endoplasmic reticulum (ER), termed calnexin, associates quantitatively with newly synthesized class I heavy chains, but the functions of calnexin in this interaction are unknown. Class I subunits were expressed alone or in combination with calnexin in Drosophila melanogaster cells. Calnexin retarded the intracellular transport of both peptide-deficient heavy chain-beta2-microglobulin heterodimers and free heavy chains. Calnexin also impeded the rapid intracellular degradation of free heavy chains. The ability of calnexin to protect and retain class I assembly intermediates is likely to contribute to the efficient intracellular formation of class I-peptide complexes.	UNIV TORONTO, DEPT BIOCHEM, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Toronto; Scripps Research Institute								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLICK EM, 1992, COLD SPRING HARB SYM, V57, P571, DOI 10.1101/SQB.1992.057.01.063; COHENDOYLE MF, UNPUB; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4223; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WADA I, 1991, J BIOL CHEM, V266, P19599; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YANG Y, 1992, J BIOL CHEM, V267, P11669	32	245	252	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					384	387		10.1126/science.8278813	http://dx.doi.org/10.1126/science.8278813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278813				2022-12-28	WOS:A1994MT03400036
J	MAULE, WF				MAULE, WF			SCREENING FOR COLORECTAL-CANCER BY NURSE ENDOSCOPISTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FLEXIBLE FIBEROPTIC SIGMOIDOSCOPY; POLYPS; RISK; EXPERIENCE; PHYSICIANS; MORTALITY; ADENOMAS; RECTUM; COLON; SIZE	Background. Case-control studies have demonstrated that screening by sigmoidoscopy is effective in reducing mortality from colorectal cancer. If nurses performed screening examinations, more patients could be screened and, at current income levels, at a lower cost. Methods. Two registered nurses and two licensed practical nurses learned to perform examinations with the flexible fiberoptic sigmoidoscope in order to screen patients for colorectal tumors. They performed 1881 independent examinations of outpatients more than 45 years of age. During the same period, 730 examinations were performed by two gastroenterologists in similar patients. Results. The mean depth of insertion of the sigmoidoscope was slightly but significantly greater in the patients examined by the physicians than in those examined by the nurses (48 vs. 46 cm in men, P = 0.003; 41 vs. 38 cm in women, P = 0.002). Adenomas were found in 14 percent of the men and 8 percent of the women examined (P = 0.001). Nine cancers were found in men and four in women. There were no significant differences between the nurses and the physicians in the proportion of examinations that were positive for adenomas or cancer. No complications occurred during the initial examinations or during 894 follow-up sigmoidoscopic procedures. Among the patients whose initial examination results were normal, more of those examined by nurses returned for follow-up sigmoidoscopy after 12 months or more (45 percent, vs. 30 percent of those examined by physicians; P = 0.001). Conclusions. Nurses can carry out screening by flexible sigmoidoscopy as accurately and safely as experienced gastroenterologists.			MAULE, WF (corresponding author), OCHSNER CLIN BATON ROUGE, DEPT MED, GASTROENTEROL SECT, 16777 MED CTR DR, BATON ROUGE, LA 70816 USA.							ANASTASI A, 1968, PSYCHOL TESTING, P486; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CASS OW, 1993, ANN INTERN MED, V118, P40, DOI 10.7326/0003-4819-118-1-199301010-00008; GOLDBLOOM R, 1989, CAN MED ASSOC J, V141, P209; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; HOFF G, 1985, SCAND J GASTROENTERO, V20, P356, DOI 10.3109/00365528509091664; KATON RM, 1985, FLEXIBLE SIGMOIDOSCO; MARKS G, 1979, DIS COLON RECTUM, V22, P162, DOI 10.1007/BF02586809; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; NIVATVONGS S, 1980, NEW ENGL J MED, V303, P380, DOI 10.1056/NEJM198008143030707; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SCHERTZ RD, 1989, GASTROINTEST ENDOSC, V35, P316, DOI 10.1016/S0016-5107(89)72800-5; SCHROY PC, 1988, GASTROINTEST ENDOSC, V34, P390, DOI 10.1016/S0016-5107(88)71402-9; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P94; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; TRAUL DG, 1983, DIS COLON RECTUM, V26, P161, DOI 10.1007/BF02560161; VENNES JA, 1992, GASTROINTEST ENDOSC, V38, P746; WEISSMAN GS, 1987, CA-CANCER J CLIN, V37, P26, DOI 10.3322/canjclin.37.1.26; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1984, ADV INTERNAL MED, V30, P471; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806; 1987, ANN INTERN MED, V107, P589; 1989, SUMMARY CURRENT GUID; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E; 1989, CAN MED ASSOC J, V141, P1126	31	156	157	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					183	187		10.1056/NEJM199401203300307	http://dx.doi.org/10.1056/NEJM199401203300307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264742				2022-12-28	WOS:A1994MQ86300007
J	EDES, TE				EDES, TE			HOME VISIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					173	173		10.1001/jama.271.3.173	http://dx.doi.org/10.1001/jama.271.3.173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277530				2022-12-28	WOS:A1994MQ64500001
J	SCHWARTZ, B; FRIES, S; FITZGIBBON, AM; LIPMAN, H				SCHWARTZ, B; FRIES, S; FITZGIBBON, AM; LIPMAN, H			PEDIATRICIANS DIAGNOSTIC-APPROACH TO PHARYNGITIS AND IMPACT OF CLIA 1988 ON OFFICE DIAGNOSTIC-TESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; GROUP-A STREPTOCOCCI; PHYSICIANS OFFICE; THROAT-CULTURES; PENICILLIN THERAPY; SORE THROATS; ACCURACY; PENNSYLVANIA; LABORATORIES; PERFORMANCE	Objective.-To determine the factors associated with an optimal diagnostic approach to a child with pharyngitis, characterize off ice laboratory methods for throat swab culture and group A streptococcal rapid antigen testing, and assess the potential impact of the Clinical Laboratory Improvement Amendments (CLIA) of 1988 on the performance of these tests. Design and Setting.-Mailed survey to all board-certified primary care pediatricians from seven western states with telephone follow-up for nonrespondents. Outcome Measures.-Differences in practice characteristics and use of office laboratory tests for physicians who usually (>80%) diagnose pharyngitis using a recommended approach vs those who follow this approach less often (<50%); characteristics of physicians who indicate that they intend to discontinue office throat culture because of CLIA and those who will continue to perform this test also are compared. Results.-Responses from 531 pediatricians were analyzed. Forty-four percent diagnosed pharyngitis appropriately for more than 80% of patients, and 17% did so for fewer than 50%. Optimal diagnosis was significantly more common among physicians who cultured throat swabs in their office (relative risk, 1.40; 95% confidence interval, 1.19 to 1.66) and less common among solo practitioners (relative risk, 0.71; 95% confidence interval, 0.56 to 0.88). Factors that may decrease the sensitivity of off ice throat culture include short duration of incubation (59%), lack of quality control (51%), and limited education of the persons reading results (6%). With implementation of CLIA, 24% of pediatricians reported that they already have discontinued or will discontinue off ice throat culture, and 23% have discontinued or will discontinue antigen detection testing for group A streptococci. Those most likely to stop off ice culture include solo practitioners and practitioners who do not currently perform quality control of culture methods. Conclusions.-Office culture for group A streptococci is strongly associated with an optimal diagnostic approach. Implementation of CLIA regulations may substantially decrease the number of physicians who perform this test. The balance between potential improvements in the quality of office culture with CLIA implementation and the decreased availability of this test needs to be assessed.	BOULDER MED CTR,BOULDER,CO; BIOTEXT,BOULDER,CO		SCHWARTZ, B (corresponding author), CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,MAILSTOP C-09,ATLANTA,GA 30333, USA.							ARTHUR JD, 1984, POSTGRAD MED, V75, P241, DOI 10.1080/00325481.1984.11697969; BLOCH MJ, 1988, JAMA-J AM MED ASSOC, V260, P230, DOI 10.1001/jama.260.2.230; CRAWLEY R, 1986, JAMA-J AM MED ASSOC, V255, P374, DOI 10.1001/jama.255.3.374; DAJANI AS, 1989, PEDIATR INFECT DIS J, V8, P263; FACKLAM RR, 1987, J CLIN MICROBIOL, V25, P504, DOI 10.1128/JCM.25.3.504-508.1987; GERBER MA, 1986, DIAGN MICR INFEC DIS, V4, pS5, DOI 10.1016/S0732-8893(86)80038-4; GERBER MA, 1989, PEDIATR INFECT DIS J, V8, P820, DOI 10.1097/00006454-198911000-00032; GORDIS L, 1976, PEDIATRICS, V57, P422; HARBECK RJ, 1993, J CLIN MICROBIOL, V31, P839, DOI 10.1128/JCM.31.4.839-844.1993; HUCK W, 1989, J CLIN MICROBIOL, V27, P1715, DOI 10.1128/JCM.27.8.1715-1718.1989; KELLOGG JA, 1986, JAMA-J AM MED ASSOC, V255, P2638, DOI 10.1001/jama.255.19.2638; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; LIEU TA, 1988, PEDIATR INFECT DIS J, V7, P847; LIEU TA, 1990, PEDIATRICS, V85, P246; LUNZ ME, 1987, JAMA-J AM MED ASSOC, V258, P361, DOI 10.1001/jama.258.3.361; MACKNIN ML, 1988, PEDIATR INFECT DIS J, V7, P735, DOI 10.1097/00006454-198810000-00016; MEIER FA, 1990, ARCH INTERN MED, V150, P1696, DOI 10.1001/archinte.150.8.1696; NELSON JD, 1984, PEDIATR INFECT DIS J, V3, P10, DOI 10.1097/00006454-198401000-00004; PEDDECORD KM, 1980, AM J CLIN PATHOL, V73, P380; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RANDOLPH MF, 1985, J PEDIATR-US, V106, P870, DOI 10.1016/S0022-3476(85)80228-6; REDD SC, 1988, PEDIATRICS, V82, P576; REED BD, 1990, ARCH INTERN MED, V150, P1727, DOI 10.1001/archinte.150.8.1727; ROSENSTEIN BJ, 1970, J PEDIATR-US, V76, P606, DOI 10.1016/S0022-3476(70)80413-9; SCHUMAN AJ, 1993, CONT PEDIAT, V1, P50; SHULMAN ST, 1989, PEDIATR INFECT DIS J, V8, P816, DOI 10.1097/00006454-198911000-00031; SNELLMAN LW, 1993, PEDIATRICS, V91, P1166; TIEN PC, 1992, 32ND INT C ANT AG CH, P367; TODD JK, 1982, PEDIATR INFECT DIS J, V1, P265, DOI 10.1097/00006454-198207000-00017; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WAGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695; WALD ER, 1987, PEDIATRICS, V80, P371; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; 1991, RED BOOK, P438; [No title captured]	36	38	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					234	238		10.1001/jama.271.3.234	http://dx.doi.org/10.1001/jama.271.3.234			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277551				2022-12-28	WOS:A1994MQ64500039
J	SKALHEGG, BS; TASKEN, K; HANSSON, V; HUITFELDT, HS; JAHNSEN, T; LEA, T				SKALHEGG, BS; TASKEN, K; HANSSON, V; HUITFELDT, HS; JAHNSEN, T; LEA, T			LOCATION OF CAMP-DEPENDENT PROTEIN-KINASE TYPE-I WITH THE TCR-CD3 COMPLEX	SCIENCE			English	Article							T-CELL RECEPTOR; REGULATORY SUBUNIT; HUMAN TESTIS; TYROSINE PHOSPHORYLATION; ADENOSINE-MONOPHOSPHATE; SURFACE MOLECULES; IDENTIFICATION; BINDING; SITE; ACTIVATION	Selective activation of cyclic adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase type I (cAKI), but not type II, is sufficient to mediate inhibition of T cell replication induced through the antigen-specific T cell receptor-CD3 (TCR-CD3) complex. Immunocytochemistry and immunoprecipitation studies of the molecular mechanism by which cAKI inhibits TCR-CD3-dependent T cell replication demonstrated that regulatory subunit Ialpha, along with its associated kinase activity, translocated to and interacted with the TCR-CD3 complex during T cell activation and capping. Regulatory subunit IIalpha did not. When stimulated by cAMP, the cAKI localized to the TCR-CD3 complex may release kinase activity that, through phosphorylation, might uncouple the TCR-CD3 complex from intracellular signaling systems.	NATL HOSP NORWAY,INST IMMUNOL & RHEUMATOL,N-0027 OSLO,NORWAY; NATL INST PUBL HLTH,N-0462 OSLO,NORWAY; NATL HOSP NORWAY,INST PATHOL,IMMUNOHISTOCHEM & IMMUNOPATHOL LAB,N-0027 OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	SKALHEGG, BS (corresponding author), UNIV OSLO,INST MED BIOCHEM,N-0317 OSLO,NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Tasken, Kjetil/0000-0003-2841-4697				ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1984, J BIOL CHEM, V259, P7835; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SKALHEGG BS, 1992, J BIOL CHEM, V267, P5374; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SKALHEGG BS, UNPUB; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	26	186	191	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					84	87		10.1126/science.8272870	http://dx.doi.org/10.1126/science.8272870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272870				2022-12-28	WOS:A1994MQ30100035
J	WARREN, WS; RICHTER, W; ANDREOTTI, AH; FARMER, BT				WARREN, WS; RICHTER, W; ANDREOTTI, AH; FARMER, BT			GENERATION OF IMPOSSIBLE CROSS-PEAKS BETWEEN BULK WATER AND BIOMOLECULES IN SOLUTION NMR	SCIENCE			English	Article							MULTIPLE SPIN ECHOES; NUCLEAR-MAGNETIC-RESONANCE; FIELD; LIQUIDS	Intermolecular multiple-quantum coherences between bulk water and a glycoprotein fragment at modest concentration (20 mM) have been experimentally produced and detected, although such coherences are inconceivable in the normal theoretical framework of nuclear magnetic resonance. A density matrix treatment explains these results by including the long-range dipolar interaction between spins and by discarding the high-temperature approximation. These results imply that peak intensities (critical for structural determinations) can be distorted in many gradient experiments, and show that magic-angle gradients provide substantial improvements with reduced gradient strengths. They also suggest methods for contrast enhancement in magnetic resonance imaging.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,PRINCETON,NJ 08543	Bristol-Myers Squibb	WARREN, WS (corresponding author), PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1980, CHEM PHYS LETT, V69, P567, DOI 10.1016/0009-2614(80)85130-X; BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; BOWTELL R, 1992, J MAGN RESON, V100, P1, DOI 10.1016/0022-2364(92)90361-A; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MAUDSLEY AA, 1978, CHEM PHYS LETT, V55, P9, DOI 10.1016/0009-2614(78)85120-3; MCCOY MA, 1990, J CHEM PHYS, V93, P858, DOI 10.1063/1.459457; WARREN WS, 1992, J CHEM PHYS, V96, P1659, DOI 10.1063/1.462156; WEITEKAMP DP, 1983, ADV MAGN RESON, V11, P111	13	343	355	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2005	2009		10.1126/science.8266096	http://dx.doi.org/10.1126/science.8266096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266096				2022-12-28	WOS:A1993MN10800029
J	WISE, JA				WISE, JA			GUIDES TO THE HEART OF THE SPLICEOSOME	SCIENCE			English	Editorial Material							MESSENGER-RNA; INTRONS				WISE, JA (corresponding author), UNIV ILLINOIS,DEPT BIOCHEM,ROGER ADAMS LAB 318,600 S MATTHEW AVE,URBANA,IL 61801, USA.							CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YU YT, 1993, CELL, V75, P1049, DOI 10.1016/0092-8674(93)90315-H	19	58	60	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1978	1979		10.1126/science.8266091	http://dx.doi.org/10.1126/science.8266091			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266091				2022-12-28	WOS:A1993MN10800024
J	SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N				SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N			IS FRIDAY THE 13TH BAD FOR YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article							SUPERNATURAL BELIEFS	Objective-To, examine the relation between health, behaviour, and superstition surrounding Friday 13th in the United Kingdom. Design-Retrospective study of paired data comparing driving and shopping patterns and accidents. Subjects-Drivers, shoppers, and residents. Setting-South West Thames region. Main outcome measures-Numbers of vehicles on motorways; numbers of shoppers in supermarkets; and hospital admissions due to accidents. Results-There were consistently and significantly fewer vehicles on the southern section of the M25 on Friday the 13th compared with Friday the 6th. The numbers of shoppers were not significantly different on the two days. Admissions due to transport accidents were significantly increased on Friday 13th (total 65 v 45; p < 0.05). Conclusions-Friday 13th is unlucky for some. The risk of hospital admission as a result of a transport accident may be increased by as much as 52%. Staving at home is recommended.			SCANLON, TJ (corresponding author), MID DOWNS HLTH AUTHOR,DEPT PUBL HLTH,HAYWARDS HEATH RH16 4BE,W SUSSEX,ENGLAND.		Luben, Robert N/H-5519-2015	Luben, Robert N/0000-0002-5088-6343				Aderinokun G A, 1991, Afr Dent J, V5, P26; Burleigh E, 1990, Med Anthropol, V12, P419; GOUTEUX JP, 1992, B SOC PATHOL EXOT, V85, P256; LaPiere RT, 1934, SOC FORCES, V13, P230, DOI 10.2307/2570339; LEYGUES M, 1989, SOC SCI MED, V28, P1255, DOI 10.1016/0277-9536(89)90344-4; Lorie P., 1992, SUPERSTITIONS; MAHDIHASSAN S, 1990, AM J CHINESE MED, V18, P87, DOI 10.1142/S0192415X90000125; RADFORD A, 1961, ENCYCLOPEDIA SUPERSI	8	26	26	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1584	1586		10.1136/bmj.307.6919.1584	http://dx.doi.org/10.1136/bmj.307.6919.1584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292946	Green Published, Bronze			2022-12-28	WOS:A1993MN10700009
J	MAGILL, AJ; GROGL, M; GASSER, RA; SUN, W; OSTER, CN				MAGILL, AJ; GROGL, M; GASSER, RA; SUN, W; OSTER, CN			VISCERAL INFECTION CAUSED BY LEISHMANIA-TROPICA IN VETERANS OF OPERATION DESERT STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANT RECIPIENT; FATAL LEISHMANIASIS; MEDITERRANEAN LEISHMANIASIS; OPPORTUNISTIC INFECTION; SODIUM STIBOGLUCONATE; DISEASE; CULTIVATION; DONOVANI; INVITRO; THERAPY	Background. visceral leishmaniasis, usually caused by Leishmania donovani, has rarely been reported from eastern Saudi Arabia, so it was not expected to affect the soldiers of Operation Desert Storm. Methods. We evaluated eight soldiers with visceral leishmanial infection, examining their serum with an immunofluorescent-antibody assay, examining their marrow or biopsy tissue for amastigotes with an indirect immunofluorescent-monoclonal-antibody assay, and culturing the parasites. Cultured promastigotes were isolated and characterized by isoenzyme analysis. Results. None of the eight soldiers had classic signs or symptoms of visceral leishmaniasis (kala-azar). Seven soldiers had unexplained fever, chronic fatigue, malaise, cough, intermittent diarrhea, or abdominal pain that began up to seven months after they returned to the United States; one had no symptoms. Five had adenopathy or mild, transient hepatosplenomegaly. None had cutaneous manifestations. Diagnoses were made by bone marrow aspiration (seven patients) or lymph-node biopsy (one patient). Six isolates have been identified as L. tropica, which usually causes only cutaneous disease. Of the six patients treated with sodium stibogluconate, five improved and one remained symptomatic. Conclusions. L. tropica can produce visceral infection that can cause unexplained systemic illness in persons returning from areas where this organism is endemic.	WALTER REED ARMY MED CTR,INFECT DIS SECT,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	MAGILL, AJ (corresponding author), WALTER REED ARMY INST RES,DEPT IMMUNOL,DIV EXPTL THERAPEUT,WASHINGTON,DC 20307, USA.							AEBISCHER T, 1993, INFECT IMMUN, V61, P220, DOI 10.1128/IAI.61.1.220-226.1993; AGUADO JM, 1986, J INFECTION, V13, P301, DOI 10.1016/S0163-4453(86)91553-7; ALTES J, 1991, AIDS, V5, P201, DOI 10.1097/00002030-199102000-00011; ALVAR J, 1989, J INFECT DIS, V160, P560, DOI 10.1093/infdis/160.3.560; ANTHONY RL, 1987, AM J TROP MED HYG, V37, P271, DOI 10.4269/ajtmh.1987.37.271; BADARO R, 1986, LANCET, V1, P647; BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BROECKAERTVANORSHOVEN A, 1979, LANCET, V2, P740; BRYCESON ADM, 1987, OXFORD TXB MED, V1, P5524; CAMARGO MARIO E., 1966, REV INST MED TROP SAO PAULO, V8, P227; DELETONA JML, 1986, LANCET, V1, P1094; DONOVAN KL, 1990, J INFECTION, V21, P107, DOI 10.1016/0163-4453(90)90830-2; FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X; GASSER RA, 1991, NEW ENGL J MED, V324, P859, DOI 10.1056/NEJM199103213241229; GITHURE JI, 1984, E AFR MED J, V61, P539; GRIFFITHS WAD, 1987, LEISHMANIASES BIOL M, V2, P617; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; GROGL M, 1991, AM J TROP MED HYG, V45, P98, DOI 10.4269/ajtmh.1991.45.98; GROGL M, 1989, EXP PARASITOL, V69, P78, DOI 10.1016/0014-4894(89)90173-2; HENDRICKS LD, 1978, PARASITOLOGY, V76, P309, DOI 10.1017/S0031182000048186; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P96; HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5; KAGAN IG, 1991, HUNTERS TROPICAL MED, P1090; KREUTZER RD, 1980, AM J TROP MED HYG, V29, P199, DOI 10.4269/ajtmh.1980.29.199; KREUTZER RD, 1987, AM J TROP MED HYG, V36, P22, DOI 10.4269/ajtmh.1987.36.22; LAINSON R, 1987, LEISHMANIASES BIOL M, V1, P1; LAMAS S, 1987, NEPHRON, V45, P71, DOI 10.1159/000184076; LEE C. U., 1935, Chinese Medical Journal, V49, P1281; LEMESRE JL, 1988, ACTA TROP, V45, P99; MA DDF, 1979, LANCET, V2, P311; MEBRAHTU Y, 1989, AM J TROP MED HYG, V41, P289, DOI 10.4269/ajtmh.1989.41.289; MOST H, 1947, MEDICINE, V26, P221, DOI 10.1097/00005792-194709000-00001; OLDFIELD EC, 1991, REV INFECT DIS, V13, pS199; OLDFIELD EC, 1991, REV INFECT DIS, V13, P533; OREN R, 1991, J INFECT DIS, V164, P746, DOI 10.1093/infdis/164.4.746; PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4; PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P349, DOI 10.1016/0035-9203(74)90148-5; PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101; PETERS W, 1987, SAUDI MED J, V8, P333; SALVA M, 1986, CLIN TRANSPLANT, V1, P134; SCHNUR LF, 1981, ANN TROP MED PARASIT, V75, P131, DOI 10.1080/00034983.1981.11687421; TARIZZO ML, 1953, AM J TROP MED HYG, V2, P846, DOI 10.4269/ajtmh.1953.2.846; THAKUR CP, 1991, INDIAN J MED RES-A, V93, P103; WALTON BC, 1972, AM J TROP MED HYG, V21, P296, DOI 10.4269/ajtmh.1972.21.296; WRIGHT MI, 1959, BMJ-BRIT MED J, V1, P1218, DOI 10.1136/bmj.1.5131.1218; [No title captured]; 1992, MMWR MORB MORTAL WKL, V41, P131	48	280	295	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1993	328	19					1383	1387		10.1056/NEJM199305133281904	http://dx.doi.org/10.1056/NEJM199305133281904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB495	8292114	Bronze			2022-12-28	WOS:A1993LB49500004
J	LIPES, MA; ROSENZWEIG, A; TAN, KN; TANIGAWA, G; LADD, D; SEIDMAN, JG; EISENBARTH, GS				LIPES, MA; ROSENZWEIG, A; TAN, KN; TANIGAWA, G; LADD, D; SEIDMAN, JG; EISENBARTH, GS			PROGRESSION TO DIABETES IN NONOBESE DIABETIC (NOD) MICE WITH TRANSGENIC T-CELL RECEPTORS	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; VARIABLE REGION GENES; BETA-CHAIN; I-E; CLONAL DELETION; LYMPHOCYTE-T; EXPRESSION; MOLECULES; ANTIBODY; ANTIGEN	The T cell receptor (TCR) requirements in the pathogenesis of insulin-dependent diabetes were examined with transgenic NOD mice bearing nondisease-related TCR alpha and beta chains. In both TCRbeta and TCRalphabeta transgenic NOD mice the beta chain transgene was expressed by >98% of peripheral T cells. The alpha chain transgene was also highly expressed. Insulitis developed in both sets of transgenic animals with most of the lymphocytes in the lesion expressing the transgenic beta chain and with depletion of the endogenous TCR V(beta) genes. Nonetheless, NOD animals transgenic for TCRbeta and TCRalphabeta developed diabetes similar to controls. Thus, skewing the TCR repertoire did not diminish autoimmune susceptibility in NOD mice.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	LIPES, MA (corresponding author), JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215, USA.							BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BEHLKE MA, 1985, SCIENCE, V229, P566, DOI 10.1126/science.3875151; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BOHME J, 1990, SCIENCE, V249, P293, DOI 10.1126/science.2115690; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; EISENBARTH GS, 1982, P NATL ACAD SCI-BIOL, V79, P5066, DOI 10.1073/pnas.79.16.5066; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; GLIMCHER LH, 1982, J EXP MED, V156, P640, DOI 10.1084/jem.156.2.640; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LEIDEN JM, 1986, MOL CELL BIOL, V6, P3207, DOI 10.1128/MCB.6.9.3207; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDUFFIE M, 1991, DIABETES, V40, P1555, DOI 10.2337/diabetes.40.11.1555; MCINTYRE BW, 1983, CELL, V34, P739, DOI 10.1016/0092-8674(83)90530-5; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NISHIMOTO H, 1987, NATURE, V328, P432, DOI 10.1038/328432a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; REICH EP, 1991, NATURE, V352, P88, DOI 10.1038/352088a0; REINHERZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P4104, DOI 10.1073/pnas.80.13.4104; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIZURU JA, 1991, J EXP MED, V174, P633, DOI 10.1084/jem.174.3.633; WALKER R, 1988, DIABETES, V37, P1301, DOI 10.2337/diabetes.37.9.1301; WHITE J, 1989, J IMMUNOL, V143, P1822; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	36	57	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1165	1169		10.1126/science.8267690	http://dx.doi.org/10.1126/science.8267690			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8267690				2022-12-28	WOS:A1993KM91700040
J	JAESCHKE, R; GUYATT, GH; SACKETT, DL; GUYATT, G; BASS, E; BRILLEDWARDS, P; BROWMAN, G; COOK, D; FARKOUH, M; GERSTEIN, H; HAYNES, B; HAYWARD, R; HOLBROOK, A; JUNIPER, E; LEE, H; LEVINE, M; MOYER, V; NISHIKAWA, J; OXMAN, A; PATEL, A; PHILBRICK, J; RICHARDSON, WS; SAUVE, S; SACKETT, D; SINCLAIR, J; TROUT, KS; TUGWELL, P; TUNIS, S; WALTER, S; WILSON, M				JAESCHKE, R; GUYATT, GH; SACKETT, DL; GUYATT, G; BASS, E; BRILLEDWARDS, P; BROWMAN, G; COOK, D; FARKOUH, M; GERSTEIN, H; HAYNES, B; HAYWARD, R; HOLBROOK, A; JUNIPER, E; LEE, H; LEVINE, M; MOYER, V; NISHIKAWA, J; OXMAN, A; PATEL, A; PHILBRICK, J; RICHARDSON, WS; SAUVE, S; SACKETT, D; SINCLAIR, J; TROUT, KS; TUGWELL, P; TUNIS, S; WALTER, S; WILSON, M			USERS GUIDES TO THE MEDICAL LITERATURE .3. HOW TO USE AN ARTICLE ABOUT A DIAGNOSTIC-TEST .B. WHAT ARE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE		MCMASTER UNIV,HLTH SCI CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8N 3Z5,ON,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University			Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020; Oxman, Andrew/Y-3004-2019; Tugwell, Peter/AFD-8076-2022; Walter, Stephen/AAB-5548-2022	Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836; Oxman, Andrew/0000-0002-5608-5061; Tugwell, Peter/0000-0001-5062-0556; Walter, Stephen/0000-0003-4157-8928; Bass, Eric/0000-0001-9106-527X				FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; MAYESKI RJ, 1991, DIAGNOSTIC STRATESGI; Panzer RI, 1991, DIAGNOSTIC STRATEGIE; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P145; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; 1990, JAMA-J AM MED ASSOC, V263, P2753	14	1955	1999	1	51	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					703	707		10.1001/jama.271.9.703	http://dx.doi.org/10.1001/jama.271.9.703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309035				2022-12-28	WOS:A1994MX57000033
J	COGAN, E; SCHANDENE, L; CRUSIAUX, A; COCHAUX, P; VELU, T; GOLDMAN, M				COGAN, E; SCHANDENE, L; CRUSIAUX, A; COCHAUX, P; VELU, T; GOLDMAN, M			BRIEF REPORT - CLONAL PROLIFERATION OF TYPE-2 HELPER T-CELLS IN A MAN WITH THE HYPEREOSINOPHILIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CYTOKINE PRODUCTION; FUNCTIONAL SUBSETS; ALPHA-INTERFERON; INTERLEUKIN-5; EOSINOPHILS; RECEPTOR; LYMPHOMA; DISEASE		HOP UNIV ERASME, DEPT IMMUNOL, BRUSSELS, BELGIUM; UNIV LIBRE BRUXELLES, INST INTERDISCIPLINARY RES, DEPT MED GENET, BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Universite Libre de Bruxelles	COGAN, E (corresponding author), HOP UNIV BRUGMANN, DEPT INTERNAL MED, 4 PL VAN GEHUCHTEN, B-1020 BRUSSELS, BELGIUM.			Cogan, Elie/0000-0003-2890-766X				Ausubel FM, 1988, MOL REPROD DEV; BAGOT M, 1990, ANN DERMATOL VENER, V117, P883; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; ENOKIHARA H, 1990, BRIT J HAEMATOL, V75, P458, DOI 10.1111/j.1365-2141.1990.tb07782.x; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GRIESSER H, 1989, BLOOD, V73, P1402; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KEMP M, 1993, INFECT IMMUN, V61, P1069, DOI 10.1128/IAI.61.3.1069-1073.1993; MORAILLON I, 1991, ANN DERMATOL VENER, V118, P883; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY PT, 1990, BRIT J HAEMATOL, V75, P619, DOI 10.1111/j.1365-2141.1990.tb07811.x; O'Shea J J, 1987, Am J Med, V82, P539; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PRIN L, 1991, BLOOD, V78, P2626; RAGHAVACHAR A, 1987, J IMMUNOL, V139, P3753; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VOWELS BR, 1992, J INVEST DERMATOL, V99, P90, DOI 10.1111/1523-1747.ep12611877; WALLEN N, 1991, J IMMUNOL, V147, P3490; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	27	261	268	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					535	538		10.1056/NEJM199402243300804	http://dx.doi.org/10.1056/NEJM199402243300804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302319	Bronze			2022-12-28	WOS:A1994MX43600004
J	SCHMID, D; BAICI, A; GEHRING, H; CHRISTEN, P				SCHMID, D; BAICI, A; GEHRING, H; CHRISTEN, P			KINETICS OF MOLECULAR CHAPERONE ACTION	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ATPASE ACTIVITY; DNAK	Molecular chaperones of the Hsp70 type transiently sequester unfolded segments of proteins and promote their correct folding. Target peptides were labeled with an environmentally sensitive fluorophore so that their binding to the molecular chaperone DnaK of Escherichia coli could be followed in real time. The two-step process was characterized by relaxation times of 27 seconds and 200 seconds with 2 mu M DnaK and 0.1 mu M ligand at 25 degrees C. In the presence of adenosine triphosphate, the formation of the complex was greatly accelerated and appeared to be a single-exponential process with a relaxation time of 0.4 second. The binding-release cycle of DnaK thus occurs in the time range of polypeptide chain elongation and folding and is too fast to be stoichiometrically coupled to the adenosine triphosphatase activity of the chaperone (turnover number, 0.13 per minute at 30 degrees C).	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND; UNIV SPITAL ZURICH,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital				Baici, Antonio/0000-0002-2980-0541				BANECKI B, 1992, J BIOL CHEM, V267, P25051; BERGMEYER HU, 1985, METHODS ENZYMATIC AN, V7; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MULLEN DG, 1987, INT J PEP PROTEIN RE, V30, P705; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHMID DS, UNPUB; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	17	417	427	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					971	973		10.1126/science.8310296	http://dx.doi.org/10.1126/science.8310296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310296				2022-12-28	WOS:A1994MX16500037
J	ZINSMAIER, KE; EBERLE, KK; BUCHNER, E; WALTER, N; BENZER, S				ZINSMAIER, KE; EBERLE, KK; BUCHNER, E; WALTER, N; BENZER, S			PARALYSIS AND EARLY DEATH IN CYSTEINE STRING PROTEIN MUTANTS OF DROSOPHILA	SCIENCE			English	Article							MELANOGASTER; BRAIN; EXOCYTOSIS; MEMBRANE; MUTATION; BINDING; RETINA	Multimeric complexes of synaptic vesicle and terminal membrane proteins are important components of the neurotransmitter release mechanism. The csp gene of Drosophila encodes proteins homologous to synaptic vesicle proteins in Torpedo. Monoclonal antibodies demonstrate different distributions of isoforms at distinct subsets of terminals. Deletion of the csp gene in Drosophila causes a temperature-sensitive block of synaptic transmission, followed by paralysis and premature death.	INST ZOOL,CH-8057 ZURICH,SWITZERLAND; THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY		ZINSMAIER, KE (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Walter, Nils/P-3163-2019	Walter, Nils/0000-0002-7301-1275				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; COOMBE PE, 1986, J NEUROGENET, V3, P135, DOI 10.3109/01677068609106845; COOMBE PE, 1986, J COMP PHYSIOL A, V159, P655, DOI 10.1007/BF00612038; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KELLY LE, 1981, COMP BIOCHEM PHYS B, V69, P61, DOI 10.1016/0305-0491(81)90209-1; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KRUEGER BK, 1979, J MEMBRANE BIOL, V50, P287, DOI 10.1007/BF01868894; KURIHARA T, 1992, MEMBRANE BIOGENESIS, P309; LEVERTY T, 1986, RUBIN LAB MANUAL; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1077; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OHKI R, 1992, J BIOL CHEM, V267, P13180; PAK WL, 1975, HDB GENETICS, P703; PFLUGFELDER GO, 1990, GENETICS, V126, P91; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; REIFEGERSTE R, 1993, J NEUROSCI, V13, P2186; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SILVER PA, 1993, CELL, V16, P5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, P ELEMENT MEDIATED T, P175; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; Thomas P, 1992, Curr Opin Neurobiol, V2, P308, DOI 10.1016/0959-4388(92)90120-A; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	38	325	326	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					977	980		10.1126/science.8310297	http://dx.doi.org/10.1126/science.8310297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310297				2022-12-28	WOS:A1994MX16500039
J	SHMUKLARSKY, MJ; BOUDREAU, EF; PANG, LW; SMITH, JI; SCHNEIDER, I; FLECKENSTEIN, L; ABDELRAHIM, MM; CANFIELD, CJ; SCHUSTER, B				SHMUKLARSKY, MJ; BOUDREAU, EF; PANG, LW; SMITH, JI; SCHNEIDER, I; FLECKENSTEIN, L; ABDELRAHIM, MM; CANFIELD, CJ; SCHUSTER, B			FAILURE OF DOXYCYCLINE AS A CAUSAL PROPHYLACTIC AGENT AGAINST PLASMODIUM-FALCIPARUM MALARIA IN HEALTHY NONIMMUNE VOLUNTEERS	ANNALS OF INTERNAL MEDICINE			English	Article						DOXYCYCLINE; PLASMODIUM-FALCIPARUM; MALARIA, FALCIPARUM; TRAVEL; ANTIMALARIALS	PYRIMETHAMINE-SULFADOXINE FANSIDAR; RESISTANT MALARIA; AMERICAN TRAVELERS; MEFLOQUINE; AFRICA; THAILAND; VACCINE; SAFETY	Objective: To determine whether doxycycline, 100 mg administered as a single daily oral dose, is effective as a causal prophylactic agent, an agent active against the pre-erythrocytic liver stage of Plasmodium falciparum malaria parasites, in healthy nonimmune persons. If effective, the recommendation by the Centers for Disease Control and Prevention (CDC) that doxycycline be continued for 4 weeks after returning from malaria-endemic areas could be shortened to 1 week. Design: Randomized, double-blind, placebo-controlled trial. Setting: Medical ward at the U.S. Army Research Institute of Infectious Diseases, Fort Detrick, Maryland. Participants: 18 nonimmune, healthy, adult male volunteers, age 21.7 +/- 2.9 (SD) years, were enrolled in two groups, one of 8 persons and one of 10 persons. Six participants,in the first group and 7 in the second group received doxycycline. The remaining participants received placebo. Two volunteers were dropped from the study, leaving 16 participants for analysis. Intervention: Each participant received doxycycline, 100 mg, or placebo in a single daily oral dose starting 3 days before exposure to P. falciparum-infected mosquitoes and ending 6 days after exposure. Measurements: Monitoring for parasitemia, plasma doxycycline concentrations, and mosquitoes' salivary-gland sporozoite grade. Results: 6 of 6 (100% [95% Cl, 54% to 100%]) participants on doxycycline in the first group and 2 of 6 (33% [Cl, 4% to 78%]) in the second group were protected from malaria. No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates. The mean mosquito salivary-gland sporozoite grade was significantly higher (P = 0.02) in protected (3.5 +/- 0.3) than in nonprotected persons (3.1 +/- 0.1). Overall, 8 of 12 persons on doxycycline were protected from malaria, yielding a causal prophylactic efficacy rate of 67% (Cl, 35% to 90%). Conclusions: A dosing regimen of doxycycline, 100 mg once daily, administered as a causal prophylactic agent against P. falciparum malaria in healthy, nonimmune volunteers, had an unacceptably high failure rate. Therefore, the CDC recommendation that doxycycline should be taken daily starting 1 to 2 days before travel, during travel, and for 4 weeks after travel should still be followed.	PHARMACEUT SYST INC, GAITHERSBURG, MD 20879 USA; WHO, GENEVA, SWITZERLAND; WALTER REED GEN HOSP, WASHINGTON, DC 20307 USA; USA, MED RES INST INFECT DIS, FT DETRICK, FREDERICK, MD USA	World Health Organization	SHMUKLARSKY, MJ (corresponding author), WALTER REED ARMY INST RES, DEPT PHARMACOL, DIV EXPTL THERAPEUT, WASHINGTON, DC 20307 USA.			Fleckenstein, Lawrence/0000-0001-5320-4531				BALLOU WR, 1987, LANCET, V1, P1277; Barber MA, 1936, AM J HYG, V24, P45, DOI 10.1093/oxfordjournals.aje.a118256; BOUDREAU EF, 1982, LANCET, V2, P1335; BOYD MARK F., 1936, AMER JOUR TROP MED, V16, P157; BRASSEUR P, 1990, LANCET, V336, P59, DOI 10.1016/0140-6736(90)91578-X; BURKOT TR, 1984, T ROY SOC TROP MED H, V78, P339, DOI 10.1016/0035-9203(84)90114-7; CHAO J, 1962, J PARASITOL, V48, P252, DOI 10.2307/3275577; CHULAY JD, 1986, AM J TROP MED HYG, V35, P66, DOI 10.4269/ajtmh.1986.35.66; DELEENHEER AP, 1979, J PHARM SCI, V68, P999, DOI 10.1002/jps.2600680821; Earle WC, 1931, J LAB CLIN MED, V17, P1124; FREEDMAN DO, 1992, AM J MED, V93, P239, DOI 10.1016/0002-9343(92)90227-3; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1677; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HURWITZ ES, 1981, LANCET, V1, P1068; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245; PANG L, 1988, J INFECT DIS, V158, P1124, DOI 10.1093/infdis/158.5.1124; PANG LW, 1987, LANCET, V1, P1161; PETERS W, 1982, BRIT MED BULL, V38, P187, DOI 10.1093/oxfordjournals.bmb.a071757; PORTER RJ, 1954, EXP PARASITOL, V3, P267, DOI 10.1016/0014-4894(54)90026-0; PORTER RJ, 1952, EXP PARASITOL, V1, P229, DOI 10.1016/0014-4894(52)90013-1; RACCURT CP, 1991, AM J TROP MED HYG, V45, P319, DOI 10.4269/ajtmh.1991.45.319; REACHER M, 1981, LANCET, V2, P1066, DOI 10.1016/S0140-6736(81)91274-5; RIECKMANN KH, 1972, P HELM SOC WASH, V39, P339; ROSER B, 1982, FUNDAMENTALS BIOSTAT; ROUVEIX B, 1989, ANN INTERN MED, V110, P577, DOI 10.7326/0003-4819-110-7-577; Rowland M, 2011, CLIN PHARMACOKINET, V4, P201; SPENCER HC, 1985, T ROY SOC TROP MED H, V79, P748, DOI 10.1016/0035-9203(85)90108-7; STUIVER PC, 1989, LANCET, V2, P282; VANDERBE.JP, 1966, J PARASITOL, V52, P559, DOI 10.2307/3276326; WATKINS WM, 1988, T ROY SOC TROP MED H, V82, P21, DOI 10.1016/0035-9203(88)90250-7; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; WILLERSON D, 1972, AM J TROP MED HYG, V21, P857, DOI 10.4269/ajtmh.1972.21.857; 1990, HHS CDC918280 PUBL; 1991, MINSQ NONLINEAR PARA	37	38	39	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					294	299		10.7326/0003-4819-120-4-199402150-00006	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291822				2022-12-28	WOS:A1994MW10300006
J	JOLY, M; KAZLAUSKAS, A; FAY, FS; CORVERA, S				JOLY, M; KAZLAUSKAS, A; FAY, FS; CORVERA, S			DISRUPTION OF PDGF RECEPTOR TRAFFICKING BY MUTATION OF ITS PI-3 KINASE BINDING-SITES	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASES; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; INTERNALIZATION; CELLS; PHOSPHORYLATION; INSULIN; VISUALIZATION	Human platelet-derived growth factor receptors (PDGFRs) expressed in human Hep G2 cells internalized and concentrated in a juxtanuclear region near the Golgi network within 10 minutes after the cells were treated with PDGF. A PDGFR mutant (F5) that lacks high-affinity binding sites for the Src homology 2 domain-containing proteins phosphatidylinositol-3 kinase (PI-3 kinase), Ras guanosine triphosphatase activating protein, phospholipase C-gamma, and a phosphotyrosine phosphatase (Syp) remained at the cell periphery. Restoration of the PI-3 kinase binding sites on F5 completely restored the ability of the receptor to concentrate intracellularly. A PDGFR mutant lacking only PI-3 kinase binding sites failed to concentrate intracellularly. Thus, PI-3 kinase binding sites appear both necessary and sufficient for the normal endocytic trafficking of the activated PDGFR.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; NATL JEWISH HOSP IMMUNOL & RESP MED,DENVER,CO 80206; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,BIOMED IMAGING GRP,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; National Jewish Health; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK40330] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1989, J BIOL CHEM, V264, P1694; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; COUGHLIN SR, 1989, SCIENCE, V243, P1191; FANTL W, 1992, CELL, V69, P13; GENSHENG F, 1993, SCIENCE, V259, P1607; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUMIJAN DA, 1989, P NATL ACAD SCI USA, V86, P8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARSHALL S, 1980, ENDOCRINOLOGY, V107, P1937, DOI 10.1210/endo-107-6-1937; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; ROSENFELD ME, 1985, J CELL PHYSL, V121, P263; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS B, 1993, CELL, V73, P321; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	33	294	296	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					684	687		10.1126/science.8303278	http://dx.doi.org/10.1126/science.8303278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303278				2022-12-28	WOS:A1994MU96400050
J	KIMBALL, HR; YOUNG, PR				KIMBALL, HR; YOUNG, PR			A STATEMENT ON THE GENERALIST PHYSICIAN FROM THE AMERICAN BOARDS OF FAMILY-PRACTICE AND INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AMER BOARD FAMILY PRACTICE,LEXINGTON,KY		KIMBALL, HR (corresponding author), AMERICAN BOARD INTERNAL MED,PRESIDENTS OFF,UNIV CITY SCI CTR,3624 MARKET ST,PHILADELPHIA,PA 19104, USA.								0	43	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					315	316		10.1001/jama.271.4.315	http://dx.doi.org/10.1001/jama.271.4.315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295293				2022-12-28	WOS:A1994MR22100030
J	GOTTESFELD, JM; WOLF, VJ; DANG, T; FORBES, DJ; HARTL, P				GOTTESFELD, JM; WOLF, VJ; DANG, T; FORBES, DJ; HARTL, P			MITOTIC REPRESSION OF RNA POLYMERASE-III TRANSCRIPTION IN-VITRO MEDIATED BY PHOSPHORYLATION OF A TFIIIB COMPONENT	SCIENCE			English	Article							TATA-BINDING PROTEIN; CELL-CYCLE CONTROL; XENOPUS; COMPLEX; MITOSIS; P34CDC2; GENES; DNA; ACTIVATION; PROMOTERS	Interphase cytosol extracts prepared from Xenopus laevis eggs are active in RNA polymerase III (Pol III) transcription. Addition of recombinant B1 cyclin to these extracts activates mitotic protein kinases that repress transcription. Affinity-purified p34cdc2-cyclin B kinase (mitosis-promoting factor) is sufficient to effect this repression in a simplified Pol III transcription system. This mitotic repression involves the direct phosphorylation of a component of the Pol III transcription initiation factor TFIIIB, which consists of the TATA box-binding protein (TBP) and associated Pol III-specific factors. The transcriptional activity of the TFIIIB-TBP fraction can be modulated in vitro by phosphorylation with mitotic kinases and by dephosphorylation with immobilized alkaline phosphatase.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GOTTESFELD, JM (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777	NIGMS NIH HHS [R01 GM033279, GM26453, GM33279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033279, R01GM026453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FINK K, 1977, EUR J BIOCHEM, V80, P93, DOI 10.1111/j.1432-1033.1977.tb11860.x; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON TC, 1965, J CELL BIOL, V27, P565, DOI 10.1083/jcb.27.3.565; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KIMMELMAN D, 1987, CELL, V48, P399; LERESCHE A, UNPUB; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RUPERT S, 1993, NATURE, V362, P175; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAYLOR JH, 1960, ANN NY ACAD SCI, V90, P409, DOI 10.1111/j.1749-6632.1960.tb23259.x; TAYODA T, 1992, ANAL BIOCHEM, V203, P340; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOLF VJ, UNPUB	45	123	125	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					81	84		10.1126/science.8272869	http://dx.doi.org/10.1126/science.8272869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272869				2022-12-28	WOS:A1994MQ30100034
J	LOWELL, BB; SSUSULIC, V; HAMANN, A; LAWITTS, JA; HIMMSHAGEN, J; BOYER, BB; KOZAK, LP; FLIER, JS				LOWELL, BB; SSUSULIC, V; HAMANN, A; LAWITTS, JA; HIMMSHAGEN, J; BOYER, BB; KOZAK, LP; FLIER, JS			DEVELOPMENT OF OBESITY IN TRANSGENIC MICE AFTER GENETIC ABLATION OF BROWN ADIPOSE-TISSUE	NATURE			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; COLD-ACCLIMATED RATS; TOXIN-A-CHAIN; MOLECULAR-CLONING; BETA-3-ADRENERGIC RECEPTOR; INDUCED THERMOGENESIS; BLOOD-FLOW; EXPRESSION; FAT; ANIMALS	BROWN adipose tissue, because of its capacity for uncoupled mitochondrial respiration 1,2, has been implicated as an important site of facultative energy expenditure3-5. This has led to speculation that this tissue normally functions to prevent obesity3-5. Attempts to ablate or denervate brown adipose tissue surgically have been uninformative because it exists in diffuse depots and has substantial capacity for regeneration and hypertrophy6. Here we have used a transgenic toxigene approach7,8 to create two lines of transgenic mice with primary deficiency of brown adipose tissue. At 16 days, both lines have decreased brown fat and obesity, In one line, brown fat subsequently regenerates and obesity resolves. In the other line, the deficiency persists and obesity, with its morbid complications, advances. Obesity develops in the absence of hyperphagia, indicating that brown fat deficient mice have increased metabolic efficiency. As obesity progresses, transgenic animals develop hyperphagia. This study supports a critical role for brown adipose tissue in the nutritional homeostasis of mice.	BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV OTTAWA,FAC MED,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA; JACKSON LAB,BAR HARBOR,ME 04609	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Ottawa; Jackson Laboratory	LOWELL, BB (corresponding author), CHARLES A DANA RES INST,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019					BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Breitman M. L., 1992, Transgenic animals., P127; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CAMERON DP, 1978, CLIN EXP PHARMACOL P, V5, P41, DOI 10.1111/j.1440-1681.1978.tb00650.x; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAVIS TRA, 1960, AM J PHYSIOL, V198, P471, DOI 10.1152/ajplegacy.1960.198.3.471; DESAUTELS M, 1978, CAN J BIOCHEM CELL B, V56, P378, DOI 10.1139/o78-060; DUBUC PU, 1976, METABOLISM, V25, P1567, DOI 10.1016/0026-0495(76)90109-8; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MAXWELL IH, 1986, CANCER RES, V46, P4660; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROTHWELL NJ, 1989, AM J PHYSIOL, V257, pR253, DOI 10.1152/ajpregu.1989.257.2.R253; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SALMON DMW, 1985, INT J OBESITY, V9, P443; TRAYHURN P, 1986, BIOCHEM SOC T, V14, P236, DOI 10.1042/bst0140236	29	870	917	3	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					740	742		10.1038/366740a0	http://dx.doi.org/10.1038/366740a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264795				2022-12-28	WOS:A1993MN26400027
J	YAGI, T; AIZAWA, S; TOKUNAGA, T; SHIGETANI, Y; TAKEDA, N; IKAWA, Y				YAGI, T; AIZAWA, S; TOKUNAGA, T; SHIGETANI, Y; TAKEDA, N; IKAWA, Y			A ROLE FOR FYN TYROSINE KINASE IN THE SUCKLING BEHAVIOR OF NEONATAL MICE	NATURE			English	Article							OLFACTORY-BULB; RAT-BRAIN; LOCALIZATION; PROTEIN; GENE; MAIN	NON-RECEPTOR-TYPE tyrosine kinases of the Src family, such as Src, Yes and Fyn, are strongly expressed in the brain and have been suggested to have an important function in the central nervous system1-5. We generated Fyn-deficient mice by inserting the beta-galactosidase gene (lacZ) into the fyn gene. The homozygous Fyn-mutant neonates from homozygous Fyn-deficient parents died because of a suckling problem. Neonates were, however, able to suckle milk normally when die homozygous mother's mammary glands had been activated by suckling of a heterozygous or wild-type pup. In these homozygous pups, the modified glomerular complex of the olfactory bulb, which had been suggested to play a role in perceiving pheromones, was abnormal in shape and reduced in size, and the hippocampal cell-layer was undulated. These results suggest that Fyn may be involved in the initial step of instinctive suckling behaviour in neonates.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,IBARAKI 305,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,TOKYO 113,JAPAN	RIKEN; Tokyo Medical & Dental University (TMDU)								BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; Diem K, 1968, WISSENSCHAFTLICHE TA; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREER CA, 1982, J NEUROSCI, V2, P1744; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; OJIMA H, 1988, ANAT EMBRYOL, V178, P481, DOI 10.1007/BF00305035; PEDERSEN PE, 1986, J COMP NEUROL, V252, P555, DOI 10.1002/cne.902520411; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TEICHER MH, 1980, BRAIN RES, V194, P530, DOI 10.1016/0006-8993(80)91237-8; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, IN PRESS ONCOGENE; YAGI T, 1993, ANAL BIOCHEM, V214, P68; ZHAO YH, 1991, ONCOGENE, V6, P1725	16	144	146	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					742	745		10.1038/366742a0	http://dx.doi.org/10.1038/366742a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264796				2022-12-28	WOS:A1993MN26400028
J	GHODSE, B; RANG, E				GHODSE, B; RANG, E			ENSURING THE ROBUSTNESS OF TARGETED BRIEFS	BRITISH MEDICAL JOURNAL			English	Article											GHODSE, B (corresponding author), WILSON HOSP,MERTON & SUTTON HLTH AUTHOR,MITCHAM CR4 4TP,SURREY,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1626	1627		10.1136/bmj.307.6919.1626	http://dx.doi.org/10.1136/bmj.307.6919.1626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292963	Bronze, Green Published			2022-12-28	WOS:A1993MN10700031
J	CHEN, ZX; SILVA, H; KLESSIG, DF				CHEN, ZX; SILVA, H; KLESSIG, DF			ACTIVE OXYGEN SPECIES IN THE INDUCTION OF PLANT SYSTEMIC ACQUIRED-RESISTANCE BY SALICYLIC-ACID	SCIENCE			English	Article							SIGNAL TRANSDUCTION; BINDING PROTEIN; RECEPTOR; ASPIRIN; TOBACCO; GENE; ANTIBODIES; SYRINGAE; CATALASE; DISEASE	A complementary DNA encoding a salicylic acid (SA)-binding protein has been cloned. Its properties suggest involvement in SA-mediated induction of systemic acquired resistance (SAR) in plants. The sequence of the protein is similar to that of catalases and the protein exhibits catalase activity. Salicylic acid specifically inhibited the catalase activity in vitro and induced an increase in H2O2 concentrations in vivo. H2O2 or compounds, such as SA, that inhibit catalases or enhance the generation of H2O2, induced expression of defense-related genes associated with SAR. Thus, the action of SA in SAR is likely mediated by elevated amounts of H2O2.	RUTGERS UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick			Silva, Herman P/C-7252-2012; Chen, Zhixiang/U-1015-2017	Silva, Herman P/0000-0003-1007-7442; Chen, Zhixiang/0000-0002-5472-4560				ABAD P, 1988, ANTIVIR RES, V9, P315, DOI 10.1016/0166-3542(88)90026-5; ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN Z, UNPUB; CHEN ZX, 1991, P NATL ACAD SCI USA, V88, P8179, DOI 10.1073/pnas.88.18.8179; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; Chester KS, 1933, Q REV BIOL, V8, P275, DOI 10.1086/394440; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOHERTY HM, 1988, PHYSIOL MOL PLANT P, V33, P377, DOI 10.1016/0885-5765(88)90004-5; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; HAVIR EA, 1987, PLANT PHYSIOL, V84, P450, DOI 10.1104/pp.84.2.450; Hennig J., UNPUB; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; KULAEVA ON, 1990, FEBS LETT, V261, P410, DOI 10.1016/0014-5793(90)80604-H; LEGENDRE L, 1993, PLANT PHYSIOL, V102, P233, DOI 10.1104/pp.102.1.233; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MAUCH F, 1988, PLANT PHYSIOL, V88, P935; NAPIER RM, 1991, TRENDS BIOCHEM SCI, V16, P72; ORLANDI EW, 1992, PHYSIOL MOL PLANT P, V40, P173, DOI 10.1016/0885-5765(92)90058-4; PRASAD PV, 1991, P NATL ACAD SCI USA, V88, P5479, DOI 10.1073/pnas.88.13.5479; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; ROTROSEN D, 1987, ANNU REV IMMUNOL, V5, P127, DOI 10.1146/annurev.immunol.5.1.127; SANCHEZCASAS P, UNPUB; SCANDALIOS JG, 1980, MOL GEN GENET, V179, P33, DOI 10.1007/BF00268443; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STEIN JC, 1993, PLANT PHYSIOL, V101, P1103, DOI 10.1104/pp.101.3.1103; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; VANLOON LC, 1983, NETH J PLANT PATHOL, V89, P265, DOI 10.1007/BF01995261; VIGERS AJ, 1991, MOL PLANT MICROBE IN, V4, P315, DOI 10.1094/MPMI-4-315; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; WOLOSHUK CP, 1991, PLANT CELL, V3, P619, DOI 10.1105/tpc.3.6.619; YOSHIKAWA M, 1993, NATURWISSENSCHAFTEN, V80, P417, DOI 10.1007/BF01168337	42	908	1087	4	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1883	1886		10.1126/science.8266079	http://dx.doi.org/10.1126/science.8266079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266079				2022-12-28	WOS:A1993MM51100039
J	BRENNAN, M; RUNGANGA, J; BARBARA, JAJ; CONTRERAS, M; TEDDER, RS; GARSON, JA; TUKE, PW; MORTIMER, PP; MCALPINE, L; TOSSWILL, JHC				BRENNAN, M; RUNGANGA, J; BARBARA, JAJ; CONTRERAS, M; TEDDER, RS; GARSON, JA; TUKE, PW; MORTIMER, PP; MCALPINE, L; TOSSWILL, JHC			PREVALENCE OF ANTIBODIES TO HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN BLOOD-DONORS IN NORTH LONDON	BRITISH MEDICAL JOURNAL			English	Article							I-ASSOCIATED MYELOPATHY; HTLV-I; LEUKEMIA-VIRUS; INFECTION; TRANSFUSION; TRANSMISSION; RISK	Objectives-To determine the prevalence of antibodies to the human T cell leukaemia/lymphoma viruses (HTLV-I and HTLV-II) in blood donors in north London in order to assess the economic impact and the logistic effects that routine screening would have on the blood supply. Design-All donations collected by the north London blood transfusion centre between January 1991 and June 1991 were screened for antibodies to HTLV-I and HTLV-II by modified, improved Fujirebio gel particle agglutination test. Positive samples were titrated and retested as necessary. Subjects-96 720 unpaid volunteers, who gave 105 730 consecutive donations of blood and plasma. Setting-North London blood transfusion centre. Main outcome measure-Observed numbers of donors confirmed to be seropositive for HTLV by reference laboratories. Results-Of 2622 (2.5%) initially reactive samples, 414 (0.4% of all samples) gave a titre of greater-than-or-equal-to 1 in 16 on the modified agglutination test. Thirty five of the 414 serum samples yielded positive results on one of two enzyme linked immunosorbent assays (ELISA (Cambridge Biotech and Abbot)), and none of these results were confirmed by either reference laboratory. Five samples yielded positive results on both ELISAs and all five of these were confirmed to contain antibodies to HTLV. One of the five contained antibodies to HTLV-II and the others antibodies to HTLV-I. Four seropositive donors were white women whose only risk factor for infection was sexual contact. The fifth (positive for antibodies to HTLV-II) was an Anglo-Caribbean man who admitted to previous misuse of intravenous drugs. Conclusion-The prevalence of antibodies to HTLV in blood donors in north London was one in 19 344 (0.005%). Up to 100 donors a year might be identified in the United Kingdom as being infected with HTLV, although prevalence in different regions may vary considerably.	UCL, SCH MED, DEPT MED MICROBIOL, DIV VIROL, LONDON W1P 6DB, ENGLAND; CENT PUBL HLTH LAB, PHLS, VIRUS REFERENCE LAB, LONDON NW9 5HT, ENGLAND	University of London; University College London; UCL Medical School; Public Health England	BRENNAN, M (corresponding author), N LONDON BLOOD TRANSFUS CTR, COLINDALE AVE, LONDON NW9 5BG, ENGLAND.		Garson, Jeremy A/C-5357-2008	Tedder, Richard/0000-0002-9672-5721; Garson, Jeremy/0000-0003-0553-0126				BARBARA JAJ, 1989, MED LAB SCI, V46, P135; CANNAVAGGIO M, 1990, TRANSFUSION, V30, P780; CHEN YC, 1989, BLOOD, V74, P388; COUROUCE AM, 1993, AIDS, V7, P841, DOI 10.1097/00002030-199306000-00013; ERLICH G, 1990, PCR PROTOCOLS GUIDE; FUJINO R, 1991, JPN J CANCER RES, V82, P367, DOI 10.1111/j.1349-7006.1991.tb01856.x; HALL WW, 1993, FOCUS HIV; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096; KIYOKAWA T, 1991, LANCET, V338, P312, DOI 10.1016/0140-6736(91)90450-4; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MCALPINE L, 1992, AIDS, V6, P387, DOI 10.1097/00002030-199204000-00005; MEYTES D, 1990, LANCET, V336, P1553; MINAMOTO GY, 1988, NEW ENGL J MED, V318, P219, DOI 10.1056/NEJM198801283180405; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V2, P104; PILLONEL J, 1993, GAZETTE TRANSFUSION, V84, P15; SALKER R, 1990, LANCET, V336, P317, DOI 10.1016/0140-6736(90)91856-6; SANDLER S G, 1991, Transfusion Medicine Reviews, V5, P93, DOI 10.1016/S0887-7963(91)70197-1; TAJIMA K, 1982, GANN, V73, P893; TOSWILL J, 1989, LANCET, V2, P328; TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L; WILLIAMS AE, 1990, TRANSFUSION TODAY, V7, P5; 1988, LANCET, V1, P217	25	55	56	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1235	1239		10.1136/bmj.307.6914.1235	http://dx.doi.org/10.1136/bmj.307.6914.1235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281054	Green Published, Bronze			2022-12-28	WOS:A1993MH00100017
J	HUNTER, JB; LONSDALE, RJ; WENHAM, PW; FROSTICK, SP				HUNTER, JB; LONSDALE, RJ; WENHAM, PW; FROSTICK, SP			LESSON OF THE WEEK - HEPARIN-INDUCED THROMBOSIS - AN IMPORTANT COMPLICATION OF HEPARIN-PROPHYLAXIS FOR THROMBOEMBOLIC DISEASE IN SURGERY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDUCED THROMBOCYTOPENIA; PLATELETS; THERAPY	Heparin induced thrombocytopenia with thrombosis, or the ''white clot syndrome,'' is a rare but recognised complication of heparin therapy. The syndrome is idiosyncratic, immune mediated, and not dose dependent and therefore is equally likely to occur with prophylactic and therapeutic heparin dosage regimens. Despite published reports on the subject we were alarmed that many surgeons who regularly use heparin to prevent or treat thrombosis were unaware that heparin can induce thrombotic complications in susceptible patients. We present three typical case histories, a brief discussion of the condition, and some guidelines on its prevention and treatment.	QUEENS MED CTR, DEPT VASC SURG, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham	HUNTER, JB (corresponding author), QUEENS MED CTR, DEPT ORTHOPAED & ACCID SURG, NOTTINGHAM NG7 2UH, ENGLAND.							ABURAHMA AF, 1991, AM J SURG, V162, P175, DOI 10.1016/0002-9610(91)90183-E; CHONG BH, 1981, BRIT J HAEMATOL, V49, P531, DOI 10.1111/j.1365-2141.1981.tb07261.x; COLE CW, 1990, CAN J SURG, V33, P207; GOUAULTHEILMANN M, 1987, HAEMOSTASIS, V17, P134; KAKKASSERIL JS, 1985, J VASC SURG, V2, P382, DOI 10.1067/mva.1985.avs0020382; SCURR JH, 1990, ACTA CHIR SCAND, P22; SIKORSKI JM, 1981, J BONE JOINT SURG BR, V63, P171, DOI 10.1302/0301-620X.63B2.7217137; WARKENTIN TE, 1990, HEMATOL ONCOL CLIN N, V4, P243, DOI 10.1016/S0889-8588(18)30515-X; WARKENTIN TE, 1989, ANNU REV MED, V40, P31	9	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1993	307	6895					53	55		10.1136/bmj.307.6895.53	http://dx.doi.org/10.1136/bmj.307.6895.53			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL369	8280214	Green Published, Bronze			2022-12-28	WOS:A1993LL36900034
J	MANNING, WJ; LI, W; EDELMAN, RR				MANNING, WJ; LI, W; EDELMAN, RR			A PRELIMINARY-REPORT COMPARING MAGNETIC-RESONANCE CORONARY ANGIOGRAPHY WITH CONVENTIONAL ANGIOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MR ANGIOGRAPHY; ARTERY; STENOSIS; ECHOCARDIOGRAPHY; VISUALIZATION	Background. The ability to assess the patency of coronary arteries by noninvasive means would represent an important advance. We have developed a magnetic resonance imaging (MRI) coronary angiographic technique that permits the display of areas of abnormal coronary blood flow. We have compared this method with conventional contrast angiography for the identification of coronary-artery stenoses. Methods. MRI coronary angiography was performed with an electrocardiographically gated sequence in 39 subjects, 33 to 84 years of age, who were scheduled for elective cardiac catheterization with coronary angiography. Sequential overlapping transverse and oblique sections were acquired during periods of breath-holding and were displayed as cine loops for analysis. MRI and conventional angiographic.data were compared in a blinded manner. The four major epicardial coronary arteries were classified by MRI coronary angiography as being normal (or having only minimal irregularities) or as having disease that was moderately severe to severe. Results. The sensitivity and specificity of MRI coronary angiography, as compared with conventional angiography, for correctly identifying individual vessels with greater-than-or-equal-to 50 percent angiographic stenoses were 90 percent and 92 percent, respectively. The corresponding positive and negative predictive values were 0.85 and 0.95, respectively. The sensitivity and specificity of the technique were 100 percent and 100 percent, respectively, for the left main coronary artery, 87 percent and 92 percent for the left anterior descending coronary artery, 71 percent and 90 percent for the left circumflex coronary artery, and 100 percent and 78 percent for the right coronary artery. Conclusions. MRI coronary angiography provides a new approach to evaluating the patency of coronary arteries. These preliminary data suggest that this technique may provide a noninvasive means of evaluating patients with known or suspected coronary artery disease. At its current stage of development, this procedure may be most helpful for excluding clinically important stenoses in patients referred for diagnostic contrast angiography.	BETH ISRAEL HOSP,CHARLES A DANA RES INST,DEPT RADIOL,BOSTON,MA 02215; HARVARD UNIV,THORNDIKE LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Harvard Medical School	MANNING, WJ (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [R01 HL45180] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALFIDI RJ, 1987, AM J ROENTGENOL, V149, P1097, DOI 10.2214/ajr.149.6.1097; BAIM DS, 1986, CARDIAC CATHETERIZAT, P173; CHO ZH, 1991, MAGN RESON MED, V20, P134, DOI 10.1002/mrm.1910200114; DOUGLAS PS, 1988, J AM COLL CARDIOL, V11, P565, DOI 10.1016/0735-1097(88)91532-X; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOULD KL, 1978, CIRC RES, V43, P242, DOI 10.1161/01.RES.43.2.242; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; KENNY A, 1992, AM J CARDIOL, V69, P1265, DOI 10.1016/0002-9149(92)91218-S; KENT KC, 1991, J VASC SURG, V13, P311, DOI 10.1016/0741-5214(91)90224-I; LITT AW, 1991, AM J NEURORADIOL, V12, P149; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; MANNING WJ, 1993, CIRCULATION, V87, P94, DOI 10.1161/01.CIR.87.1.94; MEYER CH, 1992, MAGNET RESON MED, V28, P202, DOI 10.1002/mrm.1910280204; PAULIN S, 1987, AM J ROENTGENOL, V148, P665, DOI 10.2214/ajr.148.4.665; ROGERS WJ, 1991, CIRCULATION, V84, P721, DOI 10.1161/01.CIR.84.2.721; RUGGIERI PM, 1989, RADIOLOGY, V171, P785, DOI 10.1148/radiology.171.3.2717753; SCHAEFER S, 1992, RADIOLOGY, V185, P795, DOI 10.1148/radiology.185.3.1438765; VANRUGGE FP, 1992, AM J CARDIOL, V70, P1233, DOI 10.1016/0002-9149(92)90754-M; WANG SJ, 1992, MAGNET RESON MED, V23, P109, DOI 10.1002/mrm.1910230112; WEYMAN AE, 1976, CIRCULATION, V54, P169, DOI 10.1161/01.CIR.54.2.169; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; YOSHIDA K, 1990, CIRCULATION, V81, P1271, DOI 10.1161/01.CIR.81.4.1271; 1992, HEART STROKE FACTS S	23	426	429	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					828	832		10.1056/NEJM199303253281202	http://dx.doi.org/10.1056/NEJM199303253281202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8285929				2022-12-28	WOS:A1993KT81400002
J	FLEISHER, MR				FLEISHER, MR			HANDS-ON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					642	642						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309010				2022-12-28	WOS:A1994MX57000001
J	SVENSSON, PJ; DAHLBACK, B				SVENSSON, PJ; DAHLBACK, B			RESISTANCE TO ACTIVATED PROTEIN-C AS A BASIS FOR VENOUS THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-COAGULATION; C4B-BINDING PROTEIN; DEFICIENCY; DISEASE; DISORDERS	Background. In three families with various forms of venous thrombosis, we observed an apparently inherited poor response to the anticoagulant activated protein C (APC). The condition was due to a deficiency in a previously unrecognized anticoagulant factor that functioned as a cofactor to activated protein C. Methods. We conducted the present study to determine the prevalence of resistance to APC in patients with venous thrombosis. We compared 104 consecutive patients with venous thrombosis confirmed by objective tests with 130 controls. in addition, 211 members of 34 families of persons with resistance to APC were studied. The anticoagulant response to APC was measured with a modified version of the activated partial-thromboplastin time test; the results were expressed as APC ratios. Results. Forty-five percent of patients had a family history of thrombosis. A significant (P<0.001) difference in APC ratios was observed between the controls and the patients with thrombosis. For 33 percent of patients, the APC ratio was below the 5th percentile of the control values, although the results of the family studies suggested that the prevalence of APC resistance may be even higher (approximately 40 percent) in the patients with thrombosis. The inherited nature of the defect was confirmed in a majority of cases, and the family studies suggested the mode of inheritance to be autosomal dominant. The thrombosis-free survival of APC-resistant family members was significantly less than that of non-APC-resistant family members. Conclusions. There was a high prevalence of APC resistance among young persons with a history of venous thrombosis, and this resistance appeared to be inherited as an autosomal dominant trait.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT COAGULAT DISORDERS,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT MED,S-21401 MALMO,SWEDEN	Lund University; Lund University; Lund University				Dahlback, Bjorn/0000-0003-1546-0328				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BAUER KA, 1991, SEMIN HEMATOL, V28, P10; BRIET E, 1988, PROTEIN C RELATED PR, P203; Broekmans AW, 1988, PROTEIN C RELATED PR, V3, P160; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1993, THROMB HAEMOSTASIS, V69, P978; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALLUS AS, 1973, LANCET, V2, P805; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1992, BLOOD, V79, P2340; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KANE WH, 1988, BLOOD, V71, P539; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARLAR RA, 1990, SEMIN THROMB HEMOST, V16, P299, DOI 10.1055/s-2007-1002683; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; RAPAPORT SI, 1989, BLOOD, V73, P359; SCHWARZ HP, 1984, BLOOD, V64, P1297; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405	28	1134	1157	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					517	522		10.1056/NEJM199402243300801	http://dx.doi.org/10.1056/NEJM199402243300801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302317				2022-12-28	WOS:A1994MX43600001
J	HARKINS, TT; GRISSOM, CB				HARKINS, TT; GRISSOM, CB			MAGNETIC-FIELD EFFECTS ON B-12 ETHANOLAMINE AMMONIA-LYASE - EVIDENCE FOR A RADICAL MECHANISM	SCIENCE			English	Article							BOND-DISSOCIATION ENERGY; CO-C BOND; BIOLOGICAL CATALYSIS; REACTION CENTERS; ADENOSYLCOBALAMIN; THERMOLYSIS; ENZYMES; SPIN; INTERMEDIATE; COENZYME-B12	A change in radical pair recombination rates is one of the few mechanisms by which a magnetic field can interact with a biological system. The kinetic parameter V-max/K-m (where K-m is the Michaelis constant) for the coenzyme B-12-dependent enzyme ethanolamine ammonia lyase was decreased 25 percent by a static magnetic field near 0.1 tesla (1000 gauss) with unlabeled ethanolamine and decreased 60 percent near 0.15 tesla with perdeuterated ethanolamine. This effect is likely caused by a magnetic field-induced change in intersystem crossing rates between the singlet and triplet spin states in the {cob(II)alamin:5'-deoxyadenosyl radical} spin-correlated radical pair.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah					NIEHS NIH HHS [ES05728] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005728] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BABIOR BM, 1969, J BIOL CHEM, V244, P449; BABIOR BM, 1971, J BIOL CHEM, V246, P6064; BABLOR BM, 1991, B12, pCH10; BLANKENSHIP RE, 1981, ACCOUNTS CHEM RES, V14, P163, DOI 10.1021/ar00066a001; BOXER SG, 1982, J AM CHEM SOC, V104, P1452, DOI 10.1021/ja00369a062; BUCHACHENKO AL, 1991, ACCOUNTS CHEM RES, V24, P177, DOI 10.1021/ar00006a004; CHAGOVETZ AM, 1993, J AM CHEM SOC, V115, P12152, DOI 10.1021/ja00078a063; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; DIZIOL P, 1980, EUR J BIOCHEM, V106, P211; DOLPHIN D, 1991, B12, V2; DOLPHIN D, 1991, B12, V1; DOUBLEDAY C, 1989, ACCOUNTS CHEM RES, V22, P199, DOI 10.1021/ar00162a001; FAUST LP, 1992, ARCH BIOCHEM BIOPHYS, V294, P50, DOI 10.1016/0003-9861(92)90135-J; FINKE RG, 1984, INORG CHEM, V23, P3041, DOI 10.1021/ic00188a002; GENO MK, 1987, J CHEM SOC CHEM COMM, P1052, DOI 10.1039/c39870001052; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARKINS TT, 1993, MAY AM SOC BIOCH MOL; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HAYASHI H, 1990, PHOTOCHEM PHOTOBIOL, V1, P59; HOFF AJ, 1977, BIOCHIM BIOPHYS ACTA, V460, P547, DOI 10.1016/0005-2728(77)90094-9; HOLLAWAY MR, 1978, EUR J BIOCHEM, V82, P143, DOI 10.1111/j.1432-1033.1978.tb12005.x; HUMMEL K, 1989, J MOL CATAL, V54, P11; KAPLAN BH, 1968, J BIOL CHEM, V243, P1787; KIM SH, 1984, J AM CHEM SOC, V106, P8317; MCLAUCHLAN KA, 1991, MOL PHYS, V73, P241, DOI 10.1080/00268979100101181; OBRIEN RJ, 1985, J BIOL CHEM, V260, P6131; PRATT JM, 1985, CHEM SOC REV, V14, P161, DOI 10.1039/cs9851400161; ROBINTSON B, 1992, BIOCHEMISTRY-US, V31, P138; SALIKHOV KM, 1983, CHEM PHYS, V82, P163, DOI 10.1016/0301-0104(83)85354-3; SCHEPLER KL, 1975, BIOCHIM BIOPHYS ACTA, V397, P510, DOI 10.1016/0005-2744(75)90141-2; Schneider Z., 1987, COMPREHENSIVE B12; STEINER UE, 1989, CHEM REV, V89, P51, DOI 10.1021/cr00091a003; STEINER UE, 1990, PHOTOCHEM PHOTOBIOL, V4, P1; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TURRO NJ, 1983, P NATL ACAD SCI USA, V80, P609, DOI 10.1073/pnas.80.2.609; TURRO NJ, 1984, ISOTOPES ORGANIC CHE; VANAG VK, 1988, IZV AN SSSR BIOL+, V2, P215; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WESTERHOFF HV, 1986, P NATL ACAD SCI USA, V83, P4734, DOI 10.1073/pnas.83.13.4734	41	177	180	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					958	960		10.1126/science.8310292	http://dx.doi.org/10.1126/science.8310292			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310292				2022-12-28	WOS:A1994MX16500032
J	AVINS, AL; WOODS, WJ; LINDAN, CP; HUDES, ES; CLARK, W; HULLEY, SB				AVINS, AL; WOODS, WJ; LINDAN, CP; HUDES, ES; CLARK, W; HULLEY, SB			HIV-INFECTION AND RISK BEHAVIORS AMONG HETEROSEXUALS IN ALCOHOL TREATMENT PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ADDICTION SEVERITY INDEX; SEXUAL-BEHAVIOR; HOMOSEXUAL MEN; SAN-FRANCISCO; DRUG-USE; AIDS; COHORT; POPULATION; BELIEFS	Objective.-To measure the prevalence of human immunodeficiency virus (HIV) infection and high-risk behaviors among heterosexuals in alcohol treatment. Design.-Cross-sectional survey. Setting.-Five public alcohol treatment centers. Subjects.-Consecutive, sample of 888 heterosexual clients entering treatment between October 1990 and December 1991. Respondents were 51% black, 10% Hispanic, 33% white, and 76% male. The overall response rate was 68%. Measurements.-Structured interview and serotesting for HIV antibodies. Results.-The overall seroprevalence of HIV infection was 5% (95% confidence interval, 3% to 6%). There were no significant differences in rates of infection by age, gender, or race. The prevalence of infection in heterosexual respondents without a history of injection drug use was 3% in men and 4% in women, several times higher than published estimates from a similar community-based heterosexual sample. Unsafe sexual practices were common: 54% of respondents reported multiple sexual partners in the previous year, 97% of nonmonogamous respondents did not use condoms during all sexual encounters, and few respondents consistently asked new sexual partners about previous high-risk behaviors. Conclusions.-There is a substantial prevalence of HIV infection among heterosexual clients in San Francisco (Calif) alcohol treatment programs, much of which is not associated with injection drug use. Because of this and the high prevalence of unsafe sexual behaviors, there is a relatively high likelihood of heterosexual spread of HIV among the large population of clients seeking treatment for alcohol dependency. Interventions to prevent HIV spread should become a standard part of alcohol treatment programs.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO DEPT PUBL HLTH,COMMUNITY SUBST ABUSE SERV,SAN FRANCISCO,CA 94105	San Francisco General Hospital Medical Center; San Francisco Department of Public Health	AVINS, AL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,74 NEW MONTGOMERY ST,SAN FRANCISCO,CA 94105, USA.				NIAAA NIH HHS [AA08328] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008328] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AVINS AL, 1993, AIDS, V7, P109, DOI 10.1097/00002030-199301000-00017; BAGASRA O, 1989, ALCOHOL CLIN EXP RES, V13, P636, DOI 10.1111/j.1530-0277.1989.tb00396.x; BAGASRA O, 1993, J INFECT DIS, V167, P789, DOI 10.1093/infdis/167.4.789; BAGNALL G, 1990, AIDS Care, V2, P309, DOI 10.1080/09540129008257746; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CRITCHLOW B, 1986, AM PSYCHOL, V41, P751, DOI 10.1037/0003-066X.41.7.751; CROWE LC, 1989, PSYCHOL BULL, V105, P374, DOI 10.1037/0033-2909.105.3.374; DONOVAN JE, 1985, J CONSULT CLIN PSYCH, V53, P890, DOI 10.1037/0022-006X.53.6.890; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON R, 1993, AM J PREV MED, V9, P62, DOI 10.1016/S0749-3797(18)30770-0; HINGSON RW, 1990, AM J PUBLIC HEALTH, V80, P295, DOI 10.2105/AJPH.80.3.295; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JACOBSON JM, 1992, J STUD ALCOHOL, V53, P76, DOI 10.15288/jsa.1992.53.76; LEIGH BC, 1990, J SEX RES, V27, P199, DOI 10.1080/00224499009551552; MAHLER J, IN PRESS AM J ADDICT; MCCUSKER J, 1990, J ACQ IMMUN DEF SYND, V3, P729; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; OSTROW DG, 1990, AIDS, V4, P759, DOI 10.1097/00002030-199008000-00007; PENKOWER L, 1991, AM J PUBLIC HEALTH, V81, P194, DOI 10.2105/AJPH.81.2.194; SCHLEIFER S, 1990, HOSP COMMUNITY PSYCH, V248, P249; SIEGEL K, 1989, SOC SCI MED, V28, P561, DOI 10.1016/0277-9536(89)90250-5; Snedecor G. W, 1989, STAT METHODS, V8th; STALL R, 1990, MED ANTHROPOL Q, V4, P115, DOI 10.1525/maq.1990.4.1.02a00070; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; TROCKI KF, 1991, J ACQ IMMUN DEF SYND, V4, P981; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; WESTERBERG VS, 1992, AM J EPIDEMIOL, V135, P719, DOI 10.1093/oxfordjournals.aje.a116358; WESTERMEYER J, 1990, AM J DRUG ALCOHOL AB, V16, P47, DOI 10.3109/00952999009001571; ZUCKER RA, 1981, J STUD ALCOHOL, V42, P457, DOI 10.15288/jsa.1981.42.457; 1991, MMWR MORB MORTAL WKL, V40, P358; 1989, STATISTICAL ANAL SYS; 1993, STATA PC	35	101	102	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					515	518		10.1001/jama.271.7.515	http://dx.doi.org/10.1001/jama.271.7.515			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV423	8301765				2022-12-28	WOS:A1994MV42300033
J	RIGOTTI, NA; MCKOOL, KM; SHIFFMAN, S				RIGOTTI, NA; MCKOOL, KM; SHIFFMAN, S			PREDICTORS OF SMOKING CESSATION AFTER CORONARY-ARTERY BYPASS GRAFT-SURGERY - RESULTS OF A RANDOMIZED TRIAL WITH 5-YEAR FOLLOW-UP	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING CESSATION; CORONARY ARTERY BYPASS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); BEHAVIOR THERAPY; CORONARY DISEASE	RISK-FACTORS; MYOCARDIAL-INFARCTION; CIGARETTE-SMOKING; DISEASE; CASS; INTERVENTION; MORBIDITY; SURVIVAL; SEVERITY; THERAPY	Objective: To test the efficacy of a smoking cessation program for inpatients recovering from coronary artery bypass graft surgery and to identify predictors of cessation. Design: Randomized, controlled clinical trial. Setting: Postoperative cardiac surgery unit of a large teaching hospital. Patients: Patients scheduled for coronary artery bypass surgery by participating surgeons between 1 July 1986 and 1 July 1987 who had smoked 1 or more packs of cigarettes in the 6 months before admission. Of 120 eligible patients, 93 enrolled and 87 were discharged alive. All survivors were followed for at least 1 year; 94% were followed for a median of 5.5 years. Intervention: A three-session, nurse-delivered behavior modification program using a videotape and face-to-face counseling was compared to usual care. Measurements: Smoking status was assessed six times in the year after surgery and 5.5 years after surgery. Self-reported nonsmoking was validated by saliva cotinine assay 1 and 5.5 years after surgery. Results: No statistically significant differences were found between control (n = 43) and intervention (n = 44) groups at baseline. One and 5.5 years after hospital discharge, validated continuous nonsmoking rates were identical in intervention and control groups (51% at 1 year; 44% at 5.5 years). Multiple logistic regression identified four factors that were independently associated with nonsmoking for 1 year: fewer than 3 previous attempts to quit (odds ratio, 7.4; 95% Cl, 1.9 to 29.1); more than 1 week of preoperative nonsmoking (odds ratio, 10.0; Cl, 2.0 to 50.2); definite intention to quit smoking (odds ratio, 12.0; Cl, 2.6 to 55.1); and no difficulty not smoking in the hospital (odds ratio, 9.6; Cl, 1.8 to 52.2). Nonsmoking for 5.5 years was independently associated with two of these factors: fewer than three previous attempts to quit and intention to quit smoking after surgery. Cessation was not related to demographic factors, daily cigarette consumption, disease severity, hospital course, social support, or beliefs and attitudes. Conclusions: Even without specific intervention, nearly one half of smokers quit for 5 years after coronary artery bypass surgery. A short inpatient education program did not increase this rate. Future efforts should target the time after discharge and focus on increasing motivation in patients who have repeatedly failed to quit.	UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, BOSTON, MA 02114 USA; HARVARD UNIV, INST STUDY SMOKING BEHAV & POLICY, BOSTON, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University			Shiffman, Saul/K-7337-2012		NATIONAL CANCER INSTITUTE [K07CA001673] Funding Source: NIH RePORTER; NCI NIH HHS [CA01673-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILE WF, 1982, ADDICT BEHAV, V7, P373, DOI 10.1016/0306-4603(82)90006-5; BURT A, 1974, LANCET, V1, P304; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; CROUSE JR, 1991, AM J EPIDEMIOL, V134, P699, DOI 10.1093/oxfordjournals.aje.a116146; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; ENGBLOM E, 1992, EUR HEART J, V13, P232, DOI 10.1093/oxfordjournals.eurheartj.a060152; FITZGIBBON GM, 1987, CAN MED ASSOC J, V136, P45; FREUND KM, 1992, AM J EPIDEMIOL, V135, P957, DOI 10.1093/oxfordjournals.aje.a116407; FRID D, 1991, AM J PREV MED, V7, P131, DOI 10.1016/S0749-3797(18)30927-9; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; KORNFELD DS, 1982, CIRCULATION, V66, P24; LEAMAN DM, 1982, CHEST, V81, P16, DOI 10.1378/chest.81.1.16; LEMROW N, 1990, DHHS PHS903465 PUBL; MARSTON AR, 1988, AM J PUBLIC HEALTH, V78, P1226, DOI 10.2105/AJPH.78.9.1226; MOORE BL, 1987, ADDICT BEHAV, V12, P67, DOI 10.1016/0306-4603(87)90010-4; OCKENE J, 1992, HEALTH PSYCHOL, V11, P119, DOI 10.1037//0278-6133.11.5.277; Ossip-Klein D J, 1986, Health Psychol, V5 Suppl, P3, DOI 10.1037/0278-6133.5.Suppl.3; Perkins K A, 1988, J Subst Abuse, V1, P91, DOI 10.1016/S0899-3289(88)80012-9; RIGOTTI NA, 1991, J GEN INTERN MED, V6, P305, DOI 10.1007/BF02597426; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; SCHNEIDER SJ, 1983, ADDICT BEHAV, V8, P187, DOI 10.1016/0306-4603(83)90013-8; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SHIFFMAN S, 1979, NIDA23 RES MON; SIMON JA, 1992, AM J PUBLIC HEALTH, V82, P1235, DOI 10.2105/AJPH.82.9.1235; SIMONS LA, 1987, MED J AUSTRALIA, V146, P573, DOI 10.5694/j.1326-5377.1987.tb120417.x; SOLYMOSS BC, 1988, CIRCULATION, V78, P140; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; Van Vunakis H, 1987, IARC Sci Publ, P317; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; WARNER MA, 1989, MAYO CLIN PROC, V64, P609, DOI 10.1016/S0025-6196(12)65337-3; 1990, DHHS CDC908416 PHS C; 1989, DHHS CDC898411 PHS C	33	125	126	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					287	293		10.7326/0003-4819-120-4-199402150-00005	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291821				2022-12-28	WOS:A1994MW10300005
J	WEISSMAN, IL				WEISSMAN, IL			DEVELOPMENTAL SWITCHES IN THE IMMUNE-SYSTEM	CELL			English	Review							HEMATOPOIETIC STEM-CELLS; LYMPHOCYTE HOMING RECEPTOR; THYMIC EPITHELIAL-CELLS; MAMMARY-TUMOR VIRUS; BONE-MARROW CELLS; CENTER B-CELLS; T-CELLS; GERMINAL-CENTERS; TRANSGENIC MICE; INTERACTION DOMAINS		STANFORD UNIV, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University	WEISSMAN, IL (corresponding author), STANFORD UNIV, DEPT PATHOL, STANFORD, CA 94305 USA.							ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COICO RF, 1983, J IMMUNOL, V131, P2254; COOPER MD, 1992, IMMUNOLOGY 21ST CENT, P29; CRABTREE GR, 1993, IMMUNOL TODAY, V13, P136; CRUMP AL, 1993, P NATL ACAD SCI USA, V90, P10739, DOI 10.1073/pnas.90.22.10739; DAILEY MO, 1982, J IMMUNOL, V128, P2134; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DEMAAGD RA, 1985, IMMUNOLOGY, V54, P745; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EISEN HERMAN N., 1966, HARVEY LECT, V60, P1; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; EZINE S, 1987, J IMMUNOL, V139, P2195; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; Flemming W., 1885, ARCH MIKROSK ANAT, V24, P50; FORD WL, 1967, PROC R SOC SER B-BIO, V168, P244, DOI 10.1098/rspb.1967.0064; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GRIFFITHS GM, 1993, CYTOTOXIC CELLS, P273; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, J IMMUNOL, V142, P3773; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; HARDIE DL, 1993, EUR J IMMUNOL, V23, P997, DOI 10.1002/eji.1830230502; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; HU MCT, 1992, COLD SPRING HARB SYM, V57, P291, DOI 10.1101/SQB.1992.057.01.034; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; IKUTA K, 1991, J EXP MED, V174, P1279, DOI 10.1084/jem.174.5.1279; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNG TM, 1988, J IMMUNOL, V141, P4110; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KINA T, 1991, J EXP MED, V173, P373, DOI 10.1084/jem.173.2.373; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEPAULT F, 1983, J IMMUNOL, V131, P64; LEVIN R, 1975, AM J PHYSIOL, V229, P1397, DOI 10.1152/ajplegacy.1975.229.5.1397; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGRATH M S, 1978, P577; MCGRATH MS, 1979, CELL, V17, P65, DOI 10.1016/0092-8674(79)90295-2; MILLER JJ, 1964, J EXP MED, V120, P1075, DOI 10.1084/jem.120.6.1075; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NICOLAS JF, 1985, J HISTOCHEM CYTOCHEM, V33, P687, DOI 10.1177/33.7.2409128; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ONEILL HC, 1987, CELL, V49, P143, DOI 10.1016/0092-8674(87)90764-1; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; RAJEWSKY K, 1992, PROGRAMMING B CELL L, P41; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RAZZECA KJ, 1986, EUR J IMMUNOL, V16, P393, DOI 10.1002/eji.1830160414; REICHERT RA, 1983, J EXP MED, V157, P813, DOI 10.1084/jem.157.3.813; REICHERT RA, 1984, CELL, V38, P89, DOI 10.1016/0092-8674(84)90529-4; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROSENFELD P, 1992, NEUROSCI BIOBEHAV R, V16, P553, DOI 10.1016/S0149-7634(05)80196-4; Rouse R V, 1981, Ciba Found Symp, V84, P161; ROUSE RV, 1988, J HISTOCHEM CYTOCHEM, V36, P1511, DOI 10.1177/36.12.2461413; ROUSE RV, 1979, J IMMUNOL, V122, P2508; ROUSE RV, 1982, HUM IMMUNOL, V5, P21, DOI 10.1016/0198-8859(82)90028-3; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SENMAJUMDAR A, 1990, J IMMUNOL, V144, P111; SENMAJUMDAR A, 1992, J EXP MED, V176, P543, DOI 10.1084/jem.176.2.543; SENMAJUMDAR A, 1994, IN PRESS J VIROL; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1988, J EXP MED, V167, P1671, DOI 10.1084/jem.167.5.1671; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1988, J IMMUNOL, V141, P1877; SPANGRUDE GJ, 1989, J IMMUNOL, V142, P425; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRAUCH UG, 1994, IN PRESS INT IMMUNOL; STROBER S, 1981, CURRENT STATUS MODER, V7, P19; TONEGAWA S, 1989, PROGRESS IN IMMUNOLOGY, VOL 7, P243; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; VANEWIJK W, 1980, J HISTOCHEM CYTOCHEM, V28, P1089, DOI 10.1177/28.10.6999083; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONBOEHMER H, 1993, CURR OPIN IMMUNOL, V5, P175, DOI 10.1016/0952-7915(93)90001-9; WALLER EK, 1992, BLOOD, V80, P3144; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; WEISSMAN IL, 1975, ISRAEL J MED SCI, V11, P884; WEISSMAN IL, 1973, J EXP MED, V137, P504, DOI 10.1084/jem.137.2.504; WEISSMAN IL, 1976, COLD SPRING HARB SYM, V41, P9, DOI 10.1101/SQB.1977.041.01.005; WEISSMAN IL, 1975, ISRAEL J MED SCI, V11, P1267; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	144	115	119	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					207	218		10.1016/0092-8674(94)90329-8	http://dx.doi.org/10.1016/0092-8674(94)90329-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293459				2022-12-28	WOS:A1994MU67800005
J	NUSSENBLATT, RB; BELFORT, R				NUSSENBLATT, RB; BELFORT, R			OCULAR TOXOPLASMOSIS - AN OLD DISEASE REVISITED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							GONDII; MANAGEMENT; ANTIGEN; PATIENT		HOSP SAO PAULO,ESCOLA PAULISTA MED,DEPT OPHTHALMOL,SAO PAULO,BRAZIL	Universidade Federal de Sao Paulo (UNIFESP)	NUSSENBLATT, RB (corresponding author), NEI,IMMUNOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Belfort, Rubens/E-2252-2012	Belfort, Rubens/0000-0002-8422-3898				AKSTEIN RB, 1982, OPHTHALMOLOGY, V89, P1299, DOI 10.1016/S0161-6420(82)34629-1; BREZIN AP, 1991, NEW ENGL J MED, V324, P699; BREZIN AP, 1990, AM J OPHTHALMOL, V110, P599, DOI 10.1016/S0002-9394(14)77055-2; BURG JL, 1988, J IMMUNOL, V141, P3584; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; COCHEREAUMASSIN I, 1992, AM J OPHTHALMOL, V114, P130, DOI 10.1016/S0002-9394(14)73975-3; DESMONTS G, 1966, ARCH OPHTHALMOL-CHIC, V76, P839; ENGSTROM RE, 1991, AM J OPHTHALMOL, V111, P601, DOI 10.1016/S0002-9394(14)73706-7; FRIEDMAN.CT, 1969, ARCH OPHTHALMOL-CHIC, V81, P481; Gagliuso D J, 1990, Trans Am Ophthalmol Soc, V88, P63; Glasner P. D., 1992, OPHTHALMOLOGY S, V99, P150; GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5; JACOBS L, 1956, B J HOPKINS HOSP, V99, P11; LAPPALAINEN M, 1993, J INFECT DIS, V167, P691, DOI 10.1093/infdis/167.3.691; LOPEZ JS, 1992, AM J OPHTHALMOL, V113, P331, DOI 10.1016/S0002-9394(14)71588-0; MELAMED J, 1993, 3RD P INT S UV BRUSS, P283; NUSSENBLATT RB, 1989, UVEITIS FUNDAMENTALS, P291; OCONNOR GR, 1974, B NEW YORK ACAD MED, V50, P192; PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P1, DOI 10.1136/bjo.57.1.1; PERKINS ES, 1961, UVEITIS TOXOPLASMOSI, P69; REHDER JR, 1988, AM J OPHTHALMOL, V106, P740, DOI 10.1001/archopht.1988.01060130810028; SIBLEY LD, 1992, NATURE, V359, P82, DOI 10.1038/359082a0; SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0; SILVEIRA C, 1989, AM J OPHTHALMOL, V107, P682, DOI 10.1016/0002-9394(89)90274-2; WILDER HC, 1952, AMA ARCH OPHTHALMOL, V48, P127; ZSCHEILE FP, 1964, ARCH OPHTHALMOL-CHIC, V71, P645	26	73	75	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					304	307		10.1001/jama.271.4.304	http://dx.doi.org/10.1001/jama.271.4.304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295291				2022-12-28	WOS:A1994MR22100028
J	DYKE, T; BROWN, N				DYKE, T; BROWN, N			HYPOXIA IN CHILDHOOD PNEUMONIA - BETTER DETECTION AND MORE OXYGEN NEEDED IN DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article							PAPUA-NEW-GUINEA; SIGNS	Even though hypoxia is a major risk factor for death in children with acute respiratory infection in developing countries, oxygen is not part of first line treatment. Because oxygen is not readily available in developing countries it tends to be given to the most seriously ill children, whose outcome is poor. Oxygen might be useful if given earlier in the course of the disease. Clinical signs are not clear cut, however, though the presence of cyanosis and grunting together with a raised respiratory rate can significantly increase the detection of hypoxaemia. A simple oximeter would make detection easier, and oxygen concentrators are more cost effective than bottled oxygen. Ideally oxygen should be given to children in the early stages of clinical pneumonia to prevent deterioration.	UNIV PAPUA NEW GUINEA,FAC MED,DEPT PAEDIAT,BOROKO,PAPUA N GUINEA	University of Papua New Guinea	DYKE, T (corresponding author), UNIV PAPUA NEW GUINEA,FAC MED,DEPT COMMUNITY MED,POB 5623,BOROKO,PAPUA N GUINEA.							CHANTAROJANASIR.T, 1987, TXB PAEDIATRIC INTEN, V1, P199; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; ODEMPSEY TJD, 1993, BRIT MED J, V306, P1342, DOI 10.1136/bmj.306.6888.1342; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; SHANN F, 1988, LANCET, V2, P1238; SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295; WANG EEL, 1992, AM REV RESPIR DIS, V145, P106, DOI 10.1164/ajrccm/145.1.106; 1991, TECHNICAL BASIS WHO; 1993, MANUAL STANDARD TREA	11	23	24	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					119	120		10.1136/bmj.308.6921.119	http://dx.doi.org/10.1136/bmj.308.6921.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298386	Green Published			2022-12-28	WOS:A1994MR17300023
J	RIDDLE, RD; JOHNSON, RL; LAUFER, E; TABIN, C				RIDDLE, RD; JOHNSON, RL; LAUFER, E; TABIN, C			SONIC-HEDGEHOG MEDIATES THE POLARIZING ACTIVITY OF THE ZPA	CELL			English	Article							DEVELOPING CHICK LIMB; RETINOIC ACID; WING BUD; PATTERN-FORMATION; LOCAL APPLICATION; DROSOPHILA; EXPRESSION; GENES; DIGITS; TRANSCRIPTION	The zone of polarizing activity (ZPA) is a region at the posterior margin of the limb bud that induces mirror-image duplications when grafted to the anterior of a second limb. We have isolated a vertebrate gene, Sonic hedgehog, related to the Drosophila segment polarity gene hedgehog, which is expressed specifically in the ZPA and in other regions of the embryo, that is capable of polarizing limbs in grafting experiments. Retinoic acid, which can convert anterior limb bud tissue into tissue with polarizing activity, concomitantly induces Sonic hedgehog expression in the anterior limb bud. Implanting cells that express Sonic hedgehog into anterior limb buds is sufficient to cause ZPA-like limb duplications. Like the ZPA, Sonic hedgehog expression leads to the activation of Hox genes. Sonic hedgehog thus appears to function as the signal for anteroposterior patterning in the limb.			RIDDLE, RD (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.			Laufer, Edward/0000-0002-4933-1017				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BROCKES J, 1991, NATURE, V350, P15, DOI 10.1038/350015a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HORNBRUCH A, 1991, DEVELOPMENT, V111, P721; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KYTE J, 1982, J MOL BIOL, V157, P133; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LAUFER E, 1993, CURR BIOL, V3, P306, DOI 10.1016/0960-9822(93)90187-S; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P80; PARR BA, 1993, DEVELOPMENT, V119, P247; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; Saunders J W, 1983, Prog Clin Biol Res, V110 Pt A, P67; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SMITH JC, 1979, J EMBRYOL EXP MORPH, V52, P105; STOCKER KM, 1990, ROUX ARCH DEV BIOL, V198, P371, DOI 10.1007/BF00376155; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1983, LIMB DEV REGENERAT A, P109; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABATA T, 1992, GENE DEV, V6, P2631; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V11, P1986; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WEISS R, 1984, RNA TUMOR VIRUSES, V1, P209; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	61	1946	2020	5	168	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1401	1416		10.1016/0092-8674(93)90626-2	http://dx.doi.org/10.1016/0092-8674(93)90626-2			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269518				2022-12-28	WOS:A1993MP86900018
J	HENDRY, WF; AHERN, RP; COLE, PJ				HENDRY, WF; AHERN, RP; COLE, PJ			WAS YOUNGS SYNDROME CAUSED BY EXPOSURE TO MERCURY IN CHILDHOOD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE AZOOSPERMIA; DISEASE	Objective-To determine whether the incidence of chronic sinusitis, bronchitis, or bronchiectasis in men with obstructive azoospermia (Young's syndrome) has fallen in men born after 1955 when calomel (mercurous chloride) was removed from teething powders and worm medication in the United Kingdom. Design-A prospective study of aetiological factors in subfertile men with epididymal obstruction operated on between 1975 and 1993. Setting-Central London. Subjects-274 men with obstructive azoospermia undergoing epididymovasostomy; date of birth was recorded and illness in childhood, persistent nasal or respiratory symptoms, and previous urinary or genital infection were asked about. Main outcome measure-Site of epididymal block and association with possible aetiological factors, related to date of birth. Results-146 men had hold up in the head of the epididymis (capital blocks): 119 (82%) had Young's syndrome, and 11 gave a definite history of pink disease (mercury intoxication) in childhood. 128 had obstruction lower down towards the tail of the epididymis (caudal blocks): 64 (50%) had a history of genital or urinary infection, and only three had Young's syndrome; none had had pink disease. The incidence of Young's syndrome fell significantly from 114 (50%) of 227 men born up to 1955 to eight (17%) of 47 men born since then. Conclusions-The decline in incidence of Young's syndrome in those born after 1955 is similar to that observed with pink disease, suggesting that both conditions may have had a similar aetiology-mercury intoxication.	ROYAL MARSDEN HOSP, DEPT COMP & INFORMAT, LONDON SW3 6JJ, ENGLAND; ROYAL BROMPTON NATL HEART & LUNG INST, HOST DEF UNIT, LONDON SW3 6LY, ENGLAND	Royal Marsden NHS Foundation Trust; Imperial College London	HENDRY, WF (corresponding author), ST BARTHOLOMEWS HOSP, DEPT UROL, LONDON EC1A 7BE, ENGLAND.			A'Hern, Roger/0000-0003-0593-8391				BARLOW SM, 1982, REPRODUCTIVE HAZARDS, P386; BARRETT FR, 1957, MED J AUSTRALIA, V2, P242; Bidstrup PL., 1964, TOXICITY MERCURY ITS; Brown J R, 1967, Med Serv J Can, V23, P786; CHAMBERLAIN JL, 1963, CLIN PEDIATR, V2, P439, DOI 10.1177/000992286300200808; CLEMENTS FW, 1960, MED J AUSTRALIA, V1, P922; COLOVER T, 1956, BRIT MED J, V1, P897; DATHAN JG, 1965, BMJ-BRIT MED J, V1, P1181, DOI 10.1136/bmj.1.5443.1181; FORD WCL, 1982, PROGR MALE CONTRACEP, P159; GODLEE F, 1992, BRIT MED J, V305, P333; GOLDWATER LJ, 1972, MERCURY HIST QUICKSI, P182; GREENSTONE MA, 1988, THORAX, V43, P153, DOI 10.1136/thx.43.2.153; GUILLON G, 1972, C NATL SOC FERTIL ST, P391; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HENDRY WF, 1978, BRIT J UROL, V50, P598, DOI 10.1111/j.1464-410X.1978.tb06221.x; HENDRY WF, 1990, ANN ROY COLL SURG, V72, P396; HENDRY WF, 1983, BRIT J UROL, V55, P785, DOI 10.1111/j.1464-410X.1983.tb03426.x; HOLSTEIN A F, 1976, P23; HOLZEL A, 1952, LANCET, V262, P441; HUGHES TM, 1987, J UROLOGY, V137, P1238, DOI 10.1016/S0022-5347(17)44467-3; KEW J, 1993, BRIT MED J, V306, P506, DOI 10.1136/bmj.306.6876.506; LELANNOU D, 1980, ANN UROL, V14, P94; LOGAN WPD, 1949, LANCET, V256, P608; MITCHINSON MJ, 1975, J PATHOL, V115, P57, DOI 10.1002/path.1711150110; MOHAMED MK, 1986, J ANDROL, V7, P11; NEVILLE E, 1983, THORAX, V38, P929, DOI 10.1136/thx.38.12.929; PAVIA D, 1981, CHEST, V80, P892, DOI 10.1378/chest.80.6.892; SCHANKER HMJ, 1985, ARCH INTERN MED, V145, P2201, DOI 10.1001/archinte.145.12.2201; SCHRAG SD, 1985, REPROD TOXICOL, P301; WARKANY J, 1966, AM J DIS CHILD, V112, P147; WARKANY J, 1948, LANCET, V1, P8929; YOUNG D, 1970, J REPROD FERTIL, V23, P541	32	39	40	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 18	1993	307	6919					1579	1582		10.1136/bmj.307.6919.1579	http://dx.doi.org/10.1136/bmj.307.6919.1579			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292944	Green Published, Bronze			2022-12-28	WOS:A1993MN10700007
J	LEVACK, ID; MCGOWAN, SW				LEVACK, ID; MCGOWAN, SW			MACKLIN,ALEXANDER,HEPBURNE - PHYSICIAN, POLAR EXPLORER, AND PIONEER	BRITISH MEDICAL JOURNAL			English	Item About an Individual									DUNDEE ROYAL INFIRM,DUNDEE,SCOTLAND		LEVACK, ID (corresponding author), WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							HUNTFORD R, 1985, SHACKLETON, P528; KING P, 1991, S STORY SHACKLETONS; MACKLIN AH, PUBLICATION LIST; MACKLIN AH, 1920, THESIS U MANCHESTER; NANSEN F, 1897, FURTHEST N; ROBERTSON RB, 1956, WHALES MEN; Shackleton E, 1919, SOUTH; Shackleton E.H., 1909, HEART ANTARCTIC	8	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1597	1599		10.1136/bmj.307.6919.1597	http://dx.doi.org/10.1136/bmj.307.6919.1597			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292952	Green Published, Bronze			2022-12-28	WOS:A1993MN10700015
J	SCADDING, JG				SCADDING, JG			A SUMMONS TO CARTHAGE, DECEMBER 1943	BRITISH MEDICAL JOURNAL			English	Article																		MORGAN C, 1966, WQINSTON CHURCHILL S	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1595	1596		10.1136/bmj.307.6919.1595	http://dx.doi.org/10.1136/bmj.307.6919.1595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292951	Green Published, Bronze			2022-12-28	WOS:A1993MN10700014
J	FERTIG, A; ROLAND, M; KING, H; MOORE, T				FERTIG, A; ROLAND, M; KING, H; MOORE, T			UNDERSTANDING VARIATION IN RATES OF REFERRAL AMONG GENERAL-PRACTITIONERS - ARE INAPPROPRIATE REFERRALS IMPORTANT AND WOULD GUIDELINES HELP TO REDUCE RATES	BRITISH MEDICAL JOURNAL			English	Article							OUTPATIENT REFERRALS; QUALITY; CARE	Objectives-To determine the extent to which variation in rates of referral among general practitioners may be explained by inappropriate referrals and to estimate the effect of implementing referral guidelines. Setting-Practices within Cambridge Health Authority and Addenbrooke's Hospital, Cambridge. Main outcome measures-Data on practice referral rates from hospital computers, inappropriate referrals as judged by hospital consultants, and inappropriate referrals as judged against referral guidelines which had been developed locally between general practitioners and specialists. Effect of referral guidelines on referral patterns as judged by general practitioners using the guidelines in clinical practice. Results-There was 2.5-fold variation in referral rates among general practices. According to the specialists, 9.6% (95% confidence interval 6.4% to 12.9%) of referrals by general practitioners and 8.9% (2.6% to 15.2%) of referrals from other specialists were judged possibly or definitely inappropriate. Against locally determined referral guidelines 15.9% of referrals by general practitioners were judged possibly inappropriate (11.8% to 20.0%). Elimination of all possibly inappropriate referrals could reduce variation in practice referral rates only from 2.5-fold to 2.1-fold. An estimate of the effect of using referral guidelines for 60 common conditions in routine general practice suggested that application of guidelines would have been unlikely to reduce rates of referral in hospital (95% confidence interval -4.5% to 8.6% of consultations resulting in referral). Conclusion-The variation in referral rates among general practitioners in Cambridge could not be explained by inappropriate referrals. Application of referral guidelines would be unlikely to reduce the number of patients referred to hospital.	UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND; HUGHES HALL,CAMBRIDGE,ENGLAND; E BARNWELL HLTH CTR,CAMBRIDGE,ENGLAND; E ANGLIAN REG HLTH AUTHOR,CAMBRIDGE,ENGLAND	University of Manchester; University of Cambridge								ARMSTRONG D, 1991, BRIT MED J, V302, P1186, DOI 10.1136/bmj.302.6786.1186; CARTWRIGHT A, 1992, OUTPATIENTS THEIR DO; COULTER A, 1992, HOSP REFERRALS, P123; CUMMINS RO, 1981, BRIT MED J, V282, P1037, DOI 10.1136/bmj.282.6269.1037; EMMANUEL J, 1989, BRIT MED J, V299, P722, DOI 10.1136/bmj.299.6701.722; EMSLIE C, 1993, BRIT MED J, V306, P1728, DOI 10.1136/bmj.306.6894.1728; GRACE JF, 1987, FAM PRACT, V14, P170; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; GROL R, 1990, BRIT J GEN PRACT, V40, P134; HAINES A, 1992, HOSPITAL REFERRALS, P163; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; ROLAND M, 1992, HOSP REFERRALS, P136; ROLAND M, 1992, REFERRALS MED OUTPAT, P33; ROLAND MO, 1991, J ROY SOC MED, V84, P403, DOI 10.1177/014107689108400708; ROLAND MO, 1991, BRIT MED J, V302, P1124, DOI 10.1136/bmj.302.6785.1124; WILKIN D, 1992, HOSPITAL REFERRALS, P76	18	78	79	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1467	1470		10.1136/bmj.307.6917.1467	http://dx.doi.org/10.1136/bmj.307.6917.1467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281091	Bronze, Green Published			2022-12-28	WOS:A1993MK79700027
J	READING, R; RAYBOULD, S; JARVIS, S				READING, R; RAYBOULD, S; JARVIS, S			DEPRIVATION, LOW-BIRTH-WEIGHT, AND CHILDRENS HEIGHT - A COMPARISON BETWEEN RURAL AND URBAN AREAS	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; ENGLAND	Objective-To compare proportions of low birthweight babies and mean heights of schoolchildren between rural and urban areas at different levels of social deprivation. Design-Cross sectional population based study classifying cases by Townsend material deprivation index of enumeration district of residence and by rural areas, small towns, and large towns. Setting-Northumberland Health District. Subjects-18930 singleton infants delivered alive during january 1985 to September 1990 and resident in Northumberland in October 1990; 9055 children aged 5 to 8 1/2 years attending Northumberland schools in the winter of 1989-90. Main outcome measures-Odds ratios for birth weight less than 2800 g; difference in mean height measured by standard deviation (SD) score. Results-Between the most deprived and most affluent 20% of enumeration districts the odds ratio for low birth weight adjusted for rural or urban setting was 1.71 (95% confidence interval 1.51 to 1.93) and the difference in mean height -0.232 SD score (-0.290 to -0.174). Between large towns and rural areas the odds ratio for low birth weight adjusted for deprivation was 1.37 (1.23 to 1.53) and the difference in mean height -0.162 SD score (-0.214 to -0.110). Results for-small towns were intermediate between large towns and rural areas. Conclusions-Inequalities in birth weight and height exist in all rural and urban settings between deprived and affluent areas. In addition, there is substantial disadvantage to living in urban areas compared with rural areas which results from social or environmental factors unrelated to current levels of deprivation.	NORTHUMBERLAND AREA HLTH AUTHOR,MORPETH,ENGLAND; UNIV NEWCASTLE UPON TYNE,CTR URBAN & REG DEV STUDIES,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK								BAIRD D, 1974, J BIOSOC SCI, V6, P323, DOI 10.1017/S0021932000009688; BENTHAM CG, 1984, AREA, V16, P219; Bradley T., 1986, DEPRIVATION WELFARE, P151; Bradley T., 1986, DEPRIVATION WELFARE, P1; Carstairs V., 1991, DEPRIVATION HLTH SCO; Chilvers C, 1978, POPULATION TRENDS, V11, P16; COLE TJ, 1983, ARCH DIS CHILD, V58, P717, DOI 10.1136/adc.58.9.717; FEARN R, 1987, SOC SCI MED, V24, P263, DOI 10.1016/0277-9536(87)90053-0; FOSTER JM, 1983, INT J EPIDEMIOL, V12, P199, DOI 10.1093/ije/12.2.199; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; GUILLIFORD MC, 1991, ARCH DIS CHILD, V66, P235; HART N, 1993, POP STUD-J DEMOG, V47, P27, DOI 10.1080/0032472031000146716; ILLSLEY R, 1955, BRIT MED J, V2, P1520, DOI 10.1136/bmj.2.4955.1520; KNOX P, 1986, DEPRIVATION WELFARE, P99; MACFARLANE A, 1984, BIRTH COUNTS STATIST; MACINTYRE S, 1988, SOC SCI MED, V27, P327, DOI 10.1016/0277-9536(88)90266-3; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; OAKLEY A, 1985, SOC SCI MED, V21, P1259, DOI 10.1016/0277-9536(85)90275-8; PHILLIMORE P, 1992, J PUBLIC HEALTH MED, V14, P290; READING P, 1993, J EPIDEMIOL COMMUNIT, V47, P238; READING R, 1993, ARCH DIS CHILD, V68, P626, DOI 10.1136/adc.68.5.626; TANNER JM, 1986, BRIT MED BULL, V42, P131, DOI 10.1093/oxfordjournals.bmb.a072110; Townsend PP., 1988, HLTH DEPRIVATION INE; WALFORD N, 1986, DEPRIVATION WELFARE, P109; WALKER A, 1978, RURAL POVERTY, P1; WATT IS, 1993, BRIT MED J, V306, P1358, DOI 10.1136/bmj.306.6889.1358; Wynn M., 1979, PREVENTION HANDICAP; 1985, GLIM RELEASE 3 77; 1988, SPSSX USERS GUIDE; 1983, SASPAC USERS MANUAL	30	43	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1458	1462		10.1136/bmj.307.6917.1458	http://dx.doi.org/10.1136/bmj.307.6917.1458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK797	8281087	Bronze, Green Published			2022-12-28	WOS:A1993MK79700022
J	BERGMANN, JF; CHASSANY, O; CONSOLI, SM; BUTEAU, E; BENDJENANA, H; LEMERCIER, F; SEGRESTAA, JM; CAULIN, C				BERGMANN, JF; CHASSANY, O; CONSOLI, SM; BUTEAU, E; BENDJENANA, H; LEMERCIER, F; SEGRESTAA, JM; CAULIN, C			ANTIBIOTIC-INDUCED FATIGUE	BRITISH MEDICAL JOURNAL			English	Article									HOP BROUSSAIS,DEPT PSYCHOL MED,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	BERGMANN, JF (corresponding author), LARIBOISIERE HOSP,THERAPEUT RES UNIT,F-75010 PARIS,FRANCE.		Consoli, Silla M/C-8278-2013; Bergmann, Jean-Francois/L-6044-2017	Bergmann, Jean-Francois/0000-0001-6861-9748				BORTNER RW, 1969, J CHRON DIS, V22, P87, DOI 10.1016/0021-9681(69)90061-7; Lefcourt H.M., 1981, RES LOCUS CONTROL CO; MCCANN CC, 1992, BRIT J CLIN PHARMACO, V33, P107, DOI 10.1111/j.1365-2125.1992.tb04008.x; ODDSON OH, 1985, ACTA MED SCAND S, V217, P97; SCHECKLER WE, 1970, J AMER MED ASSOC, V213, P264, DOI 10.1001/jama.213.2.264	5	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1397	1398		10.1136/bmj.307.6916.1397	http://dx.doi.org/10.1136/bmj.307.6916.1397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274892	Bronze, Green Published			2022-12-28	WOS:A1993MK42000021
J	ROBERTS, SJ; HARRIS, CM				ROBERTS, SJ; HARRIS, CM			AGE, SEX, AND TEMPORARY RESIDENT ORIGINATED PRESCRIBING UNITS (ASTRO-PUS) - NEW WEIGHTINGS FOR ANALYZING PRESCRIBING OF GENERAL PRACTICES IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To derive demographic weightings to replace the existing system of prescribing units used in analysing prescribing by general practitioners in England. Design-The prescribing data for one year from a sample of 90 practices in 80 family health service authority areas were used to calculate the relative frequency with which items were prescribed, for each sex, in nine age bands and for temporary residents. Data on the variation in cost per item by age and sex then allowed estimates to be made of the relative costs for these groups. Integer values for both the item based and cost based weightings were obtained by conversion to optimal integer scales. Main outcome measures-Item based and cost based weightings for each of the 18 age-sex groups and for temporary residents. The cost based weightings were considered more appropriate to the context in which the new system was to be used. Results-Prescribing costs increased noticeably, for both sexes, in the middle years (ages 35-64). Compared with the existing system, the cost based weightings (ASTRO-PUs) gave greater weight to patients aged 45 and over, especially those in the 55-64 age band, at the expense of younger patients. Children under 5 received twice as many items as those aged 5-14, but the inexpensiveness of their drugs made the cost based weightings of the two groups equal. Similarly, women were generally given more items than men, but at a lower average cost per item, which reduced differences between the sexes in the cost based weightings. Costs for patients aged 75 and over, compared with those aged 65-74, were higher only for women. Conclusions-The cost based weightings proposed are believed to reflect the present distribution of prescribing costs, in relation to age and sex, in English general practice. They are intended for use in analyses at practice level.			HARRIS, CM (corresponding author), UNIV LEEDS,ACAD UNIT GEN PRACTICE,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,ENGLAND.							BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; EDWARDS C, 1992, PRESCRIBER, V9, P103; MANN RD, 1992, PHARMACOEPIDEMIOL DR, V0001, P00019; 1986, MORBIDITY STATISTICS; 1986, GLIM GENERALISED INT; 1990, IMPROVING PRESCRIBIN	7	73	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					485	488		10.1136/bmj.307.6902.485	http://dx.doi.org/10.1136/bmj.307.6902.485			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8305014	Bronze, Green Published			2022-12-28	WOS:A1993LU59000029
J	WOOLHANDLER, S; HIMMELSTEIN, DU; LEWONTIN, JP				WOOLHANDLER, S; HIMMELSTEIN, DU; LEWONTIN, JP			ADMINISTRATIVE COSTS IN UNITED-STATES HOSPITALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNIVERSAL HEALTH-INSURANCE; PROMOTE QUALITY; CARE SYSTEM; EFFICIENCY; ECONOMY; 1990S; PLAN	Background. Previous estimates of administrative costs in U.S. hospitals have been based on figures for California, and nationwide extrapolation has been controversial. If the costs of bureaucracy are high, major policy reforms may yield substantial savings. Methods. We obtained detailed data on hospital expenses for fiscal year 1990 from reports submitted to Medicare by 6400 hospitals. We calculated each hospital's administrative costs by summing expenses in the following Medicare cost-accounting categories: administrative and general, nursing administration, central services and supply (excluding the purchase cost of supplies), medical records and library, utilization review, and the salary costs of the employee benefits department. We classified costs in most other categories as clinical. Some small categories of expenses (e.g., gift shop) were excluded from both our clinical and administrative groupings, and for others (e.g., plant operations), a proportional share was allocated between the two groupings. Results. Nationwide, administration accounted for an average of 24.8 percent of each hospital's spending in fiscal 1990. Average hospital administrative costs ranged from 20.5 percent in Minnesota to 30.6 percent in Hawaii. Administrative salaries accounted for 22.4 percent of the average hospital's salary costs. Administrative costs were similar in states with high and low rates of enrollment in health maintenance organizations (HMOs). Conclusions. Hospital administrative costs in the United States are higher than previous estimates and more than twice as high as those in Canada. Greater enrollment in HMOs, with more competitive bidding by hospitals for managed-care contracts, an important element of proposed managed-competition health care reforms, does not seem to lower hospital administrative costs.	CAMBRIDGE HOSP,CTR NATL HLTH PROGRAM STUDIES,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University								ARCHER B, 1991, NEW ENGL J MED, V325, P1316; Burns J, 1992, Mod Healthc, V22, P44; DUKAKIS MS, 1992, NEW ENGL J MED, V327, P1090, DOI 10.1056/NEJM199210083271510; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; SHEILS JF, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.1.7; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1991, ADM COSTS STATEMENT; 1990, AHA HOSPITAL STATIST; 1989, AGGREGATE HOSPITAL F; 1991, HOSPITAL STATISTICS; 1991, UNIVERSAL HLTH INSUR; 1975, AHA HOSPITAL STATIST; 1991, GAOHRD9190 GEN ACC O	15	68	69	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					400	403		10.1056/NEJM199308053290606	http://dx.doi.org/10.1056/NEJM199308053290606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8292133				2022-12-28	WOS:A1993LQ33900006
J	NEWMAN, RD; ZU, SX; WUHIB, T; LIMA, AAM; GUERRANT, RL; SEARS, CL				NEWMAN, RD; ZU, SX; WUHIB, T; LIMA, AAM; GUERRANT, RL; SEARS, CL			HOUSEHOLD EPIDEMIOLOGY OF CRYPTOSPORIDIUM-PARVUM INFECTION IN AN URBAN-COMMUNITY IN NORTHEAST BRAZIL	ANNALS OF INTERNAL MEDICINE			English	Article							DAY-CARE-CENTER; ACQUIRED IMMUNODEFICIENCY SYNDROME; PERSISTENT DIARRHEA; ESCHERICHIA-COLI; IMMUNOGLOBULIN-M; OUTBREAK; TRANSMISSION; CHILDREN; IMMUNOCOMPETENT; ADHERENCE	Objective: To examine the transmission of Cryptosporidium infection in households with an identified person with cryptosporidiosis. Design: Prospective cohort study. Setting: An urban slum in Fortaleza, Brazil. Participants: Thirty-one households with a child less than 3 years of age (index case) who was positive for Cryptosporidium parvum using acid-fast and auramine-stained stool smears. Measurements: Three stool samples (at 0, 2, and 6 weeks after identification of the index case) and two serum samples (0 and 6 weeks) were collected from each family member in households with an index case of Cryptosporidium infection. Results: Forty-five percent of index cases of Cryptosporidium infection were associated with persistent (>14 days) diarrhea. Secondary cases of Cryptosporidium infection were identified either by stool examination or seroconversion in 18 (58%) of 31 households involving 30 persons, yielding an overall transmission rate of 19%. Of the 202 persons in this study with at least one serum sample available for analysis, 191 (94.6%) had evidence of antibodies (either IgM or IgG) to Cryptosporidium. Conclusions: Cryptosporidium parvum is highly transmissible and infective in the family setting, with transmission rates similar to other highly infectious enteric pathogens such as Shigella species. These data are cause for added concern because of the rapidly increasing rate of seropositivity for human immunodeficiency virus.	JOHNS HOPKINS UNIV, SCH MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV GASTROENTEROL, BALTIMORE, MD 21205 USA; UNIV FED CEARA, UNIDADE PESQUISAS CLIN, FORTALEZA, CEARA, BRAZIL; UNIV VIRGINIA, SCH MED, DIV GEOG & INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA	Johns Hopkins University; Johns Hopkins University; Universidade Federal do Ceara; University of Virginia			Lima, Aldo AM/D-8251-2018; Sears, Cynthia L/AAJ-6704-2020	Lima, Aldo AM/0000-0002-0299-1747; Sears, Cynthia L/0000-0003-4059-1661	NCPDCID CDC HHS [ICIDR PO1-A126512 02] Funding Source: Medline	NCPDCID CDC HHS		ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; ALPERT G, 1986, PEDIATRICS, V77, P152; BROWN EAE, 1989, PUBLIC HEALTH, V103, P3, DOI 10.1016/S0033-3506(89)80095-2; COMBEE CL, 1986, PEDIATR INFECT DIS J, V5, P528, DOI 10.1097/00006454-198609000-00008; Current W.L., 1990, P31; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DRYJANSKI J, 1986, AM J MED, V80, P751, DOI 10.1016/0002-9343(86)90839-9; EGGER M, 1990, ARCH DIS CHILD, V65, P445, DOI 10.1136/adc.65.4.445; FAYER R, 1990, INFECT IMMUN, V58, P2962, DOI 10.1128/IAI.58.9.2962-2965.1990; GAGGERO A, 1992, J CLIN MICROBIOL, V30, P3294, DOI 10.1128/JCM.30.12.3294-3297.1992; HANNAH J, 1988, PUBLIC HEALTH, V102, P539, DOI 10.1016/S0033-3506(88)80023-4; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; HEIJBEL H, 1987, PEDIATR INFECT DIS J, V6, P532, DOI 10.1097/00006454-198706000-00009; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LEMON SM, 1980, INFECT IMMUN, V28, P927; LIMA AAM, 1992, ACTA PAEDIATR, V81, P39, DOI 10.1111/j.1651-2227.1992.tb12370.x; MALLA N, 1987, INDIAN J MED RES, V86, P722; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; NEWMAN RD, 1993, AM J TROP MED HYG, V49, P270, DOI 10.4269/ajtmh.1993.49.270; Nwanyanwu O C, 1989, Tex Med, V85, P40; PAPE JW, 1987, AM J TROP MED HYG, V36, P333, DOI 10.4269/ajtmh.1987.36.333; PATTISON JR, 1975, LANCET, V1, P185; PERERA J, 1990, Ceylon Medical Journal, V35, P11; RAHMAN M, 1990, AM J TROP MED HYG, V42, P127, DOI 10.4269/ajtmh.1990.42.127; REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528; RIBEIRO CD, 1986, BRIT MED J, V292, P377, DOI 10.1136/bmj.292.6517.377; Schlager T A, 1988, Infect Dis Clin North Am, V2, P607; SCHORLING JB, 1990, AM J EPIDEMIOL, V132, P144, DOI 10.1093/oxfordjournals.aje.a115626; Sher A., 1989, Fundamental Immunology., P957; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SOAVE R, 1985, ARCH INTERN MED, V145, P70, DOI 10.1001/archinte.145.1.70; TERRY S, 1993, NY TIMES MAGAZI 0926, P42; Ungar B. L. P., 1990, Cryptosporidiosis of man and animals., P59; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; WANKE CA, 1991, PEDIATR INFECT DIS J, V10, P746, DOI 10.1097/00006454-199110000-00006; WEIKEL CS, 1985, J INFECT DIS, V151, P963, DOI 10.1093/infdis/151.5.963; WILSON R, 1981, J INFECT DIS, V143, P130, DOI 10.1093/infdis/143.1.130; ZIERDT WS, 1984, J CLIN MICROBIOL, V20, P860, DOI 10.1128/JCM.20.5.860-861.1984; 1984, LANCET, V1, P734	45	104	110	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					500	505		10.7326/0003-4819-120-6-199403150-00009	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311373				2022-12-28	WOS:A1994NB62500009
J	PACHTER, LM				PACHTER, LM			CULTURE AND CLINICAL CARE - FOLK ILLNESS BELIEFS AND BEHAVIORS AND THEIR IMPLICATIONS FOR HEALTH-CARE-DELIVERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASIAN REFUGEES; EMPACHO; AZARCON	This article presents an approach to the evaluation of patient-held beliefs and behaviors that may not be concordant with those of biomedicine. Physicians and patients often hold discrepant models of health and illness that may affect the effectiveness of communication during the clinical visit. An extreme example of such a discrepancy exists when the patient feels that he or she has an illness that is not defined within the biomedical paradigm. These are commonly referred to as folk illnesses. An example of such an illness is provided in order to discuss the effects of folk beliefs on patient-held perceptions of health and sickness, treatment-seeking behavior, clinical care, and physician-patient communication. Guidelines for addressing clinical issues surrounding folk beliefs and behaviors in a culturally sensitive way are discussed.	UNIV CONNECTICUT,DEPT PEDIAT,HARTFORD,CT; UNIV CONNECTICUT,DEPT ANTHROPOL,HARTFORD,CT	University of Connecticut; University of Connecticut	PACHTER, LM (corresponding author), ST FRANCIS HOSP & MED CTR,CTR HLTH & DEV CHILDREN & YOUTH,DEPT PEDIAT,114 WOODLAND ST,HARTFORD,CT 06105, USA.			Pachter, Lee/0000-0002-5766-0953				BAER RD, 1989, SOC SCI MED, V29, P1373, DOI 10.1016/0277-9536(89)90238-4; BARKER JC, 1992, W J MED, P157; BOSE A, 1983, PEDIATRICS, V72, P106; BUCHWALD D, 1992, WESTERN J MED, V156, P507; FELDMAN KW, 1984, AM J DIS CHILD, V138, P768, DOI 10.1001/archpedi.1984.02140460058019; Garrison V, 1977, MED ANTHROPOL, V1, P65; Guarnaccia P J, 1989, Med Anthropol, V11, P47; Guarnaccia P J, 1985, Med Anthropol, V9, P203; HARWOOD A, 1971, J AMER MED ASSOC, V216, P1153, DOI 10.1001/jama.216.7.1153; Harwood A, 1981, ETHNICITY MED CARE; Harwood A, 1981, ETHNICITY MED CARE, p482 508; HARWOOD A, 1981, ETHNICITY MED CARE, P397; Helman C. G., 1990, CULTURE HLTH ILLNESS; Kay M A, 1993, Med Anthropol, V15, P137; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KORSCH BM, 1971, AM J DIS CHILD, V121, P110, DOI 10.1001/archpedi.1971.02100130064006; KORSCH BM, 1968, PEDIATRICS, V42, P855; LOTITO BA, 1988, NOSOTROS COMMUNICATI; MARTIN HW, 1985, ETHNOLOGY, V24, P229, DOI 10.2307/3773612; MARXUACHRODRIGU.L, 1993, QUICKSILVER AZOGUE Y; Nations M K, 1988, Bull Pan Am Health Organ, V22, P335; Pachter L M, 1993, Med Anthropol, V15, P103; Pachter L M, 1992, Med Anthropol, V13, P285; PACHTER LM, 1993, J DEV BEHAV PEDIATR, V14, P163; PACHTER LM, 1992, NELSON TXB PEDIATRIC, P10; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; Reid R M, 1992, Med Anthropol, V13, P337; ROSELLE HA, 1970, ARCH INTERN MED, V125, P57, DOI 10.1001/archinte.125.1.57; Rubel ArthurJ., 1984, SUSTO FOLK ILLNESS; SANDLER AP, 1978, PEDIATRICS, V61, P921; SLESINGER DP, 1981, HISPANIC J BEHAVIORA, V3, P59; SPECTOR RE, 1992, CULTURAL DIVERSITY H; Trotter R T 2nd, 1989, Med Anthropol, V10, P211; TROTTER RT, 1985, HUM ORGAN, V44, P64, DOI 10.17730/humo.44.1.u448k01428282555; TROTTER RT, 1985, POSTGRAD MED, V78, P167, DOI 10.1080/00325481.1985.11699228; WEIDMAN HH, 1979, SOC SCI MED-MED ANTH, V13, P95, DOI 10.1016/0160-7987(79)90003-6; Weller S C, 1991, Med Anthropol, V13, P19; Weller S C, 1993, Med Anthropol, V15, P109; 1983, MMWR MORB MORTAL WKL, V32, P554; 1990, DELIVERING PREVENTIV; 1993, PEDIATRICS 2 S5, V91, P1023	41	213	215	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					690	694		10.1001/jama.271.9.690	http://dx.doi.org/10.1001/jama.271.9.690			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX570	8309032				2022-12-28	WOS:A1994MX57000030
J	VLADECK, BC				VLADECK, BC			UNTITLED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					649	649						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309017				2022-12-28	WOS:A1994MX57000009
J	ALEXANIAN, R; DIMOPOULOS, M				ALEXANIAN, R; DIMOPOULOS, M			DRUG-THERAPY - THE TREATMENT OF MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; ALTERNATING COMBINATION CHEMOTHERAPY; PLASMA-CELL MYELOMA; HIGH-DOSE MELPHALAN; PROGNOSTIC FACTORS; MULTICENTER TRIAL; INTENSIVE THERAPY; RESISTANT MYELOMA; ALPHA-INTERFERON; ACUTE-LEUKEMIA		UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Dimopoulos, Meletios Athanasios/AAD-4130-2019	Dimopoulos, Meletios/0000-0001-8990-3254				ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737; ALEXANIAN R, 1988, ARCH INTERN MED, V148, P1963, DOI 10.1001/archinte.148.9.1963; ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1992, BLOOD, V80, P887; ALEXANIAN R, 1978, BLOOD, V51, P1005; ALEXANIAN R, 1991, AM J CLIN ONCOL-CANC, V14, P188, DOI 10.1097/00000421-199106000-00003; ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693; ALEXANIAN R, 1991, NEOPLASTIC DISEASES, P453; ANDERSON KC, 1991, BLOOD, V77, P712; ATTAL M, 1992, BLOOD, V79, P1130, DOI 10.1182/blood.V79.5.1130.bloodjournal7951130; AVVISATI G, 1992, HEMATOL ONCOL CLIN N, V6, P395; BARLOGIE B, 1990, BLOOD, V76, P677, DOI 10.1182/blood.V76.4.677.bloodjournal764677; BARLOGIE B, 1989, BLOOD, V73, P865; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BARLOGIE B, 1988, BLOOD, V72, P2015; BERGSAGEL DE, 1979, NEW ENGL J MED, V301, P743, DOI 10.1056/NEJM197910043011402; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455; COOPER MR, 1986, J CLIN ONCOL, V4, P1331, DOI 10.1200/JCO.1986.4.9.1331; COOPER MR, 1993, J CLIN ONCOL, V11, P155, DOI 10.1200/JCO.1993.11.1.155; DIMOPOULOS MA, 1993, BLOOD, V82, P2324; DIMOPOULOS MA, 1992, J CLIN ONCOL, V10, P587, DOI 10.1200/JCO.1992.10.4.587; DIMOPOULOS MA, 1993, BRIT J HAEMATOL, V83, P240, DOI 10.1111/j.1365-2141.1993.tb08278.x; DIMOPOULOS MA, 1993, AM J MED, V94, P57, DOI 10.1016/0002-9343(93)90120-E; FERMAND JP, 1989, BLOOD, V73, P20; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GORE ME, 1989, LANCET, V2, P879; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; GROGAN TM, 1993, BLOOD, V81, P490; HAROUSSEAU JL, 1992, BLOOD, V79, P2827; HJORTH M, 1993, EUR J HAEMATOL, V50, P95; JAGANNATH S, 1990, BLOOD, V76, P1860; JAGANNATH S, 1992, BLOOD, V80, P1666; KYLE RA, 1980, NEW ENGL J MED, V302, P1347, DOI 10.1056/NEJM198006123022405; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; MCLAUGHLIN P, 1982, BLOOD, V60, P851; MELLSTEDT H, 1979, LANCET, V1, P245; MONCONDUIT M, 1992, BRIT J HAEMATOL, V80, P199, DOI 10.1111/j.1365-2141.1992.tb08901.x; MOULOPOULOS LA, 1993, J CLIN ONCOL, V11, P1311, DOI 10.1200/JCO.1993.11.7.1311; OSTERBORG A, 1993, BLOOD, V81, P1428; PAVLOVSKY S, 1984, J CLIN ONCOL, V2, P836, DOI 10.1200/JCO.1984.2.7.836; PEEST D, 1988, EUR J CANCER CLIN ON, V24, P1061, DOI 10.1016/0277-5379(88)90160-5; PEEST D, 1990, ONKOLOGIE, V13, P458; PERRI RT, 1981, AM J MED, V71, P935, DOI 10.1016/0002-9343(81)90303-X; QUESADA JR, 1986, BLOOD, V67, P275; REECE DE, 1993, BONE MARROW TRANSPL, V11, P139; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROWLEY JD, 1981, BLOOD, V58, P759; SALMON SE, 1983, J CLIN ONCOL, V1, P453, DOI 10.1200/JCO.1983.1.8.453; SALMON SE, 1992, P AN M AM SOC CLIN, V11, P316; SAMSON D, 1989, LANCET, V2, P882; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H	54	338	351	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					484	489						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289856				2022-12-28	WOS:A1994MW48000009
J	TAYLOR, AK; SAFANDA, JF; FALL, MZ; QUINCE, C; LANG, KA; HULL, CE; CARPENTER, I; STALEY, LW; HAGERMAN, RJ				TAYLOR, AK; SAFANDA, JF; FALL, MZ; QUINCE, C; LANG, KA; HULL, CE; CARPENTER, I; STALEY, LW; HAGERMAN, RJ			MOLECULAR PREDICTORS OF COGNITIVE INVOLVEMENT IN FEMALE CARRIERS OF FRAGILE-X SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTAL-RETARDATION; CHROMOSOME INACTIVATION; HETEROZYGOUS CARRIERS; ABNORMAL METHYLATION; DNA; GENE; INSTABILITY; FREQUENCY; REPEAT; WOMEN	Objective.-Fragile X syndrome is caused by a mutation involving expansion of a CGG trinucleotide repeat segment in the fragile X mentaL retardation-1 (FMR1) gene on the long arm of the X chromosome. This study was undertaken to determine the relative impact of three molecular characteristics of the FMR1 mutation-number of CGG repeats, methylation status, and X inactivation ratio-on the cognitive involvement of female carriers of fragile X syndrome. Design.-Retrospective study with new DNA analysis of known female carriers of fragile X syndrome. Setting.-Molecular studies were conducted in a university-based DNA diagnostic laboratory. Patients were originally ascertained through a regional fragile X clinic in a university-affiliated pediatric hospital. Patients.-Forty-eight female carriers of fragile X syndrome were studied, including 22 with a premutation (a small expansion to approximately 50 to 200 CGG repeats), 23 with a full mutation (a full expansion to >200 CGG repeats), and three with both types of mutations (mosaics). Results.-Median IQ score was significantly lower for females with a full mutation than for females with a premutation. No significant relationship was found between IQ score and number of CGG repeats or percentage methylation of the mutant allele within each mutation category. In addition, no significant relationship was found between IQ score and the proportion of normal FMR1 alleles on the active X chromosome in the carrier female group as a whole or in either mutation subgroup. Comparisons of leukocytes and saliva-borne epithelial cells in certain full-mutation carriers revealed striking differences in FMR1 mutation sizes. Conclusions.-Mutation category remains the most important predictor of affectedness in female carriers of fragile X syndrome. Our data do not support use of the proportion of normal FMR1 alleles on the active X chromosome as a predictor of cognitive involvement in female carriers with full mutations. Individual tissue-specific differences exist in the heterogeneous sizes of full mutations and in the presence of premutation/full-mutation mosaicism.	CHILDRENS HOSP,CHILD DEV UNIT,DENVER,CO 80218	Children's Hospital Colorado	TAYLOR, AK (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DNA DIAGNOST LAB,C-233,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045916] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45916] Funding Source: Medline; PHS HHS [MCJ000252] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BRAINARD SS, 1991, AM J MED GENET, V38, P505, DOI 10.1002/ajmg.1320380273; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; DEVYS D, 1992, AM J MED GENET, V43, P208, DOI 10.1002/ajmg.1320430134; FRYNS JP, 1984, HUM GENET, V65, P400, DOI 10.1007/BF00291567; FRYNS JP, 1986, AM J MED GENET, V23, P157, DOI 10.1002/ajmg.1320230110; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Hagerman R, 1991, FRAGILE X SYNDROME D, P3; Hagerman R. J., 1991, FRAGILE X SYNDROME D, P173; HAGERMAN RJ, 1992, PEDIATRICS, V89, P395; HAGERMAN RJ, 1989, AM J MED GENET, V30, P377; HANZLIK AJ, 1993, NAT GENET, V3, P44, DOI 10.1038/ng0193-44; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HULL C, 1993, AM J DIS CHILD, V147, P1236, DOI 10.1001/archpedi.1993.02160350110017; KNOLL JH, 1984, AM J HUM GENET, V36, P640; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MAZZOCCO MMM, 1992, J AM ACAD CHILD PSY, V31, P1141, DOI 10.1097/00004583-199211000-00025; MAZZOCCO MMM, 1992, AM J MED GENET, V43, P78, DOI 10.1002/ajmg.1320430112; McGavran L., 1992, American Journal of Human Genetics, V51, pA84; MIEZEJESKI CM, 1992, 1992 INTERNATIONAL FRAGILE X CONFERENCE PROCEEDINGS, P85; MIGEON BR, 1992, AM J MED GENET, V43, P291, DOI 10.1002/ajmg.1320430145; NIELSEN KB, 1983, HUM GENET, V64, P240, DOI 10.1007/BF00279401; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PERGOLIZZI RG, 1992, LANCET, V339, P271, DOI 10.1016/0140-6736(92)91334-5; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PRCHAL JT, 1980, BLOOD, V56, P1048; PUCK JM, 1992, AM J HUM GENET, V50, P742; REISS AL, 1993, AM J HUM GENET, V52, P884; REISS AL, 1988, ARCH GEN PSYCHIAT, V45, P25; REISS AL, 1993, 10 S U WASH SEATTL; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SNOW K, 1993, AM J HUM GENET, V53, P1217; SOBESKY WE, IN PRESS J AM ACAD C; STALEY LW, 1993, AM J DIS CHILD, V147, P723, DOI 10.1001/archpedi.1993.02160310025011; SUTLIFFE JS, 1992, HUM MOL GENET, V1, P397; UCHIDA IA, 1982, AM J HUM GENET, V34, P286; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WILHELM D, 1988, AM J MED GENET, V30, P407, DOI 10.1002/ajmg.1320300141; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; WORHLE D, 1992, HUM GENET, V29, P114; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]; [No title captured]	48	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					507	514		10.1001/jama.271.7.507	http://dx.doi.org/10.1001/jama.271.7.507			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301764				2022-12-28	WOS:A1994MV42300032
J	BONGAARTS, J				BONGAARTS, J			POPULATION-POLICY OPTIONS IN THE DEVELOPING-WORLD	SCIENCE			English	Article							UNITED-STATES; FERTILITY; EDUCATION	The population of the developing world is currently expanding at the unprecedented rate of more than 800 million per decade, and despite anticipated reductions in growth during the 21st century, its size is expected to increase from 4.3 billion today to 10.2 billion in 2100. Past efforts to curb this growth have almost exclusively focused on the implementation of family planning programs to provide contraceptive information, services, and supplies. These programs have been partially successful in reducing birth rates. Further investments in them will have an additional but limited impact on population growth; therefore, other policy options, in particular measures to reduce high demand for births and limit population momentum, are needed.			BONGAARTS, J (corresponding author), POPULAT COUNCIL,DIV RES,1 DAG HAMMARSKJOLD PLAZA,NEW YORK,NY 10017, USA.							BERELSON B, 1977, FAM PLANN PERSPECT, V9, P214, DOI 10.2307/2134431; BERELSON B, 1966, FAMILY PLANNING POPU, P655; BONGAARTS J, 1990, POPUL DEV REV, V16, P487, DOI 10.2307/1972833; BONGAARTS J, 1985, POPUL DEV REV, V11, P585, DOI 10.2307/1973456; BONGAARTS J, 1991, POPUL DEV REV, V17, P293, DOI 10.2307/1973732; Bos E., 1992, WORLD POPULATION PRO; CALDWELL JC, 1980, POPUL DEV REV, V6, P225, DOI 10.2307/1972729; CLELAND J, 1988, POP STUD-J DEMOG, V42, P419, DOI 10.1080/0032472031000143566; Cleland J., 1992, FAMILY PLANNING PROG, P159; Cochrane Susan Hill, 1979, FERTILITY ED WHAT DO; CONLY SR, 1993, GLOBAL POPULATION AS; DEMENY P, 1978, POPUL DEV REV, V5, P141; FINKLE JL, 1985, POPUL DEV REV, V11, P1, DOI 10.2307/1973376; FREEDMAN R, 1987, STUD FAMILY PLANN, V18, P57, DOI 10.2307/1966698; FREEDMAN R, 1982, INT ENCY POPULATION, V1, P450; FREJKA T, 1982, INT ENCY POPULATION, V1, P950; Henshaw S., 1992, ABORTION FACTBOOK 19; KEYFITZ N, 1971, DEMOGRAPHY, V8, P71, DOI 10.2307/2060339; LLOYD CB, 1988, STUD FAMILY PLANN, V19, P141, DOI 10.2307/1966750; Malthus T.R., 1959, POPULATION 1 ESSAY; Mason KO., 1987, SOCIOLOGICAL FORUM, V2, P718, DOI [DOI 10.1007/BF01124382, 10.1007/BF01124382]; MAULDIN P, 1993, 1992 UN EXP GROUP M; MAULDIN WP, 1991, STUD FAMILY PLANN, V22, P350, DOI 10.2307/1966449; MERRICK T, 1989, POPUL B, V41; Ryder N. B., 1980, DEMOGRAPHIC PATTERNS, P15; WESTOFF CF, 1991, DEMOGRAPHIC HLTH SUR, V5; WESTOFF CF, 1991, DEMOGRAPHIC HLTH SUR, V3; WILLIAMS LB, 1991, FAM PLANN PERSPECT, V23, P212, DOI 10.2307/2135755; 1989, LEVELS TRENDS CONTRA; 1951, PAST FUTURE GROWTH W; 1900, DHS METHODOLOGICAL R, V1; 1992, LONG RANGE WORLD POP; 1993, EFFECTIVE FAMILY PLA; 1992, WORLD POPULATION PRO; 1992, WORLD POPULATION MON	35	110	111	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					771	776		10.1126/science.8303293	http://dx.doi.org/10.1126/science.8303293			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MV866	8303293				2022-12-28	WOS:A1994MV86600025
J	LI, Y; FLANAGAN, PM; TSCHOCHNER, H; KORNBERG, RD				LI, Y; FLANAGAN, PM; TSCHOCHNER, H; KORNBERG, RD			RNA POLYMERASE-II INITIATION-FACTOR INTERACTIONS AND TRANSCRIPTION START SITE SELECTION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TATA ELEMENTS; FACTOR-B; YEAST; GENE; PURIFICATION; SEQUENCE; PROMOTER; CLONING	An RNA polymerase II transcription system was resolved and reconstituted from extracts of Schizosaccharomyces pombe. Exchange with components of a Saccharomyces cerevisiae visiae system was undertaken to reveal the factor or factors responsible for the difference in location of the transcription start site, about 30 base pairs and 40 to 120 base pairs downstream of the TATA box in S. pombe and S. cerevisiae, respectively. Two components, counterparts of human transcription factor IIF (TFIIF) and TFIIH, could be exchanged individually between systems without effect on the start site. Three components, counterparts of human TFIIB, TFIIE, and RNA polymerase II, could not be exchanged individually but Gould be swapped in the pairs TFIIE-TFIIH and TFIIB-RNA polymerase II, which demonstrates that there are functional interactions between these components. Moreover, exchange of the latter pair shifted the starting position, which shows that TFIIB and RNA polymerase II are solely responsible for determining the start site of transcription.	STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CONAWAY JW, COMMUNICATION; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1989, IN PRESS CELL, V56, P549; FEAVER WJ, UNPUB; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLANAGANPM, 1992, P NATL ACAD SCI USA, V89, P7659; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GAURENTE L, 1987, ANNU REV GENET, V21, P425; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENRY NL, UNPUB; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUE NF, 1993, P NATL ACAD SCI USA, V90, P8018, DOI 10.1073/pnas.90.17.8018; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SERIZAWA H, UNPUB; TOYAMA R, 1990, FEBS LETT, V268, P217, DOI 10.1016/0014-5793(90)81012-D; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	36	115	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					805	807		10.1126/science.8303296	http://dx.doi.org/10.1126/science.8303296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303296				2022-12-28	WOS:A1994MV86600034
J	CHODAK, GW; THISTED, RA; GERBER, GS; JOHANSSON, JE; ADOLFSSON, J; JONES, GW; CHISHOLM, GD; MOSKOVITZ, B; LIVNE, PM; WARNER, J				CHODAK, GW; THISTED, RA; GERBER, GS; JOHANSSON, JE; ADOLFSSON, J; JONES, GW; CHISHOLM, GD; MOSKOVITZ, B; LIVNE, PM; WARNER, J			RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; CARCINOMA; 10-YEAR; THERAPY	Background. The selection of treatment tor patients with localized prostate cancer requires reliable information about the outcome of conservative management. Previous studies of this question are generally considered unreliable because they were uncontrolled and nonrandomized. Methods.- We performed a pooled analysis of 828 case records from six nonrandomized studies, published since 1985, of men treated conservatively (with observation and delayed hormone therapy but no radical surgery or irradiation) for clinically localized prostate cancer. A Cox regression analysis was performed to determine which factors influenced survival among patients who did not die of causes other than prostate cancer (disease-specific survival). Kaplan-Meier curves for overall and metastasis-free survival among such patients were compared with use of the log-rank method and the Mantel-Haenszel test. Results. Factors that had a significant effect on disease-specific survival were grade 3 tumors (risk ratio, 10.04), residence in Israel (risk ratio, 2.48) or New York (risk ratio, 0.37), and age under 61 years (risk ratio, 0.32). Ten years after diagnosis, disease-specific survival (with data on men who died from causes other than prostate cancer censored) was 87 percent for men with grade 1 or 2 tumors and 34 percent for those with grade 3 tumors; metastasis-free survival among men who had not died of other causes was 81 percent for grade 1, 58 percent for grade 2, and 26 percent for grade 3 disease. These findings were not affected by the inclusion of men who had early-stage cancer, were older, had worse-than-average health, or underwent delayed radiation therapy or radical prostatectomy. Conclusions. The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less. New treatment strategies are needed for men with grade 3 prostate cancer.	UNIV CHICAGO,PRITZKER SCH MED,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,DEPT STAT,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,CANC RES CTR,CHICAGO,IL 60637; OREBRO MED CTR HOSP,DEPT UROL,OREBRO,SWEDEN; UNIV UPPSALA HOSP,CANC EPIDEMIOL UNIT,UPPSALA,SWEDEN; KAROLINSKA INST,DEPT UROL,S-10401 STOCKHOLM 60,SWEDEN; HOWARD UNIV HOSP,DIV UROL,WASHINGTON,DC 20060; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT SURG UROL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; RAMBAM MED CTR,DEPT UROL,HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,HAIFA,ISRAEL; MEM SLOAN KETTERING CANC CTR,UROL SERV,NEW YORK,NY 10021	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Howard University; University of Edinburgh; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Memorial Sloan Kettering Cancer Center			Thisted, Ronald A/B-1985-2008		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS007230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; AHRQ HHS [1-RO3-HS07230-01] Funding Source: Medline; NCI NIH HHS [P30 CA 14599] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLFSSON J, 1992, BRIT J UROL, V69, P183, DOI 10.1111/j.1464-410X.1992.tb15493.x; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOXER RJ, 1977, J UROLOGY, V117, P208, DOI 10.1016/S0022-5347(17)58402-5; CARTER HB, 1988, MULTIDISCIPLINARY AN, P1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COX DR, 1972, J R STAT SOC B, V34, P187; ELDER JS, 1982, J UROLOGY, V127, P704, DOI 10.1016/S0022-5347(17)54005-7; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; Fleming C, 1993, JAMA, V269, P2650; FRANKS LM, 1973, CANCER, V32, P1092, DOI 10.1002/1097-0142(197311)32:5<1092::AID-CNCR2820320513>3.0.CO;2-Z; GAETA JF, 1980, J UROLOGY, V123, P689, DOI 10.1016/S0022-5347(17)56093-0; GEORGE NJR, 1988, LANCET, V1, P494; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOODMAN CM, 1988, BRIT J UROL, V62, P576, DOI 10.1111/j.1464-410X.1988.tb04429.x; HANDLEY R, 1988, BRIT J UROL, V62, P249, DOI 10.1111/j.1464-410X.1988.tb04328.x; Hanks G E, 1992, Oncology (Williston Park), V6, P79; HANKS GE, 1991, ACTA ONCOL, V30, P231, DOI 10.3109/02841869109092359; HANKS GE, 1992, ONCOLOGY, V6, P89; HARMER MH, 1978, TNM CLASSIFICATION M; HOLUND B, 1980, SCAND J UROL NEPHROL, V14, P29, DOI 10.3109/00365598009181186; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JONES GW, 1992, CANCER, V70, P307, DOI 10.1002/1097-0142(19920701)70:1+<307::AID-CNCR2820701319>3.0.CO;2-N; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOSKOVITZ B, 1987, UROL INT, V42, P49, DOI 10.1159/000281849; MURPHY GP, 1982, J UROLOGY, V127, P928, DOI 10.1016/S0022-5347(17)54135-X; NEWLING DWW, 1985, TESTICULAR CANCER OT, V18, P443; ORESTANO F, 1991, INCIDENTAL CARCINOMA, P163; Perez C A, 1988, NCI Monogr, P85; PROUT GR, 1973, CANCER-AM CANCER SOC, V32, P1096, DOI 10.1002/1097-0142(197311)32:5<1096::AID-CNCR2820320514>3.0.CO;2-K; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; 1984, OFFICIAL STATISTICS, V3, P112; 1974, TNM CLASSIFICATION M; 1988, NCI NIH882789 PUBL; 1988, VITAL STATISTICS U A, V2; 1992, STATA REFERENCE MANU	42	722	733	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					242	248		10.1056/NEJM199401273300403	http://dx.doi.org/10.1056/NEJM199401273300403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272085				2022-12-28	WOS:A1994MR49600003
J	LOVEJOY, B; CLEASBY, A; HASSELL, AM; LONGLEY, K; LUTHER, MA; WEIGL, D; MCGEEHAN, G; MCELROY, AB; DREWRY, D; LAMBERT, MH; JORDAN, SR				LOVEJOY, B; CLEASBY, A; HASSELL, AM; LONGLEY, K; LUTHER, MA; WEIGL, D; MCGEEHAN, G; MCELROY, AB; DREWRY, D; LAMBERT, MH; JORDAN, SR			STRUCTURE OF THE CATALYTIC DOMAIN OF FIBROBLAST COLLAGENASE COMPLEXED WITH AN INHIBITOR	SCIENCE			English	Article							C-TERMINAL DOMAIN; BINDING; METALLOPROTEINASES; STROMELYSIN; THERMOLYSIN; FAMILY	Collagenase is a zinc-dependent endoproteinase and is a member of the matrix metalloproteinase (MMP) family of enzymes. The MMPs participate in connective tissue remodeling events and aberrant regulation has been associated with several pathologies. The 2.4 angstrom resolution structure of the inhibited enzyme revealed that, in addition to the catalytic zinc, there is a second zinc ion and a calcium ion which play a major role in stabilizing the tertiary structure of collagenase. Despite scant sequence homology, collagenase shares structural homology with two other endoproteinases, bacterial thermolysin and crayfish astacin. The detailed description of protein-inhibitor interactions present in the structure will aid in the design of compounds that selectively inhibit individual members of the MMP family. Such inhibitors will be useful in examining the function of MMPs in pathological processes.	GLAXO GRP RES LTD,GREENFORD UB0 6HE,MIDDX,ENGLAND	GlaxoSmithKline	LOVEJOY, B (corresponding author), GLAXO RES INST,RES TRIANGLE PK,NC 27709, USA.			Drewry, David Harold/0000-0001-5973-5798				ALLAN JA, 1991, J CELL SCI, V99, P789; BECHERER JD, 1991, J CELL BIOCH G S, V15; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BROWN FK, IN PRESS J MED CHEM; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; HASSELL AM, IN PRESS J MOL BIOL; HENDERSON B, 1990, Drugs of the Future, V15, P495; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MATHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MCGEEHAN G, 1992, PLANT PHYSIOL, V99, P1179, DOI 10.1104/pp.99.3.1179; MCGEEHAN GM, UNPUB; MONZINGO AF, 1984, BIOCHEMISTRY-US, V23, P5724, DOI 10.1021/bi00319a010; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, J BIOL CHEM, V267, P9612; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	24	306	314	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					375	377		10.1126/science.8278810	http://dx.doi.org/10.1126/science.8278810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278810				2022-12-28	WOS:A1994MT03400033
J	MARSDEN, AFA; CAFFREY, P; APARICIO, JF; LOUGHRAN, MS; STAUNTON, J; LEADLAY, PF				MARSDEN, AFA; CAFFREY, P; APARICIO, JF; LOUGHRAN, MS; STAUNTON, J; LEADLAY, PF			STEREOSPECIFIC ACYL TRANSFERS ON THE ERYTHROMYCIN-PRODUCING POLYKETIDE SYNTHASE	SCIENCE			English	Article							METHYLMALONYL-COA EPIMERASE; SACCHAROPOLYSPORA-ERYTHRAEA; MACROLIDE BIOSYNTHESIS; PROPIONIBACTERIUM-SHERMANII; MULTIFUNCTIONAL ENZYME; STEREOCHEMISTRY; ANTIBIOTICS; POLYETHER	During assembly of complex polyketide antibiotics like erythromycin A, molecular recognition by the multienzyme polyketide synthase controls the stereochemical outcome as each successive methylmalonyl-coenzyme A (CoA) extender unit is added. Acylation of the purified erythromycin-producing polyketide synthase has shown that all six acyltransferase domains have identical stereospecificity for their normal substrate (2S)-methylmalonyl-CoA. In contrast, the configuration of the methyl-branched centers in the products, that are derived from (2S)-methylmalonyl-CoA, is different. Stereoselection during the chain building process must, therefore, involve additional epimerization steps.	UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1EW,ENGLAND; UNIV CAMBRIDGE,CHEM LAB,DEPT ORGAN CHEM,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge			Caffrey, Patrick/B-1409-2008; Aparicio, Jesús F./K-8686-2014	Aparicio, Jesús F./0000-0003-4242-4701; Leadlay, Peter/0000-0002-3247-509X				APARICIO JF, IN PRESS J BIOL CHEM; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BULSING JM, 1984, J CHEM SOC CHEM COMM, V19, P1301; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1986, J AM CHEM SOC, V108, P4957, DOI 10.1021/ja00276a042; CANE DE, 1983, J AM CHEM SOC, V105, P3594, DOI 10.1021/ja00349a040; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CELMER WD, 1965, J AM CHEM SOC, V87, P1801, DOI 10.1021/ja01086a038; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P347; FULLER JQ, 1983, BIOCHEM J, V213, P643, DOI 10.1042/bj2130643; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, IN PRESS CURR TOP BI; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; MARSDEN AFA, UNPUB; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; OHAGAN D, 1989, NAT PROD REP, V6, P205, DOI 10.1039/np9890600205; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SEDGWICK B, 1977, EUR J BIOCHEM, V75, P481, DOI 10.1111/j.1432-1033.1977.tb11550.x; SHERMAN MM, 1987, BIOCHEMISTRY-US, V26, P438, DOI 10.1021/bi00376a015; SOOD GR, 1984, J CHEM SOC CHEM COMM, V21, P1421; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	27	157	163	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					378	380		10.1126/science.8278811	http://dx.doi.org/10.1126/science.8278811			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278811				2022-12-28	WOS:A1994MT03400034
J	EDERY, I; RUTILA, JE; ROSBASH, M				EDERY, I; RUTILA, JE; ROSBASH, M			PHASE-SHIFTING OF THE CIRCADIAN CLOCK BY INDUCTION OF THE DROSOPHILA PERIOD PROTEIN	SCIENCE			English	Article							MESSENGER-RNA LEVELS; VISUAL-SYSTEM; GENE-PRODUCT; MELANOGASTER; MUTANTS; RHYTHMS; ADULT	Virtually all organisms manifest circadian (24-hour) rhythms, governed by an ill-defined endogenous pacemaker or clock. Several lines of evidence suggest that the Drosophila melanogaster period gene product PER is a clock component. If PER were central to the time-keeping mechanism, a transient increase in its concentration would cause a stable shift in the phase of the clock. Therefore, transgenic flies bearing a heat-inducible copy of PER were subjected to temperature pulses. This treatment caused long-lasting phase shifts in the locomotor activity circadian rhythm, a result that supports the contention that PER is a bona fide clock component.	BRANDEIS UNIV,DEPT BIOL,HOWARD HUGHES MED INST,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute								CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DUSHAY MS, 1990, GENETICS, V125, P557; Edmunds LN, 1988, CELLULAR MOL BASES B; EWER J, 1988, NATURE, V333, P82, DOI 10.1038/333082a0; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; HALL JC, 1987, TRENDS GENET, V3, P185, DOI 10.1016/0168-9525(87)90231-9; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Johnson Carl Hirschie, 1992, P209; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUBIN GM, 1985, TRENDS NEUROSCI, V8, P231, DOI 10.1016/0166-2236(85)90094-3; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; YOUNG MW, 1989, NEURONAL CELLULAR OS, P529; ZERR DM, 1990, J NEUROSCI, V10, P2749	23	120	120	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					237	240		10.1126/science.8284676	http://dx.doi.org/10.1126/science.8284676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284676				2022-12-28	WOS:A1994MQ87900039
J	HOGQUIST, KA; JAMESON, SC; HEATH, WR; HOWARD, JL; BEVAN, MJ; CARBONE, FR				HOGQUIST, KA; JAMESON, SC; HEATH, WR; HOWARD, JL; BEVAN, MJ; CARBONE, FR			T-CELL RECEPTOR ANTAGONIST PEPTIDES INDUCE POSITIVE SELECTION	CELL			English	Article							CLASS-I MOLECULES; THYMIC SELECTION; TRANSGENIC MICE; ANTIGEN; BINDING; MHC; THYMOCYTES; CD8; BETA-2-MICROGLOBULIN; RECOGNITION	We have used organ culture of fetal thymic lobes from T cell receptor (TCR) transgenic beta2M(-/-) mice to study the role of peptides in positive selection. The TCR used was from a CD8+ T cell specific for ovalbumin 257-264 in the context of K(b). Several peptides with the ability to induce positive selection were identified. These peptide-selected thymocytes have the same phenotype as mature CD8+ T cells and can respond to antigen. Those peptides with the ability to induce positive selection were all variants of the antigenic peptide and were identified as TCR antagonist peptides for this receptor. One peptide tested, E1, induced positive selection on the beta2M(-/-) background but negative selection on the beta2M(+/-) background. These results show that the process of positive selection is exquisitely peptide specific and sensitive to extremely low ligand density and support the notion that low efficacy ligands mediate positive selection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Monash University			Eckhardt, Erik/G-1567-2010; Carbone, Francis/ABF-2141-2020; Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146; Heath, William/0000-0001-9670-259X; Hogquist, Kristin/0000-0001-9963-5687	NIAID NIH HHS [AI-28902] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1993, J IMMUNOL, V150, P1; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Janeway Charles A. Jr., 1992, Current Biology, V2, P591, DOI 10.1016/0960-9822(92)90163-5; Jenkinson E J, 1990, Semin Immunol, V2, P51; JOYCE S, 1991, ANTIGEN PROCESSING R, P109; KAYE J, 1992, J IMMUNOL, V148, P3342; KELLY JM, 1993, IN PRESS EUR J IMMUN, V10; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MANNIE MD, 1991, J THEOR BIOL, V151, P169, DOI 10.1016/S0022-5193(05)80360-1; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OGQUIST KA, 1993, J EXP MED, V177, P1469; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SPAIN LM, 1992, J EXP MED, V176, P213, DOI 10.1084/jem.176.1.213; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1990, NATURE, V344, P65	36	2241	2279	1	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					17	27		10.1016/0092-8674(94)90169-4	http://dx.doi.org/10.1016/0092-8674(94)90169-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287475				2022-12-28	WOS:A1994MR49500003
J	SASAKI, H; HOGAN, BLM				SASAKI, H; HOGAN, BLM			HNF-3-BETA AS A REGULATOR OF FLOOR PLATE DEVELOPMENT	CELL			English	Article							C-KIT RECEPTOR; CENTRAL-NERVOUS-SYSTEM; GENE FORK-HEAD; TRANSCRIPTION FACTORS; EARLY NEUROGENESIS; MESSENGER-RNA; SPINAL-CORD; SI-LOCUS; DROSOPHILA; EXPRESSION	The transcription factor gene HNF-3beta is expressed in the ventral midline of the mouse embryonic neural tube, including the floor plate, a structure important for dorsoventral patterning and axonal guidance. To assess HNF-3beta function, the gene has been ectopically expressed in the midbrain/hindbrain of transgenic embryos using an En-2 promoter/enhancer. By 18.5 days postcoitum, transgenic brains show a range of abnormalities, including absent inferior colliculus and reduced cerebellum. Earlier, several genes normally expressed in the floor plate (BMP-1, Steel factor, and HNF-3alpha) are induced within the same ectopic dorsal domain as HNF-3beta, and autoactivation of the endogenous HNF-3beta is observed. Conversely, expression of the dorsal gene Pax-3 is suppressed. Ectopic dorsal neuronal differentiation and abnormal dorsal axonal projections are also seen. These results suggest that HNF-3beta is an important regulator of floor plate development in vivo.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University	SASAKI, H (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA.							ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTMAN J, 1984, ADV ANATOMY EMBRYOLO; [Anonymous], [No title captured]; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DODD J, 1993, CELL CELL SIGNALING, P81; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HOGAN B, 1986, MANIPULATING MOUSE E; HROMAS R, 1993, BLOOD, V81, P2854; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INOUYE M, 1976, Congenital Anomalies, V16, P171; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JESSELL TM, 1992, HARVEY LECT, V86, P87; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KINTNER C, 1992, ANNU REV NEUROSCI, V15, P251, DOI 10.1146/annurev.neuro.15.1.251; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LOGAN C, 1993, DEVELOPMENT, V117, P905; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; McMahon A P, 1993, Curr Opin Neurobiol, V3, P4, DOI 10.1016/0959-4388(93)90027-V; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SLACK JMW, 1992, DEVELOPMENT, V114, P285; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	61	272	274	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					103	115		10.1016/0092-8674(94)90176-7	http://dx.doi.org/10.1016/0092-8674(94)90176-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287471				2022-12-28	WOS:A1994MR49500010
J	LUTTICKEN, C; WEGENKA, UM; YUAN, JP; BUSCHMANN, J; SCHINDLER, C; ZIEMIECKI, A; HARPUR, AG; WILKS, AF; YASUKAWA, K; TAGA, T; KISHIMOTO, T; BARBIERI, G; PELLEGRINI, S; SENDTNER, M; HEINRICH, PC; HORN, F				LUTTICKEN, C; WEGENKA, UM; YUAN, JP; BUSCHMANN, J; SCHINDLER, C; ZIEMIECKI, A; HARPUR, AG; WILKS, AF; YASUKAWA, K; TAGA, T; KISHIMOTO, T; BARBIERI, G; PELLEGRINI, S; SENDTNER, M; HEINRICH, PC; HORN, F			ASSOCIATION OF TRANSCRIPTION FACTOR APRF AND PROTEIN-KINASE JAK1 WITH THE INTERLEUKIN-6 SIGNAL TRANSDUCER GP130	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; INTERFERON-ALPHA; IFN-GAMMA; RECEPTOR; ACTIVATION; AFFINITY	Interleukin-6 (IL-6), leukemia inhibitory factor, oncostatin M, interleukin-11, and ciliary neurotrophic factor bind to receptor complexes that share the signal transducer gp130. Upon binding, the ligands rapidly activate DNA binding of acute-phase response factor (APRF), a protein antigenically related to the p91 subunit of the interferon-stimulated gene factor-3alpha (ISGF-3alpha). These cytokines caused tyrosine phosphorylation of APRF and ISGF-3alpha p91. Protein kinases of the Jak family were also rapidly tyrosine phosphorylated, and both APRF and Jak1 associated with gp130. These data indicate that Jak family protein kinases may participate in IL-6 signaling and that APRF may be activated in a complex with gp130.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,PAUWELSSTR 30,D-52057 AACHEN,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV BERN,CLIN & EXPTL CANC RES LAB,CH-3004 BERN,SWITZERLAND; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; INST PASTEUR,INSERM,U276,F-75724 PARIS 15,FRANCE; MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY	RWTH Aachen University; Columbia University; University of Bern; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Tosoh Corporation; Osaka University; Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society			Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014; Barbieri, Giovanna/AAH-3645-2019; Kishimoto, Tadamitsu/C-8470-2009; Pellegrini, Sandra -/G-5546-2015; Wilks, Andrew F/R-5542-2019; Pellegrini, Sandra/Y-6351-2019	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Wilks, Andrew F/0000-0002-8554-2399; BARBIERI, GIOVANNA/0000-0002-5895-1795				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIBI M, 1992, CELL S, V69, P1121; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, UNPUB; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGENKA UM, UNPUB; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YUAN J, IN PRESS MOL CELL BI	32	741	770	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					89	92		10.1126/science.8272872	http://dx.doi.org/10.1126/science.8272872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272872				2022-12-28	WOS:A1994MQ30100037
J	KRAUSS, S; CONCORDET, JP; INGHAM, PW				KRAUSS, S; CONCORDET, JP; INGHAM, PW			A FUNCTIONALLY CONSERVED HOMOLOGY OF THE DROSOPHILA SEGMENT POLARITY GENE-HH IS EXPRESSED IN TISSUES WITH POLARIZING ACTIVITY IN ZEBRAFISH EMBRYOS	CELL			English	Article							FLOOR PLATE; NERVOUS-SYSTEM; NEURAL-TUBE; NOTOCHORD; PROTEIN; SEQUENCE; HEDGEHOG; PATTERN	The segment polarity gene hedgehog (hh) encodes a novel signaling protein that mediates local cell-cell interactions in the developing Drosophila embryo. Here we describe the existence of an hh-related gene family in the zebrafish, Brachydanio rerio. One of these genes, sonic hedgehog (shh), is expressed in the notochord, floor plate, and posterior fin mesoderm, tissues associated with polarizing activities in various vertebrate embryos. The pattern of shh expression in zebra-fish mutants affecting axial structures, together with the consequences of its ectopic expression in normal embryos, is consistent with a role for shh in floor plate induction. By expressing shh in transgenic Drosophila embryos, we also demonstrate a strong functional conservation between the fish and fly hh genes.			KRAUSS, S (corresponding author), IMPERIAL CANC RES FUND, DEPT ZOOL, DEV BIOL UNIT, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip W/E-6710-2010; Ingham, Philip William/AAH-5884-2020; concordet, jean-paul/C-3417-2015; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; Concordet, Jean-Paul/0000-0001-8924-4316; Krauss, Stefan/0000-0001-6992-8091				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, CURR OPIN GENET DEV, V3, P633, DOI 10.1016/0959-437X(93)90100-4; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORBES AJ, 1993, IN PRESS DEVELOPME S, V119; GODSAVE SF, 1988, DEVELOPMENT, V102, P555; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HATTA K, 1993, IN PRESS P NATL ACAD; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; INGHAM PW, 1993, ESSENTIAL DEV BIOL P, P97; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYTE J, 1992, CELL, V71, P33; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SCHULTEMERKER S, 1994, IN PRESS DEVELOPMENT; STATCHEL SE, 1993, DEVELOPMENT, V117, P1261; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WESTERFIELD M, 1989, ZEBRAFISH BOOK; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	48	987	1045	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1431	1444		10.1016/0092-8674(93)90628-4	http://dx.doi.org/10.1016/0092-8674(93)90628-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269519				2022-12-28	WOS:A1993MP86900020
J	VANDENHEUVEL, S; HARLOW, E				VANDENHEUVEL, S; HARLOW, E			DISTINCT ROLES FOR CYCLIN-DEPENDENT KINASES IN CELL-CYCLE CONTROL	SCIENCE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; CDC28 MUTATION; ACTIVATION; MITOSIS; FAMILY; YEAST; PHASE; GENE	The key cell-cycle regulator Cdc2 belongs to a family of cyclin-dependent kinases in higher eukaryotes. Dominant-negative mutations were used to address the requirement for kinases of this family in progression through the human cell cycle. A dominant-negative Cdc2 mutant arrested cells at the G2 to M phase transition, whereas mutants of the cyclin-dependent kinases Cdk2 and Cdk3 caused a G1 block. The mutant phenotypes were specifically rescued by the corresponding wild-type kinases. These data reveal that Cdk3, in addition to Cdc2 and Cdk2, executes a distinct and essential function in the mammalian cell cycle.			VANDENHEUVEL, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129, USA.		van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW J, 1992, J BIOL CHEM, V267, P25922; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MENDENHALL MD, 1988, P NATL ACAD SCI USA, V85, P4426, DOI 10.1073/pnas.85.12.4426; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, IN PRESS MOL CELL BI; MEYERSON M, UNPUB; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, IN PRESS DEVELOPMENT; VANDENHEUVEL S, UNPUB; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	45	995	1017	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2050	2054		10.1126/science.8266103	http://dx.doi.org/10.1126/science.8266103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266103				2022-12-28	WOS:A1993MN10800043
J	LYNN, RB; FRIEDMAN, LS				LYNN, RB; FRIEDMAN, LS			CURRENT CONCEPTS - IRRITABLE-BOWEL-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GASTROINTESTINAL DISORDERS; PSYCHOLOGICAL TREATMENT; DIARRHEA-PREDOMINANT; MYOELECTRIC ACTIVITY; MOTILITY DISORDERS; MANNING CRITERIA; TRANSIT-TIME; COLON MOTOR; HEALTH-CARE; SYMPTOMS		THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV GASTROENTEROL & HEPATOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002094] Funding Source: NIH RePORTER; NIDDK NIH HHS [KO8 DK02094-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULER SM, 1993, GASTROENTEROLOGY, V104, P502, DOI 10.1016/0016-5085(93)90419-D; ALTSCHULER SM, 1991, J COMP NEUROL, V304, P261, DOI 10.1002/cne.903040209; BLANCHARD EB, 1992, BEHAV RES THER, V30, P175, DOI 10.1016/0005-7967(92)90141-3; BLANCHARD EB, 1990, BEHAV RES THER, V28, P401, DOI 10.1016/0005-7967(90)90159-G; CAMILLERI M, 1989, DIGEST DIS SCI, V34, P1777, DOI 10.1007/BF01540058; CAMILLERI M, 1992, ANN INTERN MED, V116, P1001, DOI 10.7326/0003-4819-116-12-1001; CANN PA, 1983, GUT, V24, P405, DOI 10.1136/gut.24.5.405; CHAUDHARY NA, 1962, Q J MED, V31, P307; COOK IJ, 1987, GASTROENTEROLOGY, V93, P727, DOI 10.1016/0016-5085(87)90434-3; COOK IJ, 1990, GASTROENTEROLOGY, V98, P66, DOI 10.1016/0016-5085(90)91292-E; DOBRILLA G, 1990, GUT, V31, P355, DOI 10.1136/gut.31.3.355; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; EVERHART JE, 1991, GASTROENTEROLOGY, V100, P998, DOI 10.1016/0016-5085(91)90275-P; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; GUTHRIE EA, 1992, GUT, V33, P361, DOI 10.1136/gut.33.3.361; HARVEY RF, 1987, LANCET, V1, P963; HASLER WL, 1991, TXB GASTROENTEROLOGY, V2, P1696; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KATON WJ, 1992, AM J MED, V92, pS7, DOI 10.1016/0002-9343(92)90130-4; KELLOW JE, 1988, GUT, V29, P1236, DOI 10.1136/gut.29.9.1236; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1992, DIGEST DIS SCI, V37, P168, DOI 10.1007/BF01308167; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KUMAR A, 1987, GUT, V28, P150, DOI 10.1136/gut.28.2.150; LASSER RB, 1975, NEW ENGL J MED, V293, P524, DOI 10.1056/NEJM197509112931103; LENNARDJONES JE, 1983, NEW ENGL J MED, V308, P431, DOI 10.1056/NEJM198302243080805; LIND CD, 1991, GASTROENTEROL CLIN N, V20, P279; LONGSTRETH GF, 1981, ANN INTERN MED, V95, P53, DOI 10.7326/0003-4819-95-1-53; MACINTOSH DG, 1992, AM J GASTROENTEROL, V87, P1407; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHIAS JR, 1989, DIGEST DIS SCI, V34, P761, DOI 10.1007/BF01540350; MAYER EA, 1990, GASTROENTEROLOGY, V99, P1688, DOI 10.1016/0016-5085(90)90475-G; MENDELOFF AI, 1970, NEW ENGL J MED, V282, P14, DOI 10.1056/NEJM197001012820104; MULLERLISSNER SA, 1988, BRIT MED J, V296, P615, DOI 10.1136/bmj.296.6622.615; NIEDERAU C, 1992, GASTROENTEROLOGY, V102, P1889, DOI 10.1016/0016-5085(92)90310-U; OKEEFE E, 1991, CLIN GERIATR MED, V2, P265; PRIOR A, 1990, GUT, V31, P458, DOI 10.1136/gut.31.4.458; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; RUMESSEN JJ, 1992, SCAND J GASTROENTERO, V27, P819, DOI 10.3109/00365529209000148; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SMART HL, 1986, GUT, V27, P1127, DOI 10.1136/gut.27.10.1127; SMITH RC, 1991, GASTROENTEROLOGY, V100, P591, DOI 10.1016/0016-5085(91)80002-Q; SNAPE WJ, 1976, GASTROENTEROLOGY, V70, P326; STEADMAN CJ, 1992, MAYO CLIN PROC, V67, P732, DOI 10.1016/S0025-6196(12)60797-6; SULLIVAN MA, 1978, NEW ENGL J MED, V298, P878, DOI 10.1056/NEJM197804202981604; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P895, DOI 10.1016/0016-5085(92)90175-X; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; THOMPSON WG, 1990, SEMIN GASTROINTEST D, V1, P57; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; WELGAN P, 1988, GASTROENTEROLOGY, V94, P1150, DOI 10.1016/0016-5085(88)90006-6; WELGAN P, 1985, PSYCHOSOM MED, V47, P139, DOI 10.1097/00006842-198503000-00005; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1992, BIOFEEDBACK SELF-REG, V17, P59, DOI 10.1007/BF01000091; WHITEHEAD WE, 1980, DIGEST DIS SCI, V25, P404, DOI 10.1007/BF01395503; WHITEHEAD WE, 1991, GASTROENTEROL CLIN N, V20, P249; WHITEHEAD WE, 1992, GUT, V33, P825, DOI 10.1136/gut.33.6.825; WHORWELL PJ, 1989, LANCET, V1, P622; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1986, GUT, V27, P1014, DOI 10.1136/gut.27.9.1014; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37; WHORWELL PJ, 1981, BRIT MED J, V282, P1101, DOI 10.1136/bmj.282.6270.1101	71	101	115	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1940	1945		10.1056/NEJM199312233292608	http://dx.doi.org/10.1056/NEJM199312233292608			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8305064				2022-12-28	WOS:A1993MM88500008
J	LANDI, G; DALESSANDRO, R; DOSSI, BC; RICCI, S; SIMONE, IL; CICCONE, A				LANDI, G; DALESSANDRO, R; DOSSI, BC; RICCI, S; SIMONE, IL; CICCONE, A			GUILLAIN-BARRE-SYNDROME AFTER EXOGENOUS GANGLIOSIDES IN ITALY	BRITISH MEDICAL JOURNAL			English	Article							THERAPY		POLICLIN S ORSOLA,SERV NEUROL,BOLOGNA,ITALY; OSPED INFERMI,DIV NEUROL,RIMINI,ITALY; OSPED POLICLIN PERUGIA,NEUROL CLIN,PERUGIA,ITALY; UNIV BARI,IST CLIN MALATTIE NERVOSE & MENTALI,I-70124 BARI,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna; Hospital of Rimini; Universita degli Studi di Bari Aldo Moro	LANDI, G (corresponding author), OSPED POLICLIN,NEUROL CLIN,I-20122 MILAN,ITALY.		Ciccone, Alfonso/AAB-6942-2022; Simone, sabella laura/K-9755-2018	Ciccone, Alfonso/0000-0002-4590-3575; Simone, Isabella Laura/0000-0002-7429-3091				FIGUERAS A, 1992, BRIT MED J, V305, P1330, DOI 10.1136/bmj.305.6865.1330; GRANIERI E, 1991, NEUROEPIDEMIOLOGY, V10, P161, DOI 10.1159/000110265; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; RASCHETTI R, 1992, LANCET, V340, P60, DOI 10.1016/0140-6736(92)92481-T; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705	5	53	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1463	1464		10.1136/bmj.307.6917.1463	http://dx.doi.org/10.1136/bmj.307.6917.1463			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281088	Green Published, Bronze			2022-12-28	WOS:A1993MK79700024
J	MACK, DJ; ERWIN, L; FULTON, JD				MACK, DJ; ERWIN, L; FULTON, JD			CHRONIC CONSTIPATION IN ELDERLY PATIENTS	BRITISH MEDICAL JOURNAL			English	Letter							LACTULOSE THERAPY		STRACATHRO HOSP,DEPT GERIATR MED,BRECHIN DD9 7DD,ANGUS,SCOTLAND		MACK, DJ (corresponding author), STOBHILL HOSP,DEPT GERIATR MED,GLASGOW G21 3UW,SCOTLAND.							FULTON JD, 1989, GERIATRIC MED    OCT, P95; FULTON JD, 1989, J CLIN EXPT GERONTOL, V10, P117; LEVINE MM, 1975, ANTIMICROB AGENTS CH, V8, P581, DOI 10.1128/AAC.8.5.581; MCCUTCHEON J, 1989, J HOSP INFECT, V13, P81, DOI 10.1016/0195-6701(89)90098-4; PASSMORE AP, 1993, BRIT MED J, V307, P769, DOI 10.1136/bmj.307.6907.769	5	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1425	1426		10.1136/bmj.307.6916.1425-c	http://dx.doi.org/10.1136/bmj.307.6916.1425-c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274909	Green Published			2022-12-28	WOS:A1993MK42000061
J	VOEST, EE; VREUGDENHIL, G; MARX, JJM				VOEST, EE; VREUGDENHIL, G; MARX, JJM			IRON-CHELATING AGENTS IN NON-IRON OVERLOAD CONDITIONS	ANNALS OF INTERNAL MEDICINE			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; TRANSFERRIN RECEPTOR EXPRESSION; HUMAN HEPATOCELLULAR-CARCINOMA; RHEUMATOID-ARTHRITIS PATIENTS; INDUCED LUNG FIBROSIS; ORAL IRON; LIPID-PEROXIDATION; DESFERRIOXAMINE TREATMENT; REPERFUSION INJURY; ALZHEIMERS-DISEASE	Purpose: To review the current clinical experience with iron chelators in non-iron overload conditions. Data Sources: The English-language literature was searched from 1983 through 1992 manually and using MEDLINE. Study Selection: Original articles, case reports, and abstracts addressing iron chelation. Data Extraction: Selected reports that described clinical applications of iron chelators in non-iron overload conditions were classified according to their stated mechanism of interference with disease activity. Articles stating the rationale for clinical use of iron chelators were also included. Results: Iron chelators were used in non-iron overload conditions to produce antioxidant effects, antiproliferative effects, and antiprotozoal effects and for aluminum chelation. In addition, several reports described singular observations in various diseases. Deferoxamine is the only iron chelator available for clinical studies. The treatment-related (side) effects appear to be associated with patient iron levels. Conclusions: Randomized clinical trials are needed to confirm the promising effects of iron chelators in non-iron overload conditions. Oral iron chelators with fewer toxic effects are especially needed.	UNIV HOSP UTRECHT, DEPT INTERNAL MED, 3508 GA UTRECHT, NETHERLANDS; UNIV HOSP NIJMEGEN, 6500 HB NIJMEGEN, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen			Marx, Joannes/AAS-9268-2020					ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265, DOI 10.1080/02724936.1990.11747441; AGARWAL MB, 1990, LANCET, V335, P601, DOI 10.1016/0140-6736(90)90380-N; AGARWAL MB, 1991, NOV INT C OR IR CHEL; ALFREY AC, 1992, AM J PHYSIOL, V263, pF637, DOI 10.1152/ajprenal.1992.263.4.F637; ALTMANN P, 1988, LANCET, V1, P1012; AMBROSIO G, 1987, CIRCULATION, V76, P906, DOI 10.1161/01.CIR.76.4.906; ANDREWS FJ, 1987, ANN RHEUM DIS, V46, P327, DOI 10.1136/ard.46.4.327; APPELBAUM YJ, 1990, FREE RADICAL BIO MED, V8, P133, DOI 10.1016/0891-5849(90)90086-X; ARDEN GB, 1984, BRIT J OPHTHALMOL, V68, P873, DOI 10.1136/bjo.68.12.873; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BECTON DL, 1988, CANCER RES, V48, P7189; BENE C, 1989, CLIN NEPHROL, V31, P45; BERGERON RJ, 1987, CANCER RES, V47, P6010; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; BIEMOND P, 1986, ARTHRITIS RHEUM, V29, P1187, DOI 10.1002/art.1780291002; BLAKE DR, 1985, Q J MED, V56, P345; BLAKE DR, 1983, ANN RHEUM DIS, V42, P89, DOI 10.1136/ard.42.1.89; BLATT J, 1989, J NATL CANCER I, V81, P866, DOI 10.1093/jnci/81.11.866; BLATT J, 1989, CANCER RES, V49, P2925; BLATT J, 1987, CANCER RES, V47, P1749; BOELAERT JR, 1988, CLIN NEPHROL, V29, P261; BOMFORD A, 1986, BIOCHEM J, V236, P243, DOI 10.1042/bj2360243; BOWERN N, 1984, J EXP MED, V160, P1532, DOI 10.1084/jem.160.5.1532; BOYCE NW, 1986, KIDNEY INT, V30, P813, DOI 10.1038/ki.1986.260; BRADLEY B, 1986, DIABETES, V35, P550, DOI 10.2337/diabetes.35.5.550; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BROCK JH, 1983, FEMS MICROBIOL LETT, V20, P439; CAROTENUTO P, 1986, J IMMUNOL, V136, P2342; CASES A, 1990, NEPHRON, V56, P19, DOI 10.1159/000186094; CHANDLER DB, 1985, AM REV RESPIR DIS, V131, P596, DOI 10.1164/arrd.1985.131.4.596; CHANG TMS, 1983, LANCET, V2, P1051; CRICHTON RR, 1980, J INORG BIOCHEM, V13, P305, DOI 10.1016/S0162-0134(00)80251-2; CROSS CE, 1985, J LAB CLIN MED, V106, P433; CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V; DEVIRGILIIS S, 1988, J PEDIATR-US, V113, P661; DEZZA L, 1989, LEUKEMIA, V3, P104; DONFRANCESCO A, 1990, CANCER RES, V50, P4929; DONFRANCESCO A, 1993, ANTI-CANCER DRUG, V4, P317, DOI 10.1097/00001813-199306000-00004; EDWARDSON JA, 1989, ANN MED, V21, P95, DOI 10.3109/07853898909149192; ESTROV Z, 1987, BLOOD, V69, P757; FAULK WP, 1980, LANCET, V2, P390; FITZCHARLES MA, 1982, ANN RHEUM DIS, V41, P97, DOI 10.1136/ard.41.1.97; FOA P, 1986, SCAND J HAEMATOL, V36, P107; FOX KAA, 1992, CARDIOVASC RES, V26, P656, DOI 10.1093/cvr/26.7.656; FULLER BJ, 1987, TRANSPLANTATION, V43, P604; GALLANT T, 1987, AM J MED, V83, P1085, DOI 10.1016/0002-9343(87)90946-6; GIORDANO N, 1984, BRIT MED J, V289, P961, DOI 10.1136/bmj.289.6450.961; GIORDANO N, 1986, CLIN EXP RHEUMATOL, V4, P25; GOLDBERG S, 1983, AM HEART J, V105, P26, DOI 10.1016/0002-8703(83)90274-0; GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101; GORDEUK VR, 1992, BLOOD, V79, P308; Goudsmit R, 1991, Ned Tijdschr Geneeskd, V135, P2133; GUERIN A, 1985, LANCET, V2, P39; GUTTERIDGE JMC, 1979, BIOCHEM J, V184, P469, DOI 10.1042/bj1840469; HAALBOOM J R E, 1991, European Journal of Clinical Investigation, V21, P58; HALLAWAY PE, 1989, P NATL ACAD SCI USA, V86, P10108, DOI 10.1073/pnas.86.24.10108; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; HALLIWELL B, 1989, FREE RADICAL BIO MED, P15; HANN HL, 1985, ADV NEUROBLASTOMA RE, P331; HANN HWL, 1992, CANCER, V70, P2051, DOI 10.1002/1097-0142(19921015)70:8<2051::AID-CNCR2820700806>3.0.CO;2-1; HASINOFF BB, 1989, AGENTS ACTIONS, V26, P378, DOI 10.1007/BF01967305; HERMAN EH, 1988, CANCER RES, V48, P6918; HERSHKO C, 1988, J EXP MED, V168, P375, DOI 10.1084/jem.168.1.375; HERSHKO C, 1991, European Journal of Clinical Investigation, V21, P57; HOFFBRAND AV, 1989, LANCET, V2, P457; HOFFBRAND AV, 1991, NOV INT C OR IR CHEL; JENSEN PD, 1992, BRIT J HAEMATOL, V80, P121, DOI 10.1111/j.1365-2141.1992.tb06411.x; KAPLINSKY C, 1988, PEDIATR HEMAT ONCOL, V5, P293, DOI 10.3109/08880018809037369; KARWATOWSKAPROKOPCZUK E, 1992, CARDIOVASC RES, V26, P58, DOI 10.1093/cvr/26.1.58; KEUSCH GT, 1990, ANN NY ACAD SCI, V587, P181, DOI 10.1111/j.1749-6632.1990.tb00145.x; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; KONDO K, 1990, CHEST, V97, P1367, DOI 10.1378/chest.97.6.1367; KONTOGHIORGHES GJ, 1991, BRIT MED J, V303, P1279, DOI 10.1136/bmj.303.6813.1279; KOOISTRA MP, 1991, BRIT J HAEMATOL, V79, P634, DOI 10.1111/j.1365-2141.1991.tb08093.x; KOUIDES PA, 1989, BLOOD, P383; KOZLOWSKI R, 1988, BRIT J HAEMATOL, V69, P275, DOI 10.1111/j.1365-2141.1988.tb07633.x; LIPSKY JJ, 1980, J IMMUNOPHARMACOL, V2, P179, DOI 10.3109/08923978009026396; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; LUNDBERG JH, 1990, CANCER RES, V50, P6466; MAGARO M, 1990, ANN RHEUM DIS, V49, P268, DOI 10.1136/ard.49.4.268-b; MARSH JH, 1990, BRIT J HAEMATOL, V76, P148, DOI 10.1111/j.1365-2141.1990.tb07851.x; MARTYN CN, 1989, LANCET, V1, P59; MARUYAMA M, 1991, J CARDIOVASC PHARM, V17, P166, DOI 10.1097/00005344-199101000-00024; MAZZAFERRO S, 1992, NEPHRON, V61, P151, DOI 10.1159/000186863; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MEHTA J, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90906-6; MENASCHE P, 1990, CIRCULATION, V82, P390; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MOWAT AG, 1968, ANN RHEUM DIS, V27, P345, DOI 10.1136/ard.27.4.345; MUIRDEN KD, 1968, ANN RHEUM DIS, V27, P38, DOI 10.1136/ard.27.1.38; NAVARRO JA, 1991, CLIN NEPHROL, V35, P213; NORDSTRAND EI, 1989, CLIN TRIALS J, V26, P365; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PAMPHILON DH, 1987, EUR J HAEMATOL, V38, P279; PATTANAPANYASAT K, 1992, BRIT J HAEMATOL, V82, P13, DOI 10.1111/j.1365-2141.1992.tb04587.x; PICKFORD MA, 1990, TRANSPLANTATION, V50, P210, DOI 10.1097/00007890-199008000-00008; POLSON RJ, 1985, BRIT MED J, V291, P448, DOI 10.1136/bmj.291.6493.448; POLSON RJ, 1986, Q J MED, V61, P1153; POLSON RJ, 1990, IMMUNOLOGY, V71, P176; PONTICELLI C, 1989, NEPHRON, V52, P201, DOI 10.1159/000185643; Porter J B, 1989, Baillieres Clin Haematol, V2, P459, DOI 10.1016/S0950-3536(89)80027-7; PORTER JB, 1988, BRIT J HAEMATOL, V69, P88; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PRAGA M, 1987, NEW ENGL J MED, V316, P547; REDDY BR, 1991, CARDIOVASC RES, V25, P711, DOI 10.1093/cvr/25.9.711; REDDY PS, 1969, ARTHRITIS RHEUM, V12, P454, DOI 10.1002/art.1780120413; ROGER SD, 1991, NEPHRON, V58, P33, DOI 10.1159/000186374; ROSENLOF K, 1989, J INTERN MED, V226, P311, DOI 10.1111/j.1365-2796.1989.tb01401.x; ROWLEY D, 1984, CLIN SCI, V66, P691, DOI 10.1042/cs0660691; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCANDERBEG AC, 1990, LANCET, V336, P1511, DOI 10.1016/0140-6736(90)93217-D; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; SOYANO A, 1984, IMMUNOPHARMACOLOGY, V8, P163, DOI 10.1016/0162-3109(84)90021-3; SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203; TABOR E, 1991, J MED VIROL, V34, P45, DOI 10.1002/jmv.1890340108; TAETLE R, 1989, J NATL CANCER I, V81, P1229, DOI 10.1093/jnci/81.16.1229; TENENBEIN M, 1992, LANCET, V339, P699, DOI 10.1016/0140-6736(92)90598-W; THEANACO EN, 1990, T R SOC TROP MED HYG, V84, P213; THEANACO EN, 1991, FREE RADICAL RES COM, V15, P1; TIELEMANS C, 1985, CLIN NEPHROL, V24, P237; UMEDA M, 1990, BLOOD PURIFICAT, V8, P295, DOI 10.1159/000169981; Van de Vyver F L, 1987, Contrib Nephrol, V55, P198; VANACKER SABE, 1993, CANCER RES, V53, P4603; VANASBECK BS, 1989, AM REV RESPIR DIS, V139, P769, DOI 10.1164/ajrccm/139.3.769; VANDERWAL NAA, 1990, BIOCHEM PHARMACOL, V39, P1665, DOI 10.1016/0006-2952(90)90109-X; VOEST EE, 1993, CELL PROLIFERAT, V26, P77, DOI 10.1111/j.1365-2184.1993.tb00008.x; VOEST EE, 1993, CANCER CHEMOTH PHARM, V31, P357, DOI 10.1007/BF00686148; VOEST EE, UNPUB ROLE IRON PATH; VREUGDENHIL G, 1989, LANCET, V2, P1398; VREUGDENHIL G, 1991, CLIN EXP RHEUMATOL, V9, P35; VREUGDENHIL G, 1990, RHEUMATOL INT, V9, P243, DOI 10.1007/BF00541320; VREUGDENHIL G, 1990, BRIT J RHEUMATOL, V29, P105; Vreugdenhil G., 1992, Drugs of Today, V28, P157; VREUGDENHIL G, 1992, NEPHRON, V61, P475, DOI 10.1159/000186973; VREUGDENHIL G, 1993, IN PRESS ACTA HAEMAT; WALKER JA, 1985, AM J KIDNEY DIS, V6, P254, DOI 10.1016/S0272-6386(85)80183-9; WANTANABE N, 1979, CARCINO EMBRYONIC PR, P273; WARD HE, 1988, AM REV RESPIR DIS, V137, P1356, DOI 10.1164/ajrccm/137.6.1356; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WEINBERG K, 1986, BLOOD, V68, P286; WEITMAN SD, 1991, J NATL CANCER I, V83, P1834, DOI 10.1093/jnci/83.24.1834-a; WHITEHEAD S, 1990, BLOOD, V76, P1250; WYLER DJ, 1992, NEW ENGL J MED, V327, P1519, DOI 10.1056/NEJM199211193272110; YEUNG TK, 1992, CANCER CHEMOTH PHARM, V30, P58, DOI 10.1007/BF00686486; YINNON AM, 1989, BLOOD, V74, P2166; YOSHINO S, 1985, ANN RHEUM DIS, V44, P485, DOI 10.1136/ard.44.7.485; 1979, ANN INTERN MED, V91, P883	149	65	68	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					490	499		10.7326/0003-4819-120-6-199403150-00008	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311372				2022-12-28	WOS:A1994NB62500008
J	BREYSSE, P; COUSER, WG; ALPERS, CE; NELSON, K; GAUR, L; JOHNSON, RJ				BREYSSE, P; COUSER, WG; ALPERS, CE; NELSON, K; GAUR, L; JOHNSON, RJ			MEMBRANOUS NEPHROPATHY AND FORMALDEHYDE EXPOSURE	ANNALS OF INTERNAL MEDICINE			English	Note							MORTALITY		PUGET SOUND BLOOD CTR, SEATTLE, WA 98104 USA	Puget Sound Blood Center	BREYSSE, P (corresponding author), UNIV WASHINGTON, DEPT ENVIRONM HLTH, F461A HLTH SCI, SEATTLE, WA 98195 USA.				NIDDK NIH HHS [DK43422, DK02142] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043422, K04DK002142, R01DK043422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAIR A, 1986, J NATL CANCER I, V76, P1071; BREYSSE PA, 1988, COMMENTS TOXICOLOGY, V3, P135; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; COUSER WG, 1988, ANNU REV MED, V39, P517; EHRENREICH T, 1977, ENVIRON RES, V14, P35, DOI 10.1016/0013-9351(77)90064-0; ELLER PM, 1984, DHHS NIOSH84100 NAT; ERLICH H, 1991, EUR J IMMUNOGENET, V18, P33, DOI 10.1111/j.1744-313X.1991.tb00005.x; HARRIS JC, 1981, JAMA-J AM MED ASSOC, V245, P243, DOI 10.1001/jama.245.3.243; HAYES RB, 1990, AM J IND MED, V18, P641, DOI 10.1002/ajim.4700180603; THRASHER JD, 1990, ARCH ENVIRON HEALTH, V45, P217, DOI 10.1080/00039896.1990.9940805	10	9	10	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					396	397		10.7326/0003-4819-120-5-199403010-00007	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304657				2022-12-28	WOS:A1994MY49700007
J	MEADOR, CK				MEADOR, CK			THE LAST WELL PERSON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									VANDERBILT UNIV,NASHVILLE,TN 37205	Vanderbilt University								BARSKY AJ, 1988, WORRIED SICK OUR TRO; MEADOR CK, 1991, JAMA-J AM MED ASSOC, V265, P1374, DOI 10.1001/jama.265.11.1374	2	33	32	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					440	441		10.1056/NEJM199402103300618	http://dx.doi.org/10.1056/NEJM199402103300618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284021				2022-12-28	WOS:A1994MV27900032
J	STEINER, CA; BASS, EB; TALAMINI, MA; PITT, HA; STEINBERG, EP				STEINER, CA; BASS, EB; TALAMINI, MA; PITT, HA; STEINBERG, EP			SURGICAL RATES AND OPERATIVE MORTALITY FOR OPEN AND LAPAROSCOPIC CHOLECYSTECTOMY IN MARYLAND	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAOPERATIVE CHOLANGIOGRAPHY; STANDARD	Background. Since 1989, laparoscopic cholecystectomy has been widely adopted as a treatment for gallstone disease. We analyzed the association between the introduction of this procedure and three variables: the rate at which cholecystectomy was performed in Maryland, the characteristics of patients undergoing cholecystectomy in routine clinical practice, and operative mortality. Methods and Results. We used 1985-1992 hospital-discharge data from all 54 acute care hospitals in Maryland to identify open and laparoscopic cholecystectomies, characteristics of patients undergoing these procedures, and deaths occurring during hospitalizations in which these procedures were performed. The annual rate of cholecystectomy, adjusted for age, rose from 1.69 per 1000 state residents in 1987-1989 to 2.17 per 1000 residents in 1992, an increase of 28 percent (P<0.001). As compared with patients undergoing open cholecystectomy, patients undergoing laparoscopic cholecystectomy tended to be younger, less likely to have acute cholecystitis or a common-duct stone, and more likely to be white and have private health insurance or belong to a health maintenance organization (P<0.001). Although the operative mortality associated with laparoscopic cholecystectomy was less than that with open cholecystectomy (adjusted odds ratio, 0.22; 95 percent confidence interval, 0.13 to 0.37) and the overall mortality rate for all cholecystectomies declined from 0.84 percent in 1989 to 0.56 percent in 1992, there was no significant change in the total number of cholecystectomy-related operative deaths because of the increase in the cholecystectomy rate. Conclusions. In Maryland, although the adoption of laparoscopic cholecystectomy has been accompanied by a 33 percent decrease in overall operative mortality per procedure, the total number of cholecystectomy-related deaths has not fallen because of a 28 percent increase in the total rate of cholecystectomy.	JOHNS HOPKINS UNIV, SCH MED,DEPT MED, PROGRAM MED TECHNOL & PRACTICE ASSESSMENT, 1830 E MONUMENT ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Bass, Eric/0000-0001-9106-527X				ALTMAN SH, 1979, DHEW PHS793216 PUBL; BASS EB, 1993, AM J SURG, V165, P466, DOI 10.1016/S0002-9610(05)80942-0; BERCI G, 1991, AM J SURG, V161, P355, DOI 10.1016/0002-9610(91)90597-7; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P1196, DOI 10.1001/jama.262.9.1196; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; MCSHERRY CK, 1989, AM J SURG, V158, P174, DOI 10.1016/0002-9610(89)90246-8; ORLANDO R, 1993, ARCH SURG-CHICAGO, V128, P494; Penninckx F, 1991, HPB Surg, V3, P291, DOI 10.1155/1991/67569; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; PHILLIPS EH, 1990, AM SURGEON, V56, P792; PONSKY JL, 1991, AM J SURG, V161, P393, DOI 10.1016/0002-9610(91)90605-D; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SOPER NJ, 1992, SURG GYNECOL OBSTET, V174, P114; 1992, SAS USERS GUIDE STAT; 1993, JAMA-J AM MED ASSOC, V269, P1018; 1991, NEW ENGL J MED, V324, P1073; 1988, J HOPKINS HOSPITAL R; 1990, 1990 SUMMARY POPULAT, P1	19	277	285	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					403	408		10.1056/NEJM199402103300607	http://dx.doi.org/10.1056/NEJM199402103300607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284007				2022-12-28	WOS:A1994MV27900007
J	GINZBERG, E				GINZBERG, E			IMPROVING HEALTH-CARE FOR THE POOR - LESSONS FROM THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GINZBERG, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,475 RIVERSIDE DR,SUITE 248,NEW YORK,NY 10115, USA.							Cisneros HG, 1993, INTERWOVEN DESTINIES; GINZBERG E, 1986, HLTH DOLLARS HLTH SE; GINZBERG E, 1993, CHANGING US HLTH CAR; GINZBERG E, 1993, EC MED ED; NOBERG CN, 1988, HLTH AFF, V7, P83; 1989, REPORT COMMONWEALTH; 1992, IMPROVING ACCESS HLT; 1992, STAT ABSTR US 1992; 1992, REPORT MAYORAL COMMI	9	29	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					464	467		10.1001/jama.271.6.464	http://dx.doi.org/10.1001/jama.271.6.464			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295322				2022-12-28	WOS:A1994MU49100035
J	PARRISH, KM; HOLT, VL; EASTERLING, TR; CONNELL, FA; LOGERFO, JP				PARRISH, KM; HOLT, VL; EASTERLING, TR; CONNELL, FA; LOGERFO, JP			EFFECT OF CHANGES IN MATERNAL AGE, PARITY, AND BIRTH-WEIGHT DISTRIBUTION ON PRIMARY CESAREAN DELIVERY RATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; SECTION; WOMEN; CARE; RISK	Objective.-To examine the effect of maternal age on cesarean delivery risk and to quantify the impact of demographic changes since 1970 on primary cesarean delivery rates. Design.-A cohort study. Setting.-Nonfederal short-stay hospitals in Washington State. Participants.-All women who delivered live singletons with linked birth certificate and hospital discharge data from 1987 through 1990. Main Outcome Measures.-Maternal age-, birth weight-, and parity-specific primary cesarean delivery rates, Mantel-Haenszel relative risk estimates for primary cesarean delivery by 5-year age category stratified by parity, and direct standardization of 1987 through 1990 primary cesarean rates to 1970 Washington State maternal age, birth weight, and parity distribution. Results.-Primary cesarean rates ranged from 3.2% for multiparous teenage women who delivered infants weighing 3500 g through 3999 g to 58.9% for primiparous women 40 years of age or older who delivered infants weighing 4000 g or more. After adjustment, the risk of cesarean delivery increased with each 5-year age increment among women 20 years of age or older. We estimated that if the maternal age, parity, and birth weight distribution from 1987 through 1990 were identical to what existed in 1970, Washington State's primary cesarean rate from 1987 through 1990 would have been 12.2%, compared with the observed rate of 14.8%. Conclusion.-The lower adjusted primary cesarean rate reflects the demographic changes in the childbearing population, which may be responsible for 18% of the 1987 through 1990 cesarean delivery rates. These findings suggest the importance of using maternal age-, birth weight-, and parity-specific primary cesarean delivery rates to compare populations and study temporal trends.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	PARRISH, KM (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SC-37,SEATTLE,WA 98195, USA.			Makimoto, Kiyoko/0000-0003-0242-1290				BERKOWITZ GS, 1989, AM J OBSTET GYNECOL, V161, P146, DOI 10.1016/0002-9378(89)90252-4; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; GORDON D, 1991, OBSTET GYNECOL, V77, P493; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; JONAS O, 1991, MED J AUSTRALIA, V154, P246, DOI 10.5694/j.1326-5377.1991.tb121082.x; MARTEL M, 1987, AM J OBSTET GYNECOL, V156, P30; MCCLOSKEY L, 1992, MED CARE, V30, P126, DOI 10.1097/00005650-199202000-00004; MEEHAN FP, 1988, J OBSTET GYNAECOL, V8, P201, DOI 10.3109/01443618809012284; MINKOFF HL, 1980, OBSTET GYNECOL, V56, P135; Notzon FC, 1991, ACTA OBSTET GYN SCAN, V70, P451, DOI 10.3109/00016349109007159; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PEIPERT JF, 1993, OBSTET GYNECOL, V81, P200; PLACEK PJ, 1988, OBSTET GYN CLIN N AM, V15, P607; REID AJ, 1989, CAN MED ASSOC J, V140, P625; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; TAFFEL S, 1993, MMWR MORBID MORTAL W, V42, P285; TANG L, 1990, Journal of Obstetrics and Gynaecology (Abingdon), V10, P526, DOI 10.3109/01443619009151259; TURNER MJ, 1990, OBSTET GYNECOL, V76, P159; YASIN SY, 1988, J REPROD MED, V33, P209; 1982, MONTHLY VITAL STA S2, V31, P1; 1990, INT CLASSIFICATION D, V1; 1991, US DHHS PHS9150212 P; 1984, PHS843345 US DEP HLT; 1990, INT CLASSIFICATION D, V3; 1974, VITAL STATISTICS US, V1; 1990, SAS STAT USERS GUIDE, V1	28	92	92	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					443	447		10.1001/jama.271.6.443	http://dx.doi.org/10.1001/jama.271.6.443			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295319				2022-12-28	WOS:A1994MU49100031
J	TALENTE, GM; COLEMAN, RA; ALTER, C; BAKER, L; BROWN, BI; CANNON, RA; CHEN, YT; CRIGLER, JF; FERREIRA, P; HAWORTH, JC; HERMAN, GE; ISSENMAN, RM; KEATING, JP; LINDE, R; ROE, TF; SENIOR, B; WOLFSDORF, JI				TALENTE, GM; COLEMAN, RA; ALTER, C; BAKER, L; BROWN, BI; CANNON, RA; CHEN, YT; CRIGLER, JF; FERREIRA, P; HAWORTH, JC; HERMAN, GE; ISSENMAN, RM; KEATING, JP; LINDE, R; ROE, TF; SENIOR, B; WOLFSDORF, JI			GLYCOGEN-STORAGE-DISEASE IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Review							UNCOOKED CORNSTARCH; DEBRANCHING ENZYME; PHYSICAL GROWTH; TYPE-1; IB; CARDIOMYOPATHY; CHILDREN; DEXTROSE; THERAPY; GLUCOSE	Objective: To identify complications amenable to prevention in adults with glycogen storage disease (GSD) types Ia, Ib, and III and to determine the effect of the disease on social tactors. Design: Case series and clinical review. Setting: Referral medical centers in the United States and Canada. Patients: All patients with GSD-Ia (37 patients), GSD-Ib (5 patients), and GSD-III (9 patients) who were 18 years of age or older. Measurements: Ultrasound or radiographic studies identified liver adenomas, nephrocalcinosis, or kidney stones. Radiographic studies identified osteopenia. Reports of the clinical examination, serum chemistry results, and social data were obtained. Results: For patients with GSD-Ia, problems included short stature (90%), hepatomegaly (100%), hepatic adenomas (75%), anemia (81 %), proteinuria or microalbuminuria (67%), kidney calcifications (65%), osteopenia or fractures or both (27%), increased alkaline phosphatase (61%) and gamma-glutamyltransferase (93%) activities, and increased serum cholesterol (76%) and triglyceride (100%) levels. Hyperuricemia was frequent (89%). Patients with GSD-Ib had severe recurrent bacterial infections and gingivitis. In patients with GSD-III, 67% (6 of 9) had increased creatinine kinase activity. Four of these patients had myopathy and cardiomyopathy. Conclusions: For GSD-Ia, hyperuricemia and pyelonephritis should be treated to prevent nephrocalcinosis and additional renal damage. For GSD-Ib, granulocyte-colony-stimulating factor may prevent bacterial infections. For GSD-III, more data are required to determine whether the myopathy and cardiomyopathy can be prevented. Most of the patients with GSD-I and GSD-III had 12 or more years of education and were either currently in school or employed.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT NUTR, CB 7400, CHAPEL HILL, NC 27599 USA; CHILDRENS HOSP PHILADELPHIA, DEPT ENDOCRINOL, PHILADELPHIA, PA 19104 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT PEDIAT GASTROENTEROL & NUTR, SACRAMENTO, CA 95817 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02115 USA; UNIV ALBERTA, DIV MED GENET, EDMONTON T6G 2B7, AB, CANADA; UNIV MANITOBA, DEPT PEDIAT & CHILD HLTH, WINNIPEG R3E 0W1, MANITOBA, CANADA; INST MOLEC GENET, HOUSTON, TX 77030 USA; MCMASTER UNIV, HAMILTON L8N 3Z5, ONTARIO, CANADA; WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, SCH MED, DIV GASTROENTEROL & NUTR, ST LOUIS, MO 63110 USA; PALO ALTO MED RES FDN, PALO ALTO, CA 94301 USA; CHILDRENS HOSP LOS ANGELES, DIV ENDOCRINOL & METAB, LOS ANGELES, CA 90027 USA; TUFTS NEW ENGLAND MED CTR HOSP, BOSTON, MA 02111 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Washington University (WUSTL); University of California System; University of California Davis; Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Alberta; University of Manitoba; Baylor College of Medicine; McMaster University; St. Louis Children's Hospital; Washington University (WUSTL); Palo Alto Medical Foundation Research Institute; Children's Hospital Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Senior, Brent/K-5368-2019	Issenman, Robert/0000-0002-1411-3925	NCRR NIH HHS [M01-RR30, RR02172] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMBRUSO DR, 1985, AM J DIS CHILD, V139, P691, DOI 10.1001/archpedi.1985.02140090053027; BAKER L, 1989, KIDNEY INT, V35, P1345, DOI 10.1038/ki.1989.133; CHEN YT, 1988, NEW ENGL J MED, V318, P7, DOI 10.1056/NEJM198801073180102; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; CHEN YT, 1993, EUR J PEDIATR, V152, pS56; COLEMAN RA, 1992, ANN INTERN MED, V116, P896, DOI 10.7326/0003-4819-116-11-896; COLEMAN RA, 1992, J INHERIT METAB DIS, V15, P869, DOI 10.1007/BF01800225; CRIGLER JF, 1978, CIBA F S, V55, P331; DAESCHEL IE, 1983, J AM DIET ASSOC, V83, P135; DEPARSCAU L, 1988, ARCH FR PEDIATR, V45, P641; FOLKMAN J, 1972, SURGERY, V72, P306; GREENE HL, 1976, NEW ENGL J MED, V294, P423, DOI 10.1056/NEJM197602192940805; GROSSMAN H, 1981, RADIOLOGY, V141, P753, DOI 10.1148/radiology.141.3.6272355; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Hers HG, 1989, METABOLIC BASIS INHE, P425; LABRUNE P, 1991, PEDIATR CARDIOL, V12, P161, DOI 10.1007/BF02238523; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; MOSES SW, 1986, ACTA PAEDIATR SCAND, V75, P289, DOI 10.1111/j.1651-2227.1986.tb10201.x; PARKER P, 1981, GASTROENTEROLOGY, V81, P534; ROE TF, 1992, NEW ENGL J MED, V326, P1666, DOI 10.1056/NEJM199206183262504; SMIT GPA, 1990, J INHERIT METAB DIS, V13, P411, DOI 10.1007/BF01799498; SOEJIMA K, 1985, Pediatric Pathology, V3, P307; WANG WC, 1991, LEUKEMIA, V5, P347; WOLFSDORF J I, 1992, Pediatric Research, V31, p190A; WOLFSDORF JI, 1992, AM J CLIN NUTR, V56, P587, DOI 10.1093/ajcn/56.3.587; WOLFSDORF JI, 1990, AM J CLIN NUTR, V52, P1043, DOI 10.1093/ajcn/52.6.1043; WOLFSDORF JI, 1990, J PEDIATR-US, V117, P384, DOI 10.1016/S0022-3476(05)81077-7; WOLFSDORF JI, 1990, AM J CLIN NUTR, V52, P1051, DOI 10.1093/ajcn/52.6.1051; YANG BZ, 1992, J BIOL CHEM, V267, P9294; YOUNG DS, 1987, ANN INTERN MED, V106, P114, DOI 10.7326/0003-4819-106-1-114	30	160	166	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					218	226		10.7326/0003-4819-120-3-199402010-00008	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273986				2022-12-28	WOS:A1994MU30300008
J	DYCK, JA; MAUL, GG; MILLER, WH; CHEN, JD; KAKIZUKA, A; EVANS, RM				DYCK, JA; MAUL, GG; MILLER, WH; CHEN, JD; KAKIZUKA, A; EVANS, RM			A NOVEL MACROMOLECULAR STRUCTURE IS A TARGET OF THE PROMYELOCYTE-RETINOIC ACID RECEPTOR ONCOPROTEIN	CELL			English	Article							RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR ANTIGEN; LEUKEMIA FUSES; CELL-LINE; T-CELLS; EXPRESSION; GENE; FINGER; PURIFICATION	Acute promyelocytic leukemia (APL) is associated with a t(15;17) translocation that creates the promyelocyte-retinoic acid receptor alpha (PML-RARalpha) fusion gene. Immunohistochemistry demonstrates that PML is a part of a novel macromolecular organelle (including at least three other nuclear proteins) referred to as PML oncogenic domains (PODs). In APL cells, the POD is disrupted into a microparticulate pattern as a consequence of the expression of the PML-RAR oncoprotein. RA treatment of APL cells triggers a reorganization of PML to generate normal-appearing PODs. We propose that PML-RAR is a dominant negative oncoprotein that exerts its putative leukomogenic effect by inhibiting assembly of the POD. According to this proposal, not only is the POD a novel structure, but it can be ascribed an imputed function such that its disruption leads to altered myeloid maturation; this may represent a novel oncogenic target.	SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; KYOTO UNIV, FAC MED, KYOTO 606, JAPAN	Howard Hughes Medical Institute; Salk Institute; The Wistar Institute; Kyoto University	DYCK, JA (corresponding author), UNIV CALIF SAN DIEGO, GRAD PROGRAM BIOMED SCI, LA JOLLA, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANSON IM, 1991, GENOMICS, V10, P417, DOI 10.1016/0888-7543(91)90327-B; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGLA.N, 1961, B ASSOC FR ETUD CANC, V48, P283; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LANOTTE M, 1991, BLOOD, V77, P1080; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Mitelman F., 1988, CATALOG CHROMOSOME A; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1992, MOL BIOL CELL, V3, P555, DOI 10.1091/mbc.3.5.555; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; WURDEN S, 1993, J HISTOCHEM CYTOCHEM, V41, P627, DOI 10.1177/41.4.8450202; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559	57	742	752	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					333	343		10.1016/0092-8674(94)90340-9	http://dx.doi.org/10.1016/0092-8674(94)90340-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293467				2022-12-28	WOS:A1994MU67800016
J	APPLEWHITE, MP; JANSEN, GR; MARRIOTT, BM; BREEN, VM				APPLEWHITE, MP; JANSEN, GR; MARRIOTT, BM; BREEN, VM			THE EFFECTS OF DIET ON PERFORMANCE - AN INITIAL REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									INST MED,FOOD & NUTR BOARD,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418									1990, JAMA-J AM MED ASSOC, V264, P1656; 1990, JAMA-J AM MED ASSOC, V264, P1655; 1990, JAMA-J AM MED ASSOC, V264, P1698	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					98	98		10.1001/jama.271.2.98	http://dx.doi.org/10.1001/jama.271.2.98			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264076				2022-12-28	WOS:A1994MQ08300004
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE .1. MORALE IN GENERAL-PRACTICE - IS CHANGE THE PROBLEM OR THE SOLUTION	BRITISH MEDICAL JOURNAL			English	Article							JOB-SATISFACTION; MENTAL-HEALTH; PRACTITIONERS; STRESS	Despite the pervading gloom about morale in general practice it can still offer a rewarding career. This article, which is the first in a series examining ways to improve general practitioners' job satisfaction, weighs the evidence for low morale in the profession and examines the factors that cause most dissatisfaction. The main causes of discontent seem to be increased paperwork and out of hours work, and many blame the 1990 contract for their problems. Dissatisfaction was growing before the contract was introduced, however, and some doctors believe that it has had positive effects. Further change seems inevitable if general practice is to offer a stimulating career for life.										Allen, 1988, DOCTORS THEIR CAREER; ALLEN I, 1992, PARTTIME WORKING GEN; ANDALO D, 1993, GENERAL PRACTIT 1015, P1; BEECHAM L, 1993, BRIT MED J, V307, P806; BERWICK I, 1992, MEDECONOMICS     JUL, P32; BRANTHWAITE A, 1988, FAM PRACT, V5, P83, DOI 10.1093/fampra/5.2.83; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P378; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; FRY J, 1983, PRESENT STATE FUTURE; GERBER L, 1983, MARRIED THEIR CAREER; Gray D J, 1980, J R Coll Gen Pract, V30, P231; GRAY DJP, 1982, J R COLL GEN PRACT, V32, P75; HANDYSIDES S, 1989, GENERAL PRACTIT 0623, P31; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; LEAVEY R, 1989, BRIT MED J, V298, P737, DOI 10.1136/bmj.298.6675.737; LEWIS G, 1993, J EPIDEMIOL COMMUN H, V47, P358, DOI 10.1136/jech.47.5.358; MAKIN PJ, 1988, J ROY COLL GEN PRACT, V38, P303; MEEK C, 1993, BMA NEWS REV    1010; Neighbour R., 1987, INNER CONSULTATION; ODONNELL M, 1986, DOCTOR DOCTOR; ODOWD TC, 1987, J ROY COLL GEN PRACT, V37, P290; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; PORTER AMD, 1987, STRESS HLTH PROFESSI, P45; RICHARDS C, 1988, J ROY COLL GEN PRACT, V38, P535; RICHARDS C, 1991, BRIT MED J, V303, P827, DOI 10.1136/bmj.303.6806.827; RICHARDS C, 1989, 78 KING EDW HOSP FUN; SCOTT MGB, 1992, BRIT MED J, V304, P1548, DOI 10.1136/bmj.304.6841.1548; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; 1993, PULSE           0911, P15; 1965, CHARTER FAMILY DOCTO; 1993, PULSE           0925, P1; 1991, PATIENTS CHARTER; 1992, YOUR CHOICES FUTURE; 1993, PULSE           0925, P3	37	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					32	34		10.1136/bmj.308.6920.32	http://dx.doi.org/10.1136/bmj.308.6920.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298352	Green Published			2022-12-28	WOS:A1994MQ09600028
J	VILLAR, RN				VILLAR, RN			MINIMALLY INVASIVE SURGERY .6. ARTHROSCOPY	BRITISH MEDICAL JOURNAL			English	Article							KNEE	Arthroscopy has reduced the morbidity and period of hospitalisation associated with orthopaedic surgery and has increased the range of procedures that may be performed. From early operations on the knee it has expanded to include procedures for the shoulder, elbow, wrist, hip, ankle, and foot. For some joints the indications for surgery are clear, for others the clinical advantages are still being assessed. This expansion has also led to the recognition of complications, though the incidence is low. Specialist instrumentation has allowed a wide variety of operations previously needing open surgery to be carried out arthroscopically. The repertoire of arthroscopic procedures will undoubtedly continue to expand, and controlled studies are required to validate their efficacy, particularly in the management of degenerative joint diseases.			VILLAR, RN (corresponding author), ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND.							BAMFORD DJ, 1992, J BONE JOINT SURG BR, V74, P328; BOEREE NR, 1991, J BONE JOINT SURG BR, V73, P452, DOI 10.1302/0301-620X.73B3.1670448; Burman MS, 1931, J BONE JOINT SURG, V13, P669; DANDY DJ, 1991, J BONE JOINT SURG BR, V73, P877, DOI 10.1302/0301-620X.73B6.1955427; EIKELAAR HR, 1980, ARTHROSCOPY KNEE, P6; GLICK JM, 1991, OPERATIVE ARTHROSCOP, P663; GOLDMAN A, 1987, J TRAUMA, V27, P1294; Gross R., 1977, ORTHOP REV, V6, P43; IKEDA T, 1988, J BONE JOINT SURG BR, V70, P13, DOI 10.1302/0301-620X.70B1.3339044; JACKSON RW, 1978, COMPLICATIONS ORTHOP, V1, P70; Jackson RW, 1991, OPERATIVE ARTHROSCOP, P319; LUNDEEN RO, 1992, MANUAL ANKLE FOOT AR, P45; Matthews L S, 1985, Arthroscopy, V1, P83, DOI 10.1016/S0749-8063(85)80036-0; ODRISCOLL SW, 1992, J BONE JOINT SURG AM, V74A, P84, DOI 10.2106/00004623-199274010-00010; SHIFRIN LZ, 1980, CLIN ORTHOP RELAT R, V146, P213; SMALL NC, 1990, CURRENT MANAGEMENT C, P1; VILLAR RN, 1992, HIP ARTHROSCOPY, P1; VILLAR RN, 1991, J BONE JOINT SURG S2, V73, P922; WILEY A M, 1991, Arthroscopy, V7, P138, DOI 10.1016/0749-8063(91)90098-I; WILEY AM, 1991, SURGICAL DISORDERS S, P157	20	19	20	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					51	53		10.1136/bmj.308.6920.51	http://dx.doi.org/10.1136/bmj.308.6920.51			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298357	Green Published			2022-12-28	WOS:A1994MQ09600034
J	FEAVER, WJ; SVEJSTRUP, JQ; BARDWELL, L; BARDWELL, AJ; BURATOWSKI, S; GULYAS, KD; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD				FEAVER, WJ; SVEJSTRUP, JQ; BARDWELL, L; BARDWELL, AJ; BURATOWSKI, S; GULYAS, KD; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD			DUAL ROLES OF A MULTIPROTEIN COMPLEX FROM SACCHAROMYCES-CEREVISIAE IN TRANSCRIPTION AND DNA-REPAIR	CELL			English	Article							RNA POLYMERASE-II; YEAST RAD3 PROTEIN; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; PYRIMIDINE DIMERS; MUTANT ALLELES; CTD KINASE; FACTOR-B; GENE; HELICASE	Yeast RNA polymerase II initiation factor b, homolog of human TFIIH, is a protein kinase capable of phosphorylating the C-terminal repeat domain of the polymerase; it possesses a DNA-dependent ATPase activity as well. The 85 kd and 50 kd subunits of factor b are now identified as RAD3 and SSL1 proteins, respectively; both are known to be involved in DNA repair. Factor b interacts specifically with another DNA repair protein, SSL2. The ATPase activity of factor b may be due entirely to that associated with a helicase function of RAD3. Factor b transcriptional activity was unaffected, however, by amino acid substitution at a conserved residue in the RAD3 nucleotide-binding domain, suggesting that the ATPase/helicase function is not required for transcription. These results identify factor b as a core repairosome, which may be responsible for the preferential repair of actively transcribed genes in eukaryotes.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOLEC PATHOL LAB, DALLAS, TX 75235 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Massachusetts Institute of Technology (MIT); Whitehead Institute; Indiana University System; Indiana University Bloomington	FEAVER, WJ (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA.		Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363; Svejstrup, Jesper/0000-0003-4964-6147	NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659, GM46498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R29GM046498, R37GM036659, R01GM046498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BARDWELL L, 1992, THESIS STANDARD U ST; BARDWELL L, 1994, IN PRESS P NATL ACAD; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1991, J BIOL CHEM, V266, P1900; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOEIJMAKERS JHJ, 1993, J CHROMATOGR, V9, P211; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1991, METHOD ENZYMOL, V194, P545; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAUMOVSKI L, 1988, MOL GEN GENET, V213, P400, DOI 10.1007/BF00339609; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NICOLET CM, 1987, YEAST, V3, P149, DOI 10.1002/yea.320030303; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	48	298	302	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1379	1387		10.1016/0092-8674(93)90624-Y	http://dx.doi.org/10.1016/0092-8674(93)90624-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269516				2022-12-28	WOS:A1993MP86900016
J	FORTINI, ME; ARTAVANISTSAKONAS, S				FORTINI, ME; ARTAVANISTSAKONAS, S			NOTCH - NEUROGENESIS IS ONLY PART OF THE PICTURE	CELL			English	Review							DROSOPHILA-MELANOGASTER; PROTEIN; LOCUS; GENE; ENCODES; ENHANCER; SERRATE; RICH		YALE UNIV,HOWARD HUGHES MED INST,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,DEPT BIOL,NEW HAVEN,CT 06536, USA.							ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BUSSEAU I, 1993, IN PRESS GENETICS; CABRERA CV, 1992, DEVELOPMENT, V115, P893; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DELACONCHA A, 1988, GENETICS, V118, P499; DELIDAKIS C, 1991, GENETICS, V129, P803; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEDERICH RJ, 1993, IN PRESS DEVELOPMENT; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; Perrimon N., 1986, GAMETOGENESIS EARLY, P221; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; XU T, 1992, DEVELOPMENT, V115, P913	30	132	143	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1245	1247		10.1016/0092-8674(93)90611-S	http://dx.doi.org/10.1016/0092-8674(93)90611-S			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269507	hybrid			2022-12-28	WOS:A1993MP86900003
J	KUROKI, R; WEAVER, LH; MATTHEWS, BW				KUROKI, R; WEAVER, LH; MATTHEWS, BW			A COVALENT ENZYME-SUBSTRATE INTERMEDIATE WITH SACCHARIDE DISTORTION IN A MUTANT T4 LYSOZYME	SCIENCE			English	Article							BACTERIOPHAGE-T4 LYSOZYME; ACTIVE-SITE; BETA-GLUCOSIDASE; EGG-WHITE; BINDING; HEN; REFINEMENT; CATALYSIS; MECHANISM; PROTEINS	The glycosyl-enzyme intermediate in lysozyme action has long been considered to be an oxocarbonium ion, although precedent from other glycosidases and theoretical considerations suggest it should be a covalent enzyme-substrate adduct. The mutation of threonine 26 to glutamic acid in the active site cleft of phage T4 lysozyme (T4L) produced an enzyme that cleaved the cell wall of Escherichia coli but left the product covalently bound to the enzyme. The crystalline complex was nonisomorphous with wild-type T4L, and analysis of its structure showed a covalent linkage between the product and the newly introduced glutamic acid 26. The covalently linked sugar ring was substantially distorted, suggesting that distortion of the substrate toward the transition state is important for catalysis, as originally proposed by Phillips. It is also postulated that the adduct formed by the mutant is an intermediate, consistent with a double displacement mechanism of action in which the glycosidic linkage is cleaved with retention of configuration as originally proposed by Koshland. The peptide part of the cell wall fragment displays extensive hydrogen-bonding interactions with the carboxyl-terminal domain of the enzyme, consistent with previous studies of mutations in T4L.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA; UNIV OREGON, HOWARD HUGHES MED INST, EUGENE, OR 97403 USA	University of Oregon; University of Oregon; Howard Hughes Medical Institute; University of Oregon					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BELL JA, 1991, PROTEINS, V10, P10, DOI 10.1002/prot.340100103; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; GRUTTER MG, 1982, J MOL BIOL, V154, P525, DOI 10.1016/S0022-2836(82)80011-9; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENSEN B, 1976, EUR J BIOCHEM, V66, P319; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KUROKI R, 1992, P NATL ACAD SCI USA, V89, P6803, DOI 10.1073/pnas.89.15.6803; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MATTHEWS BW, 1981, NATURE, V290, P334, DOI 10.1038/290334a0; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; POST CB, 1986, J AM CHEM SOC, V108, P1317, DOI 10.1021/ja00266a044; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WEAVER LH, 1985, J MOL EVOL, V21, P97, DOI 10.1007/BF02100084; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; ZHANG XJ, 1993, J APPL CRYSTALLOGR, V26, P457, DOI 10.1107/S0021889892013165	35	180	185	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2030	2033		10.1126/science.8266098	http://dx.doi.org/10.1126/science.8266098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266098				2022-12-28	WOS:A1993MN10800037
J	MASSUNG, RF; ESPOSITO, JJ; LIU, LI; QI, J; UTTERBACK, TR; KNIGHT, JC; AUBIN, L; YURAN, TE; PARSONS, JM; LOPAREV, VN; SELIVANOV, NA; CAVALLARO, KF; KERLAVAGE, AR; MAHY, BWJ; VENTER, JC				MASSUNG, RF; ESPOSITO, JJ; LIU, LI; QI, J; UTTERBACK, TR; KNIGHT, JC; AUBIN, L; YURAN, TE; PARSONS, JM; LOPAREV, VN; SELIVANOV, NA; CAVALLARO, KF; KERLAVAGE, AR; MAHY, BWJ; VENTER, JC			POTENTIAL VIRULENCE DETERMINANTS IN TERMINAL REGIONS OF VARIOLA SMALLPOX VIRUS GENOME	NATURE			English	Article								SMALLPox eradication culminated the most successful antimicrobial campaign in medical history1. To characterize further the linear double-stranded DNA genome of the aetiological agent of smallpox, we have determined the entire nucleotide sequence of the highly virulent variola major virus, strain Bangladesh-1975 (VA R-BSH; 186,102 base pairs, 33.7% G + C; Genbank accession number, L22579). Here we highlight features of the molecule and focus on a few of the 187 putative proteins that probably contribute to pathogenicity and virus host-range properties. One hundred and fifty proteins were markedly similar to those of vaccinia virus (smallpox vaccine), for which a complete sequence has been reported2,3 for strain Copenhagen (VAC-CPN; 191,636 base pairs, 33.3% G + C). The remaining 37 proteins reflected variola-specific sequences or open reading frame divergences for variant proteins, which are often truncated or elongated compared with their vaccinia counterparts.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; NINCDS, BETHESDA, MD 20892 USA; INST GENOM RES, GAITHERSBURG, MD 20878 USA	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); J. Craig Venter Institute				Kerlavage, Anthony/0000-0002-3954-9653				AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; ESPOSITO JJ, 1991, CLASSIFICATION NOM S, V2, P91; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Jezek Z, 1988, HUMAN MONKEYPOX; JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; MAHY BWJ, 1993, REV MED VIROL, V3, P131, DOI 10.1002/rmv.1980030302; MAHY BWJ, 1991, ASM NEWS, V57, P577; MARTINGALLARDO A, 1992, NAT GENET, V1, P34, DOI 10.1038/ng0492-34; MOSS B, 1990, CURR TOP MICROBIOL, V163, P41; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKUS ME, 1990, VIROLOGY, V179, P276, DOI 10.1016/0042-6822(90)90296-4; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sambrook J, 1989, MOL CLONING LABORATO; SCCHELKUNOV SN, 1993, VIRUS RES, V27, P25; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SHCHELKUNOV SN, 1993, DOKL AKAD NAUK+, V328, P629; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P163, DOI 10.1016/0014-5793(93)80059-4; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349	27	149	380	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1993	366	6457					748	751		10.1038/366748a0	http://dx.doi.org/10.1038/366748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264798				2022-12-28	WOS:A1993MN26400030
J	FOSS, M; MCNALLY, FJ; LAURENSON, P; RINE, J				FOSS, M; MCNALLY, FJ; LAURENSON, P; RINE, J			ORIGIN RECOGNITION COMPLEX (ORC) IN TRANSCRIPTIONAL SILENCING AND DNA-REPLICATION IN SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article							ACTIVE-SITE TYROSINE; MATING TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; TOPOISOMERASE-I; GENETIC-ANALYSIS; YEAST SILENCER; REPRESSION; MUTAGENESIS; HISTONE-H4	In Saccharomyces cerevisiae, the HMR-E silencer blocks site-specific interactions between proteins and their recognition sequences in the vicinity of the silencer. Silencer function is correlated with the firing of an origin of replication at HMR-E. An essential gene with a role in transcriptional silencing was identified by means of a screen for mutations affecting expression of HMR. This gene, known as ORC2, was shown to encode a component of the origin recognition complex that binds yeast origins of replication. A temperature-sensitive mutation in ORC2 disrupted silencing in cells grown at the permissive temperature. At the restrictive temperature, the orc2-1 mutation caused cell cycle arrest at a point in the cell cycle indicative of blocks in DNA replication. The orc2-1 mutation also resulted in the enhanced mitotic loss of a plasmid, suggestive of a defect in replication. These results provide strong evidence for an in vivo role of ORC in both chromosomal replication and silencing, and provide a link between the mechanism of silencing and DNA replication.			FOSS, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV GENET,401 BARKER HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031105, R37GM031105] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES01896-12] Funding Source: Medline; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1982, COLD SPRING HARB SYM, V47, P989, DOI 10.1101/SQB.1983.047.01.113; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DUBLEY DD, 1991, MOL CELL BIOL, V11, P5346; ENG WK, 1989, J BIOL CHEM, V264, P13373; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; HERSKOWITZ J, 1992, MOL CELLULAR BIOL YE, P583; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUISMAN O, 1987, GENETICS, V116, P191; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LO ST, UNPUB; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RINE J, 1987, GENETICS, V116, P9; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1990, GENETICS, V124, P237; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749	41	288	292	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1838	1844		10.1126/science.8266071	http://dx.doi.org/10.1126/science.8266071			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266071				2022-12-28	WOS:A1993MM51100026
J	RUSSELL, SM; KEEGAN, AD; HARADA, N; NAKAMURA, Y; NOGUCHI, M; LELAND, P; FRIEDMANN, MC; MIYAJIMA, A; PURI, RK; PAUL, WE; LEONARD, WJ				RUSSELL, SM; KEEGAN, AD; HARADA, N; NAKAMURA, Y; NOGUCHI, M; LELAND, P; FRIEDMANN, MC; MIYAJIMA, A; PURI, RK; PAUL, WE; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN - A FUNCTIONAL COMPONENT OF THE INTERLEUKIN-4 RECEPTOR	SCIENCE			English	Article							GROWTH SIGNAL TRANSDUCTION; HUMAN IL-2 RECEPTOR; T-CELL LINE; BETA-CHAIN; LIGAND-BINDING; GM-CSF; SUBUNIT; PROLIFERATION; EXPRESSION; CLONING	The interleukin-2 (IL-2) receptor gamma chain (IL-2Rgamma) is an essential component of high- and intermediate-affinity IL-2 receptors. IL-2Rgamma was demonstrated to be a component of the IL-4 receptor on the basis of chemical cross-linking data, the ability of IL-2Rgamma to augment IL-4 binding affinity, and the requirement for IL-2Rgamma in IL-4-mediated phosphorylation of insulin receptor substrate-1. The observation that IL-2Rgamma is a functional component of the IL-4 receptor, together with the finding that IL-2Rgamma associates with the IL-7 receptor, begins to elucidate why deficiency of this common gamma chain (gamma(c)) has a profound effect on lymphoid function and development, as seen in X-linked severe combined immunodeficiency.	NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; NIAID,IMMUNOL LAB,BETHESDA,MD 20892; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; US Food & Drug Administration (FDA)			Leonard, Warren/AAA-1397-2022; Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641				BAULA JL, 1992, J BIOL CHEM, V267, P20525; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; CARRISON M, 1989, EUR J IMMUNOL, V19, P913; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; DEFRANCE T, 1988, J EXP MED, V168, P1321, DOI 10.1084/jem.168.4.1321; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HARADA N, 1992, J BIOL CHEM, V267, P22752; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992; KEEGAN AD, 1991, J IMMUNOL, V146, P2272; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEONARD WJ, 1992, INTERLEUKIN 2, P29; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; MIGLIORATI G, 1991, CELL IMMUNOL, V136, P194, DOI 10.1016/0008-8749(91)90394-Q; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PAUL WE, 1991, BLOOD, V77, P1859; PURI RK, 1993, CANCER INVEST, V11, P479; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; RUSSELL SM, UNPUB; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SPITS H, 1987, J IMMUNOL, V139, P1142; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1174; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; VAZQUEZ A, 1989, J IMMUNOL, V142, P94; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; [No title captured]	51	808	837	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1880	1883		10.1126/science.8266078	http://dx.doi.org/10.1126/science.8266078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266078	Green Submitted			2022-12-28	WOS:A1993MM51100038
J	HARDIE, RM; WATSON, JM				HARDIE, RM; WATSON, JM			SCREENING MIGRANTS AT RISK OF TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article											HARDIE, RM (corresponding author), PUBL HLTH LAB SERV,COMMUNICABLE DIS SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND.							ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; 1992, SERIES MN, V17; 1990, BMJ, V300, P995; 1992, THORAX, V47, P770	5	41	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1539	1540		10.1136/bmj.307.6918.1539	http://dx.doi.org/10.1136/bmj.307.6918.1539			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274925	Green Published, Bronze			2022-12-28	WOS:A1993ML86900024
J	RUSSELL, RCG				RUSSELL, RCG			MINIMALLY INVASIVE SURGERY .1. GENERAL-SURGERY - BILIARY SURGERY	BRITISH MEDICAL JOURNAL			English	Article							SHOCK-WAVES; GALLSTONES; CHOLECYSTECTOMY; LITHOTRIPSY; STONES	The management of biliary tract disease has changed completely as a result of minimally invasive treatment. For most patients with gallstones that cause symptoms a laparoscopic cholecystectomy will treat the condition with minimal morbidity and a short recovery period. If complications are encountered, conversion to a mini-cholecystectomy gives results that are nearly as good. Acute cholecystitis can be treated by percutaneous drainage followed either by percutaneous cholecystolithotomy or a laparoscopic cholecystectomy. Gallstones in the bile duct are best treated by endoscopic sphincterotomy with duct clearance. The day of the large cholecystectomy scar with its subsequent incisional hernia has gone.			RUSSELL, RCG (corresponding author), MIDDLESEX HOSP,LONDON W1N 8AA,ENGLAND.							BRENDEL W, 1983, LANCET, V1, P1054; CHAUSSY C, 1982, J UROLOGY, V127, P417, DOI 10.1016/S0022-5347(17)53841-0; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; McKernan J B, 1990, J Med Assoc Ga, V79, P157; PERISSAT J, 1989, ENDOSCOPY, V21, P373, DOI 10.1055/s-2007-1012994; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SAUERBRUCH T, 1986, NEW ENGL J MED, V314, P818, DOI 10.1056/NEJM198603273141304	8	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1266	1269		10.1136/bmj.307.6914.1266	http://dx.doi.org/10.1136/bmj.307.6914.1266			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281063	Green Published, Bronze			2022-12-28	WOS:A1993MH00100030
J	CADMAN, EC				CADMAN, EC			THE ACADEMIC PHYSICIAN-INVESTIGATOR - A CRISIS NOT TO BE IGNORED	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL RESEARCH; BIOMEDICAL-RESEARCH; FACULTY; MEDICINE; CAREER; DEPARTMENTS; SCIENTISTS; SUCCESS; PROGRAM	The academic physician-investigator faces many challenges. Obtaining funding to support research is the greatest impediment. The National Institutes of Health, the single largest source of grants for the academic physician-investigator, approved only 14.2% of new investigator grant applications in 1990, compared with 40% in 1965 and 1975. Physicians submitted 25% of all applications, and they have priority scores similar to those applications submitted by investigators with PhD degrees. The 14.2% funding rate for new investigator-initiated grants is considerably less than the 56% success rate of amended renewal investigator-initiated grants. These trends in funding can be discouraging to the new physician-investigator. In addition, more emphasis is placed on clinical practice to generate money to support the new academic physician. These two facts, reduced probability of obtaining a grant and the perceived need to see more patients for salary support, may jeopardize retention of young faculty members. Moreover, training to prepare physicians for academic careers has been poor, with no attention given to the projected needs of the academic centers or the nation. This article describes the dilemma facing young physician-investigators and provides recommendations for improvement to the leaders of American medicine.	YALE UNIV, SCH MED, NEW HAVEN, CT USA	Yale University								APPLEGATE WB, 1990, AM J MED, V88, P263, DOI 10.1016/0002-9343(90)90152-4; AUSTRIAN R, 1951, B JOHNS HOPKINS HOSP, V88, P264; BEATY HN, 1986, ANN INTERN MED, V104, P90, DOI 10.7326/0003-4819-104-1-90; BLACKBURN RT, 1979, CURRENT ISSUES HIGHE, V2, P25; BLAND CJ, 1986, J MED EDUC, V61, P22; BROMLEY DA, 1991, ACAD MED, V66, P336, DOI 10.1097/00001888-199106000-00005; CAMERON SW, 1981, J HIGH EDUC, V52, P369, DOI 10.2307/1981284; CHIN D, 1985, NEW ENGL J MED, V312, P1029, DOI 10.1056/NEJM198504183121605; CHOPPIN PW, 1989, ACAD MED, V64, P382, DOI 10.1097/00001888-198907000-00006; DIBONA GF, 1979, CLIN RES, V27, P253; Eisenberg J M, 1986, J Gen Intern Med, V1, pS8; EPSTEIN DL, 1991, ARCH OPHTHALMOL-CHIC, V109, P1523, DOI 10.1001/archopht.1991.01080110059034; FREI E, 1958, BLOOD, V13, P1126, DOI 10.1182/blood.V13.12.1126.1126; Funkenstein DH., 1978, MED STUDENTS MED SCH; GENEST J, 1990, CAN MED ASSOC J, V143, P383; GENTILE NO, 1989, POSTDOCTORAL RES TRA, P1; GOLDMAN L, 1991, J GEN INTERN MED, V6, P341, DOI 10.1007/BF02597435; GOLDMAN L, 1990, CLIN RES, V38, P686; HANDLER P, 1961, J MED EDUC, V36, P1587; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; JOLLY P, 1992, AAMC DATA BOOK STATI; KELLEY WN, 1992, ANN INTERN MED, V116, P654, DOI 10.7326/0003-4819-116-8-654; KELLEY WN, 1988, J LAB CLIN MED, V111, P365; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; LEVEY GS, 1981, NEW ENGL J MED, V305, P887, DOI 10.1056/NEJM198110083051510; LEVEY GS, 1988, ANN INTERN MED, V109, P414, DOI 10.7326/0003-4819-109-5-414; MODLIN JF, 1990, PRINCIPLES PRACTICE, P1361; MORRIS WW, 1977, 9 U IOW COLL MED CUR; MORRIS WW, 1977, 8 U IOW COLL MED CUR; MOVSESIAN MA, 1990, NEW ENGL J MED, V322, P1602, DOI 10.1056/NEJM199005313222211; NEINSTEIN LS, 1989, ACAD MED, V64, P32, DOI 10.1097/00001888-198901000-00014; PALCA J, 1990, SCIENCE, V249, P351, DOI 10.1126/science.2377890; PARRIS M, 1984, J MED EDUC, V59, P465; PETERSDORF RG, 1983, NEW ENGL J MED, V309, P1053, DOI 10.1056/NEJM198310273091711; RELMAN AS, 1989, NEW ENGL J MED, V320, P933, DOI 10.1056/NEJM198904063201410; SHANNON JA, 1948, J CLIN INVEST, V27, P66, DOI 10.1172/JCI101975; SHIMM DS, 1991, ANN INTERN MED, V115, P148, DOI 10.7326/0003-4819-115-2-148; SHUSTER AL, 1983, J MED EDUC, V58, P101; SMITH R, 1988, BRIT MED J, V296, P920, DOI 10.1136/bmj.296.6626.920; SMITH WJ, 1992, REPORT MED SCH FACUL; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; WYNGAARDEN JB, 1983, CLIN RES, V31, P115; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; Zubrod C.G., 1960, J CHRON DIS, V11, P7; 1978, MED STUDENT GRADUATI; 1985, PERSONAL NEEDS TRAIN; 1991, INFORMATION SYSTEMS; 1990, CLIN RES, V38, P239; 1965, BASIC DATA RELATING; 1991, PROGRAM PLANNING EVA; 1981, STATUS MED SCH FACUL; 1992, PROGRAM PLANNING EVA	53	63	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					401	410		10.7326/0003-4819-120-5-199403010-00009	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304659				2022-12-28	WOS:A1994MY49700009
J	ORLEANS, CT; RESCH, N; NOLL, E; KEINTZ, MK; RIMER, BK; BROWN, TV; SNEDDEN, TM				ORLEANS, CT; RESCH, N; NOLL, E; KEINTZ, MK; RIMER, BK; BROWN, TV; SNEDDEN, TM			USE OF TRANSDERMAL NICOTINE IN A STATE-LEVEL PRESCRIPTION PLAN FOR THE ELDERLY - A FIRST LOOK AT REAL-WORLD PATCH USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; CIGARETTE-SMOKING; CONTROLLED TRIAL; INTERVENTION; PROGRAMS; THERAPY; SMOKERS; CARE; HELP; DEPENDENCE	Objective.-To assess transdermal nicotine use patterns and outcomes in a population of low-income older smokers. Design.-A 6-month telephone follow-up survey of smokers filling prescriptions for transdermal nicotine in the first 3 months of 1992. Setting.-Pennsylvania's Pharmaceutical Assistance Plan for the Elderly, the nation's largest state-level prescription plan for the elderly. Population.-A total of 1070 noninstitutionalized male and female smokers aged 65 through 74 years. Main Outcome Measures.-Self-reported physician/pharmacist advice and adjunctive treatments, concomitant smoking, and 6-month smoking abstinence. Results.-Respondents were predominantly long-term heavy smokers. They used nicotine patches for an average of 5 weeks, with few reporting use beyond 3 months or recalling bothersome side effects. Most of those with previous quit attempts rated quitting with the patch ''easier.'' The 29% self-reported 6-month quit rate observed is encouraging. However, compliance with patch use guidelines was far from ideal in this high-risk population: only 54% of respondents received any initial advice or materials from their physicians or pharmacists, fewer than 2% took part in a formal clinic or one-to-one treatment program, and almost half (47%) smoked while using the patch, including 20% who smoked every day. Concomitant smoking was strongly associated with failure to achieve abstinence (P<.001). More frequent contact with physicians and/or pharmacists was associated with less concomitant smoking (P<.001) and higher quit rates (P=.005). Conclusions.-This survey offers an important first look at problems and prospects for nicotine patch therapy in older adults, with implications for other groups as well. Prospective studies are needed to clarify optimal treatment regimens and adjuncts.	DUKE COMPREHENS CANC CTR, DURHAM, NC USA; COMMONWEALTH PENN DEPT AGING, HARRISBURG, PA USA	Duke University	ORLEANS, CT (corresponding author), FOX CHASE CANC CTR, 510 TOWNSHIP LINE RD, CHELTENHAM, PA 19012 USA.				NCI NIH HHS [CA34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA034856, P01CA034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELIN T, 1989, LANCET, V1, P7; BANDURA A, 1985, COGNITION PSYCHOTHER; BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BENOWITZ NL, IN PRESS J AM COLL C; BERRY GL, 1988, AM J PUBLIC HEALTH, V78, P157, DOI 10.2105/AJPH.78.2.157; BUCHKREMER G, 1991, PHARMACOPSYCHIATRY, V24, P96, DOI 10.1055/s-2007-1014448; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CURRY SJ, 1991, J CONSULT CLIN PSYCH, V59, P318, DOI 10.1037/0022-006X.59.2.318; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; DENEEF P, 1991, J FAM PRACTICE, V32, P607; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FINCHAM J E, 1992, American Pharmacy, V32, P62; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, IN PRESS CHEST; GLYNN TJ, 1990, JAMA-J AM MED ASSOC, V263, P2795, DOI 10.1001/jama.263.20.2795; GLYNN TJ, 1991, NCI NIH913104 PUBL; GORODETZKY CC, 1992, JULY US FOOD DRUG AD; HENNINGFIELD JE, 1988, NICOTINE REPLACEMENT, P35; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; HIGGINS MW, 1993, JAMA-J AM MED ASSOC, V269, P2741, DOI 10.1001/jama.269.21.2741; Hirsch J D, 1990, Am Pharm, VNS30, P20; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LICHTENSTEIN E, 1992, J CONSULT CLIN PSYCH, V60, P518, DOI 10.1037/0022-006X.60.4.518; MULLER P, 1990, LUNG, V168, P445, DOI 10.1007/BF02718163; OCKENE J, 1992, HEALTH PSYCHOL, V11, P119, DOI 10.1037//0278-6133.11.5.277; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; ORLEANS CT, 1991, HEALTH PSYCHOL, V10, P343, DOI 10.1037/0278-6133.10.5.343; ORLEANS CT, 1990, SMOKING PATTERNS QUI; ORLEANS CT, 1993, NICOTINE ADDICTION P, P181; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; POMERLEAU CS, 1990, ADDICT BEHAV, V15, P73, DOI 10.1016/0306-4603(90)90009-M; PROCHASKA JO, 1993, HEALTH PSYCHOL, V12, P399, DOI 10.1037/0278-6133.12.5.399; RANKIN K, 1992, DRUGS STORE NEW 0316, P21; RENNARD S, 1991, JAMA-J AM MED ASSOC, V266, P3133; RENNARD S, 1991, CHEST, V100, pS5; RIMER BK, 1990, CHEST, V97, P547, DOI 10.1378/chest.97.3.547; RIMER BK, IN PRESS HLTH ED RES; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; ROWE JW, 1985, NEW ENGL J MED, V312, P827, DOI 10.1056/NEJM198503283121305; SACHS DP, IN PRESS ARCH INTERN; SALIVE ME, 1992, AM J PUBLIC HEALTH, V82, P1268, DOI 10.2105/AJPH.82.9.1268; SCHAUFFLER HH, 1993, HEALTH EDUC QUART, V20, P185, DOI 10.1177/109019819302000211; SCHOENBACH VJ, 1992, HEALTH EDUC RES, V7, P369, DOI 10.1093/her/7.3.369; SLADE J, 1992, TOBACCO CONTROL S, V1, pS10; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; STUART B, 1991, ANAL DETERMINANTS CO, P1; STUART B, 1991, PROFILES PRESCRIPTIO, P2; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Tonnesen P, 1992, J SMOKING RELATED DI, V3, P241; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; WEINER JP, 1991, HEALTH AFFAIR, V10, P140, DOI 10.1377/hlthaff.10.1.140; 1992, MMWR MORB MORTAL WKL, V41, P354; 1992, NATIONAL COUNCIL PAT, V55, P6; 1986, NIH862687 NCI PUBL; 1992, NICOTINE SUBSTITUTIO; 1990, CDC908416 US DEP HLT; 1991, LIT HLTH US SELECTED; 1992, NICODERM PRODUCT INS; 1989, CDC898411 US DEP HLT; 1992, HABITROL PRODUCT INS	64	102	104	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					601	607		10.1001/jama.271.8.601	http://dx.doi.org/10.1001/jama.271.8.601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301792				2022-12-28	WOS:A1994MW47700023
J	CLINTON, JJ				CLINTON, JJ			MANAGING EARLY HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					492	492		10.1001/jama.271.7.492	http://dx.doi.org/10.1001/jama.271.7.492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301749				2022-12-28	WOS:A1994MV42300006
J	SOPER, NJ; BRUNT, LM; KERBL, K				SOPER, NJ; BRUNT, LM; KERBL, K			LAPAROSCOPIC GENERAL-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; ACUTE ABDOMINAL-PAIN; ENDOSCOPIC SPHINCTEROTOMY; GASTROESOPHAGEAL REFLUX; PANCREATIC-CANCER; OPEN APPENDECTOMY; GOLD STANDARD; CHOLECYSTECTOMY; EXPERIENCE; DIAGNOSIS				SOPER, NJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT SURG, 1 BARNES HOSP PLAZA, SUITE 6108, ST LOUIS, MO 63110 USA.							ALIPERTI G, 1991, ANN INTERN MED, V115, P783, DOI 10.7326/0003-4819-115-10-783; ATTWOOD SEA, 1992, SURGERY, V112, P497; Bailey R W, 1991, Surg Laparosc Endosc, V1, P45; BAILEY RW, 1991, ANN SURG, V214, P531, DOI 10.1097/00000658-199110000-00017; BAILEY RW, 1993, SURGICAL LAPAROSCOPY, P241; BANTING S, 1993, SURG ENDOSC-ULTRAS, V7, P57, DOI 10.1007/BF00591240; BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; BASS EB, 1993, AM J SURG, V165, P466, DOI 10.1016/S0002-9610(05)80942-0; BERCI G, 1983, AM J SURG, V146, P261, DOI 10.1016/0002-9610(83)90387-2; BERNARD HR, 1993, AM J SURG, V165, P533, DOI 10.1016/S0002-9610(05)80956-0; BRAASCH JW, 1992, ARCH SURG-CHICAGO, V127, P887; CARROLL BJ, 1992, SURG ENDOSC-ULTRAS, V6, P183, DOI 10.1007/BF02210877; Clayman R V, 1992, Surg Laparosc Endosc, V2, P29; CONDON RE, 1989, HERNIA, P253; Corbitt J D Jr, 1991, Surg Laparosc Endosc, V1, P23; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; CUSCHIERI A, 1992, AM J SURG, V163, P425, DOI 10.1016/0002-9610(92)90046-T; CUSCHIERI A, 1988, ANN ROY COLL SURG, V70, P153; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; Dallemagne B, 1991, Surg Laparosc Endosc, V1, P138; DAVIDOFF AM, 1992, ANN SURG, V215, P196, DOI 10.1097/00000658-199203000-00002; DEMEESTER TR, 1974, ANN SURG, V180, P511; DEUTSCH AA, 1982, BRIT J SURG, V69, P336, DOI 10.1002/bjs.1800690615; DEWILDE RL, 1991, LANCET, V338, P1012, DOI 10.1016/0140-6736(91)91871-Q; DODSON RW, 1993, CONTEMP SURG, V42, P42; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; Fabiani P, 1991, Surg Laparosc Endosc, V1, P162; Falcone R E, 1991, J Laparoendosc Surg, V1, P299, DOI 10.1089/lps.1991.1.299; FALK PM, 1993, DIS COLON RECTUM, V36, P28, DOI 10.1007/BF02050298; FITZGERALD SD, 1992, AM J SURG, V163, P186, DOI 10.1016/0002-9610(92)90274-U; FITZGIBBONS R, 1993, SURG ENDOSC-ULTRAS, V7, P115; FORDE KA, 1993, SURG ENDOSC-ULTRAS, V7, P71, DOI 10.1007/BF00704379; Fornari F, 1989, Surg Endosc, V3, P33, DOI 10.1007/BF00591313; Frantzides C T, 1992, Surg Laparosc Endosc, V2, P348; FUSCO MA, 1993, DIS COLON RECTUM, V36, P858, DOI 10.1007/BF02047384; GAGNER M, 1992, NEW ENGL J MED, V327, P1033; GAZZANIGA AB, 1976, AM J SURG, V131, P315, DOI 10.1016/0002-9610(76)90124-0; GER R, 1993, WORLD J SURG, V17, P46, DOI 10.1007/BF01655704; GILL BD, 1993, SURG ENDOSC-ULTRAS, V7, P116; GILLILAND TM, 1990, SURG GYNECOL OBSTET, V170, P39; GOLDSMITH MF, 1989, JAMA-J AM MED ASSOC, V262, P3248, DOI 10.1001/jama.262.23.3248; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V263, P1496; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P2723, DOI 10.1001/jama.264.21.2723; GREEN FL, 1992, SURG ENDOSC-ULTRAS, V6, P271, DOI 10.1007/BF02498856; GROSS E, 1984, BMJ-BRIT MED J, V288, P1577, DOI 10.1136/bmj.288.6430.1577; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P1018, DOI 10.1001/jama.1993.03500080066034; HASHIMOTO D, 1993, SURG ENDOSC-ULTRAS, V7, P54, DOI 10.1007/BF00591239; HELMS B, 1992, MINIMALLY INVASIV S1, V1, P118; Hinder R A, 1992, Surg Laparosc Endosc, V2, P265; HUNTER JG, 1992, SURG CLIN N AM, V72, P1077; Jacobs M, 1991, Surg Laparosc Endosc, V1, P144; JEFFERS L, 1988, GASTROINTEST ENDOSC, V34, P235, DOI 10.1016/S0016-5107(88)71319-X; KATKHOUDA N, 1991, AM J SURG, V161, P361, DOI 10.1016/0002-9610(91)90598-8; KATKHOUDA N, 1993, MINIMALLY INVASIVE S, P123; KERBL K, 1993, J UROLOGY, V150, P396, DOI 10.1016/S0022-5347(17)35491-5; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; LEAPE LL, 1980, ANN SURG, V191, P410, DOI 10.1097/00000658-198004000-00004; LEGRAND M, 1992, MINIMALLY INVASIV S1, V1, P90; LEIGHTON TA, 1993, SURGERY, V113, P527; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; LICHTENSTEIN IL, 1976, AM J SURG, V132, P307, DOI 10.1016/0002-9610(76)90381-0; LIGHTDALE CJ, 1982, GASTROINTEST ENDOSC, V28, P99, DOI 10.1016/S0016-5107(82)73014-7; LILLEMOE KD, 1990, SURG CLIN N AM, V70, P1355; LILLEMOE KD, 1992, ANN SURG, V215, P669, DOI 10.1097/00000658-199206000-00014; Liu S Y, 1991, J Laparoendosc Surg, V1, P241; MACFADYEN BV, 1993, SURG ENDOSC-ULTRAS, V7, P155, DOI 10.1007/BF00594097; MACFADYEN BV, 1992, SURG CLIN N AM, V72, P1169; MCANENA OJ, 1992, BRIT J SURG, V79, P818, DOI 10.1002/bjs.1800790837; MCKERNAN JB, 1993, SURG ENDOSC-ULTRAS, V7, P26, DOI 10.1007/BF00591232; MCSHERRY CK, 1989, AM J SURG, V158, P174, DOI 10.1016/0002-9610(89)90246-8; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MONSON JRT, 1992, LANCET, V340, P831, DOI 10.1016/0140-6736(92)92694-B; MOURET P, 1990, BRIT J SURG, V77, P1006, DOI 10.1002/bjs.1800770916; NAGY AG, 1989, AM J SURG, V157, P490, DOI 10.1016/0002-9610(89)90642-9; NASH JM, 1992, TIME            0325, P52; NEUGEBAUER E, 1991, BRIT J SURG, V78, P150, DOI 10.1002/bjs.1800780207; NISSEN R, 1961, AM J DIG DIS, V6, P954, DOI 10.1007/BF02231426; OKITA K, 1984, SCAND J GASTROENTERO, V19, P91; PATERSONBROWN S, 1986, BRIT J SURG, V73, P1022, DOI 10.1002/bjs.1800731230; PELLEGRINI C, 1992, ANN SURG, V216, P291, DOI 10.1097/00000658-199209000-00008; PERISSAT J, 1990, SURG ENDOSC-ULTRAS, V4, P1, DOI 10.1007/BF00591401; PETELIN JB, 1993, AM J SURG, V165, P487, DOI 10.1016/S0002-9610(05)80947-X; PETERS JH, 1993, MINIMALLY INVASIVE S, P297; PHILLIPS EH, 1993, WORLD J SURG, V17, P22, DOI 10.1007/BF01655700; PHILLIPS EH, 1992, ANN SURG, V216, P703, DOI 10.1097/00000658-199212000-00015; PIER A, 1993, WORLD J SURG, V17, P29, DOI 10.1007/BF01655701; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; REIERTSEN O, 1985, ACTA CHIR SCAND, V151, P521; ROBINSON HB, 1976, SURG GYNECOL OBSTET, V143, P829; SALKY B, 1993, SURG LAPAROSC ENDOSC, V3, P132; SATAVA RM, 1993, SURG ENDOSC-ULTRAS, V7, P111, DOI 10.1007/BF00704392; SCHIRMER BD, 1992, AM J SURG, V163, P46, DOI 10.1016/0002-9610(92)90251-L; SCHLINKERT RT, 1991, DIS COLON RECTUM, V34, P1030, DOI 10.1007/BF02049971; SEMM K, 1983, ENDOSCOPY, V15, P59, DOI 10.1055/s-2007-1021466; SHIMI S, 1992, BRIT J SURG, V79, P317, DOI 10.1002/bjs.1800790411; SMITH PC, 1992, SURGERY, V111, P230; SMITH RS, 1993, SURG ENDOSC-ULTRAS, V7, P137; SOPER NJ, 1993, SURGERY, V113, P1; SOPER NJ, 1992, SURG CLIN N AM, V72, P1139; SOPER NJ, 1993, AM J SURG, V165, P663, DOI 10.1016/S0002-9610(05)80784-6; SOPER NJ, 1992, SURG GYNECOL OBSTET, V174, P114; SOPER NJ, 1993, AM J SURG, V165, P522, DOI 10.1016/S0002-9610(05)80954-7; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; SOPER NJ, 1991, CURR PROB SURG, V28, P587, DOI 10.1016/0011-3840(91)90041-M; SOSA JL, 1992, ARCH SURG-CHICAGO, V127, P109; Spaw A T, 1991, Surg Laparosc Endosc, V1, P2; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; SPINELLI P, 1975, BRIT MED J, V4, P554, DOI 10.1136/bmj.4.5996.554; SPINELLI P, 1991, PROBL GEN SURG, V8, P329; Stoker M E, 1991, J Laparoendosc Surg, V1, P287, DOI 10.1089/lps.1991.1.287; STOPPA RE, 1984, SURG CLIN N AM, V64, P269; SUGARBAKER PH, 1975, LANCET, V1, P442; SWANSTROM L, 1993, SURG ENDOSC-ULTRAS, V7, P122; THOR KBA, 1989, ANN SURG, V210, P719, DOI 10.1097/00000658-198912000-00005; VEREECKEN L, 1993, SURG ENDOSC-ULTRAS, V7, P123; VOYLES CR, 1993, AM J SURG, V165, P472, DOI 10.1016/S0002-9610(05)80943-2; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; WARSHAW AL, 1993, SURGERY, V114, P629; WITTGEN CM, 1991, ARCH SURG-CHICAGO, V126, P997; WOLFE BM, 1991, ARCH SURG-CHICAGO, V126, P1192; 1992, NEW YORK STATE DEP H, V9220; 1991, AM J SURG, V161, P324	123	256	268	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					409	419		10.1056/NEJM199402103300608	http://dx.doi.org/10.1056/NEJM199402103300608			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284008				2022-12-28	WOS:A1994MV27900008
J	CLINE, MJ				CLINE, MJ			THE MOLECULAR-BASIS OF LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE CHAIN-REACTION; T-CELL LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; NON-HODGKINS-LYMPHOMA; P53 GENE-MUTATIONS; CHROMOSOMAL TRANSLOCATIONS				CLINE, MJ (corresponding author), CTR HLTH SCI, DIV HEMATOL, 10833 LECONTE AVE, LOS ANGELES, CA 90024 USA.				NATIONAL CANCER INSTITUTE [R01CA050275] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 50275] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AHUJA HG, 1991, BLOOD, V78, P3259; AHUJA HG, 1990, BLOOD, V75, P819; AHUJA HG, 1990, BLOOD, V75, P1684; ALLIERI MA, 1992, EXP HEMATOL, V20, P312; ATHAN E, 1991, AM J PATHOL, V138, P591; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARELI M, 1989, BLOOD, V73, P281; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BOS JL, 1987, BLOOD, V69, P1237; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; CROCE CM, 1985, BLOOD, V65, P1; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; FENAUX P, 1991, BLOOD, V78, P1652; FIEDLER W, 1991, ANN HEMATOL, V63, P282, DOI 10.1007/BF01698379; FISCH P, 1992, ONCOGENE, V7, P2389; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; FOTI A, 1991, BLOOD, V77, P2441; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GINSBERG AM, 1991, BLOOD, V77, P833; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERRASIO A, 1992, LEUKEMIA, V6, P507; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JANSSEN JWG, 1992, LEUKEMIA, V6, P463; JONVEAUX P, 1991, LEUKEMIA, V5, P839; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; MEEKER TC, 1990, BLOOD, V76, P285; MIWA H, 1992, LEUKEMIA, V6, P405; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKAI H, 1992, CANCER RES, V52, P6588; NEVINS JR, 1992, SCIENCE, V258, P424; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; RAGHOEBIER S, 1991, BLOOD, V77, P1560; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SAKASHITA A, 1992, BLOOD, V79, P477; SHERIDAN BL, 1990, TUMOR BIOL, V11, P44, DOI 10.1159/000217676; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VANKAMP H, 1992, BLOOD, V79, P1266, DOI 10.1182/blood.V79.5.1266.bloodjournal7951266; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VONCKEN JW, 1992, BLOOD, V79, P1029; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WARRELL RP, 1992, J CLIN ONCOL, V10, P1659, DOI 10.1200/JCO.1992.10.11.1659; WASSERMAN R, 1992, J EXP MED, V176, P1577, DOI 10.1084/jem.176.6.1577; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS ME, 1991, BLOOD, V78, P493; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	81	155	157	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					328	336						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277954				2022-12-28	WOS:A1994MU48900007
J	KLEBER, HD				KLEBER, HD			OUR CURRENT APPROACH TO DRUG-ABUSE - PROGRESS, PROBLEMS, PROPOSALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ALTERNATIVES; LEGALIZATION; PROHIBITION				KLEBER, HD (corresponding author), COLUMBIA UNIV, CTR ADDICT & SUBSTANCE ABUSE, NEW YORK, NY 10019 USA.							ELLICKSON PL, IN PRESS HDB DRUG AB; FARRELL M, 1990, BRIT J ADDICT, V85, P5; GLADWELL M, 1993, WASH POST       0607, pA1; HOMER JB, 1993, J DRUG ISSUES, V23, P281, DOI 10.1177/002204269302300208; INCIARDI A, 1992, WAR DRUGS, V2, P233; INCIARDI JA, 1989, AM BEHAV SCI, V32, P259, DOI 10.1177/0002764289032003006; JOHNSTON LD, 1992, MONITORING FUTURE AN; KAPLAN J, 1988, PUBLIC INTEREST, P32; KAPLAN J, 1983, HARDEST DRUG HEROIN; KLEBER HD, 1993, 1993 SEN COM LAB HUM; Kleiman M., 1993, ECONOMIST       0612, P8; Kleiman M, 1992, EXCESS DRUG POLICY R; Kleiman M., 1990, HOFSTRA LAW REV, V18, P527; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; MCAULIFFE WE, 1990, J HEALTH POLIT POLIC, V15, P357, DOI 10.1215/03616878-15-2-357; MCLELLAN AT, 1993, J SUBST ABUSE TREAT, V10, P243, DOI 10.1016/0740-5472(93)90071-9; Musto D F, 1989, Wilson Q, V13, P59; Musto David F., 1992, V166, P7; MUSTO DF, 1987, AM DISEASE ORIGINS N; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; NADELMANN EA, 1992, DAEDALUS, V121, P85; PENTZ MA, 1989, JAMA-J AM MED ASSOC, V261, P3259, DOI 10.1001/jama.261.22.3259; REUTER P, 1992, ANN AM ACAD POLIT SS, V521, P151, DOI 10.1177/0002716292521001009; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; STERNBERG L, 1991, SAP PREVENTION MONOG, V8, P13; Szasz T, 1992, NUESTRO DERECHO DROG; WILSON JQ, 1990, COMMENTARY       FEB, P21; 1992, DRUG ABUSE WARNING N; 1993, NATIONAL HOUSEHOLD S; 1989, NATIONAL DRUG CONTRO; 1991, MANDATORY MINIMUM SE	31	24	25	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					361	365		10.1056/NEJM199402033300514	http://dx.doi.org/10.1056/NEJM199402033300514			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277959				2022-12-28	WOS:A1994MU48900014
J	ORENTLICHER, D				ORENTLICHER, D			RATIONING AND THE AMERICANS-WITH-DISABILITIES-ACT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; STRATEGIES; INSURANCE		UNIV CHICAGO, SCH LAW, CHICAGO, IL 60637 USA; NORTHWESTERN UNIV, SCH MED, ETH & HUMAN VALUES PROGRAM, CHICAGO, IL 60611 USA	University of Chicago; Northwestern University	ORENTLICHER, D (corresponding author), AMER MED ASSOC, OFF GEN COUNSEL, 515 N STATE ST, CHICAGO, IL 60610 USA.							ABRAHAM KS, 1985, VA LAW REV, V71, P403, DOI 10.2307/1072963; ACKOUREY HA, 1991, EMORY LAW J, V40, P1183; ALBRECHTSEN D, 1991, ORGAN REPLACEMENT TH, P404; Boyle Philip J, 1993, Hastings Cent Rep, V23, pS1, DOI 10.2307/3562073; BROCK DW, 1988, SUBSTITUTION TECHNOL, P86; Buchanan A., 1989, MED ETHICS, P291; CLIFFORD KA, 1987, HARVARD LAW REV, V100, P1806, DOI 10.2307/1341233; COHEN C, 1991, JAMA-J AM MED ASSOC, V265, P1299, DOI 10.1001/jama.265.10.1299; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FELDBLUM CR, 1991, LABOR LAWYER, V7, P11; FUCHS VR, 1993, JAMA-J AM MED ASSOC, V269, P631; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P2527; GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; HADORN DC, 1991, HASTINGS CENT REP, V21, pS11, DOI 10.2307/3563329; KALB PE, 1989, JAMA-J AM MED ASSOC, V261, P2389, DOI 10.1001/jama.261.16.2389; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; Menzel P T, 1992, Law Med Health Care, V20, P57; MENZEL PT, 1992, HASTINGS CENT REP, V22, P21, DOI 10.2307/3562943; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SULLIVAN LW, 1992, COMMUNICATION   0803; TRIBE LAURENCE H., 1988, AM CONSTITUTIONAL LA, V2d; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; 1993, HLTH CARE POLICY R S, pS1; 1993, DIRECTORY PRACTICE P; 1993, INTERIM ENFORCEMENT; 1993, HARVARD LAW REV, V106, P1296	29	36	36	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					308	314		10.1001/jama.271.4.308	http://dx.doi.org/10.1001/jama.271.4.308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295292				2022-12-28	WOS:A1994MR22100029
J	HODGKINSON, DW; LLOYD, RE; DRISCOLL, PA; NICHOLSON, DA				HODGKINSON, DW; LLOYD, RE; DRISCOLL, PA; NICHOLSON, DA			ABC OF EMERGENCY RADIOLOGY - MAXILLOFACIAL RADIOGRAPHS	BRITISH MEDICAL JOURNAL			English	Article											HODGKINSON, DW (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.							1993, BRIT MED J, V307, P1476	1	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					46	51		10.1136/bmj.308.6920.46	http://dx.doi.org/10.1136/bmj.308.6920.46			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298355	Green Published			2022-12-28	WOS:A1994MQ09600033
J	HIGUCHI, M; SINGLE, FN; KOHLER, M; SOMMER, B; SPRENGEL, R; SEEBURG, PH				HIGUCHI, M; SINGLE, FN; KOHLER, M; SOMMER, B; SPRENGEL, R; SEEBURG, PH			RNA EDITING OF AMPA RECEPTOR SUBUNIT GLUR-B - A BASE-PAIRED INTRON-EXON STRUCTURE DETERMINES POSITION AND EFFICIENCY	CELL			English	Article							SELECTIVE GLUTAMATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; MODIFYING ACTIVITY; MOLECULAR-CLONING; ION FLOW; CHANNELS; CELLS; PERMEABILITY; SUBTYPES	A functionally critical position (Q/R site) of the AMPA receptor subunit GluR-B is controlled by RNA editing that operates in the nucleus, since in brain and clonal cell lines of neural origin, unspliced GluR-B transcripts occur edited in the Q/R site CAG codon and, additionally, in intronic adenosines. Transfection of GluR-B gene constructs into PC12 cells revealed that the proximal part of the intron downstream of the unedited exonic site is required for Q/R site editing. This intron portion contains an imperfect inverted repeat preceding a 10 nt sequence with exact complementarity to the exon centered on the unedited codon. Single nucleotide substitutions in this short intronic sequence or its exonic complement curtailed Q/R site editing, which was recovered by restoring complementarity in the respective partner strand. Base conversion in the channel-coding region of GluR-B directed by base paired sequences may be executed by a ubiquitous nuclear adenosine deaminase specific for double-stranded RNA.			HIGUCHI, M (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,IM NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BASS BL, 1993, RNA WORLD, P383; BASS BL, 1992, DEV BIOL, V3, P425; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, MED RES REV, V9, P1, DOI 10.1002/med.2610090102; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1993, IN PRESS NATURE; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OGINO Y, 1992, J NEUROCHEM, V58, P46, DOI 10.1111/j.1471-4159.1992.tb09275.x; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAMBROOK S, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WISDEN W, 1993, J NEUROSCI, V13, P3582; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	523	549	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1361	1370		10.1016/0092-8674(93)90622-W	http://dx.doi.org/10.1016/0092-8674(93)90622-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269514				2022-12-28	WOS:A1993MP86900014
J	BERGOFFEN, J; SCHERER, SS; WANG, S; SCOTT, MO; BONE, LJ; PAUL, DL; CHEN, K; LENSCH, MW; CHANCE, PF; FISCHBECK, KH				BERGOFFEN, J; SCHERER, SS; WANG, S; SCOTT, MO; BONE, LJ; PAUL, DL; CHEN, K; LENSCH, MW; CHANCE, PF; FISCHBECK, KH			CONNEXIN MUTATIONS IN X-LINKED CHARCOT-MARIE-TOOTH DISEASE	SCIENCE			English	Article							GAP JUNCTION PROTEIN; SENSORY NEUROPATHY; HEREDITARY MOTOR; GENE; LOCALIZATION; TYPE-1A; EXPRESSION; LINKAGE; CLONING; GJB1	X-linked Charcot-Marie-Tooth disease (CMTX) is a form of hereditary neuropathy with demyelination. Recently, this disorder was mapped to chromosome Xq13.1. The gene for the gap junction protein connexin32 is located in the same chromosomal segment, which led to its consideration as a candidate gene for CMTX. With the use of Northern (RNA) blot and immunohistochemistry technique, it was found that connexin32 is normally expressed in myelinated peripheral nerve. Direct sequencing of the connexin32 gene showed seven different mutations in affected persons from eight CMTX families. These findings, a demonstration of inherited defects in a gap junction protein, suggest that connexin32 plays an important role in peripheral nerve.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV GENET,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Harvard Medical School			Chance, Phillip/AAX-5826-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS008075, K08NS001565, P01NS008075] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37751] Funding Source: Medline; NINDS NIH HHS [NS01565, NS08075] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERT K, 1976, CELL TISSUE RES, V165, P281; BECKETT J, 1986, J NEUROGENET, V3, P225, DOI 10.3109/01677068609106852; BELLIVEAU DJ, 1991, DEV GENET, V12, P308, DOI 10.1002/dvg.1020120408; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERGOFFEN J, 1993, AM J HUM GENET, V53, P977; BERGOFFEN J, 1993, AM J HUM GENET, V52, P312; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCOS IA, 1992, GENOMICS, V13, P479, DOI 10.1016/0888-7543(92)90278-Z; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FAIN PR, IN PRESS AM J HUM GE; FISCHBECK KH, 1986, ANN NEUROL, V20, P527, DOI 10.1002/ana.410200414; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FRYNS JP, 1980, HUM GENET, V55, P413, DOI 10.1007/BF00290228; GABRIEL G, 1986, ACTA NEUROPATHOL, V72, P62, DOI 10.1007/BF00687948; GAL A, 1985, HUM GENET, V70, P38, DOI 10.1007/BF00389456; HAHN AF, 1990, BRAIN, V113, P1511, DOI 10.1093/brain/113.5.1511; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; OTT J, 1974, AM J HUM GENET, V26, P588; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAIMONDI E, 1992, CYTOGENET CELL GENET, V60, P210, DOI 10.1159/000133339; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROZEAR MP, 1987, NEUROLOGY, V37, P1460, DOI 10.1212/WNL.37.9.1460; TIMMERMAN V, 1992, NAT GENET, V1, P176; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166	30	912	948	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2039	2042		10.1126/science.8266101	http://dx.doi.org/10.1126/science.8266101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266101				2022-12-28	WOS:A1993MN10800040
J	ATKINS, D; PSATY, BM; KOEPSELL, TD; LONGSTRETH, WT; LARSON, EB				ATKINS, D; PSATY, BM; KOEPSELL, TD; LONGSTRETH, WT; LARSON, EB			CHOLESTEROL REDUCTION AND THE RISK FOR STROKE IN MEN - A METAANALYSIS OF RANDOMIZED, CONTROLLED TRIALS	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MULTIFACTORIAL PRIMARY PREVENTION; SERUM-CHOLESTEROL; CEREBRAL INFARCTION; BLOOD CHOLESTEROL; CLINICAL-TRIALS; CARDIOVASCULAR-DISEASES; CEREBROVASCULAR-DISEASE; MYOCARDIAL-INFARCTION	Objective: Reducing serum cholesterol lowers the risk for ischemic heart disease, but its effects on other vascular diseases are unknown. Published trials were reviewed to determine the effect of cholesterol-lowering interventions on fatal and nonfatal stroke. Design: Meta-analysis of randomized, controlled trials. Data identification: A literature search of English-language studies examining the effect of modified diets or medications on cardiovascular end points from 1965 to 1992 using MEDLINE and a review of references of five quantitative overviews of cholesterol reduction and coronary disease. Data Analysis: Thirteen studies met three eligibility criteria: patients randomized to intervention or control; fatal or nonfatal stroke reported separately; and end points assessed without knowledge of treatment status. Heterogeneity among studies and overall effects of treatment on fatal and nonfatal stroke were estimated using the Mantel-Haenszel-Peto method to combine independent study results. The influence of various study designs and interventions was explored using subgroup comparisons. Results: For fatal stroke, the overall odds ratio associated with cholesterol-lowering interventions in 13 trials was 1.32 (95% CI, 0.94 to 1.86), and the odds ratio for the 10 single-intervention trials was 1.34 (CI, 0.91 to 1.96). Among eight trials reporting nonfatal events, the summary odds ratio for nonfatal stroke for treated participants compared with controls was 0.88 (CI, 0.70 to 1.11), and the odds ratio for total strokes was 0.98 (CI, 0.80 to 1.19). Among three trials using clofibrate, treatment significantly increased the risk for fatal stroke (odds ratio, 2.64; CI, 1.42 to 4.92) but not for nonfatal stroke (odds ratio, 0.87; CI, 0.61 to 1.26). Regression analysis showed no statistical association between the magnitude of cholesterol reduction and the risk for fatal stroke. Conclusions: Lowering serum cholesterol through modified diets or medications does not reduce stroke mortality or morbidity in middle-aged men. Clofibrate appears to increase the risk for fatal strokes, but the mechanism for this effect is unknown.	UNIV WASHINGTON, CARDIOVASC HLTH RES UNIT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle					BHP HRSA HHS [5T32PE1002] Funding Source: Medline	BHP HRSA HHS		ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; ADAMS RJ, 1989, STROKE, V20, P448, DOI 10.1161/01.STR.20.4.448; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1986, Am J Cardiol, V58, P1; [Anonymous], 1988, NEW ENGL J MED; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; CORWIN LI, 1982, STROKE, V13, P818, DOI 10.1161/01.STR.13.6.818; CUPPLES LA, 1987, NIH872703 US DEP HLT; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DICKERSIN K, 1985, CONTROL CLIN TRIALS, V6, P306, DOI 10.1016/0197-2456(85)90106-0; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; DYKEN ML, 1984, STROKE, V15, P1105; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FAGARD R, 1991, AM J MED, V90, pS62, DOI 10.1016/0002-9343(91)90440-9; FLETCHER A, 1981, ARTERIOSCLEROSIS, V1, P202, DOI 10.1161/01.ATV.1.3.202; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; HEADY JA, 1980, LANCET, V2, P379; HENNERICI M, 1991, STROKE, V22, P989, DOI 10.1161/01.STR.22.8.989; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; ISO H, 1990, AM J EPIDEMIOL, V132, P993, DOI 10.1093/oxfordjournals.aje.a115742; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KORNITZER M, 1983, LANCET, V1, P1066; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LIGHT RJ, 1984, SUMMING UP SCI REV R; LIN CH, 1984, STROKE, V15, P653, DOI 10.1161/01.STR.15.4.653; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MARQUARDSEN J, 1986, STROKE PATHOPHYSIOLO, P19; MATHEW NT, 1975, JAMA-J AM MED ASSOC, V232, P262, DOI 10.1001/jama.232.3.262; MIETTINEN M, 1972, LANCET, V2, P835; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; QIZILBASH N, 1991, AM J EPIDEMIOL, V133, P832, DOI 10.1093/oxfordjournals.aje.a115963; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; REED D, 1992, CIRCULATION, V85, pA1; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE G, 1983, LANCET, V1, P1062; ROSE G, 1983, EUR HEART J, V4, P141; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; ROSSOUW JE, 1991, NEW ENGL J MED, V325, P1813; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P189; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SIMPSON IA, 1985, THROMB HAEMOSTASIS, V54, P442; SIRTORI CR, 1987, J LAB CLIN MED, V110, P279; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; STRINGER MD, 1990, CURR MED RES OPIN, V12, P207, DOI 10.1185/03007999009111649; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; TANAKA H, 1985, STROKE, V16, P773, DOI 10.1161/01.STR.16.5.773; TANDON N, 1983, J BIOL CHEM, V258, P1840; TELL GS, 1988, STROKE, V19, P423, DOI 10.1161/01.STR.19.4.423; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YAMORI Y, 1976, CLIN EXPT PHARM PH S, V3, P205; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YATSU FM, 1989, ANN NEUROL, V26, P3, DOI 10.1002/ana.410260102; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; YUSUF S, 1987, ATHEROSCLEROSIS, P393; YUSUF S, 1987, ATHEROSCLEROSIS, P389; 1971, BRIT MED J, V790, P775; 1991, HLTH US 1990	92	170	173	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					136	145		10.7326/0003-4819-119-2-199307150-00008	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8305001				2022-12-28	WOS:A1993LU90200008
J	GUPTA, S; TRENHOLME, K; ANDERSON, RM; DAY, KP				GUPTA, S; TRENHOLME, K; ANDERSON, RM; DAY, KP			ANTIGENIC DIVERSITY AND THE TRANSMISSION DYNAMICS OF PLASMODIUM-FALCIPARUM	SCIENCE			English	Article							PAPUA-NEW-GUINEA; MALARIA; ERYTHROCYTES; SURFACE; MADANG	The average age of humans at their first infection with Plasmodium falciparum is typically less than 1 year in most endemic areas. This has been interpreted as evidence of the high transmissibility of the parasite, with the implication that control of malaria will require high levels of coverage with a potential vaccine. This interpretation is challenged by mathematical models that demonstrate that the long period required to develop immunity to malaria permits a high risk (or low average age) of infection even when parasite transmissibility is low. Patterns of seroconversion to five antigenically distinct isolates of P. falciparum in a highly malarious area of Papua New Guinea indicate that each is only mildly transmissible and that malaria, as a construct of several such independently transmitted strains, has a basic reproductive rate (or transmissibility) that is an order of magnitude lower than other estimates.	PAPUA NEW GUINEA INST MED RES, MADANG, PAPUA N GUINEA; WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND	PNG Institute Of Medical Research; Walter & Eliza Hall Institute; Imperial College London	GUPTA, S (corresponding author), UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, OXON, ENGLAND.		Day, Karen/F-3697-2015; Trenholme, Katharine/C-9244-2013	Day, Karen/0000-0002-6115-6135; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; ANDERSON RM, 1989, PARASITOLOGY, V99, pS59, DOI 10.1017/S0031182000083426; Aron J.L., 1982, P139; BANG FB, 1947, T ROY SOC TROP MED H, V40, P809, DOI 10.1016/0035-9203(47)90039-4; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; DAVIDSON G, 1953, T ROY SOC TROP MED H, V47, P522, DOI 10.1016/S0035-9203(53)80005-2; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DAY KP, 1990, PARASITOL TODAY, V6, pA68; DE ZULUETA J, 1961, East Afr Med J, V38, P1; DELORON P, 1992, PARASITOL TODAY, V8, P375, DOI 10.1016/0169-4758(92)90174-Z; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; Gibson F. D., 1958, West African Medical Journal NS, V7, P170; GRAVES PM, 1988, PARASITOLOGY, V96, P251, DOI 10.1017/S003118200005825X; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553, DOI 10.1080/00034983.1990.11812510; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245, DOI 10.4269/ajtmh.1993.49.245; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; Molineaux L, 1980, THE GARKI PROJECT; MUIRHEADTHOMSON RC, 1954, T ROY SOC TROP MED H, V48, P208, DOI 10.1016/0035-9203(54)90067-X; NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T; NOKES DJ, 1987, LANCET, V1, P1441; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WILSON D B, 1962, East Afr Med J, V39, P593; YOUNG MARTIN D., 1949, JOUR NATION MALARIA SOC, V8, P247; 1960, REPORT PARETAVETA MA	30	161	161	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					961	963		10.1126/science.8310293	http://dx.doi.org/10.1126/science.8310293			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310293				2022-12-28	WOS:A1994MX16500033
J	BRAMANTE, JP				BRAMANTE, JP			LA-CUENTA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									CENT PENINSULA GEN HOSP, SOLDOTNA, AK 99669 USA										0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					339	339		10.7326/0003-4819-120-4-199402150-00013	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291828				2022-12-28	WOS:A1994MW10300013
J	LEE, KYC; KLINGLER, JF; MCCONNELL, HM				LEE, KYC; KLINGLER, JF; MCCONNELL, HM			ELECTRIC-FIELD-INDUCED CONCENTRATION GRADIENTS IN LIPID MONOLAYERS	SCIENCE			English	Article							TRANSITIONS; INTERFACE	Externally applied electric field gradients gave rise to lateral concentration gradients in monolayers of certain binary lipid mixtures. For binary mixtures of dihydrocholesterol and dimyristoylphosphatidylcholine, the application of an electric field gradient at pressures below the critical pressure produced a liquid-liquid phase separation in a monolayer that is otherwise homogenous. At pressures slightly above the critical pressure, a field gradient produced a large concentration gradient without phase separation. The lipid concentration gradients can be described by equilibrium thermodynamic chemical potentials. The observed effects appear to be relevant to the structure and composition of biological membranes.			LEE, KYC (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.							BEHANMARTIN MK, 1993, BIOCHIM BIOPHYS ACTA, V1151, P216, DOI 10.1016/0005-2736(93)90106-A; BENVEGNU DJ, 1993, J PHYS CHEM-US, V97, P6686, DOI 10.1021/j100127a019; DEUTICKE B, 1987, ANNU REV PHYSIOL, V49, P221; HECKL WM, 1988, THIN SOLID FILMS, V159, P125, DOI 10.1016/0040-6090(88)90624-4; HIRSHFELD CL, 1990, J PHYS-PARIS, V51, P1537, DOI 10.1051/jphys:0199000510140153700; Kirkwood J. G., 1961, CHEM THERMODYNAMICS; KLINGLER JF, 1993, J PHYS CHEM-US, V97, P2962, DOI 10.1021/j100114a023; KNOBLER CM, 1992, ANNU REV PHYS CHEM, V43, P207, DOI 10.1146/annurev.pc.43.100192.001231; LEE KYC, 1993, J PHYS CHEM-US, V97, P9532, DOI 10.1021/j100139a044; LINDEN CD, 1975, ACCOUNTS CHEM RES, V8, P321, DOI 10.1021/ar50094a001; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; PHILLIPS MC, 1972, PROG SURF MEMBR SCI, V8, P184; RECTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; SEUL A, 1990, PHYS REV LETT, V64, P190; SHINITZKY M, 1984, PHYSL MEMBRANE FLUID, V1, pCH1; SUBRAMANIAM S, 1987, J PHYS CHEM-US, V91, P1715, DOI 10.1021/j100291a010; VOGEL V, 1988, THIN SOLID FILMS, V159, P73, DOI 10.1016/0040-6090(88)90618-9	19	85	87	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					655	658		10.1126/science.8303272	http://dx.doi.org/10.1126/science.8303272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303272				2022-12-28	WOS:A1994MU96400039
J	KISHIMOTO, T; TAGA, T; AKIRA, S				KISHIMOTO, T; TAGA, T; AKIRA, S			CYTOKINE SIGNAL-TRANSDUCTION	CELL			English	Review							LEUKEMIA-INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; INTERLEUKIN-6 RESPONSE ELEMENT; RAT ALPHA-2-MACROGLOBULIN GENE; CILIARY NEUROTROPHIC FACTOR; ACUTE-PHASE RESPONSE; RECEPTOR-BETA-CHAIN; NF-KAPPA-B; IL-2 RECEPTOR; ONCOSTATIN-M		OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University	KISHIMOTO, T (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BIRD TA, 1991, J BIOL CHEM, V266, P22661; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; JLIKA RL, 1992, SCIENCE, V257, P88; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERBERG DM, 1992, IMMUNOL TODAY, V13, P77, DOI 10.1016/0167-5699(92)90140-3; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAHL N, 1993, J BIOL CHEM, V268, P7628; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VENIKATARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555; YOSHIDA K, 1994, IN PRESS MECH DEV; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	91	1264	1310	0	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					253	262		10.1016/0092-8674(94)90333-6	http://dx.doi.org/10.1016/0092-8674(94)90333-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293462				2022-12-28	WOS:A1994MU67800009
J	GEJMAN, PV; RAM, A; GELERNTER, J; FRIEDMAN, E; CAO, QH; PICKAR, D; BLUM, K; NOBLE, EP; KRANZLER, HR; OMALLEY, S; HAMER, DH; WHITSITT, F; RAO, P; DELISI, LE; VIRKKUNEN, M; LINNOILA, M; GOLDMAN, D; GERSHON, ES				GEJMAN, PV; RAM, A; GELERNTER, J; FRIEDMAN, E; CAO, QH; PICKAR, D; BLUM, K; NOBLE, EP; KRANZLER, HR; OMALLEY, S; HAMER, DH; WHITSITT, F; RAO, P; DELISI, LE; VIRKKUNEN, M; LINNOILA, M; GOLDMAN, D; GERSHON, ES			NO STRUCTURAL MUTATION IN THE DOPAMINE-D2 RECEPTOR GENE IN ALCOHOLISM OR SCHIZOPHRENIA - ANALYSIS USING DENATURING GRADIENT GEL-ELECTROPHORESIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ALPHA-SUBUNIT GENE; SCREENING-TEST; D2-DOPAMINE RECEPTOR; ALLELIC ASSOCIATION; DNA FRAGMENTS; GC-CLAMP; D2; FAMILY; DRUG	Objective.-To examine the dopamine D2 receptor (DRD2) gene coding sequences for abnormalities associated with schizophrenia or alcoholism and thereby help to resolve the controversy surrounding the reported association of alcoholism with a restriction fragment length polymorphism located close to the DRD2 gene. Design.-Mutational analysis of complete DRD2 gene coding sequences by denaturing gradient gel electrophoresis followed by direct nucleotide sequencing of detected variants. Setting.-Patients and controls from clinical and epidemiologic collections in the United States and Europe. Patients.-A total of 253 unrelated individuals, including 106 patients with schizophrenia, 113 with alcoholism, and 34 controls. For alcoholism we included patients from previously published series in which an association of illness with allele A1 was reported (Taq I site 3' to the DRD2 gene) and from other published series in which nonconfirmations of this association were reported. Nearly all persons examined were white. Main Outcome Measures.-Frequency of nonsilent variations in DRD2 gene DNA sequences in the different diagnostic groups. Results.-We found three infrequent DNA variants that predict altered amino acid sequence of the receptor. None of these is associated with either alcoholism or schizophrenia. Conclusion.-No structural coding abnormalities in the DRD2 gene are present in alcoholism or schizophrenia.	NIMH, EXPTL THERAPEUT BRANCH, BETHESDA, MD 20892 USA; YALE UNIV, MED CTR, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA; VET AFFAIRS MED CTR, W HAVEN, CT USA; KAROLINSKA HOSP, DEPT CLIN GENET, S-10401 STOCKHOLM 60, SWEDEN; UNIV TEXAS, HLTH SCI CTR, DEPT PHARMACOL, SAN ANTONIO, TX 78284 USA; UNIV CALIF LOS ANGELES, NEUROPSYCHIAT INST & BRAIN RES, ALCOHOL RES CTR, LOS ANGELES, CA USA; UNIV CONNECTICUT, CTR HLTH, ALCOHOL RES CTR, FARMINGTON, CT 06032 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; SUNY STONY BROOK, HLTH SCI CTR, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA; UNIV HELSINKI, DEPT PSYCHIAT, SF-00100 HELSINKI 10, FINLAND; NIAAA, DIV INTRAMURAL CLIN & BIOL RES, CLIN STUDIES LAB, BETHESDA, MD USA; NIAAA, NEUROGENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Karolinska Institutet; Karolinska University Hospital; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	GEJMAN, PV (corresponding author), NIMH, CLIN & NEUROGENET BRANCH, 10-3N218, BETHESDA, MD 20892 USA.		kranzler, henry/AAS-1113-2020; Goldman, David/F-9772-2010; Hamer, Dean H/L-1248-2015	kranzler, henry/0000-0002-1018-0450; Goldman, David/0000-0002-1724-5405; Hamer, Dean H/0000-0002-6211-5781; Gelernter, Joel/0000-0002-4067-1859; Pickar, David/0000-0002-8596-3687	NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000931] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00931] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMADEO S, 1993, J PSYCHIAT RES, V27, P173, DOI 10.1016/0022-3956(93)90005-M; ARINAMI T, 1993, BIOL PSYCHIAT, V33, P108, DOI 10.1016/0006-3223(93)90309-2; BARBETTI F, 1992, DIABETES, V41, P408, DOI 10.2337/diabetes.41.4.408; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS A M, 1990, Journal of the American Medical Association, V264, P3156, DOI 10.1001/jama.264.24.3156; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATALANO M, 1992, NEUROPSYCHOBIOLOGY, V26, P1, DOI 10.1159/000118888; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; COOK BL, 1992, ALCOHOL CLIN EXP RES, V16, P806, DOI 10.1111/j.1530-0277.1992.tb00683.x; COON H, 1993, AM J HUM GENET, V52, P327; COOPER DN, 1992, ANN MED, V24, P427, DOI 10.3109/07853899209166991; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEARRY A, 1991, CELL MOL NEUROBIOL, V11, P437, DOI 10.1007/BF00734808; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EUBANKS JH, 1992, GENOMICS, V14, P1010, DOI 10.1016/S0888-7543(05)80124-7; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FISCHER SG, 1980, P NATL ACAD SCI-BIOL, V77, P4420, DOI 10.1073/pnas.77.8.4420; FRIEDMAN E, IN PRESS J CLIN ENDO; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GEJMAN PV, 1991, GENOMICS, V9, P782, DOI 10.1016/0888-7543(91)90377-Q; GEJMAN PV, IN PRESS METHODS ENZ; GELERNLTER J, 1989, CYTOGENET CELL GENET, V1, P100; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GERSHON ES, 1988, ARCH GEN PSYCHIAT, V45, P328; GIBBS LE, 1983, DRUG ALCOHOL DEPEN, V12, P279, DOI 10.1016/0376-8716(83)90071-6; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; GREENBERG DA, 1993, AM J HUM GENET, V52, P135; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; KARP RW, 1992, ALCOHOL CLIN EXP RES, V16, P786, DOI 10.1111/j.1530-0277.1992.tb00679.x; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAYLOR JA, 1992, LANCET, V340, P1066, DOI 10.1016/0140-6736(92)93080-7; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; NOBLE EP, 1993, BEHAV GENET, V23, P117; NOBLE EP, IN PRESS DRUG ALCOHO; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SEEMAN P, 1993, NEUROPSYCHOPHARMACOL, V8, P137, DOI 10.1038/npp.1993.15; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; SELVIE LA, 1989, DNA CELL BIOL, V8, P683; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SNYDER SH, 1984, SCIENCE, V224, P22, DOI 10.1126/science.6322304; SNYDER SH, 1974, SCIENCE, V184, P1243, DOI 10.1126/science.184.4143.1243; SPITZER R, 1971, CRITICAL ISSUES PSYC; STCLAIR D, 1990, LANCET, V336, P13, DOI 10.1016/0140-6736(90)91520-K; SU Y, 1993, ARCH GEN PSYCHIAT, V50, P205; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; TURNER E, 1992, BIOL PSYCHIAT, V31, P285, DOI 10.1016/0006-3223(92)90052-2; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; WANG ZW, 1993, ARCH GEN PSYCHIAT, V50, P212; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; 1987, DIAGNOSTIC STATISTIC	69	203	204	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					204	208		10.1001/jama.271.3.204	http://dx.doi.org/10.1001/jama.271.3.204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277546				2022-12-28	WOS:A1994MQ64500033
J	TABATA, T; KORNBERG, TB				TABATA, T; KORNBERG, TB			HEDGEHOG IS A SIGNALING PROTEIN WITH A KEY ROLE IN PATTERNING DROSOPHILA IMAGINAL DISKS	CELL			English	Article							CELL-CELL COMMUNICATION; SEGMENT POLARITY GENES; ENGRAILED GENE; PATCHED GENE; BETA FAMILY; EXPRESSION; MELANOGASTER; COMPARTMENT; SHIBIRE; EMBRYO	The segment polarity genes hedgehog and engrailed are expressed in identical posterior-compartment-specific patterns in both Drosophila embryos and imaginal discs. We show here that the hedgehog protein is secreted, and it can cross embryo parasegment borders and the anterior-posterior compartment border of imaginal discs to neighboring cells that express neither engrailed nor hedgehog. In these cells, it is localized in discrete punctate structures that are sequestered within the polarized epithelium. Analysis of animals that have expressed hedgehog ectopically, or of a mutant that expresses hedgehog abnormally in the anterior compartment of the wing disc, indicates that hedgehog is involved in regulating patched. In the embryo, hedgehog regulation of patched apparently facilitates patched and wingless expression. In the discs, hedgehog regulation of patched and other genes in the anterior compartment helps to establish the proximodistal axis. We propose that the cell-cell communication mediated by hedgehog links the special properties of compartment borders with specification of the proximodistal axis in imaginal development.			TABATA, T (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROOK WJ, 1993, DEVELOPMENT, V117, P1287; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; GRONZALEZ F, 1991, MECH DEVELOP, V35, P43; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; SCHUBIGER G, 1978, DEV BIOL, V67, P286, DOI 10.1016/0012-1606(78)90200-2; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	51	563	593	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					89	102		10.1016/0092-8674(94)90175-9	http://dx.doi.org/10.1016/0092-8674(94)90175-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287482				2022-12-28	WOS:A1994MR49500009
J	WADE, OL				WADE, OL			CYCLING FOR HEALTH - 40 YEARS AGO	BMJ-BRITISH MEDICAL JOURNAL			English	Article											WADE, OL (corresponding author), UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.							DONALD KW, 1954, J CLIN INVEST, V33, P1146, DOI 10.1172/JCI102988; DONALD KW, 1955, CLIN SCI, V14, P36; WADE OL, 1953, BRIT MED J, V2, P902, DOI 10.1136/bmj.2.4842.902	3	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 18	1993	307	6919					1607	1608		10.1136/bmj.307.6919.1607	http://dx.doi.org/10.1136/bmj.307.6919.1607			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292956	Green Published, Bronze			2022-12-28	WOS:A1993MN10700020
J	DRISCOLL, PA; NICHOLSON, DA; ROSS, R				DRISCOLL, PA; NICHOLSON, DA; ROSS, R			ABC OF EMERGENCY RADIOLOGY - THORACIC AND LUMBAR SPINE	BRITISH MEDICAL JOURNAL			English	Article											DRISCOLL, PA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1552	1557		10.1136/bmj.307.6918.1552	http://dx.doi.org/10.1136/bmj.307.6918.1552			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274929	Bronze, Green Published			2022-12-28	WOS:A1993ML86900029
J	KEELEY, D				KEELEY, D			HOW TO ACHIEVE BETTER OUTCOME IN TREATMENT OF ASTHMA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							DEPOSITION; NEBUHALER; CHILDREN; AEROSOL; SPACER	The symptoms of many asthmatic patients are poorly controlled, and there are several reasons why this may be so. Doctors fail to find out about symptoms that asthmatic patients are experiencing. Doctors wrongly assume that regular use of bronchodilators in small doses is satisfactory treatment for asthma and that taking high doses of bronchodilator in an asthma attack may be dangerous. Doctors think that inhaled steroids may be dangerous and are reluctant to use them in effective doses. Doctors do not check that patients can use their inhalers properly and do not make enough use of large volume spacers, the best available method for giving inhaled asthma treatment. Doctors undermine patients' confidence in advice on treatment by failing to ensure that consistent advice is given and often make the management of asthma more troublesome for the patient than the symptoms of asthma.			KEELEY, D (corresponding author), HLTH CTR,THAME OX0 3JZ,ENGLAND.							BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; FUGLSANG G, 1986, EUR J RESPIR DIS, V69, P109; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; JONES KP, 1992, BRIT MED J, V304, P361, DOI 10.1136/bmj.304.6823.361; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; NEWMAN SP, 1984, THORAX, V39, P935, DOI 10.1136/thx.39.12.935; NEWMAN SP, 1989, EUR RESPIR J, V2, P247; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; 1992, REPORT BETA AGONIST	11	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1261	1263		10.1136/bmj.307.6914.1261	http://dx.doi.org/10.1136/bmj.307.6914.1261			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281061	Bronze, Green Published			2022-12-28	WOS:A1993MH00100027
